<SEC-DOCUMENT>0000875045-18-000010.txt : 20180424
<SEC-HEADER>0000875045-18-000010.hdr.sgml : 20180424
<ACCEPTANCE-DATETIME>20180424165310
ACCESSION NUMBER:		0000875045-18-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		123
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180424
DATE AS OF CHANGE:		20180424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		18771947

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2018331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s64D3E911052E5DC1B2DE40C22B896F5F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-Q</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number 0-19311</font></div><div style="line-height:120%;text-align:center;"><img src="biogenlogostandarda15.jpg" alt="biogenlogostandarda15.jpg" style="height:61px;width:185px;"></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, MA 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:19%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;20, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211,007,945</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sAA83D1A1D5C5535D99AD5D8C572F543A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#sCADC1F89110558A6B2B47CA9D7AAD548"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCC7D5F8E25965665AB50E9FF93EFEDBD"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three Months Ended March 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sCC7D5F8E25965665AB50E9FF93EFEDBD">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1FFCDF119B345D379ED4A1A3225E43C9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three Months Ended March 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s1FFCDF119B345D379ED4A1A3225E43C9">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7A89F7FDC13D54E0A0C5275D6B21E0D3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of March 31, 2018 and December&#160;31, 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7A89F7FDC13D54E0A0C5275D6B21E0D3">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sF287C256C6F554569486FBB62CB20B5F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Three Months Ended March 31, 2018 and 2017</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sF287C256C6F554569486FBB62CB20B5F">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s2B684FF0019158A6964301B553F69D8D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2B684FF0019158A6964301B553F69D8D">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s4ABDD6765CA25BAFA3D94C8E747408D4"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s4ABDD6765CA25BAFA3D94C8E747408D4">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9D686E98081A5811BB0FDC560CF090FE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s9D686E98081A5811BB0FDC560CF090FE">63</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s91594537B6B350EE9B393DB583FD802A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s91594537B6B350EE9B393DB583FD802A">65</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s91B03FA6A3BA5A97AA72075B83CE8B8F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s24EF6FF39B02595E83027CF64F5FD89C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s24EF6FF39B02595E83027CF64F5FD89C">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7006096C44FB5CFAA915B02655946FF7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s7006096C44FB5CFAA915B02655946FF7">66</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2B32C4517EB05B3CACF982AA8ABDC63A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s2B32C4517EB05B3CACF982AA8ABDC63A">80</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s41B65367EB5A577BBABA6D5874358152"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s41B65367EB5A577BBABA6D5874358152">80</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE35948B8FB3550D8AB488719C16914BD"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE35948B8FB3550D8AB488719C16914BD">82</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s887983EDFA05522A9E675FC0CF048B46"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits and the potential costs and expenses related to our current or future initiatives to streamline our operations and reallocate resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated timing to complete certain business development transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated costs and tax treatment of the spin-off of our hemophilia business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, including the Tax Cuts and Jobs Act of 2017, and accounting standards.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the E.U.).</font></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are registered trademarks of Biogen. BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are trademarks of Biogen. ALPROLIX&#174;,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE&#174;, ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174; and other trademarks referenced in this report are the property of their respective owners. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sCADC1F89110558A6B2B47CA9D7AAD548"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</font></div><div><a name="sE866BFEDCFA75AEFA60DB18A0827AB69"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCC7D5F8E25965665AB50E9FF93EFEDBD"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,523.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">443.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,131.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,810.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">384.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">496.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">423.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">501.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">498.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">103.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">448.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,596.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,534.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,024.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,493.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">986.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">322.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.47</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s1FFCDF119B345D379ED4A1A3225E43C9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(29.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,185.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">742.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">742.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s7A89F7FDC13D54E0A0C5275D6B21E0D3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br>2017</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,108.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,573.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,808.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,939.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,787.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">553.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">532.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">890.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">962.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,195.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,873.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,200.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,057.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,334.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,794.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,907.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,632.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,277.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">595.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">380.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">431.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26,090.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23,652.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">231.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">345.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">395.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,571.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,152.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,368.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,929.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,331.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,640.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,628.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12,052.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,054.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(303.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17,334.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,810.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14,053.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,612.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14,037.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,598.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26,090.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23,652.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="sF287C256C6F554569486FBB62CB20B5F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">168.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">512.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(134.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(46.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(121.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(684.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">257.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(34.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,457.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,068.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,884.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,919.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,256.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration paid related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(600.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(194.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(210.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(855.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,346.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(744.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(583.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(21.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash contribution to Bioverativ Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(302.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(268.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(901.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (decrease) increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,535.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,410.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,573.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,108.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">924.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s2B684FF0019158A6964301B553F69D8D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s59E19CD51F3356D8BB5429CA8FF3C359"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS. For additional information on our voluntary withdrawal of ZINBRYTA, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy, a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our accompanying unaudited condensed consolidated financial statements (condensed consolidated financial statements) include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU No. 2014-09 that have the same effective date and transition date: ASU No.&#160;2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenues, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which provides guidance on the presentation and disclosure of collaborative arrangements. Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have any future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with AbbVie and Samsung Bioepis also represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues are recognized as the underlying sales occur. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our condensed consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborations with AbbVie and Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of our product, which may occur at a point in time or over time depending on the terms and conditions of the agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, as of that date, and recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net adjustment to retained earnings reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of the new standard resulted in the reclassification of where we recognize changes in fair value related to certain equity security investments. Prior to adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leasing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard establishes a right-of-use (ROU) model that requires all lessees to recognize ROU assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required to leases existing as of, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our condensed consolidated balance sheet with no material impact to our condensed consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;offset by a corresponding net increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read Note 15,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Net Periodic Pension Cost</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our condensed consolidated statements of income. We adopted this new standard on January 1, 2018, using the retrospective method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of this new standard, the other components of the net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our condensed consolidated income statements. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was reclassified from operating income to other income (expense), net in our condensed consolidated income statement to conform to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;This new standard provides guidance to better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this new standard resulted in additional disclosures. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon the adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our condensed consolidated balance sheets. Changes in the fair value of derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an on-going basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instrument used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in the same line item as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="s362a8514f6db4f66af597fb8ba0aef09"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Karyopharm Therapeutics Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm Therapeutics Inc.'s (Karyopharm) Phase 1 ready investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB100 has not yet reached technological feasibility. We have also agreed to pay Karyopharm up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$207.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments, as well as potential royalties.</font></div><div><a name="sc29136e86d16470ba5934a80cf07eee6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restructuring</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We recognized restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated statements of income during the fourth quarter of 2017. These restructuring charges were substantially incurred and paid in 2017 and were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our condensed consolidated statements of income. These restructuring charges, which will be substantially incurred and paid by mid-2018, are primarily related to severance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sB1E4634A2F555C14B4D4F610FF0ECDD3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">728.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">258.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">986.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">751.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">958.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">371.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">178.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">550.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">464.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">212.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">545.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">188.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">363.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,538.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,631.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">749.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues for the three months ended March 31, 2018, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues for the three months ended March 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">606.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">761.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">641.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">806.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(227.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(299.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(77.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(326.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(412.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">121.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">695.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">859.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">201.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">657.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">859.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">349.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">93.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">443.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Bioepis and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">140.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaborations with AbbVie and Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements.</font></div><div><a name="s596BDE19E3665D2EA3E2C508408B3A58"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">594.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">148.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">906.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">890.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">906.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="sBBED93BF500C5B68BF5E47C154878C78"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(537.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(535.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,700.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">304.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,689.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">696.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">696.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,974.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,250.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,723.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,971.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,160.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,811.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,283.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,489.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,794.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$103.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$448.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in the prior year comparative period. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily due to the prior year impairment charge related to our U.S. and rest of world licenses to Forward Pharma A/S's (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$298.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc and our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. The net book values of the TYSABRI and TECFIDERA assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,178.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$322.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In March 2018 the European Patent Office (EPO) issued its decision revoking Forward Pharma's European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of 2017. Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">330.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">402.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">379.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">255.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">242.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">270.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,907.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes in foreign currency exchange rate fluctuations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="sB508EF34B4BD5C6B869FA9E164AF30A4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,143.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,143.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,836.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,813.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,490.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,517.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,482.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">994.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">994.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,788.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,736.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,851.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,736.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,898.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,188.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,932.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,938.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals, Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$273.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Changes in the fair value of our contingent consideration obligations were primarily due to an increase in the probability of achieving certain developmental milestones in the prior year period and an increase in the interest rate used to revalue our contingent consideration liabilities for the current year.</font></div><div><a name="sDEF603B1477555589726206669CF5C9D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,561.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">948.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maturities. Upon adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">912.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">913.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">248.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">248.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,008.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,011.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,570.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,569.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,808.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,809.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,116.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,123.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,124.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">77.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">77.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,008.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,011.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,068.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,884.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 assets.</font></div><div><a name="s41E3B5321B25528CB8569746D026AC4F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2017, were modified to conform to the new disclosure requirements. For additional information on this new standard, please read Note 1, S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ummary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges and any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,734.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,875.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">110.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,971.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$127.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2018</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2017</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recognized as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$572.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$564.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">114.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s83D5F010FB1850368C2999AA99BC79CB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,631.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,559.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><a name="s69ED5E72C3AC591F978B74E03F07AEA8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, increased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by net income attributable to Biogen Inc. of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and a net cumulative-effect adjustment of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recognized to retained earnings upon the adoptions of ASUs 2016-16 and 2016-01, partially offset by share repurchases totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the adoption of ASUs 2016-16 and 2016-01, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). Our 2016 Share Repurchase Program does not have an expiration date. All share repurchases under our 2016 Share Repurchase Program will be retired. Under our 2016 Share Repurchase Program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available for share repurchase under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock (2011 Share Repurchase Program). Shares repurchased under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under our 2011 Share Repurchase Program, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="s2617F933DE1A5A57BDFCD6B2B20D9D97"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amount reclassified, net of tax, upon adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(316.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(29.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(133.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(130.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(314.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(325.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:45%;"></td><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><a name="s6C42D94368445A3B93B87D2DD2210F2F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div><a name="sB9C8D0E4C99E51F581C17D5A77134F5B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14. Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance Stock Units (PSUs)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018, we began granting awards for performance-vested restricted stock units that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of the actual performance metric achievement. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;PSUs that will settle in stock were granted at a weighted average grant date fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$317.58</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Cash</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018, we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of the actual performance metric achievement. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through the vesting date, once the actual vested and earned number of units is determined. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;PSUs that will settle in cash were granted.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="sC25FA63CF2BD5510BDB088E735A36C7A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act), which was signed into law in December 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low- taxed income (GILTI). These changes became effective beginning in 2018. We do not recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and instead account for any taxes assessed as period costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017, we recognized within our provision for income taxes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;provisional estimate under the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. During the first quarter of 2018 we recognized no significant adjustments to these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Transition Toll Tax</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax was assessed on our share of our foreign corporation's accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and all other earnings were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. As a result, our estimate of the total withholding taxes may change as the amounts are finalized. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Status of our Assessment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management&#8217;s analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the new GILTI tax on international earnings, limits on the deductibility of certain benefits and executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act. The effective tax rate for 2017 also reflected the impact of a favorable settlement related to a state tax matter in 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;offset by a corresponding increase to deferred tax liabilities of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2018 on similar matters.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</font></div><div><a name="s11E120491F055DF596BE4A4E5171D123"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(50.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(63.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$895.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$962.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and include prepaid taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$587.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$657.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">657.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">524.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">194.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">206.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">186.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">297.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">178.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">159.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">176.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,571.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sABFC2618B77E5B9FA52A15851A0943C0"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2007 we entered into a collaboration and license agreement with Neurimmune Subone AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. Our anti-amyloid beta antibody, aducanumab, for the treatment of AD resulted from this collaboration. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on sales of any resulting commercial products and make payments upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.&#160;Our royalty rates payable on products developed under the amended agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low teens.&#160;As we consolidate the results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the fourth quarter of 2017 and treated it as a distribution. Under the amended agreement, we also have an option that will expire on April 30, 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration agreement with Eisai Co. Ltd. (Eisai) for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement), Eisai may elect to share in the benefit and cost associated with the royalty reductions discussed above. Eisai has elected to not share in the benefit and cost of the October 2017 royalty reduction. For additional information on our collaboration arrangement with Eisai, please read Note 18,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="s3DF2C0F5E27A5366A73371833A061C30"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Inc. (AbbVie) for the development and commercialization of ZINBRYTA, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary withdrawal of ZINBRYTA for relapsing MS, as discussed below.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory) where development and commercialization costs and profits were shared equally. Outside of the Collaboration Territory, we were solely responsible for development and commercialization of ZINBRYTA and paid a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Article 20 Procedure and Voluntary Withdrawal of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the European Medicines Agency (EMA) announced a review (referred to as an Article 20 Procedure) of the use of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury, and recommended restrictions on its use. In January 2018 the European Commission (EC) adopted a final and legally-binding decision restricting ZINBRYTA's use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. For additional information on the Article 20 Procedure of ZINBRYTA please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The EMA subsequently started a second review following cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis.&#160;In parallel, we and AbbVie began discussions with the EMA, and in March 2018 announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS as we and AbbVie believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated. Subsequent to the voluntary worldwide withdrawal of ZINBRYTA, the EMA recommended the immediate suspension of ZINBRYTA's marketing authorization and a recall of ZINBRYTA from pharmacies and hospitals in the E.U. As a result of our voluntary withdrawal of ZINBRYTA, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in inventory charges and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in losses related to the termination of research and development contracts and clinical trials related to our voluntary worldwide withdrawal of ZINBRYTA in our condensed consolidated statements of income, net of an expected AbbVie reimbursement, in the first quarter of 2018.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenues of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect our share of an overall net loss within the collaboration, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. These results include the collaboration's estimate of future returns of product in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada. These results include the collaboration's estimate of future returns of product in the E.U. and Canada. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our recognition of income to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada was not significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with AbbVie, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai to jointly develop and commercialize E2609, a BACE inhibitor, and BAN2401, a monoclonal antibody that targets amyloid beta aggregates, two Eisai product candidates for the treatment of AD.&#160;Eisai serves as the global operational and regulatory lead for both compounds with all costs, including research, development and sales and marketing expenses shared equally by us and Eisai; and, if applicable, following marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai will co-promote BAN2401 and E2609 and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;was reflected in research and development expense in our condensed consolidated statements of income related to the advancement of our E2609 and BAN2401 programs, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have the Aducanumab Collaboration Agreement with Eisai for the joint development and commercialization of aducanumab. Under the Aducanumab Collaboration Agreement, we will continue to lead the on-going Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab incurred in support of this agreement until April 2018. Eisai will then reimburse us for&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expenses for the period April 2018 through December 2018, and&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;was reflected in research and development expense in our condensed consolidated statements of income related to the advancement of our aducanumab program, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai also co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the joint venture agreement plus a rate that will represent their return on capital. If we do not exercise this option by mid-2018, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis' shares then held by us. Should we exercise this option, our ownership percentage would increase to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of BENEPALI and FLIXABI in the E.U. in the first and third quarters of 2016, respectively. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. In August 2017 the EC granted a marketing authorization in the E.U. for IMRALDI, an adalimumab biosimilar referencing HUMIRA.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we and Samsung Bioepis will make royalty payments to AbbVie. We expect to launch IMRALDI in Europe in October 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect Samsung Bioepis's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in revenues in relation to these services, which is reflected as a component of other revenues in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on to these and our other significant collaboration arrangements, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="s58A7F831C12C5E27AAF2CDBF927F1395"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Abbreviated New Drug Application (ANDA) Litigation relating to TECFIDERA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June, July and September 2017, January, March and April 2018, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Caribe Holdings (Cayman) Co. Ltd.&#160;DBA Puracap&#160;Caribe, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceutical Inc., Slayback Pharma LLC,&#160;Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shilpa Medicare Limited, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Accord Healthcare Inc., Par Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Zydus Pharmaceuticals (USA) Inc. and Banner Life Sciences LLC. In addition, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act against Stason Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California, Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey, Accord Healthcare Inc. in the U.S. District Court for the Middle District of North Carolina, Par Pharmaceutical Inc. in the U.S. District Court for the Southern District of New York, Sandoz Inc. in the U.S. District Court for the District of Colorado and Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cases against Accord Healthcare Inc., Zydus Pharmaceuticals (USA) Inc. and Sandoz Inc. have been dismissed in the North Carolina, New Jersey and Colorado courts but will continue against those parties in Delaware. The cases against Par Pharmaceutical Inc. in both New York and Delaware have been dismissed because Par Pharmaceutical Inc.&#8217;s ANDA application has been withdrawn. The case against Stason Pharmaceuticals, Inc. in California has been dismissed, but the case against its partner Sawai USA, Inc. will proceed in Delaware. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial has been set in the Delaware actions in December 2019 against all parties other than Banner Life Sciences LLC, and a trial has been set in the West Virginia action in February 2020. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and oral argument has been set for June 2018. For additional information on this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO decided to revoke our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO issued its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information on this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to threat MS. The Polish &#8216;263 Patent was issued in 2013 and expires in February 2023. Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (on January 11, 2016), the German Patents Court (on March 3, 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">counterparts of the EU '127 Patent, which was issued in 2011 and also concerns administration of natalizumab (TYSABRI) to treat MS. The EU '127 Patent expires in February 2023. The Dutch counterpart was ruled invalid and we have appealed. In January 2018 the German court announced that the German counterpart was invalid. No date for a hearing on the merits has been set in the Italian action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018 a jury found that EMD Serono and Pfizer infringed the '755 patent but that the &#8216;755 Patent was invalid under the law of anticipation. Biogen, EMD Serono and Pfizer have filed motions for judgment as a matter of law and these motions are pending. A trial date against Bayer and Novartis has not yet been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 the tax authority of the State of Goias, Brazil issued assessments for the period January 2016 through February 2018 relating to tax on the circulation of goods and totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;including interest and penalties.&#160;We dispute the assessments.&#160;We are unable to provide an estimate of the potential loss or range of loss at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><a name="s3f5df2dc30cc45538673179a24d87930"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pfizer Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we completed an agreement to acquire from Pfizer BIIB104 (formerly known as PF-04958242), a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in the second quarter of 2018, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We may also pay Pfizer up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$515.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional development and commercialization milestone payments, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the dosing of the first patient in Phase 2b, as well as tiered royalties in the low to mid-teen percentages.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we entered into a new </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ten</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases. Under this agreement, we will make an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and purchase </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of Ionis&#8217; common stock, at a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;premium based on the closing price of Ionis&#8217;s common stock for the 10 days prior to the date of this agreement, for a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The premium paid on the equity will be recorded as research and development expense in our condensed consolidated statements of income.&#160;We have the option to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depending on the indication, and royalties on net sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The transaction is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><a name="s4ABDD6765CA25BAFA3D94C8E747408D4"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS. For additional information on our voluntary withdrawal of ZINBRYTA, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products and, unless we develop, acquire rights to and/or commercialize new products and technologies, we may be substantially dependent on sales from our principal products for many years. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in our unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="sC1BE20084FE150848022456C542DECB8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;text-align:justify;"><img src="financialhighlights.jpg" alt="financialhighlights.jpg" style="height:426px;width:317px;"></div><div><a name="s65137EA32BC9551AB1612687A6A30AFB"></a></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.54</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 60.1% over the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under "</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">," our income from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3,131.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 11.4% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,523.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 6.0% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by revenues from SPINRAZA and BENEPALI and the positive impact of foreign currency exchange gains of $93.2 million, partially offset by comparative net losses of $39.6 million recognized under our foreign currency hedging program. These increases were partially offset by a net decrease in MS revenues, primarily due to the recognition in the prior year period of approximately $45.0 million of previously deferred TYSABRI revenues in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana del </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:48px;padding-top:8px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Farmaco, or AIFA) and a decrease of approximately $40.0 million of inventory in the channel in the U.S. Product revenues, net, compared to the same period in 2017, were also negatively impacted by the elimination of worldwide ELOCTATE and ALPROLIX revenues resulting from the spin-off of our hemophilia business on February 1, 2017. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$443.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 30.1% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by royalty revenues on sales of OCREVUS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$164.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 82.7% from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to higher contract manufacturing revenues related to the volume of shipments of drug product and drug substance production provided to our strategic partners. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,596.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">10.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily driven by the prior year amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma A/S's (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">17.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in research and development and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">16.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in cost of sales.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was also favorably impacted by a decrease in our effective tax rate to 21.6% for the three months ended March 31, 2018, from 24.2% for the same period in 2017, primarily due to the favorable impact resulting from the enactment of the Tax Cuts and Jobs Act of 2017 (2017 Tax Act) in December 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Financial Condition, Liquidity and Capital Resources"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,457.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations, which were primarily driven by earnings. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$7.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased approximately 0.9 million shares of common stock at a cost of $250.0 million during the </font><font style="font-family:Franklin Gothic Book,sans-serif;">first</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the share repurchase program authorized by our Board of Directors in July 2016, which allows us to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program). </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm's Phase 1 ready investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we completed an agreement to acquire from Pfizer Inc. (Pfizer) BIIB104 (formerly known as PF-04958242), a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we entered into a new ten-year exclusive collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our transaction with Karyopharm, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our transactions with Pfizer and Ionis, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapies or biosimilars of existing products and other technologies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continue to be subject to political and societal pressures on a global basis.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition,&#160;our sales and operations are subject to the risks of doing business internationally. For example, the effects of the implementation of the U.K.&#8217;s decision to voluntarily depart from the E.U., known as Brexit, remain unclear; compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and condensed consolidated results of operations from these developments remains unknown.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our competition and pricing risks that could negatively impact our product sales, please read Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Key Pipeline and Product Developments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA (daclizumab)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018, the European Medicine's Agency (EMA) started a review of ZINBRYTA following cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis.&#160;In parallel, we and AbbVie began discussions with the EMA and in March 2018 announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS as we and AbbVie believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated. Subsequent to the voluntary worldwide withdrawal of ZINBRYTA, the EMA recommended the immediate suspension of ZINBRYTA's marketing authorization and a recall of ZINBRYTA from pharmacies and hospitals in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI (natalizumab)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018 we announced that the Phase 2b dose-ranging ACTION 2 study investigating natalizumab in individuals with acute ischemic stroke (AIS) did not meet its primary endpoint. Based on </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">these results, we have discontinued development of natalizumab in AIS. The results of the Phase 2b ACTION 2 study do not impact the benefit-risk profile of natalizumab in approved indications, including MS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie for the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">commercialization of IMRALDI, an adalimumab biosimilar referencing HUMIRA. Under the terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we and Samsung Bioepis will make royalty payments to AbbVie. We expect to launch IMRALDI in Europe in October 2018.</font></div></div></div><div><a name="s9C3BD86288AF5C6D81767665F42C0BB8"></a></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,538.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">49.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,631.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">749.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,523.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">80.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">443.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,131.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,810.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">986.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">958.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">550.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">18.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">545.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">363.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="sE58CE565E7285985BF16509B0781B59D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TECFIDERA revenues was primarily due to a decrease in unit sales volume of 6% and an increase in discounts and allowances, partially offset by gross selling price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 22% in existing markets and new markets where we continue to launch the product and expand our presence around the world. Rest of world TECFIDERA revenues for 2018, compared to the same period in 2017, were also positively impacted by foreign currency exchange gains of $26.6 million, partially offset by comparative net losses of $14.9 million recognized under our foreign currency hedging program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate a modest increase in TECFIDERA demand on a global basis in 2018, compared to 2017, with expected volume growth in our international markets partially offset by declines in the U.S., due to increased competition from additional treatments for MS, including OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="interferon.jpg" alt="interferon.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volume of 21%, which was primarily attributable to patients transitioning to other MS therapies, partially offset by gross selling price increases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to an overall decrease in AVONEX unit sales volume of 9%, primarily due to patients transitioning to other MS therapies in the E.U. Rest of world Interferon revenues for 2018, compared to the same period in 2017, were positively impacted by foreign currency exchange gains of $21.9 million, partially offset by comparative net losses of $10.8 million recognized under our foreign currency hedging program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that overall Interferon revenues will continue to decline compared to prior year periods as a result of increasing competition from our other products as well as other treatments for MS, including biosimilars.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TYSABRI revenues was primarily due to a decrease in unit sales volume of 13%, partially offset by gross selling price increases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was primarily due to the recognition in the prior year period of approximately $45.0 million of previously deferred revenues in Italy relating to the pricing agreement with AIFA, as discussed below. Rest of world TYSABRI revenues for 2018, compared to the same period in 2017, were positively impacted by foreign currency exchange gains of $29.7 million, partially offset by comparative net losses of $12.7 million recognized under our foreign currency hedging program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017 we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Consolidated Financial Statement Detail,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate a decline in TYSABRI demand on a global basis in 2018, compared to 2017, with expected volume declines in the U.S., due to increased competition from additional treatments for MS, including OCREVUS, exceeding volume growth in our international markets.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;"><img src="zinbryta.jpg" alt="zinbryta.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in ZINBRYTA revenues was primarily due to the worldwide voluntary withdrawal of ZINBRYTA for relapsing MS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with AbbVie, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy (SMA)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;text-align:left;text-indent:18px;"><img src="spinraza.jpg" alt="spinraza.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of SPINRAZA in the U.S. in the fourth quarter of 2016 and in the rest of world in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. and rest of world SPINRAZA revenues was due to an increase in unit sales volume.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate over time primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Ionis, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI and FLIXABI</font></div><div style="line-height:120%;"><img src="biosimilars.jpg" alt="biosimilars.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first and third quarters of 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in biosimilar revenues was primarily due to an increase in BENEPALI unit sales volume of 87% in new and existing markets and foreign currency exchange gains, partially offset by price decreases in certain European countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><a name="sC1668C6290A8512397C1465675D36952"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA collaboration operating profits in the U.S. and other revenues on anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;"><img src="anticd20therapeuticprograms.jpg" alt="anticd20therapeuticprograms.jpg" style="height:346px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,096.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,041.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">153.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">201.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">942.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">839.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">349.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN annual pre-tax co-promotion profits in the U.S. in excess of $50.0 million decreased to 37.5% in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded $150.0 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to selling price increases, an increase in RITUXAN unit sales volume of 1% and an increase in GAZYVA unit sales volume of 19%, partially offset by higher discounts and allowances.&#160; </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as depicted in the table above, excludes certain expenses charged to the collaboration by Genentech that we believe remain the responsibility of Genentech and we are not obligated to pay under the terms of the collaboration agreement. Accordingly, we did not recognize the effect of those expenses in the determination of our share of pre-tax collaboration profits and Genentech has withheld approximately $120 million from amounts due to us in relation to collaboration activity for the first quarter of 2017, representing Genentech&#8217;s estimate of our share of these expenses. We remain in discussions with Genentech about a resolution relating to these amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in collaboration costs and expenses was primarily due to lower RITUXAN cost of sales and a decrease in GAZYVA and RITUXAN research and development costs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits on RITUXAN in Canada. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, other revenues from anti-CD20 therapeutic programs increased primarily due to the launch of OCREVUS in the second quarter of 2017. Royalty revenues on sales of OCREVUS totaled $76.7 million in the first quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. Food and Drug Administration (FDA) approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of RMS and PPMS. Under the terms of our agreement with Genentech, we will receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24% if annual net sales exceed $900.0 million. There will be a 50% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a 3% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS was approved for treatment of RMS and PPMS in Australia, Switzerland and the E.U. in July 2017, September 2017 and January 2018, respectively. Marketing applications for OCREVUS are currently under review in numerous markets worldwide, including in Latin America and the Middle East. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div></div><div><a name="sA7A566EAB4A55B02B732A9CAD2D379A8"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">151.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">92.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships include revenues earned under our 50% share of the co-promotion profits or losses of ZINBRYTA in the U.S. with AbbVie, revenues from our technical development and manufacturing services agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in revenues from collaborative and other relationships was primarily due to higher revenues earned under our manufacturing services agreement with Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;"><img src="otherrevenues.jpg" alt="otherrevenues.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty and other corporate revenues was primarily due to higher contract manufacturing revenues related to the volume of shipments of drug product and drug substance production provided to our strategic partners.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><a name="s466F351F0E185FC1B200D3ED14B8BBF3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:left;"><img src="reserves.jpg" alt="reserves.jpg" style="height:373px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 24.3%, as compared to 22.8% in the prior year comparative period.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by an increase in rest of world product revenues, due in part to an increase in biosimilar revenues. This increase was partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher managed care rebates and co-payment assistance in the U.S. and other governmental rebates and allowances in the U.S. and rest of world, due in part to an increase in SPINRAZA sales volumes worldwide and an increase in gross selling prices in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenues are recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in return reserves was primarily due to our voluntary worldwide withdrawal of ZINBRYTA. For additional information on our voluntary worldwide withdrawal of ZINBRYTA, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><a name="sC9E96DC04A475E43ABD195D4E056DFCD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">384.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">496.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">423.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">501.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">498.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">103.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">448.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">104.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(156.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,596.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,786.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s902C4F699BEE5128988BCA22F0ED1093"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="costofsales.jpg" alt="costofsales.jpg" style="height:240px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher biosimilar sales, higher contract manufacturing shipments of drug product and drug substance production provided to our strategic partners and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, royalty cost of sales were relatively consistent with prior year amounts as the recognition of royalties payable to Ionis on sales of SPINRAZA were offset by the expiration of certain third-party royalties related to sales of TYSABRI.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><a name="s58DD10D29E715CBC82EFADEF70665382"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="rd.jpg" alt="rd.jpg" style="height:746px;width:317px;"></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-align:center;"><img src="rdpiechart2018.jpg" alt="rdpiechart2018.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="rdpiechart2017.jpg" alt="rdpiechart2017.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to an increase in costs incurred in connection with our early and late stage programs, partially offset by a decrease in costs incurred with our marketed products and other research and development costs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with early stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to spending associated with the development of BIIB092 in AD and progressive supranuclear palsy pursuant to our license agreement with Bristol-Myers Squibb Company, the development of opicinumab in MS and the development of BIIB093 in large hemispheric infarction.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with our late stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to increased costs associated with the development of aducanumab and E2609, a BACE inhibitor, in AD and the development of BIIB098 in MS pursuant to our license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our marketed products for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to a decrease in costs associated with our MS projects, partially offset by costs related to the termination of research and development contracts and clinical trials due to our voluntary worldwide withdrawal of ZINBRYTA.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="sga.jpg" alt="sga.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in selling, general and administrative expenses was primarily due to an increase in operational spending on sales and marketing activities in support of our marketed products, including increased commercialization costs related to SPINRAZA, partially offset by a decrease in corporate giving and a reduction in operational spending resulting from the spin-off of our hemophilia business.</font></div><div><a name="sB6F3E26E15C15EFD828C287A31D54B7B"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="amortacqintanassets.jpg" alt="amortacqintanassets.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The results of our TECFIDERA, AVONEX and TYSABRI analyses were impacted by changes in the estimated timing of impact of other alternative MS formulations, including OCREVUS, which may compete with TYSABRI, TECFIDERA and AVONEX. The outcome of this most recent analysis did not result in a significant net change in our expected rate of amortization for acquired intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily due to the prior year impairment charge related to our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement with Forward Pharma. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In March 2018 the European Patent Office (EPO) issued its decision revoking Forward Pharma's European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">In Process Research &amp; Development (IPR&amp;D) related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2017, resulted in no impairments. Changes to clinical development plans, regulatory feedback received, life cycle management strategies and changes in program economics, including foreign currency exchange rates, are evaluated regularly. The field of developing treatments for forms of neuropathic pain, such as trigeminal neuralgia (TGN), is highly competitive and can be affected by changes to expected market candidates and changes in timing and the clinical development of our product candidates. There can be no assurance that we will be able to successfully develop BIIB074 for the treatment of TGN or other indications, including our ability to confirm safety and efficacy based on data from clinical trials, or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market. Changes in events and circumstances for these programs may have a material impact on the value of our related IPR&amp;D.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of our acquired intangible assets, including our TECFIDERA settlement and license agreement, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><a name="s2B949DBB0D955D23B3F35EF9BDE23EFD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</font></div><div style="line-height:120%;"><img src="acquirediprd.jpg" alt="acquirediprd.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Karyopharm Therapeutics Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we completed an asset purchase of investigational oral compound BIIB100, from Karyopharm. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Karyopharm, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB100 has not yet reached technological feasibility. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our transaction with Karyopharm, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div><a name="s32834D80B0375FDBA8C8C4FFD78874A3"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="collabprofitshare.jpg" alt="collabprofitshare.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing includes our partner's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our partner's 50% share of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie on the commercialization of ZINBRYTA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we shared biosimilar collaboration profits with Samsung Bioepis and therefore recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to $20.8 million in the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">prior year comparative period. The increase in profit sharing expense for the comparative period was primarily due to increased collaboration profits resulting from increased biosimilar product sales.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's 50% sharing of the net collaboration losses in the E.U. and Canada. Our recognition of income to reflect AbbVie's 50% sharing of the net collaboration losses in the E.U. and Canada for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our agreements with Samsung Bioepis and AbbVie, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="s6CD55E7FB68754BAB193B5B01593809E"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="gainlossonfvcontcons.jpg" alt="gainlossonfvcontcons.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a loss (gain) on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The change in fair value remeasurement of contingent consideration for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2017, was primarily due to an increase in the probability of achieving certain developmental milestones in the prior year and an increase in the interest rate used to revalue our contingent consideration liabilities for the current year.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><a name="sd6ff123509d04660ab84ed0c624ba189"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring charges</font></div><div style="line-height:120%;"><img src="restructuring.jpg" alt="restructuring.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to $170.0 million, primarily in 2018, and our goal is to redirect resources of up to $400.0 million annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized restructuring charges of $0.9 million in our consolidated statements of income during the fourth quarter of 2017. These restructuring charges were substantially incurred and paid in 2017 and were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our condensed consolidated statements of income. These restructuring charges, which will be substantially incurred and paid by mid-2018, are primarily related to severance.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sA5670C25E21B555687607153DE27EDA1"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="oie.jpg" alt="oie.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in losses recorded on our strategic investments upon the adoption of ASU 2016-01, the sale of marketable securities in anticipation of the repatriation of our long-term marketable securities previously held in foreign jurisdictions and an increase in foreign currency exchange losses. These changes are partially offset by a decrease in interest expense as a result of redeeming our 6.875% Senior Notes due March 1, 2018, in November 2017 and an increase in interest income due to higher cash and cash equivalents.</font></div><div><a name="s5225D40EA40852D295BE5B8E5C795FB2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="incometaxprovision.jpg" alt="incometaxprovision.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the new GILTI tax on international earnings, limits on the deductibility of certain benefits and executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act. The effective tax rate for 2017 also reflected the impact of a favorable settlement related to a state tax matter in 2017.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the 2017 Tax Act, our uncertain tax positions and income tax rate reconciliation for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 15, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><a name="s39957B8EF06A54FA9E847028AEBA44DF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>March 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,108.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,573.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">161.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,808.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,200.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,057.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(60.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,116.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,746.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,929.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,932.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,938.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,195.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,873.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,152.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,368.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,043.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,505.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s2D362B67E8475238AC19B751958C663D"></a></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,457.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million used for share repurchases; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$194.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$235.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million payment made to Forward Pharma for the litigation settlement charge that was accrued as of December 31, 2016; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$360.0 million in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million payment made to Forward Pharma to license Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$583.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million net cash contribution made in connection with the spin-off of our hemophilia business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$210.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned from our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act, which was signed into law in December 2017, has resulted in significant changes to the U.S. corporate income tax system.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). The Transition Toll Tax was assessed on our share of our foreign corporation's accumulated foreign earnings that were not previously taxed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. As a result, our estimate of the total withholding taxes may change as the amounts are finalized. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">After repatriating approximately $3.5 billion during the first quarter of 2018 as a result of the 2017 Tax Act, approximately 85% of our total cash, cash equivalents and marketable securities at the end of the quarter were held in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Item 3. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). Our 2016 Share Repurchase Program does not have an expiration date. All share repurchases under our 2016 Share Repurchase Program will be retired. Under our 2016 Share Repurchase Program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available for share repurchase under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock (2011 Share Repurchase Program). Shares repurchased under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under our 2011 Share Repurchase Program, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $7.1 billion compared to approximately $6.7 billion as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net increase in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash flows related to operations, partially offset by cash used for contingent payments made to former shareholders of Fumapharm AG and holders of their rights, cash used for share repurchases and net purchases of property, plant and equipment. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at a discount, which are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica, we issued notes totaling 61.4 million Swiss Francs that are payable to Fumedica in varying amounts from June 2008 through June 2018. Our remaining note payable to Fumedica, payable in June 2018, had a carrying value of 3.1 million Swiss Francs ($3.3 million) and 3.1 million Swiss Francs ($3.2 million) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The change in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects an increase in total current assets of approximately $2.3 billion and a decrease in total current liabilities of $216.1 million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net increase in total current assets was primarily driven by the repatriation of our long-term marketable securities previously held in foreign jurisdictions, which were used to purchase cash equivalents and short-term marketable securities in the U.S., and an increase in accounts receivable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in current liabilities was primarily driven by contingent payments related to FUMADERM and TECFIDERA (together, the Fumapharm Products) totaling $600.0 million made during the first quarter of 2018 for accruals existing at December 31, 2017. This decrease was partially offset by the accrual of an additional $300.0 million in the first quarter of 2018 upon reaching $17.0 billion in total cumulative sales of Fumapharm Products and an increase in income taxes payable.</font></div></div></div><div><a name="s092C02E9DA955DD8AFAB3E815B5BF164"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,457.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">519.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by (used in) investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,346.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(744.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(280.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(268.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(901.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(70.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="sA9F899EB62585E57803A22FC543F31AB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges, acquired in-process research and development and share-based compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows provided by operating activities was primarily due to an increase in net income, a decrease in payments for income taxes, the timing of customer payments of accounts receivables and the $454.8 million payment made to Forward Pharma for the litigation settlement charge in the first quarter of 2017 that was accrued as of December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows provided by investing activities was primarily due to the increase in net proceeds from the sales of marketable securities primarily due to the sale of securities in preparation for the repatriation of our long-term marketable securities previously held in foreign jurisdictions and the $795.2 million payment made to license Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, in the first quarter of 2017. These amounts were partially offset by an increase in contingent payments made to former shareholders of Fumapharm AG and holders of their rights.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in financing activities was </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">primarily due to a decrease in cash used for share repurchases and the net cash contribution made in the prior year comparative period in connection with the spin-off of our hemophilia business.</font></div><div><a name="s5E78E441FCF956AEA19CFF57D94A9AA4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Corporation plc (Elan) full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. (Convergence), Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $1.1 billion in remaining milestones related to these acquisitions. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12- month period, as defined in the acquisition agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid $600.0 million in contingent payments as we reached the $15.0 billion and $16.0 billion cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2017 and accrued $300.0 million upon reaching $17.0 billion in total cumulative sales of Fumapharm Products in the first quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional $300.0 million contingent payment for every additional $1.0 billion in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed $3.0 billion, until such time as the cumulative sales level reaches $20.0 billion, at which time no further contingent payments will be due. If the prior 12 months sales of Fumapharm Products are less than $3.0 billion, contingent payments remain payable on a decreasing tiered basis. These payments are accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $4.3 billion, including approximately $0.5 billion in development milestones, approximately $1.5 billion in regulatory milestones and approximately $2.3 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">successful achievement of certain development, regulatory approval and commercial milestones.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately $50.0 million of milestone payments during the remainder of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several on-going clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $55.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $450.0 million in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have $89.4 million of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><div><a name="s87FEA68CC4FD5CF6B5A21E902BA3750C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="sD7A79C8056E55E10A86A849712B52682"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU No. 2014-09 that have the same effective date and transition date: ASU No.&#160;2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adoption. However, the adoption of the new revenue standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenues, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our concentrations of credit risk associated with our accounts receivable balances, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">"Credit Risk"</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Item&#160;3. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. We will recognize incremental deferred income tax expense as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on ASU 2016-16, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our 2017 Form&#160;10-K. Except as discussed above, there have been no material changes to these critical accounting estimates since our 2017 Form&#160;10-K.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><a name="s9D686E98081A5811BB0FDC560CF090FE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our condensed consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statement of cash flows.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $267.0 million and $286.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $12.0 million and $50.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by $6.8&#160;million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to limit the overall level of government expenditures. These measures vary by country and include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our condensed consolidated financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our condensed consolidated results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div><div><a name="s91594537B6B350EE9B393DB583FD802A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><a name="s91B03FA6A3BA5A97AA72075B83CE8B8F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</font></div><div><a name="s24EF6FF39B02595E83027CF64F5FD89C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Please refer to Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s7006096C44FB5CFAA915B02655946FF7"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products, and, unless we develop or acquire rights to new products and technologies, we will be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues are further reliant and concentrated on sales of our MS products in an increasingly competitive market, and revenues from sales of our product for SMA. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including lower-priced competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition, or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the EC and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in these and other markets. In addition to risks associated with new product launches and the other factors described in these &#8220;Risk Factors&#8221;, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the SMA market, which may impact our ability to develop relationships with the associated medical and scientific community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting pilot program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason including efficacy or tolerability concerns.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the revenues from our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing or reimbursement for our products would have an adverse effect on our business, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and could cause a decline in our stock price.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products or generic or biosimilar products marketed by others may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy, a serious brain infection, or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations, and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party contract research organizations (CROs) do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to limit their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:29px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups, &#8220;hacktivists" and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under the agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying contract with our collaborators or other third parties may fail to provide significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. While we believe we have a number of promising programs in our pipeline, failure of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. The availability of high quality, cost-effective development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them, which may prove to be an expensive and time consuming procedure, or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization, including our chief executive officer and our chief financial officer. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition and results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, such as management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot assure you that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient large scale manufacturing capacity to meet our near-term manufacturing requirements, we may need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to make significant investments to build or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possible retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the hiring freeze implemented by the federal government in 2017, including at the FDA, could impact the review and potential approval of new products, which may adversely affect our business and financial condition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws, including the 2017 Tax Act. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI. These changes are effective beginning in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings. The Transition Toll Tax will be paid over an eight-year period, starting in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management's analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial conditions. The final determination of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">uncertainties regarding the collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.'s decision to voluntarily depart from the E.U., known as Brexit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act (FPCA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, is subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and/or payers do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes stock repurchase programs, including most recently our 2016 Share Repurchase Program. The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may incur operational difficulties or be exposed to claims and liabilities as a result of the spin-off of our hemophilia business. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders in connection with the spin-off of our hemophilia business. In January 2018 Bioverativ was acquired by Sanofi and is now an indirect wholly-owned subsidiary of Sanofi.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the spin-off, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the relationship between us and Bioverativ going forward, including with respect to potential tax-related losses associated with the spin-off. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of our hemophilia business as an independent public company is intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Completion of the spin-off was conditioned upon, among other things, our receipt of a favorable opinion from our tax advisors with respect to the tax-free nature of the transaction. The opinion is not binding on the U.S. Internal Revenue Service (IRS), or the courts, and there can be no assurance that the IRS or the courts will not challenge the qualification of the spin-off as a tax-free transaction or that any such challenge would not prevail. If the spin-off is determined to be taxable, the full financial benefits expected to result from the separation may not be achieved and/or Biogen and its shareholders could incur significant tax liabilities, which could adversely affect our business, financial condition or results of operations and the value of our stock could be adversely impacted.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ has agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations. The separation and distribution agreement provides for indemnification obligations designed to make Bioverativ financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation. It is possible that a court would disregard the allocation agreed to between us and Bioverativ and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to assume responsibility for obligations allocated to Bioverativ. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation and distribution agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><a name="s2B32C4517EB05B3CACF982AA8ABDC63A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2016 Share Repurchase Program during the first quarter of 2018:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 2018</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">292.01</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">400,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,883.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">464,782</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">286.58</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">464,782</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,750.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">864,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">289.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program). Our 2016 Share Repurchase Program does not have an expiration date. All share repurchases under our 2016 Share Repurchase Program will be retired. Under our 2016 Share Repurchase Program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available for share repurchase under our 2016 Share Repurchase Program.</font></div><div><a name="s41B65367EB5A577BBABA6D5874358152"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><a name="sCE66CCA825735DC48F2E9D739669172D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex102.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex103.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement (2018 one-time transition grant) under the Biogen Inc. 2017 Omnibus Equity Plan.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex104.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement for Paul McKenzie dated December 14, 2015.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex311.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex312.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Principal Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2018331xex321.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended March&#160;31, 2018, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+&#160;&#160;&#160;&#160;Filed herewith </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">++&#160;&#160;&#160;&#160;Furnished herewith</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><a name="sE35948B8FB3550D8AB488719C16914BD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#sAA83D1A1D5C5535D99AD5D8C572F543A"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">April&#160;24, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>biib-2018331xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="se41d2758dde54cf89e1a770d9f772e35"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:126px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">PERFORMANCE STOCK UNITS AWARD AGREEMENT</font></div><div style="line-height:120%;text-align:center;padding-left:126px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:126px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GRANTED UNDER</font></div><div style="line-height:120%;text-align:center;padding-left:126px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:162px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOGEN INC. 2017 OMNIBUS EQUITY PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant of Performance Stock Units</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account (the &#8220;Grant Date&#8221;), the number of performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan.  No Granted PSUs shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law.  All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion. No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate.  If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Award will become eligible to vest upon achievement of the Granted PSUs goals (&#8220;Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of the year in which the Award is granted and communicated. The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account.  Granted PSUs that become eligible to vest are referred to as the &#8220;Eligible PSUs.&#8221; In the event and to the extent that the Performance Goals are not satisfied, such Granted PSUs shall not become eligible to vest and shall be immediately forfeited.  As specified in the Performance Goals, in the event and to the extent that the Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest.  In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs.  All Eligible PSUs shall vest on the later of the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Performance Goals have been satisfied (the &#8220;Vesting Date&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become fully vested upon the later of (a) the date of death or Disability of the Participant or (b) the determination of the Eligible PSUs based on the Performance Goals and the Committee&#8217;s approval, even if such determination occurs following the date of death or Disability of the Participant; and</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the later of the date of Retirement or determination of the Eligible PSUs based on the Performance Goals and the Committee&#8217;s approval for fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award.  For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delivery of Award</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is not eligible for Retirement, within 30 days following the date on which Eligible PSUs becomes vested, with respect to, and in satisfaction of, such vested Eligible PSUs (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan), the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.  &#160;&#160;&#160;&#160;With respect to a Participant who is or becomes eligible for Retirement at any time after the Grant Date and on or before the Vesting Date, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), subject to Section 3.C. of this Agreement or (iii) the date on which a Covered Transaction that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.         If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability.  The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unfunded Status</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates. The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld.  A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities. The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date. The Cash Value (net of the cash withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan. The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment.  If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Provisions of the Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control.  A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:292px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:342px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:294px;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:342px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>biib-2018331xex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s64c452934b604072a7615bcaae5618c0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:64px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">PERFORMANCE STOCK UNITS AWARD AGREEMENT (CASH SETTLED)</font></div><div style="line-height:120%;text-align:center;padding-left:64px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:64px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">GRANTED UNDER</font></div><div style="line-height:120%;text-align:center;padding-left:64px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:162px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">BIOGEN INC. 2017 OMNIBUS EQUITY PLAN</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant of Performance Stock Units (Cash Settled)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the &#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on each of the grant dates specified on your Fidelity stock plan account (the &#8220;Grant Date&#8221;), the number of cash-settled performance stock units (the &#8220;Granted PSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan. No Granted PSUs shall be paid unless vested in accordance with this Agreement. The Participant&#8217;s rights to the Granted PSUs are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion. No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate. If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Award will become eligible to vest upon achievement of each of three annual performance goals (the &#8220;Annual Performance Goals&#8221;), as adopted by the Committee in the first calendar quarter of each of the three years beginning on the first year in which the Award is granted and communicated. The calculation of the number of Granted PSUs that will vest is specified in the Long-Term Incentive Program Overview for Executives for the year in which the Award is granted (&#8220;LTI Overview&#8221;), which is also found on your Fidelity stock plan account. Granted PSUs that become eligible to vest upon the achievement of each of the Annual Performance Goals are referred to as the &#8220;Eligible PSUs.&#8221;  In the event and to the extent that the any of the Annual Performance Goals are not satisfied, such Granted PSUs connected to such unachieved Annual Performance Goals shall not become eligible to vest and shall be immediately forfeited. As specified in each of the Annual Performance Goals, in the event and to the extent that the Annual Performance Goals are exceeded, an additional number of Granted PSUs will become eligible to vest. In no event shall the number of Eligible PSUs exceed 200% of the number of Granted PSUs. All Eligible PSUs will vest on the later of the third anniversary of the Grant Date or the date of the Committee&#8217;s determination of the degree to which the Annual Performance Goals have been satisfied (the &#8220;Vesting Date&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will immediately terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become fully vested upon the later of (a) the date of death or Disability of the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Participant or (b) the determination of the Eligible PSUs based on the achievement of the Annual Performance Goals and the Committee&#8217;s approval, even if such determination occurs following the date of death or Disability of the Participant; and</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the later of the date of Retirement or determination of the Eligible PSUs based on the achievement of the Annual Performance Goals and the Committee&#8217;s approval for fifty percent (50%) of the number of Eligible PSUs covered by such unvested portion and for an additional ten percent (10%) of the number of Eligible PSUs covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested Eligible PSUs of the Award. For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delivery of Award</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is not eligible for Retirement, within 30 days following the date on which Eligible PSUs becomes vested, with respect to, and in satisfaction of, such vested Eligible PSUs (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan), the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, the cash value of one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested Eligible PSU. For purposes of this Agreement, the cash value of a share of Common Stock (&#8220;Cash Value&#8221;) will be equal to the 30 calendar-day average of the Company&#8217;s closing stock price ending on the Vesting Date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period, the Company shall pay to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, the Cash Value in satisfaction of each vested Eligible PSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the Eligible PSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), subject to Section 3.C. of this Agreement or (iii) the date on which a Covered Transaction that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.         If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability. The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A.  For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock that are used to calculate the Cash Value to be delivered to the Participant in satisfaction of any vested Eligible PSUs or with respect to any other aspect of the Award. Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate. Furthermore, the Participant is not entitled to vote any Common Stock or to receive or be credited with any dividends declared and payable on any share of Common Stock by reason of the granting of the Award.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unfunded  Status</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company or its Affiliates. The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant an amount of cash equal in value to the statutory minimum amount required to be withheld. A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities. The amount of cash to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date. The Cash Value (net of the cash withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan. The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment. If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Provisions of the Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control. A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:292px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:293px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Officer</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>biib-2018331xex103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s197b5c3d8cdb4afaadc1d4cefeafbc0b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.3</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:157px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2018 ONE-TIME TRANSITION GRANT </font></div><div style="line-height:120%;text-align:center;padding-left:157px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:157px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="line-height:120%;text-align:center;padding-left:157px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:157px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GRANTED UNDER</font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">BIOGEN INC. 2017 OMNIBUS EQUITY PLAN</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant of Restricted Stock Units</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the Biogen Inc. 2017 Omnibus Equity Plan (as it may be amended from time to time, the</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;Plan&#8221;), Biogen Inc. (the &#8220;Company&#8221;) hereby grants to you, an employee of the Company or one of its Affiliates (the &#8220;Participant&#8221;), on February 12, 2018 (the &#8220;Grant Date&#8221;), the number of restricted stock units (the &#8220;RSUs&#8221; or the &#8220;Award&#8221;) specified on your Fidelity stock plan account, subject to the terms and conditions of this award agreement (&#8220;Agreement&#8221;) and the Plan. No RSU shall be paid unless vested in accordance with this Agreement.  The Participant&#8217;s rights to the RSUs granted pursuant to this Agreement are subject to the restrictions described in this Agreement and the Plan, in addition to such other restrictions, if any, as may be imposed by law. All initially capitalized terms used herein will have the meaning specified in the Plan, unless another meaning is specified in this Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.&#160;&#160;&#160;&#160;The Participant shall have a non-forfeitable right to a portion of the Award only upon the vesting dates specified on your Fidelity stock plan account, except as otherwise provided herein or determined by the Committee in its sole discretion. No portion of any Award shall become vested on the vesting date unless the Participant is then, and since the Grant Date has continuously been, employed by the Company or any Affiliate. If the Participant ceases to be employed by the Company and its Affiliates for any reason, any then outstanding and unvested portion of the Award shall be automatically and immediately forfeited and terminated, except as otherwise provided in this Agreement and the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.&#160;&#160;&#160;&#160;The Award will become vested as to 33 1/3% of the RSUs on the first anniversary of the Grant Date and as to the remaining 66 2/3% of the RSUs on the second anniversary of the Grant Date (the &#8220;Vesting Period&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.&#160;&#160;&#160;&#160;Except as otherwise provided in the Plan, upon termination of the Participant&#8217;s employment with the Company and its Affiliates for any reason, any portion of the Award that is not then vested will promptly terminate, except as follows:</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s termination of employment on account of death or Disability will, to the extent not vested previously, become fully vested upon the Participant&#8217;s death or Disability; and</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)&#160;&#160;&#160;&#160;any portion of the Award held by the Participant immediately prior to the Participant&#8217;s Retirement, to the extent not vested previously, will become fully vested upon the Participant&#8217;s Retirement for fifty percent (50%) of the number of shares covered by such unvested portion and for an additional ten percent (10%) of the number of shares covered by such unvested portion for every full year of employment by the Company and its Affiliates beyond ten (10) years, up to the remaining amount of the unvested portion of the Award. For the avoidance of doubt, Retirement means the Participant&#8217;s leaving the employment of the Company and its Affiliates after reaching age 55 with ten (10) consecutive years of service with the Company or its Affiliates, but not </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">including pursuant to any termination For Cause or any termination for insufficient performance, as determined by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">D.&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, any portion of the Award held by a Participant or a Participant&#8217;s permitted transferee immediately prior to the cessation of the Participant&#8217;s employment For Cause shall terminate at the commencement of business on the date of such termination.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Delivery of Award</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A.&#160;&#160;&#160;&#160;With respect to a Participant who is not eligible for Retirement and has a minimum grant of at least six RSUs, within 30 days following the date on which an RSU becomes vested, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of common stock of the Company (&#8220;Common Stock&#8221;) in satisfaction of each vested RSU. Grants of five RSUs or less to a Participant may be settled in an equivalent value of cash instead of Common Stock at the discretion of the Committee.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">B.&#160;&#160;&#160;&#160;With respect to a Participant who is or becomes eligible for Retirement at any time during the Vesting Period and has a minimum award of at least six RSUs, the Company shall issue to the Participant, subject to applicable withholding as described in Section 7 of this Agreement, one share of Common Stock in satisfaction of each vested RSU (determined in accordance with Section 2 of this Agreement and Section 10 of the Plan) within 30 days of the earliest of (i) the date the RSU otherwise would have vested under Section 2.B. of this Agreement, (ii) the date on which the Participant experiences a separation from service (within the meaning of Section 409A), subject to Section 3.C. of this Agreement or (iii) the date on which a Covered Transaction that satisfies the definition of a &#8220;change in control event&#8221; under Section 409A occurs. Grants of five RSUs or less to a Participant may be settled in an equivalent value of cash instead of Common Stock at the discretion of the Committee.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">C.&#160;&#160;&#160;&#160;If you are a &#8220;specified employee&#8221; (as defined in Section 409A), you will be paid on the earlier of (i) the date which is six months after you separate from service (within the meaning of Section 409A) or (ii) the date of your death or Disability. The preceding sentence will not apply to any payments that are exempt from or are not subject to the requirements of Section 409A. For the avoidance of doubt, if payments would be made under Section 3.B.(i) or Section 3.B.(iii) before the six month payment date on account of other than your separation from service, such payment will be made under Section 3.B.(i) or Section 3.B.(iii), as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cancellation and Rescission of Awards</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Committee may cancel, rescind, withhold or otherwise limit or restrict the Award prior to payment at any time if the Participant is not in compliance with all applicable provisions of this Agreement and the Plan, or if the Participant engages in any Detrimental Activity.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Voting, Dividend or Other Rights as a Stockholder</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Participant shall not have any rights as a stockholder with respect to any shares of Common Stock to be issued under the Award until he or she becomes the holder of such shares.  Accordingly, the Award shall not be interpreted to bestow upon the Participant any equity interest or ownership in the Company or any Affiliate prior to the date on which the Company delivers to the Participant shares of Common Stock.  Furthermore, the Participant is not entitled to vote any Common Stock by reason of the granting of the Award or to receive or be credited with any dividends declared and payable on any share of Common Stock underlying the Award prior to the payment date with respect to such share.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Unfunded Status</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The obligations of the Company and its Affiliates hereunder shall be contractual only and all such payments shall be made from the general assets of the Company and its Affiliates. The Participant shall rely solely on the unsecured promise of the Company and nothing herein shall be construed to give the Participant or any other person or persons any right, title, interest or claim in or to any specific asset, fund, reserve, account or property of any kind whatsoever owned by the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Awards will be subject to income tax withholding and reporting as required under local law.  If statutory withholding of taxes and/or social insurance is required at the time of vesting, the Company will withhold from delivery to the Participant a number of shares of Common Stock equal in value to the statutory minimum a mount required to be withheld. A similar amount of cash will be paid by the Company on behalf of the Participant to the applicable tax authorities. The number of shares to be withheld will be calculated using the closing sales price of a share of Common Stock on the applicable vesting date. Shares (net of the number withheld for the payment of withholding taxes, if applicable) will be delivered to the Participant&#8217;s stock plan account upon vesting in accordance with the Plan. The Company may, in its discretion, permit Participants to make alternative arrangements for payment of any such taxes and/or social insurance.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In certain cases, local law may require that an award be subject to tax earlier than the date of payment. If that occurs, the Company will notify the Participant and will deduct the required tax amount from the Participant&#8217;s pay in accordance with applicable law.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Provisions of the Plan</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Award is subject to the provisions of the Plan, which are incorporated herein by reference, and in the event of any inconsistency or conflict between the provisions of this Agreement and the Plan, the provisions of the Plan shall control. A copy of the Plan as in effect on the Grant Date has been made available electronically to the Participant.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">No Right to Employment</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The grant of the Award shall not constitute a contract of employment or confer upon the Participant any right with respect to the continuance of his/her employment by or other service with the Company or any Affiliate, nor shall it or they be construed as affecting the rights of the Company (or any Affiliate) to terminate the service of the Participant at any time or otherwise change the terms of such service, including, without limitation, the right to promote, demote or otherwise re-assign the Participant from one position to another within the Company or any Affiliate.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Governing Law</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The provisions of the Award and this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the Company has caused this instrument to be executed by its duly authorized officer.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:292px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Biogen Inc.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:342px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:294px;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Michel Vounatsos</font><font style="font-family:inherit;font-size:11pt;">&#32;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:342px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Executive Officer</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>biib-2018331xex104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2c7306dd4904488eacd969bbfbbfa1a0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 10.4</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="biogenlogostandarda12.jpg" alt="biogenlogostandarda12.jpg" style="height:38px;width:116px;"></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">December 14,2015</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">REVISED</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Paul McKenzie</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">[Address]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dear Paul,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I am pleased to extend you this offer of employment to join Biogen with the job title of SVP, Global Biologics Manufacturing &amp; Technical Operations. This position will report to John Cox, EVP, Pharmaceutical Operations &amp; Technology.  Please note that neither this letter nor any other materials constitute a contract of employment with Biogen.  Your employment at Biogen is employment at-will. This means that just as you are free to leave your employment at any time, with or without cause or notice, Biogen also has the same right to terminate your employment at any time, with or without cause or notice. The specific terms of our offer are listed below; please take the time to review the offer, sign and return by December 18, 2015.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The position will be based at our Cambridge, MA facility.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Salary:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;&#32;This is a full-time, exempt position and your starting bi-weekly salary will be $17,692.31, which is equivalent to an annual salary of $460,000.06, and which will be paid in accordance w&#183;ith our standard payroll policies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Sign-On  Bonus: </font><font style="font-family:Arial;font-size:10pt;">&#32;Upon employment, you will receive $500,000 as a one-time cash bonus.  The bonus will be paid to you within two pay periods after your start date provided that you sign the enclosed Cash Sign-On Bonus Agreement, which describes the terms and conditions of the cash sign-on bonus.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Annual Bonus Plan:  </font><font style="font-family:Arial;font-size:10pt;">You will be eligible to participate in the Biogen Annual Bonus Plan, with a target bonus opportunity of 40% of your annual base salary.  Based upon your start date, your target bonus amount may be pro-rated.  Eligibility details and other terms of the Plan are included in the current year's Plan document, which will be made available upon your employment with the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">New Hire Long Term Incentive (LTI) Grant: </font><font style="font-family:Arial;font-size:10pt;">&#32;You will be granted Cash-Settled Performance Units (CSPU) in connection with the commencement of your employment.  The approximate grant date value of your CSPU award will be $400,000. The number of shares granted to you will be calculated by dividing the grant date value by the closing price of Biogen stock (NASDAQ) on the grant date, with the resulting number of shares rounded to the nearest five shares.  You will also be granted Market Stock Units (MSU) in connection with the commencement of your employment.  The approximate grant date value of your MSU award will be $400,000. The number of shares granted to you will be calculated by dividing the grant date value by the closing price of Biogen stock (NASDAQ) and the MSU accounting valuation factor effective at the time of grant, with the resulting number of shares rounded to the nearest five shares.  Your CSPU and MSU awards will be granted on the first trading day of the month following your start date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The actual terms of your CSPU and MSU awards will be communicated to you following the grant date.  Your grants will be awarded under the Biogen Inc. Amended and Restated 2008 Omnibus Equity Plan (the "Plan"). You are considered a "designated employee," as defined in the Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Plan and Prospectus are available to you on Biogen's benefits website at [website]. Please read these documents for information about your LTl grants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Future  Restricted Stock  Unit Grant:</font><font style="font-family:Arial;font-size:10pt;">&#32;Conditioned upon your receipt of an overall performance rating of "Solid" or its equivalent for the 2016 calendar year, the Chief Executive Officer (CEO) will grant you Restricted Stock Units (RSU) out of the CEO discretionary pool authorized by the Compensation and Management Development Committee.  The approximate grant date value of this RSU award will be $800,000. The number of shares granted to you will be </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">calculated by dividing the grant date value by the closing price of Biogen stock (NASDAQ) on the grant date. Your RSU award will be granted on the first trading day of the month following the date of the CEO approval of the RSU award from the discretionary pool.   Assuming your continued employment, your RSUs will vest and convert into shares of Biogen common stock over a three year period at the rate of one-third per year, beginning on the first anniversary of your grant date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The actual terms of your RSU award will be communicated to you following the grant date.  Your grants  will be awarded  under  the Plan.    The  Plan and  Prospectus  are  available  to  you on Biogen's benefits website at [website].  Please read these documents for information about your RSU grants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Relocation:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Biogen will provide relocation benefits to facilitate your move from Newtown, PA to the Cambridge, MA area.  The relocation benefits and payments will be provided to you after you sign   a   U.S.   Domestic   Relocation   Policy  Acknowledgement   and   Relocation   Repayment Agreement,  which  detail  the  terms  and  conditions  of  your  relocation  package,  and  will  be provided to you by our relocation service provider, Cartus Corporation.    Payments and reimbursements will be made in accordance  with Biogen's relocation policy, which is enclosed and to which you should refer for more details on your relocation benefits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Employee Benefits:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;Biogen offers a robust and highly competitive employee benefits program. As an employee, you will be able to choose from a menu of options through our flexible benefits program.   These benefits include a 401(k) savings plan; group health care, including medical, dental, prescription drug and vision coverage; life, dependent life and disability insurance; as well as flexible spending accounts for eligible medical and dependent care expenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">You are also entitled to up to 20 vacation days (160 hours) per year (pro-rated if you work part&#173; time). Additional benefit offerings include an Employee Stock Purchase Plan (ESPP) and work/life benefits such as a concierge service and access to subsidized back-up dependent care. Please visit Biogen's benefits website at [website]  (user ID = [user ID], password = [password]) to familiarize yourself with Biogen's complete benefit plan offerings.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Additional Executive Benefits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Supplemental Savings  Plan: </font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;You will be entitled to participate in Biogen's  Supplemental Savings Plan (SSP).  This plan allows you to make pre-tax deferrals of up to 80% of your base  salary  and  up  to 100%  of  your  Annual  Bonus  payment  and  certain  other  eligible incentive payments.   Your contributions  to this plan may be limited by your contributions towards other plans (e.g., 401(k), ESPP, medical, etc.).   You will be provided with SSP enrollment information upon your employment with the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Life  Insurance:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;You will be provided  life insurance coverage  equal to  three times your annual base salary, subject to meeting the medical standards stated in the group term life insurance policy for U.S. employees.   Biogen pays the premium for this insurance.  The IRS requires employers  to impute  the value of company-paid  life insurance  for coverage  over $50,000.  This imputed income will be displayed on your pay stub.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Severance:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;You will be entitled to severance benefits in accordance with the attached executive severance document, and should refer to the document for details regarding terms, conditions, eligibility and potential tax implications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Tax &amp; Financial Planning and Executive Physicals:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;&#32;You are eligible for annual reimbursement  of expenses  for qualified  services  such as  federal and  state  income  tax planning and/or preparation, financial and estate planning services, and the purchase of tax and/or  financial  planning  tools.    Additionally,  the  Company  will  reimburse  you  for  the expenses of an annual comprehensive  physical exam when coordinated by the Executive Health   Services  team   at   Mass.   General   Hospital   (MGH).      The   combined   annual reimbursement  you  are  eligible  to  receive  is  $5,500  per  calendar  year  (January  1 - December  31),  subject to  the guidelines  of the  Tax &amp; Financial Planning  and  Executive Physical Reimbursement Program.  The details of these benefits are available upon your employment with the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Stock Trading  Plan: </font><font style="font-family:Arial;font-size:10pt;">&#32;Upon employment with the Company, you will become subject to Biogen's Global Insider Trading Policy, a copy of which will be provided to you. The Biogen Global Insider Trading Policy sets forth guidelines designed to promote compliance with applicable federal and state securities laws that prohibit persons who are aware of material nonpublic information about the company from trading in securities of the company or providing material nonpublic information to other persons who may trade on the basis of that information.  Upon </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">your employment, you will be assigned, based on your job, to a specific trading group that will determine your obligations and restrictions under the policy, and you will be required to complete training on the policy.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">You are required to satisfy the following contingencies prior to employment at Biogen.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Pre-employment screening: </font><font style="font-family:Arial;font-size:10pt;">&#32;Employment at Biogen is contingent upon your successful completion  and  passing  of  both  a  background  check  and  drug  screen.    Biogen's background check includes verification of employment  history, educational  and professional licenses, degrees and/or credentials, a criminal records check, a Social Security Number search and verification of any other professional qualifications that your position responsibilities at Biogen may warrant.  Completion of your online Application for Employment authorizes Biogen to conduct these background checks.  If you have any questions about the background check, please contact your Biogen recruiter.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">New Employee Forms:</font><font style="font-family:Arial;font-size:10pt;">&#32;Upon receiving your signed offer letter and new hire paperwork, you will receive an email containing a link to a new hire form.   Please  complete this form  as  soon  as possible upon  receipt.   This form will allow us to  begin creating internal resources for you prior to your start date.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Authorization to Work  in the United  States:</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;The Federal government requires you to provide proper identification verifying your eligibility to work in the United States.  Please bring  your  </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">original</font><font style="font-family:Arial;font-size:10pt;">&#32;&#32;documents   necessary  to  complete  the  Employment   Eligibility Verification Form I-9 on your first day of employment.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If you will be working at one of our office  locations:</font><font style="font-family:Arial;font-size:10pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">Do not complete a Paper Form I-9.</font><font style="font-family:Arial;font-size:10pt;">&#32;Biogen, Inc. is an E-Verify employer.  You must complete Section 1 of your Form I-9 online  by going to [website] and enter code [code] to enter the system. You will enter Application Station, and then click "Sign Back In" to enter the I-9 system, using the username and password that you created for your background check. If you have forgotten your password, a reminder link is available. Please remember to use your Legal Name and provide your Social Security Number on your Form I-9. You will still need to bring your original identity and work authorization documents on your first day to our HR team to verify. Your Section 1 must be completed on or before your first day of employment with Biogen.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">If you are a field employee: </font><font style="font-family:Arial;font-size:10pt;">enclosed you will find notary instructions and a Form I-9 packet.  You are required to complete the entire Form I-9 of the I-9 packet within 3 days of your start at a Notary Public and mail your original as instructed in the packet.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Signed Proprietary Agreement: </font><font style="font-family:Arial;font-size:10pt;">In order to protect Biogen's  substantial investment in creating and maintaining its confidential and proprietary information, and to maintain goodwill with our customers, vendors and other business partners, you will be required to sign our 'Employee Proprietary Information and Inventions and Dispute Resolution Agreement' as a condition of employment.  A copy of the Agreement is enclosed with this letter for your reference.   Please sign and return this Agreement with your signed acceptance of our offer.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Paul, we are excited at the prospect of your joining Biogen.  To confirm your acceptance of this offer of employment, please sign and return this letter by December 18, 2015 and keep the other copy for your records. In addition, please review and complete the enclosed New Employee Checklist with actions required in order to begin your acceptance process.  We would anticipate your first day of employment to be February 8, 2016.  If you have any questions, please feel free to contact me.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Best Regards,</font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">/s/ Lisa DiPaolo</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Lisa DiPaolo</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">VP, HR Corporate Functions</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cc. John Cox</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">26579BR</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">I accept this offer of employment and acknowledge the contingencies of employment described above, including the at-will nature of my employment.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">ACCEPTED:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:40%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ Paul F. McKenzie</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Paul F. McKenzie</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">1/21/16</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Name (Print)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Signature Date</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>biib-2018331xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s791E5A382E645FC494B38D06188EA6D9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;24, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>biib-2018331xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s44447015C15A5C42AFA917F2EBBD862B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey D. Capello, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: April&#160;24, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>biib-2018331xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4A06E5AA9C1E55C0910966BFE16E1AF3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2018 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;24, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: April&#160;24, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>biib-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:D382F4A9C0D25C64BD89595292CCE92F,x:29e2d10c7f0d4f5589693609db24e99a-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20180331" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20180331.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_biib_AccountingStandardsUpdated201707Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">biib:AccountingStandardsUpdated201707Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">biib:RestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredTaxAssetDomain">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredTaxAssetDomain</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<biib:AdditionalPotentialPaymentstoNoncontrollingInterest contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-F02DAA3DFD37CB0D846120DAD42FCEDB" unitRef="usd">50000000</biib:AdditionalPotentialPaymentstoNoncontrollingInterest>
	<biib:Additionalreductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-87B2081636862619835A20DAB463118E" unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q1YTD" decimals="-5" id="Fact-5640251F69D55099A1498FA8A2F93B0B" unitRef="usd">-3500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-68CAB63E85335DDCB8DC844FE1132468" unitRef="usd">-2000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-5A08290FB6815954BDE80A7005799BCB" unitRef="usd">-1200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-AC75CAC030935047879963E9EB4BAD4D" unitRef="usd">-300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-74D9E4067D935FE2A871A06B7F3DD2C2" unitRef="usd">327000000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2018Q1" decimals="-5" id="Fact-80F2FB116B045A7AB90D81F5B18F34ED" unitRef="usd">77500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-BFBC5FE91F0253B09E8B8DAC82348CC6" unitRef="usd">327300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2018Q1" decimals="-5" id="Fact-CE0E757847A255B198E7512F1978764B" unitRef="usd">77200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2017Q4YTD" id="Fact-64FD8494FCD15C7A9CD15D109010321A">P17M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2018Q1YTD" id="Fact-54DD1130A55250479F94C106708D15BE">P7M</biib:AverageMaturityOfMarketableSecurities>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2018Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-C117A32650D25DFB8F99890CA7C3FDD2" unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2018Q1YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="2" id="Fact-72E92C6109A49FF9441CD947221472BF" unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Collaborationexpensesaccrual contextRef="FI2017Q4" decimals="-5" id="Fact-A3F614F91D81570D8ABA5CEB5679C9CF" unitRef="usd">183700000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2018Q1" decimals="-5" id="Fact-1ACC2FC87C0853B2AF776A20B128E5D5" unitRef="usd">176400000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q1YTD" decimals="-5" id="Fact-24EA0B0EF0B15B51B53A86478DCBA9D5" unitRef="usd">20800000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-E6EBAC6B931F5964A616DD0AA51589D0" unitRef="usd">20800000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1A6BC040C6375990B519200BDAE98CC6" unitRef="usd">42500000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2018Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-9EAE4ACEE190533A8C72F0F242CABC72" unitRef="usd">43800000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-DFD7BF480DB05E36887D12F0E3D6FA7E" unitRef="usd">1300000</biib:Collaborationprofitlosssharing>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C07D749F6EB45F1D89BC29CE596E86EC" unitRef="usd">806400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-CEA4F44FBAC4543A98DF43566AF0A1C9" unitRef="usd">641200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-C1757E64CC5950CBADE8A8A4EE8CEF10" unitRef="usd">159400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-828132E6B39F542A97297921CE9B91A6" unitRef="usd">5800000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2017Q4" decimals="-5" id="Fact-17AFDE8917345C0790684835F588AB70" unitRef="usd">532600000</biib:DuefromantiCD20therapeuticprograms>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2018Q1" decimals="-5" id="Fact-DF51AAC114E55649AC3BB388313C484C" unitRef="usd">553500000</biib:DuefromantiCD20therapeuticprograms>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2017Q1YTD" decimals="3" id="Fact-236C7C835678554889357FD82EEB2315" unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2018Q1YTD" decimals="3" id="Fact-887ED2A57B8F5657A154149E24E7F1F4" unitRef="number">0.000</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorOneMember" decimals="3" id="Fact-7E237EE0C5539EFD57921FF890BC1954" unitRef="number">0.368</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorTwoMember" decimals="3" id="Fact-61F97678DED4FC52C5671FF8B339D008" unitRef="number">0.193</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorOneMember" decimals="3" id="Fact-21FF7F08A21415EF1F781FF7F9918D69" unitRef="number">0.340</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_DistributorTwoMember" decimals="3" id="Fact-75887E6B00CBDA966A4B1FF84873AE3D" unitRef="number">0.159</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-427A6879AB1354CF9CB899F7763A9DE3" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="D2018Q2_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-F1710E0F30F869790B5EDF8874CB15CD" unitRef="usd">10000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="D2018Q2_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-5F18BD2E0CF714938799B108ECBD3B14" unitRef="usd">515000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="D2018Q2_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-B1D46D19739C3E5B72D4D92C5EDCF4BA" unitRef="usd">270000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="D2018Q2_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-6CFE68A2CD01C85D5701D92B9F95F39E" unitRef="usd">125000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" decimals="-5" id="Fact-83ECCFB3EA84CA6799661B10B93FC825" unitRef="usd">207000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2018Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-9D044D70176A5E34A2121B39B8EB7413">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2018Q1YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-8FE5C90B4D65577F9A3ED34370283C29">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2018Q1YTD" decimals="INF" id="Fact-AED76AE3007758EAA9C353AF4EE55C38" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-B7D80FCA92335B888C0E4A8B6433A368" unitRef="usd">925500000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-37C27456858C5ECE83A17C4EFB8619B3" unitRef="usd">906600000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2017Q4" decimals="-5" id="Fact-65005B34472B5D5BAEFC1E24E2D469B6" unitRef="usd">48300000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2018Q1" decimals="-5" id="Fact-14ED88717600565A86AF3CAF52D27FFC" unitRef="usd">28500000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="2" id="Fact-7CC9C4A884E3F73430DA20C2691EC41E" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-716C8F0518445C7C2A9220BF8735B4E0" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="2" id="Fact-B54004358264859410D620C1D0802FDB" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-F1E1DAC5E91A64662F4420BABB30D1FA" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q1YTD" decimals="-5" id="Fact-ED2CB31E4595552FA1621C4EADF16EA4" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2018Q1YTD" decimals="-5" id="Fact-74BF592EFE5051F0937FB8FE63988D12" unitRef="usd">200000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" id="Fact-C65E647D5582818C435B20C9EA876ED2">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q1YTD" decimals="-5" id="Fact-285B282B0E615E03A5C8D3E514CDC3EA" unitRef="usd">299700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-8690046AFE075067874651433A465B6E" unitRef="usd">227700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-2B0A31B879F45B449031F00994A85EBC" unitRef="usd">71700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-83ABCBD8E08354AB8D53D0F8DD354641" unitRef="usd">300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C8D2DC9789F25B34B68EA0883477CC29" unitRef="usd">412500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-1ACC32B63CF2594897EE314D8A6CCFC8" unitRef="usd">326400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-388391DB29515133A450DE95062CA197" unitRef="usd">77400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q1YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-AA9B3AB98BC8561EBBCB4D951A7BE546" unitRef="usd">8700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2018Q2_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-DA5C9370A8B3C2226858676D0681C477" unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2019Q1_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-2B44EE93A31832A7EF49676D76322769" unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-31E3395676675635B6B1C22B721F1EAB" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1645F632B138580288844730B07FA0C9" unitRef="usd">28500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DBA49C47EBF55243BF19560589EFE019" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C47A7475EBD35742BCC9C8E184758DDC" unitRef="usd">28500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1C05D898A62C5C818F73F1561ECEC55B" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DAC0035269A4596A8CA53F698B07E5EF" unitRef="usd">28300000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A1BA0C25FAF55C70876968A7D295176C" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BA4237C07AEE5477B946F9AE04C0DA2D" unitRef="usd">28300000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:Premiumonpurchaseofcommonstock contextRef="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="2" id="Fact-682BA1568C12328E3D51D9253CC7A8A0" unitRef="number">0.25</biib:Premiumonpurchaseofcommonstock>
	<biib:Purchaseofcommonstock contextRef="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-0B3C4B18625CCCB25BA4D922B438FB2B" unitRef="usd">500000000</biib:Purchaseofcommonstock>
	<biib:Reductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-FE4C298415372F4C9CDA20DA8CAACF25" unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2D9E95FFF7CD5A068E969F3EFBDBFD41" unitRef="usd">340600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-9A8E1637E88C6519C7EF1F5EB0B34F36" unitRef="usd">340600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2018Q1YTD" decimals="-5" id="Fact-097D33B4ADDE5380B85AC6D8B4B976A0" unitRef="usd">443200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-566D90A35F2F89C124DC1F5DBB88B9B1" unitRef="usd">443200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EDA53663BD555A3CB60295E7EE3FE2EC" unitRef="usd">45400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2018Q1YTD" decimals="-5" id="Fact-02772CB9E330513BB4DB8FD2E79BC4F9" unitRef="usd">47000000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareOfCoPromotionProfits contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-88ACFEEABA6DE093AED31F5EAC7879C4" unitRef="usd">323500000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-FB8719EAB3783EF1E7D01F5DB4F08421" unitRef="usd">349600000</biib:ShareOfCoPromotionProfits>
	<biib:StrategicInvestmentPortfolio contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-3BC78263110D5F91B2EC67F658245B9C" unitRef="usd">85800000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-11BEBA1D49415EAF8208D0E3573A9E7E" unitRef="usd">81600000</biib:StrategicInvestmentPortfolio>
	<biib:Termofcollaborationagreement contextRef="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" id="Fact-EB4A6036981E9D2FDEBCD9EB46E27680">P10Y</biib:Termofcollaborationagreement>
	<biib:Totalpaymenttoentercollaborationagreement contextRef="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-8" id="Fact-A1D1C68C9821EA59AD28D9292BEA2FD1" unitRef="usd">1000000000</biib:Totalpaymenttoentercollaborationagreement>
	<biib:TransitionTollTaxRepatriationTaxRate contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="INF" id="Fact-FCEA8BF17B82F6ADFB85679A0465EA03" unitRef="number">0.155</biib:TransitionTollTaxRepatriationTaxRate>
	<biib:TransitionTollTaxRepatriationTaxRate contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="INF" id="Fact-240EDB1A1017A2B18639679A4F2F94CA" unitRef="number">0.08</biib:TransitionTollTaxRepatriationTaxRate>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-C6052DBCF67B5E2A90B8DF076D873360" unitRef="usd">113000000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2018Q1" decimals="-5" id="Fact-EFC50A008DCA5DA18E75D6B0E329545E" unitRef="usd">-142000000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<dei:AmendmentFlag contextRef="FD2018Q1YTD" id="Fact-A334A30C35A955619310282DEF45BE47">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q1YTD" id="Fact-74BC5ADE6F885798B441C79F932E5DBC">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q1YTD" id="Fact-C57752F08F725032BADE2930E659195A">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q1YTD" id="Fact-43B5ADA725D85B1EA4740A5137FC0277">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q1YTD" id="Fact-B39F849541D35916B17794081E835673">2018-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q1YTD" id="Fact-DDE2233BADC454048AEF52970407A515">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q1YTD" id="Fact-0853E0B0694053F48E80B8DB2301C420">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1SharesOutstanding" decimals="0" id="Fact-28FF316B6226519D8FAA11F9DBF6E362" unitRef="shares">211007945</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2018Q1YTD" id="Fact-0230A21598D35C75BEB11E771E46BF74">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2018Q1YTD" id="Fact-B5AD25A4F2F7575F9701A8085C1C82C3">BIOGEN INC.</dei:EntityRegistrantName>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-517778EE9E2851F68D4C166FA8E85D77" unitRef="usd">83500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-EF7047D502EF5CF496638109307E8AF7" unitRef="usd">88700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-930E6F9BD5F3568CAA38BEC48188F766" unitRef="usd">1875600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-3F3BCC3F471B53219E818730C974B213" unitRef="usd">150900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-64CAB617847F510583779BDC395F2B93" unitRef="usd">2198700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-E2D0B6529B8F5260A9A68FF730BE45CF" unitRef="usd">564900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-A3884ABED03B5D3CA637EF7E12EB72CF" unitRef="usd">65500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F784C96B6DE05715BE7737EC5336A769" unitRef="usd">60400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-7AC6B4CD975C54059D39CB3CBB7055EB" unitRef="usd">1734900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-D410F3C4BA4155AFA56398B2D7C4F41D" unitRef="usd">110500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-4CC8FD2FF41E54C4B730BE491716F8B8" unitRef="usd">1971300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-A98F8E669B8F5391ADCD292AF1FC72A1" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q1_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7E7C6E1C06A555D6A8865B136DA9C06C" unitRef="usd">572200000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-5DB14728521B5A42BA65BA5E23EB3648" unitRef="usd">395500000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-8BA98610CC5251CE809FC1433986C4B8" unitRef="usd">345800000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-EF4865CA282F550187895E71F6634578" unitRef="usd">1787000000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-6ABE4758E229550488357C0BC53F1F27" unitRef="usd">1939200000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-968F24D3684554F58CA851C45BF6A811" unitRef="usd">206700000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-6D3CBC227680536EA3C264CEF450F5C8" unitRef="usd">194600000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-5" id="Fact-7E50D9B1D8ED55D8B48ED245D84AF50A" unitRef="usd">1559100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q1" decimals="-5" id="Fact-707E6388FFCB52DD90270AA1A75A0AA6" unitRef="usd">1631500000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-5" id="Fact-30F7B43640285E37A35DF33D82B4ED7B" unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-FBFB79A96B0D5383A8A26C3142483CF2" unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5F3E37164A355ACC99B161378F57B28A" unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-464E8814AF8E529D99E4A5107F29896F" unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-6E42BD4C1EEB5B71983E49D44B1AAED1" unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1" decimals="-5" id="Fact-5CEB1B2EC7195F98A1CD5EC2BA141434" unitRef="usd">-325200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-5C343538F01A52FC8000E0678047CC06" unitRef="usd">-32600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-676A1FB5F80C5921A2CBD04F260001FB" unitRef="usd">34000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-9F76C55853EE530CB2532DF19F80F673" unitRef="usd">-12400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-6119F0039ECF5CC68D435D47728D126D" unitRef="usd">-314200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-5" id="Fact-E18F2DCF4B69551780815CE8680EF5A9" unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8BB5A8A5BCD05E258D99C855EBCE069B" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-833E9B6CBF7C55EA986D4F44CF54E0C7" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-5103BF01B31E53D795CD038F927EA299" unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-A96621446D4A53449AE31587CA32CB26" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1" decimals="-5" id="Fact-C785D871ACAA5C5B9A9D358249164AAA" unitRef="usd">-303900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-7F930F2A83EC5A3FB33D8FAA468F49E0" unitRef="usd">-37300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B2189E28E4C55008BCAD97825F8C0F0D" unitRef="usd">-133500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-05F213B7D19956558A6512FE830E2EAF" unitRef="usd">-2300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-353EDFA0255853AC828849DD77C15827" unitRef="usd">-130800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate" decimals="-5" id="Fact-6E69C6B329EE4E14B30DD8C6507CCBCF" unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-5C3C99587E4973866669D8C64BA680B6" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-023ABA490C73EA78CA58D8C64994C146" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-3EBB677AC6E9F80DA3F3D8C646EAA3BF" unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-3A9D254E6B87BD0943DED8C64E40A559" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-5" id="Fact-48A927A748DA5D54B2DD0D2C003CA0EF" unitRef="usd">97800000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q1" decimals="-5" id="Fact-B3D94763611D565197298D4E4768EE11" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-A20597E1031A5F8BB0832DFD85D15EB2" unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-089128B743245195A9F24A3D7AF1C817" unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-94095377ABFA5DE4835B8B8F6EA74352" unitRef="usd">9600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-C8307A678E92AA1AA396679476E1B1C0" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-5E60EF2B856D1CD50B2F679474FD670F" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-CE807B91988F5F0C9BDA75E937487C3F" unitRef="usd">26900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-CB05317E6BF054C99230A7CB20F66422" unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-A28A9DDDC6CB52F3B7656CDF8C1A1D09" unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-C2B1EDAC9B7A5AB68716A0C68EA0D754" unitRef="usd">18700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-4AB727FC9B725A729BC0F11432D4B244" unitRef="usd">29400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-55A4A21AE07558448C9819A93F5BA74E" unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-7383BD29499152A1ACAF0881F6A09896" unitRef="usd">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-9436822781565A71A845955E6C2061E9" unitRef="usd">6100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-812083D43FA6A52375CC679418763244" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-9E8C4FD3912E224B5AA26793A308B68C" unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-95D7BF8845F55E4CABD4171BDD7E34C3" unitRef="usd">36100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-146661DF06F6561CB8EA0D91205E0A11" unitRef="usd">-800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-77D35D5882575533947568E3BBC74C6C" unitRef="usd">39400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-C840B3E52EB65D69A0F4B816255B0006" unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-EBEFBDFD5A1E5CD2886116A6A13BF4BC" unitRef="usd">28500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B7043D6564CB5EC2A20D756366984328" unitRef="usd">48100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-21FFFB7452EF590CB44976804DECAA94" unitRef="usd">50400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-7126014934FD5936BD07387AC3DDB192" unitRef="usd">448500000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q1YTD" decimals="-5" id="Fact-264D37637F3E506E885639BCC0CB0108" unitRef="usd">103900000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2018Q1YTD" decimals="-6" id="Fact-EE6874B95F965BF0BEED441DC2D4A68C" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-5" id="Fact-1B26C28CDBA55288ABCB355F8B0555F6" unitRef="usd">23652600000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q1" decimals="-5" id="Fact-41B45B34730D5C4BAC59090DE3B34329" unitRef="usd">26090100000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-B9E3EF816ACA50418214B8E7195B4C2C" unitRef="usd">7873300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-FA4CB6A91BBE5D00ABDB9C59C2294300" unitRef="usd">10195400000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-138AF254B415536EA9208EEEBDF62EDB" unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-500C8E57ACAA5A78BAE0C3897E423276" unitRef="usd">6433100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A6F3720CE6A45555A698D49C321A22E6" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FB012E97B0E8508BA42DED462CE4C433" unitRef="usd">6444900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6B6D0C7E9BF75A5A827E305C4536176E" unitRef="usd">22800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-969AB1750C0C5B6DB8108F44A1747611" unitRef="usd">6813400000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CDDBB38C9ED95A99A1F330214EE13399" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B1844A7A61935A48A5337AAF7A172F23" unitRef="usd">6836200000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-5" id="Fact-27DCE0F6338C52DBA7DDADD673616C7F" unitRef="usd">5173000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q1" decimals="-5" id="Fact-DEDD820647735C63B4446590FE53463F" unitRef="usd">3011000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4" decimals="-5" id="Fact-4CEBC423289858C9AA35DCEA81CDBA0B" unitRef="usd">5172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-55937AD750E15F4DA30CC3B98E5ACF38" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A8946CBA07AB563381F632F98424A4A7" unitRef="usd">643400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C31C82E399FF5CECBABAF498DD816735" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-946829A2266751168E604919B0FB8473" unitRef="usd">643400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B0B241B3217A5132B46064534B58C50B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3F1EEE9F4A925A4D88421953FB000F69" unitRef="usd">2609800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-432D3BFEB07050FA901F46CE3F63C8E8" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8F7B2A13982358B6A3263A6109F70849" unitRef="usd">2609800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-25B8DF61AFF55A5393D1F5D0AC468444" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C75D6B5850FE5218BAD8073B2230BA2B" unitRef="usd">1919300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8BFA25B9F6185D1C9B8750D1BC64AB8E" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D0B3B50D8DCA50E5A518C6F7A99847A7" unitRef="usd">1919300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-76BCDBD39C115E0F8B58D1814F07FC9E" unitRef="usd">1039300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-F77CBE6020385B87A5FC077F32999DB6" unitRef="usd">1570500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-B9B94A9A176255B99F495F99716294B4" unitRef="usd">1075100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-2A4405570E77555CB5067E4FE99A23D4" unitRef="usd">844200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-112E770A7646544B9A75105A3EAAD531" unitRef="usd">800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-EC23808DE89C56B8AF050321E0CD8A56" unitRef="usd">642600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-B3D029C258DB5F4798442284572FC5A9" unitRef="usd">11800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1" decimals="-5" id="Fact-35A5689E243753E6B56A4886CD3E4C73" unitRef="usd">3008200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-46626DBA80EE55EAAB510AC71D4E0C61" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-205827F96E665463B2B593865715D3C2" unitRef="usd">307100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7F85766493035314AE5CD89BDC033A6B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-765F7CF8283C5131B12A9F7B88BEC97E" unitRef="usd">307100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FB1DD2CB2848587BB2910B662A9317BE" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6EAF5F07183058C68D60654A6A125B33" unitRef="usd">1557900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2FA5A3029C0756BBA4BAE21F681D7D64" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-01303D84D8695D7B9C94ADB21F356397" unitRef="usd">1557900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A20A8201BCAF5155A016BF2AF4B9911F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DD42A41D8985506B8EDC28CEEEC43D3C" unitRef="usd">1143200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C3D34B24CA2E5BCFA81054D659352936" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4ACE0122BF0A50028F17CF53589407DD" unitRef="usd">1143200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-057B6C93ED975430B9F464EE15E5E9C2" unitRef="usd">912900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-FE47B497C49351EB8E684BC221D7A04A" unitRef="usd">645000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-511E0C93D27654E283C18B2A770BF567" unitRef="usd">895000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9AF16BDB7C835A8F85CBD5D258DE7635" unitRef="usd">248200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-41DEC73A0D9E543A93C823341BDFF733" unitRef="usd">100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-33C96D5174AF5548ADA6C05326A2EA75" unitRef="usd">307000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-421E87F4ABBF58119EBAA7E4B00CCE3B" unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-69EF0C0138BE54BC9DF3B819A3697927" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-6162CB867FD058F2B0E0D761A9DB05CF" unitRef="usd">900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-2EDAACA168565B5EBC4C3CA75E163174" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-EF023AAD22635018B9FDD12FE750D16F" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-C328DFB798635CC3915247EA1AC43FB5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-5DC7449B13525F7FA8D414DACDBAAC2A" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-11F33683AD055AF1807E7E73D2604642" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1" decimals="-5" id="Fact-A1BCEAB607F35761832072D32F9170E7" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-140CBF54DACB5C709CC50997AAF7A5B2" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-AB337D55EC475E1E80CBFCB86D4F5C60" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-D5FB2D3BD57959C1937699DDCD5243F4" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-DE56396D25E85C4D964969968CA4DC36" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-E5758FC2EBC854838C920CFCF28EFC62" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-4FA22E5F939759D6920E3A220FECDFA3" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-20882DF3C38C5A98B6BE1A0481CF486E" unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-8F7F8AEA95A75A8489D97CA191320B7B" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-86ADE2DE817F5A79B3C6B9259A19AAE9" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-4100F0F1E05654E995FB6CCE5622A145" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-69CAF87CC1415390B3F1093C22202F43" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0E99D732C2865DF5B667CF642F193717" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-BC08C1ED20675AA38BA5C415EDD42283" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-EE6387C2FB155BB3913157C34CA02F25" unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1" decimals="-5" id="Fact-EEE3B093114E5DABBD8600799011A6CD" unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-5A72F8CBF9C159A18C91EE36A501DD7D" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-3DE97D9EBCE452BE8D5905E8CA6A7213" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-3DD5D8A6E22F5719B9B8E6E26AAECA80" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-74147A0AFE1E518E98082862C4EF46F7" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-134B12CA029F5FF792E563BC6F82DED0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-D761F8AD7F7E58D9B40B6702B5FD3E5C" unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-595ED9EDF2F052DDA771E85AF59331D0" unitRef="usd">5173000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-A8CF9DC9CE7354259C5FFD332BF980FC" unitRef="usd">1039500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-71A597CA8A4A537FB964DF15DE963F6B" unitRef="usd">1569600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-EDCD2BBA3BA15C0B89B71B642509B703" unitRef="usd">1075700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-EC1AEAF4200E52F99F9BB039973F2700" unitRef="usd">845100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-E0027870C76B51448D6211C0C7F111A4" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-20A56FA22EBD5C609117FD8562B975D5" unitRef="usd">642300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-36AD0BA4D79C5B4EBC3ED88BA182FB93" unitRef="usd">14400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1" decimals="-5" id="Fact-08EE43DC39DE5EECB309F29BB37AE8BD" unitRef="usd">3011000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-D5071B80210250C3AC73EE6521CEA614" unitRef="usd">913700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-F9DE0A7B6DA55E078C4779A44AFE0BC6" unitRef="usd">645400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-1BA8164C85F85D71908A379A2C91D5B0" unitRef="usd">895500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-EC112237B9925071836427523521A3A5" unitRef="usd">248400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-994582E82BCE5D46B37F032A9802D2F3" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q1_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-8B858BE8F9A952729142613FABFACEE7" unitRef="usd">307900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-DAB3E25D3FFB56FCABB369D22E61D96B" unitRef="usd">2115200000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-438857367A5A5959AE2F081BCE32D3A8" unitRef="usd">1808000000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-FA969318A0A15121AC06EA1AE7DED02A" unitRef="usd">2730000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2018Q1" decimals="-5" id="Fact-BEB16DC2606457A2B485AF0CAC074898" unitRef="usd">1124200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-6932BEDD33FD56F7A0FD631D9B7EC16F" unitRef="usd">2730000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2018Q1" decimals="-5" id="Fact-68BE6E862D6D50979CDEF167E1D2492D" unitRef="usd">1123000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-E2082CF9373350D6A7509950DF44AC84" unitRef="usd">2116000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2018Q1" decimals="-5" id="Fact-3188F9D873C05DCAB6A4427070ED30E8" unitRef="usd">1809300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-CAB9045C300D543DB32F7585534D851B" unitRef="usd">2115200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2018Q1" decimals="-5" id="Fact-1A1C3FE5107350F5ADAA0EA30C61BD12" unitRef="usd">1808000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2017Q1YTD" decimals="-5" id="Fact-52A334DFFDDB53B098D4007356CFFC05" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2018Q1YTD" decimals="-5" id="Fact-63FC046C20EE5A5F8585FE22B750D82D" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2017Q1YTD" decimals="-5" id="Fact-4E01971EE66E542ABAA462EB7DF79344" unitRef="usd">1900000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2018Q1YTD" decimals="-5" id="Fact-8CB93ADD765A5E619649088064E4081D" unitRef="usd">9400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-D12D6C59DF4C5BCFBEB9781ADC628FE3" unitRef="usd">3057300000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-B42CE9EE464D551B8752CD5A1DCC8D53" unitRef="usd">1200200000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4FE6EC7413FE5DFC9EC8E75D90E3DC22" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9C0A416CD97A56C19E178DA3894C75B1" unitRef="usd">470900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AFEADD26C4645D1586808CE08951C508" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0A44BB8F2140518CBE770848EA985F2F" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E91EDC7B9D9B557CACC9585FA690E89A" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-27836CD3F8435F4492F29D80638C87B3" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-83DB6017F89A53CC9A0E5E39A730D5A9" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6E426A7E494B5C4D88AE4B2B8E177F5C" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E40C2AEECF6F5CDBB0BCF77533025E6A" unitRef="usd">498000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B279A9AB8B9553BC814C52DAB69275B6" unitRef="usd">498000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-9E4427BA71795790A8D9E2657A861196" unitRef="usd">844600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-A860FD9B78995C22B15E737E0E754D8B" unitRef="usd">524300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-A55FA73A6C4A5A2CA15B9EC0CF1A4EA1" unitRef="usd">279000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-2E4FB7DFF5595120BCE7A86D88D59F51" unitRef="usd">273700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-B3538DC350C15DD3929A73E82CEA9E90" unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q1" decimals="-5" id="Fact-1E54C704802E5AA984351BC6F3D70C73" unitRef="usd">924000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-00CD2B26A21E5C5185F8B9F28C677B05" unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="-5" id="Fact-B35234279E9A5E56A687DCD523E78675" unitRef="usd">4108000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9E3E0D0ACEBC5FB791ECBC134CCD844D" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CBEF294CAAF353BAAAB41BAF133120CF" unitRef="usd">1229400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6AD92BF0312A5038B1CDB3199E0F0ACD" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CFC5E2582C8954179E39F155EB986320" unitRef="usd">1229400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6DC619E4EBC955B388F1D97B8C31A000" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BE7B6348D85952599447D5A1EF8F7D92" unitRef="usd">3773700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-32112C392C5254799A0CDEA817881550" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A182ECD85CED59B2BF5B3B52BEF35314" unitRef="usd">3773700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B850524C428C50DF997DA5309C88A7E1" unitRef="usd">-1410400000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2018Q1YTD" decimals="-5" id="Fact-84D4A6C17CED5C18A288768F7379CEEF" unitRef="usd">2535100000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-0F01C11CCF11506FAA3F639A36EF5B5E" unitRef="usd">1229400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-B9CC380A85585D9CA7CBA9C8837593B0" unitRef="usd">30500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-1AD7132EC9505C21AD8E0ABA23E1341E" unitRef="usd">247300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-98B71B8DB5FA513DAE8F2549BE04D1BB" unitRef="usd">948000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-3EAEC1A402A55207946691497D4B9811" unitRef="usd">3600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q1" decimals="-5" id="Fact-8FD20308048B578CA062857A2774A879" unitRef="usd">3773700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-3554E678EF77590281637021D16B75E6" unitRef="usd">51500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-F90D5787229F5B9B800A555B6FB83A0A" unitRef="usd">161000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-7C825777F6CD523DBC0F4649478F7EA7" unitRef="usd">3561200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q1_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-6916E9CECA7D5469A59980C6AACDBC81" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-95242A48D6015689B71A133EBF139A41" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q1" id="Fact-F51ECBA5566255629E8C470FBE114641" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-BDEF9F8F859A57D3A88A8E8E8872BA18" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-932E2C3D79BA59F1A9482083864601C8" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-12AEF8E52DE6599D86ABC0E21C879C06" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q1" decimals="-5" id="Fact-955F5E67CBAC51CBA199E95095E3127E" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-D4B6BEB318805BA3BB84B112865DC1D8" unitRef="usd">742300000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-87DAB6E785D95B4CBD2A312045E1E132" unitRef="usd">1185900000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-65A57E519DEB505D841CDE6FAA2C2E8C" unitRef="usd">100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C36CAE84EAD55657A695DE8F0382B14A" unitRef="usd">1700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-AD4E2F6FAB69589581EB2E1FFDF868B8" unitRef="usd">742200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B0E86D8CD9925DD986AB9F867F560710" unitRef="usd">1184200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-8" id="Fact-1F537BC7D1F9502788E7E360B75A25BD" unitRef="usd">1200000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2018Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-8" id="Fact-ABD21C4C2A29556395979BFDFA7AE307" unitRef="usd">1300000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-397A5FBAB69D5AA190FBC1A0681FD0FA" unitRef="usd">159700000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-75E800E893295B60AF917785F666B181" unitRef="usd">178200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3870D7023256596BBD5CABC685E85486" unitRef="usd">384600000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3DCF156D28EE5EE29A9D30E83FA7F6E0" unitRef="usd">446000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-B0018E8BEF5B1642F615676F3049805D" unitRef="usd">2400000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q1YTD" decimals="-5" id="Fact-50212A619F9353D0A23EA52B75D6F83B" unitRef="usd">1786000000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E95DE53AC21852F48E1CE90949EF2813" unitRef="usd">1596400000</us-gaap:CostsAndExpenses>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" decimals="-5" id="Fact-4DABEF963CB903B26470D8C51261D186" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember" decimals="-8" id="Fact-7B0616FAD2052C11E3A7D8A9CE1630C6" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B8AFA7FC2C29CAD73441D8C19ABAAEAD" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember" decimals="-8" id="Fact-626F973ACF4CAF640115E4CBEBE00870" unitRef="usd">1500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember" decimals="-8" id="Fact-C4DC3DD9CB62B490C06C679D2B22633D" unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredTaxAssetDomain" decimals="-8" id="Fact-9FCCAEF848BB75BEAF82E4CB5DC22D34" unitRef="usd">2000000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember" decimals="-8" id="Fact-756BDC500F4386C4C1DA679D8A2CE82B" unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-E9961EB8243F15DABC4ED8C4816B7684" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-42FFDF59F5026E8C9875D8C417D0A8B3" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-1FF7C42AD50633072C2BD8C4CDE336C0" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:DebtCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-4BEB8ABCB9D451279384DF2AF6475C7E" unitRef="usd">3200000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-5E716B719BD05923B2D99B0E7009FCB2" unitRef="usd">3300000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-5E73C0499D6D57B1B76DA5279B62AB07" unitRef="usd">6483300000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2018Q1" decimals="-5" id="Fact-DAEAA012DE425DAF8A9CD01F609D8961" unitRef="usd">6188300000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-D5714E2EC27554E592201092A20EC8B1" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-827F7DDC03775958B3A0010C41597241" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-7EE2B5B7D3AF5F8F9BD528379EE9F384" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-DB8C3EA32883570A8361F98326FF03E0" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="-5" id="Fact-4963422F73F4568DB83382A997E838F7" unitRef="usd">76100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="-5" id="Fact-335D5EA33D30500BAA4D6BCC7B7C7259" unitRef="usd">53100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-BDE77731357C7BB7B732D89F3BD8D2B3" unitRef="usd">595900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-3967C61658FA8E896E8DD89F157B7B35" unitRef="usd">2277400000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesGrossCurrent contextRef="FI2018Q1_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-DFCB1F8998F8CF87041E6799745E12D1" unitRef="usd">85000000</us-gaap:DeferredTaxLiabilitiesGrossCurrent>
	<us-gaap:DeferredTaxLiabilitiesGrossNoncurrent contextRef="FI2018Q1_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-E8BC977252CFDCC2007BF3BADB73ECA0" unitRef="usd">989600000</us-gaap:DeferredTaxLiabilitiesGrossNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-E021B0558D315097BBC448BC95A21FC4" unitRef="usd">122600000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-4A05A0E59C9152959A7D9502ACB733D2" unitRef="usd">1331100000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q1YTD" decimals="-5" id="Fact-62C374DC28815B9BBF7409B227116DB5" unitRef="usd">512000000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q1YTD" decimals="-5" id="Fact-D646751C9A48509FB3C76757890A5BBE" unitRef="usd">168900000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-35FF3931BE445090A42DAF44D1B61486" unitRef="usd">700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-DF0DD4670737515A90CF63D10D716D4D" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8D6C191CDB645A25AA1F94C928305C81" unitRef="usd">200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F5B5313F3E2867EE9E8120476117F4CC" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9E0ED44C049452948DF434A0FFCBEC4D" unitRef="usd">1400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8553B4E9DB7B530AB8F910D739FA9D7F" unitRef="usd">84700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-AA5D75A629B15DAF9E05EC7BDAB80730" unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6DC9D2C705F57BBD95CE204874355C0F" unitRef="usd">23600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-555522A2BA4955E1B150C844C9F32613" unitRef="usd">114100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-57E12335F8175315BC85DCBCE913838E" unitRef="usd">1400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F6F6304995BE5411B9BD93C40524ECF5" unitRef="usd">32200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-5BFA7DC7520DBAAD27EC2042D941EAF3" unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-F60A16563C9C3F43B6572041ED036C20" unitRef="usd">6700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-6DBD5814304A5451857D28B372D4D9A6" unitRef="usd">1300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-62B4FBF01DF95E77BD98983CB9D2D785" unitRef="usd">-32900000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-95D6774A850FE5897AFA2043FB65E3F2" unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-52D15BC3EF06623381842043A7DC5DBD" unitRef="usd">4000000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-A409A928274B59188CCB32B0EC733B3C" unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-D889847584A553268A815E9727B2D622" unitRef="usd">-900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2018Q1YTD" id="Fact-744178999990B2091AE820393C65748B">P12M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-DA72B126F38C54F08EA4660FF2880089">P21M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2018Q1YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-1EABFB6D87AD5370BA9B860109A3B100">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q1YTD" decimals="2" id="Fact-68C8D76DB7D1526EBB7E74CB3AED82AC" unitRef="usdPerShare">3.47</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q1YTD" decimals="2" id="Fact-B8F78E3D98895B03818F1E5750EC7A17" unitRef="usdPerShare">5.55</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q1YTD" decimals="2" id="Fact-2FA7DE00BE795ED691CE334DC0161A79" unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q1YTD" decimals="2" id="Fact-236EED96B52A535C91BD383953DEF13B" unitRef="usdPerShare">5.54</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q1YTD" decimals="-5" id="Fact-C9B59827C2BF5572A39479D95DA3FCCC" unitRef="usd">7900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q1YTD" decimals="-5" id="Fact-7854DD0C02F35A33B19DDC4BCF761653" unitRef="usd">-900000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q1YTD" decimals="3" id="Fact-0A89D48D7BD05700834C49310FB3983B" unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q1YTD" decimals="3" id="Fact-E8F91C6F0439577DAE833E9829740109" unitRef="number">0.216</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q1YTD" decimals="INF" id="Fact-912D31EEDAEC5B9CA1905CEE34C7EB5A" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="2" id="Fact-837E9527A028FA4D7A4F679BBB4B782C" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q1YTD" decimals="3" id="Fact-69A7C3E8872B5669BC9D09BFBBA41933" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q1YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="2" id="Fact-D594F6C89908AAE2D5E5679C591C1817" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q1YTD" decimals="3" id="Fact-3043372FF8B9542D99177C0B9FB881F2" unitRef="number">-0.112</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2018Q1YTD" decimals="3" id="Fact-49CD8FEB213458759FC2FC8BADC89BB3" unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2017Q1YTD" decimals="3" id="Fact-9BB3420D4BAB5028910FD86E5AD1243E" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2018Q1YTD" decimals="3" id="Fact-C0D579DB6CF75427A0AD123C7573DB09" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2017Q1YTD" decimals="3" id="Fact-34312A852B275AED94C11B93EF6AB059" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2018Q1YTD" decimals="3" id="Fact-C17F3EAF19DD573CAF65BE08FA865048" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q1YTD" decimals="3" id="Fact-63F5E975609350198DE27861111FCD57" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2018Q1YTD" decimals="3" id="Fact-0FA3B59A47695DBB804459AE3CFF03F3" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q1YTD" decimals="3" id="Fact-31196ACAD8A5541684A3D2076A6A69E5" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q1YTD" decimals="3" id="Fact-40084D6039755812B9F088BFF57B7D13" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q1YTD" decimals="3" id="Fact-41748A87091857F69A2CC61AC8529D22" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2018Q1YTD" decimals="3" id="Fact-6E9EBB4A333554B685EB5BA5E0E3398C" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-BDF07339A9BF5297874685759944A398" unitRef="usd">297700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-0BE78ED8D7715706A891C5C39E19CF08" unitRef="usd">186700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2017Q1YTD" decimals="-5" id="Fact-A2F4D06472135BF6BF12A9D852311202" unitRef="usd">2700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2018Q1YTD" decimals="-5" id="Fact-D63467EF5F145A6CB026A3D27BA0CE97" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-DA4CEFDF6C515D99BCBE064727732860" unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3CCD4D205E3F52599B43021515CBCD89" unitRef="usd">7600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2018Q1_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-4F218FA146C15B7AA4C673D22E0C25C3" unitRef="number">0.054</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q1YTD" decimals="-5" id="Fact-7AE57DB8770E54939F0B374982295B3D" unitRef="usd">-10000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q1YTD" decimals="-5" id="Fact-946274D0ACF75EB3925BB87E5C57A9D6" unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q1YTD" decimals="-5" id="Fact-58B2391896545FB594DFB3211DAA5EEB" unitRef="usd">6700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q1YTD" decimals="-5" id="Fact-11391ECB4C0A505DBBA10B30A06AC702" unitRef="usd">20000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2018Q1YTD" id="Fact-EB284BD7A0225B9892AFCAD7BECBE426">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-6724479BA67C5D72AAD90864792BB172">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-DABA1A73439757A19B03AFB5D6AFB04F">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-3497EFC954835DACB19AFBD881357741">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-25DF559A20DB5CA59555EA68CCE0F538">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-1322496674045A1EA8701E66F8AB6516">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-1E764C026EA755EE85AD053C2E8334EE">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4" decimals="-5" id="Fact-994C4B5C8DD25EF09BE605AA27AC6E1E" unitRef="usd">4385000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-1E0E0D9F23105CA08384F9C185B247F8" unitRef="usd">1160400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-3B9A1A762D6C5DAF82858B7ADE497ECB" unitRef="usd">535600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-E75E8E57D2CE58B081A8C276233C5E80" unitRef="usd">2689000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-787DCA0BD01B531FB95AF88F521DA8B6" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-DD244807B13750E2B1E04A0E0E514884" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q1" decimals="-5" id="Fact-348D4EB2AE3958BFB63105DE6F6A7D3F" unitRef="usd">4489200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-E9F472D0A4015FD28ACA6C0881ACAF46" unitRef="usd">1250900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-44F4BFA203D254C79E5AB4C8B6F27811" unitRef="usd">537800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-8CF28C620C1C5A4995F99CCCA2FF3C9C" unitRef="usd">2700500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-CC3582C6A13F556288DA84F84117789E" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-BF8C7C16BF9C58869001C39FC4D62005" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2018Q1" decimals="-5" id="Fact-909E55C2FB805F3CBAF163F1B4706619" unitRef="usd">402600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2018Q1" decimals="-5" id="Fact-57CE208057FA5CAFB737ED05BC79ED07" unitRef="usd">330700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2018Q1" decimals="-5" id="Fact-F6856030BB0C57AFB01BAB5D6C92D234" unitRef="usd">211200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2018Q1" decimals="-5" id="Fact-9E0B66DB111C5A18AD640089E5FD9133" unitRef="usd">242200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2018Q1" decimals="-5" id="Fact-69912BB0E6F45DAC9B2509CBCB7DF026" unitRef="usd">255000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2018Q1" decimals="-5" id="Fact-517D40DF010D5DFBAC9055DB48856E1C" unitRef="usd">379500000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-7F357EB535995A9FBAE566235D45C4A9" unitRef="usd">3971400000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-2C947248BD3C572FBF8604682FF43DE4" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-5409AB6587915BB7981D2444D02C7E15" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-28C6A36393D3573EA903B9550237178B" unitRef="usd">3974700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-2E86981FFE47579BB849D460D839B846" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-D20767D9E9A05130A3C14F4653208AAB" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-2B306C9E7DC85C43A11D926F29143735" unitRef="usd">2811000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-F27DA727EA7C5E0FBAC72E3519E2D712" unitRef="usd">7700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-8F2409DA14025676AC6A998244F1C71E" unitRef="usd">316300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q1_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-7693CC0AAE985C94A29D206CC9515C8D" unitRef="usd">2178400000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-483D6E06053F5A01839F75BC44886189" unitRef="usd">2723800000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-2F659CB8C77BF8D96150D4F34B5A83EF" unitRef="usd">322500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-A44487E965705DCA9580D8B143864A92" unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-6F554584B53555FFA55B3D0D554138B1" unitRef="usd">304800000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-210D9017C324588ABCC6B03FD2B92450" unitRef="usd">298200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-49BBC8886003584FA128C730822A905F" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9F7AC6DE3BDB50EBAD6CC230F3960E36" unitRef="usd">2700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E4467B8216EB5F15BA17A08F22A19A1E" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FCA52883D4025DC5A202579CA12EB82B" unitRef="usd">2700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CD7FCC14EDEC53F48F674166B7A63781" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-188057298CC95F15A7B45CF8799C616B" unitRef="usd">3200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EF895E5E4BC353C1BA905C2CD0DF8495" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C49470D7D49A5E0790E745FC46B5E40A" unitRef="usd">3200000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-51F1180CEF895625982D8B705F4A14FD" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EB70BEB0160E5ED3BF6E23E46E1C4A53" unitRef="usd">111300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-65BADACFFF355969A6362D6F69D472C9" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A55C9AE0BB7453EFAF9518A52791AFAC" unitRef="usd">111300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D771A9B092D951CD814E2618BC8A2DE3" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E559F890AFCF5C339CBB98651F32B3F6" unitRef="usd">147700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ACCDF496504058ADAB8D827E97D25BD8" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4BCD7D6B9AC85E1FBE9C3D8AFCAACE2B" unitRef="usd">147700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-09EDCC1E3AC7598FAC19C04048363FF3" unitRef="usd">4000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1130A7610A3D544F8A8A1F55AEA429A8" unitRef="usd">-1000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-C863B098900C5E1798C17568109AC346" unitRef="usd">-1600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B67CB31A38785F1CBB143AC21D81FC30" unitRef="usd">5600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-118B32625CE65A5FBB812A71EE6C3A99" unitRef="usd">2400000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C39EF3F7219F5BED9CE9D7F3B2575BFD" unitRef="usd">-14400000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-5" id="Fact-EA23CFEB51115642AC2C13F8AFFDC876" unitRef="usd">4632500000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q1" decimals="-5" id="Fact-E77FE4B403A9534680EF0362206A778F" unitRef="usd">4907800000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2018Q1YTD" decimals="-5" id="Fact-57062ACFF5615F8286882DCABE65A207" unitRef="usd">270500000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2018Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-7C6BD145B4D45AF5A823C021B8185499" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2018Q1" decimals="-6" id="Fact-AD6D5F21E87F509291E68865E9E43D31" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2018Q1YTD" decimals="-5" id="Fact-9513D636ADCF510195723152108311C0" unitRef="usd">4800000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-1C8F6E1506D153CD99ACB0231AB4EEBD" unitRef="usd">986700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-7EDBF006D5AA52E7A6486525897F7145" unitRef="usd">1493700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0B351F6B2C945B9FA75E3514682780E2" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2018Q1YTD" decimals="-5" id="Fact-B3EF9A6A382D5047A3D3D91074C18D51" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2018Q1_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-6" id="Fact-1FE11786F6EF580ABB7E4682519CFD71" unitRef="usd">65000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD" decimals="-5" id="Fact-05270480A3EC51BAB01CE9FB829F9A46" unitRef="usd">239200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-F59746FB2EE456C7B91BEA0B4B916608" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-CE7EA5AA8A6F518A87F13F34F4F412DA" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-8" id="Fact-BCBE4A53E5412FEAFA9E6796DB3CAAB2" unitRef="usd">1200000000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD" decimals="-5" id="Fact-9C9945A3B9C055D9A1940BEF134BC287" unitRef="usd">322500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-ECD32CE12AD15D29B49FBD04289F0C81" unitRef="usd">29500000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-68C0A4D525395FF9A54C5D2A9C0527A5" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6A676AB5FB1656F68F13790B47178164" unitRef="usd">1600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-C1F682E56D0FEA20A6546796387237B8" unitRef="usd">184000000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q1YTD" decimals="-5" id="Fact-3080A79D476E58A1824BA2984A3DE3D4" unitRef="usd">195700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q1YTD" decimals="-5" id="Fact-82C8FBD9BA97590F988DCD0D29E892A2" unitRef="usd">134000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EEC7E427847953A390382E493CADE923" unitRef="usd">-195100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2018Q1YTD" decimals="-5" id="Fact-3F0198CDDE7C573996375E8317214352" unitRef="usd">257600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-8516CCA0A6555E828A179A524BA1834D" unitRef="usd">-684200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-54E2425B428C5AF9B4F0A7EB7E51E920" unitRef="usd">-121800000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5BACDA8B346C58AC8FB80E4127554FC2" unitRef="usd">46200000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q1YTD" decimals="-5" id="Fact-46708FD25519541A8C615D1AC72AFF52" unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EE3E37DC159450A9AB37A37079A37C24" unitRef="usd">34300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2018Q1YTD" decimals="-5" id="Fact-4D7B3A62C18C568082B334C57F5FB960" unitRef="usd">20000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-4FA253670E4A53AEB4F44322DAA1F2D2" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-E60BAABAF64BEA368557D8D7C4CF1E84" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-61BA37021A00588BA91E9BE05D498847" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4D698D7492FF5ABBBA75FF0C20E8AF92" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-E6B36C2ECE225A38BD071A509BC7A009" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-81F26EA5C8CD77872A25D8D72D4F77AC" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-25BACC14176D5E2AAE2A6C19E9DF117C" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-A867394B231757558EC45065820A471F" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-43FF909DA2465979BABA3BA92BC0698C" unitRef="usd">680600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-6DF916C3035A5826B16F6BC99C6C8FC1" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-0CFBF5A9F72752D8932F59785E26939B" unitRef="usd">696400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q1_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-A8377F0420B95CAB98D9AD8F28EBF233" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-AFEB247AF07B5F51AF87562324DB4CA6" unitRef="usd">8264600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2018Q1" decimals="-5" id="Fact-F4495AD162215C84AB34DB798B6C5CFA" unitRef="usd">8283700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-C97AF5FAA25156F292E04AF19FB7F0EA" unitRef="usd">3879600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q1" decimals="-5" id="Fact-22202CC2AF585129B5DABEF6F6E6CB8D" unitRef="usd">3794500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5F47FAD2C76E5A5EA01BD88DCB31F34E" unitRef="usd">63400000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-0D3FC8BFFAC45784AB65C84C7171C0A2" unitRef="usd">50500000</us-gaap:InterestExpense>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-DA0C9FD015725E9584C86CF74C11A0CF" unitRef="usd">157400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2018Q1" decimals="-5" id="Fact-ADCF1EF80CF45457A1A5219EA0866E4E" unitRef="usd">148000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-5" id="Fact-F098D49DB84C51829359A72173D5AAE2" unitRef="usd">902700000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2018Q1" decimals="-5" id="Fact-A5A78E35E7F4558EAE6E3F9C7CDFE77A" unitRef="usd">890800000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-29A796B9F0495B2BAC24F4ADD18A99C6" unitRef="usd">22800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-D0D98CD95E965E65984580A4BF2B4DA9" unitRef="usd">15800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-E8E6FE394E0158B0BA1FDCDDAC700F28" unitRef="usd">162400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2018Q1" decimals="-5" id="Fact-F4705854CC535AB8A2FE5E5D75A0C263" unitRef="usd">164300000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-B05D409918F45FB99A715E90B9FE46EF" unitRef="usd">605700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2018Q1" decimals="-5" id="Fact-E8921EF029735F74B894380120B8A089" unitRef="usd">594300000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-262B71B63EB251B891DC9A5B49682014" unitRef="usd">16700000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-6B6D4E73D8905204B0223E1787378E1E" unitRef="usd">26700000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-132100656F1051F998B3BCF6A4FD0DE7" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-678B5F6E5CA4520E8097F58FDBD3DE61" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D8A0302A67FB5E0691BD72314A884BAE" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6B0D91AC0D6D5D84AC1B33F13C5BBC34" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-868FAD464AD058DA9451FBF24F7DEB1C" unitRef="usd">22800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-64684C1B2B1853468A61035BA6066320" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3D46A66BD22B52459FBA176B7883C342" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4FAF7254D1F15FC79C810816050B8AE8" unitRef="usd">22800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-5" id="Fact-74EB4E52DD9B544390C2DF6CD2D81A02" unitRef="usd">11054500000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q1" decimals="-5" id="Fact-B4C199EA8E205F508B0CB06EC5FB7BE6" unitRef="usd">12052600000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-0381A202BE9357B09654853EAA4493D8" unitRef="usd">23652600000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q1" decimals="-5" id="Fact-F0C13D9E590E5359B07B7F006605B511" unitRef="usd">26090100000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-01F15653B0FB5D76B57634946A2FB1A9" unitRef="usd">3368200000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-49F1A556A51D573F8AF8EAC9EFA45E62" unitRef="usd">3152100000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-17480306715C5B78B44DBC5D160C0A02" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A9F9BCDE1FED55B3849B4989CC4A41B7" unitRef="usd">111300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FF7A3D285BCE5C2B827FE7973E8298C3" unitRef="usd">523600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BFA48A56C8E15CAF91C7456154906CFE" unitRef="usd">634900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B1D6C2BC349F5CC18A6A69B0F87556E8" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0DE56D8AE2D05087A820679AE6943B48" unitRef="usd">147700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7C70153B7EA65ED4AEF4C2C8A5194E1E" unitRef="usd">498000000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-367C7CE587D55DD4AEA77F216FB55667" unitRef="usd">645700000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="FD2017Q1YTD" decimals="-7" id="Fact-5B123511371B5F9FA80EFCE1EDDB7EC5" unitRef="usd">1250000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="-5" id="Fact-C140ADD049E3534F98F46303803A546E" unitRef="usd">5935000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q1" decimals="-5" id="Fact-AE8DE644C909578C9D7762BA78FC1E37" unitRef="usd">5929400000</us-gaap:LongTermDebt>
	<us-gaap:LossContingencyDamagesSought contextRef="FD2018Q1YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" id="Fact-784F95412DE3AA847B37D91AAE2DAB17">30.0</us-gaap:LossContingencyDamagesSought>
	<us-gaap:MinorityInterest contextRef="FI2016Q4" decimals="-5" id="Fact-A2B96ECEE4AE56B8B1E8A2D5D684E6E6" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q1" decimals="-5" id="Fact-E01A62DB65D55EC2BA6619864E52D1FA" unitRef="usd">-11600000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q4" decimals="-5" id="Fact-A8DE44C7B34A590A8A29631A419A7949" unitRef="usd">-14700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2018Q1" decimals="-5" id="Fact-7B84F9B352D8533AA13C59463CCF7DBB" unitRef="usd">-16200000</us-gaap:MinorityInterest>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-73C3B4394FBB5209A2FC8B5F5280F90A" unitRef="usd">-901400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E0EA679D183157B99086B8A2E11F7C5E" unitRef="usd">-268600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-06D3E1A4D4D7594BB9FC50CBF9CFDC7C" unitRef="usd">-744200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-CDDD2CDB413451FCBC73538D0CC9A5B9" unitRef="usd">1346600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F045FF55B07F584B9E5DEC87A76AC7C1" unitRef="usd">235200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-89FDAC5B5D045404BDC0CD5CF0552137" unitRef="usd">1457100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD" decimals="-5" id="Fact-6B18D5568E2A53129F9BD1EBD1939666" unitRef="usd">747600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-02EDF0AD4E7A52F0A0DE8607B564B206" unitRef="usd">6300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-0223D4BDBC375294A0DAB77296B4937B" unitRef="usd">1172900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-E24DE1F8D3605A9A802327F6C1769C5A" unitRef="usd">-37400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q1YTD" decimals="-5" id="Fact-D5C07A58B28951C2A7D5822415797BDA" unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2018Q1YTD" decimals="-5" id="Fact-57A62113D3785500BC388A8CB7805BD4" unitRef="usd">-1700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-EE5984345DF55CEBAF994F5BB86B693C" unitRef="usd">-38000000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1AF830A5D832531084CCE4CA3D38456F" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-82484416047C55888672F450807CFD04" unitRef="usd">-700000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1FDBA943DDBE5CA5B418462582B3710A" unitRef="usd">-41000000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-81C3FC119D005DC2A413E150BA9CAE6D" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B2F7DCD1D71B5A5EB88D795CEDBEAC08" unitRef="usd">-7600000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2017Q4" decimals="-5" id="Fact-B62ED18101855E27BBFC3B50C98DA3D2" unitRef="usd">5938200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-09F9836A9D0657F28076F2DDDC903CCD" unitRef="usd">3200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-3310B920184F5FFFA522F8ECE075C834" unitRef="usd">1722000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-1F74E94BCAE1575693CCF45A0FE88804" unitRef="usd">1736300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-D62D67E3EF905890B41C1B33658EE452" unitRef="usd">994300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-577C9C3915B7552796E87663C716B4C8" unitRef="usd">1482400000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q1" decimals="-5" id="Fact-7070AC9CC9F15D348F27F5323ECC754E" unitRef="usd">5932700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-2F039BB8B57551F99E37450FAE18F8B8" unitRef="usd">3300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-C034FB8B1E465A55B60777D017C5983B" unitRef="usd">1722100000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-D20FD79873545FCB81B9F79BB297E7B2" unitRef="usd">1736700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-ACC5EEDA19EF52A5AC0F83D968188450" unitRef="usd">994600000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-771F50C855D454F490CD4B3B463DF86E" unitRef="usd">1476000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-9537BB02C3315525B1EA9777B2EA9A0D" unitRef="usd">3200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-5F90AB179A1D5D8CA98CAD0232C15EDF" unitRef="usd">2077600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-8FA9DF37B1A052619C14385DFEB4C939" unitRef="usd">1851900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-5E9412B26BAE5390AE7393C670D45052" unitRef="usd">1032900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-DB29F3C3B250552A9E37908CC2C5EA8E" unitRef="usd">1517700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-6D64C32452CC55138AE40CB4DA7D6409" unitRef="usd">3300000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-9B78A53BC8AA562AA48D270576751D25" unitRef="usd">1898200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-9EECE17CD0305716B843DDC6F872D7D7" unitRef="usd">1788800000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-D6C5C1A2E53B521CBBBF9DC76C12174F" unitRef="usd">1007300000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q1_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-B2E1C4EFAB4958FDA6713BAA2D10FE8D" unitRef="usd">1490700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2018Q1YTD" decimals="0" id="Fact-6F976430CC175F01AF491B421FFDEBC8" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-83499BA1858E561B8AD0A72ED0B1A84A" unitRef="usd">100000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-3B9854536696508491D42E4E1E2771A7" unitRef="usd">1300000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q1YTD" decimals="-5" id="Fact-DEBD23E5BA6B5CEBA8126E1DE57006E4" unitRef="usd">1024700000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-4A8EE93880F2575AAEBBABDFD98740B4" unitRef="usd">1534700000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-A1F6448F6DC45517AE6B6BEA93B8C91E" unitRef="usd">636900000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-E3619098305055779A94560D4EA7DBF5" unitRef="usd">653400000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-634979EAC290553189E5D08E51A76443" unitRef="usd">962000000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-B25DD33DAA9D5E5492C2922A7AFBD74C" unitRef="usd">895900000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-FAE63B763A7957569653AEF6836E9883" unitRef="usd">431600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-3C83D8696099535E91EA1A4D167A3E37" unitRef="usd">380100000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2018Q1_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-CE75760D84995A8D878078EE46178F0A" unitRef="usd">260000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-C210E2D3D8DF52088484C5F1ABD4CFB5" unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-8AE0129B15A25FB7B83CEACAE374406B" unitRef="usd">-2200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-33D4BC4A5BB750D8826F1B0A67BFF4B5" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-2E4F4821E3185B639AC8A73FF564FDC5" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-3D8572FFEDB157DF8CD5F6020E741D21" unitRef="usd">-17100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-A71E8BCD2B8B5CF8976A6E7C8EEC6AE0" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-2E68D7D182445B09AF0A41F486BE9743" unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-36BE02C6B18158E382BF09044DAAEF84" unitRef="usd">-24400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-7D2F248B2D235EB6935D77EC49E983B8" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-07F8668E1298564BA4B1033D12C0B94F" unitRef="usd">-60400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-9894E26DF78055F48309429D66FA7A83" unitRef="usd">-8200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-D7F7704B4DFF594F87D9AA25E47519CD" unitRef="usd">44700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2446E550B9DC50AEB1ED5C231D18AF85" unitRef="usd">-23800000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C61B020F7050596A82C1871F81B51FD6" unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-38EEC10B1AAC5594A361CBF61C06B85D" unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-EBB1A8E5119A51B4A872EC102E26C229" unitRef="usd">44700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-D81C1275969256CC93B5D2CAD954421F" unitRef="usd">-5300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-48DE5771BE6854CBA0501EE425EA3264" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E53C37D2F550518082F23F68B12D27BB" unitRef="usd">-23800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B5A198CF9D135A9280CC53C497499A6F" unitRef="usd">-1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-0C7C72F13CA5539FAB4B64BDCDE58A06" unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-D4A7FCBD9CC25741A7898F05F3BC7F3A" unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-C1B2C6FCD7C3573D9D05FDEC3802B32D" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0DDA41890D6854FC8461DC07EE165BD4" unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-235C5D2AA62F51788697B8DECAD4ECA8" unitRef="usd">-2200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-39F3D22CB4D95C09AF7649A58F3F0A63" unitRef="usd">44700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-6483524D1FBD53869991617E753B512E" unitRef="usd">-100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-BFA6672C9D0159D0AA98380198351A68" unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-1C279D3706DA5722A246D536DD5641D5" unitRef="usd">2901300000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-CDD7267E3A94502C98105B8911E49E73" unitRef="usd">2571100000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-CF8621A40AFE5BF3A4DB18663DDA3304" unitRef="usd">1628700000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q1" decimals="-5" id="Fact-D933ECD0789352EE846F9E3F3B1C1B8E" unitRef="usd">1640000000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-FE201E935AA55819B05895AFAB5DD226" unitRef="usd">-18100000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-25F9B880392E5F78B3CAD05A7DDA9DBD" unitRef="usd">-26100000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-10EC6B17C2B7542D8510EAD8CE5EA20A" unitRef="usd">2300000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-D86B665D531B546B8586733E86646643" unitRef="usd">-1800000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD" decimals="-5" id="Fact-722AA7EEF0CB5A0F92FF4116CA1B58E3" unitRef="usd">90000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_AbbVieMember" decimals="-5" id="Fact-9717D8B98EC1E6B44AECD4CEF5E0851D" unitRef="usd">-5900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-5F65E41C8EF1C5D1CF96D4CEF772BA6A" unitRef="usd">12200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-FE34F9D577CAD7188205D4CEFA838C57" unitRef="usd">58200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-FFCC0C8F3E4B54AF9841F0E428875A18" unitRef="usd">2200000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-68734EDBB7941861459320E6112009E9" unitRef="usd">5900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2018Q1YTD" decimals="-5" id="Fact-F383DCB5AA6051199C07688EDEBF6015" unitRef="usd">164400000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_AbbVieMember" decimals="-5" id="Fact-8D2227F4C7934A195D741F7763496444" unitRef="usd">-4700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-2A733D7D31A7B2391C961F77FB96D9E0" unitRef="usd">17900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-1B5F632D007EFC0FF1411F795C74E7E3" unitRef="usd">140600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2018Q1YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-9FF3220D7B635B62875BDDFA36CBBB98" unitRef="usd">17900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-03C61BCD89E2580FB7B7A01877EF7FFA" unitRef="usd">4900000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-61AEF927ED865748A24FFCDA3E1390D3" unitRef="usd">6600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-5F3217F49A165FDAAE473840E5FD743F" unitRef="usd">-1600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F5BAF81434F457A99217EC8B42BBADCF" unitRef="usd">583600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-030B7F69EA80A79BB53B208D2E8DEA79" unitRef="usd">365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-8E7731664F75F12F9D6B208BCB095162" unitRef="usd">218200000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E17E11D06F8056E1A976178B70FB33A2" unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-63034AD6858D5CA7BBC9F074B8725335" unitRef="usd">250000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2017Q1YTD" decimals="-5" id="Fact-737EE41F970B5E4986081E834613CC1C" unitRef="usd">302700000</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2018Q1YTD" decimals="-5" id="Fact-4E5E37C2F1B55F90B86717CF69DA7106" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F9D2A928C2305E6ABE6E7901D804C505" unitRef="usd">25500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C5EF0ED3D2DB522381CC5BAA721D6092" unitRef="usd">21200000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B0A8435F2FD35D52AF700F3EBDAAF017" unitRef="usd">1256700000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-BD54B9CFE5905047B58AFE544FCF794C" unitRef="usd">1919200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2017Q1YTD" decimals="-5" id="Fact-D861479BD21F510F84A2D8821D730E0F" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2018Q1YTD" decimals="-5" id="Fact-EE88841D9B375530934F4ECEC2DB73DB" unitRef="usd">10000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-9988928C89C358DD885E2B6871E420CD" unitRef="usd">855200000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2018Q1YTD" decimals="-5" id="Fact-EED3D1B8BE9A5A0C9FAA590D63377A6F" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2017Q1YTD" decimals="-5" id="Fact-FB93C9C6BFFD503FA742006CCDE07BF8" unitRef="usd">300000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2018Q1YTD" decimals="-5" id="Fact-71973A0EAC2F51559B0BDF0214E787A1" unitRef="usd">600000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q1YTD" decimals="-5" id="Fact-19C30DF6E48B5F29ABED03F9BCD5534D" unitRef="usd">210000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q1YTD" decimals="-5" id="Fact-65C496E0E6DF54C4A8C1E34A5B966845" unitRef="usd">194700000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToMinorityShareholders contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-74C9BFEF4EB841F1B35420DA679972FF" unitRef="usd">150000000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-B0E8121EB89A5CF6B9242696AE01F1E8" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q1" decimals="INF" id="Fact-5CA9BF64D22D5418AC5E75D395DF6F12" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-6E39A8BAE71C51A881CD371ED692EECC" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q1" decimals="-5" id="Fact-0FB27347D09856CEBBB2819AB51ED9D3" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidTaxes contextRef="FI2017Q4" decimals="-5" id="Fact-463069B4ABC85EC7845D79BACA9197FB" unitRef="usd">657600000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2018Q1" decimals="-5" id="Fact-EC9F6E31475E52D0B15ED3612FDCDEB0" unitRef="usd">587500000</us-gaap:PrepaidTaxes>
	<us-gaap:PriorPeriodReclassificationAdjustment contextRef="FD2017Q1YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_biib_AccountingStandardsUpdated201707Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-70F6331B2D99D453A8D7D8DFA34A2891" unitRef="usd">400000</us-gaap:PriorPeriodReclassificationAdjustment>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-538D24144EC75307AE92227207F0C8B7" unitRef="usd">10400000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-F5BCBC95EC735E15814A04E4E278CFA8" unitRef="usd">2600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q1YTD" decimals="-5" id="Fact-70C914D1C3A7541A9C633A52CA6754E3" unitRef="usd">1884300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2018Q1YTD" decimals="-5" id="Fact-8C32512363AA5D6599890F6A0BB6DE5A" unitRef="usd">4068900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2017Q1YTD" decimals="-5" id="Fact-7DA21F4103C2517C9D3D49031A549C7D" unitRef="usd">747500000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q1YTD" decimals="-5" id="Fact-39A99F2D960E5E97B6487C24C6874C89" unitRef="usd">1171200000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-5" id="Fact-47C09EFD03865CBF97220020AEA967A5" unitRef="usd">3182400000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q1" decimals="-5" id="Fact-C39991C862B55D54B44DE604051BEC50" unitRef="usd">3334700000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F396FFB48DDD5AEDA946367272577C33" unitRef="usd">-6300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-B8B2A120376553A9BE371D9E50ED97A7" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-189C561A04FA544F81354336DC024265" unitRef="usd">-6700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6F44DCF35CB255A9B49F7EA5CB30BFB2" unitRef="usd">400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-44EC8C026C7055EE9093C323D7A245D4" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD" decimals="-5" id="Fact-8E1D481A85FC5E319AC6B72405183E8B" unitRef="usd">37400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-19C7996F00B053058A1872CE15C20045" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-653F441BCBFE5DF5AB4CE9F64949B23E" unitRef="usd">31400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B9D132CB125159259CB3C6E52361B068" unitRef="usd">6000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-6BC98413EC4B567686D868F62983C16E" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-F38613B378EFD7B0A69DD9218CADB0E7" unitRef="usd">375000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q1YTD" decimals="-5" id="Fact-2103A8D04F4F54F6835A658695B74DA4" unitRef="usd">423400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-F28F7BCF4624C2A28487676BEC9812E6" unitRef="usd">53300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-C3F8A8051554E5A54781676CB2507708" unitRef="usd">20800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q1YTD" decimals="-5" id="Fact-A2105116C52053B79DAE7337EE1D3C2F" unitRef="usd">496700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-326BC37B569C8EF551C6676BBA6DD596" unitRef="usd">63600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_E2609andBAN2401Member_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-AA5323856F661D138127676C7D7C39F3" unitRef="usd">26100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-C5434C1C474F05684545D94501AF3FED" unitRef="usd">12800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="D2018Q2_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-AAF562E764C517E2750AB108B92CB63C" unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5B2B1F8A49DC58959D3AB167BE98FB63" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q1YTD" decimals="-5" id="Fact-245C23F694B250B0A327E4669D55305B" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q1YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" decimals="-5" id="Fact-A062BBC7CF02B4CF1B0D1B0CD60D722A" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringCharges contextRef="FD2017Q1YTD" decimals="-5" id="Fact-B4C850D2DF5859B6B3810C07522EB8E8" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-EB88366ABE5B7AECCB83678598CEDB20" unitRef="usd">900000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q1YTD" decimals="-5" id="Fact-E4A6E5A45444563F8159E33D18BD6504" unitRef="usd">1600000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q1YTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-26644C7BED28719CEE956785B1EF6A31" unitRef="usd">1600000</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-5" id="Fact-ACAD8F32ADB152CB9158F17FF3BA5120" unitRef="usd">15810400000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q1" decimals="-5" id="Fact-09E832A9EBA6582DBB36EBCC4E0D4890" unitRef="usd">17334600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0A0F04C9A1665937BE90AFE656231293" unitRef="usd">2810700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1YTD" decimals="-5" id="Fact-CB50346E52FB513782F64ED8D0AB14F7" unitRef="usd">3131100000</us-gaap:Revenues>
	<us-gaap:RoyaltyRevenue contextRef="FD2017Q1YTD" decimals="-5" id="Fact-9F47D7A2B5253F799EE2D4CEF9DBECFB" unitRef="usd">25500000</us-gaap:RoyaltyRevenue>
	<us-gaap:RoyaltyRevenue contextRef="FD2018Q1YTD" decimals="-5" id="Fact-42778DC2875687F9832B1F78DE0F8FA9" unitRef="usd">10600000</us-gaap:RoyaltyRevenue>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD" decimals="-5" id="Fact-7829B6EB5BB75DF98DE2D06C7157B954" unitRef="usd">2380100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-5BDE093EF8F25A9BF7E31F5EAEB708A3" unitRef="usd">17100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-510A7D0A92EC695F11B7D4C3AF1FC001" unitRef="usd">26000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C52A0E63CC8479E74795D4C37225D30B" unitRef="usd">5000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-676287E1AC7E028DFA9C1B50FA7EC1D2" unitRef="usd">21000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-97B1D59C720E7C8FE351D4C3B43EE631" unitRef="usd">65300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-10E78F5DA4537405A29FD4C378708634" unitRef="usd">65300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-581E50BA33DF0B948F3D1B50FFEC3CB5" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-3125473B0F32408A187CD4C3AC5A3163" unitRef="usd">48400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-F39B69FD6539986B0600D4C36F8FEA1C" unitRef="usd">6200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-936C02C21EBCF794CD951B50F83021AD" unitRef="usd">42200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-C8A1FC88B0C551FC159BD4C3A3665AD5" unitRef="usd">20500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-0F9BC26A9EE1641332BBD4C36659B439" unitRef="usd">20500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-256220E290C65299B26E1B50EF196EEE" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-F03FD68BBE2BB5D5E209D4C3B70C0D8F" unitRef="usd">600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-B2B1565B159EC08DFC9BD4C37B0BD601" unitRef="usd">600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-FD89A7A080BD1A7889E11B5102D1F6DB" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-C26978E33E808AD587F1D4C3B1D419B5" unitRef="usd">9700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-18931E1B5BF0A242DBCCD4C375EF4C76" unitRef="usd">9700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-ADB7A8B586428FEE29C41B50FDCCAB6A" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-71C4FE25BE93C8073A05D4C39E95F7AF" unitRef="usd">648300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E07D405C7E744E44214AD4C360D59A86" unitRef="usd">183500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-9B0A5739F6A300D131C11B50E98BAAFA" unitRef="usd">464800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-5DE8DDD8FB417922E489D4C3A90995D1" unitRef="usd">47400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E21BA3FC53B95AD49FF5D4C36C13DAC6" unitRef="usd">1000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C13D47D91E77E23CB8461B50F502825C" unitRef="usd">46400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-28C95CE9172EBFE4EDE7D4C39C04999B" unitRef="usd">958200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-916C15C5552778CCDD5BD4C35DD890D0" unitRef="usd">207100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6A2F3D5317C558CF884E1B50E66EE24A" unitRef="usd">751100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-FA73763CE0E18A67C87CD4C3A10AA7D5" unitRef="usd">545000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-D0F2521CF88A4CA163AED4C3639F015A" unitRef="usd">239500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-22FD693111D702F071F61B50EBC90EC1" unitRef="usd">305500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-C0801CD95B72AA8BBB94D4C3A5AF427E" unitRef="usd">10700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-76FF7FD8E39B1409907DD4C368AF958F" unitRef="usd">10700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-96012CD139F94A5584C31B50F225AEC8" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B8E7624F979051E5BA97CC7C0F393892" unitRef="usd">6700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2293D562DA0ED4C9485AD4C37DD1EDAB" unitRef="usd">749100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-B4628F467217B4752AEB1B51058CD7F0" unitRef="usd">1631000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD" decimals="-5" id="Fact-1F1AE569123D58D9AE197EA2D9477328" unitRef="usd">2523500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-9AA5D578A3F13FD5D4231F5DB8D5B212" unitRef="usd">93600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-2A5DDF255AAEF3E65B6DD4C32E969F13" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-97A35615D4BCB19C918CD4C2EC7F9350" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ALPROLIXMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C4C48FE946A97E474C1C1B4ECBEB66EE" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-27FBF63E503AC9E263D5D4C333A9F850" unitRef="usd">120900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-398360D7A76C30462701D4C2F25F5914" unitRef="usd">120900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_BENEPALIMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-410C495120F2099477561B4F613F530C" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-F25FF42056527E8677EDD4C32C0ACDEF" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-C74654A2C86D83FB0DD3D4C2E9D534A7" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ELOCTATEMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-2CD18EE1E03ED67DC9B61B4E929B7A8F" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-9D3E19182B2D7DBA890ED4C322D7D1B7" unitRef="usd">24400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-5E1F1D1735D6B633BF7BD4C2E04ABE6C" unitRef="usd">24400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FAMPYRAMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8DBC0E04C002CA7D6DF91B4DB9C026DD" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-9A46D659D1D18EEF0949D4C33667FE73" unitRef="usd">6600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-64916D07B5F3FA008AC7D4C2F51E7328" unitRef="usd">6600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FLIXABIMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-DDF456094F297BC390491B4FD3A117B0" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-E8836092FE44D6D8C099D4C331404893" unitRef="usd">7000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-62FC86E39F93AF29DD38D4C2EFD0AB6B" unitRef="usd">7000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_FUMADERMMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-81C339BC621F53571E7B1B4F1F194E80" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-E859DB79F67AE491EA0CD4C31D9DCE9E" unitRef="usd">550300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-886CA2DDC467094134ACD4C2DA64E7DC" unitRef="usd">178900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_InterferonMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6FA2ACE7D7C269E171531B38572B5686" unitRef="usd">371400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-CBA9EBD05689C79B0987D4C32898685D" unitRef="usd">363900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-3F43736E82DB16C2D2A7D4C2E6626BA5" unitRef="usd">175900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-DA214046DDB0197DF8221B4E3A43C349" unitRef="usd">188000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-02977C426AB96F657549D4C31ACFD931" unitRef="usd">986900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-2054257F791DFB1CA6DFD4C2D7665D4E" unitRef="usd">258000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C8C0907B200AC3E909821B36FA157AA1" unitRef="usd">728900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-39D077891917C7184212D4C320447B3E" unitRef="usd">462100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-E04488531577FCFF8999D4C2DD996D6B" unitRef="usd">212400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6AC7B483632C90E6540F1B4D4C50BA23" unitRef="usd">249700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-1EA22B4FB62D53C5725AD4C3258A6AED" unitRef="usd">1400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-AE8687AE12E1FAFFF9BCD4C2E2E351B8" unitRef="usd">1400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-1D5E0C99684D89F9714E1B4DFB2EDD36" unitRef="usd">0</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-114D8269513F57BAAFA3403DD3535C30" unitRef="usd">32900000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_biib_RestOfWorldMember" decimals="-5" id="Fact-469AA666B321A9C9D70CD4C2F7F7E41C" unitRef="usd">985500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2018Q1YTD_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8F6D00F3A55FC28156DD1B5061E25F5E" unitRef="usd">1538000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q1YTD" decimals="-5" id="Fact-0412A1A21716503794C03A59DB38874D" unitRef="usd">498700000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q1YTD" decimals="-5" id="Fact-03140CDA06015A5FABD171AA1BF1E1D6" unitRef="usd">501300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q1YTD" decimals="-5" id="Fact-C5C1013A8C235D6CBE5B12B2393BF7F3" unitRef="usd">37000000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q1YTD" decimals="-5" id="Fact-809947E1A7B55166A6F3F3BA23A8FB63" unitRef="usd">43400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="INF" id="Fact-4399B445FEF755EC3C4B20C669C7C72F" unitRef="shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="INF" id="Fact-6BBE9A6A0A0E50EB5A0620C3ED97EF01" unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q1YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-5323E135A891A2D6B89D20C56DD55E2F" unitRef="usdPerShare">317.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-0E3C1D564F6B5903AA790B5B9080B38F" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2018Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-A854B8B92CDA52369997CDF254847238" unitRef="usd">2800000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-8E6E967976C857FC9FECAE28612A6AB7" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-793369E40706F13CE1BA208B81084A15" unitRef="shares">800000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-597886F37BD951B1BEC120B6E734BCB1" unitRef="shares">900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-E6AD22D766F459DB858792059CC349D6" unitRef="usd">12612800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="-5" id="Fact-B67C5C4AF28E584EB52DDA7685F74FB7" unitRef="usd">14053700000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-5" id="Fact-810F79EA7CE65F95AFCAB8387DD3D746" unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q1" decimals="-5" id="Fact-C5E4865370295ECA891BA351709A38B8" unitRef="usd">14037500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityPeriodIncreaseDecrease contextRef="FD2018Q1YTD" decimals="-8" id="Fact-7F4F9310BC9F50898F4FCDDCE68B716D" unitRef="usd">1400000000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-564FB4097849551D9B36B997B2BDE374" unitRef="usd">68200000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2018Q1" decimals="-5" id="Fact-22D61F4EE49D5F8682CCBFEED533DB3F" unitRef="usd">231900000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q1YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-C1869BD933746720E152208C92FD983A" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-1D1EBE8CB73D502EB0E212B6CD068D10" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2018Q1" decimals="-5" id="Fact-28CD56B76196534BA630D58DBC3F7CA7" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2018Q1YTD_biib_DerivativeMaturityAxis_biib_ShorttermderivativeMember" decimals="-5" id="Fact-3A7CA6790705DB1FF0DE2038F52A7100" unitRef="usd">127100000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4" decimals="-5" id="Fact-1675CF5175FB589C840E506DA2565518" unitRef="usd">761600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-601E0392C0F258C598A6F002488C0434" unitRef="usd">189600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-53D99674809D5705AF18314082A46DE0" unitRef="usd">572000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3D4DF915082B5AC4B0A661447C4491C6" unitRef="usd">606000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-41CFDAE83565558BB8FFF114A7DCFEA6" unitRef="usd">109600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-E167E0F4ADC6589AA92F21E1EEAB5DE1" unitRef="usd">46000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q1" decimals="-5" id="Fact-5960F97988A65B679EDFAE7D76B2E2FF" unitRef="usd">859300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-9B5779F2DF6853E3BB69CD3517F3025F" unitRef="usd">201800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-86CFF6F8126E54D2A141EB603A6886E6" unitRef="usd">657500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-777317F4DE0852978F3B6BFDCC12F46F" unitRef="usd">695100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-DF657DEAD85F50FCBCA0D244DF811C54" unitRef="usd">121100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-BC5823FF22D65C4FBC6444C0BA5D4E54" unitRef="usd">43100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q1YTD" decimals="-5" id="Fact-F4AE1293A75A5E2EB6D62B33EFA8D196" unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2018Q1YTD" decimals="-5" id="Fact-08C5186D825A5A1BA55D0990E7C2361B" unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q1YTD" decimals="-5" id="Fact-85FEC73BE3745B87BC39A954A548B0CC" unitRef="shares">215900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q1YTD" decimals="-5" id="Fact-C5D88A6FC7205BE0A12AA263F7B00E1A" unitRef="shares">211700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q1YTD" decimals="-5" id="Fact-5BB4FA89E8BC5991884941A66676E5DD" unitRef="shares">215600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q1YTD" decimals="-5" id="Fact-19E174416A6B57EEA90D1458A63D4467" unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-059ECA360FB55325B9A5ED2BE240047E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;641.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;806.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(227.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(299.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(77.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(326.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(412.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;121.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;695.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-775DC3952F785EC3A4D6715C3D35E5B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS. For additional information on our voluntary withdrawal of ZINBRYTA, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy, a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2018Q1YTD" id="Fact-2281E14B6AAC50B2AE6AD502D4C04757">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(537.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(535.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,700.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;304.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,689.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;696.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;696.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,974.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,250.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,723.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,971.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,160.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,811.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8,283.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,489.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,794.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,264.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4,385.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,879.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:OtherrevenuesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-727BDFCC04C3075290851F6B37EE2451">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Samsung Bioepis and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;140.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;164.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
	<biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-0E67D21D7C9D5B96B47C4895E5F0B7F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock>
	<biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-A16806CF750E8E2FABB11B6996E455FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;349.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;323.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;93.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;443.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;340.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-508765A89A5351BFAF00E6D4563586A3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;201.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;657.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-9B1FC870F55759BB86C567476FC44EF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(41.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$895.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$962.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and include prepaid taxes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$587.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$657.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;657.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;524.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;194.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;206.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;186.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;297.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;178.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;176.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;183.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;653.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;636.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,571.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,901.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2018Q1YTD" id="Fact-1AAB561E24E15206AEFF065AFE9960E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;912.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;913.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;895.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;895.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;248.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;248.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,008.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,011.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,570.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,569.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;845.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-AB147960776C5761A243BCD02DD47545">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our accompanying unaudited condensed consolidated financial statements (condensed consolidated financial statements) include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-8DD66872E57C9A441D131B60A872FB80">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Karyopharm Therapeutics Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm Therapeutics Inc.'s (Karyopharm) Phase 1 ready investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB100 has not yet reached technological feasibility. We have also agreed to pay Karyopharm up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$207.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, as well as potential royalties.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2018Q1YTD" id="Fact-A2C3F962396C5B40856DD36DE2DBF5D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;948.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;161.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;247.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,773.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. Upon adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;912.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;913.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;895.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;895.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;248.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;248.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,008.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,011.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,570.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,569.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;845.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,808.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,809.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,115.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,123.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,124.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;77.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;77.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,008.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,011.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,068.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,884.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-B4FB1E930AD85299BE4BD421DEB1342B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie Inc. (AbbVie) for the development and commercialization of ZINBRYTA, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary withdrawal of ZINBRYTA for relapsing MS, as discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory) where development and commercialization costs and profits were shared equally. Outside of the Collaboration Territory, we were solely responsible for development and commercialization of ZINBRYTA and paid a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Article 20 Procedure and Voluntary Withdrawal of ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 the European Medicines Agency (EMA) announced a review (referred to as an Article 20 Procedure) of the use of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury, and recommended restrictions on its use. In January 2018 the European Commission (EC) adopted a final and legally-binding decision restricting ZINBRYTA's use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. For additional information on the Article 20 Procedure of ZINBRYTA please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The EMA subsequently started a second review following cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis.&amp;#160;In parallel, we and AbbVie began discussions with the EMA, and in March 2018 announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS as we and AbbVie believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated. Subsequent to the voluntary worldwide withdrawal of ZINBRYTA, the EMA recommended the immediate suspension of ZINBRYTA's marketing authorization and a recall of ZINBRYTA from pharmacies and hospitals in the E.U. As a result of our voluntary withdrawal of ZINBRYTA, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in inventory charges and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in losses related to the termination of research and development contracts and clinical trials related to our voluntary worldwide withdrawal of ZINBRYTA in our condensed consolidated statements of income, net of an expected AbbVie reimbursement, in the first quarter of 2018.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S. for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenues of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect our share of an overall net loss within the collaboration, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. These results include the collaboration's estimate of future returns of product in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net income of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada. These results include the collaboration's estimate of future returns of product in the E.U. and Canada. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our recognition of income to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada was not significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with AbbVie, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and E2609 Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai to jointly develop and commercialize E2609, a BACE inhibitor, and BAN2401, a monoclonal antibody that targets amyloid beta aggregates, two Eisai product candidates for the treatment of AD.&amp;#160;Eisai serves as the global operational and regulatory lead for both compounds with all costs, including research, development and sales and marketing expenses shared equally by us and Eisai; and, if applicable, following marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai will co-promote BAN2401 and E2609 and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;was reflected in research and development expense in our condensed consolidated statements of income related to the advancement of our E2609 and BAN2401 programs, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also have the Aducanumab Collaboration Agreement with Eisai for the joint development and commercialization of aducanumab. Under the Aducanumab Collaboration Agreement, we will continue to lead the on-going Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab incurred in support of this agreement until April 2018. Eisai will then reimburse us for&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;of aducanumab development expenses for the period April 2018 through December 2018, and&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$63.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;was reflected in research and development expense in our condensed consolidated statements of income related to the advancement of our aducanumab program, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Eisai also co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Eisai, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control and is based on paying for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the joint venture agreement plus a rate that will represent their return on capital. If we do not exercise this option by mid-2018, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis' shares then held by us. Should we exercise this option, our ownership percentage would increase to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We began to recognize revenues on sales of BENEPALI and FLIXABI in the E.U. in the first and third quarters of 2016, respectively. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. In August 2017 the EC granted a marketing authorization in the E.U. for IMRALDI, an adalimumab biosimilar referencing HUMIRA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we and Samsung Bioepis announced an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we and Samsung Bioepis will make royalty payments to AbbVie. We expect to launch IMRALDI in Europe in October 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$43.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect Samsung Bioepis's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in revenues in relation to these services, which is reflected as a component of other revenues in our condensed consolidated statements of income, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on to these and our other significant collaboration arrangements, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2018Q1YTD" id="Fact-AE0DA8617BA054F98BED9DF22A428B73">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amount reclassified, net of tax, upon adoption of ASU 2016-01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(316.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(29.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(130.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(303.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(314.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(325.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-7D843FFC2AE4545286F527C8D170AC4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-58E2AACD47DA59EC94EDB9B961CB8C48">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2017, were modified to conform to the new disclosure requirements. For additional information on this new standard, please read Note 1, S&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;ummary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as cash flow hedges and any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,734.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,875.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;110.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;83.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,971.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,198.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$142.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect the net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$142.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$127.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is expected to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized Directly into Net Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recognized as a component of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$572.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$564.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the prior year comparative period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;114.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="FD2018Q1YTD" id="Fact-C3FD7360B83D390A38BD1B41E76AF397">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;728.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;258.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;986.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;751.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;958.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;371.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;178.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;550.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;464.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;183.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;212.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;305.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;239.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;545.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;188.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;175.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;363.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Product Revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,538.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;985.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,523.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,631.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;749.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,380.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q1YTD" id="Fact-F650F02F8D0759F5981EDE7AE345B831">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;39.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;36.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&amp;#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance Stock Units (PSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;PSUs Settled in Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2018, we began granting awards for performance-vested restricted stock units that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of the actual performance metric achievement. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; PSUs that will settle in stock were granted at a weighted average grant date fair value of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$317.58&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;PSUs Settled in Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2018, we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of the actual performance metric achievement. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs will be settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through the vesting date, once the actual vested and earned number of units is determined. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; PSUs that will settle in cash were granted.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q1YTD" id="Fact-5C80A933DF4F5F7A9B6EB1B30D6C3CBA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,172.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q1YTD" id="Fact-09BFF2B007775ED48385C3352CCECF29">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,773.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,773.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,557.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,557.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,836.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,813.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,444.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,433.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,490.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,482.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,007.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;994.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;994.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,788.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,736.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,851.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,736.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,898.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,722.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,077.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,722.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,188.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,932.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,938.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence Pharmaceuticals, Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$273.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$279.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Changes in the fair value of our contingent consideration obligations were primarily due to an increase in the probability of achieving certain developmental milestones in the prior year period and an increase in the interest rate used to revalue our contingent consideration liabilities for the current year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q1YTD" id="Fact-F59AA881D41D581DA018E47099981EDC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;470.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-AAAFAFE03989546ABF6CD29C1EB5A31C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(537.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(535.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,700.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;304.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,689.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;696.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;696.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,974.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,250.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,723.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,971.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,160.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,811.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8,283.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,489.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,794.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,264.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4,385.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,879.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$103.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$448.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, in the prior year comparative period. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in amortization of acquired intangible assets was primarily due to the prior year impairment charge related to our U.S. and rest of world licenses to Forward Pharma A/S's (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$298.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc and our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. The net book values of the TYSABRI and TECFIDERA assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,178.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$322.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;TECFIDERA License Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;in cash. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In March 2018 the European Patent Office (EPO) issued its decision revoking Forward Pharma's European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on these disputes, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2017 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the third quarter of 2017. Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;330.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;402.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;379.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;255.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;242.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;270.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,907.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 22, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other includes changes in foreign currency exchange rate fluctuations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-A56B1846D9875F4A867610D28E3BB134">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Reform&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Tax Cuts and Jobs Act of 2017 (2017 Tax Act), which was signed into law in December 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low- taxed income (GILTI). These changes became effective beginning in 2018. We do not recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and instead account for any taxes assessed as period costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2017, we recognized within our provision for income taxes a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; provisional estimate under the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$184.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. During the first quarter of 2018 we recognized no significant adjustments to these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Transition Toll Tax&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax was assessed on our share of our foreign corporation's accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and all other earnings were taxed at a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. As a result, our estimate of the total withholding taxes may change as the amounts are finalized. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have accrued income tax liabilities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the Transition Toll Tax. Of the amounts accrued as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Status of our Assessment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The final determination of the Transition Toll Tax and remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management&amp;#8217;s analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to the 2017 Tax Act, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Changes in Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same period in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the new GILTI tax on international earnings, limits on the deductibility of certain benefits and executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act. The effective tax rate for 2017 also reflected the impact of a favorable settlement related to a state tax matter in 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; offset by a corresponding increase to deferred tax liabilities of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and an increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;International Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have made payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$65 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2018 on similar matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-5559F87D264350C6BF551BC84BCF2864">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;164.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;162.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;594.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;148.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;906.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;890.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;902.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;15.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;906.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2018Q1YTD" id="Fact-B13A20DBBD1352F885281609E1E3732E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,808.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,809.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,115.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,123.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,124.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;77.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;77.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,008.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,011.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2018Q1YTD" id="Fact-39117C6C4C2F58168A920B5578964EDF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Abbreviated New Drug Application (ANDA) Litigation relating to TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June, July and September 2017, January, March and April 2018, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Caribe Holdings (Cayman) Co. Ltd.&amp;#160;DBA Puracap&amp;#160;Caribe, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceutical Inc., Slayback Pharma LLC,&amp;#160;Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shilpa Medicare Limited, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Accord Healthcare Inc., Par Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Zydus Pharmaceuticals (USA) Inc. and Banner Life Sciences LLC. In addition, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act against Stason Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California, Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey, Accord Healthcare Inc. in the U.S. District Court for the Middle District of North Carolina, Par Pharmaceutical Inc. in the U.S. District Court for the Southern District of New York, Sandoz Inc. in the U.S. District Court for the District of Colorado and Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The cases against Accord Healthcare Inc., Zydus Pharmaceuticals (USA) Inc. and Sandoz Inc. have been dismissed in the North Carolina, New Jersey and Colorado courts but will continue against those parties in Delaware. The cases against Par Pharmaceutical Inc. in both New York and Delaware have been dismissed because Par Pharmaceutical Inc.&amp;#8217;s ANDA application has been withdrawn. The case against Stason Pharmaceuticals, Inc. in California has been dismissed, but the case against its partner Sawai USA, Inc. will proceed in Delaware. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial has been set in the Delaware actions in December 2019 against all parties other than Banner Life Sciences LLC, and a trial has been set in the West Virginia action in February 2020. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and oral argument has been set for June 2018. For additional information on this matter, please read Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the EPO decided to revoke our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO issued its decision revoking Forward Pharma&amp;#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information on this matter, please read Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &amp;#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &amp;#8216;127 Patent) (&amp;#8220;Administration of agents to treat inflammation&amp;#8221;).  The Polish &amp;#8216;263 Patent concerns administration of natalizumab (TYSABRI) to threat MS. The Polish &amp;#8216;263 Patent was issued in 2013 and expires in February 2023. Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (on January 11, 2016), the German Patents Court (on March 3, 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which was issued in 2011 and also concerns administration of natalizumab (TYSABRI) to treat MS. The EU '127 Patent expires in February 2023. The Dutch counterpart was ruled invalid and we have appealed. In January 2018 the German court announced that the German counterpart was invalid. No date for a hearing on the merits has been set in the Italian action.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&amp;#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2018 a jury found that EMD Serono and Pfizer infringed the '755 patent but that the &amp;#8216;755 Patent was invalid under the law of anticipation. Biogen, EMD Serono and Pfizer have filed motions for judgment as a matter of law and these motions are pending. A trial date against Bayer and Novartis has not yet been set.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Tax Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 the tax authority of the State of Goias, Brazil issued assessments for the period January 2016 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties.&amp;#160;We dispute the assessments.&amp;#160;We are unable to provide an estimate of the potential loss or range of loss at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q1YTD" id="Fact-765C4CF12D4C55EC96EE75B5E03B5157">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements and disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU No. 2014-09 that have the same effective date and transition date: ASU No.&amp;#160;2016-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; and ASU No. 2016-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S. we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our revenues, please read Note 4, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;which provides guidance on the presentation and disclosure of collaborative arrangements. Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have any future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(iii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration with Genentech, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2017 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with AbbVie and Samsung Bioepis also represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues are recognized as the underlying sales occur. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our condensed consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaborations with AbbVie and Samsung Bioepis, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Corporate Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of our product, which may occur at a point in time or over time depending on the terms and conditions of the agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018, using the modified retrospective method, as of that date, and recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net adjustment to retained earnings reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of the new standard resulted in the reclassification of where we recognize changes in fair value related to certain equity security investments. Prior to adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leasing&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard establishes a right-of-use (ROU) model that requires all lessees to recognize ROU assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required to leases existing as of, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our condensed consolidated balance sheet with no material impact to our condensed consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; offset by a corresponding net increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information, please read Note 15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Net Periodic Pension Cost&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our condensed consolidated statements of income. We adopted this new standard on January 1, 2018, using the retrospective method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of this new standard, the other components of the net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our condensed consolidated income statements. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reclassified from operating income to other income (expense), net in our condensed consolidated income statement to conform to our current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This new standard provides guidance to better align an entity&amp;#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this new standard resulted in additional disclosures. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon the adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 9, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our condensed consolidated balance sheets. Changes in the fair value of derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess at inception and on an on-going basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instrument used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in the same line item as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-D51AEFBF3B8255B6A863FE76BF85FA36">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,631.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,559.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-ECDE3D3B7F8B5BD88B0873E06DAA0A43">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,068.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,884.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2018Q1YTD" id="Fact-4FAEAA50E9B15FA2BC1BF3535DA8CE70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-1E21545E055240B1BE11678788513147">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Restructuring&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2017 Corporate Strategy&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We recognized restructuring charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated statements of income during the fourth quarter of 2017. These restructuring charges were substantially incurred and paid in 2017 and were primarily related to severance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized restructuring charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our condensed consolidated statements of income. These restructuring charges, which will be substantially incurred and paid by mid-2018, are primarily related to severance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="FD2018Q1YTD" id="Fact-4114735A31FD5803869D4F942A5467C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Multiple Sclerosis:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;728.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;258.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;986.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;751.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;958.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interferon*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;371.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;178.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;550.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;464.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;183.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;249.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;212.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;462.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;305.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;239.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;545.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;188.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;175.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;363.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Product Revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,538.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;985.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,523.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,631.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;749.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,380.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the three months ended March 31, 2018, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.8%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues for the three months ended March 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;159.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;641.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;806.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(227.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(299.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(77.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(326.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(412.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;121.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;695.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;201.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;657.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen&amp;#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;349.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;323.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;93.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;443.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;340.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration with Genentech, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2017 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Samsung Bioepis and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;140.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;58.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;164.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our collaborations with AbbVie and Samsung Bioepis, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q1YTD" id="Fact-D56B8FA70C8951C7B4A5C58ABA8E54F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;657.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;524.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;194.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;206.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;186.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;297.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;"&gt;178.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;176.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;183.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;653.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;636.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,571.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,901.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2018Q1YTD" id="Fact-5BA6959F5CC857A4A7BDE7A6BF175217">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amount reclassified, net of tax, upon adoption of ASU 2016-01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(316.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(24.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;31.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;37.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(29.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;44.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(37.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(130.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(303.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(314.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(325.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-15B89F3FB9A15ACEBE44DEF795F56214">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,490.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,482.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,007.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;994.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;994.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,788.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,736.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,851.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,736.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,898.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,722.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,077.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,722.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,188.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,932.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,938.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-01297F6F22E95ABCBD274D6090F387B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,561.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;948.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;161.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;247.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,773.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2018Q1YTD" id="Fact-E15E202F6DC35184B706EFCF456B72FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;36.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2018Q1YTD" id="Fact-CC173B39F9965C84BA899355DBE27C21">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized Directly into Net Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2018Q1YTD" id="Fact-BF284827119B5A11947B2A6911E22EA8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of March 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;114.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;32.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2018Q1YTD" id="Fact-89E7F91E8DC35082837E37C58DDDF020">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,172.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q1YTD" id="Fact-C807FAF783FD55D9AE2ADFDE6B58A0AB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q1YTD" id="Fact-0A502D0F1390519FBEED6999B1F5B6DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;29.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(12.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;39.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q1YTD" id="Fact-357100146ABD5863A8A2ADF0E7777B75">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of March 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,773.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,773.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,557.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,557.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;307.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;28.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,836.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,813.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;645.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;498.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,444.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,433.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2018Q1YTD" id="Fact-1A3105326F58562C9969DDDA37658A70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;270.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,907.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2018Q1YTD" id="Fact-369ACD6C788B55379DA8BBFC1071672B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;164.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;162.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;594.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;148.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;906.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;890.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;902.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;15.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;906.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2018Q1YTD" id="Fact-C3FC4E74795A5968A0C4C89C42AA6383">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,734.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,875.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;110.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;65.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;83.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;60.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,971.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,198.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2018Q1YTD" id="Fact-E6566D9D26CF5575A5A23465A8D46A7A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(41.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(38.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2018Q1YTD" id="Fact-2BC8C9F4B66F5D2BA883A15A12476892">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;March 31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018 (remaining nine months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;330.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;402.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;379.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;255.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;242.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q1YTD" id="Fact-31374AC73A465A088A9BEDA6EEE2C676">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS. For additional information on our voluntary withdrawal of ZINBRYTA, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy, a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, our accompanying unaudited condensed consolidated financial statements (condensed consolidated financial statements) include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements and disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU No. 2014-09 that have the same effective date and transition date: ASU No.&amp;#160;2016-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; and ASU No. 2016-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S. we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our revenues, please read Note 4, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;which provides guidance on the presentation and disclosure of collaborative arrangements. Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have any future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i) &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;reimbursement of our selling and development expenses in the U.S. for RITUXAN; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(iii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration with Genentech, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to our consolidated financial statements included in our 2017 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with AbbVie and Samsung Bioepis also represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues are recognized as the underlying sales occur. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our condensed consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaborations with AbbVie and Samsung Bioepis, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Corporate Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of our product, which may occur at a point in time or over time depending on the terms and conditions of the agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We provide reserves against trade receivables for estimated losses that may result from a customer&amp;#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018, using the modified retrospective method, as of that date, and recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net adjustment to retained earnings reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of the new standard resulted in the reclassification of where we recognize changes in fair value related to certain equity security investments. Prior to adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Leasing&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard establishes a right-of-use (ROU) model that requires all lessees to recognize ROU assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required to leases existing as of, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our condensed consolidated balance sheet with no material impact to our condensed consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; offset by a corresponding net increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information, please read Note 15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Net Periodic Pension Cost&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our condensed consolidated statements of income. We adopted this new standard on January 1, 2018, using the retrospective method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of this new standard, the other components of the net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our condensed consolidated income statements. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was reclassified from operating income to other income (expense), net in our condensed consolidated income statement to conform to our current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This new standard provides guidance to better align an entity&amp;#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this new standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this new standard resulted in additional disclosures. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon the adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 9, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our condensed consolidated balance sheets. Changes in the fair value of derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess at inception and on an on-going basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instrument used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in the same line item as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-E6C573FFCAE257EC8A816531357B20A9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total equity as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, increased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This increase was primarily driven by net income attributable to Biogen Inc. of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and a net cumulative-effect adjustment of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; recognized to retained earnings upon the adoptions of ASUs 2016-16 and 2016-01, partially offset by share repurchases totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to the adoption of ASUs 2016-16 and 2016-01, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program). Our 2016 Share Repurchase Program does not have an expiration date. All share repurchases under our 2016 Share Repurchase Program will be retired. Under our 2016 Share Repurchase Program, we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$218.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains available for share repurchase under our 2016 Share Repurchase Program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock (2011 Share Repurchase Program). Shares repurchased under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under our 2011 Share Repurchase Program, we repurchased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Noncontrolling Interests&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended March 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(16.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q1YTD" id="Fact-291FBFB03F3625EE2D21B1129B5FE065">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pfizer Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we completed an agreement to acquire from Pfizer BIIB104 (formerly known as PF-04958242), a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the closing of this transaction in the second quarter of 2018, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We may also pay Pfizer up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$515.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestone payments, including &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the dosing of the first patient in Phase 2b, as well as tiered royalties in the low to mid-teen percentages.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we entered into a new &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year exclusive collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases. Under this agreement, we will make an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and purchase &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of Ionis&amp;#8217; common stock, at a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; premium based on the closing price of Ionis&amp;#8217;s common stock for the 10 days prior to the date of this agreement, for a total payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The premium paid on the equity will be recorded as research and development expense in our condensed consolidated statements of income.&amp;#160;We have the option to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$125.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$270.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, depending on the indication, and royalties on net sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The transaction is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q1YTD" id="Fact-5F9C087573765C83AE1D51EAEE971164">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2018Q1YTD" id="Fact-0A309EBBA9F65F8A949CDFAC0BAA0F80">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2007 we entered into a collaboration and license agreement with Neurimmune Subone AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. Our anti-amyloid beta antibody, aducanumab, for the treatment of AD resulted from this collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on sales of any resulting commercial products and make payments upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.&amp;#160;Our royalty rates payable on products developed under the amended agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low teens.&amp;#160;As we consolidate the results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the fourth quarter of 2017 and treated it as a distribution. Under the amended agreement, we also have an option that will expire on April 30, 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; amounts reimbursed were immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of our collaboration agreement with Eisai Co. Ltd. (Eisai) for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement), Eisai may elect to share in the benefit and cost associated with the royalty reductions discussed above. Eisai has elected to not share in the benefit and cost of the October 2017 royalty reduction. For additional information on our collaboration arrangement with Eisai, please read Note 18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;March&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>biib-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20180331" xmlns:biib="http://www.biogenidec.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2125100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2425402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2425403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2325301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2406401 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2131100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2431401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2431402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2122100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2422402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2322301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2126100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2426402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2326301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2124100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2424402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2424403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2324301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2120100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2420402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2420403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2420404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2420405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2320301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2121100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2421402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2421403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2421404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2421405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2421406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2421407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2321301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2128100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2428402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2428403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2328301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2119100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2419402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2419403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2319301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2118100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2418402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2318301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2130100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2430401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2132100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationLitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails">
        <link:definition>2432401 - Disclosure - Litigation Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2129100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2429402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2429403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2329301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2123100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails">
        <link:definition>2423401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuring" roleURI="http://www.biogenidec.com/role/RestructuringRestructuring">
        <link:definition>2114100 - Disclosure - Restructuring Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetailsTextual" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual">
        <link:definition>2414401 - Disclosure - Restructuring Restructuring (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2416406 - Disclosure - Revenues Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2416403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2416404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenues" roleURI="http://www.biogenidec.com/role/RevenuesRevenues">
        <link:definition>2116100 - Disclosure - Revenues Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails">
        <link:definition>2416402 - Disclosure - Revenues Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual">
        <link:definition>2416407 - Disclosure - Revenues Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2416405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables">
        <link:definition>2316301 - Disclosure - Revenues Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2127100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2427402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2427403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual">
        <link:definition>2427404 - Disclosure - Share-based Payments Share-based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2327301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents">
        <link:definition>2133100 - Disclosure - Subsequent Events Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails">
        <link:definition>2433401 - Disclosure - Subsequent Events Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2011ShareRepurchaseProgramMember" name="A2011ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramMember" name="A2016ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017CorporateStrategyMember" name="A2017CorporateStrategyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXMember" name="ALPROLIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AccountingStandardsUpdated201707Member" name="AccountingStandardsUpdated201707Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalPotentialPaymentstoNoncontrollingInterest" name="AdditionalPotentialPaymentstoNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeInstrumentsTextualAbstract" name="DerivativeInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityAxis" name="DerivativeMaturityAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeMaturityDomain" name="DerivativeMaturityDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_E2609andBAN2401Member" name="E2609andBAN2401Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningsintheformofcashandcashequivalentsMember" name="ForeignearningsintheformofcashandcashequivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeAxis" name="ForeignearningstypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeDomain" name="ForeignearningstypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_KaryopharmMember" name="KaryopharmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherForeignEarningsMember" name="OtherForeignEarningsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherrevenuesAbstract" name="OtherrevenuesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PfizerMember" name="PfizerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Premiumonpurchaseofcommonstock" name="Premiumonpurchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" name="ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" name="ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestOfWorldMember" name="RestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprograms" name="RevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShorttermderivativeMember" name="ShorttermderivativeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxcontingencyAbstract" name="TaxcontingencyAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Termofcollaborationagreement" name="Termofcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Totalpaymenttoentercollaborationagreement" name="Totalpaymenttoentercollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_TransitionTollTaxRepatriationTaxRate" name="TransitionTollTaxRepatriationTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_U.S.2017TaxActMember" name="U.S.2017TaxActMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>biib-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20180331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20180331.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20180331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20180331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20180331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20180331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20180331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20180331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20180331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20180331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20180331.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20180331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20180331.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20180331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20180331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20180331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20180331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20180331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20180331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20180331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20180331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20180331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20180331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20180331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20180331.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20180331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20180331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20180331.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20180331.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20180331.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20180331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20180331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20180331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:href="biib-20180331.xsd#RevenuesRevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:href="biib-20180331.xsd#RevenuesRevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20180331.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:href="biib-20180331.xsd#RevenuesRevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20180331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20180331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20180331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:href="biib-20180331.xsd#ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20180331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20180331.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20180331.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_25eb7974-3b7b-f164-2633-c5b5794b9c17" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_25eb7974-3b7b-f164-2633-c5b5794b9c17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_79b86299-04f6-ff11-6b66-c6ef1f697685" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_79b86299-04f6-ff11-6b66-c6ef1f697685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_962cfc51-230d-a221-126b-1d12af7a5921" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_962cfc51-230d-a221-126b-1d12af7a5921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_9cebbd9b-269e-5a19-54b8-1c32e2660d83" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_9cebbd9b-269e-5a19-54b8-1c32e2660d83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8bd7b051-5be0-703c-6635-0cad16b52005" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8bd7b051-5be0-703c-6635-0cad16b52005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a83917b5-0d97-08b8-a37b-5a651675d415" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a83917b5-0d97-08b8-a37b-5a651675d415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_96b318db-5cfb-7c2a-3933-0632d73c101c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_96b318db-5cfb-7c2a-3933-0632d73c101c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2652b636-1a3b-e639-2800-d9ed5b9b4fc0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2652b636-1a3b-e639-2800-d9ed5b9b4fc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_351eeed0-a987-88e4-c007-095f3644ffff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_351eeed0-a987-88e4-c007-095f3644ffff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ae796c5c-1c01-d654-6a3c-3b5dd2c89517" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ae796c5c-1c01-d654-6a3c-3b5dd2c89517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_9e3a4c1c-d826-987b-b5de-c5b578fdbfae" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_biib_Collaborationprofitlosssharing_9e3a4c1c-d826-987b-b5de-c5b578fdbfae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c520208-bae2-1c51-b4b4-935e91f5fece" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c520208-bae2-1c51-b4b4-935e91f5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9684315-a9e4-a270-d882-14da209d6338" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9684315-a9e4-a270-d882-14da209d6338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_792de6b4-2056-4259-2de2-c302f546025c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_792de6b4-2056-4259-2de2-c302f546025c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_38f7f811-0e73-faf3-e7e6-c5b578fd26c9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_38f7f811-0e73-faf3-e7e6-c5b578fd26c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_169d77af-5216-aa2b-07d9-c5b5792bdf8b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_169d77af-5216-aa2b-07d9-c5b5792bdf8b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b4cebb29-0be8-9a62-3a11-985fb541a531" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b4cebb29-0be8-9a62-3a11-985fb541a531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7737f022-7814-d1ba-7a34-4005044fb373" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7737f022-7814-d1ba-7a34-4005044fb373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_744a85ef-de6a-dc1b-540c-cd37e4ee0e8e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_744a85ef-de6a-dc1b-540c-cd37e4ee0e8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_d23f3a10-8672-f1d4-6f93-c5b5791c8b49" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_d23f3a10-8672-f1d4-6f93-c5b5791c8b49" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a2377e00-ed9e-3dc2-4fbd-c7e624463b5d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a2377e00-ed9e-3dc2-4fbd-c7e624463b5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_303ce027-35e0-90c6-b665-c64d3c33d4e9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_303ce027-35e0-90c6-b665-c64d3c33d4e9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_2b463f4d-0504-7100-db99-2977b50900b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:to="loc_biib_ShareOfCoPromotionProfits_2b463f4d-0504-7100-db99-2977b50900b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6cf3013c-890b-ea8a-d84d-af0ec88302d5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ba20f6b9-d55b-6ca6-9a65-1e800c90ae83" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6cf3013c-890b-ea8a-d84d-af0ec88302d5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ba20f6b9-d55b-6ca6-9a65-1e800c90ae83" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d7f86d22-9204-660e-e7a4-c5b5794becca" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6cf3013c-890b-ea8a-d84d-af0ec88302d5" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d7f86d22-9204-660e-e7a4-c5b5794becca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>biib-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20180331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20180331.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20180331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20180331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20180331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20180331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20180331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20180331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20180331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20180331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20180331.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20180331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20180331.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20180331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20180331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20180331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20180331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20180331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20180331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20180331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20180331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20180331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20180331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20180331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20180331.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20180331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20180331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20180331.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20180331.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20180331.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20180331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20180331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20180331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:href="biib-20180331.xsd#RevenuesRevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:href="biib-20180331.xsd#RevenuesRevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20180331.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:href="biib-20180331.xsd#RevenuesRevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20180331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20180331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20180331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:href="biib-20180331.xsd#ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20180331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20180331.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20180331.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_473B152F03BC992DCC1CDE5F305E1B95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_473B152F03BC992DCC1CDE5F305E1B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:to="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:to="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_E8BA4D9893106D3AF536DE5F305FF828" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_E8BA4D9893106D3AF536DE5F305FF828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:to="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:to="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FA18542024A6F5A85832DE5F3048F77E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FA18542024A6F5A85832DE5F3048F77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_E18B7F5284C6021816CBDE5F30489E1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_E18B7F5284C6021816CBDE5F30489E1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_416C2379E356FC15FD85DE5F304D7E06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_416C2379E356FC15FD85DE5F304D7E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_695B1DCF114FA08DE8F8DE5F304D70AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_695B1DCF114FA08DE8F8DE5F304D70AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5F54101AF31095705D07DE5F304E10BD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_NetIncomeLoss_5F54101AF31095705D07DE5F304E10BD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A" xlink:to="loc_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_B6313A0401A7F4A1738EDE5F31BA86BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_B6313A0401A7F4A1738EDE5F31BA86BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D631C3D0220A470F3BE5DE5F31BA0511" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D631C3D0220A470F3BE5DE5F31BA0511" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:to="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:to="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:to="loc_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:to="loc_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:to="loc_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:to="loc_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:to="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:to="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="loc_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="loc_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="loc_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_1B2B619349DA3CBF5022F7ED19DE7FAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_1B2B619349DA3CBF5022F7ED19DE7FAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_BAE402FD606AE1D0E322F7ED19DE4742" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_biib_Collaborationprofitlosssharing_BAE402FD606AE1D0E322F7ED19DE4742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:to="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:to="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:to="loc_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_372D6BE859286586897DDE5F30BA1A15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_372D6BE859286586897DDE5F30BA1A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:to="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:to="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:to="loc_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:to="loc_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_388A80D0EFA1EC5DB486DE5F30C006FA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_388A80D0EFA1EC5DB486DE5F30C006FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:to="loc_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:to="loc_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:to="loc_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:to="loc_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:to="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:to="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:to="loc_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:to="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:to="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_71C012FA6A3060A389B3DE5F30C4D7B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:to="loc_us-gaap_MinimumMember_71C012FA6A3060A389B3DE5F30C4D7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9C5B28D6BC8175630D44DE5F30C460FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:to="loc_us-gaap_MaximumMember_9C5B28D6BC8175630D44DE5F30C460FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5801B44D4DC1BF44E378DE5F30C48433" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5801B44D4DC1BF44E378DE5F30C48433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:to="loc_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A5BC9ABDB4AD6900AB4EDE5F3078DD0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03" xlink:to="loc_us-gaap_RetainedEarningsMember_A5BC9ABDB4AD6900AB4EDE5F3078DD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:to="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_74D9FAA1A0C9EAC2C820200E8747BCE7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_74D9FAA1A0C9EAC2C820200E8747BCE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_DAB2BD38F605EC5669EA200E8747173A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_DAB2BD38F605EC5669EA200E8747173A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_08DD2BEBF6CC25173123200E87472912" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_08DD2BEBF6CC25173123200E87472912" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8E9AAFA76D067F8959C2200E874741F6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8E9AAFA76D067F8959C2200E874741F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_16285140B6870FA86F13D9FE83CC34BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_16285140B6870FA86F13D9FE83CC34BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:to="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:to="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_F44141B7960753CB8531C4BA62D0DA7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_F44141B7960753CB8531C4BA62D0DA7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:to="loc_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:to="loc_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:to="loc_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:to="loc_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:to="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:to="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:to="loc_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:to="loc_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:to="loc_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_E6B01F4CFE30BA56DD27D4C55BBB66A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47" xlink:to="loc_biib_TysabriProductMember_E6B01F4CFE30BA56DD27D4C55BBB66A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="loc_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="loc_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:to="loc_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_5EAE1A2C109A8433A2AED4C55BBCD08C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:to="loc_biib_TecfideraMember_5EAE1A2C109A8433A2AED4C55BBCD08C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:to="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:to="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:to="loc_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:to="loc_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:to="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_87266171A7E93E254F61DE5F31700978" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5" xlink:to="loc_biib_TecfideraMember_87266171A7E93E254F61DE5F31700978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530" xlink:to="loc_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2AB0CDB4532E65AC9938DE5F3171B225" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2AB0CDB4532E65AC9938DE5F3171B225" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:to="loc_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_724226747D379C0F5CEADF5CCA403664" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_724226747D379C0F5CEADF5CCA403664" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8" xlink:to="loc_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_724226747D379C0F5CEADF5CCA403664" xlink:to="loc_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AB181188D229FBEC7AF3DE5F2FB25F66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_AB181188D229FBEC7AF3DE5F2FB25F66" xlink:to="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8EA9949F89050EE27620DE5F2FB23365" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8EA9949F89050EE27620DE5F2FB23365" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:to="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:to="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:to="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:to="loc_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:to="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:to="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:to="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_A2017CorporateStrategyMember" xlink:label="loc_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:to="loc_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:to="loc_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:to="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04" xlink:to="loc_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:to="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_28E9310B96967244BAEDDE5F3199A0D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:to="loc_biib_AbbVieMember_28E9310B96967244BAEDDE5F3199A0D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_D4B36885AC4FE2F5A0C6DE5F31990010" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_D4B36885AC4FE2F5A0C6DE5F31990010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_91F366F8B14B312EA89DDE5F319988B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:to="loc_us-gaap_OtherSalesRevenueNet_91F366F8B14B312EA89DDE5F319988B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:to="loc_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="loc_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:to="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:to="loc_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:to="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_FE3329B9244D53EC3292DE9538864A38" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_ZINBRYTAMember_FE3329B9244D53EC3292DE9538864A38" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_404FD421EF6276695275DE9538859399" xlink:to="loc_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:to="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1B08F56B123A4C306D25DE9A06F2520A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:to="loc_country_US_1B08F56B123A4C306D25DE9A06F2520A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:to="loc_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1A21B8592529FF104428DEB042CFB52D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1A21B8592529FF104428DEB042CFB52D" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:to="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:to="loc_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:to="loc_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1A21B8592529FF104428DEB042CFB52D" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:to="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2" xlink:to="loc_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="loc_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7BC08D4F339367D6CDBBDE5F300A11C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7BC08D4F339367D6CDBBDE5F300A11C8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:to="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D9FE6FA7D991B471AB23DE5F3004C177" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_MarketStockUnitsMember_D9FE6FA7D991B471AB23DE5F3004C177" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_C48C6FF0753167976279DE5F300A3D71" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_C48C6FF0753167976279DE5F300A3D71" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_0BD02C54D11C40D67E12DE5F300A132C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_0BD02C54D11C40D67E12DE5F300A132C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7BC08D4F339367D6CDBBDE5F300A11C8" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_87E084C0E460533EE94EDE5F300BA311" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_87E084C0E460533EE94EDE5F300BA311" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8CB4CA232982AFDEF4E5DE5F300BA904" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8CB4CA232982AFDEF4E5DE5F300BA904" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:to="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_E468188BEFFD00C7FE89DE5F2FF55D6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_E468188BEFFD00C7FE89DE5F2FF55D6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_AAE19DDB253A34F691E1DE5F2FFA7255" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_AAE19DDB253A34F691E1DE5F2FFA7255" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:to="loc_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:to="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:to="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:to="loc_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:to="loc_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0" xlink:to="loc_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:to="loc_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:to="loc_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C0A57AD6EA4329E3D59AF7EEC463C77F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C0A57AD6EA4329E3D59AF7EEC463C77F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:to="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_F2F3391205A5C2BBC1AAE4CF61CAE694" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_F2F3391205A5C2BBC1AAE4CF61CAE694" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AccountingStandardsUpdated201707Member" xlink:label="loc_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:to="loc_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3296186298D4FB704804E4CF61CA7294" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:to="loc_us-gaap_RetainedEarningsMember_3296186298D4FB704804E4CF61CA7294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6D790F07DA573396A23EE4CF61CB56B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6D790F07DA573396A23EE4CF61CB56B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>biib-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A3028AC4648317CFA33F3A22895F67A5_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_11BB0566D9F25AA5AA96FA0D629B0F53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_11BB0566D9F25AA5AA96FA0D629B0F53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_11BB0566D9F25AA5AA96FA0D629B0F53" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_11BB0566D9F25AA5AA96FA0D629B0F53" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:to="lab_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C" xlink:to="lab_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:to="lab_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:to="lab_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:to="lab_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_1D012EB5F7AA1C7F4EA75B8D218D9C46_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F32B469C29C79EF849F95B8D218DEF6A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F32B469C29C79EF849F95B8D218DEF6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_982990D158B7216499A55B8D218D7189_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_982990D158B7216499A55B8D218D7189_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5EE526C8F0063087308F5B8D217BB652_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43D4ED5E780D5DB9925D2CC0963CFFD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43D4ED5E780D5DB9925D2CC0963CFFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43D4ED5E780D5DB9925D2CC0963CFFD5" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43D4ED5E780D5DB9925D2CC0963CFFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EAEAD0FA2D2333BBFA6D5B8D217BFC1B_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EAEAD0FA2D2333BBFA6D5B8D217BFC1B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_838195A2C8F55B6C62805B8D2197D315_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_D190036728915C00BBACAB7331471C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D190036728915C00BBACAB7331471C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_D190036728915C00BBACAB7331471C5D" xlink:to="lab_us-gaap_EquityAbstract_D190036728915C00BBACAB7331471C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06C0B7B3443AFFF4F4735B8D2197144D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06C0B7B3443AFFF4F4735B8D2197144D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:to="lab_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:to="lab_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Asset Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:to="lab_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:to="lab_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="lab_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="lab_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33_label_en-US" xlink:label="lab_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:to="lab_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:to="lab_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:to="lab_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2_label_en-US" xlink:label="lab_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:to="lab_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9_label_en-US" xlink:label="lab_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:to="lab_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:to="lab_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:to="lab_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:to="lab_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:to="lab_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:to="lab_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05_label_en-US" xlink:label="lab_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:to="lab_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:to="lab_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="lab_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:to="lab_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:to="lab_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:to="lab_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:to="lab_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:to="lab_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:to="lab_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_A6718145665D3782EC095B8D21AA9ED7_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_8B0B65456F4525CF06D25B8D21AA907B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_8B0B65456F4525CF06D25B8D21AA907B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7D22502A32441BF7FC395B8D21AA115A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7D22502A32441BF7FC395B8D21AA115A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4920793F84FE260A071F5B8D21AA3A34_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4920793F84FE260A071F5B8D21AA3A34_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:to="lab_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:to="lab_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:type="arc" />
    <link:label id="lab_country_US_274D68D99862056C6223DF77A1CDBE17_terseLabel_en-US" xlink:label="lab_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_274D68D99862056C6223DF77A1CDBE17_label_en-US" xlink:label="lab_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:to="lab_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">E.U. and Canada</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:to="lab_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:to="lab_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:to="lab_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:to="lab_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A_label_en-US" xlink:label="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A_documentation_en-US" xlink:label="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:to="lab_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612_label_en-US" xlink:label="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612_documentation_en-US" xlink:label="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:to="lab_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:to="lab_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="lab_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:to="lab_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:type="arc" />
    <link:label id="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:to="lab_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab</link:label>
    <link:label id="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A_label_en-US" xlink:label="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A_documentation_en-US" xlink:label="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:to="lab_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory charges</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:to="lab_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:to="lab_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:to="lab_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1_label_en-US" xlink:label="lab_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:to="lab_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:to="lab_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:to="lab_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:to="lab_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:to="lab_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:to="lab_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:to="lab_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:to="lab_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A_label_en-US" xlink:label="lab_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:to="lab_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:to="lab_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_BB98F63EB90991BCFB775B8D21FD01C6_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_AAFCF1D76EF10C25A1EB5B8D21FDC2E9_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_AAFCF1D76EF10C25A1EB5B8D21FDC2E9_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_AAFCF1D76EF10C25A1EB5B8D21FDC2E9_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_85E58726F87F3207D6DD5B8D21FD00E0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_85E58726F87F3207D6DD5B8D21FD00E0_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0B0BABE7A247E36528995B8D21FD1364_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0B0BABE7A247E36528995B8D21FD1364_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2_label_en-US" xlink:label="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2_documentation_en-US" xlink:label="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:to="lab_biib_TecfideraMember_C9789F2FB1944536F407DE95388679E2" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC_label_en-US" xlink:label="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC_documentation_en-US" xlink:label="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:to="lab_biib_InterferonMember_21C592B5364F33A7F383DE95388610BC" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753_label_en-US" xlink:label="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:to="lab_biib_TysabriProductMember_C7104B89016675DA3F3DDE953886B753" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335_label_en-US" xlink:label="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:to="lab_biib_FAMPYRAMember_53485FA6DFDC7769209EDE953886D335" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD_label_en-US" xlink:label="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:to="lab_biib_SPINRAZAMember_FDE0F02DA68C5F403117DE953886DCBD" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F_label_en-US" xlink:label="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:to="lab_biib_ELOCTATEMember_FA35797B582CD6708F6DDE9538869F2F" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472_label_en-US" xlink:label="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472_documentation_en-US" xlink:label="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:to="lab_biib_ALPROLIXMember_58A4F32C68C32133FF4ADE9538868472" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5_label_en-US" xlink:label="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:to="lab_biib_FUMADERMMember_F13C3DFEA663DB9337D9DE953886EDE5" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11_label_en-US" xlink:label="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:to="lab_biib_BENEPALIMember_54F729AC7D83698E6A15DE9538867C11" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D_label_en-US" xlink:label="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:to="lab_biib_FLIXABIMember_23C459CE9A236FF1FF43DE953886483D" xlink:type="arc" />
    <link:label id="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7_terseLabel_en-US" xlink:label="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7_label_en-US" xlink:label="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7_documentation_en-US" xlink:label="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest of world.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:to="lab_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C" xlink:to="lab_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="lab_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD_terseLabel_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD_label_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD_documentation_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:to="lab_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E_label_en-US" xlink:label="lab_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:to="lab_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102_label_en-US" xlink:label="lab_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:to="lab_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E_label_en-US" xlink:label="lab_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:to="lab_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448_label_en-US" xlink:label="lab_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:to="lab_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:to="lab_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:type="arc" />
    <link:label id="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B_terseLabel_en-US" xlink:label="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B_label_en-US" xlink:label="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B_documentation_en-US" xlink:label="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:to="lab_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:to="lab_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="lab_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:type="arc" />
    <link:label id="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:to="lab_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:to="lab_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:type="arc" />
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15_terseLabel_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15_label_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15_documentation_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:to="lab_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:type="arc" />
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB_terseLabel_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB_label_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB_documentation_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:to="lab_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:to="lab_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:to="lab_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:to="lab_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D3FDF3A9C58F970EB7BB5B8D216385DD_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D3FDF3A9C58F970EB7BB5B8D216385DD_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:to="lab_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:to="lab_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:to="lab_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:to="lab_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39_label_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:to="lab_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F_label_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:to="lab_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F_terseLabel_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F_label_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F_documentation_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:to="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:type="arc" />
    <link:label id="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435_terseLabel_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other foreign earnings</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435_label_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435_documentation_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:to="lab_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:type="arc" />
    <link:label id="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231_terseLabel_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231_label_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act [Member]</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231_documentation_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:to="lab_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:to="lab_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remeasurement of our deferred tax balances in our provisional estimate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:type="arc" />
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA_terseLabel_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Toll Tax repatriation tax rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA_label_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA_documentation_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:to="lab_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payment, including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_3E72038F2D23B230BB005B8D21955E83_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_3E72038F2D23B230BB005B8D21955E83_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_3E72038F2D23B230BB005B8D21955E83_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B5E43CC50E3802F8D4DA6FDF215E1F7B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B5E43CC50E3802F8D4DA6FDF215E1F7B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_684650C8122F0B62644E6FDF215E80B6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_684650C8122F0B62644E6FDF215E80B6_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:to="lab_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_972FA0D418EC5179AF256FDF215EBB6B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_972FA0D418EC5179AF256FDF215EBB6B_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:to="lab_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_1AE890C4653138E1CEB56FDF215EE104_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_1AE890C4653138E1CEB56FDF215EE104_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_09E48DB04A7A73B2960D6FDF215E1F5D_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_09E48DB04A7A73B2960D6FDF215E1F5D_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:to="lab_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_FCD9C58449F9FA39F0D66FDF215E7EE9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_FCD9C58449F9FA39F0D66FDF215E7EE9_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:to="lab_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_0C6DF974894EEB80ED6E6FDF21631747_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_0C6DF974894EEB80ED6E6FDF21631747_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_31078C35A27677BDD4456FDF21630052_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_31078C35A27677BDD4456FDF21630052_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_DC89AAAEBDAD66F77C586FDF2163604B_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_DC89AAAEBDAD66F77C586FDF2163604B_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88_verboseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to technical development and technology transfer services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:to="lab_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_35DCDBB53D8B7613E8745B8D2183FC14_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_35DCDBB53D8B7613E8745B8D2183FC14_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:to="lab_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:to="lab_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:type="arc" />
    <link:label id="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B_terseLabel_en-US" xlink:label="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Corporate Strategy</link:label>
    <link:label id="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B_label_en-US" xlink:label="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Corporate Strategy [Member]</link:label>
    <link:label id="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B_documentation_en-US" xlink:label="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Corporate Strategy</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_A2017CorporateStrategyMember" xlink:label="loc_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:to="lab_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:to="lab_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A63DDA24CB56EAC43165B8D216C5989_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A63DDA24CB56EAC43165B8D216C5989_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:to="lab_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:to="lab_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031_label_en-US" xlink:label="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031_documentation_en-US" xlink:label="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:to="lab_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:to="lab_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:to="lab_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Forward Pharma</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018 (remaining nine months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:to="lab_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_5CFF7FE230BB88E714C15B8D2209C415_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_98DDDBC2D19D5FB487263B2470A1F722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_98DDDBC2D19D5FB487263B2470A1F722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98DDDBC2D19D5FB487263B2470A1F722" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_98DDDBC2D19D5FB487263B2470A1F722" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_60116D6DDE5EE0E006145B8D22096B9E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_60116D6DDE5EE0E006145B8D22096B9E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16ED7873280E37C5FE2C5B8D216B8DDE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16ED7873280E37C5FE2C5B8D216B8DDE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1D72D2DD81934E352EE65B8D2275D63C_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3643E366009BD71215AA5B8D227542EC_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_8A347D56C2FC5772BE593375E1E02CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8A347D56C2FC5772BE593375E1E02CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_8A347D56C2FC5772BE593375E1E02CB1" xlink:to="lab_us-gaap_NetIncomeLoss_8A347D56C2FC5772BE593375E1E02CB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_865555F4D9ACF87C84F15B8D227581A7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_865555F4D9ACF87C84F15B8D227581A7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1D355BBD53F356F3531A5B8D2275A054_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1D355BBD53F356F3531A5B8D2275A054_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_C8653F0ED19EB273536C5B8D2276D7A8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_C8653F0ED19EB273536C5B8D2276D7A8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D90A537A220B55E9610B5B8D227682DA_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D90A537A220B55E9610B5B8D227682DA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EE9BAEA3D7AF1A5C60D65B8D22762D0D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EE9BAEA3D7AF1A5C60D65B8D22762D0D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_AAD500BFB5488CBA9AC35B8D227655F7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_AAD500BFB5488CBA9AC35B8D227655F7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_681AC65BF8FB1FEE08135B8D2276C722_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_681AC65BF8FB1FEE08135B8D2276C722_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1273BF4339F11E3171DF5B8D227687FA_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1273BF4339F11E3171DF5B8D227687FA_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_442E279C0D07D05160BC5B8D2276CC4B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_442E279C0D07D05160BC5B8D2276CC4B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_A913158B2AE7B75393615B8D2207DBE4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_A913158B2AE7B75393615B8D2207DBE4_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:to="lab_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BB66AEBF2B426C8F42D05B8D22075B9F_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BB66AEBF2B426C8F42D05B8D22075B9F_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1887A1C52C3FDBA907D25B8D2207AB36_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1887A1C52C3FDBA907D25B8D2207AB36_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2725426902C2CE4F27DC5B8D2207C57D_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2725426902C2CE4F27DC5B8D2207C57D_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_EC4E01CBC77E833719AB5B8D2207EB96_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_EC4E01CBC77E833719AB5B8D2207EB96_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_EC4E01CBC77E833719AB5B8D2207EB96_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_52CE19628A4B82DB20F35B8D2207043E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_040F3362D3005217B062EFF29BD4E7B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_040F3362D3005217B062EFF29BD4E7B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_040F3362D3005217B062EFF29BD4E7B3" xlink:to="lab_us-gaap_InventoryNet_040F3362D3005217B062EFF29BD4E7B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_4E113F9022D521C218A85B8D220702A5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_4E113F9022D521C218A85B8D220702A5_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:to="lab_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Non Controlling Interests [Abstract]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">NCI, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6" xlink:to="lab_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to NCI, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment and other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">NCI, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB" xlink:to="lab_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_327F97D9948D07A0BBFC5B8D22597D5E_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_327F97D9948D07A0BBFC5B8D22597D5E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_755EF68846D4F80F8DB75B8D2259DE39_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_755EF68846D4F80F8DB75B8D2259DE39_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D_label_en-US" xlink:label="lab_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:to="lab_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C" xlink:to="lab_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49" xlink:to="lab_us-gaap_PrepaidTaxes_A7229F846959448E2F21E4D306CFDC49" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8DD843C4CAF5C8BE6EC15B8D21AC33C8_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8DD843C4CAF5C8BE6EC15B8D21AC33C8_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6D189B89347425BA999A5B8D21C33DF5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6D189B89347425BA999A5B8D21C33DF5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_D5D7CA5112AEF74F20FD5B8D21C39054_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_D5D7CA5112AEF74F20FD5B8D21C39054_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5CD4D2C415EE7BF1F6315B8D21C34D81_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5CD4D2C415EE7BF1F6315B8D21C34D81_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_CCC17421EFE3E382DC985B8D21C32934_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_CCC17421EFE3E382DC985B8D21C32934_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:to="lab_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:to="lab_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:to="lab_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="lab_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C_label_en-US" xlink:label="lab_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:to="lab_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:to="lab_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:to="lab_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:type="arc" />
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB_terseLabel_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB_label_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB_documentation_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:to="lab_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="lab_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases under the 2016 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase and retire of common stock, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity increase during the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:type="arc" />
    <link:label id="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF_terseLabel_en-US" xlink:label="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Updated 2017-07</link:label>
    <link:label id="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF_label_en-US" xlink:label="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Updated 2017-07 [Member]</link:label>
    <link:label id="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF_documentation_en-US" xlink:label="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Standards Updated 2017-07 [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AccountingStandardsUpdated201707Member" xlink:label="loc_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:to="lab_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Charge [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:to="lab_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior period reclassification adjustment</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:to="lab_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:to="lab_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_51B780EEF8C94FA9EDF55B8D218E3032_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_51B780EEF8C94FA9EDF55B8D218E3032_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CEEA347CAA1B27727A615B8D224888F5_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CEEA347CAA1B27727A615B8D224888F5_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F44877E223AEA2B433325B8D21FFEDAE_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F44877E223AEA2B433325B8D21FFEDAE_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_292D97ACCF94B36A983A5B8D21E6BC9F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_292D97ACCF94B36A983A5B8D21E6BC9F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6009DD97364DC762A31A5B8D21E68756_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6009DD97364DC762A31A5B8D21E68756_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AA32C3B3C88FD0361A4E5B8D21E6AF10_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AA32C3B3C88FD0361A4E5B8D21E6AF10_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_54BB547E1B0325C7946B5B8D210D7C13_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_54BB547E1B0325C7946B5B8D210D7C13_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations and milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:to="lab_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:to="lab_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B_label_en-US" xlink:label="lab_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:to="lab_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_7C4270342BFBE8BA91AD5B8D21562C74_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_7C4270342BFBE8BA91AD5B8D21562C74_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4A840B35FE876E9CA6605B8D215631A7_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4A840B35FE876E9CA6605B8D215631A7_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7801C7089BCBA42F3C5A5B8D217A8978_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7801C7089BCBA42F3C5A5B8D217A8978_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2E11DEAC0948E37374F85B8D217A86F6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2E11DEAC0948E37374F85B8D217A86F6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_80907D7538F7A92DB2115B8D21B3C75B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_80907D7538F7A92DB2115B8D21B3C75B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_A5DD5CBD5ADC307914475B8D21B31C53_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_A5DD5CBD5ADC307914475B8D21B31C53_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_F9C879C82CDF534AB3A95B8D21B36881_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_F9C879C82CDF534AB3A95B8D21B36881_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="lab_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:to="lab_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518_label_en-US" xlink:label="lab_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:to="lab_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666" xlink:to="lab_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:to="lab_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:to="lab_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:to="lab_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708" xlink:to="lab_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:to="lab_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:to="lab_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:to="lab_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2424810F920CFE112CFD5B8D219B6A9D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2424810F920CFE112CFD5B8D219B6A9D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F7722013744F79FB6D0F5B8D2160B5EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F7722013744F79FB6D0F5B8D2160B5EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A3615D5D2BF551634F205B8D216080E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A3615D5D2BF551634F205B8D216080E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_28B9D3229B8BF39147625B8D21B1FD10_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_28B9D3229B8BF39147625B8D21B1FD10_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_28B9D3229B8BF39147625B8D21B1FD10_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:to="lab_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:to="lab_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:to="lab_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:to="lab_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:type="arc" />
    <link:label id="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:to="lab_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:to="lab_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="lab_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:type="arc" />
    <link:label id="lab_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161_verboseLabel_en-US" xlink:label="lab_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161_label_en-US" xlink:label="lab_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:to="lab_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:type="arc" />
    <link:label id="lab_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34_terseLabel_en-US" xlink:label="lab_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34_label_en-US" xlink:label="lab_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:to="lab_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:type="arc" />
    <link:label id="lab_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF_verboseLabel_en-US" xlink:label="lab_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF_label_en-US" xlink:label="lab_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:to="lab_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:type="arc" />
    <link:label id="lab_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A_terseLabel_en-US" xlink:label="lab_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A_label_en-US" xlink:label="lab_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:to="lab_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22_label_en-US" xlink:label="lab_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:to="lab_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:to="lab_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:to="lab_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:to="lab_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:to="lab_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:to="lab_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:to="lab_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:to="lab_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:to="lab_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:to="lab_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:to="lab_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivatives designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428_verboseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="lab_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on foreign currency derivatives, net, before tax</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:to="lab_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities by Classification of Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE_label_en-US" xlink:label="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:to="lab_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Neurimmune</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723_terseLabel_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723_label_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723_documentation_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:to="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F_terseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:to="lab_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:to="lab_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:to="lab_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966_label_en-US" xlink:label="lab_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:to="lab_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC" xlink:to="lab_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:to="lab_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash contribution to Bioverativ Inc.</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3E63F1F92C721498569C5B8D21821189_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3E63F1F92C721498569C5B8D21821189_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="lab_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance, as of January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income loss before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A_label_en-US" xlink:label="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:to="lab_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F_label_en-US" xlink:label="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:to="lab_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_ED8949E5F182580168FC5B8D21C5B1DA_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_ED8949E5F182580168FC5B8D21C5B1DA_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:type="arc" />
    <link:label id="lab_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844_label_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:label id="lab_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844_documentation_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:to="lab_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:type="arc" />
    <link:label id="lab_country_BR_30F864720D50DEBEEC65DF634AB89542_terseLabel_en-US" xlink:label="lab_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil</link:label>
    <link:label id="lab_country_BR_30F864720D50DEBEEC65DF634AB89542_label_en-US" xlink:label="lab_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:to="lab_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brazil tax assessment, including interest and penalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:to="lab_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1_terseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:to="lab_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:to="lab_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8572DA76F8827ED8BAF95B8D2169AA3A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8572DA76F8827ED8BAF95B8D2169AA3A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_CD48E2636C51BC33C7D25B8D2169A694_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_AD3538B0565A56C5B0C550F7F5FA17A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_AD3538B0565A56C5B0C550F7F5FA17A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_AD3538B0565A56C5B0C550F7F5FA17A8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_AD3538B0565A56C5B0C550F7F5FA17A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_27B2EBA892BBF702CA515B8D2169BC79_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_27B2EBA892BBF702CA515B8D2169BC79_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_69E4677703E22D1D7EEF5B8D216911D4_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_69E4677703E22D1D7EEF5B8D216911D4_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_B545AEF03EDF017B35AD5B8D21696566_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_B545AEF03EDF017B35AD5B8D21696566_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_A506AFBE31AAB801DAA05B8D21693823_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_A506AFBE31AAB801DAA05B8D21693823_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4577FB5685F643CEE72B5B8D21690B05_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4577FB5685F643CEE72B5B8D21690B05_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4577FB5685F643CEE72B5B8D21690B05_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A39F27B980CE506384745B8D2169F20B_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A39F27B980CE506384745B8D2169F20B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5AD0B2314C8B515F94945B8D2169A9EC_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5AD0B2314C8B515F94945B8D2169A9EC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0D60ACDEE37CF4BE17C35B8D216997D5_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0D60ACDEE37CF4BE17C35B8D216997D5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_98B6CC2C6E66AFAC592B5B8D22881392_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_98B6CC2C6E66AFAC592B5B8D22881392_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_1E7FB7C5E49B8C842DCF5B8D22889CA3_label_en-US" xlink:label="lab_dei_EntityRegistrantName_2B20BA99C02B5DA19D3D156D0C2D97D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2B20BA99C02B5DA19D3D156D0C2D97D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_2B20BA99C02B5DA19D3D156D0C2D97D5" xlink:to="lab_dei_EntityRegistrantName_2B20BA99C02B5DA19D3D156D0C2D97D5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_A41DD316C582A218D44D5B8D2288FC72_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_682903EE8F305D139B0DB23F3E6D2CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_682903EE8F305D139B0DB23F3E6D2CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_682903EE8F305D139B0DB23F3E6D2CE4" xlink:to="lab_dei_EntityCentralIndexKey_682903EE8F305D139B0DB23F3E6D2CE4" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7C2158058E985D7B9AC95B8D2289D493_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_22CF44A2F1A8508C95D359F899CF030A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_22CF44A2F1A8508C95D359F899CF030A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_22CF44A2F1A8508C95D359F899CF030A" xlink:to="lab_dei_CurrentFiscalYearEndDate_22CF44A2F1A8508C95D359F899CF030A" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_E0E9839AFC28F63C03435B8D22897561_label_en-US" xlink:label="lab_dei_EntityFilerCategory_8FCB29BEAA585957B37AAD490F0B3EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8FCB29BEAA585957B37AAD490F0B3EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_8FCB29BEAA585957B37AAD490F0B3EF5" xlink:to="lab_dei_EntityFilerCategory_8FCB29BEAA585957B37AAD490F0B3EF5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_708CB1C4502B4B8E5D4D5B8D2289BE72_label_en-US" xlink:label="lab_dei_DocumentType_BBF7A8D3371D524099D2050D7CA6A47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_BBF7A8D3371D524099D2050D7CA6A47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_BBF7A8D3371D524099D2050D7CA6A47B" xlink:to="lab_dei_DocumentType_BBF7A8D3371D524099D2050D7CA6A47B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_7735EA41E6514EFCDAAA5B8D2289032A_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_65904BAFB0DE5C3DBBECB1DD1CFABAAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_65904BAFB0DE5C3DBBECB1DD1CFABAAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_65904BAFB0DE5C3DBBECB1DD1CFABAAB" xlink:to="lab_dei_DocumentPeriodEndDate_65904BAFB0DE5C3DBBECB1DD1CFABAAB" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6404FBA098A0319BF0065B8D2289648F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_D7C3E1779AF1555091A2D6B58A399258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_D7C3E1779AF1555091A2D6B58A399258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_D7C3E1779AF1555091A2D6B58A399258" xlink:to="lab_dei_DocumentFiscalYearFocus_D7C3E1779AF1555091A2D6B58A399258" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B9D3EBB296D052CA72E25B8D22897FEC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_89EED028FFFD5A4D96D4EC6E43D16E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_89EED028FFFD5A4D96D4EC6E43D16E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_89EED028FFFD5A4D96D4EC6E43D16E02" xlink:to="lab_dei_DocumentFiscalPeriodFocus_89EED028FFFD5A4D96D4EC6E43D16E02" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_07C95A16E2877B7AE6085B8D2289CBEA_label_en-US" xlink:label="lab_dei_AmendmentFlag_48ECA6E8EAAE5ACFAE868B7DB3595ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_48ECA6E8EAAE5ACFAE868B7DB3595ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_48ECA6E8EAAE5ACFAE868B7DB3595ED1" xlink:to="lab_dei_AmendmentFlag_48ECA6E8EAAE5ACFAE868B7DB3595ED1" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_24F4936137ED7DD2AC5C5B8D228928D6_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_8BC62078307254C6B564338D48E788DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8BC62078307254C6B564338D48E788DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8BC62078307254C6B564338D48E788DA" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_8BC62078307254C6B564338D48E788DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8_terseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB_terseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9_terseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5" xlink:type="arc" />
    <link:label id="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424_terseLabel_en-US" xlink:label="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Karyopharm</link:label>
    <link:label id="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424_label_en-US" xlink:label="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:label id="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424_documentation_en-US" xlink:label="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:to="lab_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4FC5AC1D645F735A7EFA5B8D20F3B212_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7AFB929047115A3CBF3275D4759A5C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7AFB929047115A3CBF3275D4759A5C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7AFB929047115A3CBF3275D4759A5C9F" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7AFB929047115A3CBF3275D4759A5C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_ED38CCD428C2A995356B5B8D20F4F770_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_ED38CCD428C2A995356B5B8D20F4F770_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:to="lab_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:to="lab_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF_totalLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3E77CEB8DACF3F4485765B8D21E8417C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3E77CEB8DACF3F4485765B8D21E8417C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3_label_en-US" xlink:label="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20180331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:to="lab_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:to="lab_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:to="lab_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF" xlink:to="lab_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF" xlink:to="lab_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>biib-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20180331.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20180331.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20180331.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20180331.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20180331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20180331.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20180331.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20180331.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20180331.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20180331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20180331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20180331.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20180331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20180331.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20180331.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20180331.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20180331.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20180331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20180331.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20180331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20180331.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20180331.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20180331.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20180331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20180331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20180331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20180331.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20180331.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20180331.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20180331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20180331.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20180331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20180331.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20180331.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20180331.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20180331.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20180331.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20180331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20180331.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20180331.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20180331.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20180331.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20180331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20180331.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenues" xlink:href="biib-20180331.xsd#RevenuesRevenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:href="biib-20180331.xsd#RevenuesRevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:href="biib-20180331.xsd#RevenuesRevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20180331.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:href="biib-20180331.xsd#RevenuesRevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20180331.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20180331.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20180331.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:href="biib-20180331.xsd#ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20180331.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20180331.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20180331.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20180331.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C0083F8100C55B58B88FFD174D358214" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C0083F8100C55B58B88FFD174D358214" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_589F6D1D1E8355FF83F1CB78A87DC706" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_619C0CB254B68E6F6E21DE5F30580685" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_619C0CB254B68E6F6E21DE5F30580685" xlink:to="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C0362D43F0310379427DE5F305DA6B3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_473B152F03BC992DCC1CDE5F305E1B95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_796AD5B3CBFC5DA433EFDE5F305D0495" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_473B152F03BC992DCC1CDE5F305E1B95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_37E7839B38923293BA39DE5F305EF56B" xlink:to="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_A0DDEE031FDD93846436DE5F305E2E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DB29C4F62702C2DEBD13DE5F305E67FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_0E1BD28FA7B795E0BEDDDE5F305EBA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_D309AD71C6537591580DDE5F305E1FA4" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_13FD1FECCC370EEE231CDE5F305E3AF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5470A7422F6E8072D329DE5F3058431D" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AB5E3877685C6F6E8802DE5F305E8959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C81083F35A281EC792C0DE5F305EA558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_E8BA4D9893106D3AF536DE5F305FF828" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_E8BA4D9893106D3AF536DE5F305FF828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_84C5DDC028DA02C14787DE5F305F4D3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1C3EAADBBAA3499F8D9DDE5F305F7F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_E64E52EECFA2322C6706DE5F305F9AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_D6308B076E059A7B915ADE5F305EEF19" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9E453CD3F230D03E8817DE5F305F7A4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C0B9F98189C5DEFB9887DE5F3048D799" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C0B9F98189C5DEFB9887DE5F3048D799" xlink:to="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A90E5A5A1DBF57F9D840DE5F30485D52" xlink:to="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FA18542024A6F5A85832DE5F3048F77E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FA18542024A6F5A85832DE5F3048F77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_E18B7F5284C6021816CBDE5F30489E1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3D1D8941467AE5D303D5DE5F3048824D" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_E18B7F5284C6021816CBDE5F30489E1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_88F7F64F0A2D2A85C6F0DE5F30486440" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_23D6D234D8BE3D94CE3ADE5F3048EDA6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_352F894758B236CFF148DE5F3048A98E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_18AABC3C48CC2E719164DE5F3048E56E" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_777376E843F648B2A5BDDE5F304D6870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_416C2379E356FC15FD85DE5F304D7E06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_416C2379E356FC15FD85DE5F304D7E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_695B1DCF114FA08DE8F8DE5F304D70AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_695B1DCF114FA08DE8F8DE5F304D70AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_OperatingExpenses_B73A6317D2AAD98E6D2DDE5F304E360D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5F54101AF31095705D07DE5F304E10BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_292D772D5B8D8462DDBBDE5F304D1102" xlink:to="loc_us-gaap_NetIncomeLoss_5F54101AF31095705D07DE5F304E10BD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_49D6F3E5E38353F291C3DDDC2794C883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_349BE7E97C2C50CD96B3CAA5AB768243" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4FD5EDCBC3755AD19D32B4F54C636274" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F130342F95B124A4073F6767F9791E0B" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_88022C9E234E359FD52A6767F979BE8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_022EDF387F7DE90DA13BDE5F31B972DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_022EDF387F7DE90DA13BDE5F31B972DC" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_626B56E55D18453CAA0EDE5F31B974F6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B33C9C208BFB70FA3EEBDE5F31B92B6A" xlink:to="loc_biib_KaryopharmMember_8A44DF6338788EEC49DDDE5F31BA3424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5E868C97F14EA36ADC53DE5F31B9D810" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_B6313A0401A7F4A1738EDE5F31BA86BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_B6313A0401A7F4A1738EDE5F31BA86BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D631C3D0220A470F3BE5DE5F31BA0511" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8CC5534219D682DDA61EDE5F31BA7508" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_D631C3D0220A470F3BE5DE5F31BA0511" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C362715693695E9AA70FBAF72373AB49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C362715693695E9AA70FBAF72373AB49" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_844CB65E4F9C5FEF9DAA0324A94DE9F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5C8625D6E9643981B411DF5B914E032C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_F0817546DE9464442686DF77A1730B37" xlink:to="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:to="loc_country_US_274D68D99862056C6223DF77A1CDBE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_5DF03195F46408948401DF77A1779489" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_68C03FB874D1D9E2503BDF782998BFB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5EC4DE27663869D32EBBDF5B914E2168" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_657B419255F63A405C68DF5B914EE0E9" xlink:to="loc_us-gaap_ScenarioForecastMember_F06B8FCAA76A3EBD6109DF5B914E1C2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C95E1B0F9E08D0126291DF5B914E2D8A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:to="loc_biib_AbbVieMember_5D31303779D595F86E2CDF5B914F035A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DAF0C7D4936F959E7538DF5B914F51F4" xlink:to="loc_biib_EisaiMember_175A0FE9368803A4075DDF5B914F9612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_16CED37A4CBAC6D4521BDF5B914F8BB9" xlink:to="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="loc_biib_ZINBRYTAMember_038CC486B68DC41720E9DF5B914FB558" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_E2609andBAN2401Member" xlink:label="loc_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="loc_biib_E2609andBAN2401Member_BF3B9D15C3170F6976B3DF5B914FA4A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_46D2ABBB33FEE85AB4D4DF5B914F7298" xlink:to="loc_biib_AducanumabMember_7133B9332F7C464AC3F4DF5B914FC53A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_74260A5EACBC40A22874DF5B914E11E7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_CostOfGoodsSold_4E4C4E60B7DE915B38B4DF5B9154B644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_377B6F1330F293CF91CFDF5B9155266D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_us-gaap_OtherSalesRevenueNet_C516DAC33E87B15B7609DF5B9155EE34" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_biib_Collaborationprofitlosssharing_872D63AECCF6EA19E2CADF5B91556E43" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_25D699A13AFE2DB27D5FDF5B91551A4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_F2667030760C59DEF4C0DF5B914FF6D9" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A86D04A43994B8E8E3C5DF5B915554B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F1021305F04C9A6E4623F7ED19DDA19F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F1021305F04C9A6E4623F7ED19DDA19F" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3D7FCB3BD284056FD50EF7ED19DE1082" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_9314953E53C205D3AF2EF7ED19DEFBDF" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_154B734FFB7C07A9659CF7ED19DE4C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_C52F279268897083FBF2F7ED19DD5251" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3F46F1D0E345FCBB21E4F7ED19DED28E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_65B9DF3AF4E2649161DDF7ED19DEFF88" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_1B2B619349DA3CBF5022F7ED19DE7FAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_1B2B619349DA3CBF5022F7ED19DE7FAE" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_BAE402FD606AE1D0E322F7ED19DE4742" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_biib_Collaborationprofitlosssharing_BAE402FD606AE1D0E322F7ED19DE4742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_CFCCBE2C2E01DC181FF0F7ED19DEC4AC" xlink:to="loc_us-gaap_OtherSalesRevenueNet_DD8F1013DCBF5D8D0F4BF7ED19DF75FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:to="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1657C325FB0E247BB12AF79085D6E1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_B0A0757B8B5A905DA392F79085D6CCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9C9ACFC8305451EB5F00F79085D60BD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_0378D804785F6348F6F9F79085D6F761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_us-gaap_InventoryNet_6CCF7403B8A414D3AF0FF79085D60D33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_us-gaap_OtherAssetsCurrent_31C253D0993BFD9C76FDF79085D6DA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_183760D6E6BA3D27F14AF79085D6F7BE" xlink:to="loc_us-gaap_AssetsCurrent_0DA2C693669272EC3839F79085D6D092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_5501E3D1EDA22CB08BF3F79085D6E761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_FF6648F4B7A00E774EDBF79085D6A1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_09ACF825CE09066B0339F79085D6F636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_Goodwill_FF24FD44E27B5D8427EDF79085D696F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_B6BC8E33E962C5318F60F79085D73F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ADD1BFC464E47797429F79085D71AD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_31AB61E2CB52D3A38909F79085D68492" xlink:to="loc_us-gaap_Assets_6194FA989EB1BCF05FEFF79085D781A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7EC5DD53424565AC69F79085D6699E" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:to="loc_us-gaap_DebtCurrent_211220FFD4176F1F88EBF79085D732DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:to="loc_us-gaap_TaxesPayableCurrent_BAD05A14222947858534F79085D7E168" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:to="loc_us-gaap_AccountsPayableCurrent_E73D82F2E810E2662923F79085D7370B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_15B185B98C652FA602E0F79085D7E2EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7165B382736CFBEE9F71F79085D71380" xlink:to="loc_us-gaap_LiabilitiesCurrent_426B7806C46FE1B4A7F8F79085D7B62A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_LongTermDebt_9633AFFCA9C1A04196B7F79085D745D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_12B1E716821F331F3FB1F79085D76C0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6DFB53D765715557EAECF79085D78A5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_Liabilities_C907AD4091D6C253A640F79085D70C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_CommitmentsAndContingencies_BDE0926845E676B56F70F79085D78C2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_PreferredStockValue_3A844E5C3BDF36A055A8F79085D860EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_CommonStockValue_ABB188B8FCD638316B56F79085D847D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_AdditionalPaidInCapital_08FD0B0287B8FAFA2BF5F79085D826C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3C8AD24FE54020047B46F79085D858B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6AB35101258A662EC33FF79085D8064F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_TreasuryStockValue_1884FE9F09B53D5455F7F79085D8192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_90CA1C05847DBA94D3D6F79085D720DF" xlink:to="loc_us-gaap_StockholdersEquity_B617C580766F7D5657C9F79085D8E774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:to="loc_us-gaap_MinorityInterest_0D1B12D85898C1F957EEF79085D8D3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_AD9F03636554CB8A58DDF79085D74ED6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B33D5E6159F0A8940566F79085D8A4C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4C7B949E65BDE1900339F79085D74C52" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_C0210FF7D05343BE64BEF79085D8B90A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7A1CE1F5A8FC5567BD342DE9BA2E1453" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7A1CE1F5A8FC5567BD342DE9BA2E1453" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9FA0DE05E2235F8E8816C565A500101A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7A1CE1F5A8FC5567BD342DE9BA2E1453" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2B5EE1B2EDA05070BCFF15AEADCB8146" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:to="loc_us-gaap_ProfitLoss_6A2A634A29A512077CC0F7A13EFFD1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_89B6AED1132EA1EC7838F7A13EF57423" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_521FEA16D4BCDB40E49FF7A13EFF8CFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_CAEA3775E59667DD3FF8F7A62171E0B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_CAEA3775E59667DD3FF8F7A62171E0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_ShareBasedCompensation_80D47D5F0D81C6C13854F7A13EFF1BF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E1DBB2E7FF5D8C1456FF7A13EFFBB06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_478BD987C2E62FD2ED9BF7A13EFFD19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18D0ABC8E606B3C4F578F7A13EFF0E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_AC5D2AE6948F8181D10FF7A13EFF9938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_30D5E02E94C1BDE58924F7A13EFFC484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_A389EEF7C05EF403625DF7A13EFF0BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B394F997B56C860A46C4F7A13EFF8979" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_E52FF1B2B301B9C2B448F7A13EFF3E8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_80EA31ABC7BE8031F7D0F7A13EFFBC08" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_FAB643435FB900853874F7A13EFFC120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E76B00EF9DE8FCC633FDF7A13EFF0112" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_ECC2E4E4DBC07A59BA3DF7A13EFFD75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_4DA1755BD7276FB35809F7A13EFF2E7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_E50AF99A783F3A779646F7A13EFFD082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_71C3C0661B4D60CAB4D1F7A13EFF01F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_D2BBF40D6D8FB9BC4E86F7A13EFF7430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_8700359432EF5BD09B92F7A13EFF14C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_92C75F0DF113712A0CA7F7A13EFFF885" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A0CD2D434801BEC1A9CF7A13EFF02D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_96341EA81BEFF21756ADF7A13EFF3362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3B893AEDC48EDD23FF4CF7A13EFF88EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_702D9129F1E846FBF457F7A13EFF3E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_A1E43D000074371CADD3F7A13EFF0637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88B98A58AFF04AACF560F7A13EFF5F3A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_F5923A64A01B94C25E71F7A13EFF2F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_C70294D41906D1497B07F7A13EFF1963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_F8779601124113B60974F7A13EFF369E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_43B3E047047F5885F142F7A13EFFD958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_AA393CD1DA12116A7867F7A13EF594A7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_416D53ACA0CB89C245D7F7A13EFFFE6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8A347D56C2FC5772BE593375E1E02CB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:to="loc_us-gaap_NetIncomeLoss_8A347D56C2FC5772BE593375E1E02CB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_AB78EA79AF5A5724B73BB691A840BE4B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53C8FADA503B55BBB044387607D952EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_8BDE834F4F3D552DAEC66171393B7681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_42760F5198D85B7DA894147461E6E34B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4FC49F8B32365BB4BAD48BE7DD2CD27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30CD93F241815027AEA5299E477427E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_CB158124188159FCBC9A4B65A97E34B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2A75B429D930502DB57E845CEDE5DF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6B2A0D41E52C5AA69BD7016C11680AC3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_94D26EB43604563BBEFE04792493E919" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_4BC0A7ED0D5DEAA255FCDE5F31EC7B02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_4BC0A7ED0D5DEAA255FCDE5F31EC7B02" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_7E0C05C696719E8706FADE5F31EC5A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_0F4BC301685B81FA2C14DE5F31EC7C82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:to="loc_us-gaap_OtherSalesRevenueNet_0F4BC301685B81FA2C14DE5F31EC7C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_44786D4867026DB72465DE5F31ECFB7A" xlink:to="loc_us-gaap_Revenues_E69E676DB74972F1CC1EDE5F31ECB518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_CostOfGoodsSold_4F512AA6E49077AA277CDE5F31EC0666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C1B38954AC9CF874CF07DE5F31EC6950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1DF2077B39961B5752FBDE5F31EC7B03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_91E9BDD39A314D897054DE5F31ED3851" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_91E9BDD39A314D897054DE5F31ED3851" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_17407B837E9055F08D34DE5F31ED032D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_biib_Collaborationprofitlosssharing_17407B837E9055F08D34DE5F31ED032D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3E34C91E6A0F54A21028DE5F31ED7B50" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3E34C91E6A0F54A21028DE5F31ED7B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A52F0071DE81A684EB77DE5F31ED5729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_5A708B6992773914D7C5DE5F31ED1403" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_RestructuringCharges_5A708B6992773914D7C5DE5F31ED1403" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_7C37098D52595BBB7AF4DE5F31EC4E73" xlink:to="loc_us-gaap_CostsAndExpenses_0C8C5E37BF890CE0D661DE5F31EDAADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_OperatingIncomeLoss_9B6594ABBAF898C9E944DE5F31ED4F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8EBC0AFC73CD0C12EE5CDE5F31ED85C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A546547DA32EA9A877F5DE5F31EDF0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0B3365ACB9452B898DFBDE5F31EDA391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4073939EA4C67253B68CDE5F31ED16A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_ProfitLoss_0461DD17411F0D8ACC88DE5F31ED9DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6914F7050491889B3DEFDE5F31EDD2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_NetIncomeLoss_98388E1951D5BC520A28DE5F31EED708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:to="loc_us-gaap_EarningsPerShareBasic_C15A57AB0A6277C98CA5DE5F31EEABAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B72C1938EC1B258E8556DE5F31EE6332" xlink:to="loc_us-gaap_EarningsPerShareDiluted_A1535F42804A4E2C8E1EDE5F31EE3A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_66BE628337D8C0C641A4DE5F31EECBF2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1C29E5BE48936F3270D3DE5F31ECC533" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_66BE628337D8C0C641A4DE5F31EECBF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_66BE628337D8C0C641A4DE5F31EECBF2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07AF87C514163C3BAE4DDE5F31EE99B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_66BE628337D8C0C641A4DE5F31EECBF2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1652FD05918EED617933DE5F31EE5F3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6C13D9F0CE9B5B6E8342DC7244068AA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6C13D9F0CE9B5B6E8342DC7244068AA9" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_400A61EC13D855018296FC82C6001D01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2542F872F0048CDDEC6BDE5F30B93BEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2542F872F0048CDDEC6BDE5F30B93BEA" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityAxis" xlink:label="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeMaturityDomain" xlink:label="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_87679AEBACDB4BCBAFE8DE5F30BAB5D3" xlink:to="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShorttermderivativeMember" xlink:label="loc_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_0B7F30C6F7F74406B1E1DE5F30BAFFE8" xlink:to="loc_biib_ShorttermderivativeMember_4E0AF2FE0CD3F784B257DE5F30BAB743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_B72A33504F2F61C53047DE5F30BAFF6F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_372D6BE859286586897DDE5F30BA1A15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_29780216D599D526FF86DE5F30BACDF3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_372D6BE859286586897DDE5F30BA1A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_385985870B801BED3465DE5F30BA65B7" xlink:to="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_EUR_5FED2B73EA627DEC3129DE5F30BA6161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_GBP_48AEF4B2F6DE0322F28FDE5F30BACA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_CAD_0731A7D50F7065D20B27DE5F30BBF6FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_3923AAA48998F554B188DE5F30BAA100" xlink:to="loc_currency_CHF_71B6B45CB1E6FDA1D8C5DE5F30C0445A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FAD133E417B7D01572E1DE5F30C0D162" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:to="loc_us-gaap_SalesMember_CCA7595DA9733A8B784EDE5F30C07B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:to="loc_us-gaap_OperatingExpenseMember_55063497E285772CE000DE5F30C0C6C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_388A80D0EFA1EC5DB486DE5F30C006FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2A4C2036F994D03371B3DE5F30C0358F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_388A80D0EFA1EC5DB486DE5F30C006FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6F4DFBCACCAF6D2EB360DE5F30C00DA3" xlink:to="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:to="loc_biib_CashflowsrevenueMember_68B4F1C0A5266CC649F5DE5F30C0EFA5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_569BA517CC910CDA3514DE5F30C0DC6E" xlink:to="loc_biib_CashflowsoperatingexpensesMember_D643329C71DA1A8F93C2DE5F30C1FFBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_559C3F7EDCAAB1FB650BDE5F30C19E28" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:to="loc_us-gaap_ForeignExchangeContractMember_814BC0D0D37FAB0EBE95DE5F30C1FDF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4B053503DC4194338AC8DE5F30C1BA66" xlink:to="loc_us-gaap_InterestRateSwapMember_3FFF9F58E8542C948611DE5F30C1E9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3B44C0A6906B59899307DE5F30C16725" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_5541244412F277C1709FDE5F30C1B17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_OtherInvestmentsMember_E1EC6FE328F1AC936CF5DE5F30C1F21C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_1540CF84059EC97C8B6CDE5F30C12846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_A8DC6B292F3F2D4A55FDDE5F30C1ABB3" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_2F0AAC1421A4671F810CDE5F30C1BC84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_A8DDCD7B769BE6F1F426DE5F30C33BC5" xlink:to="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_C743A916E6987594B7B3DE5F30C3ACC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_85D90E5D903F4520A4DADE5F30C33A55" xlink:to="loc_us-gaap_NondesignatedMember_06D39A82C7DC308F7F94DE5F30C30FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_F849F307EB623C0B13C3DE5F30C368E0" xlink:to="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_71C012FA6A3060A389B3DE5F30C4D7B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:to="loc_us-gaap_MinimumMember_71C012FA6A3060A389B3DE5F30C4D7B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9C5B28D6BC8175630D44DE5F30C460FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_406E0C9B6EA46B8AD8D6DE5F30C36C89" xlink:to="loc_us-gaap_MaximumMember_9C5B28D6BC8175630D44DE5F30C460FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_C270D13614C6E354AF81DE5F30BA527C" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_34FE47C76321C5387F24DE5F30C4CBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_43A386C93C2C2C28F915DE5F30C43F57" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A9481313254DE34C8193DE5F30C42D15" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_95204A6A161DA898A9D8DE5F30C46C10" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_95C1222F0888949B6C8ADE5F30C42F35" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_35904982AD74BE457955DE5F30C401DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_B702D14D70E2CD5EB52CDE5F30C44FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_941C7A8F66D4ECA4E3ADDE5F30C43CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_115186055E5F8E2C8E67DE5F30C4B2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5801B44D4DC1BF44E378DE5F30C48433" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5801B44D4DC1BF44E378DE5F30C48433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_invest_DerivativeNotionalAmount_7B4D7ADFB348EA66BB42DE5F30C4FF20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_FF65EC61BCC36ACEBCD3DE5F30C4C428" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_4F41DBF3A192C3842C50DE5F30C4D2EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_0607CC5CC41E5C50BE3F107196627BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_5E97C982E3C15B29A9DF3AF639957167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_147D69708CBF58ACBD3CBBE989D7DDF6" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_DA32A309550F54188E9573CBBD4D9F79" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2B20BA99C02B5DA19D3D156D0C2D97D5" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_EntityRegistrantName_2B20BA99C02B5DA19D3D156D0C2D97D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_682903EE8F305D139B0DB23F3E6D2CE4" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_EntityCentralIndexKey_682903EE8F305D139B0DB23F3E6D2CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_22CF44A2F1A8508C95D359F899CF030A" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_CurrentFiscalYearEndDate_22CF44A2F1A8508C95D359F899CF030A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8FCB29BEAA585957B37AAD490F0B3EF5" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_EntityFilerCategory_8FCB29BEAA585957B37AAD490F0B3EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_BBF7A8D3371D524099D2050D7CA6A47B" xlink:type="locator" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_DocumentType_BBF7A8D3371D524099D2050D7CA6A47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_65904BAFB0DE5C3DBBECB1DD1CFABAAB" xlink:type="locator" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_DocumentPeriodEndDate_65904BAFB0DE5C3DBBECB1DD1CFABAAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_D7C3E1779AF1555091A2D6B58A399258" xlink:type="locator" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_DocumentFiscalYearFocus_D7C3E1779AF1555091A2D6B58A399258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_89EED028FFFD5A4D96D4EC6E43D16E02" xlink:type="locator" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_DocumentFiscalPeriodFocus_89EED028FFFD5A4D96D4EC6E43D16E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_48ECA6E8EAAE5ACFAE868B7DB3595ED1" xlink:type="locator" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_AmendmentFlag_48ECA6E8EAAE5ACFAE868B7DB3595ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8BC62078307254C6B564338D48E788DA" xlink:type="locator" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_2B7F7DFE10485A38A02470EFDF9E2A3C" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8BC62078307254C6B564338D48E788DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_719A34BBA445551690874D65EEB88092" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_719A34BBA445551690874D65EEB88092" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_BCD96F09A3E8508BAEE464ABFC16D743" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9EF8C121FDFC5CCF7410D8F82429374C" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_979A58DD2D8D534666A6D8F82429EF4A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_80C16A3CEAA43DC15C33D8F8242970C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_2D131341A43998994CE1D8F824291C26" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_MarketStockUnitsMember_660F3F56726220CA868ED8F824294D25" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7FB4B54263B039B053FED8F8242993AB" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_C8C9184D02C55F4B3327D8F82429DE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4C442BBE4E92F33C0192D8F824294B8A" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_A7D397B097ACFB07D1F5D8F824291279" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6D1BD2152E99B8790E6AD8F82429D632" xlink:to="loc_us-gaap_NetIncomeLoss_FB3871D19E1D80A30540D8F824291F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_9A4A9C1EC74FB6543AE4D8F824291B21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1FFF1C3104F908E8E806D8F82429A9B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3DE849C50056DFA75B9CD8F82429CF41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_EACDA4CC6A41FE911FF9D8F824293943" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_630F629008209347080CD8F824294D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0B37943A5E1AC257E3A9D8F8242923A4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8E1DD26E1699AC8A6C5ED8F82429E761" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_EDB860D6539E527B8B6DB18030F233FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_EDB860D6539E527B8B6DB18030F233FC" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5786909C068953BB9497FC8DD7CB6377" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D190036728915C00BBACAB7331471C5D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D190036728915C00BBACAB7331471C5D" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_EBFFC1A3F2CF59D78F0DAD0B60C27063" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D4543AB9B1A4BEB83021D89F6470B9ED" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D4543AB9B1A4BEB83021D89F6470B9ED" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:to="loc_us-gaap_MinorityInterest_726D2CE6BC644103B87BD89F647031C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_338A9119DAE277C9D9BBD89F647096FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_5CB8E6D85C348B809C51D89F64705D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_859B521F09F5FAE40313D89F64705618" xlink:to="loc_us-gaap_MinorityInterest_A49B32A3A3D73F9389EAD89F64701DBB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D6047A48E244EF9828D7DE5F30789A32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D6047A48E244EF9828D7DE5F30789A32" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9AE53B42D143472738A6DE5F3078C99D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A5BC9ABDB4AD6900AB4EDE5F3078DD0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_F4950AC45817F2F5BEA1DE5F3078DF03" xlink:to="loc_us-gaap_RetainedEarningsMember_A5BC9ABDB4AD6900AB4EDE5F3078DD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1274280C0FAFDB852003DE5F30782A41" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_8B3D6D6C1465E52CED9FDEEC7B57E755" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_35292105BCBE58ADE3A4DE5F30787C74" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_C0EC696C33FCC1E95194DE5F3078D5BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13BE65DF35F455AD420DDE5F30782950" xlink:to="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_FAC56693998D4B98B695DE5F3078A819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_43DE58B8375E27BB84AADE5F307921BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2317188255A5334E344EDEF1593C6C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_117A224D54DAC452ACFEDE5F30794BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4CE5380820B5B676AFD3DE5F3078D18F" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_A992400F3355CEF39C0CDE5F30794F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D6047A48E244EF9828D7DE5F30789A32" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_A591E823A9E382891C9CDE5F3079FA42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FB686849CC269B0BCCC2DE5F3079A507" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D6047A48E244EF9828D7DE5F30789A32" xlink:to="loc_us-gaap_NetIncomeLoss_FB686849CC269B0BCCC2DE5F3079A507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_B2585739B617D90CE000DE5F3079F372" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D6047A48E244EF9828D7DE5F30789A32" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_B2585739B617D90CE000DE5F3079F372" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_97A31D95701C5EB0B4B859A71457F077" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_97A31D95701C5EB0B4B859A71457F077" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_1680418634A9539B87EE833BAB6D8848" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1D735E8F424F536DB6F484E8D906B570" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1D735E8F424F536DB6F484E8D906B570" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5A5339C82B3E5EE581BF2DF1C61F5D59" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6C650C1979AE42E1C2BA6767F934EACB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6C650C1979AE42E1C2BA6767F934EACB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0669B65BB3A8E49804DF6767F9348F09" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_51B83AAC88818123B7EB6767F93504C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_29AFC905C12AE18979A26767F935D3EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7B00D401D463182147D46767F9349C87" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_C8D95150B4FD2E7426946767F935F54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_824C7BB168629637BCB46767F9353379" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9558232ECA9501B5CE1D6767F935AAEC" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_B22C27A6A1903A0764646767F935242F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_89512F55CD41357C6F366767F935C62D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7FC8C76F4F362A165C366767F935F5D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_9E66A05D80C9CC8622E76767F935DC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_40214546FBC1C33535F66767F9359E55" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_850287CF9F2FEADD09F46767F9353AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D3C7CD056A71D44626586767F934EC0D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_506B2C0926DA33C0FB0A6767F93545DB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_EB9D91356575A9B6E2B36767F9363642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_531214C3CFAAA32E2A1C6767F936F3A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_C0D4A259DD93EB2F2B736767F93626BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_19EFF4DDD9788E0C79FB6767F9367EF8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_C87F1FFF2ACE422086E06767F9364ECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_BA68D71599CA9008A3886767F935C63A" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_03618743A08CBDE2D6BB6767F936CB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9430AF72459BE5A5C0806767F935462B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3E0F04320F6706EBCE0B6767F936B36C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_523F69849F34CAD600B46767F93654A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B5E7FFF8B53BA053AABD6767F936EB33" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_F0D340FA1F3439925C736767F9367C23" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2123BD576268D58F5BA3200E87478F32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2123BD576268D58F5BA3200E87478F32" xlink:to="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:to="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_E0E153553C70836F019F200E8747938E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_NotesPayableToFumedicaMember_A008489E4F965868AE45200E87475793" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_74D9FAA1A0C9EAC2C820200E8747BCE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_74D9FAA1A0C9EAC2C820200E8747BCE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_DAB2BD38F605EC5669EA200E8747173A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_DAB2BD38F605EC5669EA200E8747173A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_08DD2BEBF6CC25173123200E87472912" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_08DD2BEBF6CC25173123200E87472912" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8E9AAFA76D067F8959C2200E874741F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_70FDC43EFBE93C9768D1200E87478E8F" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_8E9AAFA76D067F8959C2200E874741F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F55742C39078948B30CE200E8747E873" xlink:to="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_AB35B49AD2392B480CB0200E8747C73F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_NotesPayable_261AD7C69EBE51D823FB200E8747101C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_CEEE88429BE89BFDC6D3200E87479610" xlink:to="loc_us-gaap_DebtInstrumentFairValue_D0B6C866D8C322DFE3EC200E874793C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A77E2771BBD6318D64C3D9FE83CC7C08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A77E2771BBD6318D64C3D9FE83CC7C08" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_96B89ADF2C90B9072860D9FE83CC9C77" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_16285140B6870FA86F13D9FE83CC34BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_87AEBAFA1461BEB54ADBD9FE83CCE9E3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_16285140B6870FA86F13D9FE83CC34BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_A3BFE28516A07559788CD9FE83CC4A92" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A39EE7DA410D57D71248D9FE83CC89FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DDFC74444FC9B8042813D9FE83CC27E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1C3A21BC0CE3BB2B2791D9FE83CC76BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_B046B325830FEDC53FC6D9FE83CC5595" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8031EC259897E50197CD9FE83CC10C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CE8DD8BDDE9C4B5A0FD9201CF83D972E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:to="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8667EB2466E42D830B65201CF84240FB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E3DCFE3031ED2AB21456201CF842993E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_1D7AD9F2AA98A1078C75201CF84227BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_23F3E65A629BC03F66D9201CF8424337" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_FAD063AF43DA694DDC50201CF842174C" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_CAE180B8731A81DDE1F9201CF852F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_12B8482173DF39A0BCD1201CF8414F63" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_AssetImpairmentCharges_D5169C5C5927A1EA7461201CF852B242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_35E50E9C20F233C89FAA201CF852F541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14EA22A6EC7F57CB38A8201CF85240A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C2C83C06B1DE5028E839201CF852779D" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2BE6049D9F35B0D50CB3201CF85210D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FE032D3642F155B6B74898F6C23D27BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FE032D3642F155B6B74898F6C23D27BE" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_DAB16379259B54ADA9CD80325A1210C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FE032D3642F155B6B74898F6C23D27BE" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_21AF01EC55425BDF9CEA1575F2BE0E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FE032D3642F155B6B74898F6C23D27BE" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B46595A079EA5218817A558F1423F750" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3A07A71E38C35ABC8BD66758C6DA85D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3A07A71E38C35ABC8BD66758C6DA85D4" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_E14A008BADA95A558B4B24836E6E367D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5077A542C1945833AF40D0DF783BD1A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5077A542C1945833AF40D0DF783BD1A7" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:to="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_61F0EAB1E5635D2FAEBB6E3E1E5F388E" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_CommercialPaperMember_2FFAE0CDBC495001920B59F150EE413F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_733124759ECF5B3F8E2C0FD80B6A8096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_MoneyMarketFundsMember_FD8541C92D445FF3BA2AD48A58B27CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_EB569A12C7CC5409BB59F4AD9B571721" xlink:to="loc_us-gaap_DebtSecuritiesMember_A33989ACBCC75626BFBB812CF5A00BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_716D3645EA805A08B76BAD9501D9BE7F" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_BEA87F4D8E3956F7A862809125A994BF" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_137EFFA2759E5032ACCA212BDACD4B1C" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_C990248AA032509F9EED93EF79F789DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DA2862304A3C1621520FD4C55B8EEF96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DA2862304A3C1621520FD4C55B8EEF96" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_82936B3D4BE3004C4694D4C55B8E026F" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_A2D281CF64C77E73EDC5D4C55B8EB32D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_393255E06CD4915596B8D4C55B8EFED2" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_ACFAA719674A9D85981DD4C55B8E8AA9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_E7A6921A648C89CE1A26D4C55B8FA159" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_8DFD0492C2D66DB832DED4C55B8FE4C1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_E3A958E3CD9EA8B66FDBD4C55B8FD854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_90F307990FF20F0E6F78D4C55B8E1091" xlink:to="loc_us-gaap_EquitySecuritiesMember_B190343324E66F7D1B0DD510859E59DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9513E1F66779524556F3D4C55B8EA2E1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_85AEAD1BDAD8BEC58076D4C55B8FFFFF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecurities_05B3E4D24DF4BDF025F8D4C55B8FD96D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_D6F1391E11A9423398FED4C55B8FCCA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_173F0635EF7E141BE076D4C55B8FAAF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_B8BB97B73B77359E0E8BD4C55B8F9FCD" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_DD54C294EA5C19D2F9AAD4C55B8FE09F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_11BB0566D9F25AA5AA96FA0D629B0F53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_11BB0566D9F25AA5AA96FA0D629B0F53" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_651CA32E5F585B28BCDC7F8404879149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_7C6C7E4544B555579408FCF75EF2EA8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1E66572F08E6564DBE5FE472575F7434" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_E19BF67EACDB55D8A9C6B4066F9D09DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_9E5656D0AA78507B810A4583504A8E06" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_C51EC21CDA855027B20D13967901217C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_6E8FBD94F86C5050A083D8C6CDEEBE2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_2A99A0F800D15D6BBA1FCB9FE26D3D4C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7A992A6C5DEC50B2B59178A3C59B644D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E0EB97FA938356749F8D95EBBA5B2262" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E0EB97FA938356749F8D95EBBA5B2262" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6BF33DBA66485473AA5D21DB00A369E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E0EB97FA938356749F8D95EBBA5B2262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_BA6905759DA3597F831BF7876B0B0838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E0EB97FA938356749F8D95EBBA5B2262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_9A0BB1BC9CF051E282D603F2E4F226B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CEB56BCCD1A35107BE61297078506710" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CEB56BCCD1A35107BE61297078506710" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_99F5479425955A47973CD3A2155415DB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_2EF14626E5075FA210C2D4C55B82AA1D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_55E2CCBEDF743EF8A69ED4C55B828B12" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_8747A86D6228A9ADD45FD4C55B82A40F" xlink:to="loc_biib_StrategicInvestmentsMember_FB6D3A5B9823FF0CE5C5D4C55B82C5F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_941D18676A787566B7AFD4C55B82497A" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9A816D6D9B776BDFC780D4C55B830DD4" xlink:to="loc_biib_StrategicInvestmentPortfolio_50787309CC7A689F0501D4C55B832609" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_477C437F1C8B535FB4CC525BDD2F0786" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_477C437F1C8B535FB4CC525BDD2F0786" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_E8B509488F6D5AF8817C4A407EC5BE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_477C437F1C8B535FB4CC525BDD2F0786" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_10B23B52C5D55578BC4D921A2CD8E2B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_477C437F1C8B535FB4CC525BDD2F0786" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_A0BE6204C9FE5FE997611DA2662E018D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_477C437F1C8B535FB4CC525BDD2F0786" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_2D56FEF1EAC35F73AD3B61ACA416DDE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2597FD4FF391580A9883A02083C26957" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2597FD4FF391580A9883A02083C26957" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_E5C19895658C5902AD0DD163C7C8B4DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B9A872E002F3529B894F05977D0C7D7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B9A872E002F3529B894F05977D0C7D7E" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_AD3538B0565A56C5B0C550F7F5FA17A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_AD3538B0565A56C5B0C550F7F5FA17A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_B39C6B7136DD56A490D0CD35E00710AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70EB176C70DA5B14922F01465962CBF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_E80F1F01E8C653978417AD07E9951F22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_528CD8C4E4D65336BF186CB30AA45D94" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_E7D91BC82CC052D2A27C5D81C1B86425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A649B858A44854F49160536586597197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7DFBCB283949554E85E3B801EC2895AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_C06FF11A1C0355D3B60A595F2BE8B8C1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_720D48A115075425A3BC0FB786FC5EE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_095E20DB577B86ED14DEF7E99E308965" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_2C7A9AAD234099C5CE22F7E99E315299" xlink:to="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_F2B57996D693EBCFD1C9F7E99E318292" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_02EB02DE915509043EBDF7E99E318D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_05670EC84264CE660256F7E99E31159C" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_D22AA79B094AC05F59ECF7E99E314591" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:to="loc_biib_DeferredtaxliabilityMember_5FC82868B3FB1F312FC9F7E99E315FC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE3D132ADBDBBD674537F7E99E31EF5B" xlink:to="loc_us-gaap_RetainedEarningsMember_AC50E95A747A7B88D6B5F7E99E317A05" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeAxis_39C953C19A026481B7F3F7E99E313B39" xlink:to="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_FB6FB8F11B8950F559DCF7E99E31554F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_AA6526BD4C3383C2F5EEF7E99E31926F" xlink:to="loc_biib_OtherForeignEarningsMember_648A8D9C626C603DC40AF7E99E318435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_35A297B2BE74D844B0D0F7E99E32B2AF" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:to="loc_biib_U.S.2017TaxActMember_0DBFD0BFD7D292AF12EBF7E99E32C231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_50AAEC9AFB5C374CE908F7E99E3291C6" xlink:to="loc_us-gaap_ForeignCountryMember_B6CBE9901FAEB24C26C4F7E99E32390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_3416E458D0A7D0231124F7E99E304B1F" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_94B1C4F4607A4F628616F7E99E32ADB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1E1A8113992BE3B0C3C5F7E99E32E7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent_CF855D9859B111BC6CFAF7E99E32A4F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_83BBE4AFE22F526FC307F7E99E325764" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_88A44AE812394DCACF7CF7E99E3264CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGrossCurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGrossCurrent_9D5B5665E21578F27474F7E99E32A167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_9481028DF8F47B96EAE3F7E99E32B115" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_DEEDAE4E9880F5C1182EF7E99E329B1A" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DCDA5BD2685DD3067405F7E99E327BB4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27DA26B64D595C8D939C24BD9B68CDB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27DA26B64D595C8D939C24BD9B68CDB0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3DAF556AFAA85C04BE7B4CF4170EC090" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E54D92E227CC54949E65855788E9C239" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_E54D92E227CC54949E65855788E9C239" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FD60120F0C6953249CDFE629DE223413" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FF79839AE58240891E87D4C55BBBAA75" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_E6B01F4CFE30BA56DD27D4C55BBB66A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6D1A5FDC7847B0461773D4C55BBBAA47" xlink:to="loc_biib_TysabriProductMember_E6B01F4CFE30BA56DD27D4C55BBB66A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0F09D5A16F2222A8EB8CD4C55BBB8C1C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_EE8B11E1263E208B553AD4C55BBBED41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5B42D69C6AEB18D81832D4C55BBB4E06" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_8EAE6C906BBE11A5F736D4C55BBBF0D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_825CF94B4610F5BCAC0FD4C55BBB8F7A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="loc_biib_OutLicensedPatentsMember_B5FBB599C430362187E9D4C55BBC6E36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F547BB421BD1CE42C369D4C55BBCCB2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9C2B87037B723A577E40D4C55BBB5549" xlink:to="loc_biib_InLicensedPatentsMember_7081674E028E725DB4CFD4C55BBC1A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_C7AC5ED447B5D538710DD4C55BBC333F" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:to="loc_biib_AVONEXMember_F8F788140DC7984F5156D4C55BBCA031" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_5EAE1A2C109A8433A2AED4C55BBCD08C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_3656049F17E336EB5103D4C55BBC7D21" xlink:to="loc_biib_TecfideraMember_5EAE1A2C109A8433A2AED4C55BBCD08C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9CFF998162884D8D8706D4C55BBC8773" xlink:to="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:to="loc_us-gaap_MinimumMember_4A3EC3C2A55C3527C503D4C55BBCFF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_4BFD17B6D779DF256995D4C55BBCC1C5" xlink:to="loc_us-gaap_MaximumMember_52B7EDCDD4236219B112D4C55BBC95A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3A9E6D2FA4CE7EC69053D4C55BBBF03C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4A306CA20A7618D84F0AD4C55BBD0C96" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_3636C2224AAE90F89DFDD4C55BBD76CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E55FC9E8F64191B3503CD4C55BBD7BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_60AF968034A27019652FD4C55BBD506A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_A5108E6BC45FEB93F5A8D4C55BBD9A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3E490C08F82F1BC0EDAED4C55BBD4E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12D0D755E9A007D05C31D4C55BBDCB09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2FE58F72BD72E74021DAD4C55BBD457D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_978DBF7655ACC6154050D4C55BBCA93C" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD6A03DDC720D245FE1D4C55BBDDD07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D8422C70106C412E8D0BD4C55BBC1502" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8AA45E9CAA24092761D5D4C55BBD593C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_FACB8C509E004971DE14D4C55BBDC8A3" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_27C80E1FAD8E32BF4F6BD4C55BBD3DA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_EDC8F4F016F48E3CA31CD4C55BBD9179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_F15FA68CC853E6B35A3AD4C55BBD4BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_75C54B5D28D722539321D4C55BBD6D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C79D4332F3D89C61BB07D4C55BBEA9CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F1930D14200B70B668BFD4C55BBE48FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D90D6DE2FC70C280982D4C55BBB194B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4E2CE8034A0265FB2A72D4C55BBEE4E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_249F4CA279A324724C4BDE5F3170E515" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_249F4CA279A324724C4BDE5F3170E515" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:to="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_FB2DFBF9820B5DF81555DE5F3170C9B3" xlink:to="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_87266171A7E93E254F61DE5F31700978" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_9957705E952AF48D154BDE5F317050B5" xlink:to="loc_biib_TecfideraMember_87266171A7E93E254F61DE5F31700978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A05E04D907A27FA2424FDE5F31709474" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_276EF1BBA08BB52E5EEFDE5F31702530" xlink:to="loc_biib_FumapharmAgMember_FDDE90A8FE090E166672DE5F317197F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_2015B0BFB339CD857899DE5F3170F2A8" xlink:to="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_14344B1861F6909EF3C2DE5F317171BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2AB0CDB4532E65AC9938DE5F3171B225" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_E94C688CA48803B127E6DE5F3171BCCA" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2AB0CDB4532E65AC9938DE5F3171B225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_249F4CA279A324724C4BDE5F3170E515" xlink:to="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:to="loc_us-gaap_Goodwill_6453F28492995C48FAFFDE5F317155AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_6E318DC74B28E46DE53FDE5F31714A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_23A0A89F6A2C7699D115DE5F317115FE" xlink:to="loc_us-gaap_Goodwill_DA9BF19B4F4F4FBA7328DE5F317105AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_5AE895DD3C5A5335954B46B8130C57D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7B9D797DE544589AAD5F0FED79EE0E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301A79A83CF556D788373879D619E662" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_BD4DC2D0F39C574997B463C0B6F344E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4C33F1B83801D501B649D4C55BC92456" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4C33F1B83801D501B649D4C55BC92456" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_81A3B2C95376A9A870E2D4C55BC9760C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_04CBE31E869054708228981227C6EA0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_04CBE31E869054708228981227C6EA0B" xlink:to="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_D079C564E5D85A1E9653CA12B76C493B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_FF8EA9A64B185982A278D0D70EC01808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_82883A79B55351C5A190496F3774F93A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_3E807ABABCD955CD99420859FC0DC4E4" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_6BAF9476350B5E579D62A64708423788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_040F3362D3005217B062EFF29BD4E7B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_04CBE31E869054708228981227C6EA0B" xlink:to="loc_us-gaap_InventoryNet_040F3362D3005217B062EFF29BD4E7B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_04CBE31E869054708228981227C6EA0B" xlink:to="loc_us-gaap_InventoryNoncurrent_5CAF4DF066655EB1B49EB77222AD336D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_98DDDBC2D19D5FB487263B2470A1F722" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_98DDDBC2D19D5FB487263B2470A1F722" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_52E5641050715C8798946637A38017DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_D361C319356A50BD9973AA5AA2AAB3A0" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_78F6EFB3B7865110A447FDF6A38EDD66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_AC7F796B576DF5050286208DC25BF98C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_AC7F796B576DF5050286208DC25BF98C" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_6BE984B7B2A635830A63208DC25B7D3C" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_C0302675701CF5A5CC30208DC25C1253" xlink:to="loc_biib_NeurimmuneMember_C7580C194336B0C5C834208DC25C5FFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_1D529D79BAD4DF069D16208DC25B8701" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_79BA32D41620B7DB962120DB375A4315" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_788AB447A7B7816E9A5220DB595D5EEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_A5A31B593BADBF5D395920DB7B3DC959" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_A547A374CACA5DAFCC2220DBA35DC723" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_38D042212C90CF11C9CD208DC25C1D72" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_AFAAC783C585A51522E620E26322F13F" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_F2E2B8557E78D75452D5208DC25CBD49" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7AFB929047115A3CBF3275D4759A5C9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_7AFB929047115A3CBF3275D4759A5C9F" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_B9E1261A13CD5E868A18A1D3F9253D19" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxcontingencyAbstract_7483ABC54647F7F7B022DF5CCA402844" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_38E239ABEECF93E2F0BBDF5CCA401D2A" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_394FC5CB6B54B9DD04B2DF5CCA4051B8" xlink:to="loc_country_BR_30F864720D50DEBEEC65DF634AB89542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_724226747D379C0F5CEADF5CCA403664" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_30BCB0851A071F63E7CEDF5CCA40B54D" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_724226747D379C0F5CEADF5CCA403664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_724226747D379C0F5CEADF5CCA403664" xlink:to="loc_us-gaap_LossContingencyDamagesSought_A09A126607E113E4B830DF64F9EA6B31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FA65167326ED5F67AD3662822473566C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FA65167326ED5F67AD3662822473566C" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F01D5868E0BF586B95BC08ACE6E120C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94E5D24F9ABBCD9AA825DE5F2FB28F12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94E5D24F9ABBCD9AA825DE5F2FB28F12" xlink:to="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ABB84134001107437C8BDE5F2FB2D382" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_8EA9949F89050EE27620DE5F2FB23365" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7AB2AC4B1C4890EC540FDE5F2FB24BBA" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_8EA9949F89050EE27620DE5F2FB23365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_AB181188D229FBEC7AF3DE5F2FB25F66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_392E6C4148C176B3F392DE5F2FB245F8" xlink:to="loc_us-gaap_StatementLineItems_AB181188D229FBEC7AF3DE5F2FB25F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94E5D24F9ABBCD9AA825DE5F2FB28F12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_588F8D632068404B7667DE5F2FB2DE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_00B54E7F447AB329BF96DE5F2FB278EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_3CD356A115E3226051B2DE5F2FB2F5E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_BF3C460B94DFA2505053DE5F2FB2D2C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_3B0CF7066B51A95215A5DE5F2FB3EA01" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_biib_Collaborationexpensesaccrual_30CE8B0EE22AF1C66DBBDE5F2FB370D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_F8A906811D7DCBBDFB80DE5F2FB31872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_0B22FFF492E75B259FF4DE5F2FB2C558" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3FBB1AFC05D401E81303DE5F2FB394DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94E5D24F9ABBCD9AA825DE5F2FB28F12" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="loc_us-gaap_InvestmentIncomeInterest_53167B2AFB961D8D3251DE5F2FB38687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="loc_us-gaap_InterestExpense_4FA4D7965AD2E2E9DAE5DE5F2FB3709B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_757C71F3957553EBF71CDE5F2FB394A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_602E975CEFC38F16D807DE5F2FB389EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0201CFAEC96F85D78612DE5F2FB32669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_2E709B643EF648B28A6EDE5F2FB383DB" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5082CE9B3E269ECF810DDE5F2FB3B816" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:to="loc_us-gaap_OtherAssetsCurrent_D3A2C2EC2F7C5D6BB7CAE4D3402B181C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_8E1378696D2C99136CF7E4CF5FEFB0C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_FE6CCF0155CDB1041347E4D306C64F1D" xlink:to="loc_us-gaap_PrepaidTaxes_8E1378696D2C99136CF7E4CF5FEFB0C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F5A68D8F1C1A58B99A53E499D18D6367" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F5A68D8F1C1A58B99A53E499D18D6367" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7ECC6DF145B65421AE40E9ADDC5B7C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F5A68D8F1C1A58B99A53E499D18D6367" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6615F632B695520FAC7B86D9E49C98E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_BA747CAA06055DCA977F5D31052A6CDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_BA747CAA06055DCA977F5D31052A6CDF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9A06ED137BDB58D4A63160A8F4D99031" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_59E4CCB22D3A81247C5ADE5F3093869A" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:to="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_588A340C5D48B64B83AADE5F3098D10C" xlink:to="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_C73F3C6FE423FB6F5B6FDE5F30984BB1" xlink:to="loc_biib_SolothurnSwitzerlandMember_11AF5C50BD9E78C84F09DE5F30981D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_A9494648E98320274CB2DE5F30939352" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_E07CECC78D4D00338B5EDE5F30994FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_ConstructionInProgressGross_87033E59661AE9030FA9DE5F3099C703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_859881547C66F481BDF0DE5F309993EF" xlink:to="loc_us-gaap_OtherCommitment_55B21B1E3EE8BB6C9F27DE5F309975B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_FB5AEEC7B260B033622EDE5F31B77507" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_02039D07B02205EB9BDBDE5F31B7C510" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6CE9256638179858E856F7A13E9AD68D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6CE9256638179858E856F7A13E9AD68D" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:to="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_7BEF6537DBEA58629A60F7A13E9A9A9A" xlink:to="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_A2017CorporateStrategyMember" xlink:label="loc_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_56348F9FB3D69B3329BAF7A13E9A104B" xlink:to="loc_biib_A2017CorporateStrategyMember_CED418D0FEC3E6069ECCF7A13E9A0A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_FE7D86C5F2C3AAB56827F7A13E9A4A83" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50CFADFAED29D1F46748F7A13E9AA969" xlink:to="loc_us-gaap_RestructuringCharges_FB9D021955AB0DE13F45F7A13E9AB10D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherrevenuesAbstract" xlink:label="loc_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_F1B66B147B802A05D005DE5F31982248" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:to="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_98BBD9E7D603495295D5DEAA3B342E8E" xlink:to="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_8002561FE0DC04EEE15DDEAD94F9AF04" xlink:to="loc_biib_OthercorporaterevenuesMember_35F1E5FBD87B377D04F1DEACC5D5CC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:to="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_D3E33F6683862739E180DEAA3B4215FF" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_28E9310B96967244BAEDDE5F3199A0D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:to="loc_biib_AbbVieMember_28E9310B96967244BAEDDE5F3199A0D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_D4B36885AC4FE2F5A0C6DE5F31990010" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_EE884F719B98D4CDA243DEAA3B43ED0C" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_D4B36885AC4FE2F5A0C6DE5F31990010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E999C93E76249D862B9DEAA3B22F34E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_91F366F8B14B312EA89DDE5F319988B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:to="loc_us-gaap_OtherSalesRevenueNet_91F366F8B14B312EA89DDE5F319988B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:label="loc_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3E06D6B3DF35716E6A41DEAA3B436A93" xlink:to="loc_us-gaap_RoyaltyRevenue_A70648D30E2A1126A786DE5F31995966" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_33E29114FB744AB17902DEB84BC3322A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_33E29114FB744AB17902DEB84BC3322A" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_28F5234E6E7155C68221DEB84BC4E4FA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_80A44DE0A1C408914BCEDEB84BC447D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="loc_biib_ContractualAdjustmentsMember_4E59368D5DE44FC33BF1DEB84BC4D227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_D7EBD5C55AB298246BD9DEB84BC4DDC4" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_CA0ED5A7BA8850DE5E8CDEB84BC4A5EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_F0CADFEBC71993AB4EB9DEB84BC49A33" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_48854FA3950467AEA3AFDEB84BC4F7BE" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1D12B3751FB8B8699C33DEB84BC57D6F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_F76E8ABF51D1C6BAC10FDEB84BC56880" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_8DEBCD56B16C3BE2DC4EDEB84BC57408" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_54B0AD235A223C867252DEB84BC567D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_21F64561A1A60C2ED88DDEB84BC46439" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_CF83EEB414E12299538ADEB84BC52956" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_82086D1B9FC448E4B8FADEB8682F6BCB" xlink:to="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A291D02F64BC13D599EFDEB868305E42" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:to="loc_us-gaap_AccountsReceivableMember_978105B6EA2F2F02C4B9DEB868306755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_193709E2633BC87DF32DDEB86830C8B8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_B7458569915F197431E1DEB86830B86F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1B62D702A49101A9D611DEB86830A1F1" xlink:to="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_809C82C3105D03DFC227DEB868306D57" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_859F887142EEECC1DB03DEB86830A2E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A21DBB6C7B93AF7EDA4DE5F31AFB2FD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0707A030A3D916B95A4BDE5F31AF51EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_6365C5243D2AFF8054C2DE93AFB280B5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:to="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_4227EE5CAE1788887557DE95388518D2" xlink:to="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_BA3E8ABB0927ABADDF5DDE5F31AA9121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_TecfideraMember_BA3E8ABB0927ABADDF5DDE5F31AA9121" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_B77C1141B51EF382BF17DE5F31AAECDC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_InterferonMember_B77C1141B51EF382BF17DE5F31AAECDC" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_7438DA7A9DF8B0117B18DE5F31AA6E26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_TysabriProductMember_7438DA7A9DF8B0117B18DE5F31AA6E26" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_7D0CE80CDD72252B045FDE5F31AA190D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_FAMPYRAMember_7D0CE80CDD72252B045FDE5F31AA190D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_C1EC290551DAABF84690DE5F31AADCC9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_ZINBRYTAMember_C1EC290551DAABF84690DE5F31AADCC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_753B76C1973FAD07A70DDE5F31AA5222" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_SPINRAZAMember_753B76C1973FAD07A70DDE5F31AA5222" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_7A14B8240C135C265CB8DE5F31AA5FA1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_ELOCTATEMember_7A14B8240C135C265CB8DE5F31AA5FA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_7156F723EE22B33CE783DE5F31AAD339" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_ALPROLIXMember_7156F723EE22B33CE783DE5F31AAD339" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_DD5E55FC025FE407373CDE5F31AA3567" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_FUMADERMMember_DD5E55FC025FE407373CDE5F31AA3567" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_610693702139AEB35607DE5F31AA102A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_BENEPALIMember_610693702139AEB35607DE5F31AA102A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_A17212D20BF0A4E6F121DE5F31AA269E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_D77B2883D870C1EA0910DE5F31AA526B" xlink:to="loc_biib_FLIXABIMember_A17212D20BF0A4E6F121DE5F31AA269E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:to="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_175860273F65555FE916DE9411B8BFC7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1B08F56B123A4C306D25DE9A06F2520A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:to="loc_country_US_1B08F56B123A4C306D25DE9A06F2520A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RestOfWorldMember" xlink:label="loc_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_465CE382D18C102EA7C6DE994253799E" xlink:to="loc_biib_RestOfWorldMember_86269B1169159BAA8877DE9A340407A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_A8941DACFF31D46CF958DE9411A7E3AB" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_15E16FF58904B85FD0F3DE9411C618F0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_FB9BAE0DEFEA844A8618DE93AFB7912C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BE160C94E1AA074D60ECDE5F3194D005" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BE160C94E1AA074D60ECDE5F3194D005" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:to="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_DDB1EC0BB437FD33B879DEB042CFF70C" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:to="loc_biib_DistributorOneMember_D3ECFFCD37D552D90535DE5F3195CB9A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_01E18B5DC5139059EB78DEB042CFD932" xlink:to="loc_biib_DistributorTwoMember_983A081A13748D1FB91BDE5F3195AB6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1A21B8592529FF104428DEB042CFB52D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0E8C687243A2F81F5C4CDEB042C0293C" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1A21B8592529FF104428DEB042CFB52D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1A21B8592529FF104428DEB042CFB52D" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6A620BE78EE43749169FDE5F3195BF28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_14CC42F308D4917DB0C5DE5F319C4D9C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_14CC42F308D4917DB0C5DE5F319C4D9C" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:to="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_6FFCE9407CC731166547DEA787D78789" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E51163B9919447E44F43DEA787D7AFC2" xlink:to="loc_biib_RocheGroupGenentechMember_A47A139B681B05B0FEB5DE5F319CB633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_75EEF5BF5C4A47AD328ADEA787D3A94C" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_biib_ShareOfCoPromotionProfits_C817A76F8E56EE0A44A8DE5F319C74BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_D9BCB3A8D6A59BB00452DE5F319CF0A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0103D401AB17E0A65232DEA787D8643A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_871BEB1CCA64F0C9C1A6DE5F319D4BDF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FDDA163E8CA7F5AC4E58DE5F31AD9BF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FDDA163E8CA7F5AC4E58DE5F31AD9BF5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_103B97B96813E32A0D84DE87470AED8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FDDA163E8CA7F5AC4E58DE5F31AD9BF5" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_90EFDC7B558469219665DE5F31AD9BD1" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FDDA163E8CA7F5AC4E58DE5F31AD9BF5" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_00E6CF1663A753216DC0DE5F31ADE87D" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FDDA163E8CA7F5AC4E58DE5F31AD9BF5" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_78BAE459EBFED71750B7DE5F31AD556C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_FDDA163E8CA7F5AC4E58DE5F31AD9BF5" xlink:to="loc_biib_OtherrevenuesTableTextBlock_424A90CF51BD0FDB406EDE5F31AE16A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43D4ED5E780D5DB9925D2CC0963CFFD5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43D4ED5E780D5DB9925D2CC0963CFFD5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_CBE1305587D559CA820E2A7F0A21C90D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E88C19C6770DFA04FB5ED970EC759D8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E88C19C6770DFA04FB5ED970EC759D8F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1BFDD753C489BE78E5CBD970EC75AFE6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ED16BEE6DFE8D14F7D1AD970EC758513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_389128979856151F9E18D970EC750FB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6DFE2C02820DA0B1835BD970EC7558AB" xlink:to="loc_us-gaap_ParentMember_6460F2BBC7DDF4E0B8B2D970EC75F84A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1E8C1BA05283707EC1C9D970EC754A8A" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D93366D093FCE5E40309D970EC75EC31" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D253B47407EB70FDAE54D970EC75F33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_08B196EFCA02DEFD49D6D970EC759D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_DCC9CE03B440EEB749D7D970EC75EE65" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_F157CDC399C2AFF8007DD970EC758EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_6CF24E70645564A05AAED970EC756940" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4CE1EC332EF4BB34A2B5D970EC7A4A29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7C52A7A32DCA05CB486DE5F3004F022" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D7C52A7A32DCA05CB486DE5F3004F022" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:to="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A20AB7FD8FC13498FF2ADE5F3004935A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_D9FE6FA7D991B471AB23DE5F3004C177" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_MarketStockUnitsMember_D9FE6FA7D991B471AB23DE5F3004C177" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_C48C6FF0753167976279DE5F300A3D71" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_C48C6FF0753167976279DE5F300A3D71" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_CashSettledPerformanceSharesMember_5A4815CF676F9C9A77D9DE5F300AA6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_us-gaap_PerformanceSharesMember_CC8BAD8BE37BED7847D2DE5F300A69E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_0BD02C54D11C40D67E12DE5F300A132C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_0BD02C54D11C40D67E12DE5F300A132C" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_AC85C0FF0C8FE6B391AFDE5F300A405F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30276C7075FC1177862ADE5F3004B879" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_38D4EF61C4AE9E02A2FADE5F300A7E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7BC08D4F339367D6CDBBDE5F300A11C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CD2F4C52F5E698B3DB4CDE5F3004FD1E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7BC08D4F339367D6CDBBDE5F300A11C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7BC08D4F339367D6CDBBDE5F300A11C8" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_73503DBAB0D0CE58D937DE5F300BF605" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_56480309BC2E74DF9A74DE5F300BA42C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_87E084C0E460533EE94EDE5F300BA311" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_87E084C0E460533EE94EDE5F300BA311" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8CB4CA232982AFDEF4E5DE5F300BA904" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_49D0F2225A4687FCAB31DE5F300AE3DC" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_8CB4CA232982AFDEF4E5DE5F300BA904" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7DA7E2091EAB05D34E83DE5F2FF4CE44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7DA7E2091EAB05D34E83DE5F2FF4CE44" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:to="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6DD4557C9A5C08320B2CDE5F2FF5D779" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_E468188BEFFD00C7FE89DE5F2FF55D6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_E468188BEFFD00C7FE89DE5F2FF55D6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_AAE19DDB253A34F691E1DE5F2FFA7255" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1284F9B9D9F7D2ABE037DE5F2FF5C7A9" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_AAE19DDB253A34F691E1DE5F2FFA7255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A3ECCC532B6FD2FCA6DE5F2FF5052C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_56B5A400311F18798321DE5F2FFA3CE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_32A82B710229AB48D168DE5F2FFA6CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_250B827BA23FCBCC52D1DE5F2FFBFADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4A8849694545F288D47DDE5F2FFB9A36" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0185973C63071CD76AE6DE5F2FFA0169" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_8AE8985FF7F9BFB6C8EFDE5F2FFAD9D9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2B54D11F5A8352A38080C55BD01D7BFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2B54D11F5A8352A38080C55BD01D7BFD" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30D3C5200DCB50A6844344F5C770E4DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2B54D11F5A8352A38080C55BD01D7BFD" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_92E5CBEF0085567FBABBB798123ECBD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_573933A136AA6FA7021EDF8730792881" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_573933A136AA6FA7021EDF8730792881" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_570990E4E9212077C59EDF8730790C48" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F21F925CB51BD9F23C33F7EEC4600D3C" xlink:to="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_F1F56AB3458B96B257ECF7EEC4606759" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_2577287C8E17EFAD53B8F7EEC46020A3" xlink:to="loc_biib_DevelopmentMilestonesMember_79B794CD56D84018C0BBF7EEC460B3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_CC6359345C3750E61399F7EEC461885E" xlink:to="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:to="loc_us-gaap_MinimumMember_DCAF9A0D2393EAF39ABAF7EEC4612F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_C557E0E96FC53259E153F7EEC461A102" xlink:to="loc_us-gaap_MaximumMember_3B214792AA9EF2B6D650F7EEC4618448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_42694C4C3BC9F89336E8F7EEC461B6B3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D7F978D78C5636DC3E3F7EEC46256B0" xlink:to="loc_biib_IonisPharmaceuticalsMember_0BBDB310AAC8CB623F30F7EEC462B330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5BED23925EB4E6A9F367F7EEC4621EAD" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A6868345956A45D410F2F7EEC4627ADB" xlink:to="loc_biib_PfizerMember_57D9BB92A29FA418A265F7EEC462D35B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_35362550518F2ADD1F6AF7EEC46259E5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_E8B0491E664B748B01E5F7EEC462013C" xlink:to="loc_us-gaap_SubsequentEventMember_B0FE951016793B10003DF7EEC462AE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_6948B10F39947100EB4CF7EEC460ED86" xlink:to="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_A312EE79E0313206714EF7EEC46374C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_40CF1ACD36B8C08B95CEF7EEC463C785" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Termofcollaborationagreement_B7F3F08334E0C53BA23FF7EEC464E565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C0A57AD6EA4329E3D59AF7EEC463C77F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_C0A57AD6EA4329E3D59AF7EEC463C77F" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Purchaseofcommonstock_898F157280C30636F72FF7EEC4644CAF" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_8C86065D2881223BC2BFF7EEC4644B15" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_CC0255D5EFB497D47E93F7EEC4635F39" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_D95CB62774709DE2F8A5F7EEC4645BEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_A44E08A2DC185A14AFB9836CD7D33AFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_A44E08A2DC185A14AFB9836CD7D33AFB" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_17EA0CFDDAED54DF8C6B0F5B21DF9C86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7D8F8590585DEC94110FE4CF61C9532A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7D8F8590585DEC94110FE4CF61C9532A" xlink:to="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B3552784B160B54C7188E4CF61C90399" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_091DE908A8E2D0DF3642E4CF61CADC65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_F2F3391205A5C2BBC1AAE4CF61CAE694" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_F2F3391205A5C2BBC1AAE4CF61CAE694" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_AccountingStandardsUpdated201707Member" xlink:label="loc_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8E499C1D51E813932D44E4CF61CA07D8" xlink:to="loc_biib_AccountingStandardsUpdated201707Member_4FD4524ACED68D165C1EE4CF61CADDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C74067E3C8054B5AF9C1E4CF61CACFB8" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_38712671C372410E10C8E4CF61CACF2F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8D03785B927C4E7BE71CE4CF61CA059C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6D006C604B43AFF71DD8E4CF61CA43CF" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_F3C895BDF7E08B8ABA38E4D14C78B775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3296186298D4FB704804E4CF61CA7294" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BAE4A61394617368DCCAE4CF61CAB0F7" xlink:to="loc_us-gaap_RetainedEarningsMember_3296186298D4FB704804E4CF61CA7294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_741C38F1C6AD31821898E4CF61C981FC" xlink:to="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6D790F07DA573396A23EE4CF61CB56B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6D790F07DA573396A23EE4CF61CB56B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B87BA588058C656CDB90E4CF61CB0065" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_4A43A2B0E0CBE111E755E4CF61CBEADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7D8F8590585DEC94110FE4CF61C9532A" xlink:to="loc_us-gaap_NumberOfReportableSegments_44B918AF63764A1B7470E4CF61CB6121" xlink:type="arc" />
    <link:loc xlink:href="biib-20180331.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7D8F8590585DEC94110FE4CF61C9532A" xlink:to="loc_biib_InterestInSubsidiary_98A98F4400FF0A992BDEE4CF61CBABA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:type="locator" />
    <link:loc xlink:href="biib-20180331.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_E86DBC115ED051693808DE5F31C52972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0CA9578F2EB177503B0FDE5F31C59E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8004BE0E91FCBE07DABCDE5F31C5721D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:to="loc_us-gaap_UseOfEstimates_35006021964F7DA8CF98DE5F31C64C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_998C3822AC3267B3D18CDE5F31C52861" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_335475B33EC5F419E43CDE5F31C6CE62" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>acquirediprd.jpg
<TEXT>
begin 644 acquirediprd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
M]FGQI^TMXK^/NH>)#I>A_#_PWI/AG0O'G@G3+KPX-$O;G5)/%G@*Y\1>+-5N
MVU739O#%CIOAZ&/3=<F\6VPL?2;C]O/]FBT%A;77BCQQ!XCU/Q)XG\'6GP_?
MX(_&_P#X6H?%/A'P'I7Q2UK0KGX4CX>'XBV&H)\-=:T[Q[I\=[X:@CUGPE<#
M6](EO;.*9XOG]/\ @EA\)%\/W_A$?$;XE)X9O-8_::O+:T27P^;[PSI'Q^A\
M):?X/\+>#]1GTNX31=!_9TT;P'X-T/X.6-Q9:I!::=X<T^T\0P:O$;R*Z];\
M#?L6'1/BSH7QX\;?%_Q/X_\ BO#K_B_7?%>MS>%_"_A?1_$0UWX4Z-\'_#NC
MV'AW1D>+PUHWA'P[H\VKVT5O>ZE?:QXHU_Q!J.HWXL)],TG2 #RK7O\ @J5\
M'[;Q[=>$?"_@[Q]XGT&P^(O[,?@__A92^%_%UOX!\6>'_P!J+PE=>+?!'BGX
M5:S8>%-7_P"%F7DEH=(M-+\)^'XY-:\47.KJ^BAX+&ZD7Z*T[]N+]FS5[CP5
M9Z/XS\0:S?\ CFS?4+73M&^%WQ7U?4?"EA#X^UGX4W=[\4]/TWP1=7GP>M=/
M^)_AWQ#\/M2F^*,/A)--\7>'O$6CWYMYO#VMM8>!^"O^";GA_P !ZU\&[G1O
MB[XKD\/?"O1_V4_M_A^]\,>&)9O%WC#]DOP5>_#CP9XJFUN/RKW0X/$G@R^E
ML/%'ARRAN]._M*WM-7T6?3)?[0@U&3QO_P $XM$\70^%K.+XO>(M$M]"^(WQ
M>^(#:WI_@'X=?\+)\/7?Q;_:$\8_M":C<_"/XMQZ1;?$?X2>(K+5_%S>$I]9
MT;7]7TC6O#&C:7+J'A)/$ N=8G /KSXP_M&_"/X$OH\'Q'\0:K8WVN:9XCU^
MQTKPYX+\<>/M:B\+>#%TR3QGXTU31? /ASQ-JFB>!?!T>M:.?%7C76;2P\,:
M#)JVE6NH:I%>:II]M<\7:_MH_LU7GC74O </Q*A75=&\1ZQX/U76;GPUXQL_
M %AXKT7X56?QRNO#D_Q0NO#\7PW_ +:G^#EXOQ-TS3T\4M<:KX+MK_7=.6YM
M-/NFC\X_:W_80^&O[5WB?X?^.?$4GAZS\7^ ?#GC?P-97GB[X5?#?XS:(_@G
MXBZAX5U;Q+%8^%/B?HNM:+H_B^QU3P;H5]X4\86L$W]DM_:5AK6B>)]'U*33
M$S-6_P""?/PPUSP[JG@K4?$6N-X(UKXZ:[\8M0\,V&FZ+I%D=&\0_LJ:E^R9
M>?#FR;2+>R72?#T7@C4IM7T_4-+@L[W3M7BM[;3X+72K>"UB )/#O_!13X%:
M_P"+O&^EH?%MMX5\/>#/@!XA\(:M)\.?BTOCKXG>(/C_ *M\=(/#?A;P-\'+
MGX=VOQ&\2M)X=^"TOC/1-8\-:/KMEXA\+ZOJ.MA=-TCPKJ^H4OQE_P""B/P,
M^''P_3Q=X,O;_P"*.LWNA> _$VG^']%\/>/;2QT_1/'_ ,5X?A#H\_Q!\40^
M"-4TOX3:A=^+K3Q5H6EZ'\25\-:SJOB?P7XG\,)8V^I:)JXT_P H\:?\$Q=&
M^*-JVI?%SXRZI\7/'6C1_!6+P9K/Q'^$OPG\2>#M(7X%:=\??#?AD>)?AA)H
ML/A7QN?$GA/]HOQ]8^-I-1?3[J[UR6P\3>$KCP;/IVEV&G:MY_P31\)V_AAO
M!/@?XK>(OAYX/\4>#/AMX5^+7ASPC\./A3X?T;QY<_";XE>(?BMX0UK1='T'
MPMH6A_#>:Y\2^,/$^F^+K'PEI*VOB7PQ>6%JS:?XCL;CQ5J0!^G2MN!.,89U
M]?N.RY_';GVSCGK3J:JA1@?WF;GU9BQ_(G ]J=0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,?[H_WX_;_ ):+_/H?4<4^B@#^
M6;QS\5_BEI7[)/QA_9D3XJ?$V+7)_#>L_MZ^'?B,/'7C&'Q39? BZ\<:CK.N
M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"+S_ .2: -[(]_R/^%&1[_D?\*P?^$8T7_GR'_@1>?\ R31_PC&B_P#/D/\
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M[#X3^.WP_P!>\&Z;X6;]ICQ$_P /?$'B75OV:[O7= \6Z=X!\!:Q\'?#FJ>
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MU1]>T445_5X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_L,ZI_Z77%9%:_B#_D/Z[_V&=4_]+KBLBOXWQ?^]XK_ +"*W_IR0!1117.
M4444 %%%% !1110 5ZW\%?\ D=D_[!&I_P#H=G7DE>M_!7_D=D_[!&I_^AV=
M?0\)_P#)39%_V,\)_P"G8C6TO3]4?7M%%%?U>(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_RDD_X(4_\
M9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(K\0_P#@I/\ \I)/^"%/_9UO[4'_ *QS
M\0:_;R/_ %<?^XO_ *"* /@'Q!_R']=_[#.J?^EUQ616OX@_Y#^N_P#89U3_
M -+KBLBOXWQ?^]XK_L(K?^G) %%%%<X!1110 4444 %%%% !7K?P5_Y'9/\
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M\-7-YIC+:6UG/]GOKV%KAX+J6%OE'_AS+>_]):_^"U'_ (FQH'_SEZ /J7Q
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MXFQH'_SEZ /VFWI_>7_OH?XT;T_O+_WT/\:_%G_AS+>_]):_^"U'_B;&@?\
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M^*SU"&UU*"\M(/5J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>amortacqintanassets.jpg
<TEXT>
begin 644 amortacqintanassets.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJU:2J57/%1<*4I4:LE*SG[.*E*";2D6MO\^ZT3VWZI:V5]+[GZ]_\+Q\+_\
M/AK'_?NQ_P#DVC_A>/A?_GPUC_OW8_\ R;7YD?LY>-]<\4:!XT\.>-O$'CK6
M/B5\-O&Q\->/=/\ B-X&^%O@/Q+X>GUSPOX>\;>%+1+/X+:KKOPT\0>'M6\(
M>(-+\0>'_%OAO6]1_M:'4;NRU0V6IZ1<Z?;?0]>=6\4.)J%25*5#)I.-O>AA
M<9R3C*,9PG!RQL7*G4A)3ISY4IPE&<;Q:;3T_K^OF?6'_"\?"_\ SX:Q_P!^
M['_Y-I#\<O"P!/V#6, $G$=D> ,GC[;Z5\H4C?=?_<?_ - -9/Q5XD2;^KY/
MHO\ H%Q?_P W^O\ 2U:U:7=H^]H-;U"XAAN(?#M^T4\4<T3&^T92T<J!T)4Z
MAD$JP)!Y'0UJ6-W=7/F_:=-GT_9LV>=<64_F[MV[;]CN+C;LP,^9LSN&W=AL
M1Z+_ ,@;2?\ L&6'_I+%6G7] T9NI1I5)6YITJ<W;17E%2=M]+O35B"BBBM0
M"BBB@ HHHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
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MVH/_ %CGX@U^WD?^KC_W%_\ 010 ^BBB@ HHHH **** "BBB@ HHHH ****
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M=P&)DVL0QW %6_:B.#Q#Y:?\331ON+_S K[T'_4QU^+G_!2?_E))_P $*?\
MLZW]J#_UCGX@U^WD?^KC_P!Q?_010!D^1XA_Z"FC?^"*^_\ FCH\CQ#_ -!3
M1O\ P17W_P T=66U;2T9D?4M/5T8JRM>6RLK*2&5E,@(92""" 0001FD_MC2
M?^@IIW_@;;?_ !VL?K.'_P"?]'_P;#_Y+S7W@5_(\0_]!31O_!%??_-'1Y'B
M'_H*:-_X(K[_ .:.K']L:3_T%-._\#;;_P".T?VQI/\ T%-._P# VV_^.TOK
M.&_Z"*'_ (-I_P#R7FOO K^1XA_Z"FC?^"*^_P#FCH\CQ#_T%-&_\$5]_P#-
M'5C^V-)_Z"FG?^!MM_\ ':/[8TG_ *"FG?\ @;;?_':/K.&_Z"*'_@VG_P#)
M>:^\"OY'B'_H*:-_X(K[_P":.CR/$/\ T%-&_P#!%??_ #1U8_MC2?\ H*:=
M_P"!MM_\=H_MC2?^@IIW_@;;?_':/K.&_P"@BA_X-I__ "7FOO K^1XA_P"@
MIHW_ ((K[_YHZ/(\0_\ 04T;_P $5]_\T=6/[8TG_H*:=_X&VW_QVC^V-)_Z
M"FG?^!MM_P#':/K.&_Z"*'_@VG_\EYK[P*_D>(?^@IHW_@BOO_FCH\CQ#_T%
M-&_\$5]_\T=6/[8TG_H*:=_X&VW_ ,=J6#4+"YD\JVOK.XEVEO+@N899-JXW
M-LC=FVC(R<8&1D\BFL10DU&->C*3=DE4@VV[622E=MW6W= 4O(\0_P#04T;_
M ,$5]_\ -'1Y'B'_ *"FC?\ @BOO_FCK9HK8#YJ^.<>HI#X9^WW5E<@S:MY7
MV2PGLBA$=AO\PS:EJ'FAAMVA1%LPQ)?< OSY7TA\?O\ 4^%?^NVL?^B].KYO
MK^9/$3_DL,V],!_ZK,& 4445\4 4444 %%%% !1110 4A^Z^?[C_ /H)^M+2
M-]U_]Q__ $ TI;/T?Y#CNO5?F?=^CP:^=(TLIJ6D*ATZQ**VAWKLJ_9HMH9Q
MX@0,P& 6"(&.2%4' WK2/4$\S[?=65SG;Y7V2PGLMF-V_P SSM1U#S-WR[=O
ME;<-G?N&V#1?^0-I/_8,L/\ TEBK3K^RL+_NV'_Z\4?_ $W$04445N 4444
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MJC_B$N;?]#3+O_ <5_\ *OZMZ ?56]/[R_\ ?0_QHWI_>7_OH?XU\J_\./\
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MS_LD-X^:;]K?]M7]J/\ X3P>&E5?VOOC;I_QA7P5_P (V=<);P"+'P5X0_L
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MS\<OA?;^*O#^D>+-8^)?PS\/7O@RPUY]&\+?"O6_'?BK3/B'H,WQ#\#3:O\
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+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>anticd20therapeuticprograms.jpg
<TEXT>
begin 644 anticd20therapeuticprograms.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: 3T# 2(  A$! Q$!_\0
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MQKIUO%ICB\\&Z/J_AVRU+7-$+ZI'%<^*;&QN?#=A]AUN2ZU)8M"U5K6/Q/\
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M&!_>9O\ OIBQ_4TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB]+]C^Q>BBBOXX/]'0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$1?(U%?._P"JF0^VGB/J4O;3Q&+Q;J?6\;S+$8RG"E6J1:Q*Y7"%.'U51M'
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M&V]10 4444 %%%% !1110 445',TJPRM#&LLRQNT43R>4LD@4E(VEV2>6KL
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M !- 'XQ>(/ 'PY\>?M6?&NQM=&\,V2V7QI^&FF^+?#?Q#_:NTKP'K,U\=2^
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M+^:4 ?Y;/[4:)'^TW^TA'&JI''^T'\<$1$4*B(GQ4\7*J(J@*JJH"JH "@
M "O"J]W_ &I?^3GOVD_^SA?CE_ZM7Q=7A%?VO@O]SPG_ &#4/_34#_/O,?\
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MA&&,=%%>]^/]>1\U^']>85^YW_!O#_RD6L?^R!_&+_TM\ 5^&-?N=_P;P_\
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MX+_<\)_V#4/_ $U _P ^\Q_W_&_]A5?_ -.R"BBBNDXPHHHH **** "BBB@
MK]SO^#>+_E(M8_\ 9 _C%_Z6> :_#&OW'_X-Z;=;G_@HE8Q/)/&I^ ?QC.ZW
MGFMI.;GP(G$L#I( /,+ !L;UC;&4%?.<7_\ )+Y];?\ LS%6_P#!;/K.!/\
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M_(1_<A_*)_P=#_\ (#_8H_[#?Q__ /33\*:_D:K^N7_@Z'_Y ?[%'_8;^/\
M_P"FGX4U_(U7]3>&W_)&91_BS#_U9XP_C;Q9_P"2]SOTRS_U3Y>%%%%?='YP
M%%%% !1110 4444 %5KW_CPU'_L':A_Z1SU9JM>_\>&H_P#8.U#_ -(YZ<=U
MZK\Q2V?H_P C_5&_9W_Y('\$O^R1?#/_ -0?0:]CKQS]G?\ Y('\$O\ LD7P
MS_\ 4'T&O8Z_B;%_[UB/^OU3_P!+9_H1@O\ <\)_V#4/_34 HHHKG.D****
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MG6VHQ6OQ%N[6*_M[/5((;V.VN[JWCNDE2"YN(@DS^;_\,+_\%)_^D97[;?\
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M7CD19(W4]59'#*P]F!'M44-K;6X<000PB1E>010Q1AV4 *SA$7<P  !;)
M(P*L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2
M%&3G'LK,?R4$_I0 M%(&!QC/.>JL#QCJ" 0>> <$CD9%+TZT %%'7I03CUY.
M. 3_ "Z#W/% !1103@9Y_ $G\ADT %%%% !112$@8SGDX& 3^> <#W.![T +
M1110 4444 %%%% !12%@N,[N?16;H,\[0<?CC)X'/%+0 44$X_0=">IQV_4]
M .3Q10 44F><<]^QQQ[XP/;/7M2T %%&?KTST/\ G/MUI"P R<X]E)/_ 'R
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MP%IM_P#$**^\*21GX=+X=E\5?$9;[P#??8'^3O&'[:'[;/A+X=?L_:W>>+?
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M;6>R^$WA3QY9W'C^T@^*Q\1K_8'B>/PWX?U^^L=/T_50#]***^%_%W[9E_\
M"_QS:P?%_P"#FN_#;X.:]XE^,WA+PE\4-6\8>&K_ %[4;KX'?#GX@?%;Q-XO
MUOX7:=$^KZ%\,?$?@GX6>-]8\">+;3Q#K^KZG;6N@7'B;PCX0L_%>BW,W4?
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M05L%F'$D\PAPWEN8YA/"TZ]#)8X>6+67TJKI0JRI551]JDING44+N,K>9_\
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biogenlogostandarda12.jpg
<TEXT>
begin 644 biogenlogostandarda12.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M86-K970@96YD/2)W(C\^_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$
M<')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                 /;6  $     TRU!1$)%
M                                       *9&5S8P   /P   !T8W!R
M=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&
M03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@
M CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,@
M                                                      !T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
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MW%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G-
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M_P"  (  Y;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&&
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MY"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V
M=)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-
M4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z
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MJWDZ?=&P_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(
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MT9^2>OJM#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H
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M\W_X<<*YD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H
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M*J30<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8
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M?(9!9D/"A83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X
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M5*EV9DJ^**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(
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M0Z@L<+-X%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT
MH1EU^;9VB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT
M><\,N#IT]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$
MX>.$+G?ES#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"
MF7O3$]^$G7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8!
M5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2
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M#;'CB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X"
MK!2:G,"=FM.7OKMOB+Z5 +96=?>2>+&B8I^0.:W-3GJ.3*M=./R,KJ9E'[Z,
M/I5V +2(I8!ZI FJD70YDY^F['2\@K&C?'5/<06@177\7G.=2G;%2KR:J'>B
M-5>8OGAK&T"9:WCL  "-GG\1HS"IEGSCDPNEYWR;@B2B<'QS<':?-'QP7=J<
M.7R72B*9FWS>-+^7K7TM&M"8-7V8  ",;(  HG.HBH6(DC^DY(2%@6RA9H.D
M;[*>,8+^71^;/(*(27F8HX)$-"R6LH(K&FV7&8+&  "+8(  H;"GE8XOD6.C
M]HR#@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X
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M5+<A?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(
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M!))P=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8
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M]7.M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(
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M9Y?6:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH
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MPGH17UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H
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MZIRS7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8
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MGJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+1I@_-26*%I>4&]&*+)+/  "#E8
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M?7]>>@J<EG\-:1^9[7[@5T:7>G[01#N59G[9+V*4!W[H%525>'\(  "$!(
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MO:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(
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M.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  " DX
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M,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (
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M<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (
M??"T_I0&<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>
MHX32  "  (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z
M'GZ?+I*G!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC
M7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=
M4F2F@J/K0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7
MK&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (
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M'X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "  (
M<C"_4)C393^Z8I;@5ZZU?Y4*26.PSY.-.C^LD)+"*;:I.),'%F"H+8\A D>A
MM(&*  "  (  <A.^TZ!@93VYS)X:5[&TU9ON262P%IHZ.CJKTIFV*;>H?9AY
M%H6G38\Z HV@LX&Z  "  (  <?Z^=J@V94.Y4*6B5[NT0Z,H26NO=Z%K.D6K
M*:!1*="GRIQ%%JBFCX]2 KJ?\X'8  "  (  V;5Q@6RJQ0YRUVXWK[]T&V^W
MF9MU27$M@JQV:W*C:NMWBG0;4@5XH'6"-GIYH'; $@)Z>7:MU[=O5W?>PW!P
MW'A'KDER07BWF$MSCWDT@71TTGF^:<=V#GI14.MW-'K6-6AX(7L^$,YXPGJM
MU>)MA(,=P:1O&X)GK+5PF8'"ELQR (%)@!QS7H#J:)-TLH"<3]EUY8!*-&QV
MO'_O#\!W07\BU!EKZHY*O]5MCHR0JNYO&8KPE3IPEXEU?K!R#H@Q9U=S=H<$
M3LQTM(7B,X!U<H3;#M9U\X,PTGIJE)EOOCML0);,J51MUI0_DZYO7I'5?5)P
MXH^49B5R7HV13<YSI(NH,J5T1XH8#@YTU(:HT29IBJ2=O.MK.*$CJ )LSYVJ
MDF%N7)I1?!QOZ)<J90IQ:)0_3.-RMI&F,>!S/X_.#65SXXD.T!5HN:_4N]UJ
M9ZN*INMK^:<KD4EMA:+G>QAO&)[F9"9PGYLS3!EQZ)?O,3IR6I84#-ES&XBP
MST=H'[L5NQ!IR[8!I@QK4[##D%YLUJN8>B]N:J;&8U=O^*)M2W!Q0Y[(,*IQ
MEYN0#&=R>8ABSKEGO,9@NH!I8<!]I6%JVKICCYQL3;1@>6UMVJ[/8J=O:*GO
M2LYPKJ90,!IPZY_N# QQ]X@EREIYY&N+MWUZ9&U+H\%ZYF[KCP)[:'!T>55[
M[G'Z8K5\?'-_2M)]%73N+^%]T'8>"SE_9'8WR.EWZ'8\ME=XD7;DHJ1Y+7>#
MC>QYQ'@B>$)Z77C*8:]Z_WEZ2=E[HGH:+O5\27J0"FM]L7JHQV5V*H#DM*YV
MYH"'H1QWE8 LC'-X0W_H=O)X]7^Y8(5YK7^82,]Z6G]S+@=ZY7] ";9\,W[6
MQ=-TI8MZLPMU:XHSGWAV)XCRBP-VY(?$=:)WKH:_7U]X>(701]5Y+83O+3!Y
MG(0T"1EZZ()WQ%MS7983L9=T*I/VG@1T\)'9B9=UMX_-=&5VB8WA7DAW9HPM
M1NUX((J=+&QX<HF*")-YS(63PR1R6Z#"L&)S+)W7G,YS\IK>B&ATOI?T<TIU
MEY4S74MV=)*N1AMW-)"+*[UW:X]Z"")XW86 PBMQCZM^KV9R8:?,F\US(Z/Y
MAVAS[J S<EUTSYRL7'UUL9EV16IV:9;1*RQVAY57!\1X%X5 P6YP^+9-KJ1Q
MQ['9FOIR@:TQAHYS1*B3<8=T)J1-6[UU$:",1,YUR9W *JYUQYHC!WAW=H4-
MP/!PE,$VKA=Q7KP#FE)R";:)A=9ROK$><-5SF:PK6QYTA*@(1#MU.Z40*BIU
M(YR"!SMV]H3DNVZ"E&J<JC&".&QXE^N!^6XJA'F!T6^_;_R!N7%-6G"!N'+9
M0X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6
M0G?=67" 4'BF0I. >'E:*"Z _'G(!,B"#'K2N1Q_#G[-I\)^^7ZWE9A^WWZ<
M@B1^V'Z&;<]^W'Z#6'E^^'Z-0;I_)WZ2)VY_CGY\!&* D7Z2M[Q]E(C5IEQ]
MAH?NE Y]?(;^@,E]@885;)!]GX5,5V%]S(280,Q]_X/V)JA^1(.$! E_2('4
MMFU\69+AI0M\4)$XDK]\4(]_?X1\78W(:W=\@(PM5FA\OHK'/_Y\](F0)?]]
M&(D& [Y^+X*(M55[8IT,H_-[7IJCD:A[7I@>?G5[;I6;:GE[E9,\58I[SY$>
M/T9\"8]U)6A\#X\  WY]08)<M'5ZGJ=)HPUZG:0FD+QZF:#5?8IZIYV(::!Z
MU)IU5,Y[$I>_/JQ[/I7&).Q[*I0@ TE\?8(YL\QZ"[&@HEAZ#*W&C_AY_ZFO
M?,)Z!*69:-QZ,:'=5!IZ>9ZZ/AEZHYSD)']Z:IA2 QY[W8(<LUQYI[P@H=)Y
MI[>8CU9YC;*^?!1Y@ZWI:#EYJ*F74XQY[J9!/9=Z&J-\) MYS9A? OQ[7H($
MK-B+O6G:G/F*@&N[B_V)?FUP><"(J6\(9FF'\7"84>R'8G(D.^B'('.%(;&'
M]71.  "'@7<DJ_.* G-EG >(^'15BNZ(#'4R>+F'/W8(97&&C7;B40>&!G>\
M.Q&%P'AX(/:&:GC'  "%E7L5JO"(:GS;FM6'>WSYB=F&F'T+=YV%VGTA9'&%
M-'U&4"F$N'UU.E&$<GV9(%6$]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4
M=HN$AH138WF#[8/#3UR#>8-).::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$
MX(Z*AX.$%XTB=6*#9XNV8F^"UHID3FN"=8E*..&",HAN'S*"9HA[  "!+H
MIZN$UYE^EY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!
M6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R
M-\> =I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!*
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M!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (
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M$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (
MCYB<(7G9@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3
M+WLE  "  (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"
M*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1
M'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)!
M8 J2'XZZ3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5
MSYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (
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MB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (
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M&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (
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M?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (
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MOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "  (
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M(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (
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MW8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (
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M8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "  (
ME-&/#&.2AO*-G67Q=_",>6@@9Y^+B6HG5AN*NVP50SV**FWA+G:**6]'$\B,
MFV\4  "  'I E!"-+6QZABN+]VW^=PZ*Y6]H9LN)]'# 55F))7(+0I&(DW,_
M+=^(?70>$V**?7.L  "  'VVDS&+7W5'A1R*378.=AB)2';$9=2(9'=P5'V'
MGW@:0=>'$WBY+4F&[GD?$P.(?WB:  "  (  DBR)N'W[A N(LGXD=/*'P7XU
M9.J&XGX[4ZF&+GY'02Z%J7Y5+,N%=GY4$KF&H'X&  "  (  D3"(3(;,@P^'
M4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "  (
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MJ(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (
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MS&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "  (
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MGI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (
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MDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (
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M)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "  (
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M&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "  (
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M+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "  (
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M?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG&I+
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MR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "  (
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M,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (
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MQ7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (
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M8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "  (
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M6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (
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MUH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (
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MCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (
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M&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "  (
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M"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "  (
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M,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (
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MWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "  (
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M>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "  (
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M5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "  (
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M^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (
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M"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (
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M8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "  (
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MO'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "  (
M9/>)XGSP6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PO_XGT024-#
M7U!23T9)3$4  A*'$GVU  " &X    "  (  9%J(B(2+65*'YH1W36B'((0O
M0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (  8]Z'@(Q%60V&
M[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "  (
M8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "
M (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X
M!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y.968P&-R*U&8
M%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69&V7\19^7O6>B
M.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (  6K:80&M:4#B6
MYVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "  (
M6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A!S&0*G7>  "
M '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,
M!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.
MI8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$
M-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0
M<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (
M4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "
M '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('
M  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A
M!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!
M+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@
M:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (
M3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "
M (    "  (  37.?$WU50W^=@WVB.*N;SWVP++>:-WV>'R:977V,#M&9Y7VU
M +"2"7[.  "  (    "  (  322> X190TJ<<X1Q.(&:MH0R+)F9"(/?'PJ8
M$H/D#JJ8=X-[ +60F8![  "  (    "  (  3/&=*8N/0RB;E(N&.&29T(L(
M+(:8$(J.'Q.6\XJO#MF7'HA$ -V/9X"6  "  (    "  (  J<Y:ZE.IF:U=
MQU=\B/-@AELU=U!C+%[,9*AENF)#4.%H%665.\)IW6BC(R5I<&KI ^=Y9VS+
MI\)6HUX@F!19X&#^AX=<[F/&=@U?V&9X8X!BGVD03]9E(FN-.M-FYVW0(F5E
MV&]L \AYG'%GI=Q2S&B-ED=656ISA?M9IVQ,=)5<QFX<8C)?NV_?3K9B7G&0
M.>5D&',5(;%BL709 ZUYRG9BH_E/4W+=E'I3('/:A#Q6H734<Q]9\77(8.%=
M%':[39E?T'>H.0%A?'AX(0I@!'CY Y5Y\GKUHC),0'T=DN!02'U$@KY3_'UH
M<:]7;7V&7\1:LWVJ3)Y=B'W8.#I?(7X!('I=R7X= X%Z%'[?H+!)I(=9D8M-
MW8:P@9%1N87_<)U53H5.7L-8J82I2]A;B80>-YA=#8.S( %;](.@ W!Z,((K
MGW9'<9&*D'A+TY -@)Y/SXZ';\13?XT*7?=6\8NJ2R=9V(IV-QI;0(F/'Z1:
M=8F6 V)Z2())GH1%K)NDCZ-*+IE,?^!./Y;P;QI1_Y2K75=5?Y*?2HY8;)#?
M-IM9N8^P'U590([5 U9Z7()"G>)$7Z6&CP](\*))?U5-"9\5;IM0SIP67.M4
M4YER2C57/Y=(-D!8:98@'OY81)+_ TUZ:X(\G8=B)E. CJ1D95=8?O9FE5L&
M;CIHMUZ(7&%JQ6'F25%LJ647-+-N!F?M&]=M@FF;  "  &WPF\1>$%UTC5Y@
ML6!D?=IC)V,U;4)E?F7F6X1GMVAW2))IMFKD-!=K VT!&V=J36X@  "  '+3
MF@M:6F=9BYY=0VEF?$]?]6M<:\QB?FT\6CQDXF\)1W=F^W"\,RMH+7(N&KIG
MD7+/  "  '>#F%)6_7$FB>Y:(G)?>JY= W.':GA?MG2=60AB176G1G5D<7:D
M,F%EA7=V&BME.W>V  "  'N6EKA4!7KLB'5777M?>4E::GN]:1Y=/GP*6 )?
MZGQ618YB*'RD,:UC&WSE&;!C1'SN  "  '\2E611@H2UASQ5 81D>"M8,8/Z
M:!5;)8."5PQ=XX,21-5@)(*Y,1I@](*!&4AAI8*A  "  (  E%%/:(YSAC]3
M!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "  (
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M[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (
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M#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "  (
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MJ)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "  (
M>/UY[E+^;01Z8E:/8 U[ %GV4==[L%TI0D=\:& ?,/]]06*N'.)^;&0C!(2
MZ63M  "  'D@=[-V8%M(:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J
M'(A[!6CQ!)M^*6FR  "  'S =GUS#6.7:K!T%V747?QU"6?S3_QUZFGK0+EV
MOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "  '_O=41P!6O?:7-Q.FU]7+IR3V[^
M3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (  =!-M5W0W:$MN
ML'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "  (
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M>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (
M9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "
M (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;
M$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS- MR
M?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+J5?]
M/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^52N)
M$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "  (
M7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]":.'46CK  "
M '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8
M"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%.HN!%7)O+,"!
M)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_"G>%1CU_'W@<
M.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (  6SQ\\'X]4-=]
M3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "  (
M6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "
M (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR
M"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*,R:5 ECZ),^5
M=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R31%G@/L62IUQ=
M,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (  4LN1#%X_2-R0
M>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "  (
M4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ= A^*\&RD  "
M 'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F
M BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-+^J(C'6/(FF(
M:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'N'LM.UB'5'MU
M+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (  3V"&8X'$18B&
M4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (
M3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "
M (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE
M  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\&46>
MH5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;;U^.
M)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z/(29
M;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "  (
M1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "
M (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D
M  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2
M'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX
M),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60
MSH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (
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MN'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (
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M/(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (
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MHXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (
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MQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (
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M (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (
M9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "
M &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1
M#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IU
MYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=
M/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L
M!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (
M7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "
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M5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "
M &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O
M!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ
M?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV
M,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R
M;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (
M4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "
M (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P
M!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X,3EMSH7S)!%M
M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-:DXV.-6-@U%I
M++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (  2Y.)RU&40CB)
MYE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "  (
M2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z  "
M ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"
M  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6
MP6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H
M*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z
M+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (
M1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "
M (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&
M  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4(:J945$[$GF<
M,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25CE'9+"R5F51B
M($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (  /D&2%E5X-3J2
M&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "  (
M/6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z  "  &Y6  "
M 'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'
M  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)
MI&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y
M'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#
MSW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (
M.@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "
M (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
M          $                    !   !   "   ") 0=!=H':0C9"C8+
MA0S'#?\/,1!>$8L2MQ/B%0L6,A=7&'D9F!JU&](<[QXE'UD@AR&R(MHC_R4C
M)D0G9BB&*:<JQROH+0@N*"](,&DQB3*F,\(TWC7[-Q@X-3E1.FT[B3RE/<(^
MWC_X01%"*4-"1%Q%=4:/1ZE(PTG=2O=,$DTL3D-/65!O4892G%.R5,E5WU;V
M6 U9(UHZ6U%<9EUX7HI?FV"M8;YBSV/@9/%F F<2:"-I,VI":U)L7FUG;G%O
M>G"#<8QRE'.<=*-UJG:Q=[=XO7G#>LA[S7S.?<U^S'_+@,F!QX+%@\*$OX6[
MAK>'LXBNB:F*I(N>C)B-D8Z&CWN0<)%DDEB33)1 E3.6)I<9F R8_YGRFN2;
MUIS(G;N>K9^?H(ZA?*)JHU>D1:4SIB"G#J?\J.JIUZK%J[.LH:V/KGVO:[!9
ML4>R-K,DM!*U +7MMMJWR+BUN:.ZD+M^O&N]6;Y'OS7 (L$0P?["[,/:Q,?%
MM<:CQY'(?LELREG+1,PNS1C. <[KS]70OM&GTI#3>=1AU4G6,=<8V #8YMG-
MVK+;F-Q]W6+>1]\LX!#@].'8XKOCGN1[Y5?F,^<.Y^CHP>F:ZG'K2.P=[/#M
MP^Z6[W;P5?$S\@_RZO/#])SU<_9)]Q[W\_C&^97Z8?LI^^O\I_U<_@O^M/]:
M__\   'H Z<%+ :$![\(YPH$"Q8,' T>#AP/&1 7$102$!,+% 04_!7S%N87
MV!C,&=8:WAOA'.$=WQ[;']8@T2'+(L0COB2X);,FKB>J**8IHBJ@*YXLG2V:
M+I4OD3"-,8DRAC.#-($U?S9_-W\X@#F".G\[?CQ\/7P^?#]]0']!@D*%0XE$
MC4621IA'FDB;29U*GTNC3*9-JDZO3[10NE' 4L=3SE355==6V5?;6-Y9X%KC
M6^=<ZEWM7O%?]6#X8?QC &0#90%E_V;\9_IH^&GU:O-K\&SN;>MNZ&_E<.%Q
MWG+:<]9TS77#=KEWKWBE>9MZD'N%?'I];WYD?UB 38%!@C6#*80<A1"%_H;M
MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6R9>ZF*>9DYJ FVV<
M6IU(GC:?): 4H02A]:+FH]BDRJ6]IK&GIJB;J9&JAZM_K'>M;ZYGKV"P6K%4
MLD^S3+1)M4:V1;=$N$6Y1KI(NTJ\3KU2OE>_7<!CP6K"<L-[Q(3%BL:0QY;(
MG<FERJW+MLR_S<C.TL_<T.;1\=+[U ;5$M8>URK8-]E$VE';7MQKW7G>AM^4
MX)SAHN*HXZWDLN6VYKKGO>C Z</JU.OE[/7N!.\2\"#Q+/(X\T/T3O59]F/W
M:OAN^6_Z;/MD_%;]1/XO_Q?__P   @4#V 5H!L8(!@DR"E(+90QR#7@.>@]Z
M$'H1>1)U$W 4:!5>%E(711@W&2D:-!L]'$ =/QXZ'S0@+"$C(ADC#R0$)/DE
M[B;C)]@HS"G!*K8KJRR?+9,NAR]\,' Q9#)9,TTT034V-BLW(3@6.0LZ #KV
M.^T\XSW;/M,_RT#$0;U"MT.R1*Q%ID:A1YQ(ETF42I!+CDR+38I.B4^(4(A1
MB5*(4XA4B%6(5HE7BEB+68U:CUN17)-=EEZ87YM@G6&?8J!CH62C9:1FIF>G
M:*AIJ6JJ:ZILJVVK;JMOJW"I<:ARI7.C=*!UG7:9=Y5XD7F,>H=[@GQ\?79^
M;W]I@&&!6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<
ME)*5B9: EWB8<)EJFF.;7IQ9G56>4I]0H$^A3Z)0HU*D5:59IE^G9JANJ7BJ
M@JN.K)RMJZZ[K\RPW['SLPFT(+4XME&W;+B'N:2ZPKOAO0&^(;]#P&7!A\*J
MP\[$\<85QSG(7LF"RJ;+RLSMSA#/,M!4T732E-.RU,_5Z]<&V![9-MI,VV'<
M=-V'WIC?I^"SX;[BQ^/-Y-'ETN;0Y\SHQ.FZZJSKF^R'[6_N6.]<\%OQ5O),
M\SWT*O42]?;VUO>S^(WY8OHO^O3[L?QF_1']L_Y-_N'_<?__   !V0.-!0D&
M5 =_")8)H0JD"Y\,DPV"#G /7Q!,$3<2(1,)$_ 4UA6[%I\7@QB!&7T:=!MF
M'%4=01XL'Q<@ "#J(=,BO2.F)) E>B9D)TXH.2DE*A J_2OJ+-<MQ"ZQ+YXP
MC#%Y,F<S531$-3(V(C<1. $X\3GB.M,[Q#RU/:8^F#^*0'U!;T)B0U5$244\
M1C!'(T@720M)_TKS2^A,W$W03L5/N5"M4:%2E5.(5'I5;59?5U%80UDU6B9;
M&%P)7/I=ZU[<7\Q@O6&L8IMCB61X969F5&=":#!I'FH+:OAKY6S2;;YNJF^6
M<()Q;')6<T!T*742=?MVY'?->+9YGGJ&>VY\5GT^?B5_#7_T@-N!PH*H@XV$
M<H57ACN'((@%B.J)SXJSBYB,?8UBCD>/+9 2D/B1WI+$DZJ4D95XEF"71Y@O
MF1B: 9KJF]2<OYVJGI:?@Z!QH5^B3Z,_I#"E(J85IPBG_:CSJ>JJXJO;K-6M
MT*[+K\>PQ+'"LL&SP;3"M<6VR+?-N-.YV[KCN^V\^+X$OQ' (,$PPD##4L1F
MQ7K&C\>FR+[)ULKQS S-*LY'SV/0@-&?TK_3X-4#UB?73-ASV9O:Q-OOW1K>
M1M]SX*'AS^,"Y$WEF>;GZ#;IANK8["OM@.[7\#'QD/+O]$WUJO<$^%KYJ_KV
M_#K]>_Z[____ (  @ #F3W_.?UC-F7^H?LVTVG^9?GF<%'^C?F6#3'_&?H5J
MA7_^?L!1OX!C?STY ($2@ _\Q7Y\BS3DM7YCB6S,0'Y=A\RSFGYNAF::V'Z8
MA4."&'[9A$]I6G\O@V=0KG^O@J$X%(!V@>;ZO'TVEG'B^WTPDY+*RWT^D,^R
M.GUICEZ9DWVLC"R [WX'BB)H3GYUB!-/P7\,A@ W07_H@ZSXXWPNH;?A07PS
MG;_),WQ-F?"PPGR%EE>817S?DQI_RWU/C_-G5GW1C+5.[WY\B4TVAW]GA5SW
M-WMCK0/?I7MFI^O'JGN'HPJO8'O)GFF6^'PKF?A^LGROE;=F;GU#D4%.+GW]
MC'LUY7[TAN_UO'K*N%7>+WK'LA3&0WKDK!2N&7LLIF&5W'N9H-I]I'PDFUEE
ME7S(E:A-@GV1CX$U6WZ1B%_T=WI2PZK<['I&O#+%"7I=M0JL^7JGKCN4Z7L?
MIYM\V7NVH.ADV'Q@F=U,[7TUDE TZ'X]B:?S8WGWSP';V'GCQD##^GGRO>2K
M]WHZM>R4 GJXKB1\('M;ID!D2'P0G>5,;WSJE.,TB7WWBL7R=7FTVEK:ZWF7
MT#+##WF?QI2K&'GCO6J3.WIDM&I[=WL-JT!CPGO,H99,"7ROES,T/7V^B[;N
M4XC;?C;7AH?$?<+ GX;#?7"IC(7F?5624H4J?75[!X2&?<9CQ(/Q?C5,CX-X
M?NDUDH,H@ #L/8=]B,O6%(9PAT"_:X6#A>.H8X2[A,&1'H0;@]]YU(.4@RUB
MG(,=@HU+DH+#@A8TV(*0@<'J>H9'DV74=(5-D-J]_(1OCG.G"X/$C%B/[8,Y
MBG=XRH+*B+UAMH)IAP-*S8(FA4PT,X('@V_HVX5/G?[2X(1?FG2\>H..EQ2E
MJX+GD^B.M()RD0MWNX(5CD%@UH''BV1*&(&7B&@SHH&+A03G7(2+J*#1;(.=
MI!6[$(+4G[JD6X(WFY2-@('"EY5VNH%XD[M@"($YC[))=8$:BV4S)($?AGOF
M (/QLTO0&X,$K;JYS8(ZJ%BC,H&CHRV,>X$VGB!UR(#NF11?2H"^D]M(Y("O
MCCHRN8#!A\_DU8-SO?C.^H*'MU:XM8&\L.*B+X$FJJB+GX#$I(IU$8"#GE5>
MIX!4E]%(:8!3D-DR8(!RB/OCUH,.R*7.!8(DP.*WQH%7N5.A2H"_L?J*T(!A
MJKMT:X NHUQ>*8 'FY5( H 'DSLR%X PB?[C (*]TU3--X'6REFV^H$'P9J@
MB(!NN1.*(X 1L*)SVG_BJ 9=MW_&GOU'JW_0E58QW'_[BM?>$I'B?+#([H_Q
M?&.SL8X8?#J>.XQH?$>(C8K>?(]RQ8EI?0I=$8?\?:A'>X:9?I,R484Y?_'<
M*I"TAI?'E([!A5*RDHSTA#R=-HM7@UN'CHGD@K9QTHB(@CU<*X<S@=A&N87I
M@:(QRX2B@9W:HX^.D)7&.8VHCE>Q<HO=C#Z<%8I7BG"&>(CXB-EPT(>UAVA;
M2(9WA?Q&!85&A)\Q5(09@S390HZ;FI?$V(R_EVRP!XL'E&N:R(F"D:2%4H@Y
MCQUOV8<%C*A:@X78BB9%;X2ZAX\P[(.@A*_7[HWAI)3#AXP)H(&NNHI;G)N9
MCXC>F.2$.H>-E4]N\(9KD=59SH5*CC1$Z(0]BELPD8,UA@O6M8U+KIS"7(MW
MJ9VMF8G*I,28@HA2H!>#3(<(FWYN&H7AEN)9*X3.DAU$<X/0C/\P18+:AT35
MIXS0N*/!7(K_LK"LH8E1K-J7FX?=IRJ"AH:;H8IM=X5ZF]!8H81BE=!$$H-S
MCVPP!8*-B%;4PHQJPJ; AHJ=N[*KSXCQM-26T8=[KA*!SH8]IUMLXX4IH()8
M-H06F4Y#P8,GD9POT8).B4'4!(P3S*F_U8I-Q*"K'XBCO*66)X<MM+Z!-X7Q
MK-YL9X3@I-57U(/9G&U#>(+TDX4OIX(;B@7.3YL;>X"ZHIA9>U&F[Y6L>T:3
M"I,G>W-^Z)#&>]IJJ(YU?'=6B(PB?3E"EHG"?E O0H="?^+,G9H/A-*Y@9<\
M@[ZF!I27@M62-)(@@B1^$X_3@:UIVHV8@6-5QHM9@3%!_(D1@3<N[X:F@7K+
M0ID1CB&X1)9%C"ZD^9.=BEJ1+I$WB-5](([ZAWUI HS1ADI5#HJEA1]!=(AP
MA HNI88;@OK*(9@>EXZW&)5CE+FCRY+)D@&0&Y!7CXQ\'8XMC5%H((P4BRE4
M6(GYB/E \H?;AL$N986?A%[(_Y=FH/:V!Y2MG42BKY(;F;^.^H^]EFE[((V)
MDS-G48M_D!%3OHEMC,U BH==B6$N+H4TA:''[);8JF"T_I0BI=>AKI&2H7".
M"X\YG3%Z3(T)F0)FEXKXE,Y3-HCPD'1 ,(;OB],M_X38AL'&^Y9DL[^T().N
MKE:@UY$?J06-08[(H]%YGHRAGJ=F"HJ3F6-2QHB"D^(_YX:/C@TMV(2,A[O&
M+I8#O1FS99-.ML2@(9# L'R,DHYIJD1X_HQ&I!%EB8I$G;I2:X@VEQ8_JH9!
MD LMN(1,B)#%A96OQG&RS9+\OQR?B9!RM\:+_HX=L'=X>XO[J2AE((G^H;)2
M&H?]F>P_<(81D<(MGX0:B4"_(*2'>JVLR:#Z>HV:?YU\>I:(%)H?>MAU<I;>
M>U9BM).E? Q0*I!;?.D]X8SN?B L:HD[?].]HJ.<@W"KXI_R@GR9SIQS@;6'
M;ID?@25TQ97O@-)B"I+'@*Y/B8^/@*8];HPU@-PL28B7@5F\@Z*IC#:JW)\&
MBFZ8[)N%B,^&C)A!AW5S\Y4<AE!A4I(#A5!.\X[9A%L]"HN0@X4L+(@%@L2[
M@J'=E.RIT)Y$DEN7V9K,C_F%E9=^C<)S$Y1DB\U@F)%4B>9.9HXTA_H\LHK[
MAA L$X>$A!&ZI:$:G<.HZ9V.FF66YYHAES2$H9;:E"9R/).ID3]?YI"ICFM-
MX8V4BWT\88IOB'8K_8<5A3VYO*"/IIJH'IS]HFF6))F,GF"#WY9)FG]QB),K
MEJ]?39 BDMI-=HT5CN,\(HG^BK<KZH:WAD6X[: @KUJG8)R*JEB5;ID:I7&#
M-97;H*IP]Y+$F^M>UX^_EQ5-'HRGD@L[\(F;C, KVX9HARJX-Y_'N FFP9PM
MLB>4UIB\K%B"I95^IIQP<Y)KH.1>;8]PFPQ,UXQ9E/,[QXE+CHPKSX8HA^NW
MH)]YP+2F/IO9N=Z45IAJLPZ"*94PK$IP")(@I8E>&H\JGJ1,F8P@EX$[GXD<
MD!0KQ87TB(FPG:XH>B:?BJG->@F.CJ5^>AM]@*%(>FIL2ITA>OA;!9CP>\!*
M"92@?+$Y:I 1??\IT(L<?\2O7*U2@F:>U*C9@8*.!J2$@-!\_J!0@%IKOYPR
M@"):?9@/@!U)C9/*@#8Y(8]+@),IX(IK@3FN=ZQKBI^> J?WB/>-4J.=AWM\
M1Y]SAD=K$YM=A4A9Z9=%A'-)&I,+@ZXXY(Z;@Q I[HG/@I&MM*N;DL^=+J<T
MD&J,<Z+CCC)[>YZQC#5J7)JCBG!95):2B,%(L))@AQ(XKXW^A6XI^HE'@\FL
M[:K]FO6<:J:6E]2+JJ))E.=ZM)X9DBQIL)GYCX-8S97RC/A(5)'%BE8X@HUQ
MAZ4J!(C1A."L1*IBHS>;R:7]GU*+"Z&PFYEZ&IV$F AI(YEFE(585I51D05(
M I$PC6LX6HSPB:\J#8ANA=2KGJGOJUZ;1*6 IJB*CJ$MHAAYG9T G:]HLYCO
MF517_93FE.5'Q9"[D$TX/HR(BX<J%(@<AJ6K!JF7LVB:PZ4?K=J*&:#*J&QY
M,9R>HQ]H5)B3G=M7L)25F'Q'DY!JDNPX*HPUC24J&8?8AU2J@ZE,NV2:5Z3)
MM.B)M*!UKH5XU9Q-J$%H!YA&H@E7>)1+F[5';I OE3,X%XP#CH(J'H>CA^.B
MX;?\><>3 ;+,>:.#/*VJ>;AS=:B6>A%CF:-]>JQ3OYY(>X-$1IC??(8U2I,<
M?><G?XS9?[:AY+<M@8V2=['H@+""UJR\@ QS$:>C?ZAC*Z*,?X=36)U=?YY#
M\9?Z?]8U+))$@%4GO(P9@1RA/[9&B4*1V[$)A[""3ZO8ADURA*;"A3EBJ*&N
MA%Q2ZYR&@ZY#I9<J@Q0U%I&#@J@G\HMP@F*@M[5RD.:11+ ^CJ6!J:L2C)5Q
M[*7RBL1B(*#GB2U2@9O&A[%#8)9QACHU!9#9A-HH(8K>@XB@++3'F(>0MZ^2
ME92!&:IIDMEQ6Z5,D$]AIJ SC>E2(YL<BYM#)Y7.B4 T^)!#AN0H2(IAA(V?
MF[1"H"60-Z\$G'F HZG6F0)P[J2ZE;QA1)^DDHE1U9I^CU5"^94XC!0T[8^_
MB,$H:8GWA6Z?+K.ZI["/UJYZHT" 2:E,GP-PG*0UFO)@_9\EENY1H9H"DMM"
MUI2KCJHTY8]&BF8HA8F@AB^>M[-<KQF/C:X,J<V #JC2I+1P7J.QG\U@PIZE
MFOI1<9F:EA%"O)14D04TY8[NB]HHFXE9AL^>3;,*MF>//*VNL#1_RZASJC!P
M**-7I&1@G)Y0GK116YE(F.]"M)00DPTTZHZVC1(HK8D@AU&5[,']>7^',KOR
M>5!XD;7X>6)I_*__><);9ZGK>FA,[*.A>T\^ZYT.?&(QA98%?=,E=(YO?ZF5
M/,$F@-B&T;L8?_EX1;44?UQIKJ\/?P=;%:CS?OQ,IJ*G?RP^O9P3?X QDY46
M@!\EW(V=@0&4V< RB ^&:[HSAHMWZ[0KA3MI3:XBA$%:O*@#@X1,8J&\@OH^
MFILM@HDQI91 @DLF-HSF@CB4D;]0CRZ&%+E4C0AW@K-/BQEH[:T\B6U::*<E
MB ),):#EAK4^?II?A70QN).$A%,FA(Q(@TZ40KZ3EDB%QKB2DWEW,[**D.IH
MF:QZCI-:):98C&5+^* GBE0^:YFLB#PQRY+BAC,FQXO"A$*3Y+W]G5V%>[?P
MF=QV];'AEIMH9JO2DY)9]J6UD*5+UI]]C<$^7YD-BM,QW9)5A^8F_HM2A163
MB;V#I$Z%.K=HH ]VQ+%1G!!H/ZM!F$M9V*4OE*)+Q)[\D/$^6)B#C2TQ[)'<
MB64G+(KUA<:33;T!JQ.%#K;EI@IVI[#-H49H+*J_G+]9R:2SF%)+NIZ1D]4^
M59@9CT0Q^I%QBJ\G48JIAEJ3 +RBL;6$\K9TJ[]VG[!1IA)H)ZHYH+E9S*0L
MFXY+QYX2EE<^;I>ZD1$R&)$PB\8G;XINAM&)E<PD>7![]<4V>2AN9KYH>2]@
M[+>.>8]3D+!X>CQ&::D)>RXYVJ$W?$PN!IC4?<DCI(_A?YR)2<LJ@&5[O\1B
M?W9N+[V.?M5@M+:<?HA36Z]P?HM&2:?V?M$YV: =?SPN0Y?'?_0D,X[\@.F)
M,\H:AR)[E\-JA:!N"+R3A%=@A[65@W!3-*YA@LM&-J;J@F YY9\7@A(N@);6
M@?PDL(XV@A.)+\D=C;Y[B<)GBZ=MZ+N0B<]@:K2(B$!3'ZU<AOI&,*7PA=<Y
M]YXLA,4NN98%@]TE&XV-@QJ)(\A"E%![@L& D9IMYKJ?CRY@7[.:C0)3':QJ
MBP5&.J42B2HZ$9U@AU$N[I51A94E=8S]A ")"<>$FMA[>\"VEW=M\+G-E&1@
M=;+)D953+ZNDCN=&4*1-C$DZ+YROB:LO'Y2YAR EP8R%A,6([,;AH2][=L *
MG1AM_;D:F51@CK(8E=I32ZL DG]&;J.UCR<Z4)P9B\@O2Y0YB'DE_XPBA6J(
MS<94IU![<;]WHG9N#;B"G?A@JK& F<I3:ZIPE<)&CZ,YD;8Z<INJC:0O=)/1
MB:$F,HO2A?.(L<70K3)[<;[QIX=N);?ZHCU@TK#YG5=3FZGPF*-&PZ+%D^XZ
MI)M+CS<OH9.'BI8F6HN3AF'RSWMC>;#;W7N\>=+$J'P<>@>M)7R#>EZ5<7SW
M>MU]K7U\>X)E\'X5?#Y.1'[9?30VRW_I?GWPLGFYA,_:+7HT@\K#*GJS@NBK
MSWL[@C*4-'O0@:I\B'QV@4)DX7TN@.--57X0@)\V 7\Z@&CNS'A9D +8:GCE
MC=K!GWEXB]*J7GH9BA"2ZGK)B'U[9'N+AP5CY'Q?A89,?7U;@_XU3'Z;@C_M
M!G<SFS'6KG?(E^^_^'AHE-BHX'D9D?*1F'GACU1Z07J[C,-B\GNGBAI+N'RY
MAT<TK7X,@_WK:79'IE75&W;>H@.^<G>%G=ZG=WA!F>R037D6EAUY*'H&DG)B
M#7L&CI9+ GPLBF\T)'V-A9WJ!'63L6_3OW8GK!&]'G;-IM>F-W>/H<^/+WAN
MG.9X'WEIE_UA.7I\DNM*7WNRC6TSKWT?AQ?HVG4%O'O2G765M@Z[_W8WK[JE
M)';[J92./7?DHXUW47CJG7-@@7H&EPQ)U'M+D#,S37S"B&CGYW2<QW'1L'4G
MO^Z[$'7"N'ND-W:"L2N-8'=QJ?AVFWB#HJY?\GFJFOQ)7GKVDKLR_'QTB8SG
M)W15TD'0]G39R9NZ3'5JP/^C;G8DN(",HG<3L!5U]'@KIXA?:GE;GHY(^7JQ
ME/HRO'PVBH'BF801>!O-C8.%>'BX'(,.>.&B.(*K>62,"8)<>@QUO((?>ME?
M@('P>\-)58'B?.PS?(($?G7@X8*.@JG,7((7@>:W$H&S@3^A*(%E@,&*Z8$K
M@&MTH($)@#E><X#^@!E(=8$5@!\RX(%:@$G?48%!C4'*P8#9BVZUEH""B;B?
MQ8!-B#Z)LH NAO!SE( IA;Y=CX UA(I'NH!D@U@R5H"_@@?=OX HE\7))7_'
ME/2T 7]\DD*>7']0C[F(=']+C6YRAW]<BS%<MW]_B.-'$W_%AG0QW8 T@ZS<
M1']"HD''LW[BGGNRFGZ@FM*=!WZ ETJ'07Z"D]UQB7ZJD)-;[W[@C2!&>W\Y
MB6TQ='^ZA3#:^GZ0K+[&='XQJ 2Q8WWNHUB;XWW3GL6&/7W?FDAPGGX,E=!;
M.7Y6D39%]'["C#LQ&W]1AH[9Z'X"MS+%;'VDL7ZP7'U>J\>:Y'U#IB&%7GU:
MH)%OYGV2FO):GGWAE1=%@7Y<CM$PT'[YA\/9#7V7P9C$EGTZNN*O?WSMM!::
M!GS-K4V$D7SGIIMO.7TMG]=:&GV'F,-%(7X(D2LPDWZOB,[89GU*R^[#[GSN
MQ">NQ7R8O#691'QOM#N#X'R(K%ANIGS5I&!9K'T[G!1$TWW(DSTP8WYTB:W2
M[XSK=MF_DHM\=U>KO8HM=]V77XC^>'R"J8?F>4-MT8;>>C19&(7>>T9$>X3Q
M?*$P6H0:?FO1=8N4@,&^9(HU@#RJHXCT?]&66H?5?X:!KX;2?V5LZ(7C?V=8
M0(3]?WM#S(0L?[HO[H-N@"K0)HI4BKF]%HD%B36I@X?)A\J5-(:_AI. FX70
MA8-K\83YA)%7;80L@Z)#*X-W@K\OC8+4@=+.SHE"E*6[M(?XDC>H$(;.C^*3
MZ87+C;-_=H3UB[1J^H0SB<)6JH-\A\-"G8+;A:\O.8)+@UW-@8AIGH2Z:(<B
MFS2FR88 E_J2LH4&E-E^9(0QD<YJ%H.%CMI5^H+>B\1"'X)0B'DN\8'3A,;,
M6X>^J&FY3(9ZI#:EM(57H F1K(1BF^U]>8.5E]]I1X+ID\Y578)4CYQ!LH'8
MBQ<NLX%LA@O+9H<SLD2X7H7RK2>DQX3.I_^0R8/:HM]\LH,7G<IHI()SF*!4
MV8'=DSU!5X%RC7XN@($6AR?*H(;'O ^WG(6*M@&D (1CK]60!(-JJ:%[_(*J
MHW=H"X(4G3)4:8&'EJ5!"X$>CZ<N5H#.B!K*"H9UQ<VW X4\OL"C6800MWV/
M68,2L"5[8H)1J-1GC8' H6A4!H$_F;! Q8#AD8@N-("5B.3#NY7X==ZQRI.R
M=G*?;Y&0=Q",E(^1=\EY7(VI>*IE_HO+>;A2RXGK>NH_Q(@-?&LM:88D?F#"
M?)3!?S2PT)*#?MB>A)!M?I.+MHYZ?G)XA8RB?GEE-8K9?J52%(D/?N<_.X='
M?ULM*X5T@ S!69.BB'^OHI%OAT"=>X]:AA**KXUWA1MWEHNPA$1D98G\@XI1
M:(A&@M<^P8:4@C8L](37@9W 19*3D=BN?)!LC[J<2XYEC:J)IXQ]B\=VGHK,
MB@UCD8DIB&)0PH>'AJ\^4(7OA/(LQ81+@Q"_)Y&^FR:M=(^8F#&;/(V7E5&(
MBXO DHEUJ(H.C]=BQ8B C350*8;MBG8][85DAY LG(/2A&*^)Y$;I'.L=H[X
MH*N:0HSXG.B'H8LEF35TUXEXE8MB$H?GD=Q/IH9BC@X]F83KB?XL>8-KA8Z]
M3I"8K:ZKI8YXJ0V9<XQVI&"&VHJDG[9T*(C^FQ)AA8=SEEA/.87ID6P]582"
MC#4L7(,5AI*\GY QMMFJ^HX3L5>8PXP0J[6&+8HYI@=SB(B6H%I@_X<7FI1.
MVX64E(X]&X0LCBXL18+.AW"\&8_?O_>J<HW&N8:8+HO LMN%EHGEK!=S 8A!
MI5-@DX;&GG1.AH5/EU4\X8/SC]\L,H*5B">U#I\]=3*D8YPH=<Z38IDW=GJ!
M\99E=T5P+).C>#I>1I#A>5Y,G8X1>J@[-HLL?$0JK8@>?E2T!YXI??RCHYL4
M?;>2KI@G?8Z!1)5;?8IO?I*D?;)=HX_R?@%,"HTR?FHZU(I@?PLJG8=E?^ZS
M'9T7AKRBK9H-A:"1T9<@A*" 9)1B@]%NLI&Y@RE<\X\9@I]+?HQI@A\Z?8FI
M@;LJCX;!@6NR*9PICV*AJIDEC7^0PI9!B[Q_>Y-^BA1MW9#DB)Q<18Y1ARU*
M_8NQA;PZ,8D$A$HJ@X8Q@LBQ3)M+F!^@Q9A1E72/UY5VDN)^CY*[D&)M%Y 4
MC?M;H(V4BZ5*A8L#B3@Y[(ALAK(J>86TA .P=)JKH-J@!I>PG66/'932F?I]
MSI(9EJ%L8H^ DU);"HS\C_]*&XIWC)$YL(?OB/(J<(5*A1BONYHNJ7F?49<U
MI3J.:915H/-])9&=G+)KSH\)F'5:DXR)E"9)Q8G]CZPY@H>$BODJ:83RA@BO
M(9G.L?Z>O9;4K.N-U)/RI[Y\DY$VHHAK2(ZDG51:(XPNF =)>HFEDH<Y6X<K
MC,0J8X2JAM*NJIF!NG:>1I:(M(&-5).CKEE\$I#CJ!QJUXY0H>%9RXO=FXY)
M-HEAE0HY,(;RCDDJ7H1PAWBG :BZ=,&7?J3<=5N'N*$>=@QWFYUU=N)G.9G.
M=^96Q)89>1Q&H9)%>G@VX(Y$?"HH+XG^?DBF,J?$?0J6\Z/@?,^'-J =?+=W
M&IQS?,EFM9C1?0M6294G?7A&-Y%>?@$VJ(UM?L@H2XDX?]&E?Z:_A3V6,Z+D
MA#J&C9\>@UAV:IM\@JQF%)?C@BI5P91'@<I%T9",@7HV>(RK@4PH9(B*@3ND
MQJ7/C5N59J'\BYZ%L9X^B@!UJIJ9B(YE9Y<.AT95-Y-]AA!%<8_0A-LV3(O_
M@Z\H>H?R@H6D!*41E6J4IJ$_DOB$[IV%D*5TYYGCCG%DR)9*C$I4N9+(BCM%
M'8\EB!@V*(MDA>HHC8=P@ZNC8Z1CG8^4!Z"8FF"$3YS>ET-T3ID\E#ED/)6F
MD3=42I(9CCA$U(Z#BR<V"(K9A_4HG(<!A*RBSZ/EI9:3BJ 7H:2#U)Q6G;1S
MSYBOF<YCQI4BE?)3[9&?D@E$EXX"C@ U[XIGB<\HJ8:FA8FB3J.(K7J3$9^W
MJ,"#79ORH_5S79A&GRMC7Y2ZFF=3F)%!E9!$8(VGD)8UVXH+BVXHM(9;AD*A
MZ*,_M4B2KI]JK[B"]INAJ?]R^)?RI#YC"91EGH=35Y#NF+]$,XU?DM<UQ(G/
MC,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ=:UMOJ2S=HQ>L* :=YU/HIM@>.)
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MDGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W2IGFAW4M!Y*,A7LD:(L6@ZJ
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MCGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"JWQ7C-DO5WV!AI_..7>\NFBZ[W@
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M!'64E;9YIW:GDGYF.G?=CT-3&'DUB_! .GJZB%4N(7QUA$;#W7(:J3*QUW,
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M=*CYGR9O3:3)G#ECCZ!LF,=7CIORE1=+PY>"D8) 5I,?C@ ULXZHBI$KZ8I
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M@9,F;H&F@,B4:X;)CH^'8X71C5IYH(3>B^QK28/VBE9<SX,IB+Q.6H)\ARE
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M'VKYDO!L+&UAD!9;-V_^C31*K'+*BCHZAG7CAQ,K>WD[@ZBLT&-XI$"=3V7
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M?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G@UM(WI0X@NY
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M)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#;FQLA3 UQW&
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M>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T<U=I^6FT=,);W&RH=C5-MV_3=[]
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M#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6*#QUFR&)GD,
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M?[<HGG8A@!F.#T@4APN"!DUCAFAU;5*0A;)H.U?-A/5:L5U'A#U-)F,*@XU
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M<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;#&<F==9/26K
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
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M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
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M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
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M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
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M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
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M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
M:_\/ 6+_%@);_QX#5/\F!4[_+@9)_S4(1?\\"T'_0PT^_T@.._].$#C_4Q$U
M_U@2,_]>$S'_9!0N_VH5+/]R%BK_>A<G_X,8)?^.&23_F!HC_Z :(O^J&R'_
MK1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0 7O\-
M %;_$@%/_QD"2?\@ T/_)P0__RX%.O\T!C?_.@<S_S\',/]$""[_20DL_TX)
M*?]3"B?_6 HE_UX+(_]D"R'_; P?_W0-'?]]#AO_APX9_X\/&/^9#QC_FQ 8
M_YL0&/^;$!C_FQ 8_YL0&/^;$/],*@/_2#,%_T\T!O]4-PC_6D$._UQ*%O]:
M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
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M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
MB-0& '_N#@!Y[1L!<>TG VKN,@AD[CL-7NY#$UCN2Q=3[E(:4.]9'DSO8"!)
M[V<C1^]O)43P=R=!\( I/_"**CWQE2P[\:$M.?*N+CCROB\W\] O-_/G+S;Q
M\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL   G[L  )+&  "&T $ >]T%
M '3W$0!M]QP!9O@F U_X+P9:^3@*5/E #E#Z1Q%,^DX42/M5%D7[6QA"^V(:
M0/QH'#W\<!TZ_7@?./V"(#;]C2(T_I@C,OZD)#'_L24P_[\F+__/)B[_XR8N
M_^,F+O_C)B[_XR8N_^,F+O_C)JVM  "?MP  DL(  (;-  !YV@  </(( &C_
M$0!A_QH!6O\C U3_*P1/_S,&2O\["$;_0@M#_TD-0/]/#CW_51 Z_UL1./]A
M$S7_:!0S_V\5,/]X%B[_@A<L_XT9*O^9&BG_I!HH_Z\;)_^Z'";_QQPF_\<<
M)O_''";_QQPF_\<<)O_''*&T  "3OP  ALH  'C6  !LX@  8_P' %S_#P!5
M_Q8!3_\> DG_)@-$_RX$0/\T!3S_.P8Y_T$'-O]&"#/_3 @Q_U$)+O]7"BS_
M70HJ_V0+*/]L#"7_=0TC_W\.(?^*#R#_E1 >_Z 0'O^H$1W_L1$=_[$1'?^Q
M$1W_L1$=_[$1'?^Q$96\  "&QP  >=,  &O@  !>[0  5O\# $__# !)_Q(!
M0_\9 3[_( (Y_R<#-?\M S+_,P0N_S@$*_\]!2C_0@4F_T<%)/],!B+_408@
M_U<&'?]>!QO_90<9_VX(%_]X"!7_@P@3_XT)$_^6"1+_G@D2_YX)$O^>"1+_
MG@D2_YX)$O^>"?]"+0/_0C($_T@R!/],-@;_3CP(_U!'#O]04A7_3E\:_TMK
M'_](=R3_18,G_T*.*O]!ERS_/Z N_S^G+_\^KC#_/;4Q_SV\,O\\Q3+_/,XS
M_SO?,_\[ZC3_._,T_SO[-/\\_S/^//\S_#W_-/8__S7U/_\U]3__-?4__S7U
M/_\U]3__-?]#+ /_1# $_THP!/].- ;_43H(_U-&#O]2417_45T:_TYI(/]+
M="3_2( H_T6+*_]#E2W_0ITO_T&E,/] K#'_/[,R_S^Z,_\^PC3_/LPT_S[<
M-?\]Z#7_/?$U_S[Z-?T^_S7[/_\T^#__-O)!_S?P0?\W\$'_-_!!_S?P0?\W
M\$'_-_]$+ /_1RX#_TTN!/]1,@7_5#D(_U=$#O]63Q7_5%H;_U%F(/].<B7_
M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
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M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
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M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
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M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
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M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
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M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
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M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
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M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
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M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
M )Z6  "3FP  AY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4KD #
M4:U(!4ZM3P=+K5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFKL!<X
MJ\,7.*KA%S>I\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8  )>;
M  "+H0  ?Z8  '.K  !GKP  6K0  %.V# !1MQ< 3[<D $VX, !*N#H!2+A#
M D:X2P-$N%($0;A:!C^X8@<]N&L).KAU"SBW@0PVMXX.-+>=#S.WK0\RM\$/
M,;?>#S&V\A PM/P1,+/_$C"S_Q,PL_\3,+/_$[*.  "EE0  FIL  (ZB  ""
MJ   =:T  &FS  !>MP  4[L  $? !0!#PA  0L(; $##)P _PS( /L0\ #S$
M1 $ZQ$T!.,15 C;$70,UQ&8$,\5P!#'%? 8OQ8H&+<6:!RO%J@@JQ;X(*L7:
M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
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M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
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M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@
MKV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF":E(,?FE9#WMH8!)W
M9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65BNB9D8L\F9&+J)F5B
M^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@  +QN  "S<0  JW,
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M(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0  GW\  ))^  "*?P<
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M&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T
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M""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@
ME9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ U
MO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_
MH@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X
M ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T
M)LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9
MSJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M
M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9
M !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0
M#>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=
MO   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH
M&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG
M  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0
M0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #
M]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #W
MIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$
M "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A
M /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@
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M#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0
M[T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S1TH"L$94!*Q%706J
M1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I H1&80*P2ET"X$I5
MR!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_$_\\  #Y1   Y$H
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M?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  #
M60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ2
M9@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K
M&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@
MM%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+6%4(B%=<"H968PR#
M56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2NAMQ4LT<<%+H&W!3
M^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH  ,!?  "W8@  KV$
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M&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;   HVP  )EI  "2:@L
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M&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0
M:7\O 69_.0)B?T(#7WY)!5U]4 =:?5<)5WQ>"U5\90U2>VX/4'IW$DYZ@A1+
M>8X627F<%TAXJQA&>+T91GC5&49W[QA'=OP81W;_&$=U_Q='=?\71W7_%\EE
M  "Z;P  KG<  *1]  "8?P  BW\  'Y_  !S@0  ;(,) &B$$P!EA2  8H8L
M %^&-@%<AC\"685& U>%3@54A54'4H1<"4^#8PM-@VL-2X)T#TB"?Q%&@8P3
M1(&:%4* J19!@+H60(#2%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U
M=0  JGT  )^"  "2@P  A80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.
M,@!5CCL!4XY# E".2@-.C5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8
M$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P
MI8,  )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-
MES8 2Y<_ 4F71P)'ETX#1995!$.6705!EF4&/I5O"#R5>@DZE8<+.)65##:4
MI0TUE+8.-)3,#323Z0TTDO@.-)#_#S20_P\TD/\/-)#_#[5X  "J@@  GH@
M ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ  1Y\; $:@)@!$H#
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M,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G
M 1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@
M8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :
MPR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'
MU  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0
M $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$
M#-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !
MU=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_
M   TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@
M  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$
M .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   H
MS   ']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I
M'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[
M  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@
M%-P   [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@
M]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_
ML   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!=
M /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P
M^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M
M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$
M9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P
M /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\
MY@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_
M"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)
MM@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_
M ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8
M\Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@
M#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B
M$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J
M .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L
MSA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_
M)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>
M;0#2'W4 T!]] ,X?@P#,'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$
M < AU@&\(NH"N2+X [8B_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4
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M#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20
MOT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:4
M07 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!
M^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P
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M$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7   IEH  )]6  "85@T
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M$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R<
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M$4ELIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P
MK&X  *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;
M>#P!67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-S
MI1!"<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',
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M!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0
M<(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ W
MFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:F@,IFJP$*)K !">9
MW@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD  (2*  !VC   :H\
M %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$ +J0J "VD,@ LI3H
M*Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@IJ@!'Z6[ 1ZEUP$>
MI.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=
M  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z
M !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L
M$Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%
MK   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]
M-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P
M  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@
M,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #
MRC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,
M[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$
M !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH
M -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@
MWN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//
M   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G
M  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8
M .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #
MW@   .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T
M(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO
M /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X
M_P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R
M +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3
M' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S
M /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H
MZ #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_
M$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /(
M=P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP##
M -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1
M_Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F
M!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - '
MSP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@-
M /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74
MV U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##
M$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?
M#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W
M ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.(
MLQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W
M(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?
M> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W :PAQ@&K(=T!IR+O
M J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*   \BH  .4K  #?* 4
MW"$+ -(A% #))"0 PR4R +XF/P"Z)TH MR=4 +0G70"R)V0 L"=L *XG<@&M
M)WD!JR=_ :HGA@&H)XX!IR>6 J4GG@*C**@"HBBS J HP0*?*-4"G"GL YHJ
M^@.8*O\$ERK_!)<J_P26*O\$EBK_!/\H  #U+@  Y3,  -HU  #0,P$ S"T&
M ,8J$ "^+1X N"XL +,O.@"O+T4 K#!/ *DO6 "G+U\!I2]F :,O;0&A+W,"
MH"YZ IXN@0*=+HD"FRZ1 YDNF@.8+J0$EB^O!)4OO023+\\$D3#H!8\P^ 6-
M,?\%C3'_!8PQ_P6,,?\%C#'_!?\M  #J-0  W#H  ,X]  #&/   P#<" +LS
M#0"S-!D KC8G *DW- "E-T  HC=* )\W4P&=-EH!FS9A 9DV: *7-6\"E35U
M Y0U? .2-80$D#6-!(\UE@6--: %BS6K!HHUN0:(-<H'AS;E!X4V]@>$-_\'
M@S?_!X,W_P>"-_\'@C?_!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J
M.Q0 I3PB * ], "=/3L F3U% )8]3@&4/%8!DCQ= I \8P*..VH#C#MQ!(H[
M> 2(.H %ASJ(!H4ZD@:#.IP'@3JH"( ZM0E^.\8)?3OA"7L\\PE[//\)>CS_
M"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20  KD8  *E!! "C01$
MG4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%068#@T!M!(% = 6
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M"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D
M>%0T '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@
M48\+7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*
M  ##4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q
M '!7.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+
M652:#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  #
M5@  LUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;
M-P!H6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8
M#5-8I@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60
ML%\  *-A  "68   BU\  (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C
M8#T!85]% 5]?3 )=7U,#6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=
MI U-7;0.3%W(#DQ=Y@Y-7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,
M )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L
M7&1# 5ID2@)89%$"5F18 U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(
M8K(-1V+'#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF
M  "-9@  @F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI
M 55J1P%3:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,
M0F?%#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  ")
M:0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P
M10%.<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6["
M"CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0
M>&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,=S$ 2W@Y $EX00!(
M>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEVG @W=:T(-W7 "#9U
MW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$  (MQ  !^<0  <W(
M &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4
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M B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@
M0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @
MGDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;
M_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P
M #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD,
M$ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -
MJ/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ
M   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#
M  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<
M +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :
MN   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$
M1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N
M (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@
M#,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.
MU$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@
M  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M
M  #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38
M .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !B
MKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
M    XP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S
M  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD
M_P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[
M (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P
MT0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4
M /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X
M\@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A
M .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"
M%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_
M .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T
MT0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_
M!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L
M@0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J
M ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0
M_PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*
M!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+
M^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5
M .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T
MO0Z# +P.B@"Z#I$ N0Z8 +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I
M$O\ J!/_ *<3_P"G$_\ IQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.
M%P#/$28 R!(T ,030 "_%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^
M *\6A0"N%HP K!:4 *L7G "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!
MG!O_ 9P;_P&;&_\!FQO_ ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"
M&B  O!PM +<=.@"S'D4 L!Y/ *T>5P"K'E\ J1]F *@?; "F'W, I1]Y *,?
M@ "B'X< H""/ )\@F "=(*( FR"L 9HAN0&8(<H!EB+D 90C]0&2(_\!D2/_
M 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH
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M!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T
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M!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3
MLE(  *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J
M3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#7DQR!%Q,? 5:3(@&64R5!U=,
MHPA63+((54S&"55,X@E53/4(54S_!U5,_P=63/\&5DS_!LQ(  "\4   KU4
M *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"  :E J &=0,P!E4#P
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M1@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC
M"$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P
M?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !1
M7DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=
MV@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T
M &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@
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M!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@
M37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U
M>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU
M_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@
M $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E
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M )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@
M'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *
MI%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#
M  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@
M !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,
M +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !X
MB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV
M   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6
M  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0
M8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"
MQ    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/
M60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<
M $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T
M -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P
MY%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y
M   UO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\
M  #A    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T
M /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_
M ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8
MB #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q
M .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\
M_P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K
M (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@
M^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F
M /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4
MW@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#(
M /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$
M+ #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"&
M ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T
MNP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A
M #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,
MAP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_
M *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL
MS ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R
M!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-
M_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP
M +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4
MI0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5
M%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4
M-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>(
M )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\
MB1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A
M'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@
MC0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_
M >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4
MDR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0&
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M FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@
MM4(  *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U
M.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,Z
MH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4
M *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\
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M!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P
M?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !7
M24H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+
MTP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT
M '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@
M4DY/ %!.5P%/3E\!3DYG 4Q.<@)+3GT"24Z+ TA.F01'3Z@$1D^Z!$9/T01&
M3^T$1D[\!$9._P-'3O\#1T[_ [U,  "N4@  G%$  (U1  "!40  =U   &Y,
M  !G3@  8D\  %U0#0!:4!0 5U$> %51)P!343  45(X %!2/P!.4D8 35)-
M $Q350!*4UT!25-E 4A3;P)&4WL"15.) T-3EP-"4Z<$05.X!$%3SP1!4^P$
M05+[ T)2_P-"4O\#0E'_ [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B
M4@  7%,  %A4"@!451( 4E4; $]6) !.5BT 3%<U $M7/ !*5T0 2%=+ $=8
M4@!&6%H!1%AC 4-8;0%!6'D"0%B& CY8E0,]6*4#/%BW!#Q8S00\5^H#/%?Z
M SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@
M5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 !
M75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;
M_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T
M $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4
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M :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0
M+G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @
M>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI
M  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$#
M "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF,
M%89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!
M;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-
M!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J
M  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P
M;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .
MF@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<
M<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H
M %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4
M Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:
MJ7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)
M  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'
M  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X
M +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"
MG   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_
M!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU
M  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP
M+[   "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,
MS0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@
M?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P
M !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0
M -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P
M\X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0".
M /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\
MX0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^
M $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4
MCP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_
M -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L
M\ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3
M )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$
M_P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!!
M -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P
MPP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T
M /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T
M10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0".
M +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\
MI@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\
M $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *<
MD0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_
M /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4(
MK09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":
M"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81
M  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$
M )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90
MC1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<
M(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )06
M1P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F;
M ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0
MORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"'
M'TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4B
MI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(
M *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0
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M 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/
M@SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A
M-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58YF0%5.:@"5#FY E,Z
MSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P  ?CT
M '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;.TH
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M D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P
M7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(
M2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)
M_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P  64@
M %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358
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M :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@
M/5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O
M76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5
M  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F -
M #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D
M)V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")
M6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI
M$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR
M !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7
M=5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A
M<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U
M?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$
M &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X
M%GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,
M?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F
M  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.
M  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,
M (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0
M<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3
M$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.
M  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0
M/WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@
MGQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "B
MF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L
M "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T
M *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@
ML:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>
M   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,
M  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<
M ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4
ML0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*
M"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>
M  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@
M!,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
MW@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #P
MGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!-
M /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4
MZ@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#>
M /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0
M4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6
M -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\
MRP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D
M %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D
MF0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_
M /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %
MS@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y
M )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\
M  #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2
M +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@
MJ0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
M    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X
M4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "=
M )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P
MW T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@
M %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"
MI ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4
M +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X
MDPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!
M#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<
M  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/
M (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX
M=1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<
M(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P7
M4 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[
M &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*
MC24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q
M'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$C
MS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H
M ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T
M9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9
M*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM
M  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0
M %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4
M4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O
M+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P
M4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V
M $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P
M93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0
M-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X
M_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8
M %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54
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M :I"  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP
M1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X
M1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$
M  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0
M #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H
M,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".
M2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.
M%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U
M "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@
M>DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q
M5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57
M@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X
M &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4
M*%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =
M7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12
M  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8
M !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L
M%&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !7
M5@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M
M&@ 5;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+
M  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G
M 'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"
M8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "#
M#0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[
M  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0
M,FT  "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0
MCPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5
MB   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD
M "%_   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<
M )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0
MII0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-
M   1D@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$
M  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@
M +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,
MH@   Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
M    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1
M  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0
M +8   "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.
MT    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #G
ME@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!#
M /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L
MXP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/
M /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P
M2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ",
M ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\
MO@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5
M $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T
MC@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_
M /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4
MOP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L
M )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\
M  #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!'
M *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L
MFP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
M    TP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X
M1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/
M (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3
MP0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/
M $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X
ME@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P
M *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $(
M@@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q
M )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1
M  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1#
M '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T
M90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'
M%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,
M1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K
M %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0
M>!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B
M$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6
MN@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$
M &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$
M6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*
M'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C
M  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U#
M $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP
M0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<
M)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B
M1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH
M #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*
M5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P!
M)TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L
M^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H
M $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@
M.BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S
M,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N
M  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%.
M #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\
M+S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _
M,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V
M50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_
M )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@(
M-S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I
M.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV
M  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL(
M "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L
M(D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X
M.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"
M#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E
M !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0
M9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A
M2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+
M<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$
M %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT
M&% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .
M4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%
M  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<.
M !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D
M!EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(
M2   04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@
M$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&
M  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3
M/4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@
M:!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !I
ME   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0
M #!7   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1
M '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@
M<Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@
M   B9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1
M  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T
M '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;
M;P  %',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*
M$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK
M  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?
M#H$   B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#
MF@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?
MMP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I
M  "4    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D
M *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK
MLK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
M    J    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&
M  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\
M ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S
MMP   +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/
M P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M
M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %
M\ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9
M )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\
M  #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2
M -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8
MQ "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,<
M4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@":
M +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]
M[@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R
M %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$
MGP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@
M ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T
MH0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0
M *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H
M  "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!-
M )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *
M@ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
M    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (,
M30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J
M '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!
MC@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V
M $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &<
MM@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L
M 'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $<
M:@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!<
M \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.
M  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=)
M %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,<
M4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G
M$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-
M2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E
M $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P
M7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.
M$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7
M]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD
M %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH
M11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 [
M'/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\<
M @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/
M #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\
M-B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'
M( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B
M50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_
M )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4
M/R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P
M)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH
M  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+
M #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L
M*BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X
M+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L
M#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E
M "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P
M9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K
M,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U
M<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,
M %DT  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q
M)#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8
M.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V
M  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2
M !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P
M$D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*
M.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#
M%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,
M  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/
M0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 0
M2A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+
MF@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X
M #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410
M"5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@
M4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#
M   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7
M  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4
M %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H
M3   (D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A
M&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V
M  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P
M'%<  !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0
M;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !K
MR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F
M !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8
M '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0
M=]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO
M   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85
M  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$
M (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]
M@0   (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7
M%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?>
M $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0
M )4   "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@
MJA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F
M   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4
M  "H    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T
M +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R
M>   )X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
M    NP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-
M  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_
M_P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G
M %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P
MK #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P
M /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D
MS@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y
M +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T
M  #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9
M +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T
MI@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+
M  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *<
M6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V
M )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  (
MKP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6
M %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4
MP@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ '
M )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$
MA@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V
M -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L
M"P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0
M '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D
M:0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![
M  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L
M4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A
M %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D
M;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !?
M %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %,
M[P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+
M &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X
M50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*
M!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)
M#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1
M $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L
M0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3
M#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.
M5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_
M ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L
M2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [
M$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;
M  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4.
M $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L
M,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X
M(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9
M$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD
M "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P
M9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S
M'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B
M;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8
M %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$
M+"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @
M)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I
M  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4
M "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL
M&BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*
M+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L
M&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+
M !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@
M02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :
M,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! U
MG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C
M #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D
M$S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +
M.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S
M   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<
M  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@
M SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N
M-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$
M(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y
M  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0
M)3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'
M2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*
MS@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$
M !Q#   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\
M %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@
M4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*
M   230  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA
M  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0
M %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .
M5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G
M(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P
M $]&  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8
M F,   !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0
M="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*
M  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\
M  !R    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X
M (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _
M4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M    @P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@
M  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60
M+UT  "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1
MDP   )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I
M(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH
M !UP   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I
M *4   "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&
MOB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:
M   -B   !8\   "6    G    *(   "G    K    +    "S    M@   +<
M  "Y    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L
M -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_
M  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X
M8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#,
M ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L
M[0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$
M &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X
MXP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ .
M ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T
ML !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"=
M /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8
M$@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!;
M )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@
MBP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"?
M !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L
M6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U
M 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$
MBP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![
M %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X
M_@!N /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4
M 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0
M; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A
M /\ 80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T
M%@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6
M %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\
M5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A
M !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4
M6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_
M )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !,
M5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!*
M %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-
M  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5
M $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H
M0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\
M$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(
M%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC
M #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0
M:1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _
M#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0
M;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H
M %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4
M-Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I
M%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>
M  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07
M "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D
M(AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*
M(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8
M&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V(
M !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@
M02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A
M'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<B
MF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0
M #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL
M&R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1
M)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F
M   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<?
M !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD
M#2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O
M*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M
M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY
M  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@
M*2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -
M,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (S
MS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP
M "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0
M!C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@
M..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q
M   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH
M   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0
M #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6
M.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%
M+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R
M %4T  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P
M#T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*
M3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X
M  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD
M  =+   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP
M %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"
M/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q
M  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P
M.C\  #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>
M80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O
M-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40
M "M'   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0
M &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@
M?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50
M   <50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X
M  !_    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,
M ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   5
M8@  #F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
M    D@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z
M  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<
M!W<   !^    A    (H   "/    E    )@   ";    G@   )\   "B
MI    *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[
M0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@
M  "/    E@   )L   "A    I@   *H   "N    L    +$   "T    M@
M +@   "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.
MT4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D
M&P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H
M -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\
MN #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#?
M "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H
M9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_
M *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L
MP  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F
M &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4
M_P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  >
M *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &
MD0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"#
M /\ @0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ),
M(0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@
M '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\
M= #_ ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"
M ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '
M80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_
M +@   "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T
M<  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A
M &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@
M  "5    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ?
M &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X
M5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %<
M( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C
M $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P
M<0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!,
M "  2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $
M:P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X
M %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P
M0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V
M '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1
M  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(=
M #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W,
M+@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,
M%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)
M'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR#
M "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P
M0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L
M#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0
ME@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD
M #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X
M)1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8
M%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;
M   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A
M !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8
M$ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O
M'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8
M)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY
M  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@
M*1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3
M'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@
MR@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\
M ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8
M#B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &
M(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A
M   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K
M  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$
M 2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;
M)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M
M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP
M %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P
M%2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0
M,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G
M  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX
M  \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,
M #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&
M+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU
M   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z
M  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P
M.2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %
M/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(
M00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(
M # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@
M $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/
M44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T
M   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$
M  !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0
M %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C
M/   '#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-
M  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1
M%DD  !!-   *40  !%4   !:    70   &    !C    9@   &@   !J
M:P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X
M60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0
M  I9   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P
M 'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@
MBV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M    ;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\
M  "1    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED
M *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W
M?0   (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
M    I@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E
M  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP
M )8   ";    H    *0   "H    JP   *P   "O    L@   +0   "V
MN0   +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-
M<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J
M .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X
MQ@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P">
M /\ FP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -(
M+0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N
M *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\
MCP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S
M "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P
M;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_
M .<   #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D
MFP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "'
M '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8
M  #     KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J
M (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D
M=0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
M    FP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4
M*@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M
M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9
MB@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E
M "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %<
M<@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?
M '$   !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4
M5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!*
M 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8
M  !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E
M $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4
M/P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5
M!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $(
M)0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"!
M #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#
M2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y
M "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T
MCP L *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX
M #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "(
M,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E
M )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0
M   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C
M "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT
M'@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q
M$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "()
M)@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP
M !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P
M*A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <
M#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /
MR0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0
M "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@
M%1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,
M$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6
M   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M
M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT
M"17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <
M%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9
M,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL
M %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0
M%Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P '
M'CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:
M  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL!
M !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4
M ")    C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !(
M'P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$?
M @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]
M   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0
M.R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -
M)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M
M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0
M # D   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@(
M!BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@
M,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG
M   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($
M   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP
M #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F
M*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [
M!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7
M  !":@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@
M'RL  !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @
M104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+
M9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$
M !4T   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$
M $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@
M5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\
M   ,0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H
M  !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L
M &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &
M2@   $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[
M  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P
M %P   !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z
M?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%
MBP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L
M  !O    =    'D   !]    @    (,   "%    AP   (H   ",    CP
M )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0
MFID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
M    A@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8
M  "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X
M *^D ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5
MF@   )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
M    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6
M /P   #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8
MW@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\
M ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0
M  #L    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W
M +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H
MI0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
M    V0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8
M. "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!]
M (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT0
M24-#7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
M +6Z @"HQP( G=8$ )/\#@&+_QT&@_\K#WK_-1=Q_SP?:/]")F#_22Q9_T\Q
M4_]6-4[_73A)_V4[1?]M/4'_=C\^_X!!._^+0SG_F$4X_Z1&-O^R1S7_Q$@U
M_]U)-/_P23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X23?^^$G)JP  MK0  *C!
M  ";SP  CM\! (?_$0%^_QT$=?\G"VS_+Q)D_S<87/\^'5;_12)0_TLE2_]2
M*$;_6"M!_U\M/O]G+SO_;S$X_W@S-O^"-#/_C38Q_YDW,/^E."__LCHN_\ [
M+O_3.RW_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/"W_ZSRXL   J+P  )K)  ",
MV0  @?4# 'G_$ %N_Q8#9?\?!E[_)PM7_S /4?\W$TO_/A=&_T490?],&SW_
M4ATY_U@?-O]?(33_9B(Q_VXD+_]W)2W_@"8K_XPH*?^7*2C_HBHG_ZTK)O^Y
M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
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M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
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M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
M/_\= 3K_)0(V_RP",O\S R__.@,K_T$$*/](!"7_3P4B_U<%(/]@!AW_; <:
M_WD'&/^*"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/__PH3__\*$___"A/_
M_PJ:L0  B[T  'S(  !MU   7^   %'F  !']0  0?\  #S_"0 W_Q  ,O\5
M 2[_'0$J_R,!)O\I 2+_+P(?_S4"'/\[ AG_0@,6_TD#$_]1 Q'_6@,/_V8$
M#?]T! O_A00*_Y8%"?^H!0C_N04'_] %!__C!0?_XP4'_^,%!__C!0?_XP6-
MN@  ?<<  &W3  !?X   4.<  $+M   Z_P  -?\  "__ @ J_PH )O\/ "+_
M%  >_QH!&O\? 1;_(P$3_R@!$/\M 0[_,P$,_SD""O]! @?_20(#_U," /]>
M @#_; ( _WP# /^- P#_G0, _ZP# /^U P#_M0, _[4# /^U P#_M0/_.2<"
M_S,R O\U- /_.#8#_S@[!/\V0P7_,TX'_S%;"?\O: W_+781_RN$%/\ID1;_
M*9L8_RBD&?\HK1K_*+4;_R>^'/\GR!S_)]0=_R?D'?\G[Q[_)_D>_R?_'O\G
M_Q[_)_\=_RC_'?\K_Q[_+?\?_"__'_PO_Q_\+_\?_"__'_PO_Q__.B<"_S0Q
M O\X,0/_.S0#_SLY!/\Z007_-TL'_S58"O\S90[_,7,2_R^!%?\MCA?_+9@9
M_RRA&_\LJAS_*[(=_RN['O\KQ!__*] ?_RKA(/\J[2#_*O<@_RK_(/\K_R#_
M*_\?_RS_'_\O_R'\,?\B]S/_(O<S_R+W,_\B]S/_(O<S_R+_.R8"_S4P O\[
M+P+_/C$#_S\V!/\^/07_/$@'_SM5"_\Y8@__-V\3_S5]%_\SBAG_,I4;_S&>
M'?\PIQ[_,*\?_S"W(/\OP"'_+\LB_R_<(O\OZB/_+_4C_R_^(_\O_R+_,/\B
M_S#_(_LS_R7U-?\E\#?_)O W_R;P-_\F\#?_)O W_R;_/"8"_SDM O\_+ +_
M0RT#_T0R!/]#.07_0T4'_T)2"_] 7Q#_/FL5_SMX&/\YA1O_-Y >_S>:(/\V
MHR'_-:LB_S6S(_\TO"3_-,8E_S34)?\TYB;_-/$F_S3[)O\U_R7^-?\F^C;_
M*/,X_RGL.O\IYCS_*N8\_RKF//\JYCS_*N8\_RK_/24"_STJ O]#* +_1RD#
M_TDM!/]*-@7_2D$'_TE-#/]'6A'_16<6_T)T&O] @!W_/HP@_SV5(O\\GB3_
M.Z8F_SNN)_\ZMRC_.L$H_SK-*?\ZX2G^.NXI^SKY*?<[_RGV.O\K\#O_+>@]
M_R[A/_\NVT'_+MM!_R[;0?\NVT'_+MM!_R[_/B4"_T$F O]() +_3"4"_T\I
M _]2,P7_43X'_U%)#/]/5A+_3&(7_TIO'/]'>R#_188C_T.1)?]"FB?_0:(I
M_T&J*OU LBO\0+PL^S_(+?@_VRWT0.LM\$#W+>U _R_K/_\QY$'_,MM#_S/1
M1/\SRT;_,\M&_S/+1O\SRT;_,\M&_S/_0"0"_T4C O],( +_4B$"_U8F _]9
M+P3_63H'_UE&#/]641+_5%T8_U%J'?Y.=2'\3($E^4J+*/=)E2OU1YTL\T>F
M+O)&KB_P1;@P[T7$,>U%TS'H1N@QY4;V,N)%_S7?1/\VTT?_-\I(_SC$2O\X
MOTO_-[]+_S>_2_\WOTO_-[]+_S?_02,!_TD? ?]1' '_5QP"_UPC O]@+ /_
M8#8&_V!!"_]>31']6U@8^%AD'?15<"/Q4WPG[E"&*^M/D"[I39DPYTRA,N5,
MJC/C2[0TXDO ->!+SS7;2^8VU4KT.-%*_SK.2O\\Q$S_/+U-_SRX3_\\M$__
M.[1/_SNT3_\[M$__.[1/_SO_0B(!_TP< ?]5& '_7!D!_V,@ O]F* /_:#(%
M_V@]"?IF2!#T8U,7[F!?'>I=:R/F6G8HXE>!+=]5BS#<4Y0SV5&=-M50ICC3
M3Z\ZT$^[.\Y.R3S+3^$]QT_R/L-/_T# 3_]!MU'_0;%2_T"M4_] JE3_/ZI4
M_S^J5/\_JE3_/ZI4_S__1A\!_U 9 ?]9%0'_8A<!_V@= ?]L) +_;RX#^6\X
M!_%N1 [K:TX5Y6A;'-]D9R/:8'$JU%U[+]!;A33,6(XXR5>7.\=5H#W$5*D_
MPE.T0;]3PD*]4]9#N5/M1+93_46S5/]%K%;_1*=7_T2D6/]#H5C_0J%8_T*A
M6/]"H5C_0J%8_T+_2!T!_U,6 ?]=$@'_9A0!_VT9 ?]R(0'[=2D"\G8S!>EV
M/@OB<TH2VV]7&M)K8B/-9VPKR&1V,<1A?S? 7HD[O5R2/KI;FD&W6:1$M5BN
M1K)7NT>P5\U(K5CH2*I8^DFG6?](H5K_2)U;_T>;7/]&F5S_19E<_T697/]%
MF5S_19E<_T7_2QH!_U<3 ?]A$ #_:Q( _W(6 /]X' 'U>R0!ZWTM ^)^.0?9
M>T80T'93&LEQ7B3#;6@LOFIQ,[IG>SBV9(,]LF*,0:]@E46L7I]'J5VI2J9<
MMDND7,=,HESB39]=]TR<7O],F%__2I5@_TF38/](D6#_1Y%@_T>18/]'_^)]
M$$E#0U]04D]&24Q%  H2D6#_1Y%@_T?_3A@!_UH1 ?]D#@#_;Q  _W83 /Q]
M%P#O@1X!Y(0G MN$- 70@4,/R'Q/&<%X6B.[<V0LM7!M,[%L=CJM:G\_J6>(
M0Z5ED4>B8YM*GV*E39QAL4^98,%0EV#<4)5A\T^38O].D&/_3(YD_TN,9/]*
MBV3_2(MD_TB+9/](BV3_2(MD_TC_4!8!_UP0 /]H#0#_<@X _WH0 /:!$@#I
MAA< WHH@ =**, 3)AD .P8)-&;I]5R.T>6$LKG5J-*ER<CJD;WM H&R$1)UJ
MC4B9:)=,E6>A3Y)FK5&09;U2CF744XQF\%&+9_]0B&?_3H=H_TR&:/]+A6?_
M285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ
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M4EJ.WE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4
M]70  -J"  #+C@  P9<  +B> 0"QI0  J:L' *.M&@"<K"P$E:LZ#(VH11:&
MID\??Z17*'FB7R]SH&8U;9YN.VB<=T!CFH%%7YF,25N8F4Q7EZA.59>[3U27
MW$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D
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M/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@
MHZD  )BQ  ".N0  A,$" 'G)!P!TRQ0 <,PF 6O+-05ERT *8,I+$%O*5!97
MR5T:4LEE'T[(;R-+R'HF1\B&*43(E"Q"R*0N0,BX+S_)UR\_Q_4P/<3_,SO#
M_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\
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M$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V
M4=\  $GN! !&_ X 0OT7 #[^(0 [_BH!-_\S C3_.@(P_T(#+?]* RO_4P0H
M_UP%)?]F!2+_<P8@_X,''_^4"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G_
M_PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4
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M.)=7_S>75_\WEU?_-Y=7_S?_210 _U,. /]<# #_90T _VL/ /IO$P#L<AD
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M26MUU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60<
M_V4  .)R  #1?   QX0  ,"* @"YCP( LY(, *R4'0"FDR\$GI$\"YB/2!21
MC%$<BXE:)(:'8BJ!A6DP?()Q-7B!>CIT?X,^<'V.0FQ\FD5I>Z='9GJX2&1[
MT$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD
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M0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0
MLY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50&&VC6!YH
MHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\3)G_/$R8
M_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H
M **?  "9I0  CJL  (6P"P"!L1L ?+$K G>P. =QKT,-:ZY-%&:M51EAK%T>
M7:ME(UFJ;B=5J7<K4:B"+TVGCS)*IYXU2*>O-D>GQC9&INDV1:3^-T6C_S=&
MH/\W2)S_-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND
M  "0JP  A;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B
M'%*U:R!.M'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R
M0*C_,D&F_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'
ML0  ?+<  '"^ P!HP@X 9L,= &/#+0%>PSD$6L-$"%;"3@Q2PE<03\%?%$O!
M:1=(P7,:1<!^'4+ C" _P)LB/<"M(SS!Q",\P.DC.K[^)CB\_R@WN_\I.+C_
M*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N
M<;X  &;% P!;RP@ 5\T3 %;.(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y
MSV\0/L][$SO/B14YSYD7-\^K&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(
M_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8
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M Q/Y_P.=I0  CZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]
M*_\* "C_$  E_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$.
M_V<!#/]W 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?_
M_P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$
M !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0
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M4"P!_4XW O9+0P3P25 'ZTA="N=&:0WC1700X$1^$]U#AQ7;0I 7V$&8&-5
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M.GMBSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P<
M_UD  .9D  #7;   S',  ,1W @"_>00 N7H. +)\( "L?#$#I7H^"9]X2A":
M=5,7E7-<'9%Q9"*-;VPGB6UT*X5L?"^":H4R?VF/-7QHFSAY9Z<Z=F:V.W1F
MS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP
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M=@  OWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8"
M71]\?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[
M.6)V_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@
MNX$  +*'  "KB@  HHP" )R.% "7CR8!D8XT!8N,0 N%BDH1@(A3&'N&6QUV
MA6,B<H-J)VZ"<BMJ@'LO9W^&,V-^D39@?9XY77RN.EM\P3M;?.,Z6WSZ.%Q[
M_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8
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M+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0
MAJ(  'JF P!VIQ, <Z@D &ZH,@-JJ#T&9:='"V&F4 ]=I5@46:1@&%6C:!Q2
MHW$?3J)\(TNAB"9(H98H1:"F*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27
M_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@
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M%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R (
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M"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>
M 1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP
MBZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9
M_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_
M@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4
M &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@
M#O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0
M_WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')
M  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&
M  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4
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M248"U4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I
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M*)%0T"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10<
M_TL  /!5  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE
M7U</H5U@%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4
MRRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\
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M+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@
MOW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!
M;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG
M_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,
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M*5IT_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@
MD8<  (J)# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA
M@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z
M_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T
M (./" !^D!< >Y$G 7:1- -RD#\&;8])"VF.40]EC5D38HQ@%UZ+:!M;BG$>
M5XE[(52(AB11AY0G3X:B*4V&M"I+ALPJ2X7N*4R$_RE,@_\H3(/_)TV!_R9.
M@?\F3H'_)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0  A),  'J5
M @!UEQ( <I@B &^8, )JESL$9I=%"&*63@Q?E58/6Y1=$UB391=5DVX:49)X
M'4Z1A"!+D)$C29"A)$>0LB9%D,HF18_M)46-_R5%C/\E1HO_)$:*_R1&BO\D
M1HK_)$:*_R38:0  PW8  +6!  "KB@  GX\  )63  "*E@  ?IH  '"=  !K
MGPX :)\< &:@*@%BH#<"7Y]!!5N?2@A8GE(+5)Y:#E&=8A).G&L52YQU&$B;
M@1I%FX\=0IJ?'T":L" _FL@@/YGK'S^8_R ^EO\A/I7_(3^4_R$_E/\A/Y3_
M(3^4_R'-<   O'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@
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M!RO J@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC
MI90  )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  N
MRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/
MI0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H
M )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H
M&]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3
MXK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I
M  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D.
M !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J
M!?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !I
MN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ
M#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD
M  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q
M3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0
M_PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_
MI@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8
M #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4
M /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C
M_Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+
M. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H
M /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\
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M$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H
M_SP  /]!  #U10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y
M15\&M41H";-#<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J%
MT!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\
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M('U1_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@
MQ%X  +Q?  "V7@  L5P+ *M>&@"E8"L H& Z IQ?10677E )E%Q8#)!;8!"-
M6F@3BUEP%HA8=QB%5X ;@U:)'8!6E!]^59\A>U6M(GE4O2-X5=<C=U7R(G96
M_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(
M +=D  "Q8P  JV$( *1C%P"?9"@ FF4W I9D0P618TT(CF%5#(I@71"'7V43
MA%YL%H%==!E^7'T<?%N&'GE:D2!W6ITB=%FJ)')9NB5Q6=(E<%KP(V]:_R)O
M6O\@<%K_'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H
M  "L:   I68% )]G% "::24 E6DT I!H0 2,9TH(B&93#(1E6Q"!9&(3?F-J
M%GMB<AEX87H<=F"$'G-?CB%P7IHC;EZH)6Q=N"5J7LXF:5[N)&E>_R)J7O\@
M:E[_'VI>_QYJ7O\=:E[_'6I>_QWY2@  XU4  ,]?  #!90  MVH  *]L  "G
M;   GVH! )EK$0"4;2( D&XQ 8MM/02';$<'@VM0"W]J6 ]\:& 3>&=G%G9G
M;QES9G@<<&6!'FUDC"%J8Y@C:&*F)69BMB9D8LPF9&+L)61B_R-D8O\A96+_
M'V5B_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<
MF6X  )-P$ "/<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM
M:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F
M_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',
M (UT#0")=AP A7<K 8%W. -\=D,&>'5,"71T5 UQ<UL1;G)C%&MQ:Q=H<',:
M96]\'6)NAR!?;90B76RB)%ILLB59;,<E6&SH)5EL_2-9:_\A6FO_'UMK_QY;
M:O\>6VK_'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0  C7<  (=Y
M"P"#>Q@ ?WPH 'M\-0)W>T %<WI)"&]Y40QL>%D/:'=A$V5V:!9B=7 97W1Z
M'%QTA1]:<Y$A5W*@(U5RL"13<L4D4W+G)%-Q_")4<?\@5'#_'U5P_QY5;_\=
M56__'55O_QWE5P  S60  +YM  "R=0  J'L  )]^  "3?0  AWT  (!_!P!\
M@!4 >($D '6",@%Q@3T$;8!&!VF 3PIF?U8-8WY>$6!]9A1=?&X76GMW&E=Z
M@AU4>H\?47F=(4]YKB).><,B37CE(DUW^R%.=_\?3G;_'D]U_QU/=?\=3W7_
M'4]U_QW?7   R&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$
M<8@@ &Z(+@%JB#D"9X=#!6.'3 A@AE,+785;#EJ$8Q%7A&L45(-U%U&"@!I.
M@8T<2X&;'DF!K!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\
M_QS680  PFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T :(\:
M &:/*0!BD#4!7X\_ UR/2 59CE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH8
M18J9&D.*JAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-
M9P  O'0  *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7
M(P!:F"\ 5Y@Z 5281 -2ETP%3Y=4!TR77 E)EF4,1Y9O#D25>A%!E8@3/Y27
M%3V4J!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@
MMGL  *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/
MH2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"H6$'/Z!K"3V@=PLZH(4-.*"4#C:@
MI@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,
M *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\
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M !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0
M<*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0
MTAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9
MY@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0
M %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$
M!=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR
MY_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#
M   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1
M  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M
M /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   N
MT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V
M#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/
M  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0
M%N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@
M_PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_
MPP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/
M /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +
M_P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T
M /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\
M^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_
M &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H
MN0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L
M_P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P
M!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+
M_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA
M /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T
MY0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_
M)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P7
M9@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G*
M - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!
M_RD+ /\H!@#_*PL _RL0 /\I%P#])B( ]",N .PA.P#F($D XB!5 -X@8 #:
M(6H UB%T -,A? '0(80!SR*, <TBDP'+(IL!R2*C <@CK +&([8"Q"/$ L(D
MVP*^)>X#NR7^!+@E_P6V)?\%M27_!K4E_P:U)?\%M27_!;4E_P7_+ T _RT%
M /\N 0#_,04 _S$+ /TO$ #Q*Q@ YRDE -\H,P#8*$( T2I/ ,TK6@#)*V4!
MQRMN <0L=@+"+'X"P"R& [XLC@.]+)8#NRR>!+DLIP2X++$%MBR_!;4MT06Q
M+>H&KB[[!ZLN_PBI+O\(J"[_"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$  /\U
M  #V-P  ZC8" .<S" #D+P\ V2X; ,\Q+ #),SP Q#1) , U50&\-5\"NC5H
M K<U< .U-'@$LS2 !;$TB :P-) &KC29!ZPTH@BK-*P)J32Y":<TR@JE->4*
MH37X"Y\U_PR=-?\,G37_"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E
M/@  W$   -0]! #2-PD RS@5 ,,Z)@"]/38 N#Y$ ;0^4 &Q/5H#KCUC!*P]
M:P6I/',&ISQ["*8\@PFD.XL*HCN4"Z [G0R>.Z@-G3NT#IL[Q0Z9.^ .ECOT
M#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@
MT$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?
M0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"
M_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X
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M%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P
MH5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y
M5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5
M_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP
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M%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14
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M%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@
MP&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B
M@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[
MI!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL
M *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX
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M""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0
MAHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 U
MI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$)J7& R:D
MZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4
M '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT
M)K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;
MK_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB
M  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ
M !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L
M#[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2
ML0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*
M)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_
M  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0
M.;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@
MV"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?
M_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8
M "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L
M .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0
M\/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75
M   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7
M  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4
M /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #
MY@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_
M$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1
M  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_
M ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X
M_P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,
M^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_
M%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#(
M .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D
M_Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X
M '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0
MU #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0
M /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G
MZ@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3
M!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:
M!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US
M -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D
MPA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_
M(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6
M=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV
M ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P
M\24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z
M(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F
M_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\
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M"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@
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M#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD
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M$E==I1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3
MQU8  +A?  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L
M9S<!:F=  F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)B
MHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH
M +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0
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M#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0
MC70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,
M@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]
MY@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD
M 'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X
M08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <P
MA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_
M  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)
M #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$
M)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !C
MB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=
M00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_
M AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0
M4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :
MJ4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E
M_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*
M #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38
M#+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (
ML_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P
M   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V
M  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\
M ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?
MO0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1
M-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_
M  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP
M#<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P
MY3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K
M_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@
M  #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0
M /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !Q
MK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A
M  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R
M_P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\
MX0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL:
M /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H
M_P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U
M .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(
M% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!]
M /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8
MZ #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_
M Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T
M?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P
M -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP
M_PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#>
M (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,<
M^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\-
M /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L
MRP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V
M#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0
M#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^
M +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\
MIQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>
M#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:
M@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__
M 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @
MQ!D2 +T<(@"W'C$ LR ^ *\A20"M(E, JB-< *@D9 "F)&P I"1S *,D>@"A
M)8(!H"6+ 9XEE &=)9X!FR:J 9DFMP&8)LD"E2?F I(G^0*0*/\"CRC_ HXG
M_P*.)_\"CB?_ HXG_P+_)@  \BD  .,Q  #2-   R#0  , P  "[*0( N",.
M +$F' "L*"L J"HX *0K1 "A+$X GRU7 )TM7P";+6<!F2UN 9@N=0&6+GT"
ME"Z& I,ND *1+IH#CRZF XTNLP.,+L4#BB_A!(<O]@2%+_\$A"__ X0O_P.#
M+_\#@R__ X,O_P/[*0  ZS$  -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O
M%P"B,28 GC,T )HT0 "8-4H E353 ),U6P&1-6(!CS5I HTU<0*,-7D#BC6"
M X@UBP2&-98$A#6B!8(UKP6!-< &?S;<!GTV] 9[-O\%>S;_!7HV_P1Z-O\$
M>C7_!'HU_P3U+0  Y#<  - _  #"0P  MT0  *U   "G.@  HS8& )TW$P"9
M.2( E3HO )(\.P"//$8 C#Q/ 8H\5P&(/%X"ACQE H0\;0."/'4$@#Q]!'\\
MAP5]/)(&>SN>!WD[K =W.[P(=CS5"'0\\0AS//\'<CS_!G(\_P5R//\%<CO_
M!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT
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M"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P
MRTD  +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T
M4CD <E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/
MH0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT
M +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8
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M#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80
MD6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>9"T 7&0W %ID0 %8
M9$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=BF@I&8JH+1&*_"T1B
MX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,
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M!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0
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M 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@
M<WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  B
ME28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67
MR0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((
M %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L
M$Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +
MHN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.
M  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;
M  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4
M *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$
MGP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y
M'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK
M  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0
M,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%
MQQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.
M]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P
M !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$
M -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@
MY?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*
M   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.
M  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0
M /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
MW0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z
M"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6
M  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X
M_P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_
M +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /
M_P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D
M /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0
M]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_
M"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L
M: #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y
M .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1
M_PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L
M &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4
MP #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP'
M /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4
MVP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#"
M ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*
M  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F
M ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,<
ML@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R
M#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%
M: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O?
M *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0
MVQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K
M$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6
M] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0
M ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4
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M G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P
MF"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@ ?C5? 7TU9@%[
M-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L-OP#:S;_ VLV
M_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@  D#8
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M UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q
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M!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2
MN5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;
M5RD 65@S %A8/ !6640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7
ME09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58
M *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8
M4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=D@5
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M S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P
M>&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z
M<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQ
MR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<
M &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X
M,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)ZQ0$B
M>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L
M  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O
M ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8
M&('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4
M=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.
M,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ
M  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@
M0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +
MFC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8
M_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT
M #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@
M *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_
MI?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>
M   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H
M  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\
M +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6
ML   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##
M)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_
M  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0
M!L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P
MV"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?
M_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P
M  #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@
M .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !J
MJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
M    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6
M  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@
M_P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T
MSP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1
M /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '
M_P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O
M .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\
M#0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R
M /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -,
MW@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_
M  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .(
M<P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D
M ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0
M_P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#,
M '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +<
M\ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ #
M .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X
MN@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G
M /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H
M!P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O
M *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD
MF0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"
M! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+
M<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_
M (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0
ML@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2
M$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9
M_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4(
M * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\
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M 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q,
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M E9 E0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P
MO44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C
M0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6% E%$
MDP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@
M *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@
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M SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40
M?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(
M5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL".%>M C=7
MQ (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0
M &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8
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M 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78
M36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E
M<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP
M_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D
M #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D
M&'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1
M>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET
M   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[
M  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\
M"8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J
M@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3
M/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__
M  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0
M&I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0
MH$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<
M_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX
M  VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<
M *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!
MA   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
M    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X
M  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0
M:)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
MP0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5
M.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X
M %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP
M -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@
M[3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT
M   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,
M  #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP
M /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_
M !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\
M?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T
M /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \
M_P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y
M (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D
M_@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0
M /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H
MZ0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2
M /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P
M%@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z
M -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\
MOP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G
M !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,
M>@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_
M *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4
MS  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O
M 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X
M_P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9
M +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4
MGP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0
M /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P
M'@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X
M )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\
M@PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=
M!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.
M?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_
M '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L
MCQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y
M%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:
M_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB
M ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\
M;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@
M)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C
M*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B(
M &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+
MPS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M
M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %PO
MD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H
M *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L
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M 44_P0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@
M?4$  '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !0
M0CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(0VX 1T-[ 45#B0%#0YD!0D.K 4!#
MP $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40
M &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD
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M 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30
M44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V
M5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5
M_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(
M $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$,
M+5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C
M6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8
M   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-'
M "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\
M'&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W
M8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL
M3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_
M !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P
M*VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /
M=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP
M_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(
M !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL
M G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")
M9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:
M   0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0
M  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0
M<VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +
MCP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "9
M5@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,
M &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G
M *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3
MJ5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^
M  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X
M  "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(
M +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#
MD   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
M    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8
M  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0
M+J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
MT    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I
M7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD
M !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@
M .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P
M_V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\
M(@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"&
M /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\
M\P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_
M "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /(
MA@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_
M -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0
M_0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@
M (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L
M_P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J
M .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (
MR "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W
M /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -(
M+@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"!
M +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\
MI0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[
M #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0
M@@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_
M )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P
MJ  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4
M (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@
M_P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P
M )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($
MA0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q
M#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T"
M,P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F)
M '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@
MT!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0"
M#38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1
ME !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0
M + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$
M=!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C
M&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I
M  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU
M &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP
M62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2
M+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E
M.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ
M % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@
M@#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9
M+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DO
MNP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4
M '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H
M4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"
M--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW
M  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_
M $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=,
M/#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B
M.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\
M1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR
M #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0
M6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00!
M0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #)
M_P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\
M $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148
M.45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N
M1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#
M  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI,
M #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\
M*$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _
M2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M0
M4@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_
M "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@
M-5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B
M5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2
M_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54
M "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754
M&%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"4
M40  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>
M   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=
M  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50
M>E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9
M:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N
M90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H
M &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0
M#G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@
M>&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>
M  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X
M  * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@
M (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !2
M9   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ",
M P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S
M  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0
M/W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
MF@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B
M@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX
M "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0
M *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P
MM8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4
M   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L
M  "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\
M ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1
MJP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
M    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,
M  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O
M ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
MY    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]
MEP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V
M /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T
M^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7
M /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\
M/0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ".
M .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\
MP@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S
M $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0
MD #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_
M +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L
MW !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"]
M )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *<
M_P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^
M ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L
MJ "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T
M0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ".
M )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M[P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@":
M $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@
ME0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D
M ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P
MBP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y
M )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0
M  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^
M 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH
M; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">
M%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)
M0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI
M &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0
MB1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I
M$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4
MN@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(
M 'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX
M7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.
M&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F
M  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]!
M %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT
M1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F
M*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F
M10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM
M #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0
M72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(
M+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM
M_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\
M %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4<
M03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U
M,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P
M  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9,
M #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\
M,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'
M-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z
M4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_
M "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@
M/SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N
M/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]
M_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\
M #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@
M)T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":
M/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!&
M P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA
M !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@
M@$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F
M30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0
M:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8
M &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P,
M'%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /
M5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*
M  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P'
M !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G,
M!5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !7
M3@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF
M"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>
M  !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@
M2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0
M;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !Q
MCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<
M #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L
M 'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B
M?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C
M   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+
M  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD
M (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D
M<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5
M"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK
M  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0
M$H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0
MIP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "N
MO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@
M  .=    H@   *8   "J    K@   +    "Q    LP   +0   "V    N
M +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP
MQ=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
M    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T
M  #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T
M .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
MQ    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
M    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$
M  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@
M_P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U
M *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,(
M_P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!,
M /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H
MX@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@
M3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "=
M ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M_P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #*
M $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +(
MH0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P
M /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@
ML@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"=
M *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0
M  #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !)
M )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$
MBP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
M    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X
M20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J
M 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0
MH@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^
M $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X
MM@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL
M (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0
M<0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A
M ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /
M  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-&
M &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8
M5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q
M$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-
M2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J
M $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@
M9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4
M$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46
M_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT
M %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@
M2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^
M'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?
M  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!-
M $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\
M."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/
M(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF
M4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_
M #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@
M1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V
M*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ
M_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L
M #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@
M,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<
M+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ
M"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A
M "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0
M@S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R
M-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y
M;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8
M &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL
M*CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;
M/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY
M  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(.
M ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'<
M$T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:
M/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)
M$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'
M  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60
M34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 2
M4!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50
ME@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0
M $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!
M"E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0
M5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'
M   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2
M  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(
M %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R
M3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H
M$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV
M  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@
M)%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$
M=!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !T
MTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,
M !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1
M ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0
M@O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU
M   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/
M  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H
M )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
MB0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E
M#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X
M  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@
M )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0
MN@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\
M_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +
M  "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(
M - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&
M@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
M    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8
M  #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8
M_P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_
M %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X
MLP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P
M /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %<
M\0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5
M +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\
M  #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7
M -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +(
MNP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
M    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T
M5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[
M *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
MT    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F
M %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )(
MR0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@
M +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\
MD@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"
M .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *
M  "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!.
M ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\
M<0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+
M  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ',
M3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H
M &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M>P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F
M $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@
M^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8
M &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L
M6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !.
M _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+
M P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/
M %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\
M10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:
M#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.
M50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_
M #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P
M4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!
M%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5
M_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8&
M $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@
M.1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"=
M'P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<
M# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@
M #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@
MA"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [
M(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE
M:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<
M &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X
M-"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D
M*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK
M  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1
M "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8
M'2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;
M+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q
M%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2&
M !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0
M3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @
M-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$Y
MF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0
M $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14
M&#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +
M/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W
M   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8
M !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4
M D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X
M.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*
M&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY
M  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0
M+SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P
M41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0
MV   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,
M "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D
M %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0
M6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-
M   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;
M  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(
M &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   2
M60  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P
M'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_
M  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9
M!F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@
M?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z
M_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8
M  !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8
M )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!5
M60  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
M    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06
M  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80
M0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
MH0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\
M%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7
M "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP
M +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@
MU!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(
M   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H
M  #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\
M .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_
M  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\
M90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@
M ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M_P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I
M &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B
M?1!)0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T
M1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2
M +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M_P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"]
M $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *,
ME@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@
M .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T
MHP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@".
M )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P
M  "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ]
M (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0
M>@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
M    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T
M/0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "=
M &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
MC0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N
M #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T
MJ != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(
M '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@
M8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1
M +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*
M  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y
M %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +(
M1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>
M#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!
M.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/(
M #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@
M4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$
M"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,
MZ0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314
M $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP
M/0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M
M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08
M  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1
M #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\
M*!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^
M&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X9
M1@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_
M ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@
M.!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G
M'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>
M_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R
M # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H
M(215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%
M(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE
M   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3
M !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0
M;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D
M*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N
M70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH
M %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P
M'# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .
M,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N
M  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4%
M !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4
M!SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !)
M,0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \
M"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR
M   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-
M/C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )
M0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$
M@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<
M #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P
M $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0
M2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y
M   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -
M  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\
M %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G
M0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:
M#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC
M  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2
M&DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@
M9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !H
MNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4
M  Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD
M '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP
M=>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'
M  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\
M (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M>P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":
M!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON
M  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0
M )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
ML0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P
M_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4
M  "J    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@
M ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W
M<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
M    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$
M  #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M_P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_
M %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D
MJ@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P
M /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T
M[ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#(
M +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T
M  #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!,
M ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D
MK@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
M    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$
M2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q
M )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
MO    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8
M $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (,
MO@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@
M )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $,
M@P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P
M -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P
M  "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!"
M '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,(
M8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &,
M0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #>
M %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6
M $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D
M\P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P
M %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X
M2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _
M /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &
M  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!!
M $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D
M-@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'
M"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%
M10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_
M "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@
M0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R
M#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-
M_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$!
M #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L
M*A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&
M%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2
M!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13
M "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P
M;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L
M%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T9
M70 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT
M %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4
M)1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6
M'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA
M  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" *
M !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V<
M$"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+
M)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF
M#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT
M  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P
M/R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2
M+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M
M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D
M #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T
M#3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P
M,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K
M   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0
M  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(
M #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K
M+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]
M$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG
M   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P
M)#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$
M1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$
MP   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4
M !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$
M $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O
M2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_
M   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1
M  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,
M %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +
M2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D
M$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\
M  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@
M %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@
M=1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N
M_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@
M  !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T
M (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&
M2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M    @0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-
M  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@
M,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
ME    )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U
M#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$
M !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D    J
M *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0
MT0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y
M   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,
M  #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8
M .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_
M  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P
M6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5
M -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M_  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B
M %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T
MZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@
M .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %,
MOP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C
M /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@
M  #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1
M *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /
MC0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F
M  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X
M3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_
M '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $
MBP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X
M $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &<
M_P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  %
M '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@
M9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9
M /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8
M"0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !(
M %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\
M30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8
M  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P
M2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_
M $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D
M30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!!
M $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D
M_P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  +
M $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D
M-P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P",
M"0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!
M#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0
M "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#
M<@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U
M!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'
M60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$
M %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL
M+PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @
M#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5
M  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X-
M "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8
M%Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+
M&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2
M#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T
M !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P
M/QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;
M%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9
MA  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T
M #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!
M%1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  '
M'I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?
M   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2
M ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$
M "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J
M(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF
M%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F
M   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P
M)"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $
M*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   K
MO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0
M !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14
M #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO
M,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG
M   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8
M   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0
M #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4
M+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  !
M&P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\
M   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P
M#38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@
M2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$
M_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X
M  -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D
M %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%
M-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;
M  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/
M.CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R
M(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X
M "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :
M &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P
MAB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(
M   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X
M  "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH
M )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   5
M60  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
M    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>
M  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0
M!7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
MK    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1
M)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0
M  "-    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@
M ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@
M["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X
M#@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B
M /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\
MM@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z
M  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8
M8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_
M )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L
MVP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V
M %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L
M_P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP .
M +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %<
MF0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V
M /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@
M$ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6
M ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\
M9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_
M !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T
M5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_
M %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X
M:P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!<
M %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\
M_P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0
M %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$
M30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
M    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X
M$0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5
M $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!#
M !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #<
M6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,
M &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !
M.0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M
M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*
M  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1
M #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &
M) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.
M#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!
M$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L
M !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$
M0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D
M!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(
M?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(
M #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q(
M'0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /
M#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4
M   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4
M !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)
M"1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J
M%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2
M&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C
M  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&
M(Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .
M%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7
MN0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D
M !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@
M"!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0
M&]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:
M   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <
M  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X
M ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8
M&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F
M(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y
M   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@
M$QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0
M+"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H
M_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",
M  XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$
M #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,
M)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ
M   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF
M   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0
M.RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !
M-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%
M+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X
M "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /
M #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P
M3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO
M   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D
M  !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP
M %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D
M,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT
M  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P
M%3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M:P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  "
M/@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL
M  =1    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@
M (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P
METD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M    :    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8
M  "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX
M +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M>P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
M    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+
M  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D
M )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
MRP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J
M6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9
M /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H
M[@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6
M /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /<
M&P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J
M ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\
M@P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2
M !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P
M:0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_
M '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@
MK0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/
M &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@
M_P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9
M (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &(
M=@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
M    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '<
M&@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D
M &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
MGP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C
M !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %(
M: !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0
M 'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8
M4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!#
M '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\
M  !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6
M $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D
M-P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H
M%P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S
M "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @
M2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P
M !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0
M@@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@
M #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4
M)P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  <
M ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+
M   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6
M !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\
M%0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L
M#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$
M&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B
M  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P
M) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4
M"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'
MMP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1
M !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D
M$ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  #
M#-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1
M   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =
M  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0
M  [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6
M$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2
M(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U
M   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$
M$Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "
M%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3
M_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,&
M ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0
M !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1
M%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5
M!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J
M   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0
M/QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +
M&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G
M,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X
M #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P
M!"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@
M+CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA
M   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<
M   I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8
M #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D
M(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!
M   _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0
M'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M/@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*
M3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@
M !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&    2
M $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@
M5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R
M   *-@   SH    _    0@   $8   !)    3    $\   !2    50   %@
M  !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(
M &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "
M0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA
M  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40
M %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M@@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1
M<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@
M  !N    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0
M )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0
MJ(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
M    B0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4
M  "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P
M ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
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M________________________________________________
M          $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P
M,C,T-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ
M:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*C
MI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=
MWM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_________________________
M_____________________________P                     ! P0%!@@)
M"@L-#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"
M1$5&1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\
M?7Z @8*#A8:'B(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2U
MMKBYNKN]OK_!PL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN
M\/'R]/7V]_GZ^_S^____________________________________________
M__________\  0(#! 4&!P@)"@L,#0X/$!$2$Q05%A<8&1H;'!T>'R A(B,D
M)28G*"DJ*RPM+B\P,3(S-#4V-S@Y.CL\/3X_0$%"0T1%1D=(24I+3$U.3U!1
M4E-455976%E:6UQ=7E]@86)C9&5F9VAI:FML;6YO<'%R<W1U=G=X>7I[?'U^
M?X"!@H.$A8:'B(F*BXR-CH^0D9*3E)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JK
MK*VNK["QLK.TM;:WN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8
MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?+0S_HS<4_ZY
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M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
M8?]T05__>4->_WU$7?^ 15S_A$5;_X=&6O^*1UC_CT=8_Y!(6/^02%C_D$A8
M_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(Q,<' +?;
M!P&I_Q8&G_\J#9#_,!6#_S8<=_\^(F[_1RAF_U L8?]:+UW_9#%;_VPS6?]Q
M-5C_=396_WDV5O]\-U7_?S=4_X(X4_^%.5+_B3E2_XHY4O^*.5+_BCE2_XHY
M4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY4O^*.5+_BCE2_XHY_Y(=!/^0*0G_
MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
MY@T!LOP@"*?_,Q.:_SD=C?\_)H+_1BYZ_TXU<_]8.FW_8S]I_VQ"9?]R1&+_
M=T9@_WQ'7_^!2%W_A4E<_XA*6_^,2UK_D$Q8_Y5-5_^935?_F4U7_YE-5_^9
M35?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-S<$& +[0!P"Q]@X"
MI?\A"9G_+A*,_S09@/\[(';_0R=M_TPL9O]4,&+_8#->_VDU7/]O-UK_=#A9
M_WDY6/]].E?_@#M6_X0[5?^'/%3_BSU3_Y ]4O^3/E+_DSY2_Y,^4O^3/E+_
MDSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^O<4% +#7!0"C_Q #F?\B
M"8O_*0]^_S 5<_\X&FG_0!]B_TDC6_]1)E?_6BA5_V(J4O]I*U'_;RQ0_W,M
M3_]W+D[_>BY._WTO3?^ +TS_A#!+_X@P2_^+,$O_BS!+_XLP2_^+,$O_BS!+
M_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP_XL<!/^(* C_A#0._X\Z%/^7
M0AS_GDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72C
MBM]QJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^70AS_
MGDLG_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72CBM]Q
MJ([=;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^70AS_GDLG
M_YY7-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72CBM]QJ([=
M;ZZ1VVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^70AS_GDLG_YY7
M-/^=8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72CBM]QJ([=;ZZ1
MVVVSE-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^70AS_GDLG_YY7-/^=
M8D+_F6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72CBM]QJ([=;ZZ1VVVS
ME-ILN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;_XL<!/^(* C_A#0._X\Z%/^70AS_GDLG_YY7-/^=8D+_
MF6U/_Y-X7/B-@F?RB(MQ[(*3>>A\F8#D>)Z&X72CBM]QJ([=;ZZ1VVVSE-IL
MN9;8:\*8U6G,FLQERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;_XL<!/^)* C_A3,._Y Y%/^80AS_GDLG_Y]6-/^>84+_FFU0
M_Y5W7?>/@6CQB8MRZX.2>^=]F(+C>)V(X'2CC-URJ)#;;ZV3VFZSEMALNIC6
M:\*;T6G*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IF
MRIS*9LJ<_XP< _^))PC_B#(._Y,X%/^;01S_HDHG_Z14-/^B7T/_GVI1_9IT
M7_64?FSMCHAXYX>/@>* E8K=>YJ0VG>@EM9TIIK4<:R>TF^RH=!MN://;,.F
MQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
M:<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:
M?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O
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MAYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL
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M@\2EC8/$I8V#Q*6-@\2E_XD9 _^') ;_DRD)_Y\Q#?^I.1/_L4$<_[E)*?;
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M-Q=E_S\;7O]''EC_3B%4_U<C4?]?)4[_929-_VPG2_]Q*$K_=BE)_WLJ2/^
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ME)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D-0__K#T7_K)%(O:X3##MO%1
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MKC)#_ZXRN+H" *K(  "=V0  DO\, HG_&@1]_R$(<O\H#&C_,!!@_S@46O]
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MI6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN
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M!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G 6E&MNF%?H[1G;)FP;7>0JW2
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M4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ;YUB[VRE9^UIK6OK9K9OZ&/
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M ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S:6:'L&]N@*UV=7FJ?7MSJ(2
M;::-A6BEEXAEI*.*8J2PBV"DP8MBIMF(8Z+>@66>XWIEGN-Z99[C>F6>XWIE
MGN-Z99[C>F6>XWIEGN-Z_W88 O^)$P'_FA8!_ZD8 ?:X&P'GQQH!V]D< <W6
M, O TC\=M,U*+ZC(4C^=PUI-DK]A6(F[9V* N&UK>;9T<7*S>W=LL8-\9[",
M@&*OEH->KJ&&7*ZOAUJOOX=;L-J$7:S@?UZGY7A>I^5X7J?E>%ZGY7A>I^5X
M7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ, _[ 3 ._ $ #9U P SM\< <3=+PFY
MV3T:K=-(+*'/4#N5RUA)B\=?5(+$95YYPFQF<L!R;&N^>G)FO8)V8;N+>ER[
ME7U9NJ%_5[JO@%6[OX!5O-E_5KCC>EBRYW58LN=T6++G=%BRYW18LN=T6++G
M=%BRYW18LN=T_X 2 ?^4$ #_I@\ X[@+ -+&"@#,UPL P^,> KGB,0JOX#T8
MI-U&)YG93C>-U%9$@]%=3WK/9%ARS6I?:\MR967*>6I@R8)O6\F+<E?(EG54
MR*)W4LBO>%')P'A0RMMW4<;H<U+ ZV]2O^QO4K_L;U*_[&]2O^QO4K_L;U*_
M[&]2O^QO_X<. ?^;#0#?K@< T+P( ,?)" #!VPL M^@@ ZWG,0VDYCT9F>1$
M)H[B3#.$X%0^>]Y<1W/=8T]KW&I69=IR7&#:>F!;V8-D5]F,9U/9EVI0V:-L
M3MFQ;4W:PFU,V]QL3=CL:D[/\&=.S_!G3L_P9T[/\&=.S_!G3L_P9T[/\&=.
MS_!G_X\+ .FD! #1M 8 Q;\& +S-" "TZ0X!JNXB!:+N,PZ7[3L9C>Q")(/K
M22Y[ZE,V<^E</FSI9$1GZ6Q)8NAT35[H?%%:Z(545NB.5E/IF%E1Z:-:3NFP
M7$WJOEQ,Z])=2^KI74KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<
M^9D# -2L @#%MP0 N<,% +#2" "G]A$!GO4D!I7U,@Z*]3H7@?5!('CU2"=P
M]5 N:O1:-&7T8SA@]&L\7?5T/UGU?$)7]81$5/6-1E'VETA/]J%*3?:L2TOW
MN4Q*]\A-2?C@34CW\TU(]_1-2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-VJ,
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M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@
MA.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]
M_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_
MIQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<
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M8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6
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M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
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MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
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M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
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M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
MWZH6 -&L)@/'J#<-O*-$&K.>3R>JF5@SHY1@/9R0:$66C&],D(EV4HN&?5>&
MA(5;@H*.7WZ EV-Z?Z%F=WZM:'5^O6ES?M)I=H'N8GB"^EMX@OY6>8'_47F!
M_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX _Y . /6;#@#HI@X V:\/
M ,RO) +"JS4,N*=#&:ZB3B:FG58QGIE>.Y>59D20D6U+BXYT48:,>U:!B8-;
M?(>+7WB&E6)TA)]E<8.K:&Z#NFEM@\YI;X;K8W*'^5QSAOU6<X7_4G.%_U)S
MA?]2<X7_4G.%_U)SA?]2_V@1 ?]X#0#_A@T ]I,, -Z@"0#6J0H TK(- ,>R
M(@*]KS,*LZM!%ZJG3"2AHE4PF9Y=.I*:9$*+EVM)A91R4("2>55[CX%:=HV)
M7G*,DF)NBIUE:XFI9VB)N&AGB<MH:8OI8VR-^5QMC/U7;8K_4FV*_U)MBO]2
M;8K_4FV*_U)MBO]2_VL0 ?]["P#_B@H XI@& -:C" #0K D R[4+ ,&V'P&X
MM#$)KK _%J2L2B*<J%,NE*1;.(R@8D"&GFE(@)MP3GJ9=U-UEGY8<)2'7&R3
MD&!HDIMC9)&G96*0MF9@D<EF8I+G8F64^%QGDOU79Y'_4F>1_U)GD?]29Y'_
M4F>1_U)GD?]2_VX. /]_"0#QC@4 V9L% ,^F!P#)KP< Q+D( +NZ' &RN"\'
MJ+4]$Y^Q2""6KE$KCJI9-8:G8#Z I6=%>J)N2W2@=5%OGGQ5:IR%66:;CEUB
MFIE@7IFF8ER9M&-:F<=C6YKE8%^;]UM@FOY689C_4F&8_U)AF/]289C_4F&8
M_U)AF/]2_W(+ /^#!0#?DP$ T9\$ ,FJ!@#!L@4 N[T$ +2_& "KOBP%HKLZ
M$9FX11V0M4\HA[)7,H"O7CIYK65"<ZML2&ZI<TUIIWI19*:#5E^DC5E<HYA<
M6*.D7E:CLU]5H\9?5:3D75BD]EA:H_]46Z'_4%NA_U!;H?]06Z'_4%NA_U!;
MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
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M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
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M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
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M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
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M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
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M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
M /]M  #_?@$ _XX! /^; 0#_J0$ _ZL! /^K 0#_JP$ _ZL!_RHM ?\N*P'_
M,"L!_S N O\N-0+_*3T#_R5)!/\C5P3_(60%_Q]R!O\=?P;_'8H&_QV4!O\=
MG ?_'*,'_QRJ!_\<L0?_'+@&_QR_!O\<R0;_'-8&_QWE!O\=[P;_'?D%_QW_
M!?\=_P7_'?\%_QW_!?\=_P7_'?\%_QW_!?\=_P7_'?\%_RPK ?\P* '_,R@!
M_S,K O\Q,0+_+3H#_RM'!/\H5 7_)F$%_R1O!O\B? ?_(H<'_R*1!_\AF0?_
M(:$(_R&G"/\AK@C_(;4(_R&\"/\AQ@?_(=$'_R'B!_\B[0?_(O<'_R+_!OTB
M_P;\(O\&_"+_!OPB_P;[(O\&^R+_!OLB_P;[(O\&_RXH ?\S)0'_-B4!_S<G
M ?\U+0+_-#@#_S)$!/\O407_+%X&_RIK!_\I=P?_*(,(_R>-"/\GE@G_)YT)
M_R>D"?\GJPG_)[()_R>Y"?\GP@G_)\T)_R?>"?\GZPG\)_8(^2C^"/<H_PCV
M*/\(]2C_"/4H_PCU*/\(]2C_"/4H_PCU*/\(_S(E ?\W(@'_.B$!_SLC ?\[
M*0+_.S0"_SE !/\V307_-%H&_S%F!_\P<PC_+G\)_RZ)"O\ND@K_+9D+_RVA
M"_\MIPO_+:X+_RVU#/\MO@S^+<D,^RW9#/@MZ OT+O0+\2[^"^\N_PON+O\+
M[2[_"^PN_PKL+O\*["[_"NPN_PKL+O\*_S4B ?\['@'_/QT!_T ? ?]")@'_
M0C$"_T \ _\^2 7_.U4&_SEB"/\W;@K_-GD+_S6$#/TTC0W\-)4-^C2<#ODS
MHP[W,ZH/]C.R#_4SN@_S,\4/\C/2#^XSY0_J-/(/YS3]#^4T_P_D-/\.XC7_
M#N(U_PWA-?\-X37_#>$U_PWA-?\-_SD> ?\_&@'_0Q@!_T8: ?])(P'_22T"
M_T@X _]%1 7_0U '_T!="?L^:0OX/70-]3Q_#O,[B _Q.Y 0[SJ8$>TZGQ+L
M.:83ZCFN$^DYMA3G.<$4YCG.%>(YXQ7>.?$5VSK\%-@Z_Q/5._\2TSO_$M([
M_Q'2._\0TCO_$-([_Q#2._\0_ST; ?]#%@#_2!0 _TP7 ?]/'P'_4"@!_T\S
M O]-/P3[2DH&]4=7"?%&9 SM1&\.Z4-Y$>="@Q/D08L4XD"3%N _FQ??/Z(8
MW3ZJ&=L^LQK8/KT:UC[*&](^WQO./N\;RS_[&LE _QC'0/\7QD'_%<5!_Q3$
M0?\4Q$'_%,1!_Q3$0?\4_T$7 /]'$@#_3!  _U(4 /]6&P#_5R0!_U8N OA4
M.0/Q444&ZT]2">9-7@SA2VD0W4ET$]E(?1;51H88TD6.&M!%EAS.1)T=S$2E
M'LI#K1_(0[8@QD/#(<5#TR'!0^DAOD3W'[Q%_QVZ1O\;N4?_&;A'_QBX1_\7
MN$?_%[A'_Q>X1_\7_T04 /]+$ #_40X _U<1 /];%@#_71X ^5TH >];,P+G
M63\$X%=-"-I460W34F02SE!N%LI.=QG'3( <Q4N('L)*D"# 2I<AODF?([Q(
MIR2Z2+ EN$B\)K=(RR>T1^,GLDGS);!*_R*N2_\?KDS_':U,_QNM3?\:K4W_
M&JU-_QJM3?\:_T<1 /]/#0#_5@P _UP. /]@$@#]8A@ \&,A .9B+ '>8#H#
MU%Y(!\U;5 W'6%\3PU9I%[]4<AN\4GH>N5&"(;90BB.T3Y$ELDZ9)[!-HBBN
M3:LJK$RV*ZI,Q"RH3-LLIDWO*J1/_2:D4/\CHU'_(*-2_QZB4O\=HE+_':)2
M_QVB4O\=_TH/ /]2"@#_6@D _V + /]E#@#U9Q$ Z&@8 -UG) #29C4"RF1$
M!\-A4 V]7EL3N5QD&+5:;1RQ6'4@KE=](ZQ5A"6I5(PHIU.4*J52G2RC4J8M
MH5&Q+Y]1OC"=4=$PFU'J+YI3^BJ:5?\FF5;_(YE6_R&95_\?F5?_'YE7_Q^9
M5_\?_TT- /]5!@#_704 ^V0' .]I"0#I:PP X6P0 --M'@#);#$"PFI ![MG
M3 VU9%<3L&%@&:Q?:1VH77$AI5QX)*):@">@68<JG5B0+)M7F"Z95J(PEE6L
M,I15N3.35<HSD57E,Y%7]RV16?\ID5K_)9%;_R.16_\AD5O_(9%;_R&16_\A
M_T\+ /]7 @#_80( ZF@! -YM! #8< @ U7 + ,MR&P#"<2X"NF\]!K1L20VN
M:503J6==&:1D91VA8FTAG6%T)9I??"B87H,KE5V++9);E#"06YXRC5JH-(M9
MM36*6<8VB%GA-HA<]#"(7?\KB5[_*(E?_R6)7_\CB5__(XE?_R.)7_\C_U$)
M /]:  #U9   X&P  -=Q P#0= 8 S74) ,1V%P"\=BH!M'0Z!:YQ1@RG;E$2
MHFM:&)YI8AV:9VDAEF5Q)9-D>"B08H KC6&(+HM@D3&(7YHSAEZE-8->LC>"
M7L(W@%[<.(!?\C.!8?\M@F+_*8)C_R:"9/\E@F3_)8)D_R6"9/\E_U,& /]=
M  #G9P  VV\  -!T @#*> 4 QGD' +YZ%0"V>B@!KW@W!:AV1 NB<TX2G'!7
M&)AM7QV4:V<AD&IN)8UH=2B*9WTKAV6%+H1DCC&!8Y<T?V*B-GQBKSAZ8KXY
M>6+5.7EC[S1Z9?XO>V;_*WQG_RA\9_\F?&?_)GQG_R9\9_\F_U4# /]@  #C
M:@  U7(  ,QX 0#%>P, P'T% +E^$@"Q?B4!JGTU!*-Z00J==TP1EW15%Y)R
M71R.<&0@BFYK)(=L<BB$:WHK@6J"+GYIBS%[9Y4T>&>@-G9FK#AT9KPY<V;1
M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
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MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
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M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
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M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
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M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
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M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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M(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@
MC)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4
MFF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5
M_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\
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M#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL   :K4  %ZZ  !2O@
M1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P QRU$!,,M; 2[,90(L
MS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'
M_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@  /<H
M #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@
M'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7
MVO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9
M   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG
M !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\
MEZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8
M[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]
M9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL
M 'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@
M#O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P
M_V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]
M  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\
M  +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX
M /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_
M(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)
ME@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[
M /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20
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M!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4
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M#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33
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MJB&!4;@B?U'+(GY2YR%^4_D=?E3_&GY5_Q=^5?\6?E7_%7Y5_Q5^5?\5_TH
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M)FE>WB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90
MPVL  +EO  "Q<0  JG$  *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^
M:5D/>VA@$G=F9A1U9FX7<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1B
MVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\
M +9S  "N=0  IG4  )US!0"6<Q0 D70D (MS,@*&<CX$@7!'"'UO3PMY;5<.
M=FQ>$7-K9!1P:FP7;6IS&FMI?!QH:(8?9F>1(F-GGB1A9JPE8&:])E]GUB9?
M9_$B8&C_'F%H_QQB:/\:8FC_&6)H_QEB:/\9[%<  -EB  #':P  O'(  +-W
M  "J>0  H7D  )=W 0"0>!$ BW@A (9X+P&!=SL$?'5%!WAT30IT<E4.<7%<
M$6YP8Q1K;VH6:&YQ&69N>AQC;80>8&R/(5YLG"-<:ZHE6FN[)EELTR9:;.\C
M6VS_'UQM_QQ=;?\:76W_&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F
M?@  G7X  )%\  "*? \ A7T> (%]+0%\?#D#=WI#!G-Y2PEP>%,,;'=:$&EV
M81-F=6@68W1O&&%S>!M><H(>6W*-(%EQFB)7<:@D57&Y)51QT"54<>XB5G'^
M'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@
MF(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ?E +9WU7#F1\7A%A
M>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]WSB-/=^PA4'?]'E%W
M_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP  DH<
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M%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@  ?YD  '.<  !DGP
M7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M
MGG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9
M_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP  4JH
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MA@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90
M )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0
M'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2
MUX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A
M  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H%
M !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH
M!>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !W
ML0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ
M"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"
M  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@
M7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0
M_ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_
M@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T
M $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P
M /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P
M_X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0
M+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@
M /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_
M#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"
MH@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_
M /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\
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M \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\
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ML1&:/K\1F#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST
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M&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P
MR%P  +]?  "W7P  L5P  *I9# "D6AH GELJ )E;. &46D,#D%E,!8Q850B)
M5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U' &W%1
MVQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P  Q&
M +IC  "S8P  K&$  *1>"0"=7Q< F%\G )-?-0&.7D #BEU*!89<4@>#6UD*
M@%I@#'U99PY[6&X0>%AU$G97?A1T5H@7<E:3&&]6GQIN5:P;;%6]'&M6U1UK
M5O ::U?_%VM8_Q1L6/\2;%C_$6Q8_Q%L6/\1\4L  -]6  #,7@  P&0  +=G
M  "N:   IV8  )]B!@"88Q0 DF0D (UC,@&)8CT"A&%'!(%@3P=]7U8)>EY=
M"W==9 UU7&L0<UQS$G!;>Q1N6X47;%J0&6I:G!MH6:H<9EJZ'65:T1UE6NX;
M95O^%V9;_Q5F7/\39US_$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K
M;   HFH  )EG @"29Q$ C6<A (AG+P&$9CL"?V5$!'MD309X8U0)=6);"W)A
M80UP86D/;6!P$FM?>11I7X,79EZ.&61>FAMB7J@<85ZX'5]>SAU?7NP;8%_]
M&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<
MGFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S:%((<&=9"FUF8 UK
M96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IBS!U:8NH<6V/\&%QC
M_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=   FG,
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M$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P(
M;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/
M>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X
M_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<-
M &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/
M1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q!
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MB@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5_PLQE/\+,9/_"S&3_PLQD_\+N'H
M *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H   3J(  $6D"0!"I!,
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M !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@
M?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1
MS!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.
MK  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P
M &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P
M!MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0
MW[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]
M  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-
M  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$
M .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \
MR@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N
M"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC
M  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU
M(MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_
MGP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!!
M /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@
M_P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[
M /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\
M2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J
M /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\
M\P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
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M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
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M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
M ,-0  "\3@  MTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.21UX%
MCT9E!HU&; >+17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$VA%[
M1/$/>D7_#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0  +U5
M  "V5   L%   *E,"P"B31@ G4XH )A.-@"43D$!D$U+ HU-4P2*3%H%ATMA
M!H5+: B#2F\)@$IW"WY)?PQ\28D.>DB3#WA(GQ!W2*P2=4B\$G1)TA-S2>X1
M<DK_#W)*_PUR2O\+<DK_"W)*_PIR2O\*\D(  .!,  #.4P  P5@  +A:  "P
M60  J58  *)2!P";4A4 EE,D )%3,@"-4SX!B5)' H914 2#45<%@%!>!GY/
M90A[3VP)>4YS"W=.>PUU384.<TV0$'%-G!)O3:D3;DVY%&Q-SA1L3>L3;$[]
M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
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M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
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M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
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M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
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M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
M8&4P %YE.@!<94(!6F5* EAD40)69%@#5&1?!%)D9P508W$'3F-["4QCB I*
M8Y<+2&.F#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@  +IB
M  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$ 6FHM
M %AK-@!6:S\!56M' 5-J3@)1:E4#3VI=!$UJ905*:6X&2&EY!T9IA@E$:94*
M0VBE"T%IMPQ :<\,0&CN"T%H_PI!9_\)06?_"$)G_PA"9_\(Q5T  +9F  "J
M;0  H',  )9V  "+=P  @'8  '!R  !E<0  7' ' %AP$0!6<!T 5'$H %)Q
M,P!0<3P 3W)$ 4UQ2P%+<5,"27%: T=Q8@1%<&P%0W!W!D%PA <_<),(/6^C
M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
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M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
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M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
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M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
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M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
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M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_^)]$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A
M /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T
M_P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[
M 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H
M[ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P )
M /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8
M[ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4
M /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\
M#0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V
M -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\
MOP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M
M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,,
M=0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X
M *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P
MU@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q
M '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T
M_P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0
M ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\
MH0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ".
M /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0
M$@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O
M )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\
M@ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B
M!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.
M<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_
M '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q
MD! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W
M%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;
M_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6
M ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G
M:QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A
M(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A
M'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U
M &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\
MSS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K
M*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL
M?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8
M +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\
M82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1
M,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"
M  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E
M %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4
M2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F
M2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W
M*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3
M $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@
MF5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y
MH@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0
M (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P
M1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X
M1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9
M  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$
M,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^
M70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*
M-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$['
M "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80
M<%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R
M4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93
MYP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64
M &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8
M*E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?
M6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH
M  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ
M "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D
M&%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,
M;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG
M/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_
M !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=
M.W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .
M<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN
M_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T
M "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T
M WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P
M>/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'
M   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"
M  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\
MD'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2
MDP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "6
M1@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8
M (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP
M!*    "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/
MIDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1
M  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T
M  "O    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\
M +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?
MG0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
M    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#
M  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@
M1*L  #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+
MRP   ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D
M2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4
M "BY   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0
M -\   #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.
M^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\
M%@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P""
M /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\
M\P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_
M !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8
M@P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_
M .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D
M_P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D
M (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L
M_P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @
M .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P
MS "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W
M /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L
M)0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\
M +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\
MI #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#"
M "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *<
M? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_
M )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ",
MKP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6
M 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8
M_P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F
M )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '<
MA@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X
M!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"
M*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\
M '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\
MX1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!
M#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0
M@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0
M ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R<
M<Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A
M&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ
M  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK
M &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X<
M5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K
M.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B
M+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3
M $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P
MG$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5
M*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<L
MH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44
M (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\
M32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@!
M,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)
M  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\
M.C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  "
M3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U
M-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$
M #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4
M<TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_
MY  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(
M &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J
M0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2
M  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4]
M "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/<
M)4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !5
M50  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+
M0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_
M !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P
M1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @
M44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1
M_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\
M #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4
M%EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 1
M6/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E
M   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+
M  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\
MFV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D
M;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K
M4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT
M (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@
M%78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@
M=5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ
M  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((
M  J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4
M (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![
MA   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
M    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=
M  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP
M9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=
MG0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@
M9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698
M $N9   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@
M *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@
ML6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C
M   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@
M  "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(
M ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   D
MKP  %K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
M    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K
M  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0
M#;P   &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<
MWP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X
M=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H
M_0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F
M /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\
M,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"*
M .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\
MS #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V
M #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L
MBP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_
M +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #,
MX0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #"
M (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P
M_P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W
M ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4
MK0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"<
M /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0
M.@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "&
M )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\
M^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A
M #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L
MB@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H
M -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4
MD  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![
M (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7
M  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W
M (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL
M; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V
M(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(
M. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5
M & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P
MI"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G
M$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83
MH@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(
M )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30
M7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,
M&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W
M  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW
M %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X
M1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#
M.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB
M.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?!
M #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P
M=CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#
M)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<L
MX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T
M &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD
M/"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q
M,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5
M  !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^
M #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4
M+37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !8
M0   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U
M1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_
M "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@
M3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J
M.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]
M_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@
M $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@
M(T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >
M0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*
M   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/
M !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\
MHE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O
M3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,
M5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<
M )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@
M(E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .
M4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D
M  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T
M !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX
M!%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$
M;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F
M 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I
M  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0
M>'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &
M<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O
M=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT
M &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04
M 'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P
M>H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%
M  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&
M  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P
M (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%
MCP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7
M!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+
M  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0
M+)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
MI@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "J
MF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,
M !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0
M +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0
MP:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
M    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<
M  #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D
M -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
MOP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
M    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A
M  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$
M_P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W
M )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D
M_P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!&
M /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ),
MY0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y
M /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D
M2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5
M ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\
M_P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/
M $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +<
MF "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P
M /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4
MN !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C
M )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$
M  #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!&
M *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4
MCP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
M    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4
M1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P";
M 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0
MN P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$
M $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '
MI !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14
M *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $
M=0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B
M *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<
M  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)
M &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T
M5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+
M(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+
M0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _"
M $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0
M?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2
M$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5
MWP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L
M &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX
M2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP [
M'/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM
M  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q!
M $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0
M-2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=
M+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA
M10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_
M # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P
M42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R
M)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ
M_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,
M $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@
M+"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F
M+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T
M   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/
M "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\
MID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V
M-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U
M6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<
M )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0
M*CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9
M.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51
M  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T %
M " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&
M$D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")
M6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%
M"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M
M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8
M?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  1
M3 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.
M>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@
M '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D
M"54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P
M58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O
M  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -
M  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<
M %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !=
M=   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J
M#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8
M  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P
M2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0
M=A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !S
MJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,
M #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT
M (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I
M@+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-
M   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,
M  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8
M )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1
MF   "9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B
M"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)
M  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP
M *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
MLP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "Z
MW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$
M  "T    N    +L   "\    O    +X   "_    P    ,(   #$    Q@
M ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q
MU.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
M    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\
M  #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4
M_P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_
M %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /
MIP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P
M /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %,
M\ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #;
M *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\
M  #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5
M -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4
MP "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,(
M50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J
M *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
MY0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L
M %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )<
ML@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP
M ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X
MF0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$
M +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8
M  "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!-
M (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0
M<P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
M    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D
M3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90##
M &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P
MCP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J
M $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@
MW !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\
M 'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8
M70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-
M!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42
M  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9'
M %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\
M0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F
M%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-
M20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_
M #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0
M618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^
M$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06
M_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X
M $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH
M-A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N
M&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?
M  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0
M "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\
MJ38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [
M( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA
M6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH
M )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@,
M,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B
M)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#
M  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@)
M "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V
M&RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+
M2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L
M#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M
M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P
M@%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <
M,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V
M?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8
M '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X
M%3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *
M.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');
M  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0
M  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H
M 4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F
M8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'
M$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;
M  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@
M660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0
M4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/
MK@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD
M $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,
M %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP
M5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N
M   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05
M  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$
M %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K
M=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P
M%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB
M  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P
M%WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0
M?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X
M]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD
M  >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$
M (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P
MB?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
M    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0
M  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D
M<(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
MI0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R
M#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),
M %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M
M +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P
MR0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@
M   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8
M  #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04
M .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H
M8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"]
M .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M_P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F
M &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P
MR0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P
M /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P
MS !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T
M -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8
M  #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!;
M +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L
MGP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'
M  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *(
M6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B
M (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $
MK@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P".
M %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D
M\0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  &
M )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %(
M?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I
M /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T
M"@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2
M &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8
M7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![
M  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &
M4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_
M %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @
M:P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3
M %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8
M_P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800*
M %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\
M1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \
M!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(
M# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3
M #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\
MK2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&
M# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.
M6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP
M )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D
M.Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L
M$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV
M  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10-
M #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V
M)!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-
M/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8
M#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL
M !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00
M@4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E
M'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B
M>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8
M '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1
M'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2
M)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*
M  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2
M !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL
M#2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I
M3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M
M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<
M  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@
M75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -
M,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   V
MKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4
M %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q<
M!CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K
M.\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8
M  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;
M  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,
M $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]
M6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+
M'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD
M  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80
M+%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P
M5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0
M^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@
M !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX
M %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P
M6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O
M   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB
M  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\
M@'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $
M>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X
M)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT
M '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@
M (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('
MB"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&
M  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4
M  "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\
M )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0
MD   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
M    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA
M  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F
M-9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
MLP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%
M)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8
M !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP
M ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&
MXRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\
M"@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I
M /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X
MV0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_
M  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P
M: #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[
M ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P
MZ  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#!
M &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H
M_P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0
M ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$
MJ@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5
M /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +,
M$P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!?
M )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\
M@0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ ">
M !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0
M7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_
M '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !(
MB@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R
M %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$
M_P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4
M '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D
M8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5
M /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P
M%@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!;
M %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\
MN1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!=
M !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D
M7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD
M *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !,
M4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^
M &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D
M  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4
M $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$
M,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0
M+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&
M%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML
M "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@
M@S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q
M#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/
M>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<
M '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!(
M*! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :
M$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[
M  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5
M " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D
M$QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I
M/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7
M%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<
M  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@
M7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4
M'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HB
MK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0
M %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD
M$"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #
M)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$
M  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=
M  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$
M "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'
M1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O
M(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A
M   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30
M.DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(
M-BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U
M]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X
M "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8
M #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0
M._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52
M   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L
M  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\
MB%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   5
M5P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/
M,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64
M 'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08
M"5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0
M63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP
M  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H
M  !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0
M &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N
M>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([
M  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@
M57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M@P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""
M0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<
M #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0
M )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.
ME$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2
M   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H    *
M  "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4
M *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4
MG0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
M    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)
M  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP
M *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
MQ    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?
M4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9
M /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\
MYP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$
M /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /,
M'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N
M ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\
MJ0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7
M ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8
M;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_
M )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X
MN0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"?
M &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8
M_P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A
M *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &<
MBP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U
M /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )
M(P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H
M '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\
MTP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!]
M "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@
M:@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0
M +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X
M:P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8
M &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-
M  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ?
M %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@
M2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9
M%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$
M'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O
M #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0
MB1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!%
M "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0
M>@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0
M 'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L
M.@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J
M (@ * "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
MN@   +L   "]    OP   ,$   #$    QP   ,L   #-#   SAH  ,\O  #/
M2   T&(  -"   #0G0  T+@                       $#! 4&" D*"PT.
M#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'
M24I+34Y/4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!
M@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZ
MN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T
M]?;W^?K[_/[_________________________________________________
M_____P                     ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@
M(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA9
M6UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3
ME)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,
MS<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^________
M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M__________^6-        $^G______________________________9I'0
M"0P&"5*Q_____________________________\L[#A,U3%M-3%[#________
M_____________________ZE@-F"&G[:LJ;C9________________________
M_____^"7C;[E_______________________________________M^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]G*O,?__________________________________\^:@6U:1HCJ____
M____________________________Q'P^)A   %2P____________________
M___________@@SP      "Z'[?____________________________^L4Q
M     !=MUO____________________________N ,0        EAS/______
M_____________________]): @        !=S/______________________
M_____Z@U          !<T____________________________WT-
M  !4UO__________________________[GU%          !$U/__________
M_________________*ID+P(   0B-TE8SO__________________________
M_^FD:T$H/V-_E:>ZVO______________________________U;*LLLSD^O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y;N7=V+(____________________
M_____________]N>9S8*  *,________________________________R'\_
M!0    !>S______________________________9@3D        \JO______
M______________________^>3          CD/______________________
M_____]QO&@         0??G__________________________Z](
M    ;^[__________________________X03            9.;_________
M________________[%$             5][_________________________
MN!4             2-;_________________________=!0
M.,_________________________YHEH3            (\7_____________
M____________WYM<+           #;K__________________________^^Q
M?54Y(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^.^G8!\^_________________________________*WA%<P#@ =K/______
M________________________THI,%0      <O/_____________________
M_______6?S8         2\G___________________________J1/@
M    +ZO__________________________\!:            &I7_________
M_________________XTD            "(3_________________________
MYUX              '?_________________________M"4
M &K_________________________?0               %OT____________
M___________]*P               $SK______________________^E
M             #SA______________________\P#                "W9
M_____________________YF*82<              "?7________________
M_______MOHE5)P           "7<__________________________[*G79=
M2CPR+2PP.4?>_______________________________]YMW6TM#3V>3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]2[UO______________________
M___________GN(]J2R\5;_______________________________Y*%G- <
M    /,G____________________________6@CL         $I?_________
M_________________^V%,0           &__________________________
M_Z9"             %#A________________________[&D
M #?)________________________LR\              "*V____________
M____________>0               !"G_______________________R-
M              "9______________________^I                  ",
M______________________]&                  !_________________
M_____]\                   !T_____________________Y<
M          !J_____________________\X                   !C____
M__________________\I(@$               !A____________________
M__^YHX!7-Q<           !H___________________________ZTZZ4AGQU
M<7!R=X&4____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]NZG8)I:=/_________
M_____________________\B393T9    '9[_________________________
M___;CDP3         &[__________________________]M\+
M $77_________________________XLJ             "*T____________
M____________PD0               .7________________________?0$
M              !________________________G-@                !J
M______________________^=                  !8________________
M______]&                  !'^/___________________^D
M           UZ?___________________Y8                    EV___
M_________________[P                    8SO__________________
M_^L                    /PO____________________\
M       *N?____________________\G                   *M?______
M______________]P                   -N?_____________________@
MG(QP54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,
MS];@_/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O3O./________________________________2J85E2"P2
M 87____________________________QJW$\#P       $_@____________
M_____________]5_-0           !^R________________________XW4=
M              ")________________________D",               !G
M_______________________50P                !(]O______________
M______^*                   NW?____________________\X
M           7R/___________________[X                    $MO__
M_________________YP                     I?__________________
M_[H                     D____________________]P
M        @O____________________\                     =/______
M______________\3                    :/____________________]"
M                    8/____________________]Z
M    7?_____________________1                    8?__________
M____________)                   9O______________________R:R9
MB7UV<6QI9V9G:W!ZC/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^+%JI%Y87?_____________________________
MW:9W4"P,     #'$_________________________^"23A,           "/
M________________________TG =              !@________________
M_______N;P\                WXO____________________^6'
M           4P/____________________]                     H___
M_________________ZX                     B?__________________
M_YX                     <O___________________[P
M        7____________________]H                     3?______
M______________H                     ._____________________\.
M                    *OG___________________\S
M    &^G___________________]>                    #]O_________
M__________^/                    !M#____________________0
M                 ,K_____________________*P
M ,C_____________________@                    ,O_____________
M________]Q8!!04# 0       08-&,O_______________________SKX=C/
MS,W/T-+4U]SBZO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________QVL;_
M______________________________'&HX1H33(8 !6K________________
M__________^Y?$88          !Q________________________UWPO
M           [X______________________?9 D                ,M?__
M__________________]T P                  C?__________________
M_\45                    :O___________________YD
M        2____________________[8                     ,/W_____
M_____________]<                     &>?___________________8
M                    !=/___________________\.
M     ,'___________________\O                     *__________
M__________]2                     )[___________________]Y
M                 ([___________________^E
M (#____________________8                     '3_____________
M________-@                   &W_____________________?
M             &G_____________________UPT                  &C_
M_____________________W                   &'_________________
M______]0/$9.5%E=861H;'!V?HG_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^_5NZ.+<UJ5___________________________XOXYD02$%      !2_/__
M____________________]YU6&              7P?__________________
M___E;!8                 C?____________________]C
M        7O___________________YT                     -?S_____
M_____________Z$                     $=G__________________\H
M                     +O__________________^X
M     *'___________________\,                     (K_________
M__________\M                     ';___________________]-
M                 &3___________________]O
M %+___________________^4                     $#_____________
M______^\                     ##____________________J#@
M             "+_____________________1                    !7_
M____________________@0                    OU________________
M____R L                   +L_____________________UX
M          #E_____________________\D<                  #:____
M__________________^= 0             '#A?%____________________
M____U;F\P<?.U=OAYNWT^_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^-_/____________________
M_________^S&I8AM5#LA!P RWO_______________________]>262D
M        H/______________________B38                 9_______
M______________]F                    ,O;__________________Y4
M                     \C__________________Z<
M     *#__________________]<                      'S_________
M__________\                      %[___________________\E
M                 $/___________________](
M "S___________________]J                     !C_____________
M______^+                      7S__________________^O
M              #A___________________5                      #/
M____________________)                     "^________________
M____5                     "N____________________BP
M          "?____________________RPX                   "2____
M_________________U<                   "&____________________
M_ZH*                  !Y______________________]M
M      !F_______________________W50                !%________
M_________________VHC*S4_2E5@:G5^AY&<________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________HS[:=@VE.N?______
M___________________LLH-<.AT"        >_______________________
MQ6TI                0/____________________^#&P
M    !\O__________________Y(                      )C_________
M_________Z0                      &K__________________]T
M                 $'___________________\.
M !W___________________\Y                      #H____________
M______]@                      #.__________________^%
M              "W__________________^H                      "C
M___________________+                      "0________________
M___O%@                    !]____________________/@
M          !L____________________:0                    !:____
M________________F0                    !)____________________
MTA8                    Y_____________________U@
M       I_____________________Z(                    9________
M______________56                   $______________________^[
M+P                  ^/______________________JRD
M    S________________________\E'      <3("X^4FB$[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________35R?____________________________K2L))W74(H
M#   2O_______________________\5]11<             $=C_________
M___________$4                    )___________________Z(,
M                 &C__________________Y0
M #;__________________]H                       ?L____________
M______\5                      #$__________________](
M              "B__________________]U                      "#
M__________________^=                      !I________________
M___#                      !2___________________G#P
M           ^____________________,P                     K____
M________________6                      8____________________
M@0                     %____________________K
M        ____________________WB(                     \O______
M_____________UP                     W____________________Y\
M                    S/___________________^A*
M    M_____________________^@%@                  G/__________
M____________>@(                 =________________________WH+
M               %3/________________________^B5VAT@(V<J[S0Y___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________MX___________________________
MTJ-Z6#HI(QP6#@8  )______________________K%(.
M &G__________________^1#                     #3_____________
M_____WD                       #C_________________\T
M              "R__________________\3                      "%
M__________________]/                      !=________________
M__^#                       Z__________________^R
M           <___________________; P                     "____
M________________*@                      ^___________________
M3P                      Y___________________=
M        U/__________________FP                      P/______
M____________Q <                     K?__________________\#,
M                    FO___________________V<
M    AO___________________Z,                     <O__________
M_________^-$                    7/____________________^1!@
M                0?_____________________K7P
M'?______________________RDL                  /______________
M_________\M7   ,&"0Q/TY@=(NGQ___________________________U^?R
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9
M$0D"          #;_________________W8                       "G
M_________________[H                       !U________________
M__\'                      !&__________________].
M           :__________________^,                        _?__
M_______________!                        V__________________Q
M&0                      OO__________________1
M        I/__________________:P                      C?______
M____________D0                      >?__________________MP
M                    9O__________________WB$
M    4____________________TH                     /___________
M_________W<                     *____________________ZP*
M                %O___________________^=%
M /____________________^*                     /______________
M_______630                   /W_____________________IRX
M             -7______________________Y@J           &&"U%8.#_
M______________________^H8W2!CYRKN\WB^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___B,X!)0T-?4%)/1DE,10 2$O__________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
M  #_[@ .061O8F4 9(      _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#_\
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M(Y672)EUIY.*.1LE(U58Y'=BH8 ?$4^T1; ] .YERV2J>GG?;<[=&BM5KO\
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M>US7L:YJHDRCEBE3FBD9(GI8Y':>SHO!2Y)-"\1R
M
M
M
M
M
M
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M\DH84X)/*:X4]2B(CN[>O_:Y-$5?^"OT7?"9)RZ1F0(X
M
M
M
M
M
M
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M ^1FMULT]=11=]&RH=3U#E@;4%/5PU*?H;M')VQNX/3VOSR>M#N@5R9(R)
M
M
M
M
M
M
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MS0]O#R]'EVG$YNG%.SX 4S5TW;P[/9]DE,T6A\ I>L@^EY?#Z"4S1]OK\O?
M*7JX>WAY?$2F9G;Y>PO8 =2-T<.?:+K+>Z5LC[?=JF669557NI;A*JRS,D<[
MF<K*IRND8J]B\S>&B:]7]R<06T7)UWHXW+;KG,]\B)JJ4E=)J^6-RKJJ1U#M
M7L\R+JW@B)KU]S[$TM-:MTHXT2W7"5RO:B?-I*MVKWQZ=B13<7,\R<6\$1-9
M!=YI:-&RHJ]R]>77^H?VHU?4Y$U3VRU:1>?E]U?B52VB1>I$]GC\I;Y(O95/
M4GYI3$EY_K^WU_)V_ ?7=>IOE[1])'[">PGYA]=SZE]U/S2%=>>/T]/;^)!W
M7J;Y>T?O=^OWONG[W7];[_W3C^_/K\O^,.Z]3?+VC\6/7T+[*?FGYW/J7W4^
MZI]MO7I?[Z_'JBGRL?\ 6^Y\B*?*Q>I/:X?(?*Q>RGLI^814=Y_KO7V^6A\+
M&GK3V3X6+U*GOH?"Q>I%]Y280WGS\_OE2V6X2*Z.@FY7HNK:>15TDUT3EIUU
MX2(NFD:?2U^:FOS43M/T\[OOQRL@P?)*I5Q^X3\MFK9WKI9KA._A2O<Y=&6R
MND7TZ0S+S:(U[W)K<>.SX4:]1N(W'J[Z?L8CEW\V_L;7;G8K9Z5&5^\> 6.D
MTCN5'30,1+KN/@UM@TIT5/K=UL\7U)KI9J2W4SOJHGCJE21JHDB)H[^O1.SV
M7)[OF]!4QW[-&PA              #GC9Z?;]7J]DY&-\Z^U\I^HFJZ'TUNJ
M^KS_ "$QBB]7M?%\IS-;KV]B>^<[6^9/+UJ<Q-H(==.'Q$2UNO'S)[_W")8S
MS>9.U?+T@G5/!V</=]PB6-\ZI[!%L;V+[B KC$[]D6'7VU91B5^O6,9+9*N.
MNLV08]<ZVSWJU5L>J1U=NN=OFIZVBJ&(Y41\;VNT54UXDRHIZFBJ(:JCJ)Z2
MK@<DD-332O@GA>G8Z*6)S9&.37M144K+"<RS';G*;%G.WV59'@^:XQ7Q77'<
MNQ&]W+',EL%RA1R15]FOEHJ:2Y6VLC:Y422&5C]%5-=%4YH^9BH]%5KD^BJ*
MJ*WUHJ<44V9N@[QHHKNZR[5]84]/05S_ *K;+'OE14L=-;:J16MAACW,ME*C
M(;9+(]$1;O11I2ZN1:F"!C9:I>U6WN^"3=Q:,T<V.1>2*GO[&(V-Z_11+K"Q
M$;$JJG]F8G+Q^<UJ(KS=9\*;[3%1WZ7&MA?$:JZ*SW27ZC8\5ZI;90Q45DKI
ME8VGIX][['1-CIK%/-(U&NR*VPMH>:1KJVDI8V3UZSNFN.NC*CAV(DJ=G_5I
MYO90V**&NHKG14=RMM92W"W7"EIZZ@KZ&HBJZ*NHJN)E12UE'54[Y(*FEJ8)
M&OCD8YS'L<BHJHIV5CD9*QDL3V21R,;)')&Y'LD8]$<Q['M56N8YJZHJ<%0W
M(K5=;9?;9;KW9+C07BS7B@H[K:+O:JRGN%LNMLN%/'5T%QMU?2234E=05U),
MR6&:)[HY8W(YJJBHI-T77BG%%XHJ><BC[(\
M
M
M
M
M
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M6\JTELO3G4K'Q15MNI&5+0U\=4G)JB2(FNG]4B=JIZT\Y,SLX:UQ,0
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MK**KB@K*.IC?#-''(QS4G;'M>U',5'-7L5/+M*V(XNH?0
M
M
M
M
M
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MVBJ&LGIIV*UR=BK.F/:]J.:NJ+Y:+Z%0N 3 O2?0
M
M
M
M
M
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M-$5%1%1=47BBD\.<K(_0
M
M
M
M
M
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M0.Y/FN7@JZI_6JOF]LV%2_AOGD8
M
M
M
M
M
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M(O:B)[9D!*X-@(^P
M
M
M
M
M
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MHZZG5ROIJR"6)WSF*AS%0',7,
M
M
M
M
M
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MJ!<NW6K5K?F+YM$T7C[/H*JI:/7153WCE!4C;3\WZ+>ST>@F:4?#Z*Z>PG
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M2.7F<U%_3(R5D;3X
M
M
M
M
M
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M015*1SQ<RNBF:YB\6J";'(5L
M
M
M
M
M
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M0C5FD=)4?>W*::[PNY/F4].^E9HW5NH[>E0F=0
M
M
M
M
M
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M^;7W9KY&)3K<*^&._P")R=V_YKJJ7*+#2T<3DTD:VL>B*J.<UPRM%=F[$
M
M
M
M
M
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MNE!*CDT1R24M4Q=?/J"-/HJ$
M
M
M
M
M
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M78<4J\#J62.5TE.S;^^W7#[9"Y>*<OWDLU*]B(JHD;VIP5%1!=PCSO>
M
M
M
M
M
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MIZT3VE\Q R)P7U+\>A 2^?\ X7RDNF\_K1/AT+IV=WT/<]SBGO$%)VN]CXB
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MJONL5<O!K&*G9J[G4'9PG)F<
M
M
M
M
M
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MZ9))&HNO.QKM-&ZCN"3\V!P
M
M
M
M
M
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M1+HY5UXHK4]8.Z14!L>@
M
M
M
M
M
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MBIZF*#N:3\V.
M
M
M
M
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MZ(OZ%2U#W>PYK8OAE0SOF;PTC2^8 !^M3540 $4Q..OH^,$7"WL3VO=XKI[
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M[F5TTF?U=8B\.;O8$@@TT7327CKYAVT)T9^0
M
M
M
M
M
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M1_*%WR_?7SO_ "BN/]N '^NL\6__ 'C76!_#CG'ZZC^4+OE^^OG?^45Q_MP
M_P!=9XM_^\:ZP/X<<X_74?RA=\OWU\[_ ,HKC_;@!_KK/%O_ -XUU@?PXYQ^
MNH_E"[Y?OKYW_E%<?[< /]=9XM_^\:ZP/X<<X_74?RA=\OWU\[_RBN/]N '^
MNL\6_P#WC76!_#CG'ZZC^4+OE^^OG?\ E%<?[< /]=9XM_\ O&NL#^''./UU
M'\H7?+]]?._\HKC_ &X ?ZZSQ;_]XUU@?PXYQ^NH_E"[Y?OKYW_E%<?[< /]
M=9XM_P#O&NL#^''./UU'\H7?+]]?._\ **X_VX ?ZZSQ;_\ >-=8'\..<?KJ
M/Y0N^7[Z^=_Y17'^W #_ %UGBW_[QKK _AQSC]=1_*%WR_?7SO\ RBN/]N *
MNM/CQ>,19:&.WT?B'=24T$3I'-DNV8QW^N599'2.22YWV@N-RF:CG?-1\KD8
MW1K41J(A'0=2N_-/&D4>ZF6N:BJJ+/7I4R<5U76:IBEE<FJ\-7<$[ "]&/?:
M7/' QAZOMO7CE52JTK*/3(=H.G/+F=TQ8U:](\KV>O3$JE6--9]._<BJBO7F
M=K4%+U=]1=&NL.Y=:_YB1_W58L4KDY4TXZ5MAJ$Y^'TOI+Z>(!VQP/[7QXQV
M(3MER'*NGC=2-LBO6FSS8NV6Z![5FI94A<[;"^[<5*1HRG?&BI(C^2=Z\W.D
M;HZWMG77OW0.1U56XK>DUUY+GC<,353F8O*JV>IM+]-&JG;KHY?/HJ =_P#:
M?[;UU.VAU,F^?0YL/N"Q.%8[:?<?<'9UTFL4+>>F9F%'OFD/+.DC^5[G\S'-
M9S(K5>^Y]D\13,8%9^R3;G&KHG_;%LEVNEA5?FM35B5\>1\NCM5T55U1437A
MJH&6O8G[:%X<N>ST5LWPV5ZE]@;A4QQNJ;S3V3$-VL$M\G(SZQ'477&<CM&<
MS<LKE2)8<:D21C5<[NUT8M\,:\0+:BYNCAR/'LOQB5Z(KJAE/07RVQ+HG,CY
MJ.K@N+M%7ARTBZHG'3L ,]72[XO?AF]9DM#;^G?K0V/S+);GW"6_ KWDSMMM
MS*YU0Y(VMH=LMT*7#<^K^[F>V.1T%ND9'(]C7*BO9S=F,-WVV@S]T<6*[@XY
M7U<W+W5LJ*S[T7B17KHB16>\LM]SET<J(O+$J(JHB]J:@9'R[(
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MM4_U>*2=SW,A[Z5SN5.&KE4 VO#NR
M
M
M
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M)L-;EU5E&95C4CY%<ETR"NH[7*]_!9G36&V4C^9431%1J:HU%476(T[]
M     \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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ML<B.:YKFJJ.:Y%U14X*AW-145$5%145-45.**B]BHOG10#Z/T
M    TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^U^\@'FB&(@
M ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M
M
M
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M\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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M\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                              =3>N?:Y^\'2=O;
MAM+!]8NK,.J<IL,3(UDJ);Y@]13YA;:.DT17-J+I-9/JB*G:E0J+\U5+4;XX
MN[+]J<ULT4?>526>6Z4#4;S2/KK))'=Z:&+1%5)*I]%W*>J147@JD+6Q][2S
M,3MY.9/98J/1$]:\N@-+FDJM-./W/5[9AFAF]?EY=I2(*EI:OL^=H36*;LX^
M7EYSE:[7@O;\()]!6=G'W_+0F$<_KT\O1VI[1]@FD==Z]?+M(ME0OI^3WOD
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MX:;=?@O=/U6: :09CK
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MV8 W/3("
M
M
M
M                     ?BHCD5KD1S7(J.:J(J*BIHJ*B\%14"HBHJ*FJ+P
M5%XHJ+VHJ &CMU8;3OV$ZDMWMK6T_P!6MF/9?75&-QHU4:N(7]L618GR*J(U
M[H\>NM,R3E^:DK'(G880]UL47 ]Q\NQ=(^[IK?=YY+:WS?>BO1MQM.B\$5S;
M=51H[3AS(J>8HZJB[FHEC\S7KR_\%WSF_P#6J"R%/5Z:<5TX>RGME%13=G'X
MOS/@. $YAK>"<?+T^LCF3^O[GQGVCU3U^7I!,&5OK]_X5])$MG]>NGL+[_!3
MZ1Z>P#F^N^MIR=^OI_\ I?*?O.WT^\OR X7UOK]K7C[2G&Z?U^OS)\JGXKT]
M:@ET]=V_.U\O>U^$AI)^WCKY>[[I\J]5]7EZ026HJ^W5R^_Z_,0$L_K\OC^
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M?*KHK<U8HUX+4O1.]=YOT)B\(TT\ZZN]2%O[GESY5=%;D6)BJJ+4R)^B._\
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M           'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L
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M']S+-OP[=^U^S &YZ9 0
M
M
M
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M\%[I^JS0#2#,=8
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M         :87VVC\07I1_*_I_P")C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M      >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
M
M
M
M
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MMOFD9I37#<"X,6*PTK=>7O?O'1.GN+U8[FAJ(Z7F3EE!W3)\;,H
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MGQ:!7N=DN-MGJZ>D@;Q;+>*!T3:^T(C53G>]KZ9KEY4F<NFH&!XZU
M        &TK]DMZ\JGI6\2FW=/>3WN2AVEZW+''M1<:2HG6.U46\F.MN-_V4
MOLD:R-5]PN-QFN6+TS6M>KYLE8KD1K.9G<WH?W+?A>[D6+5E0L=CW$IDLDK'
M.TACO]*DM5CU2J:\99972T;-$75U6FO!-4 ]6,S5@        &F%]MH_$%Z4
M?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_ !!>J[\K
M^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
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MKUN=;3??.\W3OJY:>&E6?OKU<+C/'^@4[&\K'-9PUTU554#N>7
M
M                                                  *?DRS%8<HI
M,'FR;'XLUK['69/0XA)>;<S**W&K=74=LN&0TF/NJ4NU18Z&Y7"GIYJMD*T\
M4\\<;GHY[46%6NHFUK+<ZLI6W"6FDK(Z!:B)*V2DBDCAEJF4JO[]]-%-*UCG
MHWE:YR(JZJ@!4!%
M
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MX@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MHG];Z #8D.U0
M
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M.95XJB^8 ]:TSA
M
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MOJJEJ**JJ:*KB=!54D\U+4P/T1\-13R.BFB?HJIS1R,5%]: $G.
M   ]+/[$MFM7<.A+JTV\D[Q:/%.K./+Z5SDB6-)L[V?V^L]7%&Y$[_YJ;>QN
M5KEY$5^K417/5<NOAXW!\NVV<6I=>[HLW2O8JZ:<USL5K@>U%^EP^]2+IV<>
M':H!NBF0,
M
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MNM$R[4J5T:N7@ULM&Y[57S(H![D9L;
M
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MM.">VOEYR433=O'R\O=!#/?IZU7WCB)3--V\?+Y?@!P@EKWJ]=5[/,@ /@
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M3E+X@                \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK-
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MM6FGJ^[=%003R1M[BF>O,J(W5--=5 ,57]+ \$K^<;N!_P"SOO?_ ,R"RO\
M+:Z>/\:[I_DKD7ZW #^E@>"5_.-W _\ 9WWO_P"9 _EM=/'^-=T_R5R+];@!
M_2P/!*_G&[@?^SOO?_S('\MKIX_QKNG^2N1?K< /Z6!X)7\XW<#_ -G?>_\
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M5CFOJ]S]PZI[6\C7U.:Y).YK=57E:Z6YN5&ZJJZ=FH!)?]83U]?SX>K_ /\
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M45U-<;374UQH:A$715@JZ.6:GE1%_J7* 5P3$
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M355*3J-W-UZQZ2U>YVX=5(UB,;)49IDD[T8BN<C$?+<G.1B.<JZ=FJJ 2?\
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MJ*US535%14X*BH <A^@
M   &$;Q:?"?L76?CE;O-LU;;?8^J7&K9!%&U):&U6K>6S6Z&.GI,7RBMK9Z.
M@H<FMU'&D=IN\\C6MC8VCJW?5NXEHN@?6=T:V[?>USYU@M+36_=ZU4D;&IST
M]'1YU04K&Q0VF[U$\D%-3W:E@:C:*MD<B(QJ03+W7=OI[5;C;>PY-3ONELC;
M%?Z>-."<K&72*-NC:>=SE:UM0QJ:12*O8G*[YNBL&$_:'[/WOW?I*>IWPW6P
M;:JDYVNJK'C%!<-Q,JA1BL6:BJ^>7%L<H*E_SF)+#75[(U^=R2?17I7M_P"%
MKN=>.XJ=Q<YQC"J5_*^2WV2GJLNO36IRJ^";]$LMGIY7IJU)(ZJJ:WMY7?17
M&]E.]UKQZOKK1!8+Q4W2VUDU%6T]R9]Y&P3T[W13,>RHCJ*]DL<C51624\:^
MG0&5W97P5^B/:A::OR;&,EWLO\"Q3)7[G7Z22S15+6Z2_5L2Q>'';#4T4BKP
MAN,=RY4_/*O$[R;=>'9TXX.L-5>;->-QKI$L<GUG,KH]UNCF:FC^YL5E9:;9
M-3/5?['6-K-/ZI5XEF[UO9FUUYXZ.>DL=.Y)&<ENIVNJ'1OX-[RKK%J962L3
ML?#W*Z\092,4P[$,#LM-C6#8KC>&8Y1:_4[!BECMF.V6DU:QB_5K5:*6CH8-
M61M3YD:<&HGF.ZMCQ^P8Q;H;/C5DM&/6BF_^U[58[;16FW0:HUJ]S0T$-/31
M:M:B?-:G!$+5UE=6W&H=57"LJJ^J>B(^IK*B:JJ'HU-&HZ:=[Y'(U.S5> *D
M)N0H/Q51$!\N<C4!#O?YU[?,GEY@2Z:;MX^7E[@(9[]/6J^\<3G:\$[/A)3/
M/IKQ\OD!#.=YD[?.OEYSX)1--V\00KG>9.SSKY>8$JFF[>/EY>Z"&>_W/A.-
MSM>">VI*9Y]->/E\H(5[_.OM(<9)YINWCY>7N AGO\Z]OF3R\P)5--V\00SW
MZ>M5]XXW.UX)[:DHGGUUX^7R@AG.\R=OG7R\YQDIFF[>/EY>Z"%<[S)V>=?+
MS E,TW;Q\OE^ $,]^OJ1/?.-SM>">VI*)Y^WCY>7N AGO\Z]GF3R\YQDIFF[
M>((9[_.OM("4SS]O'R^-5!#/?YU[?,GEYCX<[3@GMKY><E$TW;Q\O+W00SWZ
M>M5]XXB4S3=O'R^7X <():]ZO75>SS( #X        !-+-9KC?[C36JU4SZJ
MMJG\L<;>#6M3B^65Z_-B@B;Q>]=$:B'VQCI'(QB:N7RU7T(A7>VFVF:;O9I9
M-O\ ;^R5-_R>_P!2D%'1P)RQ01-^=57"X53M(:"UT$*+)45$BMCBC:JJO8BC
MO#@6"T&$6I*:+NZFZ5*-?=+BC-'3R)Q;!"KOGLHZ?71C>',NKE35=$GM/3M@
M9HG%Z_3=Z5]">AJ&U5TC=)^(=+. 1V6A2CO6?7R."ISO-6TRQS7:M;J^*UVU
M9D6HI<<M"O5E-$O*LKN:>1J22*UHKLB#MF                  #S@_MO/X
MT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6           >EW]B7_$%ZKO
MROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(                          !
MXW/VC2X45S\:[KZJ:"HCJH(]S,/M[Y(E56MK;3L_MS:KC3KJB?HE'<*.6)_H
M>Q3 ;U7RQS=0NYSXGH]J7B@B54[$D@L5IAE9[,<L;FKZT ,)IUY
M  /1U^Q"8B^BZ8>N7/%AF;'DF_.VF(LJ'5%.ZGE?A.WMPO,D,5*U?K4,T#<_
M:Z21Z=W*V1B,XQR:98?#KH5CP[<>Y<KN6KR6T4*.5S%:JV^URU"M1B?/:YJ7
M--57@J*FG8H!O!F1<       TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^
MU^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S
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M99'JKY))'JJN<JJJJNJG6!SG.<KG*KG.57.<Y55SG*NJJJKQ554 XS\
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MV^H7'\PCB[RLQ&[3QI6N1C.:6HLU4B1PWJB9HJJL:-GC:FLD4:*U5 S>G8H
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MB*NNMO7?&9+N]N7>X7]Y35V;9&ZCDU1W/0P72IIJ%^K5<WYU'"Q>"JB>950
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MEIYN[O\ ?H.+7+>[A3O7N*2=O;1T[DBY7*V5\Z:*@&KX=.
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MEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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MQ]\RI1WAL+%?/78U-.]9*F)&-5\E*]5J:=J.7]$C:LJ@;$!VI
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M"[:<D-%?)%T;%(U&PU;EY=&3<J3 ;K)D*
M                  )'>\?H;Y#R5#>[J&-5(*N-J=[%Y^5>Q)8E7M:OM:+Q
M!9K>#8[#=Y+3]5OD'U"^TD+V6;***)BW.VN55>V*5JNC;<;:Z155]-*[E^<J
MQNC>O.@LG>K'7V.7DJX^:)RJD%5'JZ"9.W1'::L>B=K7:*GK315&(3=G9G-]
MGKI]2R:@[VV5,CVVG(Z!'S6:ZL:G,B1SJU'4M8UOTZ>9&2MTU1',5KW"GGO\
MZ]OF3R\P+*33=O'R\O<!#/?IZU7WCB<[7@G9\)*9Y]->/E\@(9SO,G;YU\O.
M?!*)INWB"%<[S)V>=?+S E4TW;Q\O+W00SW^Y\)QN=KP3VU)3//IKQ\OE!"O
M?YU]I#C)/--V\?+R]P$,]_G7M\R>7F!*IINWB"&>_3UJOO'&YVO!/;4E$\^N
MO'R^4$,YWF3M\Z^7G.,E,TW;Q\O+W00KG>9.SSKY>8$IFF[>/E\OP AGOU]2
M)[YQN=KP3VU)1//V\?+R]P$,]_G7L\R>7G.,E,TW;Q!#/?YU]I 2F>?MX^7Q
MJH(9[_.O;YD\O,?#G:<$]M?+SDHFF[>/EY>Z"&>_3UJOO'$2F:;MX^7R_ #A
M!+7O5ZZKV>9  ?         +G8+M?>\R?'5R(^UV)'?HERFC7GJ4:[1\=NA=
MRK4/7BG>+I$U47BJIRK%4](^?C]"/^J5.WU-3S_ =[.D_H,W2ZEJJCR&MBJ,
M#VG;,BU>;72C<M1>XHI.6>CPRV3+$^\5#E:YBU;E;0P.1VKY)&=PX=Q<>QNS
MXO;X[;9J1E- W1TLB_/J*J731T]5.J(Z:9WKX-3@U$:B(DZCB9$WE8W1//Z5
M7TJOG4V5-FMDMMMA,-I,'VSQZ"R6F'EEKJMZI4WF_7!&<LMVO]T>UL]RN$W'
MB[ECB;I'$R.)K6-$].0NP                      #S@_MO/XT_0_^3_N%
M_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6           >EW]B7_$%ZKOROZC^)C:X
MR[^'C^YEFWX=N_:_9@#<],@(                        !T*\4#J_L_0=
MT"=4G5)<;A2T-XVVVIR%-O8:J1&)=]VLHA3$MI[(QJ-?*]MSW!O=N9,L;)'0
MTO>S*U61NTMGO'G<&VNV.9YG+*R.>T62J^]37KIW]\K&_4;)3HG%RI-=*B)'
M:(JM9J[31% /$ EEEGEEGGEDFGFD?+--*]TDLLLCE?)++(]5?))(]55SE555
M5U4UU'.<YRN<JN<Y5<YSE57.<JZJJJO%550#C/P         CK9;+C>KE;[/
M:**JN=VNU=26RV6VA@DJ:VX7&OGCI:*BHZ:%KI:BJJZF5L<;&HKGO<B(FJG)
M##+4314\$;YIYY&0PQ1M5\DLLKD9''&QJ*KGO>Y$1$XJJ@'N4>'WTT4_1QT0
M]*O3 RFI:>X;+;&[?89E*T4K)J6NSVEL%)5[B7B&6)SXI&WW.ZRXUNK%5BK4
M?-X:&QQM=B#<!VZPK#D8QDN/XY:[?6]VY',DN;*9DEUG:Y-6JE3<I)9.'#YW
M  [A%>       &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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MVS<:D@7ZM,Q&TM#F%-3QZR55%$J]W3WN*-BOJ:5NC7HBRPHC$?'"!M8'=4
M             X:BHIZ.GGJZN>&EI:6&6HJ:FHE9!3T]/ QTLT\\TKFQPPPQ
MM5SG.5&M:BJJZ'R][8VN>]S6,8U7O>]4:UC6HJN<YRJB-:U$U55X(@!YAOVC
M[[0Q?NM?*LOZ(.CC+JBT='&)7AUHW*W%L%54TM?U/Y)9JABU$$=4UM/-!LG8
M;M J4-(U59D%1 VX3N?3_4XHL._5EU35.X=;7[=8%7/@P&AJ%@N]UI7O9+F-
M73O3G:CT1CFX]33M_0F)PJG-25VK>[:T#3_.B(
M                  !4N,87F.;5J6W#,3R;+KBLU)3I08Q8KI?ZU:BOE6GH
M8$I;52U<ZS5LZ<D3>7FD?P:BJ1E';Z^XR=U;Z&LKI>9C>ZHZ::JDYI7<L;>2
M!CW<TCN#4TXKV ':C"O#D\0G<EL,FWW0IUBYO#4-=)%58KTS;T7ZC6%E7]0E
MJ'UELPNII8J6"M18I)7O;''(BHYR*BE9V[:?=*[HU;7MMGMQ:Y%5KZ+$,@J8
M^5).Z<]9(;>]C6-D^:KE5$1>T [9X=X WC)YRB+9?#WW^HD5L[O_ +\;58=N
MUTIWQLD16[@7_&51SED3D3ME356(Y&N5*XH.F/?VY?\ VOM;D\?!R_W?!36K
MZ*HB_P#W4JJ/BNO#T^;710#<_P#LK?A<^)#X:^Y/5O-UA[#T>SVVV^>![9?>
M29VZNT.>W6OS;:^_9&ZS0R6W;#<#-'6^CGL.Y5V7O*E(W-DIU:O)S,[W(#T7
M;-;M;1W?.'9YC4=AM&26RS_5W+>K%<YY+C9JFK6G:L-FNEP6*-U-=Y^+]%16
M:<-4U W.3(        86/&@\:38GPBMD&76^);]Q.IW<BSW5=@]AHJN9DU\J
M:5[:&7/-P*FB7O\ &=K\>KY4[Z9715=XGC?1T&KV5511]?.H'J"QO8O'4FJ.
MZNN8W:";]C.-->Y'5#V+W:W.Z/C^?1V:EE7YSM4?.Y%CBXH]T8'DD]7G6)U$
M]=>^65=1'4]N1>-R=R\JD;"M97.2FLF,V&FEFDM6'X3CU/R6K$L/LB5#TIJ"
MCCCB1\DDTG>5$TTTF#K.L]RO<G(ZW*LQNU1=[O6JC>\D7DIZ.F8KEAH+=2LT
M@H:"GYEY(HT1NJJY=7.<Y0.LA1X                              !4F
M'YCENWN58]G6!9/D&%9KB-XH,AQ7+L4O%PQ_)<;OUJJ(ZNV7FQ7RU5%)<K5=
M+?51-DAG@D9+&]J*UR*A%T%?76JMI;E;*RJM]PH9XJJBKJ*>6EJZ2IA>CX:B
MFJ8',F@FB>B*US5145. !ZCWV=W[0I8O$:QNS=)G55=K7C77)AV/S/LM^2&F
MM5@ZG<7QZ@?47#*+%24[(*"T;J66V4KZF_V6%L<%7!')<[<QM.E926W,MTK=
M4M-NO24^$9I/#2;CT%*Y:>IY604N84=+$KI:VF8U&Q07JGA8KZJG:B->U%FB
M1&=XR(#:V.ZX            !YP?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/
MU6: :09CK         -KW[&W_M<,C_) WE_;MM"=V>@;]W*K_ 2__JC8@#U.
MS,^ =7^LOJ]V4Z$>F[<_JCZ@,A^\&W&V%C=<:N&F^KRW[*+W52-HL;PG$K?4
M3TS+KEF6WF:&BH8%D9'WLO>2OB@CEE91V?YWCVVN)7C,\HJOJMIL],LKVLY7
M5-94O5(Z2W4,3G,2>NKJAS8XVZHFJZN5&HYR >-9XF'B.[\>*#U2YEU)[W7"
M:BI:R:6R[6;845TK:_$MGMMJ2=ZV+"<8CJN[C?,D?]TW6O;# ^[766>K?''W
MC88\!.[V[&2[QYG<,NR*5T;)'.I[+9XYI)*&PVACE^K6ZC1^B*Y$^?/*C6K/
M.YSU1-4:@&/HM<                       <D4LL$L4\$LD,\,C)89HGNC
MEBEC<CXY8I&*CXY(WHBM<BHJ*FJ'ZUSFN1S55KFJCFN:JHYKD75%14XHJ* >
MI9]F"\;:X]?^SE9TA=3&6NNO5_T_8S#763+;W5R37G?[9>WRT=KI\NN-;4.<
M^Y[C8)5UE/07Y[U^L7&FFI+BJSSR7!\.9KHZZB)=S[!)@F7URSYWB]&V2FKJ
MAZNJ,GQ^)8X6UTLCN,UVMKY&Q5*K\Z5CF2_.<LJM VR#NZ
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M,@IZ:G@8V*"""")K8H888FHUC&HC6M1$1- ?0.8
M   'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]
M+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M        #S9_M?\ XJMLWTWBQ;PW-E<EI[KMSTZ9(N9]1%VM%5%/17[J CH*
M^T6?;_ZW2O>R>GV@L%UJVW*)'JS[_P!SEIIXF5-I:IB3Z[MZH<DOU%M+CU8V
M:TXI5_?#*IX'M='4Y0D4L%/:^=BJCFV*EG>DK==/K,SF.1'P( :3YCS
M      -B?[,-T"576WXH&V669'8W7+9CI%=0]16Y534T;:FT5>1XU<6)LYB%
M4^9WU5U5?MQHZ>X.II62MJ[79:]BLY4<YO:OH[VQ?N)O'9ZZKIEFQ_!5CRN[
MO?&CX'U=)*GW@H'J[YBOJ;LC)58J*CX:>5-/.@'KHF<T         TPOMM'X
M@O2C^5_3_P 3&Z)C^\0[]S+"?P[;^U^\@'FB&(@           ]+O[$O^(+U
M7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0          #J3UQ=:NQ7A\]-&
MXW5+U#9"ZRX'@%M7ZG:J!(9\GSS+ZZ*9F+;=X3;9I8&73+LNN,24]*Q[XJ:G
M9WE552P4<%1414/N-N%C>UV(7;,\JJEI[9;(?T.&/E=67.OD:Y**U6Z)SFI-
M75TK>5B*J,:FKWN;&USF@>.9XFOB5]0GBD]3&0]0V^UU^IV^'ZW8-I=K;54S
M28=L_MTVNFJK7B./1/;%]=N$O.D]VNLK&U5VKE=*](XFP4\&!/>#=W*=YLOJ
MLJR6;NXF\]+8[-"]RT%AM*2.?#0TK51.\E77FGF<B/GDU<NC4:UH&/ M6
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M6+)$RKA;(^EJ.[<YK*NCE5T4S=5Y)6.:O% "^Q4@
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MU)1//KKQ\OE!#.=YD[?.OEYSC)3--V\?+R]T$*YWF3L\Z^7F!*9INWCY?+\
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MV(V7#[!3(U4H;/2I$^JE:WD^MW.NE=+<+O7O:FCZBJEFG?\ GGJ":'V5X
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MV[RFH6ZT..V;O.>&RV2&1[J:E;I\Q]5*KEEJ)$3]$F>JIHU&M:!C5+1@
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M>&I*[5$7GK^U4X- W>S(H
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MFFJ:F:6HJ*B62>>>>1\LT\TKUDEFFED5SY997N5SG.55<JZJ 2\X@
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M)69D<U9R,K,BO/=\E1?+Y)$QM76R:_.93,5O=T\6J]U UK55SN9S@,CY=D
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MD3ZB[8D^9WS:6_00+)<K8U[G<K(KK0P++&W@G?P*B:OFX@>CH980
M#S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6         ;6/V.R
MXV^T>+!F5VNU=1VNUVOHTWNN-RN5QJ8:*WVZWT68;25-975U94OBIZ2CI*>)
MTDLLCFLC8U7.5$15.ZO07+%!O;7SSR1PPPX!D4LTTKVQQ111U]C?)))(]48R
M-C$55551$1-5 ,6WC:^(C<O$S\0S>?J HKE55.T=@KEVFZ=K;.RHIX[;LE@=
MPN5/C-R;0U*NGH:[/+E65V2UT+U5T%;>9847NXHVMLUU#[JS;O[IY!D\<SWV
M*ED^\>*Q.1S4AQVVRS,HY4C>JNCDN4TDE7(U>+9*A6]B(B 8ERQX  !56#X-
MFNYN7XYM_MQB.39]G>87:DL.)X7AMBN>395DM[KY$AH;18;!9J:MNMVN57*O
M+'!!%)(]>Q%(VW6VX7BOI+7::&LN=RKYXZ:AM]!335E;65,J\L<%-2T[))IY
MI'<$:UJJH!N;>';]C7Z@]X+;C^X_B$[K_P F?$KE'#7KLCMBVQYIOI54$R-<
MVGR/+*M;IMMMI<)87I*QD<.4U$?]BJ::FF1[&=_]JN@7*;]#2W;=*]_L0H94
M;+^QVSI37#)'Q.T5&5==)WUHM$JM75$1M:Y.Q[&.U1 -N'IK^SJ>#OTQ4-$S
M'^C';O=B_P!/'&E;EO4>E7OW<[M41,?&VMJ<?W$FN^WMKJ.5_%MLLE!#S(C^
M3G1''>3$>E/8;#HXTI=O[5>ZIB)WE=EG/DTT[T1421]+=73VJ%^B]D-/$W7C
MIKQ ,H^)],G3;@4"4N#=/>Q^&4K:=E(VFQ/:? L=@2EC>LD=,D-GL%'&E.R1
MRN1FG*CEU1-2\M%A^(VQO);<6QRWLY49R45DME(WD1=49RP4L:<J*NNG9J 6
MSW5\/[H4WRHZJAWAZ-^E_<F*KDGGDJ,PV*VSO=RCJJE=:BMH[O68U)=;?<)5
MXK4031SZ_GB47K:_;;(XWQW[ <-N[9%<YSJ_&[143(]_TI&3R4BSQ2K_ %;7
M([U@&NCUX_8^N@/?VT7C).CF^91T:[J.C?4VZSP7"][G[&WBL1CGOIKOB.67
M>JS/&_K\S6L;46B]LI*%KG/;;:C1L9U2W+Z$-L<G@J*O JFLP"]*BOBIVRU%
MXQR>1$559/0UT[[A2=ZY$3G@J$9&BJJ0N[ #S[?$'\,SJ^\,C=I=J.JG;>;'
MDNCJN? ]R,>FFO\ M5NA::.1K);M@F8LI:6&M="V1CJFWU<5'=Z!)6?6Z2!9
M&<V+S=':#.]G[Y]Y,TM#J7OED=;+M2N=4V6\P1KHL]MKT8QLBM145\3TCGBU
M3G8W5-0.@9;$             ST?9HNIV;IB\8WI3J:FX-HL5WYNU[Z8LPA5
M_=K=(=YJ#[T8%;V2JO*QW^>6BQB?16N[Q(%C31ST>WLOTB9B[#M^\*>^7NZ+
M)9ZC#J]NNG?-O\7<6R)%7@B_?^.C=Y]>73M75 /80,\(
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MV2/NU>Z16<ELI*5O(KW*[333554$:?15(
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M_;BYO=H'\%I:[*+U/1HBM8QR-HWUJTK.=(TYM&)S*FJZJ =+BWP
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M5SFW]VR._P!JAJ:FGC<KFT5SA5U+=[?JJN<OU"YP2Q(J\7(Q%\X!W'*^
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M;W7"SUS)*[&+^V+NH;Q;$>C')(Q%<V"Y4+W)'4PZKR.5KDUC?&YP&*<LH
M        5KMKGM]VKW&P#<_%IW4N3;<9MBN>XY4LD?"^GON'WV@R&T3MEC_1
M(G17"W1N1S>+535.),;1<ZFRW:V7BB<K*RTW&BN=(]%5JLJ:"IBJH'(Y.+5;
M+$BZIV 'O+X%F=DW'P;"]P\:G^M8YGF)XYF=@J=6K]8LF46>COEJGU8KFKWM
M#71NX*J<399MEPI[M;;?=:-W/27.AI+A2OX?/IZV".I@=PX?.BD10"K".
M
M                                                  /.#^V\_C3]
M#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
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MZ5$ZPV.^SMQ7(T5RI$EKO4T,,=7+IKHRUW)D%4Y417*R%S4^D >R09\@
M  #Q9?'1R2X95XP/B)7.Y.YJBEZH-Q<;C7O)I?\ P?AU='B%I;S5$DLB<MKL
M<*<J*C&:<K$:Q&M37TZD*N6MWWW5FF75[,RNM(G%SOT*@D2A@35RN7A#3MX=
MB=B:)H@!BA+)           'K0?9*]IK=MQX+>S&6T5/2P5F_&[6_N[-[= V
M5L]1<;7N3==DJ:HN'>1L:ZJ=8MG*)K%8KF+3-BXZZHF;[H?L<5IZ?<?KHVL;
M)DM\R>^5"M14<^6&[38ZQTNJ)J]::P1HFFJ<B- -E@[=
M   'CF_:3,$M.W/C<]>N/V9(VT=PSC;/.YDB@^K-^^VZ6PNU.YU^58^^GYI'
M7S+ZA7R<R=Z]5?RLYN1N!3JVMD%IZB-S*6GT[N6Y6BYNT;R)W]ZQFR7BIX<S
MM56IKWZK^>7CHFN@!@Y.N0          !Z]WV6[,*G+O! Z/(ZWO'U>)UF_F
M'OJ'LIXVU%-:^HK=6JM/<QTT<36QT=EN--3*KD621\#GO5SG*Y<ZW1I7OKNG
M3 TDU5]#)DU KE1B(YD.57I\'*C$:FD=/*QG'BJMU755U -@H[1     'F4_
M;'^O67>KK-V\Z'L.O#:C .DG&8,DS^&CJ8Y:6Y;Z[J6FWWB>FJDA8Z.=V#[;
MOM<$*]XKZ>LNUQ@>QCFNUQ =?&YCLAS^U;<T$Z.M>#T;:NYMC>CF39)>H(IW
M,?RHJ.6W6E86MXZMDGE:J(J &FZ=!@        "L]N-O<PW;W"P7:O;VQUF3
M9[N5F&-X%A6.V^-TM=?<KRZ\4=@Q^T4D;457U%QNM?%$Q/ZIY,+3:Z^^72VV
M6UTTE9<[O7TELM])$BNDJ:VNJ(Z:E@C1.*OEGE:U/9 /;<\-CH8P#PX^B[9'
MI+P'ZK7KMYC,=1GF604[89MP-U,A=]^-QLXJ7.AAJG0WK)JJ9*"*?GEHK3%2
M4?.YE.PV(-H]N+7M/M]CN#VSDD^]5&C[G7-:C772]52]_=KB]>5KU;45CW=T
MCM71P-9'JJ,0 [TER                   #!%]HA\-*@\2+P[]Q+3C%A=<
M^H?IVH;[OGT]U%OHOK5]N^08Y9*B?+MK:%(T2IJ8=U\7I'T$-*CV0OOD-LGD
MU2F0ZU]5.T46[6U=U@HZ99LJQ6.IR3%G11\]3/54E,]U=9H]$YWMO=&Q8FLU
M1JU+87+]  \>0P-@          'H'_8I.MZ>LMO4]X>F5W.25+/W'5%LW3U$
MC'I!05E18-OMY;+3R3/26*GBN,V,7"DI(>9G>55QG5K7.D<_*%X>NXKI(<QV
MLK9E=W'+F5@:Y47EBD=2VN_T[5<O,C6RNHY6,;JFKY7:(NJJ!OTF38
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MQ
M                                                      'G!_;>
M?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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MW+W-S/-9'O=!>;U4K:VOUUALE'RT%D@5%TT=%:J6%':(FK]5T34 Z&EM
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MM<UR(YKD5%34U['L=&YS'M<Q['*Q['HK7,<U51S7-5$5KFJFBHO%% .$^0
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MTT51TZ[:/B=SM;07N%5Y7-TEILIOM/,W1R-7YDT3DU[%TU35-% ,YYV/
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MNDUK;FZLL6&I,S7ZO;87]Q>KS!S(J))75<;J.-Z:/;'#,GT9>(&]N9)@
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M
M                                                     \X/[;S^
M-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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M/NIE5)U%X!%$G=TC[)O=2_LPR&&WT^B,I+;9=R:B^VRGA9I'%%0M:Q$8C43
M?U580W!-\\WH*>%(+=>JUF5VMK4T8M-D3/K]4V)NB(R&GNSZF%K4X-;&B)P
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M/K.)97=Z%8%75S**ZMI[W33HB)HD<U575+4XJO-$[S: &V =V@
M        #Q&?%QWKINHCQ.^N_=ZW5?U^R9-U0;MT.+U_UA*IM=AN(957X3AE
M:R5/F)'5XICE'(UC5<R)KD8USFM1RZ[F^60LRK>'<J^Q/[VFK,QOD=%+S\_>
M4%#6RV^WR(Y.&CZ*DC5$35&HNB*NFH!CM+5           'M1^!UM)4;)>$7
MX?."5<#J6MFZ:L#W KJ62-\4U)7[PP5&[U=2U$4DTSXZJFJ\Y?'*U5321KOF
ML^@W8.Z<[&_'=C-KK;(U62.Q&VW21BHK7,EOS77V1CVJYRH]C[DJ.]:=B=B
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M(UUN]@N]@J)&M7D1;!<(+A3)(Y/FI)(W(I.77151BZ:HW@!HWF.0
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M9L&*6>/N[9CUIH;11(J-1[X:&GC@2:7E1$=45"L621W:Y[E5>*@%Z"H
M            #S2_MLFUL5BZZ.E'>&"F[ANY/2W5815RL8UD59<MJ]T<MNDM
M3(Y&HZ6L;;-SZ2%[E55[F*)O!$XXBO$-LS:;<C";\UG*EVPQ]N>Y$1$DFLMY
MKIE>O#C(D-X8U5_J4:GF -+LQ^           'K ?9$JBHG\&K XIIYIHZ/?
MK?BGI(Y97R,I:=V2456Z"G8]RM@A=554LJM;HU9)'.TU<JKFTZ%WN=L%;4<Y
MSDCR;)6,15548U:N-ZM8BKHUJO>JZ)PU55\X!L\'<0
M
M                                   \X/[;S^-/T/\ Y/\ N%_&+ 8F
M_$3_ ,--NOP7NGZK- -(,QU@
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M<B(EXO\ =,@J6-7YW)C]!%04R/TX]U(_(GJB+P<Z/7M: ><D8H
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M:EM/8MQ:>GLW/*]&0P9)2RR28[,]SET_NIU1/1M1$U=+51JJHC5 /59,U
M              !C*\87KILWAV>'CU&=24]VAMV=4.&UV";)4KI8FU=WWPS^
MDJL?VYAH:>5K_KK;!=)W7NMB:G,EJM54_@C%5+/[\;D4^U6U>5Y:Z=L5RCM\
MEMQUFJ(^?(KHQ]+:6QM5%[SZM,Y:B1/_ *S ]?, >)\][I'.>]SGO>Y7O>]5
M<Y[G*JN<YRJJN<Y5U55XJIKT*JJJJJJJJNJJO%55>U57SJH!\GX
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M;58KID=3&U>#I+[7LMM*LB:Z<\++!+R\$5$E7T@&C28XP          #VA?
M5VJ@V;\'/P\\1IX/J\=WZ=,7W5='R0LYI]]JVZ[WU,^D#G,7ZS4[AODU5>=W
M/J]$>KD38%Z9[*VP;";64+6\J3XI1WI4T:FKLEDGR)[M&JJ?/==57TKKQXZ@
M&7,OF                       :4WVV_$*6MZ*NCO/7TDCZ[&NJ.\XA3UR
M4D;XJ:ES?:?*KS64CZY8734\E;-M] ]L39&-F2G<YS7K$U68]?$0H62;>X%<
MU8JR4F95%"V3D16L9<;)6U$C%DY5<Q9'6MJHU%1'<JJJ+RIH!YL!B1
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MY45VGCYZ7"[#=LB7F:JQNK96PV.@C54X)*R6[NG9KYX-?, >KV9LP
M           #S^?MS-%1QUOAA7)E-"VOJZ7K-HJFL;&U*B>CM\O2K/0TTLNG
M,^&EFN=0Z-J\&NF>J?24Q@>(['&DFSLJ,:DKV;@1OD1$YG1Q.PIT;%7M5K'3
M.5$\RN7T@&@:8Q@          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_ (49
M)_WQ  ;/QW&
M
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M<4         TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
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M9"[1/T.OO%SMU-$_5>/&AIZENFG'F[>&B@>G89A@
M  #5?^V$[20[A>$-59TE+"^KV'ZDMFMQ6UJT_/4T]!D:9/L[5TT=2V2-]/2U
M=7N?2ND:[GBD?#'JSG;&]G2_KQL;;IL4^Y<C5DQK+;!=4DY=7LBJ_KEA>Q'H
MJ*UDC[PQ51=456IPU1%0#RIS"N           9"/"9W6?LEXG70)N6M4VBH;
M!U;;$TM_JG/IXTBQ+)=P[%BN9*DE744E)$YV*7NL:CI98XFJJ*]S6HJI=+9"
M]KCN\.V-WYTCBI<XQME4]5:G+0U=UIJ*OXO?&Q%6BJ).+G(U/.J( >W@;$P
M   !CJ\5_H4LWB/= _4'THUBT-'E.9XJE^VHO]<V)L6-;PX35191MS=)*M\<
MDE!;:S(+;';KG)%I*ZSU]7$B_HBHMJ=[=MJ?=G;+*,)D[N.MN%%]9LE3(B:4
M=^MSVUEIF5ZHJQ1254213*WBL$KT\X!XGF68KD>"93DN$9C9;AC>78;D%YQ7
M*L=NU.^DNMAR/'KC4VB^66YTLFCZ:X6NYT<L$T;N+)(U1>PUYZZBJ[;6UENK
MZ>6DKJ"JJ**MI9VJR:FJZ65\%33S,7BR6&:-S7)YE0 I\A0        "(I*N
MJH*JFKJ&IJ**MHJB&KHZRDFDIJJDJJ:1LU/4TU1"YDT%1!,Q'L>Q4<UR(J*B
MH?;'OB>R6)[XY(WM?'(QRL>Q[%1S'L>U4<U[7)JBIQ10#U;OLYWCMXGXD.SE
MBZ:NH3*[?:.NW:3&TH[G'=*AE(O4;@^/TD<<6Z6++.YK*S.*&@C3]E5KC5TJ
M3,==*=B4D\T-!FNZ4>I.AW9L%-B.4UL4&Y-CI.[F29Z,_99;J5B(V\T2N722
MY11)_=L*?.YD69J<CG-B V@CN.             2N^7RRXS9;QDF27BUX]CN
M/6NX7R_W^^7"DM-EL=EM-)-7W6\7BZU\U/0VVUVVAIY)JBHFD9%#$QSWN1J*
MJ<-34T]'3SU=7/#2TE+#+4U554RL@IZ:G@8Z6:>>:5S8X888VJYSG*C6M155
M= #R=OM)GC04_B>=2%KVBV*O55-T9]-EVO%'M[6M;-21;R;DU"26K)MZ*JCD
M9#,VPK0L^]N+PU+5J(+6M15N2"2Z3TL&$CJVZ@6;Q9;#8L;J'NP#$IYX[7)H
MYC;_ '=VL-9D#XU1KDIN[3N:-KTYFP\TB\JS.8T#6D.H@          !O%?8
MS/#NJ\[WMW5\2+/K,Y,/V3H;OLKL1+64[D9=-VLSLM.NX^4VZ1R(O+@^V]V;
M:M='1S291)RJDE*Y$R,] .U4ERR*];M7.G7ZACT<^/8TLC5TFOEPIV_?:MB5
M?-;K3.D/G1RUB^=B@'HW&5\     \B#[4SNU)NGXUG5%0Q5GUVS[2V/9C:6Q
MO29LK8(['M)B&1Y'1M:U.6#ZIG667:-S-7+SM5RZ*Y6MP6]9U\6]=0N91MD[
MR"QT^/V.G7F1R-2FL=!55<:(G!O=W*MG14X\4U\^B :\QU9           ,K
M&%>.+XM.W.&XEM[@_7=OEC.%8)C-APW#\;METLL5MQ_%\8M5+9,?LEOB=9'N
MCH;5::&&")JJJI'&B:J7JM_49OA:J"AM=NW*R2CM]MHZ:@H*2&>G;#2T='"R
MGI:>)JTZJD<$$;6M3T( 5-_K]_&2_P!X3U ?IQ8_UA(S^4WOY^^EE']\4_\
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M?F(F3KPY[RO/NICTCUT5N*WFDC\R*U;W0W!_%VFKN:F3@GFXKV 'H!&3X
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M_P!\0 &S\=Q@
M
M    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
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M[JWIS-75%9B=KB>JM^:E'!?JNH8U$=SISK71*NJ:+RIHO: ;ZIDP
M               ,+GVB+!V[A>"SU_V%T$E2E!M)9,X2.*AEN#FNVRW,P3<E
MDZP0RQ/CCI7XFDKYU564K&+,YKFQJU>OO53;DNG3YN?3*Q7]U8Z>XZ)&Z546
MSWBVW9'\K5:J(Q:+F5W8Q$YEU1- #QJC 2           5'AV3W#"LNQ7,K2
M^2.Z8EDECR>VOAJ)J25EPL-SI;K1OBJZ9S*BED;44C5;)&J/8O%JHJ(1=!62
MVZOHKA JI-0U=-60JU[F*DM-,R>-4>Q4>Q>=B<4XIY@#WQ[9<J&\VVWWBV5#
M:NVW6AI+E;ZIC9&,J:&NIXZJDJ&LE8R5K9H)6N1'-1R(O%$4V:89HZB&*>%R
M/AGC9-$]$5$?'(U'L<B.1%1'-<B\4U (XY     #SM?M<'@UW/#<UN/BH].V
M+S5>#9S56JU]7N+6.W(C,*S=[:&Q8UOA%3T3$C9CN>*V"W9!(K&+3WY(*R1\
M[[K4.I\5?7)L%-07"7>C%:-S[=<GPPYW14T7"WW%4CIJ3(T9&FB4EST;%5+H
MG)4\LBJY9W*P#11,;8          !56#YSF>V688SN%MUE>18+G>&7JWY'B.
M98E>*_'\FQJ_VJH95VV\V.]VN>EN-KN5#4QM?%-#(Q[')JBD;;;E<+/7T=UM
M-;5VVY6^HBJZ&OH9Y:6LHZF%R/BJ*:HA<R6&:-Z:HYJHJ* ;\?A4_;$[(VSX
MWLQXI^-7*FNU$VCM-OZMMKL=6Y45TIT1(OKV\VU5C@;<:"NIV,YIKMBL%8E6
MY[6_>:!625$N3397KTIT@I,?WHHYF3QI'!%G%FI>^CF;]'O+_9:=J2Q2,1-7
M3T39.=51/J[=%<X#=IZ>.J_IFZM,0BSSIFWYVIWSQ5T-/+4W+;3-K#E,EH?5
M1MECHLCMEMK)KMB]V8UZ))17&"EJX7?-DC:Y%0R'XKFV(9Q0-N>(9+9,DHE:
MQSYK1<::M6!7HBI'5PQ2.GHYT1>,<K62-7@J(H!V"*H       ,3'7%XX7AF
M>'Y0WFFWRZF,/OFY%ICJF,V-V=JJ3=;>2KN5,QLC;-78MC%9-08-653%7N9L
MHKK#02*U4^L(O!;(;C=1>T&U\=0S(\OH*F[0(]$QRPO9>[_),Q$7ZO)14<CH
MK=(]/HNK)*:-=/I 'G5^,?\ :0>J;Q0H[OLS@%#6=-/1XZL5';4X_?):W-MU
M(*=S4I*S>O,Z-E%'=[>LC%J(L=H(H+-32/:E2MRGIZ>L;BHW\ZL\SWD2?'[9
M')B.!K)QLE+4K)<;TUFG))D-PC2-)XN9.=M+$UM.Q53G[YS&R(!KA'4T
M       [3]%71[O-UZ=36U72OL/9/OMN!NED$=M96U+94L>(X[2,=7Y5G>55
M<3'NH<7PZPT\]=6/1'2R,B2&!DM1+#$^M-O<#O\ N7F%DPO&J?O[I>:I(4D>
MCOJU#21HLM;<JU[458Z.@IFNDD7BY4;RM17*UJ@>U/T2=(.U/0;TL[-=*.S-
M VFPG:'$:.Q??62EBI;IF.2SN?<<QS_(60ODC=D6<Y15U=SK$:Y8HIJE8HD;
M#'&QNP?MW@EDVTPRP83C\2,MUBH8Z;OE8UDU?6.59:^YU2-54^M7&LD?-)HN
MB.?HW1J(B =JBM0    #Q%_%RSZ;<[Q2?$-S.2H=505_65U$VVU5#TJ&ODQ[
M&-TLEQ;&5='5N6>%R8]9:5%C71(U3E1K6HC4UV]\[FZ\;S;IW!7*]LN?95#
MY>=%6EH[S64=)JCUYFK]5IV</-V:(G  QWEJP
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M:'H(MS:+8RHJD1$==\XO]>Y45RJO=45FM::\R:)HEN[&\//VJH!M;'=<
M               T _MSG_RN_P#IL_\ PCF,/Q'O_0U_ZP__ #& - ,QA@
M        'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O\ PHR3_OB  V?CN,
M
M                                               ><']MY_&GZ'_R
M?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP          #TN_L2_P"(+U7?E?U'
M\3&UQEW\/']S+-OP[=^U^S &YZ9 0                      "WNZVTVV.
M^FWN4;3[RX!B.Z&V>;6U]HRS!<ZL-NR7&+];W/9,V"XVBZT]323.IZF)DT,G
M*DD$\;)8W,D8UR2N]V.SY):ZVR7^UT-YM%QA6"NMMRIHJNCJ8E5'(V6"9KV.
M5CVHYJZ:M<B.145$4 \S_P ?O[--D70;1Y/U?]$M'D6?]'\=5/<]Q=MJF2NR
M'/.FR"KGD?\ ?)MPD^LW+,MF:-SVQ??.H=)=+(Q6??!U3"DEP3$-U.](M7MI
M'69WMY'57/ T>Z:ZVAZR55SQ%KW*O?=ZO/+7V!BJB=\Y5FITT[U7MUE -0DZ
M*             'H4_8YO%-JLDL>7^%KO'D,U3<L2H;]NQTH7"Z5+7NEQ5:E
MURW7V?I7RR,D5U@N%8[)[1 QLSW4M3>>9\<-'3QKE*Z"=YWU=-7[,W^J<^:A
MCJ;WA,LS]5=1<ZRWNPL5RHO]RRR?7(&HCE5CZC54;&U #?/,EP      !IA?
M;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_8E_Q
M!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("     >*_P".5>ZC(/%]\1.O
MJ8H89*?JFW-LC60<_(ZGQF[?L;I)7=X][N^J*6U,DDX\O>.=RHB:(FOEU'5#
MJK?;=61[6M5N9WBG1&ZZ<M)/]48Y=55>9S(45?-JH!BG+*           'IE
M_8G,9^J^'CU19CW-O;]_NL^]XSW\<>EUD_8EL?LQ=>YK9?J[>>WP_LUUIF]Z
M_EDDG7D9S:OR^>'E1\FU>95_+%_=.X%11\R)^CK]1QS'YN61W*FL3?OA\Q.9
M=%5W!->(&Y:=_                       #'5XOEFH[]X4WB34-<LR0P="
MW55>6+ ]L;_KF.;)9KD-O1SG,>BPNK[7$DC=-71\R(J*NJ6IWVIXZG93=N.3
MFY6[;YK4)RJB+WE)CMPJHM55%^;WL*:^E #Q'#7=             />"Z6[Q
M49#TR].E_K*QMQJ[YL3M%>*JX,6%S*^HN>W^/5L]8U:=&P*VJEG5Z*Q$9H[A
MPT-E/#)WU6'XI522)*^IQJQ3OE3ETE?-:Z61TB<NC='J[7APX@%]BI0    "
MF\RP[%=P\1R? LZQVSY=A6:X_>,4R[%<AH*>ZV'),:R"WU%JOEBO-LJXY:6X
M6NZVVJD@GAD:YDD3U:J*BD)7T%%=:&LMERI8*ZWW"EGHJZBJHF34U72543H*
MFFJ(7HK)89X7JUS5145%T /*6\?[[/\ ;D^&9N+D74%L!C]ZSCH*S>_.JK->
MJ-M?>;OTYW6^7%D-#MIN54U$]=<9<9=6U<=-C^1U#WLK4='1ULC:_NWUN%+J
M>Z8+OM!=JO*,8I:BX[9W&I5]/41I+43XI-4RHV.T7=[W22K1K(]&4M6Y5235
M(Y%2719 -90Z?@            %589G6;;<9#0Y=MYF.58'E=L=SVW)\,R&[
MXOD-O>JM<KJ&]6.KH;E2.5S$76.5JZHGH(VWW*XVFJCKK57UMLK85UBK+?53
MT=5$NJ+K'44TD<K%U3S*@!E>VG^T!^,MLO34U)AOB![Y72"D;&R!-TIL2WTD
M1D4"T\;9)][L7W"GG:D3N*2.<BN1'+JY$5+V63J?W^Q]C&4&Z&1S-8B(W[\N
MH<D71K>1$5V14=T<Y-/2J\>/: =K:3[5SXW--2TU/-U,X17S04\,,M=5].NP
MC*JMDBC:Q]74LH=OJ*B945+FJ]Z0PQ1(YR\C&MT:E;LZV.HAC&,=E]ME<UC6
MNE?BF,H^16HB*]Z16N.-'O5-5Y6M;KV(B< "D\M^U(^.%E4+J6+K&H\5HY:=
ML$\&); =.%MFE<R?OTJ6W6KVFN-\HZA=$8JTU5"Q6)HK>+N:!KNLSJ+K6JQN
M>QT4;F(US:'&,3A<Y4=S<Z3R62:IC?YOF/:FGF[=0,<V^GBB>(SU+T];;]\N
MMSJ:W L-QA2"NQ&X;O9E;<%J8N1L;DDP*PW2U88KI&-1'N^H\TGYY54M1DF\
MFZ^7LDBR/<3,+I32MY9*&6^U\5M>FB(NMLIIH+?JJ)Q7N]5\X!T/+:
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MK^*^=0"RQ3P
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MH5_<#M_X49)_WQ  ;/QW&
M
M              /.#^V\_C3]#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
M         !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M           #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MBH8ZIH9J>:6GJ(I()X)'PSP3,=%-#-$Y6212QO1KXY(WM5'-5$5%310"!.,
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ME371-9&NJ?KM;65G)W?UNJJ*GN^;G[OOY7R\G/RLY^7FTUT37T $@(4
M                                              V/?LH'^VUZ<?P
MZB/XCLX.V71+^,/BG_ZKRK]KMQ /6[,XP    !YP?VWG\:?H?_)_W"_C%@,3
M?B)_X:;=?@O=/U6: :09CK           /7Z^RX_["CH9_Z3/_OA]01G:Z-?
MQ;=N/_+#]OF4 &?X[/                   &@']N<_^5W_ --G_P"$<QA^
M(]_Z&O\ UA_^8P!H!F,,           ]7K[(;_L;<+_* WV_5RUF;+H5_<#M
M_P"%&2?]\0 &S\=Q@
M
M         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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M$0           >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M    >*CXW5OK;9XNWB+TU?3R4L\G5IO!<&1RHB.=17;**NZVZH315_0ZRWUD
M4K/2QZ&O=U$Q21;Z;K-D:K'+G%]E1%[5CFK'S1.]A\4B.3U* 8M2S
M    !Z>/V*:MHY/"_P"H2VLJ875])UZ[CUM31MD:M1!1W#IZZ8X*&IEBUYF0
MU4ULJ&QN7@YT+T3Z*F8CP]I(UV<RF)'M65FYEVD?&BIS-CEQ;#VQO5.U&O="
MY$7SJU?0 ;@YWP                       ,?GBS310>%AXE;YI8X6.Z!.
ML.%'RO;&U9:CIZW#@@B1SU1%DGGD:QC>USW(B:JJ%K][W-;LONZKE1J?YL<\
M;JJHB<SL6NK6IJOG<Y41/2J@'B%&NN             >[)T96>BQ[H^Z4;!;
M6R-M]CZ:]B[/0-FD665M%;-K\6HJ5LLJHBR2)! WF<O:O$V2MOX(Z7 \)IHM
M4BI\1QN"-'+S.[N&S44;-5\Z\K4X@'90JX       H/<[=';?97 LGW2W=SO
M$]L]N,+M<]ZRS.,XOUMQK%\?M=.B=Y672\W:HI:&EC5SD8Q'/YI)'-8Q'/<U
M%EEXO-IQZV5EYOMRH;/:;?"ZHKKC<:F*CHZ6%O;)-43N9&Q-5T35=5541-54
M T6/%(^V.T%KFR3:'PL\/I;W4,;<;14]6&[F-U+;5#*J.IXKOL_M%>XJ:HN#
MHM>^IKCEL$</.WDELDT:H]<;V\O7O%"ZKL6S% RH<B2P/S>^4C^Y:[BUL]AL
M50UCI=/I,EKFHW5-'4[DX@&A[O9O?NWU'[IYEO;OKN!DFZ.Z^X-T^_.89SEE
M<M?>[U7-IX**G[V1&QP4U'04%+%34M-!'%34E+#'##''%&QB8U<BR*^99>J_
M(LDNE7>;W=)N_K[C72=[45$B,;&WF71&LCBB8UC&-1K&,:C6HC41 "UA)0
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ML@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';!/\ C9!^LP _H3'7W_.NZ/\
M^^=Z/]%H_P!7CN;_ ([8)_QL@_68 ?T)CK[_ )UW1_\ WSO1_HM'^KQW-_QV
MP3_C9!^LP _H3'7W_.NZ/_[YWH_T6C_5X[F_X[8)_P ;(/UF ']"8Z^_YUW1
M_P#WSO1_HM'^KQW-_P =L$_XV0?K, /Z$QU]_P Z[H__ +YWH_T6C_5X[F_X
M[8)_QL@_68 ?T)CK[_G7='_]\[T?Z+1_J\=S?\=L$_XV0?K, /Z$QU]_SKNC
M_P#OG>C_ $6C_5X[F_X[8)_QL@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';
M!/\ C9!^LP _H3'7W_.NZ/\ ^^=Z/]%H_P!7CN;_ ([8)_QL@_68 ?T)CK[_
M )UW1_\ WSO1_HM'^KQW-_QVP3_C9!^LP _H3'7W_.NZ/_[YWH_T6C_5X[F_
MX[8)_P ;(/UF ,LO@H_9C^J'PT>OO >KK>;?G8'/\4P7"=S+%2XYMG4[C+D<
MU[SG$:[$J2J>S*,$L=KEMM+1W:H=*GUEDB/Y%:CM%:M[NGKH^S+:'<ZV9S?\
MFQBZ45MMUXIF4EH==?K;JBY4,M#&]4K+;3PK"QD[E7YZ+KIIKV &ZN9"0
M #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_QV>
M     - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0#,88          !Z
MO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
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MMK-I]L*MC7-95;>854L:_3F:V?&[9*UKM%5.9$=QT734 [M%PP
M                                  #S@_MO/XT_0_\ D_[A?QBP&)OQ
M$_\ #3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=
M&OXMNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8
MP_$>_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O
M[@=O_"C)/^^( #9^.XP
M
M           !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M        #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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M*ZV[XPW'DTCR'#;%<>\1%Y72TE1<K+(Q5TT61D=LC54\S7-](!JE'2@
M      WL/L/6Y4=NWC\0/9^2;67,=L]B=RJ2G=J[ECVURG<3%[A-#K,C8^=V
MZ]*V72-5?RQZN3D1'9)/#HNZ17_="PJ[C7V?&[NQJZKHEHK;K1RN;\[1NJWM
MB+PXZ)QX 'HD&50                       US?M6>Y,> ^"?U)69*KZG7
M;KYIL)MM;9&SN@FED=O+AN>W2E@Y7M67ZYCF!UL4K/G(ZG=)JFFJIU1ZUKNE
MKZ><MI^?NY;W<,9M$*H[E<JK?Z"YS,;HJ<W>4ELD1R>=JJ >1R8-0
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MA+6MGWQW6HU:K$?G.07%C51$Y8[Q7RW>)&HC(T2/NZY.5-.#=.*]J@8P2S@
M         ![6O@FY8[-/"-\.:\/J9*I:/I$V5Q-)9::*E<UN!8=;L%93)%"R
M-CHZ-F.)"R14YYF,21RN<Y7+L*=/%<MPV,VHG5ZO[O!<>H=58UBHELH(K:C-
M&HB*D:4G*B]KD35=54 RAEY
M        #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
M    >OU]EQ_V%'0S_P!)G_WP^H(SM=&OXMNW'_EA^WS* #/\=G@
M         #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\ ,8 T S&&
M   >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #9^.XP
M
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M1R/2.+*K%?\ &WO<J(WF6E9?:9CE5>V:LL4;&^E[D0 ]9TS>@
M           &DM]MMWMCQ[I%Z.>GB"N[FMW4Z@\JW8JZ2&H='-4V?97;ZKQA
M8ZN*-Z++;WW7>RGE1LB*QT],QR?.B16X\?$0R)*7!<"Q5LG+)>LIK;W(QKM'
M/@QZUOH^5[475T2SY"QVB\%<Q%[4 /-P,2H          !G[^S#;*2;T^-+T
ME]_0NK;#M,_<K>O(GM9*Y*"/ ]MLG7%*YZQJU&-CW'NED9JY4;K(B+S*J-=V
M=Z.\>7(>H+!^:-9*:QK=\AJET<O=I;+36?4I%TTT1+M-3IQX<?/V 'K^F=L
M    \BK[2AXIEQ\1GKSR;#L$R!U9TO\ 2G<LCVDV:I+?7R5%BS#(:*Y?5-S-
MXFM:]U+539M?K8RDMT\?Z&['[90/:C9)9U?@QZM]YY=U]RZR@MM4LF'85-5V
M.P1Q2JZFKZJ.;N[O?M$7D>ZX5,*,B<G!:6&)4T5SM0-=PZJ@      &\Y]BC
MZ.\?S'>7JGZW\LM,=;7;+X_C&R&T-34PQSP4&3[G07>][FWZB5[>\H[Y9\.L
M=MML4K%^=0Y%61JFCN.1[P]<"I:^_P":;BUL"22X_2T>.V)[VHYL59>&SU%X
MJ8]4UCJ8*"FAA14[8ZJ1/. >BX96@
M           #R7/M9^T#ML/&?WDR=M)]3HM]]J-B]WZ"-E/%34TK:? Z/:"Y
M5=,V%K&R?7;]M+62SR*G/)5/E<Y5555<('6_8EL_4#?ZQ(^[CR6R8W?8D1K6
M,<C;9'8II&(U$1>\J;'(KE[5>KE4 UJCJ,           >O)]EHW+AW%\$OI
M1HUG;/=-M+MO?MI>E;P2*:T;VY[?K) K=/FNBP_);8B\5YE^=PUT3.GT97=M
MUZ>,)CYD=-:)\BM%1I^==!D5SJ:=NGI2@K(=?3V@&PH=I0
M                              #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\
M#3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=&OXM
MNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8P_$>
M_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O
M_"C)/^^( #9^.XP
M
M       !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M    #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                ..::*GBEGGEC@@@C?---,]L<4,4;5?)++(]6LCCC8U5<
MY51$1-5/QSFM:KG*C6M17.<Y41K6HFJJJKP1$0 \.SQ+NH^EZN_$!ZP^I"UU
M[KGC>Z_4%N3D&#UKT<CY=N*;(JNS;:L=SLB=S4^ VNVQKJUJZL[$[#7.W=RQ
MF=;H9YEL,BS4E[RB[U5ND775;2RJDI[0BZHBZMMD,2=B=@!T>+<@
M  &?;[,!C'[*/'&Z)(Y:6HJ*&QU&_63UTE._N_J?WBZ9=Y:NU54[NWZO^R'Z
MG&Y.//WB-[%54[.='-']=ZC=NT<Q[XZ9^35DBM73N_JV(7]\#W+_ %'UKNT7
MTZZ 'L!&=P     TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M          #TN_L2_P"(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
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MRO35$7@;(5'5TUPI*6OHIF5%'6TT%725#->2>FJ8FS03,U1%Y)8GHY-41=%
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M,L%V?;6V2RR,>Z.>*Z7^>*TP55,]KF*E1;8JI]4WC_VCS]B@>+L:_(
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MJY%;&4:,C:JZ]W'48Z]RZ<$=+Q[0#=I,AP
M                  !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;=?@O=/U6
M: :09CK           /7Z^RX_P"PHZ&?^DS_ .^'U!&=KHU_%MVX_P#+#]OF
M4 &?X[/                   &@']N<_P#E=_\ 39_^$<QA^(]_Z&O_ %A_
M^8P!H!F,,           ]7K[(;_L;<+_ "@-]OU<M9FRZ%?W [?^%&2?]\0
M&S\=Q@
M                                                          #S
M@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K\%[I^JS0#2#,=8          !Z7?
MV)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M        &OG]I4\1N@Z /#;W%LV,WV&@W]ZKJ&_]/^S5#3UOU:]VZWY%:'4N
MZ^Y%"R&6*O@AV_P:YO9!6P__ &G?KK:N9425#J[U<[L1;8;27:GHZEL63YM'
M58O8(VR<E1%%5P<E[NT:-5)&MM=MF5&R-^A4S0Z]H!Y"9@I
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M<T5*_'+W<K+4KIRMDDMU7+3=_'Q5%AJ&QH]BHJHYCD5%5% +'%.
M  'K??9;>N.#K"\*[;'"+]>)+ANKT@UB]..;0U=0^:NFQ3':2*X;-7QC99)9
MOO7-MK5TEHCD<[]$K+'5Z(C6HAG'Z,]QFYYLO9[=4U"RWK!)/V)W%LCU=*ZB
MI6)+8*E$<JN[EUH>R!%5>,E,_P! !L=';$                   H7=#<G#
MMF]M=P=W=Q+Q#CV ;783E.X>;7VH170V;$\,L==D60W.1K?G/;0VFW2R<J?.
M=RZ)Q4EMYN]!8+1=+[=9VTMLLUNK;K<:EW%M/0V^FDJZJ943BO=P1.73M70
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MEO-'4R1(J\7SQ0QIQ<@!Z=AF&
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M #/\=G@                  #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\
M,8 T S&&           >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #
M9^.XP
M                                                         !YP
M?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK           /2[^Q+_
M (@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M    .O?5-U3;%]%^Q>>=1W4=GEKV[VIV[M;KA>[W<'++5U]7*O=6K&\;M46M
M=D669%7*VEMUNI6OJ*NH>UK6Z:JE+9IFF-[?8W<\LRRYPVJR6J%9:BHE7626
M1?FP4E) W]$JZZKDT9%$Q%>]ZZ( >.KXOGB@;F^*[U@93U"9?3W#%]N+)3R8
M1L'M945C:B#;C:VWU]556ZGK6T\CZ"IS3)JFH?<;[61\W?5DJ0QO6DI:6./
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M6FJ;]_,U6.KO;8U_1*'%:*H1[6/5-%C?>KG V-NBKS003M<FCDU \S(Q!
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MBFBD:CXY8I&*YDD<C'(K7(JHJ+JAW_:YKFHYJHYKD1S7-5%:YJIJBHJ<%14
M.0_0                                      "C]P\#QC=/ ,XVQS>V
MQWG#-QL/R; \NM$VG=77&,OLM;C]_MLNK7)W==:KA+$[5%31W80%UMM'>K9<
M;/<8DJ+?=J"LMM= [LFHZZGDI:J)>WA)!*Y/; /#&ZP>F_*^C_JFZ@.E_-6U
M#LAV+W8S3;F>NJ(/JRWVW8]>JJEQ_*:>%%5&V_+<>2EN=*J<'4U7&[SFN%GF
M)5N"9GE&'7!'+58W>[A:72/;R?68J6H>REK&M_\ K5=2\DS/2QZ '7 I,
M      JC",URO;;-,0W%P2_7#%LXP'*+!FN&Y/:9?J]UQS*\6NU)?,=OULG5
MKDAN%HN]!#40OT7EDC1=",MUPK;1<*&ZVVIEHKC;*REN%OK('<L])6T4[*FE
MJ87<>66">-KFKYE0 ]KGPIO$"P;Q,>A_9GJDQ2IM=/E%]L<&,;T8?;IVO=M[
MO9C-)24FX6*34RS355);WW*1MQM"S\LU38KA15+FM[[1-A793="W;O;<X_F=
M$^%E94TS:/(*")R*MKR*C8R.Z43F<SGLB694E@YOG/II8WK]( R+EUP
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M;]7+69LNA7]P.W_A1DG_ 'Q  ;/QW&
M
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M[*PWVGB1\V&Y1:KK4/1G,]MLN,=38JEK=$5R-6MN-*]WF1L>J]G #ROS"^
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M
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M999Y9)YY))III'RS32O=)+++(Y7R222/57OD>]5555555750"#.,
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M6XS;<SQ?(,3N[.>VY%9Z^SUFB(KV0U]-)3K/%KIRU%.YZ21N145KVHJ*BIJ
M>'IU6=->Y71YU'[S],&[UM=;-P]D\^OF#7]$AFAI+HVVU'/9LGLZ5#6RS8[F
M%AGI;K;)E32HM];#*G!Z&NAFN(W? LLR##K[$L-UQVYU-MJOFN:R9(7:T]9!
MS:.=2U],YD\+OST4C5\X!U^*7
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M_84=#/\ TF?_ 'P^H(SM=&OXMNW'_EA^WS* #/\ '9X
M  T _MSG_P KO_IL_P#PCF,/Q'O_ $-?^L/_ ,Q@#0#,88          !ZO7
MV0W_ &-N%_E ;[?JY:S-ET*_N!V_\*,D_P"^( #9^.XP
M
M                                    !YP?VWG\:?H?_)_W"_C%@,3?
MB)_X:;=?@O=/U6: :09CK
M              /IC'2.:QC7/>]R,8QB*YSW.5$:UK415<YRKHB)Q53]1%54
M1$555=$1.*JJ]B(GG50#UNOLSWA3U'AP=#E+G6ZV-.L_51U7ML.Y6[5+<8'Q
M7G ,+IZ.IDVJVAJ8IFQR4%=CEGNU1<[Q Z*.HAOEWJ:29TK*&G<W.-TA[*OV
MFVY9<KW2+!FF;?5KO?&2M5*BV6]D;ULMB>CM%CDI()W33M5$<VIG>QVJ1LT
MV/#MB       :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$,1
M       !Z7?V)?\ $%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
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M"*-B+WM?8.9ROX<TE(YWSOT"-C@/-$,1
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MH_7L=5NCT5>ZD: >F(9>@        #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M6GB3?OGDFUCZVUL9'+4K6[?WQM)! K$D<Z6LLE93K1OY'\5E<J,>FCFZHK5
MS ^&!]K"Z,>MG),:V9ZF,<DZ+]]\BJ*>TV"LRC)Z;)-@\XO<[HZ>DMUHW/FH
M;#5X1?+O/S.AH<AH:6A:YT=-#=:NJDCC???9SK;V_P!PZNDL&7TB[?Y+5.9!
M2R5E8RKQFXU#E1C(H+PZ.F?;JF=VJMCJHV1IP8V=[U1% VMCNN
M
M                             ><']MY_&GZ'_P G_<+^,6 Q-^(G_AIM
MU^"]T_59H!I!F.L
M        W&/LK_@EUO5ENY9O$+ZDL1D_DQ;%Y8VHV4QJ_P!"B6_?C>O&*[GC
MNZ4=4Q4NVV>T=WIFRUDJM^J7/(8HJ!'3QT5VIF=]NB_IXDS>^T^Z>6T*_L.Q
MNNYL>HZJ/]"R7(:.35)^[>GZ/9['.S61=.2:J1(M7)'.Q /3@,P0
M!IA?;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_
M8E_Q!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("           :2GVLCP7
M'[ZX#6^)GTUXDZIWCVGQV&DZHL2L5$LE=N5M%8*2."V;J4M+3:/J\NVEMT'<
MW1>[DEK<8:QZR,2SQQSX\.MSI]7)+9)N_B-"K[_9*5L>94--'K)=[%2L1L-Z
M8QG%]=8XF\LW!724:(NJ=PB. \W(Q+
M         &\)]EL\!BNWARO#/$PZP,+DI]G<,ND-_P"E7:[)J%\;MU<TM-1'
M-;-ZL@MM7$G/MOAUPB[RP0O1/OW=X&U:_P#@^DC;<LB_1GTT27ZMM^[V>6]6
MV&WS-JL*LU9&J+>KA ]'0Y#50O3C::"5NM*U?_MB=J/_ +$Q$E ]'0RP@
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MLE/2[BX]2,=71M5(X\DM<:1PI?Z.)=.2I9*Y&5L+=6LD<V1FC).2,#9@.W@
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M>][U5SGN<JJYSG*JJYSE7557BJDL555555555=55>*JJ]JJOG50#Y/P
M          RT>#KX3N\'BT]4UIVAQ!MRQ;9?"IK1DO4;O)%3L=1;<;?U%7,U
MM!:I:F"HHJW<;-DH*BCQZ@<R5)*ADM5,SZE1U<D=\-A=D;]OAF<%BH$EHL?M
MSH*O++^C$[NTVM[W?H4#GM?')=KCW3XZ6)475Z*]R=W&]4 ]C;8?8S:SIGV<
MVXV"V2Q"VX'M3M1BMMP[",5M37?5[;9[9&J))45$KGU5RNURJGR5=?6U#Y*J
MOKIY:F>22:5[W9[,:QNRXA8+3C&.T$-LLEDHH:"W44*+R0P0IVN<NKYIYGJK
MY9'*KY9'.>Y5<Y54"[1/         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M7WRRI?JIU!8[C;)\6DU5M5)>K)7.8E,B*Z58>9O!($50/09,HH
M
M                          !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;
M=?@O=/U6: :09CK
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M,1           !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M!#2TE+#%34M+31,@IZ:G@8V*&""&)K8X888VHUK6HC6M1$1- ":',
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MZ)(]%>YK$CA:YRI'''&C6- L$4P
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M5YFQ2/1.2EN]+&Y$J*=='-=\YO-&YCW 8FRR(
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M_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_I,_\
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MUXFPC(HT8SE5'UU!&Z65?S\E2Y55550#T-S*<
M
M              ><']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M                                             #DBBEGEB@@BDFGF
MD9%##$QTDLLLCD9'%%&Q%?))(]41K41555T0_6M<YR-:BN<Y4:UK457.<JZ(
MB(G%550#<>\&#[*9O5U15^*]0WB*6?*NG[IQ9-17NP[&5+:K'M]MZJ%G<U,$
M.0TKE@NFS& W+F5DTU4V/)JR%CVTM-0LFIKHG?CI^Z*<AS*6BRG=:"MQ?$T=
M'44V./1]+DN0QIRO:VJ8O+-C]LFUT<Y^E9(U%1C(T<R8 ])C:W:S;?9';S$-
MI=H<(QG;?;/ ;+2X]AN#X=:*2QXWCMFI.98J*VVRACB@A:^61\LK]%DGFD?+
M(YTCW.7+99;+:<=M5#8[%;J.TVBV4[*6WVZ@@934E)3LUY8X88T:UNKE557M
M<Y5555550"OB9@          &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:
M_>0#S1#$0           >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#
M<],@(            !(<IQ;&<YQG(,+S3'[+EF(999;GC>48ODELHKUC^1X_
M>J*:W7BQWRSW&&HM]TM-TM]1)!44\\;XIHGN8]JM54(:MHJ.XT=5;[A2T]=0
M5U/-25E'5PQU%+5TM1&Z*>GJ()6OBF@FB>K7-<BM<U514 /,W\?'[,KF_1O5
MYAU<]!.-Y%N/TE.=5Y%N%M%1NKLDW$Z<87NFJKE<K:SDGNV;;*VUOSDK5=47
M:P4W_P!T._I89;DF(3J:Z/[C@,E?G.V=)57;!U5]5=+%'WE7=<3:O,^:6)-'
M3W''HDX]Y\Z>F9_9>9C73 &G:="P                            ".ME
MLN5[N5OLUFM]==[Q=ZZDMEJM5LI*BON5SN5?41TM#;[?0TL<M56UU;52MCBB
MC:Z221R-:BJJ(<D,,U1-%3T\4D\\\C(8((6.EFFFE<C(XHHV(Y\DDCW(C6HB
MJJKH@!OG^!?]E,N=SJ\2ZLO%.P^:U6BDFH<AVUZ,[U C+C>98W1U=OOG4?3O
MU=;;3&J(]N&(GUFJ<J-O#H8F3VNIR7]-_13--)0YOO/0.A@8Z*JM& 5#=):A
MR*CXJG+&+_8H$[4M_P!-Z\)U:B.A>!Z!]NMUOM%OH;3::&CM=KM='36ZVVVW
M4T-%;[=;Z*%E-1T-#1TS(J>DHZ2GB;'%%&UK(V-1K41$1#*#%%%!%'!!''##
M#&R*&&)C8XHHHVHR...-B(QD;&(B(B(B(B:( 1AR           $ARG*<9P;
M&<@S3-,@LN)XAB=EN>291E&27.BLN/XYC]EHIKC>+Y?+Q<9J>WVNTVNWT\D]
M143R,BAB8Y[W(U%4AJVMH[=1U5PN%53T-!0T\U765E7-'3TM)2T\;I9ZBHGE
M<R*&"&)BN<YRHUK4554 \YOQN?M7&X&\EQR[I@\,7([UMCLW3S5]AS/JLHTK
M[%NENDR.1*::FV>;,RDNFUN"S<DBI=WMCR2YL?&L/WIC9*RLQ1=1/6O=+_+7
M8=L]5U%GL#'2TUPS6/O*:\WE&KR.984<C)K-;7:+^CJB5<R*G+W"(J2 :2-7
M5U5?55-=75-16UM;435=965<TE355=54R.FJ*FIJ)G/FGJ)YGJ][WJKG.555
M553'@][Y7OEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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M4.1P0M5M#4IJC6SHB4TZJG*K7JL30-?8ZN@
M     &=KP<_ 6ZIO%CS"ARNDI;ALOTC6.\+2YWU%Y%9Y9*2[OH*IL5TP_9^S
MU3Z3]G^:)R/BFEC>VTV=S56MJ&S+!25/9/83IGS/>ZOCK6,EQ_!J:?DN65U=
M.Y8YUB?RS4%A@>K/OI<$T5'.1>X@7^R.1W*QX'JR=$G0UTU>'KL+C/3KTN[?
M4.$8+86MJ[O<Y64M9FFX>4RT\-/<\\W)R>*DI*K+,RO#:=C9:F5K(J>GCBI:
M2*FHJ>GIHLUFW>W&([6XS1XIAMKCMUMID1\\RHR2X76M5K6S7*[5B,8^NKYT
M:FKU1&M:C6,:R-K6- [=%<@            'G!_;>?QI^A_\G_<+^,6 Q-^(
MG_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_ *3/_OA]01G:Z-?Q
M;=N/_+#]OF4 &?X[/                   &@']N<_^5W_TV?\ X1S&'XCW
M_H:_]8?_ )C &@&8PP          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_A
M1DG_ 'Q  ;/QW&   -#'[<+LY>J[!/#^Z@:&CF=CN+9=OILYE%>O>NIX+UGM
MFV]S; Z-NC>YAFJJ';?(WKJO-(V%-$T8IC1\1>P5$EMVORB.-RTM'79)8*R7
MBK&U%SI[7<;9'_4M<^.TU:^E4;Z@#=.Z4M_,8ZINF;8/J/PVNH[ACN]VT>!;
MET,M"]'14TN68W;[M<;3,SF<^EN%CN=1-155/)I+355/)%(C9&.1,@V$Y-1Y
MIA^,99021RTF16*V7>-8UU:QU=213RP.3559+33.=&]B_.8]JM7BB@'DT>#1
MT";&>)3XK63],'4169Y0[;W6U[_YE53[<7^W8UDR7?$*^6KM38KI=;#D=(RC
M=+4.[YBTRN>FFCFF$38+;'&]W-[*S#LJ?<H[1/#E%>]UIJHJ.L[^AE=) C9I
MJ:K8D:N<O,G)JOI0 [<?:1? LVI\*";IRW5Z7*O="^]/^[4>1[?9C4[F7VU9
M3=<5WBL3ILCLT"WRT8[B]-';\YPJ:H=14BTSY&28]6R+*J2-:VN>K3INLFR3
ML3O6&/O-3B]\2KM=>^[U,-;-17ZF5U73M^LP4E&Q(KE;W/6-G(JHM+(NO%$0
M#T O!!W0Z<]YO"\Z2MQ>F+;3 =G<$O>W-+191MIMW;*:UV?$MWL8GEQ3=R@K
M(F,9<J^Y3YU8ZRH2X7%7W"Z4DT%9,^3OVR.R?=.MYQ2_[-X/=<.M%LL-MJ+2
MR.LM%JA9#!0WVC<M%?(I$1$FEF=<J:1W>RZRS1N;(Y5YD50-3OQ@-T&]2OVK
M_P ,O9K;.#[_ %PZ6]S.B+'<UAHECJ5@O=CWSGZG=P:ML\#7?W/CFU>044E1
M&JN6GFHZA'*UW,UO23?>\_LNZVMH+!:&_69<,O&W=+<&QZ/Y:BGR-V871_,U
M%^9266JC5Z?G71NUTXH@'H0F4<
M
M   \X/[;S^-/T/\ Y/\ N%_&+ 8F_$3_ ,--NOP7NGZK- -(,QU@
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MU;+E5UIV,^IN>UK966&V=Y/3VB-VBIWG-+5*USFK-R+R@&?0[-@
M   'R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-:U$U55X(A^*J(BJJHB(FJJO!
M$1.U57S(@!Y>_P!I9\?&^];6Y.5=$'2=F\U'T9[9WYUHW#R_&:Y[(NIW<'':
M]%JJQ]RIN[6NV9Q"\TO)9J6-[Z.]UM/]]Y'5$7WL2EPX]774U4[AW>MVZPBX
MNCP"T5*P76OHY51,PNE)+\^196:=Y8*"H9I3L15CJ)&]^JN;W/(!J(G18
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M.:JM1'-5%3@4_/3STLBPU,$U/,U$5T4\;XI&HY$<U59(UKD1R+JG#B@!+3A
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M9EN^"9)(V'^Z4MK[A&ZWW-(?T:6SU]7$S1TB*6JWJVQH=WMN,APBJ?%3U5=
MRKLM?*Q7MMM]H7=_;:M4;\](5E18IN7YSH)7M3BH!IA^ +XQ&0>$[N?F_A >
M*31W39+#<,W(OU!MKN#F[)**V;!YK?Z]]TO6&YO5.C6G39/<6Z5_W]LV30N?
M04-1<Y*N:62TW!*RW8_^F+?FJV1O-QV)WFCFQV@M]VJ8[1=+BBQPXS<*J19J
MB@N+U3E3'KK-)]9IZQJK%&^97N58)>\B S.^$S]FYL_AY];E/U]8_P!=5MZA
M[%D>([E4MGPRS=/]+A=IN5MW:CCJZ*]VW<6BW^W#H[C0T%.]KXG16QT=:QR.
M:^-%0[ ;(])<&UNXK=SJ7<F'*J:KH;NR"WT^+LM\$T-\1'QU$-UCR>ZQRQQ-
M5%:K8=)$75%0 S0^*9X>&!>*+T9;C=(^<Y-^P"HRBX8QE&";GQ8TF85NV>>X
MC>8+C:LKHL9=?\69>^_M;ZVUU5,MPI.^M]RJ&-EC>K7M[ [S[5VS>3;^[8-<
M:S[UNK9:.LMMX2D^OR6BYT-0V6"MCH_K5$E1S0K)"]G>LYHIG(BHNBH!K%V3
M=3:K[(WTG]0?3[<NMK&>NC?O>J]4&Y'3ITNTFST^U]WVNS^Y8U^QV_[C;J3V
M[>W=-;1M3?J"@L=2M+,VS7"YRVE\5N=/]8J:FW]/*>]67H:PC*,7FW$H]R,F
MR&HBNV*8:RPNLT]FN<M)]5JKM>G19%>NXLM3%%3/Y')3RS.@5(N;G>^(#HGX
M-W1)U/V/I8\3G[0CU#WW)K5U&7/I"ZV=R^D++<EMM/%E5=N->-GMP<MRSJFB
MM]91LHJ2AJJ^%UIQF/ZO]2K*&IN$K:?ZFMODEMOL'MWF--A>\/5)E5360Y7-
M@FX=WP2NJXFMK9+K/8;I75V9I%(Q(V1OE:L%&G+W<D;Y7(WN^Z5P'HWF5\
M
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M<1Q_&V.9R2R6FUTE+55+45%UK*YD?UVM=P3YTLCW:(B:Z(@!V@*R
M           -7?[53T*=6/7OT>=.^W'2+LW>MZLUP[J5AS;);#9+UB5CJ+5B
MS=KL_L3KO+49AD&.T,T*7:[TT/)%*^7FE1>7E153IMUI[;9ON9@>*VG!;!49
M#<*#+FW&LIJ:HH:=T%$EFN=-W[G5]521N;W\[&Z(JNU=V: &B;_1O?&U_F$;
M@?P@[(?Z4#&U_),ZA_WLKI^FF._KR /Z-[XVO\PC<#^$'9#_ $H#^29U#_O9
M73]-,=_7D ?T;WQM?YA&X'\(.R'^E ?R3.H?][*Z?IICOZ\@#^C>^-K_ #"-
MP/X0=D/]* _DF=0_[V5T_33'?UY ']&]\;7^81N!_"#LA_I0'\DSJ'_>RNGZ
M:8[^O( _HWOC:_S"-P/X0=D/]* _DF=0_P"]E=/TTQW]>0#>R^RK="G5CT$=
M'G41MQU=;-WK97-<QZE9LVQJPWN]8E?*BZXL[:[ +$V[Q5&'Y!D5##"MVM%3
M#R2RLEYHE7EY515R2]%FVV;[9X'E5ISJP5&/7"ORYUQHZ:IJ*&H=/1+9K93=
M^UU!55<;6]_ ]NBJCM6]F@!M$'<D                   L?U!]-/3_ -5^
MW%TVBZDMGMO]Z]N+OJ^IQ3<+&[?D%!35G=20PW>S35<3J['L@HFRN6EN-!+3
M5](]>>&9CT1Q3F4XAB^;6F:Q9;8;7D-IGXOHKI2154;).56MGIW/;WE+51HY
M>26)S)6+Q:Y% -.SKK^Q<;"Y[47K,O#[WZO6PMYJ7255'LOOA]]MR-JFSO>K
M8[;8-QZ+O]TL/M,$.CN>YP9C5R2(Y%D:UR=WT,W)\/O&;FZHN&U^35&,U#U5
M\>/Y'W]VLJ.5=$AIKM'S7F@@:WCK,VO>JZ\41> &I1U8?9]?%NZ/JFXSYWT@
M;@;D8?0R3K%N+T\TZ;ZXE5T%/S=Y>*FEV_;=<SQ:UHC%7GOUHM+VMT5S$145
M>CN;]+N^.!OE=<L$NEVH(U=I=<6;^R2A?$S76=[+6DUPHH>';4P0*B=J &'&
MZVFZV*Y5MGO=LN%FN]MJ)*2XVJZT=3;KE0542\LM-6T-7'#54M1$[@YCVM<U
M>U"PDT$U-+)3U$,M//$Y62PS1OBEB>WM9)'(C7L<GG1410"7G$
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M%             /;)\&C=.KWG\*7P^L_N-1)672KZ5-H,;O%=,L;I[A>]O\
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MN:O:A82:":FEDIZB&6GGB<K)89HWQ2Q/;VLDCD1KV.3SHJ(H!+SB
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M?K]MFEIII:;Z[E^07&EYI:2:HIW=]15<<B<KUT1VBZ+JB 9CB_8
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M!]5I?JOU'ZM3_4OJ_P!5^I]S']5^J]WW/U;ZOR]U]7[KYO)IR\O#30 G!S@
M
M
M
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MQU$\3^+)HK?5LN+X'IHNK)TI>14\Z.\P![9!L-
M           'FE_:N_!9P+I*RK'_ !!>EG#Z?$=E=Z,TDQ/??;;'J!(,9VVW
MAOD=PO5FS?&*&E3ZOC^%[F1T=5%4T+(XJ&UWN!B0.1ES@I:;$5UL=/ELP>MI
M=T<+H&T./9!<%HLEM%+'RT=HOU2DM13W&CC9\VEM]W2-[7QHC8X:AJ<JZ3-8
MP#2[,?@          ![#'V92^/R'P..A&O?3MI5I[#OA8TB;(LJ.9C'4[O7C
M4=0KE8Q4=6,M*3*W31BO5J*NFJYX^D"I6JZ<MM958C.6FR*FT1>;5*/,,AHT
M?KHG&1(.;3S:Z &> [*@                %@]Z>E3I@ZD:-+?U"].>Q>^E
M&V-(HX-WMIL#W';3M:K'1K2NR^PW=]))"^-KHWQ*Q\;VM<U45J*E,Y#A6'9;
M'W64XIC>21Z<J-OMDMMV1J)HJ<BUU-.K%:J(J*FBHJ(J=@!BCW1^S2^"ANO4
M35]TZ(\9Q"YRS/F;6[7;C[Q[9T\"RO@=-'#CN'[@VO$4AD;3HU&NMSDA:YW=
M=VY[E6R=YZ1.GF]N=)-MW1T$SG*[O+-=K_:&MYE:KD;2T%TAH>549IHL2\NJ
M\NBJH!T9R_[&WX2&2\_WFR3K V^Y^XY?V(;R816]WW.O><G[/=H,WU^M:_HG
M-S::?,Y..MN*[H&V-J]?J]7G=KUY=/J-_MTG+R]NGWSL5Q^GY]=?5H 68O?V
M)[PYIZJ-^.=3G6O:J%*=C9:>]Y)L7?ZI]4DDJOFCK*#8W&H8J=T*L:D2P/<U
MS7.[Q4<C6T_4>'GM0YZ+29AN'!'R(CF5%7C=4]7ZNU<DD6.4;48K=$TY575%
M77CH@$98_L4/AK4\4Z9)U)=<=VG=(U::2QYEL)CT4,2-T>R>&OZ?,G?42.?Q
M1S9(D1.'*O:?=-X>FT;6N^MY;N-.Y53D6FK\9I6M;IQ1S9<7K%>JKYT5OL %
M^<-^QY>#_B[Z5U[BZHMQFT[;<DL>9;VV^A97+1*BU+ZI=O<#P21CKNB:5'<.
MA1J+^@) NFE34'0;L11JQ:AN977D2+F2OR**-)>[TYU?]Z[9;519_P _R\NG
MYWE .]>U/V<OP6-GWTM1CO0=MMDE;3M8LM7NMDVYV\C*VH2GIX):FJM.Z><Y
M=CZ.J/JR/=%#1Q4S)'/6.)G,Y%N39>E#I\L*L=2;:6BKD8B:OO59>+^DCN5C
M7/?!>KE74NKN37E;&UB*JZ(FJ@&5/:+IWZ?^GZV2678;8S9W9*S2PQT\MIVB
MVRPK;:V24\2HZ*"2@PVR66E?#$Y-6M5BM:O8A>FQ8KB^+PK3XSC=AQV!S48Z
M"Q6>WVB%6M^BU8[?3T[%:WS)IH@!>(GP
M
M
M
M
M
M        !(\GR"WXEC60Y5=ED2UXS8[MD%R6%84E2WV:@J+E6+$M3-34Z2)3
MTSN7O)(V:_2<U-52&K*J*AI*JMGU[FCIIZJ;EY>;NJ>)TLFG.YC->1B]JHGI
M5 #P3L\S.][C9SF>X62S_6LCSO+,BS._U.KE^L7O*+Q67NZSZO5SE[ZNKI'<
M55>)K/7.X5%VN5PNE6[GJ[E75=PJG\?G5%9/)43.XZK\Z215 *4($
M[9]!>_-%TN=;?23U&7622.Q;*=1FSNY&3)# M3+-B6*Y[8[KEM+% U%?))68
MU!51-1OS]7_-5':*5OMGDT>&;B8/E<RJE-CV5V&[5G*WG<ZAHKG335S&M[56
M2D:]J:<>/#B >YW0UU%<Z*CN5MK*6X6ZX4M/74%?0U$5715U%5Q,J*6LHZJG
M?)!4TM3!(U\<C'.8]CD5%5%-CZ.2.:..:&1DL4K&R12QN:^.2-[4<R2-[55K
MV/:J*BHJHJ* 11]@                              &*+QS]H;!O9X0?
MB'8ED=+2U5)C_2]N;N]0_6D=I3W_ &&LLF]F.54#XV/DCJH;W@$'=JFB.5>5
MRHQSBR?4?8J7(MB=TZ&K8Q[*7#;Q?8^?7YM5C5.N14CVJB*J/;46QNGN+P50
M#Q9#7S           /9A^SUXK78=X,'A^VBX]Y]8K-F*K*H^]IWTSOJ.=9[F
M.;VO2-[GN='][<AAY)-=)F:/1$1R(F?KI:HI*#I^VO@EUYGX^^M35JL7N[E<
MZ^XP\%5=4[FJ;HOYY./G ,RY?X
M
M
M
M
M
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M7+Q55U7B 7^*G
M
M
M
M
M
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MA<U5T6-[NU$T4#V)#/.
M
M
M
M
M
M                                  >,S]H Z7*WI+\7+K.P-+?)18QG
MNZ%PW]P.7NTCHJS%-^&MW,6*U-YG.^]^.9+?[E94UTTEM;T35J(JX ^I[#9,
M'WSW MG=+'1W.\RY/;'::1R462HEXY8$U5>ZI*NJEI_^%"OF ,-I8,
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MYIE@R7<-*2Z/BFC:D]OQR!LRV*D5517QR5T50ZKD35.$T;7-1T:@&TT=S@
M
M
M
M
M
M
M            #2$^V8>'=<=T-D=HO$5VYQYUPR+I[;%M!OS+0QQ.KEV8R^_R
M5FW^4U3>[;//;<#W+O=312HQ[WL;E7?*Q(8)I(\=?7[M5+><=L6ZUII5EJ\6
M1+%DRQHBR?L?KJE9+76O3EYG0VR[U#XW:*JHE;S:<K7*@'G!&)L
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M8*A9F\JOYHDAN#^\;R(JZIJFB:@%=?RLNEC^<OT__P ,NW7_ #C)C^S?"_\
M&_%_T_M/_*P!_*RZ6/YR_3__  R[=?\ .,?LWPO_ !OQ?]/[3_RL M_DGB%=
M F&_7_V7]<71_BOWJ[O[Z?LDZE]E['][>^[KNOK_ -],UI?J?>]^SE[SEYN=
MNG:A+*O=+;*@[WZ]N-@E%W&G??6\OQ^F[GFY>7O>^N#.[UYDTUT[4 .K6?\
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M6M:C6HC6M1&M:U$1K6HFB(B)P1$0 Y#]
M
M
M
M
M
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M2O;VIR7*U=XG]SSO:B,;=+8LC8JEFC=7:2-1(Y&:@8C2Q@
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M'20-1."?.EJ*B33GJ*RJE59)I7ZOED<KG*JJH!?(J,
M
M
M
M
M
M
M Z1>(-X?G3KXEG3=E/3/U(X_55V,7F:GO.+9?8'4-'GFV&;6YLK;-G6 WJOH
M;C#:K]0-GDAE;)#-2UU#//2544M//)&ZW6Z.U^*;NXE6XAEM*^2CJ'-J**OI
M5CCN=GN,2+]7N5LJ)8Y6PU,2.5JHK7,DC<YCVN8Y44#R//%5\('JL\)W>&?"
M=ZK!-E.T>27:NAV<ZA\9ME:W;K<VUQK/4TM')/)]8;B.X5);8N>Y8[63.JJ5
M['R4\E91=S6S8-]ZMB<UV1OSK=D-*ZML=7/(VP951PR?>J\0IS/9&KEYDH;H
MR)NLU+(Y7L5%5JR1\LC@,4Y90
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M/4SOU?++(KI99%5[W.<JJH%X"?
M
M
M
M
M
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M[!%3;#[<7RFG^N4U5@^VMQ6M=E-ZM<W*V.\9%)5(LD$=526^VSIPRC[*]%N
M;</I+[F#H<^RV%8YHG5M*C,:M-2QW>,?;K1+WBUM1"[1$GJU?Q:CV10N -J
M[H
M
M
M
M
M
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MWINZ2-_MW;;='<M+E6+;:9,[ 8^S1]PW%N%#0X):85U1$DJ[C"Q55$1=2O\
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MP01LBAABC:C61Q11HUD<;&IHB(B(B $P.4
M
M
M
M
M
M
M             L_OA_F"_8%<OY2?^9__ #7\/OO_ )\/V%_L"[.'WR_9[_\
M>]V?_720Y'^QC[V2_LN^\/WF_P"W_LC^]_WL_P#WOWS_ +E]T U9>L;^AS][
M=_\ /;_(,^^'>?W=_)/_ &<_7_KG,_7N_P"0_P#-^N=_KWWFY_[/YSICGO\
M(*YI_P!D7^;3O=?T7]A/WR[WO-5UY?\ -UP[SF^EZ_I &LWU)-^R*NEG;M5+
MXJT#W32-IINGZ# JJU0JL<J0RSTW5?44=UJ+;'+RJ^-LL52]$1$>W57)U!RU
M.AA5>EE7>IJJY48[%VVQ\+>#N57,S9\<SX4735.9KU]* &,7.L3\#.X+/_FS
MW\\6#$6N;5I3)G72+T@;B+$Y[(4H5G6P=;>UR5#:9[9%E1J1+,CFHU8N55?9
MZY473A+S?>C)M[:'5'\GWRP;!+KRJJ-[OF^J[B6;G1BZ\VG+S:IIRZ<0.JV5
MX;T(4;ITP;J0ZM\B8VHB;3.ROHHV<PQTM*L6L\T[+1U_9XE/41S_ #61-=*U
M[/G+(U?FE%UUOVUC5WWMRS.:M$>U&+7;>V"WJYG+\YSD@W.N?*]'<$1-45..
MJ=@!9.ZVK9V&KJF63.]R[A0L_P#M*INNT^+6:KJ/T)JK]:HJ3>B^PT?Z,JM^
M943_ #41W:O*E/30V!KWI3W*\2QI_8WS6.B@>[@GTXV9#4MC^=PX.=PX^H M
MH2<     NG9[1LG/6M9?]P=T[9;^[D5U59]G<2OE:DJ(G=,;05N^>/0.C>OT
MG?645OF:XG4$&.ND1*FZ7J*+1=7P6&AJ)-?,B1R9)2M5%\Z\_#T* 7^P["/#
MNJNX?G_4]UHV']!CDJJ?#NA/8[+-:A)F)+205EZ\1?"^6%U/S*VH= KFOT18
M53B5/06[:M_*MTS'<&F^:BO;0;;8Y7?.YDU8V2HW6M^C59KH]6ZZ_G0#N+M_
M8OL]MM?3KNINEXRV91MYOK;=O]A>B/;1\^L\KF?5Y,CZD-V6TO+2JQB\S9M9
M&N?P1R,;7MKINEN)6??J\[_7!J:\Z6O&=N[0KOG.5.1:O+;VC/F:)Q1W%%7S
MZ(!FRZ2?Z&']8M?^<O\ E:??+O+?]6_E;?Y\OJ_U_P"LS]U]]/Y)7_WJ=WWG
M=_6/K?\ X-[KE[SYG?G8;!_]7_SP_??]G'>ZQ<G[./V1\G>\[M.^_8/_ '%I
MKIS]Y^@Z::\.8 VP>AO^C?\ /9/Y$_\ JR/V7_6(_O-]1_S._P"?+O\ O_[G
MT_SE?_[I_P#MG^P][\WFTY/,=VMN/Y)FM/\ YO/\S_U[G3ZOW?WA_9'S\WS/
M_NO_ /?!]/Z.OG[ #/7#W7=1=QW?<=VSN>YY>Z[KE3N^ZY/F=WR:<NG#3L.S
M+>7E3ETY=$Y>73EY=.&FG#30 Y#]
M
J                                                     /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biogenlogostandarda15.jpg
<TEXT>
begin 644 biogenlogostandarda15.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M86-K970@96YD/2)W(C\^_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$
M<')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                 /;6  $     TRU!1$)%
M                                       *9&5S8P   /P   !T8W!R
M=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&
M03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@
M CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,@
M                                                      !T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
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MW%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G-
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M_P"  (  Y;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&&
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MY"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V
M=)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-
M4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z
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MJWDZ?=&P_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(
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MT9^2>OJM#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H
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M\W_X<<*YD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H
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M*J30<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8
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M?(9!9D/"A83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X
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M5*EV9DJ^**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(
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M0Z@L<+-X%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT
MH1EU^;9VB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT
M><\,N#IT]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$
MX>.$+G?ES#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"
MF7O3$]^$G7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8!
M5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2
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M#;'CB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X"
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M]HR#@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X
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M5+<A?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(
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M!))P=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8
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M]7.M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(
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M9Y?6:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH
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MPGH17UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H
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MZIRS7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8
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MGJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+1I@_-26*%I>4&]&*+)+/  "#E8
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M?7]>>@J<EG\-:1^9[7[@5T:7>G[01#N59G[9+V*4!W[H%525>'\(  "$!(
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MO:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(
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M.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  " DX
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M,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (
M?W*Y_VUL<>&UP&YI8[&QO6]Q5*NMZ7" 1)FJ8'&-,P&GDW)X'KNFT7+!!;VG
M/W-M  "  (  ?S.Y'W50<<>TR76,8Y&PGG7I5(JLJ79B1':I"7;P,NNF)G=U
M'L2E,'>2!B"E(7C%  "  (  ?OFW\7S^<6^SGWR=8T6O9WQ>5#.K:'Q41"JG
MPGQK,K:DU7R6'KFCM7RA!G*C-GVC  "  (  ?JJVOX22<06R<8.P8L:N/8+Q
M4\JJ.()F0\FFEH(4,G*CI('P'J2B8H(6!K:A?X'D  "  (  ?DRUOXPX<*2Q
M<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (
M??"T_I0&<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>
MHX32  "  (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z
M'GZ?+I*G!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC
M7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=
M4F2F@J/K0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7
MK&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (
M<J+$=W1P9<._L72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^I
MZ7CG  "  (  <J/#.GNX9:J^<GM%6":YM7K]2=:U)'KW.HBQ WL2*9ZM\GLX
M%6ZMWGL$ *.GTWTN  "  (  <I7![8+:98"])H'X5^>X:H%"2:BSTH#,.F:O
MK8"6*9RLBH"0%:^L,(#, 2&E^(#$  "  (  <G; THH+95^\!XC(5\"W18>V
M276RJ(;:.E&N<X91*9ZK1X9)%>VJKX:0 9&D58$/  "  (  <E&_^9%H94J[
M'X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "  (
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M0X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6
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M-'U&4"F$N'UU.E&$<GV9(%6$]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4
M=HN$AH138WF#[8/#3UR#>8-).::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$
MX(Z*AX.$%XTB=6*#9XNV8F^"UHID3FN"=8E*..&",HAN'S*"9HA[  "!+H
MIZN$UYE^EY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!
M6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R
M-\> =I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!*
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M!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (
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M$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (
MCYB<(7G9@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3
M+WLE  "  (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"
M*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1
M'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)!
M8 J2'XZZ3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5
MSYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (
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MB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (
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M&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (
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M?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (
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MOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "  (
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M(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (
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MW8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (
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M8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "  (
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M4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "  (
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MJ(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (
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MS&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "  (
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MGI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (
M=K.:19GK:DN8!IB#7-V5KI;+3G.3894,/QZ199/6+F./^Y/2&S"/C)$]!-6,
M'(-%  "  (  =FN9UJ(K:@*7C:![7(N5)YY<3AR2S)Q$/M*0Q)L9+B>/2YGP
M&P>.S9)&!-B+4H-&  "  (  ;@:M.6&38@.J76.253JGMV6#1VFE.V=7.$VC
M'6CW)S:B%VH;$BJD?VFG  "8TVYB  "  (  ;8.L$&D_8;JI&VJ/5/VF1FOA
M1T"CH&TJ.#>A8&Y3)S^@,6\;$G&B+6Z*  "7+7-I  "  (  ;1>J@7"S83FG
MDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (
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M)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "  (
M:O"DH9WC7U:AI)RH4IF>F)KW1-B;HIE6-C.9%YC/)?R7:I;G$JJ7J8R>  N/
MBH (  "  (  8;.X?&")5?2U?&)22:&RD&08/&&OPV7#+;NMC&<E')*M1&>X
M"%RNI&=K  "36'+8  "  (  83"WD6?;5<>T3VD"29*Q%6HX/&^N"VMF+>6K
MGVQD'/"K"FRZ"/&L"6QI  "2%W=N  "  (  8.JV"V[L57>ROV^225VO<G!%
M/$.L47$'+=:ISG&G'12I!7')"5RII7&=  "0X7N   "  (  8*JT9'78526Q
M&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "  (
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M+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "  (
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M?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG&I+
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MR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "  (
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M,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (
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MQ7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (
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M8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "  (
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M6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (
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MUH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (
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MCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (
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M&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "  (
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M"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "  (
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M,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (
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MWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "  (
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M>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "  (
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M5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "  (
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M^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (
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M"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (
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M8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "  (
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MO'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "  (
M9/>)XGSP6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PO_XGT024-#
M7U!23T9)3$4  A*'$GVU  " &X    "  (  9%J(B(2+65*'YH1W36B'((0O
M0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (  8]Z'@(Q%60V&
M[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "  (
M8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "
M (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X
M!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y.968P&-R*U&8
M%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69&V7\19^7O6>B
M.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (  6K:80&M:4#B6
MYVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "  (
M6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A!S&0*G7>  "
M '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,
M!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.
MI8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$
M-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0
M<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (
M4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "
M '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('
M  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A
M!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!
M+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@
M:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (
M3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "
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M!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "  (
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M[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (
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M#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "  (
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MJ)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "  (
M>/UY[E+^;01Z8E:/8 U[ %GV4==[L%TI0D=\:& ?,/]]06*N'.)^;&0C!(2
MZ63M  "  'D@=[-V8%M(:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J
M'(A[!6CQ!)M^*6FR  "  'S =GUS#6.7:K!T%V747?QU"6?S3_QUZFGK0+EV
MOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "  '_O=41P!6O?:7-Q.FU]7+IR3V[^
M3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (  =!-M5W0W:$MN
ML'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "  (
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M>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (
M9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "
M (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;
M$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS- MR
M?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+J5?]
M/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^52N)
M$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "  (
M7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]":.'46CK  "
M '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8
M"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%.HN!%7)O+,"!
M)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_"G>%1CU_'W@<
M.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (  6SQ\\'X]4-=]
M3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "  (
M6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "
M (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR
M"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*,R:5 ECZ),^5
M=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R31%G@/L62IUQ=
M,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (  4LN1#%X_2-R0
M>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "  (
M4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ= A^*\&RD  "
M 'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F
M BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-+^J(C'6/(FF(
M:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'N'LM.UB'5'MU
M+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (  3V"&8X'$18B&
M4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (
M3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "
M (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE
M  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\&46>
MH5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;;U^.
M)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z/(29
M;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "  (
M1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "
M (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D
M  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2
M'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX
M),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60
MSH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (
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MN'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (
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M/(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (
M?A-']8VE<=),"HS#9*I/MHNR5G=2^(J<1R=5JHFX-H17"HDK)#=6PHEB#25I
MR(<V  "  (  ?8)&()9G<4A*4Y3R9!].$9,V5?-16Y%Z1KI4"Y 7-C%53X]1
M(]]54(]D#.%J/(BU  "  (  ?)5I<TX3< 9K#5'\8KILMU725&%N6%F#1,9O
MW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "  '6&>K-DLE:1;IQFMUG<88-HJ5T+
M4UAJ?6 50^)L(6+J,M)M965H'T1M3V<*!Q]TZF>_  "  'FM>1U@15\K;1=B
MIF')8$EDVF1.4C=FVF:O0O%HF6CD,A!IRFK.'KII36OW!PUT%6RE  "  'U2
M=Y)<+F?3:YI>VFF^7N1A1&N743MC<FU80A=E2V[K,6UF97!%'EAEWG$!!PYT
M$W'.  "  (  =B-8AW!X:EY;;W&]7;5>"7+M4 )@5'0!02UB074 ,)IC.W76
M';AB^W8]!N=T57>$  "  (  =/-54WDA:4)8:7G'7+!;*WI.3Q%=EGJ\0%1?
MB7LB, =@6'N#'4]@B7N[!M9T<GSJ  "  (  <_U2D8&Y:&!5SX'&6^%8L8&F
M3E!;,H%S/Z!=)H%/+W5=Q(%+'0Q>?H&(!MAT;X%I  "  (  <SU00XHY9Z]3
MHXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (
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MQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (
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M (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (
M9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "
M &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1
M#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IU
MYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=
M/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L
M!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (
M7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "
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M5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "
M &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O
M!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ
M?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV
M,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R
M;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (
M4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "
M (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P
M!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X,3EMSH7S)!%M
M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-:DXV.-6-@U%I
M++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (  2Y.)RU&40CB)
MYE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "  (
M2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z  "
M ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"
M  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6
MP6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H
M*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z
M+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (
M1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "
M (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&
M  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4(:J945$[$GF<
M,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25CE'9+"R5F51B
M($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (  /D&2%E5X-3J2
M&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "  (
M/6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z  "  &Y6  "
M 'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'
M  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)
MI&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y
M'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#
MSW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (
M.@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "
M (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
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MC,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ=:UMOJ2S=HQ>L* :=YU/HIM@>.)
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MDGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W2IGFAW4M!Y*,A7LD:(L6@ZJ
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MCGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"JWQ7C-DO5WV!AI_..7>\NFBZ[W@
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M!'64E;9YIW:GDGYF.G?=CT-3&'DUB_! .GJZB%4N(7QUA$;#W7(:J3*QUW,
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M=*CYGR9O3:3)G#ECCZ!LF,=7CIORE1=+PY>"D8) 5I,?C@ ULXZHBI$KZ8I
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M@9,F;H&F@,B4:X;)CH^'8X71C5IYH(3>B^QK28/VBE9<SX,IB+Q.6H)\ARE
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M'VKYDO!L+&UAD!9;-V_^C31*K'+*BCHZAG7CAQ,K>WD[@ZBLT&-XI$"=3V7
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M?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G@UM(WI0X@NY
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M)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#;FQLA3 UQW&
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M>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T<U=I^6FT=,);W&RH=C5-MV_3=[]
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M#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6*#QUFR&)GD,
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M?[<HGG8A@!F.#T@4APN"!DUCAFAU;5*0A;)H.U?-A/5:L5U'A#U-)F,*@XU
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M<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;#&<F==9/26K
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
M_YU05?J@4&7OHU%UY*13AMJB6Y;0H&6DR)UPL,6<>[7"G(.YOYJ)OKR5B\*Z
MD(S%N(R/R;:(DLRSA)?/LH&?TJU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_
MHM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9 _YY/
M5/JA3F3OI$]UY:91A=JE6)71HF*CR9]MK\6?=[7"GH"YOYV(OKR9B<.YE(O'
MMH^-R[.*D,^QAI;4KH.@UZ>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU:>!H=6G
M@:'5IX&AU:>!H=6G@:'5IX&AU:>!H=6G@:'5IX&AU?^C.2K_H$9 _YY.5/JB
M363PI4YTY:A/A-NG5932I5^ARJ-IK<6B=+3"H7VYOZ"%OKN=B,.XF(G(M9.+
MS;&.CM.NB9;8IX6=VJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6
MH86@UJ&%H-:AA:#6H86@UJ&%H-:AA:#6H86@UO^C.2K_H$9 _Y]-5/NC3&3P
MITQTYJE.@]RJ4Y+2J5N@RZ9FJ\:E<+/#I7JXOZ2"O;NBA\.XG8?)LYB)S["4
MCM6KDI?:H(J<W)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?
MV)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V/^C."K_H$5 _Z!,5/ND2V/QJ$MS
MYJM,@]VM4)'4K%B>S*IBJ<>J;+'$JG:VP*I^O+RHA,*XI(;)LZ&(SZR<C=6C
MEI3:FI&<W):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>V):.GMB6CI[8EHZ>V):.
MGMB6CI[8EHZ>V):.GMB6CI[8EHZ>V/^D."K_H$5 _Z!+4_NE2F/QJ4ERYZU*
M@=ZP39#5L%6<SK!>I\FP:*_&LG.SP[)\N+VP@,&VK(+)KJ>%SZ6ABM6<G)':
ME9F<W)&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4GMF1E)[9D92>V9&4GMF1
ME)[9D92>V9&4GMF1E)[9D92>V?^D."K_H$5 _Z%*4_NF2&+RJTAQZ*](@-^S
M2H[6M5&:T+9:I,RX9:O*O7&NP;E[MK>R@,"NK(3(IJB%SIVDA]24H([8CI^9
MVXR;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9
MC)N>V8R;GMF,FY[9C)N>V?^D."K_H45 _Z))4_RG1V'RK49PZ;)&?^"W1XS9
MNTZ7T[]7G]#%8Z3%P'"MNKAYM["R@,"IK87'H*B$S9>EA=*.H8G7AZ"2V8>A
MG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<
MV(>AG-B'H9S8AZ&<V/^D-RK_H41 _Z-(4ORI16'SKD1OZK5#?>*\1(G<PDJ3
MV,I4F<K&8J2\O6ZPLK9XN:JQ@,&DK87'FZF$S).FA-"*HX?4@Z*.UH*BEM:"
MHI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*B
MEM:"HI;6@J*6UO^E-RK_H41!_Z1&4OVJ1&#TL4)NZ[A!>^3!0H;?S$:-T\]2
ME\'$8:>SNVVSJ[5XNZ6Q@,&?KH3&F*N$RI"HA,Z(IH;1@J2,TX"DDM. I)+3
M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
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M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
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M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
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M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
ME_03 8_U) >']3$/?O8[&'3V0B!L]D@G9?9/+5[W53%9]ULU5?=B.%'W:#M-
M^&\]2OAV/T?X?D%$^8=#0OF114#ZFT8^^J9'//NQ2#O[ODDZ_,]).?SC23G\
MXTDY_.-).?SC23G\XTDY_.-).?SC2<>M  "WMP( JL," )[0! "3XPD C/T8
M H3^)P=[_S$/<O\X%FG_0!QB_T8B7/]-)E;_4RI2_UDM3O]?,$K_93)'_VLT
M1/]Q-4'_>3<__X$X//^*.CK_DSLX_YT\-O^G/37_L3XT_[X^,__*/S/_RC\S
M_\H_,__*/S/_RC\S_\H_,__*/[BR  "JO0  G<H  )'8 @"(^PT!?_\9 G;_
M) 9N_RT,9O\U$E__/!=8_T,;4_])'D[_3R%*_U4D1O];)D/_8"= _V8I/O]K
M*CO_<BLY_WDM-O^!+C3_BB\Q_Y0P,/^<,2[_I3(M_Z\S+/^W,RS_MS,L_[<S
M+/^W,RS_MS,L_[<S+/^W,ZNX  ">Q0  D-(  (/@  !]_P\!<O\6 FC_'@1A
M_R<(6O\O#%3_-Q!._SX32?]$%D7_2AA!_T\9/O]5&SO_61PY_U\=-O]D'C3_
M:1\R_W @+_]W(2W_?R(K_X<C*/^0)"?_F24F_Z$F)?^G)B7_IR8E_Z<F)?^G
M)B7_IR8E_Z<F)?^G)I_   "1S0  @]L  'CV @!O_PT!9/\2 ES_&0-4_R $
M3O\G!DC_+PA#_S8*/_\\##S_0@XX_T</-?],$#/_41$P_U82+O]:$RS_7Q0J
M_V44*/]K%2;_<18C_WD7(O^!&"#_B1@>_Y$9'?^7&1W_EQD=_Y<9'?^7&1W_
MEQD=_Y<9'?^7&?]6)P3_43(%_U8U!_]?/0[_9$46_V9.'_]D6"?_86(O_UYN
M-?]:>3O_5X0__U2/0_]1F$;_3Z!(_TZG2O]-KDO_3+5,_TN\3?]*Q$[_2<Y/
M_TG>3_](Z5#_2/)0_$GV4/=+^5#Q3/I/ZT[[4.I/^U#J3_M0ZD_[4.I/^U#J
M3_M0ZD_[4/]6)P3_43(%_U@T!_]B.P[_9T06_VE-'_]G5B?_8V O_V!K-?]<
M=SO_6() _U6-1/]3ED?_4)])_T^F2_].K4W_3;1._TR\3_]+Q5#_2L]1_TG@
M4?])ZU'^2?)2^4OW4O--^5'_XGT024-#7U!23T9)3$4 !1+M3_I1YE#Z4N50
M^E+E4/I2Y5#Z4N50^E+E4/I2Y5#Z4O]7)P/_4C$%_UHR!_]D.@[_:D(6_VQ+
M'_]J5"?_9UXO_V)H-O]>=#S_6H!!_U>+1?]4E4C_4IU*_U"E3/]/K4[_3K1/
M_TV\4?],Q5'_2]%2_TKB4_])[5/[2_-3]4SW4^Y/^%/H4/E3X5+Z5.!2^E7@
M4OI5X%+Z5>!2^E7@4OI5X%+Z5?]8)@/_5# %_UTQ!_]G. [_;4 6_V])'O]N
M4B?_:EPO_V5F-O]A<3S_77U!_UF(1O]6DDG_5)Q,_U*D3O]0JU#_3[-1_TZ[
M4O]-Q%/_3<]4_DS@5?M,ZU7X3/15\$_W5>E1^%7B4OA6VU3Y5]E4^5?95/E7
MV53Y5]E4^5?95/E7V53Y5_]9)@/_5RX%_V O!_]J-@W_<3X5_W-('O]R42;_
M;UHN_VIC-O]E;CS_87I"_UV%1_]:CTK_5YA-_U6@4/]4J%+^4J]3_5&W5?Q0
MP%;Z3\M6^$_<5_5/Z5?R3_-7ZE+V5^%3]UC:5?A9T5;X6L]6^%K/5OA:SU;X
M6L]6^%K/5OA:SU;X6O]9)@/_6BP%_V0M!_]N,PW_=3T5_WA&'?]W3R7_=%@M
M_W!@-?]J:CS_9G9"_V*!1_Y>BTO[6Y1/^5F=4OA7I%3V5JQ6]52T5_-3O%CR
M4\=9\%+56NQ2YEKI4_)9X53U6]=6]ES/5_==R%GX7<=9^%W'6?A=QUGX7<=9
M^%W'6?A=QUGX7?]:)0/_72H%_V<J!O]R,@S_>3L4_WQ%'/]\323_>E4L_W5>
M-/]O9SS\:G)"^69]2/9CATSS7Y!0\5V94^];H5;M6:A8ZUBP6NI7N5OH5L-<
MYE;17.-6Y%S?5O!=U5?U7\Q9]F#&6O9@P%OV8;Y<]F&^7/9AOESV8;Y<]F&^
M7/9AOESV8?];)0/_8"@%_VLH!O]W, O_?CH3_X%#&O^"2R+_?U,J_WM;,_EV
M9#KU<&Y!\6QY2.UH@TWJ9(Q1YV&55>5?G5CC7:5:X5NM7-Y:ME[<6<!?VEG.
M8-59XF#16>]AREKT8L)<]&.\7?1DMU[S9+9?\V2V7_-DME_S9+9?\V2V7_-D
MME_S9/]<) /_8R8$_V\F!?][+PO_@CD1_X9!&/^'22#_A5$H^()9,/)]8#CM
M=VI Z')U1^1N?TWA:8A2W6:15]ECF5K58*%=TE^H8,]=L6+-7+MCRUS'9,E<
MVV7%7>MEOUWR9KA?\6>S8/%GKV'Q9ZYB\6>N8O%GKF+Q9ZYB\6>N8O%GKF+Q
M9_]=) /_9B0$_W(D!?]^+@K_AS<0_XL_%O^,1QWYBT\E\HA6+>R#73;F?F<^
MX'AQ1MMS>TW5;H-3T&J,6,QGE%W)99Q@QF.C8\-AK&7!8+5GOU_!:+U?T&FZ
M8.9IM6'O:J]B[VJK8^]JIV3O::9E\&FF9?!IIF7P::9E\&FF9?!IIF7P:?]>
M(P/_:2($_W8C!/^"+ G_BS8._X\^%/V111OTD4PB[8Y3*N:*6C+?A64[UWYM
M1=!X=DW+=']4QG"'6L)LCUZ_:9=BNV>?9;AEIVBV9+!JLV.[:[%CRFRO8^%L
MJV3M;:9F[6RC9^ULH&CN:Y]H[FN?:.YKGVCN:Y]H[FN?:.YKGVCN:_]?(P/_
M:R #_WDB!/^%*PC_CC0,_Y,\$OB60QCOEDH>YY50)N"16"[7BF$ZSH1J1<A^
M<TW">7M5OG6#6[EQBV"U;I)DLFR:9Z]JHVJL:*QLJ6>V;J=GQ&^E9]IOHFCK
M;YYI[&^;:NQNF6OM;9AK[6V8:^UMF&OM;9AK[6V8:^UMF&OM;?]?(P/_;AX#
M_WLA!/^(*@?_D3(+_Y<Z#_2:017KFT<:XYM-(=J652W/CUXYR(EG1,&#;TV[
M?G=5MGE_6[%VAV"M<X]EJ7"6:*9NGVRC;*ANH&NR<)UKP'&<:])RFFSI<9=M
MZG"4;>MPDF[L;Y)N[&Z2;NQNDF[L;I)N[&Z2;NQNDF[L;O]A(0/_<!T#_WX@
M _^+*0;_E3$)^YLX#?">/A'GH$06WZ!*'=.:4BO*DUPXPHUD0[N';4VT@G14
MKWY\6ZIZA&&F=XMEHG23:9YRFVV:<*1PEV^O<I5OO'.3;\USDG#F<Y!PZ7*.
M<>IQC7'K<(QQZW",<>MPC''K<(QQZW",<>MPC''K</]C( /_<AL#_X ? _^.
M)P7_ER\(^)XV"^VB.P[DI4 2VJ1&',Z>42K%EUHWO9%B0K6,:DROAW)4J8)Y
M6Z1_@&"??(AEFWF0:I=WF&V3=:%PD'.L<XUSN'2+<\EUBG3B=(ETZ'.(=>ER
MAW7J<8=UZG"'=>IPAW7J<(=UZG"'=>IPAW7J</]E'P/_=!H"_X,> O^0)@3_
MFBT&]*$T">FF-PO@JCT.U*=$&\FA3RG FU@VN)5@0K"0:$NIBV]3HX=V6IZ#
M?F"9@(5EE'V-:I![EFZ,>9]QB7BI<X9WM76$=\5V@WC?=8-XZ'2">.ES@GCJ
M<8)XZG&">.IQ@GCJ<8)XZG&">.IQ@GCJ<?]G'0/_=QD"_X4< O^3) /_G2L%
M\:0P!N:J,PC<KC<,SZI#&L6E3BB\GU<ULYE?0:N49DJDD&U3GHMT6IB(>V"3
MA8-ECH*+:HJ DVZ&?IQQ@GVG=']\LW5]?,-V?'W;=GQ]Z'1]?.AS?7SI<GU\
MZG%]?.IQ?7SJ<7U\ZG%]?.IQ?7SJ<?]I' +_>1@"_X<; O^5(P/[H"D$[J@L
M!..O+P77LC0+RZU!&<&H3">WHU4TKYU=0*>99$F?E&M2F9!R69.->5^.BH!D
MB8>(:82%D6V @YIQ?(*D='F!L79W@<!V=H'6=G:!YW1W@>AS>(#I<GA_ZG%X
M?^IQ>'_J<7A_ZG%X?^IQ>'_J<?]K&P+_>Q<"_XH: ?^8(0+XHR8#ZJPG ]^T
M*0/2M3(*Q[! &+RL2R:SIU,SJJ);/J*=8TB:F6E1E)5P6(Z2=UZ(CWYD@XV&
M:7Z*CFUZB9AQ=H>B<W.&KG5QAKUV;X?2=G"'Z'1QA>AS<H3I<G.$ZG%SA.IQ
M<X3J<7.$ZG%SA.IQ<X3J<?]M&0+_?A8!_XT8 ?^;'@'TIR("YK @ =JZ(0'-
MN#$)PK0^%[BP222NJU(QI:9:/9VB84>5GFA/CIMN5XB8=5V"E7QC?9.$:'B0
MC&QTCY5P<(V@<FV,K'1JC+MU:8W.=6F-Z'1KB^ES;8GJ<6V(ZG%MB.IQ;8CJ
M<6V(ZG%MB.IQ;8CJ<?]P%P+_@14!_Y 6 ?^>&@'PJQL!XK86 -.]'0'(NR\(
MO;@\%;.T1R.IL% PH*M8.YBH7T60I&9.B:%L58*><UM]G'IA=YF!9G*7BFIN
MEI-N:I2><6:4JG-DD[AS8Y3+<V.4YG)EDNIQ9X_J<&>.ZG!GCNIP9X[J<&>.
MZG!GCNIP9X[J</]S%0+_A1,!_Y04 /RC%0#JL!( V;X, ,W!&P'"P"T'N+TZ
M$ZZY1B&DM4\MFK%6.9*N7D.*JV1,@ZAJ4WRE<5EVHWA?<:%_8VR?AVAHGI%K
M9)V<;F"<J'!>G+9Q79S)<5V<Y'!>FNMP8);K;V&5[&]AE>QO897L;V&5[&]A
ME>QO897L;_]W$@'_B1$!_YD1 /.H#@#7M0H S\$* ,;%& "\Q"H%LL(X$:>_
M1!Z>NTTKE+A5-HNU7$"$LF))?*]I4':M;U9PJW9;:ZI]8&:HAF1BIX]G7J::
M:ENEIFQ8I;5M5Z;';5>FXFQ7I.UL6I_M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL
M6I[M;/]\$ '_CA  ]IX- -BM"0#-N D Q\0( +[*% "URB<$J\@V#Z'%01N7
MPDLHC;]3,X6]6CQ]NF%%=KAG2W"W;5%JM7169;1\6V"RA%]<L8YB6+&9956P
MI693L+-G4K'&9U*QX6=1K_%H4ZKP:%2I\&A4J?!H5*GP:%2I\&A4J?!H5*GP
M:/^"#@#_E P VZ4& ,ZQ!P#%NP< O<<' +70$ "LT",#H\\S#)G-/QB/RD@D
MALA1+GW&6#AVQ%\_;\)F1FG!;$MDP'-07[][5%N^A%A7O8U;5+V875&\I%]/
MO+-@3;W%8$V]X%],O/!A3;?U8DVV]6)-MO5B3;;U8DVV]6)-MO5B3;;U8O^)
M"P#AG , T*H% ,6U!0"[OP0 LLL( *O8#0"CV2 "FM@O"9#6/!2'U$8??M)/
M*7;05C)OSUXY:,UD/V/,:T1>S'-)6LMZ3%;*@T]2RHU23\J85$W*I59+RK-7
M2LO%5TG+X%9)R?!81\?Z64C%^UI(Q?M:2,7[6DC%^UI(Q?M:2,7[6O>1! #4
MH@( QZ\$ +JY P"PQ 4 I] ) )_A$ "8X2$#C^ P"8;@.Q)]WT0;==Y-)&[=
M52MGW%PR8MMD-UW;:SM9VG(_5=IZ0U+:@T5.VHU(3-J82DG:I4M(V[-,1]S$
M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
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M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
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M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
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M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
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M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
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M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
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M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
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M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
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M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
M5= N 5'0.0).T$,$2]!,!DG04PA&T%L+0]!C#4'0:P\^T'41/-& $SK1C!0X
MT9H6-M&I%S71NQ<TTM(7-=#L%C3/]Q@SSO\:,\[_&C/._QHSSO\:,\[_&K.9
M  "FH0  FJD  (ZQ  "!N0  =<   &K'  !>S0, 5-0( $S=#0!*W1@ 2-XF
M $;>,@%$WSP"0M]% S_?300]X%4%.^!=!CG@9@@WX&\)->%Z"C/AA@PQX90-
M,.*C#B[BLPXNX\<.+>/C#BW@\@XLW_L/+-_]$"S?_1 LW_T0+-_]$*B@  "<
MIP  C[   (.X  !VP0  :LD  %[/  !3U0$ 2=P& $7I#P!"Z1D 0.HD #WJ
M+@ ZZS8!..P^ 3;L1@(S[4T#,>U5 R_N700M[F4%*^YP!2GO>P8H[XD')O"7
M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
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M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
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M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
MGGPB )A\+P*2>CL%C'A%"H=W30Z#=542?W-<%GMR8AIX<&D==6]P(')N>"-O
M;8$F;6R+*6ILEBMH:Z$N9FNO+V1JOS!C:]@P8VOO+V1K_"UD:_\M96O_+&5K
M_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX  *9^ 0"??Q  F8 ?
M ). +0*-?SD%B'U#"8-[2PU^>E,2>GA:%G9W81ES=6<<<'1N'VUS=B)J<G\F
M:'&)*&5PE"MB<* M8&^M+U]OO2]>;]0O7F_M+U]O^RU?;_\L8&__+&!O_RQ@
M;_\L8&__+.M>  #8:0  QW(  +QY  "S?P  JX(  *&"  "9@PX E(0= (Z$
M*P&(@S8$@X) "'Z 20QY?U$0=7U8%')\7QAN>V4;:WIL'FAY=")E>'TE8G>'
M)V!VDBI==9XL6W6K+EITNR]9==$O673L+EET^BU:=/\L6G3_*UIT_RM:=/\K
M6G3_*^9A  #1;0  PW8  +E]  "O@P  IH8  )R&  "4B P CHD9 (F)* &#
MB30#?H<^!WF&1PMTA4\/<(16$VV"71=I@6,:9H!J'6-_<B!@?GHC77V$)EI\
MCRE8>YPK5GNI+%1[N2U3>\XM5'KJ+51Z^2Q4>?\K57G_*E5Y_RI5>?\J57G_
M*N%E  #,<0  OWH  +2"  "KAP  H8H  )6+  "-C0D AXX6 (*/) %]CS$"
M>(X[!7.-1 EOC$P-:XI4$6>)6A5DB&$888=H&UZ&<!Y;A7@A6(2")%6$C292
M@YHI4(*G*D^"MRM.@LPK3H+H*TZ!^"I/@/\J3X#_*4^ _RE/@/\I3X#_*=MJ
M  #'=0  NG\  +"'  "FC   G(\  (^1  "&DP4 @)02 'N5(0!WE2T!<I4X
M!&V40@=IDTH+99)1#F*16!)>D%\56X]F&%B.;1M5CG8>4HV (4^,BR--BY@E
M2XNE)TF+M2A(B\HH2(KG)TF)]RA)B/\G28?_)TF'_R=)A_\G28?_)]%O  #!
M>P  M80  *N,  "@D   E90  (F7  !^F@  =YL. '.<' !OG2D!:YPU F:<
M/P5BFT<(7YI/"UR:5@]8F5P259AC%5.8:Q=0EW,:399]'4J5B1]'E94A196D
M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
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M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
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M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
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M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@
MKV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF":E(,?FE9#WMH8!)W
M9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65BNB9D8L\F9&+J)F5B
M^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@  +QN  "S<0  JW,
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M(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0  GW\  ))^  "*?P<
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M&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T
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M""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@
ME9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ U
MO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_
MH@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X
M ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T
M)LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9
MSJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M
M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9
M !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0
M#>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=
MO   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH
M&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG
M  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0
M0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #
M]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #W
MIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$
M "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A
M /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@
M_Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0 _QHE /\5)P#_$2X _Q Z /\.
M1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_"HX!_PJ5 ?\*FP'_": !_PFE
M /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)ZP#U"?8 \PG_ /(*_P#Q"O\!
M\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA /\9) #_%RP _Q4W /\31 #_
M$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!_PZ2 ?\.F '_#IT!_PZC ?X.
MJ '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N#O4 [ [_ >L/_P'J#_\!ZA#_
M >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?( #_'RD _QPT /\:0 #_%TP!
M_Q58 ?\48P'_$VX!_Q-W ?X3@ '\$X@!^A*. ?D2E0'X$IH!]A*@ ?42I@'T
M$JP!\Q*S ?$2O 'P$L<![1+8 >D3Z 'F$_4!Y!3_ >(4_P+A%?\"X17_ N 5
M_P+@%?\"X!7_ O\E&P#_)A< _R06 /\E' #_)B4 _R0P /\A.P#_'T@ _QU4
M ?T;7P'Y&FD!]QIS ?09? 'R&80!\1F+ >\9D0'N&9<![!F= >L9HP'I&:H!
MZ!FQ ><9N@'E&<4!XQG5 =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32
M'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$ _RPK /\I-P#])T, ]R5/ ?,C
M6@'O(F0!["%N >DA=P'G(7\!Y2&& >0AC0'B()0!X2": =\@H '>(*<!W"&O
M =HAN +8(<,"U2'3 M$BYP+-(O0#RB/_!,@C_P7'(_\&QB/_!L8C_P;&(_\&
MQB/_!O\L$@#_+@\ _S 0 /\S% #_,QL _S(E /HP, #R+CP ["Q) .<J50'C
M*E\!X"EI =TI<@':*'H!URB" M4HB0+3*) "T2B6 \\HG /.**,#S"BK \HH
MLP/)*+X$QRC,!,4IX@3!*O$&OBK^![PJ_PBZ*O\(NBK_"+DJ_PFY*O\)N2K_
M"?\P#P#_,@L _S8- /\X$ #_.14 ^3<> .\U* #G,S4 X#)" -LR3P#5,5H!
MT#%D LTP;0++,'4#R3!\ \<O@P3%+XH$Q"^1!<(OEP7!+YX&OR^F!KTOKP:\
M+[D'NB_'![@PW0>U,.X)LC#["K P_PNN,/\+KC#_"ZTP_PNM,/\+K3#_"_\S
M# #_-@8 _SP) /\^# #]/1  [SP5 .0Y'P#;.2T TCH\ ,TZ20'(.50!Q#E>
M L$X9P._-V\$O3=V!;LV?0:Y-H0'MS:+![8UD@BT-9H)LS6A";$UJ@JO-;0+
MKC7!"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_
M.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!1 &]04\"N4!9 [8_
M802T/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=#:4[I@VC.K .HCN\
M#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0
M[T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S1TH"L$94!*Q%706J
M1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I H1&80*P2ET"X$I5
MR!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_$_\\  #Y1   Y$H
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M?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  #
M60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ2
M9@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K
M&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@
MM%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+6%4(B%=<"H968PR#
M56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2NAMQ4LT<<%+H&W!3
M^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH  ,!?  "W8@  KV$
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M&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;   HVP  )EI  "2:@L
MC&H6 (=K) "":S !?FHZ GII0P1V:$L&<V=2"'!G60IM9F -:V5F#VAD;A%F
M9'849&. %F)CBQA@8I<:7F*D'%QBLAU;8L4=6V+A'5MB]!Q;8O\;7&+_&EQB
M_QI<8O\:7&+_&N!5  #+7P  O6<  +)L  "I<   GV\  )1L  ",;0@ AFX3
M ()O(0!];RT!>6\X G5N00-R;4D%;FQ0!VMK5PII:UX,9FIE#F1I;!%A:703
M7VA^%EUGB1A;9Y4:66:B&U=FL!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI7
M9O\:5V;_&MM9  #'8@  NFH  *]P  "F<P  FG,  (]P  "'<04 @7(1 'QS
M'@!X<RH =',U 7!S/P-M<D<%:G%.!V=Q50ED<%P+8F]C#E]O:A!=;G(26FU\
M%5AMAA=6;),95&R@&U)KKQQ1:\$<46O<'%%K\1M2:_X:4FK_&E)J_QE2:O\9
M4FK_&=1<  ##9@  MFX  *QT  "B=P  EG8  (EU  "!=@$ >G</ '9X&P!R
M>2< ;WDR 6MX/ )H>$0$97=,!F)W4PA?=EH*775A#%IU: ]8=' 157-Y$U-S
MA!91<I 83W*>&4UQK1I,<;\;2W'9&TQQ\!I,</T:37#_&4UO_QE-;_\936__
M&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0
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M$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P
MI8,  )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-
MES8 2Y<_ 4F71P)'ETX#1995!$.6705!EF4&/I5O"#R5>@DZE8<+.)65##:4
MI0TUE+8.-)3,#323Z0TTDO@.-)#_#S20_P\TD/\/-)#_#[5X  "J@@  GH@
M ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ  1Y\; $:@)@!$H#
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M,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G
M 1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@
M8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :
MPR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'
MU  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0
M $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$
M#-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !
MU=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_
M   TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@
M  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$
M .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   H
MS   ']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I
M'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[
M  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@
M%-P   [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@
M]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_
ML   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!=
M /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P
M^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M
M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$
M9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P
M /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\
MY@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_
M"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)
MM@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_
M ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8
M\Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@
M#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B
M$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J
M .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L
MSA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_
M)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>
M;0#2'W4 T!]] ,X?@P#,'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$
M < AU@&\(NH"N2+X [8B_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4
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M#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20
MOT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:4
M07 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!
M^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P
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M$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7   IEH  )]6  "85@T
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M$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R<
M<6<R &YG.P%K9D,":&9+ V5E4@5C95D&861?"%YD9PI<8V\,6F-X#EAC@Q!6
M8H\25&*<$U-BJA528KL546+2%5%A[1528?L44F'_$U-A_Q)38?\24V'_$M%6
M  # 7P  LV8  *EK  "<:P  D&H  (5G  !]:0  =VH- '-K%P!O:R0 ;&PO
M &EL. %F:T$"8VM) V%K4 1>:E<&7&I=!UII90E8:6T+56AV#5-H@0]19XT1
M3V>:$DYGJ11-9[D43&?/%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\
M8P  L&H  *5O  "8;@  C&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q
M-@%A<3X!7G%& EQP30-9<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8
M$4ELIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P
MK&X  *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;
M>#P!67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-S
MI1!"<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',
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M!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0
M<(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ W
MFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:F@,IFJP$*)K !">9
MW@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD  (2*  !VC   :H\
M %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$ +J0J "VD,@ LI3H
M*Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@IJ@!'Z6[ 1ZEUP$>
MI.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=
M  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z
M !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L
M$Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%
MK   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]
M-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P
M  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@
M,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #
MRC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,
M[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$
M !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH
M -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@
MWN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//
M   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G
M  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8
M .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #
MW@   .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T
M(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO
M /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X
M_P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R
M +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3
M' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S
M /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H
MZ #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_
M$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /(
M=P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP##
M -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1
M_Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F
M!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - '
MSP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@-
M /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74
MV U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##
M$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?
M#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W
M ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.(
MLQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W
M(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?
M> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W :PAQ@&K(=T!IR+O
M J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*   \BH  .4K  #?* 4
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M"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20  KD8  *E!! "C01$
MG4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%068#@T!M!(% = 6
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M"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D
M>%0T '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@
M48\+7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*
M  ##4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q
M '!7.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+
M652:#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  #
M5@  LUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;
M-P!H6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8
M#5-8I@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60
ML%\  *-A  "68   BU\  (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C
M8#T!85]% 5]?3 )=7U,#6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=
MI U-7;0.3%W(#DQ=Y@Y-7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,
M )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L
M7&1# 5ID2@)89%$"5F18 U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(
M8K(-1V+'#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF
M  "-9@  @F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI
M 55J1P%3:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,
M0F?%#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  ")
M:0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P
M10%.<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6["
M"CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0
M>&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,=S$ 2W@Y $EX00!(
M>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEVG @W=:T(-W7 "#9U
MW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$  (MQ  !^<0  <W(
M &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4
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M B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@
M0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @
MGDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;
M_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P
M #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD,
M$ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -
MJ/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ
M   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#
M  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<
M +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :
MN   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$
M1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N
M (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@
M#,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.
MU$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@
M  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M
M  #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38
M .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !B
MKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
M    XP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S
M  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD
M_P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[
M (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P
MT0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4
M /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X
M\@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A
M .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"
M%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_
M .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T
MT0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_
M!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L
M@0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J
M ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0
M_PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*
M!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+
M^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5
M .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T
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M 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH
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M!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T
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M!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3
MLE(  *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J
M3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#7DQR!%Q,? 5:3(@&64R5!U=,
MHPA63+((54S&"55,X@E53/4(54S_!U5,_P=63/\&5DS_!LQ(  "\4   KU4
M *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"  :E J &=0,P!E4#P
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M1@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC
M"$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P
M?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !1
M7DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=
MV@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T
M &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@
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M!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@
M37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U
M>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU
M_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@
M $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E
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M )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@
M'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *
MI%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#
M  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@
M !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,
M +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !X
MB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV
M   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6
M  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0
M8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"
MQ    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/
M60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<
M $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T
M -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P
MY%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y
M   UO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\
M  #A    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T
M /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_
M ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8
MB #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q
M .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\
M_P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K
M (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@
M^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F
M /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4
MW@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#(
M /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$
M+ #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"&
M ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T
MNP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A
M #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,
MAP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_
M *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL
MS ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R
M!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-
M_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP
M +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4
MI0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5
M%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4
M-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>(
M )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\
MB1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A
M'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@
MC0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_
M >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4
MDR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0&
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M FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@
MM4(  *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U
M.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,Z
MH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4
M *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\
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M!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P
M?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !7
M24H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+
MTP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT
M '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@
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M SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@
M5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 !
M75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;
M_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T
M $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4
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M :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0
M+G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @
M>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI
M  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$#
M "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF,
M%89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!
M;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-
M!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J
M  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P
M;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .
MF@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<
M<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H
M %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4
M Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:
MJ7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)
M  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'
M  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X
M +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"
MG   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_
M!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU
M  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP
M+[   "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,
MS0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@
M?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P
M !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0
M -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P
M\X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0".
M /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\
MX0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^
M $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4
MCP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_
M -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L
M\ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3
M )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$
M_P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!!
M -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P
MPP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T
M /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T
M10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0".
M +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\
MI@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\
M $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *<
MD0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_
M /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4(
MK09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":
M"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81
M  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$
M )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90
MC1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<
M(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )06
M1P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F;
M ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0
MORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"'
M'TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4B
MI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(
M *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0
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M 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/
M@SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A
M-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58YF0%5.:@"5#FY E,Z
MSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P  ?CT
M '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;.TH
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M D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P
M7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(
M2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)
M_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P  64@
M %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358
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M :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@
M/5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O
M76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5
M  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F -
M #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D
M)V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")
M6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI
M$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR
M !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7
M=5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A
M<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U
M?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$
M &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X
M%GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,
M?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F
M  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.
M  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,
M (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0
M<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3
M$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.
M  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0
M/WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@
MGQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "B
MF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L
M "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T
M *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@
ML:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>
M   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,
M  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<
M ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4
ML0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*
M"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>
M  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@
M!,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
MW@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #P
MGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!-
M /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4
MZ@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#>
M /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0
M4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6
M -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\
MRP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D
M %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D
MF0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_
M /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %
MS@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y
M )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\
M  #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2
M +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@
MJ0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
M    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X
M4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "=
M )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P
MW T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@
M %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"
MI ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4
M +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X
MDPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!
M#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<
M  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/
M (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX
M=1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<
M(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P7
M4 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[
M &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*
MC24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q
M'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$C
MS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H
M ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T
M9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9
M*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM
M  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0
M %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4
M4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O
M+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P
M4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V
M $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P
M93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0
M-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X
M_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8
M %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54
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M :I"  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP
M1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X
M1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$
M  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0
M #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H
M,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".
M2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.
M%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U
M "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@
M>DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q
M5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57
M@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X
M &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4
M*%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =
M7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12
M  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8
M !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L
M%&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !7
M5@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M
M&@ 5;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+
M  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G
M 'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"
M8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "#
M#0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[
M  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0
M,FT  "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0
MCPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5
MB   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD
M "%_   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<
M )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0
MII0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-
M   1D@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$
M  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@
M +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,
MH@   Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
M    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1
M  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0
M +8   "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.
MT    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #G
ME@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!#
M /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L
MXP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/
M /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P
M2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ",
M ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\
MO@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5
M $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T
MC@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_
M /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4
MOP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L
M )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\
M  #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!'
M *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L
MFP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
M    TP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X
M1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/
M (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3
MP0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/
M $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X
ME@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P
M *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $(
M@@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q
M )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1
M  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1#
M '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T
M90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'
M%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,
M1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K
M %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0
M>!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B
M$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6
MN@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$
M &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$
M6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*
M'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C
M  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U#
M $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP
M0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<
M)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B
M1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH
M #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*
M5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P!
M)TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L
M^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H
M $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@
M.BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S
M,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N
M  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%.
M #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\
M+S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _
M,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V
M50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_
M )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@(
M-S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I
M.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV
M  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL(
M "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L
M(D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X
M.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"
M#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E
M !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0
M9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A
M2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+
M<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$
M %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT
M&% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .
M4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%
M  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<.
M !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D
M!EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(
M2   04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@
M$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&
M  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3
M/4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@
M:!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !I
ME   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0
M #!7   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1
M '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@
M<Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@
M   B9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1
M  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T
M '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;
M;P  %',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*
M$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK
M  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?
M#H$   B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#
MF@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?
MMP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I
M  "4    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D
M *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK
MLK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
M    J    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&
M  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\
M ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S
MMP   +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/
M P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M
M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %
M\ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9
M )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\
M  #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2
M -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8
MQ "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,<
M4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@":
M +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]
M[@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R
M %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$
MGP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@
M ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T
MH0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0
M *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H
M  "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!-
M )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *
M@ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
M    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (,
M30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J
M '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!
MC@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V
M $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &<
MM@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L
M 'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $<
M:@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!<
M \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.
M  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=)
M %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,<
M4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G
M$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-
M2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E
M $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P
M7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.
M$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7
M]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD
M %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH
M11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 [
M'/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\<
M @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/
M #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\
M-B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'
M( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B
M50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_
M )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4
M/R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P
M)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH
M  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+
M #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L
M*BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X
M+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L
M#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E
M "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P
M9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K
M,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U
M<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,
M %DT  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q
M)#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8
M.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V
M  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2
M !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P
M$D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*
M.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#
M%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,
M  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/
M0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 0
M2A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+
MF@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X
M #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410
M"5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@
M4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#
M   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7
M  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4
M %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H
M3   (D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A
M&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V
M  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P
M'%<  !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0
M;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !K
MR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F
M !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8
M '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0
M=]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO
M   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85
M  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$
M (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]
M@0   (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7
M%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?>
M $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0
M )4   "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@
MJA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F
M   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4
M  "H    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T
M +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R
M>   )X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
M    NP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-
M  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_
M_P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G
M %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P
MK #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P
M /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D
MS@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y
M +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T
M  #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9
M +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T
MI@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+
M  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *<
M6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V
M )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  (
MKP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6
M %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4
MP@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ '
M )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$
MA@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V
M -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L
M"P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0
M '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D
M:0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![
M  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L
M4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A
M %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D
M;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !?
M %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %,
M[P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+
M &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X
M50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*
M!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)
M#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1
M $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L
M0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3
M#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.
M5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_
M ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L
M2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [
M$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;
M  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4.
M $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L
M,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X
M(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9
M$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD
M "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P
M9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S
M'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B
M;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8
M %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$
M+"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @
M)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I
M  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4
M "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL
M&BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*
M+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L
M&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+
M !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@
M02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :
M,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! U
MG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C
M #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D
M$S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +
M.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S
M   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<
M  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@
M SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N
M-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$
M(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y
M  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0
M)3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'
M2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*
MS@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$
M !Q#   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\
M %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@
M4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*
M   230  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA
M  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0
M %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .
M5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G
M(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P
M $]&  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8
M F,   !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0
M="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*
M  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\
M  !R    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X
M (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _
M4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M    @P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@
M  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60
M+UT  "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1
MDP   )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I
M(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH
M !UP   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I
M *4   "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&
MOB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:
M   -B   !8\   "6    G    *(   "G    K    +    "S    M@   +<
M  "Y    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L
M -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_
M  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X
M8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#,
M ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L
M[0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$
M &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X
MXP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ .
M ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T
ML !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"=
M /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8
M$@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!;
M )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@
MBP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"?
M !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L
M6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U
M 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$
MBP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![
M %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X
M_@!N /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4
M 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0
M; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A
M /\ 80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T
M%@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6
M %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\
M5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A
M !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4
M6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_
M )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !,
M5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!*
M %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-
M  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5
M $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H
M0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\
M$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(
M%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC
M #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0
M:1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _
M#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0
M;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H
M %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4
M-Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I
M%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>
M  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07
M "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D
M(AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*
M(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8
M&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V(
M !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@
M02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A
M'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<B
MF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0
M #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL
M&R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1
M)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F
M   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<?
M !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD
M#2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O
M*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M
M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY
M  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@
M*2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -
M,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (S
MS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP
M "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0
M!C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@
M..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q
M   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH
M   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0
M #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6
M.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%
M+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R
M %4T  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P
M#T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*
M3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X
M  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD
M  =+   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP
M %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"
M/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q
M  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P
M.C\  #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>
M80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O
M-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40
M "M'   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0
M &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@
M?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50
M   <50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X
M  !_    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,
M ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   5
M8@  #F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
M    D@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z
M  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<
M!W<   !^    A    (H   "/    E    )@   ";    G@   )\   "B
MI    *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[
M0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@
M  "/    E@   )L   "A    I@   *H   "N    L    +$   "T    M@
M +@   "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.
MT4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D
M&P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H
M -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\
MN #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#?
M "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H
M9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_
M *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L
MP  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F
M &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4
M_P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  >
M *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &
MD0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"#
M /\ @0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ),
M(0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@
M '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\
M= #_ ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"
M ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '
M80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_
M +@   "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T
M<  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A
M &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@
M  "5    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ?
M &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X
M5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %<
M( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C
M $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P
M<0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!,
M "  2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $
M:P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X
M %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P
M0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V
M '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1
M  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(=
M #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W,
M+@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,
M%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)
M'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR#
M "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P
M0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L
M#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0
ME@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD
M #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X
M)1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8
M%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;
M   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A
M !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8
M$ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O
M'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8
M)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY
M  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@
M*1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3
M'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@
MR@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\
M ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8
M#B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &
M(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A
M   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K
M  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$
M 2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;
M)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M
M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP
M %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P
M%2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0
M,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G
M  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX
M  \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,
M #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&
M+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU
M   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z
M  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P
M.2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %
M/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(
M00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(
M # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@
M $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/
M44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T
M   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$
M  !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0
M %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C
M/   '#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-
M  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1
M%DD  !!-   *40  !%4   !:    70   &    !C    9@   &@   !J
M:P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X
M60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0
M  I9   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P
M 'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@
MBV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M    ;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\
M  "1    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED
M *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W
M?0   (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
M    I@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E
M  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP
M )8   ";    H    *0   "H    JP   *P   "O    L@   +0   "V
MN0   +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-
M<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J
M .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X
MQ@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P">
M /\ FP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -(
M+0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N
M *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\
MCP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S
M "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P
M;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_
M .<   #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D
MFP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "'
M '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8
M  #     KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J
M (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D
M=0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
M    FP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4
M*@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M
M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9
MB@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E
M "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %<
M<@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?
M '$   !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4
M5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!*
M 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8
M  !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E
M $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4
M/P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5
M!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $(
M)0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"!
M #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#
M2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y
M "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T
MCP L *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX
M #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "(
M,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E
M )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0
M   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C
M "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT
M'@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q
M$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "()
M)@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP
M !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P
M*A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <
M#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /
MR0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0
M "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@
M%1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,
M$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6
M   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M
M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT
M"17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <
M%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9
M,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL
M %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0
M%Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P '
M'CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:
M  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL!
M !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4
M ")    C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !(
M'P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$?
M @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]
M   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0
M.R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -
M)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M
M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0
M # D   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@(
M!BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@
M,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG
M   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($
M   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP
M #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F
M*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [
M!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7
M  !":@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@
M'RL  !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @
M104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+
M9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$
M !4T   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$
M $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@
M5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\
M   ,0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H
M  !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L
M &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &
M2@   $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[
M  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P
M %P   !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z
M?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%
MBP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L
M  !O    =    'D   !]    @    (,   "%    AP   (H   ",    CP
M )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0
MFID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
M    A@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8
M  "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X
M *^D ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5
MF@   )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
M    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6
M /P   #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8
MW@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\
M ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0
M  #L    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W
M +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H
MI0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
M    V0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8
M. "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!]
M (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT0
M24-#7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
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M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
MLVR]MJY\Q;"IA\RIIH;0HZ2%U)RBA-:5H878CY^'VHJ?B]N'GY+:B*&<UXB?
MH=2'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRDT8><I-&'G*31AYRD
MT8><I-'_MA((_[<;'?^U)SG_L#-:ZJH^?=:H1)O)J$^OQ[!3LL6X6;6YLVV_
ML:U]QJRJALNEIX7/GZ:$T9BDA-.2HX35C**&UXBABM>%H8[7@Z*6UH2DG]2$
MHJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82BH]&$HJ/1A**CT82B
MH]'_MQ$'_[@:'/^V)3G_L3%:ZJL\?M>L.YG*K42MR;E%KKVX6;BRLF_ K*Y^
MQJBKA<JAJ83-FZ>#SY6F@]"/I832BJ2&TX:CB-2#HXS4@:.1U("DF=. IJ'1
M@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH='_
MN! '_[D9'/^W)#G_LR]:Z:TY?MFT+Y;,N#*IPKU L+.V7;JLL7'!IZY^Q:2L
MA<B=JX/*EZF#S)*HA,Z-IX3/B:>&T(6FB-""IHO1@*:.T7ZFE-!]IYK/?:>:
MSWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL]]IYK/?:>:SWVGFL__N0\'
M_[H7'/^Y(CG_M2U:[+,P>MW 'Y#)PR&HM;I(M*NU8KRFLG/ HZ]^PZ"NA,:9
MK(/(E*N$R8^JA,J+JH7+B*F&S(6IB,V"J(K-@*B-SGZHD<U\J9;-?*F6S7RI
MELU\J9;-?*F6S7RIELU\J9;-?*F6S7RIELU\J9;-?*F6S7RIELW\NPX'_+P5
M&_Z['SC_MRE:\+TD=-_3#H:YP2JJJKE/MJ2U9;R@LG2_GK%_PINOA,.6KH3%
MD:V$QHVMA<>*K(;(AZR'R86KB,F"JXK*@*N,RGZKC\I\JY+*?*N2RGRKDLI\
MJY+*?*N2RGRKDLI\JY+*?*N2RGRKDLI\JY+*?*N2RGRKDLKQO0P&^;X2&OJ^
M&S?\NB5:Y\X3:,C9"XFMPS*GH;A6N)VU:+N;LW6^F;)_P)BQA,&3L(7"CZ^%
MPXROAL2)KH;%AJZ'Q82NB,:#K8K&@:V+QG^MCL=]K9#'?:V0QWVMD,=]K9#'
M?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,??P @%]<(/&?;"%C;N
MR!50S=P,9K7:#XBBR3:@FKY6L)>W:KF5M7:\E+1^OI2SA+^0LH7 C;&&P8JQ
MAL&(L8?"AK"(PH2PB<*#L(K#@;"+PX"OC<-^KX_#?J^/PWZOC\-^KX_#?J^/
MPWZOC\-^KX_#?J^/PWZOC\-^KX_#?J^/PWZOC\/9P@<%Y,<+&._($#31V@M%
MNND.:*;>&(*8T3>5D<A3H8_"9:F.OG*NC;Q[LHRZ@;6)N(*WA[B$N(6WA;F#
MMH:Z@K:'NH&UB+N M8F[?K6*O'VTC+Q\M(V]?+2-O7RTC;U\M(V]?+2-O7RT
MC;U\M(V]?+2-O7RTC;U\M(V]?+2-O7RTC;W4Q <$ULL)%=/4"R>]X@Q)J?04
M99GF)7B.W#F&B-1/D(;/8)>$S&V<@\EUH'_'>*)]QGND>L5]IGG$@*=WPX&H
M=L*#J77"A*ITP8:K<\&'JW+ B:QQOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZUQ
MOXNM<;^+K7&_BZUQOXNM<;^+K7&_BZW/Q@<"T,T)$L#9"2RL]P](F_H>7(_O
M,6N&YT)V@.)0?G[=7X5[V6F*=]5NCW33<Y)QT7>4<-!ZEF[/?9=MSG^9;,V!
MF6O-@YIJS(6;:<R'G&C+B9UGRHR=9\J,G6?*C)UGRHR=9\J,G6?*C)UGRHR=
M9\J,G6?*C)UGRHR=9\J,G6?*C)W*R @!PM('$Z[F"2V=_Q5!D?\H4(?Z.5R!
M\TAF?.U4;G?H7G5QY&5Z;>%K?FK?<(%HWG6$9MQXA67;>X=CVGZ(8MJ!B6'9
M@XI@V86*8-B'BU[8BHQ>UHV-7M:-C5[6C8U>UHV-7M:-C5[6C8U>UHV-7M:-
MC5[6C8U>UHV-7M:-C5[6C8W$R@<#L=H$%9__#2B2_QTWB?\N0X+_/4Y\_4M7
M=_A67V_S765H\&)J9.UI;F'K;W%?Z7-S7>AW=5SG>W9;YGYW6N: >%GE@WE8
MY85Z6.2(>E?DBWM6XXY\5N..?%;CCGQ6XXY\5N..?%;CCGQ6XXY\5N..?%;C
MCGQ6XXY\5N..?%;CCGS_JAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)X
MI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"
MO'NDPKQZJ,.\>:W#N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\+_JAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2
M@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'ND
MPKQZJ,.\>:W#N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\+_JAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$
MDHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZ
MJ,.\>:W#N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\+_JAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFV
MPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\
M>:W#N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\+_JAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.
MN,&.D+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#
MN'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_
MJAP%_ZHG%_^G-B__HD1*^IU29>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.
MD+K BI*\OX>4O;Z$EK^^@IG O8";P;U^GL&\?:'"O'NDPKQZJ,.\>:W#N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\+_JAL%
M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
MJL1QP*K_D1(!_Y4G"_^5.QS_DTLO_X]90_^,9%3[C&MC\HIR<>J(?'WCAH2'
MWH**C]I_CY;6?92;TWJ8G]%XG*+0=Y^DSG6BILUTIJC-<JFIS'&MJLQPLJO+
M<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1Q
MP*K_DA(!_Y8G"O^6.QS_E$LP_Y!90_^/8U3ZCFED\8UP<NF+>G[BB8*)W(6)
MDMB"CIG4?Y.>T7V7HL][FZ;->9ZHS'>BJLMVI:S*=*FMR7.MKLERLJ_)<;>O
MR'&\K\)SO:Z^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:__
MDQ(!_Y<G"O^8.QS_E4LP_Y%91/^18%7ZD&9D\(]M<^B-=X#AC("+VXB'E-6%
MC9S2@I&ASW^6ILQ]F:G+>YVLR7FAKLAWI;#'=JFQQG6MLL9TLK/&<[FSPG6Z
ML[QUNK.X=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK/_E!$!
M_Y@G"O^9.QS_EDLP_Y)91/^27E7ZDF1E\)%J=.>/<X'@CGV,V8N%EM2(BY[0
MA9"DS8*4J<I_F*W(?9RPQWN@LL9YI+3%>*BUQ':NML1UM+;!=K>VO'>WMK=W
MM[:S>+>VLWBWMK-XM[:S>+>VLWBWMK-XM[:S>+>VLWBWMK-XM[;_E1$!_YDG
M"O^9.QS_ETHP_Y-81/^47%7ZE&%E\)-G=.>1<(+?CWJ.V(V#F-*+BJ#.AX^G
MRX23K,B!E[#&?YNSQ'V?M<-[I+?">:FYPG>ON<)VM;F\>+:XN'BVN+-XMK>P
M>;>WL'FWM[!YM[>P>;>WL'FWM[!YM[>P>;>WL'FWM[!YM[?_EA$!_YHG"O^:
M.QS_ETHQ_Y151/^6657ZEEYE\)5D=.>3;(+>D7:.V(]_F=&-B*+-BHZIR8>2
MKL:$EK/$@9JVPGZ?N<)[I+K!>:JZP7>QNKUXM;JW>+6YLWFUN:]YMKBL>K:W
MK'JVMZQZMK>L>K:WK'JVMZQZMK>L>K:WK'JVMZQZMK?_EQ$!_YLF"O^;.QS_
MF$DQ_Y931/^85U7ZF%ME\)=A=.>6:(+>DW*/UI%[FM"/A*/+C8RKQXJ1L<2&
ME;;#@YFXP7^>NL%[I+O >:N\OW>SO+AXL[NR>;2[KGFUNJMZM;FH>[:XJ'NV
MN*A[MKBH>[:XJ'NVN*A[MKBH>[:XJ'NVN*A[MKC_EQ$!_YLF"O^<.AS_F$DQ
M_YA11/^:5%3ZFUAD\)I==.>88X+>EFV/UI-WFM"1@*3*CXFLQHV/L\.)E+?"
MA)BZP'^>O+][I;Z_>:Z^N7BROK)YLKVM>K.\J7NTNJ9[M;FD?+:XI'RVN*1\
MMKBD?+:XI'RVN*1\MKBD?+:XI'RVN*1\MKC_F!$!_YPF"O^<.1S_F4@Q_YE/
M1/^<4E3[G55C\9U:<^>;7X'>F6F/UI9RFL^3?*7*D86MQ9"-M,.+DKC!A9:[
MOX"=OKU[I<&[>:_!LGJPP*Q[L;ZH>[.]I7RTNZ)]M;F@?;:XH'VVN*!]MKB@
M?;:XH'VVN*!]MKB@?;:XH'VVN*!]MKC_F1$!_YTF"O^=.1S_F4<Q_YM-0_^>
M3U/[GU)C\:!6<NB?6X#?G62.UYIMFM"7=Z3*E(&MQ9**M<*.D+F_AY6]O8"<
MP;M[I\2S>JW$JWNOPJ9\L;^C?;*]H'ZTNYY_M;F<?[:XG'^VN)Q_MKB<?[:X
MG'^VN)Q_MKB<?[:XG'^VN)Q_MKC_F1$!_YXF"O^=.!S_FD<Q_YQ+0O^@35+\
MHE!B\J-3<>FC5W_@H5Z,V)YGF-";<:/*F'NMQ96%M,*2C;J^BI*_NH&;Q;=\
MJ<FK?*O'I'VNPZ!^L,"=?[*]FX"SNYF!M;J8@;:XF(&VN)B!MKB8@;:XF(&V
MN)B!MKB8@;:XF(&VN)B!MKC_FA$!_YXF"O^>.!S_FD8R_YY)0O^B2E']I$U@
M\Z90;^JG5'WAIEB*VJ1BEM*A:Z'+G76KQIJ L\*8BKJ\CH_"MH.9RZQ]ILZB
M?ZK)G8"MQ)J!L,"8@K*^EX.SO)6#M;J4@[:XE(.VN)2#MKB4@[:XE(.VN)2#
MMKB4@[:XE(.VN)2#MKC_FA$!_Y\F"O^>-QS_FT8R_Y]'0?^D2%#^ITI?]*E,
M;>NK4'OCK%2'W*M<D]2I99W.IF^GR*-ZL,.?A+B[EHO$L(R9SJ"#I-&9A*G*
MEH6MQ92%K\&3A;&^DH6SO)&%M+J1A;6YD86UN9&%M;F1A;6YD86UN9&%M;F1
MA;6YD86UN9&%M;G_FQ$!_Y\F"O^?-QS_FT4R_Z%%0/^F1D__JD==]JU):^VP
M3'CFLT^#W[15CMFU7Y?3M6F@SK5VI\&K?+:PGX7$H962SI2.H]*0BZC+CXJL
MQHZ*K\*.B;&_CHFRO8Z(M+N.B+6YCHBUN8Z(M;F.B+6YCHBUN8Z(M;F.B+6Y
MCHBUN8Z(M;G_FQ$!_Z F"O^?-AS_G$0Q_Z-#/_^H0T[_K41;^+%%:/"V2'3I
MNTQ^X\!1A]_&6X[6R&N4QKUQIK6S>+6EJ('#E)^-S8F<HM*'E*?,B)&KQXF/
MKL.)CK# B8VROHJ,L[R*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNT
MNHJ+M+K_G! !_Z$F"O^@-AS_GD(Q_Z5 /O^K0$S_L4!9^K=!9/.]1&_NQ4EW
MY<Y2?-W68G_,SFB2O,5NI*N[=K2:L7_!BJJ*RW^GG<^ GZC,@IFKQX.5K<2$
MDZ_!A9&QOX:/L[V'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.
MM+O_G1 !_Z(F"O^@-1S_H#\P_Z<]/?^N/$K_M3Q5^KT]8/#&0F?FT4ILWMY.
M=LW:5X>^T&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2 F:_"
M@9:PP(*4LKZ#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[S_
MGA !_Z(F"O^A-!S_HCPN_ZHZ._^R.$?\NS=1\L4Z6.;105S;WD)IS>)&?+[7
M48RNS%^;H<-MJ)B\>;*1M82[A;&)PGRND<5XKI_%=:VLQ7BEKL1ZH*_"?)RP
MP'Z9L;Y_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKW_GA !
M_Z,E"?^B-!S_I3DM_ZXU./^X,T+TPS-*Y] X3MG>.5K+YCUNON!"@*[44)"A
MRU^=F,-MJ)&]>;&+N(.X@[2(O7VQD,%YL9K!=;&EP7*OK\)UJ*_!=Z.PP'F?
ML;][G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKW_H! !_Z0D
M"?^C,AS_J#0K_[,O-/F_+3SIS2] V=XO2LKG-%^]ZCISK]Y!@Z'349&7RV"=
MD,1NIHR_>JV&NX&S?[B'N'JVC;MWM96\=;6?O'*TJ+UNL[*^<:RROG2GLKYV
MH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKW_H1 !_Z4C"?^D
M,1S_K2XG_[DI+^[()C/:W"8WRN<L3[WR,F.OZ#EUH=U"A);44Y"/S6*:BL=P
MHH;#>JB OX"M>[V%L7:[B[1SN9*U<;F:MG"YH[5MN:NV:KBTN&NRMKANK+:X
M;JRVN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKC_HQ !_Z<B"?^E+QO_
MLR<B],(A)MW8'23+YR,\O?(J4Z_S,F:AYSMVE=Y&@XW65HV'T&26A,MQG'_(
M>*%ZQ7ZE=L*#J7+!B:MOOX^M;+^6KFN^G:YJOZ:N:+^NKF6]N+!EN;NP9;F[
ML&6YN[!EN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[#_I1 !_Z@@"/^L)A?\NQT:
MX]$3&<SE&2F]\B)!K_TJ5:'S-&:6Z3]TC.%+?X7;68B U6:/?-%OE'?.=IES
MRWR<<,F!GVW(AZ%JQXRC:,:2I&;%F:5DQ:"E9,6HI6/&LJ1@Q+NF8,2[IF#$
MNZ9@Q+NF8,2[IF#$NZ9@Q+NF8,2[IF#$NZ;_J!  _ZH>"/^S'1'LR0X/SN,.
M%;[R&"VO_B)#H?\M59;T.62,[$5OA.51>7[@7(!YW&>&=-ENBG#6=(YLTWF1
M:=)_DV?0A)5DSXJ78LZ/F&#-E9E?S9R:7LVBFUW-JYM<S;2:7,VTFES-M)I<
MS;2:7,VTFES-M)I<S;2:7,VTFES-M)K_JP\ _ZT:!_+ #0C.TPH&OO .&J_^
M&3"A_R1#E?\R4HOX/UZ#\4MH?>Q6<'?H7W9QY&5Z;.%L?FG?<H%FW7B$8]Q]
MAF';@HA?VH>)7=F,BUO8DHQ9UYB-6-:>C5?6I8Y6U:R.5M6LCE;5K(Y6U:R.
M5M6LCE;5K(Y6U:R.5M6LCE;5K([_KPT _[<. \W)" &^V D)KOT0'*'_'"^5
M_RD_B_\W3(+^159\^5!>=?199&[Q7VEH[F1M9.MJ<&'J<'-?Z'5U7>=Z=UOF
M?WA9Y81Y6.2)>U;CCGQ5XI-]5.*8?E+AGGY1X:5_4>&E?U'AI7]1X:5_4>&E
M?U'AI7]1X:5_4>&E?U'AI7_QM @ SL & +W.!P&NX <+H/\2')3_("N*_R\X
M@?\]0WK_24MS_U)1;/Y75V7[75MA^6->7O=H8%OU;6)8]')D5O-W9E7R>V=3
M\8!H4?"$:5#PB6I/[XYK3NZ3;$SNF6U+[9]N2^V?;DOMGVY+[9]N2^V?;DOM
MGVY+[9]N2^V?;DOMGV[1N0, O,4% *W6 P&?^ L+D_\6&(G_)"2 _S0O>?]!
M-W#_2#YH_T]#8O]51UW_6DM9_V!-5O]E4%/_:E%1_VY33_]R5$[_=E5,_GM6
M2_U_5TG]A%A(_(A91_N-6D;[DUM%^IA<1?J87$7ZF%Q%^IA<1?J87$7ZF%Q%
M^IA<1?J87$7ZF%R]O0, K<T! )[?  &2_PT(A_\9$G[_*1MU_S4C;/\\*F3_
M0R]>_THT6/]0-U3_5CI1_UL\3O]@/DO_9$!*_VA!2/]L0D;_<$-%_W1$1/]X
M14+_?49!_X%'0/^&2#__C$D]_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4H]_Y%*
M/?^12CW_D4JNQ0  GM<  (_U  &&_P\$?/\;"W'_)!%G_RP77_\U'%G_/2%4
M_T4F3_]+*4S_4BQ(_U<O1O]=,$3_83)"_V8S0/]J-3__;C8]_W,W//]W.#O_
M?#DZ_X$Z./^&.C?_C#LV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2
M/#;_DCS_@Q,!_X0B!O^%-13_@T8D_W]5-/^!7D+_@690_W]N7/E\=V;S>H!O
M[G>(=^IUCWWG<I6"Y'":A>-NGHCA;**+X&NGC=]IJX[>:*^0W6>TD=UFNI'<
M9<&2W&7)DMMET)+29]*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YH
MTI'_@Q,!_X0B!O^%-13_@T8D_W]5-/^!7D+_@690_W]N7/E\=V;S>H!O[G>(
M=^IUCWWG<I6"Y'":A>-NGHCA;**+X&NGC=]IJX[>:*^0W6>TD=UFNI'<9<&2
MW&7)DMMET)+29]*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'_
M@Q,!_X0B!O^%-13_@T8D_W]5-/^!7D+_@690_W]N7/E\=V;S>H!O[G>(=^IU
MCWWG<I6"Y'":A>-NGHCA;**+X&NGC=]IJX[>:*^0W6>TD=UFNI'<9<&2W&7)
MDMMET)+29]*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'_A!,!
M_X4B!O^&-13_A$8D_X!5-/^$74/_A650_X-M7?B =6CR?7YQ['J&>>AWC7_E
M=9.%XG*8B>!PG8S?;J*.W6RFD-QKJY+;::^4VFBUE=IGNY7:9L.6VF;,EM-H
MSY;,:<^5R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;_A1(!_X<B
M!O^'-13_A48D_X14-?^(7$/_B&11_H=K7O>#<FGQ@'QSZWV%>^=ZC(+C=Y*'
MX'27C-YRG(_<<*&2VVZFE-ELJI;9:K"8V&FVF==HO9G7:,::TVC,FLQJS)G&
M:\R:PFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FL)LS)K_AA(!_X@A!O^(
M-13_AD8E_X=3-?^+6T/_C&)1_HIJ7O:'<6KPA'ITZH"#?>5]BH3B>I"*WG:6
MC]QTFY+:<:"5V&^EF-9MJYK5:[";U6JWG-1IOYW4:<F=S&O*G<9LR9W ;<F=
MO6[)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9W_AQ(!_XDA!O^*-13_
MB$8E_XI2-?^.6D/_CV%1_HYH7O:+;VKOAWAUZ82!?N2 B(;@?(^,W7F4D=IV
MFI78<Y^9U7"EF]1NJI[3;;&?TFNXH-)KPJ'-;,>AQF['H<!NQZ&[;\>AN'#'
MH;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ'_B!$!_XHA!O^+-13_B48E
M_XU1-?^26$/_DEY1_I!E7O:.;&OOBW5VZ(=^@..$AHC>?XV/VWN3E-AXF9G5
M=9Z<TW*DG]%PJJ+0;K*CT&VZI,YLQ*7&;\2DOW#$I;IQQ*6U<<2ELG+$I+)R
MQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I+)RQ*3_B1$!_XLA!O^,-!3_BD8E_Y!/
M-/^45D/_E%M1_I-A7O:1:&ONCG!VZ(M[@.*'@XG=@XJ1V7Z1E]5ZEYS3=YV@
MT'2DH\]QJJ;.;[.GS6Z]J,=PPJB^<<&IN'+!J;1SP:FO=,*HK73"IZUTPJ>M
M=,*GK73"IZUTPJ>M=,*GK73"IZUTPJ?_BA$!_XPA!O^--!3_BT8F_Y-.-/^6
M4T+_EUA0_I9>7O:49&KNDFQVYX]V@>&,@(K<AXB2V(*/F=-]E9_0>9RCSG6C
MI\QRJZK+<+2KR'"_K+]SOJRW=+ZMLG6^K*YVOZRJ=K^KJ'? JJAWP*JH=\"J
MJ'? JJAWP*JH=\"JJ'? JJAWP*K_BQ$!_XT@!O^.-!3_C44F_Y9-,_^94$'_
MFE5/_YI:7?>88&GOE6AUZ))P@.&/>XK<BX23UH:,FM* DZ'.>YJFS'>BJLIT
MJZ[(<KBOP'2\K[=UO+"P=KRPJW>\KZAXO:^E>;ZMHWF^K:-YOJVC>;ZMHWF^
MK:-YOJVC>;ZMHWF^K:-YOJW_BQ !_XX@!O^/-!3_CT0E_YA*,_^;34#_G5%.
M_YU76_B<7&CPFF-TZ)=J?^*3=8K<CX"3UHJ)F]&$D*/-?IBIR7FBKL=UK;'$
M=+JSMW:YLZ]XN;.J>;JSIGJZLJ-[N[&@>[RPGWR]KI]\O:Z??+VNGWR]KI]\
MO:Z??+VNGWR]KI]\O:[_C! !_X\@!O^0-!3_DD,E_YI(,O^=2C__GTY-_Z!3
M6OF@6&;QGU]RZIQE?>.8;XC<DWJ2UH^$F]"(C:/+@9:KQWNAL<5VL+6Z=[>V
MKWFWMJAZN+:C?+BTH'RYLYY]NK*<?KNQFWZ\L)M^O+";?KRPFWZ\L)M^O+";
M?KRPFWZ\L)M^O+#_C1 !_X\@!O^1-!3_E$,D_YM&,?^@2#[_HDM+_Z106/JD
M563SI%IPZZ)A>^2?:87>FG.0UY5^F=".B*/*A9.LQ'V@M+UXL+FO>;6YIGNV
MN*%]M[:=?KBUFW^YM)E_NK.8@+JREX"[L9> N[&7@+NQEX"[L9> N[&7@+NQ
MEX"[L9> N['_C1 !_Y @!O^1-!3_ET(D_YU#,/^B13W_I4A)_ZA,5?RI46'U
MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
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M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
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M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
M\&G_81<!_W$0 ?^"#@#_D X ]9T- ..I# #9M0P S[D: ,6X+@>[M#T5L;!)
M(Z>K4C&>IUL^EJ-C2(Z?:E&&FW)9?YAZ8'B5A&9RDX]L;9&<;VF0JG)FD+YS
M99'A<FB.ZW!JBNQN;(CM;&V&[VMNA/!I;H3P:6Z$\&ENA/!I;H3P:6Z$\&G_
M8Q4!_W4. ?^&#0#XE L W*(( -2M"0#/N H R;T7 +^\*P:UN3L3J[9'(:&Q
M4"^8K5D[CZIA1H>F:$]_HW!7>*!X7G*>@61KFXQI9IJ9;6*9J&]?F;QP7IG?
M;V"6[&YCD>UM9H[N:V>+[VIIB?!H:8GP:&F)\&AIB?!H:8GP:&F)\&C_9Q(!
M_WD, /^*"@#?F@0 TZ8' ,RQ" #'NP@ P<(3 +C"* 2NOS@0I;Q$'INX3BR1
MM5<XB+%>0H"N9DMXJVU3<:EV6FNG?V!EI8ID8*.7:%NCIFM9H[IL6*/<:UF@
M[FM<FN]J7Y;P:6&2\6ACC_%F8X_Q9F./\69CC_%F8X_Q9F./\6;_:Q !_WX)
M /&0! #6G@, S*H& ,2T!@"^O@4 N,@0 +#() .GQC4-G<-"&Y/ 3"B*O50S
M@;I</GFW9$9QM6M.:[-T5&2Q?EI?L(E?6J^68E:NI653KKEF4J_;95*K\F95
MI/)F6)_R9EJ;\V5<E_-D7)?S9%R7\V1<E_-D7)?S9%R7\V3_< T _X0$ -V6
M  #.HP, Q*X$ +NW! "TP@4 KLT, *?.( *>S3$*E<L^%HO(22."QE(N>L-:
M.'+!8D!KP&I'9+YS35Z]?%-9O(A75+N56U"[I5U.N[E>3;S;74NY]U].L?9@
M4:KV8%.E]F!5H?9@5:'V8%6A]F!5H?9@5:'V8%6A]F#_=P@ ZXP  -.;  #&
MJ ( N[$" +*[ @"JQP8 HM,* )W6&@&5UBP&C-0Z$8/21AUZT$\G<LY8,6K-
M8#ADRV@_7LIR15C*?$E4R8A-3\F544S)I5-*R;E42<K<4T?(]U5(P/Q82KC[
M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
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M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ
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M4EJ.WE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4
M]70  -J"  #+C@  P9<  +B> 0"QI0  J:L' *.M&@"<K"P$E:LZ#(VH11:&
MID\??Z17*'FB7R]SH&8U;9YN.VB<=T!CFH%%7YF,25N8F4Q7EZA.59>[3U27
MW$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D
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M/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@
MHZD  )BQ  ".N0  A,$" 'G)!P!TRQ0 <,PF 6O+-05ERT *8,I+$%O*5!97
MR5T:4LEE'T[(;R-+R'HF1\B&*43(E"Q"R*0N0,BX+S_)UR\_Q_4P/<3_,SO#
M_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\
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M$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V
M4=\  $GN! !&_ X 0OT7 #[^(0 [_BH!-_\S C3_.@(P_T(#+?]* RO_4P0H
M_UP%)?]F!2+_<P8@_X,''_^4"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G_
M_PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4
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M.)=7_S>75_\WEU?_-Y=7_S?_210 _U,. /]<# #_90T _VL/ /IO$P#L<AD
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M26MUU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60<
M_V4  .)R  #1?   QX0  ,"* @"YCP( LY(, *R4'0"FDR\$GI$\"YB/2!21
MC%$<BXE:)(:'8BJ!A6DP?()Q-7B!>CIT?X,^<'V.0FQ\FD5I>Z='9GJX2&1[
MT$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD
M -UV  #-@   PX@  +N.  "TDP$ K9<) *>8&@"@F"P#F98Z"I*411*,DD\:
MAH]7(H"-7RA[BV<N=HEO,W*'=SAMA8$\:82+0&:"ET-B@:5&8(&V1UZ!S4=>
M@>]&7X'_1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y
M  #(A   OHP  +:3  "NEP  IIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95
M'WJ4729UDF4L<)!L,6R.=39GC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$
M6(C_0UF&_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##
MB   N9$  +"7  "GFP  GJ$  )BC$P"3HR4!C:(T!H:A0 V GTH5>9U3''2;
M6B-OF6(H:IAJ+F:6<C)AE7PW792&.EF2DSY6DJ% 4Y&R05*2R4)2D>M!4I#_
M0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0
MLY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50&&VC6!YH
MHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\3)G_/$R8
M_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H
M **?  "9I0  CJL  (6P"P"!L1L ?+$K G>P. =QKT,-:ZY-%&:M51EAK%T>
M7:ME(UFJ;B=5J7<K4:B"+TVGCS)*IYXU2*>O-D>GQC9&INDV1:3^-T6C_S=&
MH/\W2)S_-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND
M  "0JP  A;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B
M'%*U:R!.M'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R
M0*C_,D&F_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'
ML0  ?+<  '"^ P!HP@X 9L,= &/#+0%>PSD$6L-$"%;"3@Q2PE<03\%?%$O!
M:1=(P7,:1<!^'4+ C" _P)LB/<"M(SS!Q",\P.DC.K[^)CB\_R@WN_\I.+C_
M*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N
M<;X  &;% P!;RP@ 5\T3 %;.(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y
MSV\0/L][$SO/B14YSYD7-\^K&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(
M_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8
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M Q/Y_P.=I0  CZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]
M*_\* "C_$  E_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$.
M_V<!#/]W 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?_
M_P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$
M !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0
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M4"P!_4XW O9+0P3P25 'ZTA="N=&:0WC1700X$1^$]U#AQ7;0I 7V$&8&-5
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M.GMBSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P<
M_UD  .9D  #7;   S',  ,1W @"_>00 N7H. +)\( "L?#$#I7H^"9]X2A":
M=5,7E7-<'9%Q9"*-;VPGB6UT*X5L?"^":H4R?VF/-7QHFSAY9Z<Z=F:V.W1F
MS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP
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M=@  OWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8"
M71]\?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[
M.6)V_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@
MNX$  +*'  "KB@  HHP" )R.% "7CR8!D8XT!8N,0 N%BDH1@(A3&'N&6QUV
MA6,B<H-J)VZ"<BMJ@'LO9W^&,V-^D39@?9XY77RN.EM\P3M;?.,Z6WSZ.%Q[
M_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8
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M+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0
MAJ(  'JF P!VIQ, <Z@D &ZH,@-JJ#T&9:='"V&F4 ]=I5@46:1@&%6C:!Q2
MHW$?3J)\(TNAB"9(H98H1:"F*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27
M_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@
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M%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R (
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M"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>
M 1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP
MBZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9
M_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_
M@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4
M &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@
M#O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0
M_WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')
M  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&
M  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4
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M248"U4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I
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M*)%0T"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10<
M_TL  /!5  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE
M7U</H5U@%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4
MRRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\
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M+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@
MOW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!
M;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG
M_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,
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M*5IT_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@
MD8<  (J)# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA
M@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z
M_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T
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M(3^4_R'-<   O'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@
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M!RO J@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC
MI90  )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  N
MRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/
MI0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H
M )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H
M&]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3
MXK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I
M  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D.
M !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J
M!?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !I
MN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ
M#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD
M  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q
M3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0
M_PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_
MI@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8
M #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4
M /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C
M_Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+
M. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H
M /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\
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M$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H
M_SP  /]!  #U10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y
M15\&M41H";-#<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J%
MT!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\
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M('U1_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@
MQ%X  +Q?  "V7@  L5P+ *M>&@"E8"L H& Z IQ?10677E )E%Q8#)!;8!"-
M6F@3BUEP%HA8=QB%5X ;@U:)'8!6E!]^59\A>U6M(GE4O2-X5=<C=U7R(G96
M_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(
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M'V5B_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<
MF6X  )-P$ "/<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM
M:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F
M_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',
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M'4]U_QW?7   R&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$
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M%3V4J!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@
MMGL  *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/
MH2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"H6$'/Z!K"3V@=PLZH(4-.*"4#C:@
MI@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,
M *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\
M0:LK $"K-P _K$$ /:Q* 3NL4P(YK%P#-ZQG!#6L<P4RK($&,*R1!RZLHP@M
MK+@)+*S9""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1
M  "1E@  A9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A
M #*V+  QMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#
M([G2 R.W] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(
MG0  >Z,  &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#
M'P APRH (,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+
M !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0
M<*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0
MTAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9
MY@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0
M %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$
M!=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR
MY_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#
M   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1
M  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M
M /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   N
MT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V
M#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/
M  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0
M%N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@
M_PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_
MPP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/
M /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +
M_P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T
M /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\
M^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_
M &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H
MN0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L
M_P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P
M!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+
M_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA
M /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T
MY0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_
M)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P7
M9@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G*
M - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!
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M#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@
MT$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?
M0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"
M_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X
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M%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P
MH5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y
M5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5
M_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP
M )5>$ "08!\ C&$N (AA.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03
M<%M]%6Y:B!=K6I09:5FA&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E
M6?\495G_%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P  E6$  (]B
M#@"+9!P AV4K (-E-P%_94(#?&1+!GAC4PAU8UL+<V)B#G!A:A!M8'(3:V![
M%6A?AA=F7I$98UZ?&V%=KAQ@7<$<7UWA'%]=^!I?7?\87UW_%V!=_Q9@7?\5
M8%W_%6!=_Q7K2@  U%8  ,->  "V90  K&D  *)I  "89P  CV4  (EF# "%
M:!D @6DH 'YJ-0%Z:3\#=FE)!7-H40AP9UD*;6=@#6MF9Q!H97 2961Y%6-D
M@Q=@8X\97F*=&UQBK!Q:8K\<66+?'%EB]QI:8O\96F'_%UMA_Q9;8?\56V'_
M%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14
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M%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@
MP&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B
M@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[
MI!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL
M *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX
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M""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0
MAHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 U
MI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$)J7& R:D
MZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4
M '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT
M)K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;
MK_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB
M  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ
M !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L
M#[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2
ML0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*
M)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_
M  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0
M.;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@
MV"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?
M_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8
M "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L
M .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0
M\/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75
M   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7
M  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4
M /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #
MY@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_
M$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1
M  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_
M ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X
M_P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,
M^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_
M%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#(
M .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D
M_Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X
M '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0
MU #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0
M /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G
MZ@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3
M!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:
M!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US
M -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D
MPA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_
M(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6
M=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV
M ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P
M\24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z
M(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F
M_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\
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M"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@
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M#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD
M@U@G (!9- !]63\!>EE( W=84 1T6%@&<E=?!V]79@EM5FX+:U9W#6A5@0]F
M58T19%2:$F)4J1-@5+H47U33%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3
M_PWG1   SU   +]8  "S70  J%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD
M 'I=,0!W73P!=%U& G%=3@1O7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L1
M7EF8$EQ8IQ1;6+@465G0%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC
M2   RU,  +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B
M+@!R8CD!;V)# FQA2P-J85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6
M$E==I1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3
MQU8  +A?  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L
M9S<!:F=  F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)B
MHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH
M +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0
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M#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0
MC70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,
M@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]
MY@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD
M 'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X
M08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <P
MA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_
M  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)
M #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$
M)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !C
MB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=
M00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_
M AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0
M4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :
MJ4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E
M_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*
M #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38
M#+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (
ML_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P
M   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V
M  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\
M ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?
MO0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1
M-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_
M  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP
M#<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P
MY3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K
M_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@
M  #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0
M /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !Q
MK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A
M  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R
M_P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\
MX0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL:
M /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H
M_P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U
M .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(
M% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!]
M /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8
MZ #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_
M Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T
M?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P
M -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP
M_PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#>
M (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,<
M^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\-
M /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L
MRP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V
M#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0
M#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^
M +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\
MIQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>
M#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:
M@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__
M 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @
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M!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT
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M"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P
MRTD  +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T
M4CD <E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/
MH0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT
M +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8
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M#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80
MD6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>9"T 7&0W %ID0 %8
M9$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=BF@I&8JH+1&*_"T1B
MX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,
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M!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0
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M 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@
M<WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  B
ME28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67
MR0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((
M %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L
M$Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +
MHN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.
M  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;
M  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4
M *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$
MGP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y
M'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK
M  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0
M,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%
MQQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.
M]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P
M !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$
M -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@
MY?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*
M   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.
M  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0
M /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
MW0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z
M"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6
M  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X
M_P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_
M +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /
M_P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D
M /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0
M]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_
M"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L
M: #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y
M .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1
M_PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L
M &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4
MP #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP'
M /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4
MVP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#"
M ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*
M  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F
M ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,<
ML@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R
M#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%
M: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O?
M *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0
MVQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K
M$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6
M] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0
M ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4
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M G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P
MF"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@ ?C5? 7TU9@%[
M-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L-OP#:S;_ VLV
M_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@  D#8
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M UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q
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M!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2
MN5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;
M5RD 65@S %A8/ !6640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7
ME09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58
M *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8
M4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=D@5
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M S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P
M>&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z
M<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQ
MR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<
M &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X
M,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)ZQ0$B
M>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L
M  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O
M ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8
M&('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4
M=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.
M,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ
M  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@
M0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +
MFC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8
M_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT
M #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@
M *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_
MI?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>
M   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H
M  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\
M +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6
ML   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##
M)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_
M  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0
M!L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P
MV"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?
M_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P
M  #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@
M .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !J
MJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
M    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6
M  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@
M_P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T
MSP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1
M /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '
M_P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O
M .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\
M#0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R
M /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -,
MW@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_
M  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .(
M<P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D
M ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0
M_P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#,
M '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +<
M\ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ #
M .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X
MN@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G
M /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H
M!P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O
M *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD
MF0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"
M! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+
M<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_
M (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0
ML@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2
M$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9
M_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4(
M * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\
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M 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q,
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M E9 E0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P
MO44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C
M0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6% E%$
MDP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@
M *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@
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M SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40
M?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(
M5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL".%>M C=7
MQ (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0
M &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8
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M 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78
M36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E
M<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP
M_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D
M #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D
M&'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1
M>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET
M   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[
M  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\
M"8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J
M@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3
M/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__
M  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0
M&I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0
MH$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<
M_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX
M  VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<
M *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!
MA   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
M    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X
M  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0
M:)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
MP0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5
M.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X
M %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP
M -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@
M[3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT
M   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,
M  #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP
M /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_
M !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\
M?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T
M /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \
M_P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y
M (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D
M_@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0
M /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H
MZ0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2
M /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P
M%@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z
M -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\
MOP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G
M !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,
M>@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_
M *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4
MS  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O
M 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X
M_P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9
M +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4
MGP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0
M /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P
M'@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X
M )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\
M@PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=
M!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.
M?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_
M '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L
MCQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y
M%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:
M_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB
M ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\
M;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@
M)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C
M*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B(
M &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+
MPS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M
M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %PO
MD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H
M *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L
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M 44_P0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@
M?4$  '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !0
M0CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(0VX 1T-[ 45#B0%#0YD!0D.K 4!#
MP $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40
M &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD
M2D=! $E'2 !(1U  1D=8 $5'80!#2&P 0DAX 4!(AP$^2)<!/$BI 3M(O@$Z
M2-\!.D?X 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'
M  !C1@  6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^
M $-+1@!"3$T 04Q6 $!,7P ^3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!
M-4OW 35+_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?
M20  54@  %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y0
M0P \44H .U%3 #I17  X46< -U%S #51@@ S49,!,E&E 3!1N@$O4=H!+U#V
M 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30
M44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V
M5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5
M_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(
M $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$,
M+5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C
M6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8
M   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-'
M "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\
M'&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W
M8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL
M3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_
M !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P
M*VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /
M=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP
M_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(
M !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL
M G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")
M9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:
M   0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0
M  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0
M<VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +
MCP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "9
M5@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,
M &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G
M *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3
MJ5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^
M  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X
M  "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(
M +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#
MD   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
M    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8
M  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0
M+J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
MT    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I
M7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD
M !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@
M .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P
M_V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\
M(@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"&
M /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\
M\P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_
M "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /(
MA@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_
M -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0
M_0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@
M (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L
M_P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J
M .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (
MR "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W
M /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -(
M+@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"!
M +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\
MI0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[
M #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0
M@@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_
M )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P
MJ  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4
M (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@
M_P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P
M )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($
MA0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q
M#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T"
M,P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F)
M '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@
MT!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0"
M#38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1
ME !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0
M + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$
M=!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C
M&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I
M  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU
M &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP
M62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2
M+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E
M.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ
M % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@
M@#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9
M+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DO
MNP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4
M '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H
M4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"
M--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW
M  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_
M $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=,
M/#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B
M.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\
M1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR
M #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0
M6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00!
M0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #)
M_P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\
M $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148
M.45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N
M1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#
M  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI,
M #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\
M*$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _
M2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M0
M4@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_
M "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@
M-5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B
M5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2
M_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54
M "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754
M&%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"4
M40  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>
M   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=
M  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50
M>E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9
M:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N
M90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H
M &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0
M#G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@
M>&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>
M  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X
M  * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@
M (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !2
M9   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ",
M P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S
M  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0
M/W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
MF@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B
M@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX
M "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0
M *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P
MM8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4
M   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L
M  "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\
M ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1
MJP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
M    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,
M  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O
M ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
MY    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]
MEP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V
M /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T
M^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7
M /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\
M/0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ".
M .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\
MP@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S
M $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0
MD #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_
M +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L
MW !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"]
M )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *<
M_P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^
M ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L
MJ "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T
M0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ".
M )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M[P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@":
M $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@
ME0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D
M ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P
MBP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y
M )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0
M  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^
M 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH
M; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">
M%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)
M0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI
M &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0
MB1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I
M$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4
MN@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(
M 'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX
M7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.
M&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F
M  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]!
M %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT
M1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F
M*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F
M10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM
M #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0
M72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(
M+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM
M_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\
M %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4<
M03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U
M,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P
M  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9,
M #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\
M,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'
M-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z
M4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_
M "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@
M/SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N
M/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]
M_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\
M #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@
M)T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":
M/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!&
M P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA
M !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@
M@$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F
M30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0
M:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8
M &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P,
M'%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /
M5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*
M  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P'
M !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G,
M!5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !7
M3@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF
M"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>
M  !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@
M2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0
M;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !Q
MCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<
M #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L
M 'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B
M?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C
M   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+
M  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD
M (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D
M<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5
M"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK
M  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0
M$H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0
MIP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "N
MO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@
M  .=    H@   *8   "J    K@   +    "Q    LP   +0   "V    N
M +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP
MQ=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
M    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T
M  #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T
M .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
MQ    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
M    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$
M  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@
M_P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U
M *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,(
M_P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!,
M /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H
MX@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@
M3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "=
M ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M_P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #*
M $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +(
MH0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P
M /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@
ML@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"=
M *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0
M  #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !)
M )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$
MBP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
M    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X
M20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J
M 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0
MH@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^
M $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X
MM@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL
M (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0
M<0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A
M ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /
M  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-&
M &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8
M5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q
M$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-
M2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J
M $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@
M9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4
M$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46
M_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT
M %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@
M2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^
M'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?
M  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!-
M $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\
M."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/
M(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF
M4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_
M #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@
M1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V
M*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ
M_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L
M #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@
M,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<
M+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ
M"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A
M "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0
M@S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R
M-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y
M;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8
M &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL
M*CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;
M/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY
M  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(.
M ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'<
M$T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:
M/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)
M$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'
M  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60
M34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 2
M4!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50
ME@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0
M $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!
M"E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0
M5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'
M   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2
M  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(
M %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R
M3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H
M$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV
M  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@
M)%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$
M=!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !T
MTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,
M !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1
M ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0
M@O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU
M   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/
M  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H
M )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
MB0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E
M#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X
M  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@
M )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0
MN@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\
M_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +
M  "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(
M - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&
M@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
M    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8
M  #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8
M_P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_
M %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X
MLP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P
M /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %<
M\0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5
M +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\
M  #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7
M -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +(
MNP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
M    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T
M5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[
M *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
MT    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F
M %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )(
MR0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@
M +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\
MD@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"
M .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *
M  "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!.
M ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\
M<0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+
M  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ',
M3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H
M &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M>P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F
M $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@
M^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8
M &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L
M6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !.
M _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+
M P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/
M %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\
M10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:
M#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.
M50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_
M #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P
M4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!
M%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5
M_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8&
M $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@
M.1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"=
M'P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<
M# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@
M #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@
MA"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [
M(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE
M:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<
M &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X
M-"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D
M*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK
M  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1
M "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8
M'2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;
M+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q
M%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2&
M !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0
M3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @
M-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$Y
MF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0
M $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14
M&#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +
M/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W
M   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8
M !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4
M D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X
M.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*
M&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY
M  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0
M+SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P
M41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0
MV   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,
M "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D
M %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0
M6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-
M   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;
M  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(
M &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   2
M60  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P
M'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_
M  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9
M!F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@
M?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z
M_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8
M  !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8
M )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!5
M60  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
M    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06
M  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80
M0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
MH0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\
M%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7
M "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP
M +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@
MU!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(
M   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H
M  #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\
M .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_
M  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\
M90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@
M ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M_P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I
M &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B
M?1!)0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T
M1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2
M +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M_P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"]
M $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *,
ME@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@
M .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T
MHP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@".
M )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P
M  "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ]
M (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0
M>@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
M    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T
M/0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "=
M &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
MC0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N
M #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T
MJ != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(
M '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@
M8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1
M +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*
M  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y
M %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +(
M1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>
M#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!
M.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/(
M #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@
M4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$
M"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,
MZ0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314
M $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP
M/0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M
M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08
M  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1
M #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\
M*!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^
M&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X9
M1@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_
M ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@
M.!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G
M'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>
M_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R
M # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H
M(215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%
M(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE
M   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3
M !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0
M;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D
M*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N
M70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH
M %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P
M'# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .
M,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N
M  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4%
M !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4
M!SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !)
M,0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \
M"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR
M   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-
M/C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )
M0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$
M@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<
M #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P
M $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0
M2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y
M   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -
M  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\
M %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G
M0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:
M#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC
M  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2
M&DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@
M9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !H
MNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4
M  Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD
M '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP
M=>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'
M  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\
M (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M>P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":
M!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON
M  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0
M )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
ML0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P
M_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4
M  "J    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@
M ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W
M<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
M    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$
M  #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M_P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_
M %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D
MJ@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P
M /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T
M[ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#(
M +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T
M  #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!,
M ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D
MK@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
M    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$
M2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q
M )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
MO    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8
M $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (,
MO@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@
M )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $,
M@P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P
M -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P
M  "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!"
M '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,(
M8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &,
M0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #>
M %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6
M $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D
M\P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P
M %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X
M2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _
M /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &
M  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!!
M $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D
M-@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'
M"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%
M10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_
M "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@
M0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R
M#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-
M_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$!
M #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L
M*A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&
M%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2
M!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13
M "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P
M;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L
M%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T9
M70 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT
M %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4
M)1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6
M'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA
M  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" *
M !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V<
M$"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+
M)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF
M#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT
M  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P
M/R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2
M+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M
M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D
M #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T
M#3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P
M,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K
M   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0
M  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(
M #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K
M+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]
M$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG
M   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P
M)#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$
M1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$
MP   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4
M !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$
M $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O
M2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_
M   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1
M  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,
M %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +
M2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D
M$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\
M  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@
M %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@
M=1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N
M_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@
M  !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T
M (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&
M2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M    @0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-
M  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@
M,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
ME    )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U
M#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$
M !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D    J
M *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0
MT0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y
M   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,
M  #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8
M .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_
M  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P
M6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5
M -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M_  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B
M %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T
MZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@
M .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %,
MOP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C
M /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@
M  #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1
M *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /
MC0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F
M  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X
M3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_
M '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $
MBP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X
M $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &<
M_P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  %
M '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@
M9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9
M /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8
M"0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !(
M %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\
M30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8
M  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P
M2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_
M $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D
M30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!!
M $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D
M_P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  +
M $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D
M-P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P",
M"0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!
M#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0
M "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#
M<@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U
M!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'
M60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$
M %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL
M+PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @
M#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5
M  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X-
M "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8
M%Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+
M&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2
M#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T
M !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P
M/QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;
M%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9
MA  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T
M #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!
M%1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  '
M'I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?
M   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2
M ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$
M "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J
M(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF
M%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F
M   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P
M)"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $
M*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   K
MO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0
M !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14
M #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO
M,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG
M   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8
M   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0
M #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4
M+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  !
M&P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\
M   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P
M#38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@
M2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$
M_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X
M  -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D
M %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%
M-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;
M  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/
M.CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R
M(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X
M "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :
M &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P
MAB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(
M   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X
M  "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH
M )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   5
M60  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
M    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>
M  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0
M!7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
MK    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1
M)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0
M  "-    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@
M ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@
M["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X
M#@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B
M /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\
MM@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z
M  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8
M8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_
M )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L
MVP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V
M %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L
M_P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP .
M +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %<
MF0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V
M /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@
M$ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6
M ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\
M9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_
M !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T
M5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_
M %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X
M:P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!<
M %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\
M_P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0
M %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$
M30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
M    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X
M$0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5
M $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!#
M !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #<
M6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,
M &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !
M.0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M
M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*
M  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1
M #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &
M) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.
M#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!
M$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L
M !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$
M0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D
M!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(
M?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(
M #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q(
M'0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /
M#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4
M   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4
M !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)
M"1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J
M%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2
M&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C
M  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&
M(Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .
M%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7
MN0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D
M !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@
M"!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0
M&]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:
M   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <
M  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X
M ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8
M&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F
M(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y
M   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@
M$QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0
M+"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H
M_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",
M  XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$
M #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,
M)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ
M   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF
M   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0
M.RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !
M-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%
M+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X
M "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /
M #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P
M3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO
M   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D
M  !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP
M %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D
M,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT
M  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P
M%3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M:P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  "
M/@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL
M  =1    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@
M (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P
METD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M    :    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8
M  "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX
M +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M>P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
M    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+
M  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D
M )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
MRP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J
M6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9
M /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H
M[@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6
M /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /<
M&P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J
M ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\
M@P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2
M !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P
M:0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_
M '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@
MK0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/
M &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@
M_P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9
M (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &(
M=@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
M    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '<
M&@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D
M &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
MGP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C
M !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %(
M: !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0
M 'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8
M4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!#
M '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\
M  !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6
M $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D
M-P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H
M%P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S
M "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @
M2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P
M !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0
M@@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@
M #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4
M)P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  <
M ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+
M   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6
M !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\
M%0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L
M#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$
M&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B
M  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P
M) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4
M"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'
MMP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1
M !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D
M$ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  #
M#-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1
M   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =
M  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0
M  [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6
M$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2
M(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U
M   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$
M$Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "
M%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3
M_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,&
M ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0
M !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1
M%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5
M!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J
M   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0
M/QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +
M&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G
M,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X
M #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P
M!"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@
M+CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA
M   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<
M   I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8
M #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D
M(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!
M   _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0
M'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M/@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*
M3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@
M !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&    2
M $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@
M5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R
M   *-@   SH    _    0@   $8   !)    3    $\   !2    50   %@
M  !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(
M &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "
M0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA
M  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40
M %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M@@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1
M<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@
M  !N    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0
M )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0
MJ(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
M    B0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4
M  "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P
M ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?+0S_HS<4_ZY
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M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
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MQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
M:<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:
M?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O
MJK=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2E
M_XT; _^+)PC_C# -_Y@W$_^@0!O_IT@F_ZM2-/^K7$3_J694^J5P9/"?>7/G
MF(*!WX^(C=F(CY?2@96@SGN;I\IVH:W'<ZBQQ7"OM<%MM[>Y:[BULVZ]KK!P
MP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&H_XX;
M _^+)@C_CC -_YHV$O^B/QK_J4@F_ZY1-/^N6T3_K&15^:IN9>^E=W;EG7^%
MW)2%DM2,C)W.A)*GR7V8K\1XGK7"=:>YP72QN[APL[NQ;[:XK'&[L:ESOZNI
M<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^K_XX; _^,
M)@C_D"\-_YLV$O^D/QK_JT<F_[%0-/^Q643\L&-5]JYL9^VJ=7CCH7R(V9B#
MEM&0B:/*AX^MQ8*7M,)_H+B^?*B[NWJPO;%TLKVI<K2[IG2YLZ-VOJVC=KZM
MHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZM_X\; _^,)@?_
MD2X,_YTV$O^F/AK_K4<E_[-/-/^T6$3ZM&%6\[)J:.RO<WKAIGJ+UIV FLV4
MAJ?&C8VOOX>4M;J"G+FU?Z2\LGVLOJMYL;^C=K*]H'BXM9YYO:^>>;VOGGF]
MKYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VO_X\; _^-)@?_DRX,
M_YXU$?^H/AG_KT8E_[9.,_ZW5T3WMV!6\+9H:>BS<'O>JG>-T)]\G<>7@Z>_
MD(JON(N1MK*&F+JM@Z"]J8&IOZ5^L,"<>;&_FGNWMYA]N["8?;NPF'V[L)A]
MN["8?;NPF'V[L)A]N["8?;NPF'V[L)A]N["8?;NP_Y : _^-)@?_E"T,_Z U
M$?^I/AG_L48D_[A-,_R[5D3UNU]6[;MG:>.U;GW6K'./RJ-ZG<&;@*>XE(>P
ML8^.MJN*E;NFAYV^HH6EP)^$K\&6?K#!E'^VN). N[*3@+NRDX"[LI. N[*3
M@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3@+NR_Y : _^.)@?_E2T,_Z$U$?^K
M/1C_LT8D_[I-,_J^543SOUU6ZK]E:M^X:W[0KW&/Q:9XG+N??J>RF(6OJY.+
MMJ6.D[N?BYJ^FXFBP9B(K,*0@J_"CX.UN8^$NK./A+JSCX2ZLX^$NK./A+JS
MCX2ZLX^$NK./A+JSCX2ZLX^$NK./A+JS_Y : _^.)0?_EBP+_Z(U$/^L/1C_
MM44C_[Q,,OC!5$/PPUQ6Y\-C:MJ[:7[,LG"/P*IVG+:B?*>MG(*OI9>)MIZ3
MD+N9CYB^E(V@P9&,J<*+B*["BHBTNHJ(N;2*B+FTBHBYM(J(N;2*B+FTBHBY
MM(J(N;2*B+FTBHBYM(J(N;2*B+FT_Y$: _^/)0?_F"P+_Z0T$/^N/1C_MT4C
M_[],,O;%4T/NR%M6X\9A:M2_:'['MFZ.NZUTG+&F>J:GH("OGYN&M9B7CKN3
ME96^CI*=P8J2I\*&CJ["A(VTNX6,N;2%C+FTA8RYM(6,N;2%C+FTA8RYM(6,
MN;2%C+FTA8RYM(6,N;2%C+FT_Y$: _^/)0?_F2P+_Z8T#_^P/!?_N40B_,%+
M,?3)4D+KS5E5W\E@:L_"9GW"N6R-MK%RFZNK>*:BI7ZNF:"$M9*=B[J,FI.^
MAYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL
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M@\2EC8/$I8V#Q*6-@\2E_XD9 _^') ;_DRD)_Y\Q#?^I.1/_L4$<_[E)*?;
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M-Q=E_S\;7O]''EC_3B%4_U<C4?]?)4[_929-_VPG2_]Q*$K_=BE)_WLJ2/^
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ME)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D-0__K#T7_K)%(O:X3##MO%1
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MKC)#_ZXRN+H" *K(  "=V0  DO\, HG_&@1]_R$(<O\H#&C_,!!@_S@46O]
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MI6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN
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M!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G 6E&MNF%?H[1G;)FP;7>0JW2
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M4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ;YUB[VRE9^UIK6OK9K9OZ&/
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M ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S:6:'L&]N@*UV=7FJ?7MSJ(2
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MN4Q*]\A-2?C@34CW\TU(]_1-2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-VJ,
M ,>Q @"XNP, K<D$ */9!P":_10"DOTG!X?^+PU]_C<4=/\_&VS_1R!F_TXE
M8/]7*5S_8"U9_VDP5O]Q,E/_>#11_X V3_^)-TW_DCE+_YPZ2?^F.TC_L3Q&
M_[T]1?_,/43_YCY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YSY$_^<^RZP  +FV
M 0"LP@$ H- " )7E!P"._Q@#A/\D!GK_+ MP_S00:/\\%6'_1!E;_TL=5O]3
M(%/_6R)0_V,D3?]K)DO_<R=)_WHI2/^"*D;_BBM$_Y0L0O^>+4'_IRY _[$N
M/_^\+S[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TPN[$  *R\  "?
MR0  D]D  (G\"P& _Q<"=O\@!6S_* ED_S -7?\X$%?_0!-1_T<63?].&$K_
M5AE'_UP:1/]C'$+_:1U _W >/_]X'CW_@!\[_X@@.O^1(3C_FR(W_Z0B-O^M
M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@
MA.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]
M_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_
MIQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<
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M8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6
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M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
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M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
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MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
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M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
M %_V  !6_P  3O\* $?_$ %!_Q8"//\= C?_) ,R_RH#+_\P!"O_-@4G_SL%
M)?] !2+_108@_TH&'O]0!AO_5@<9_UP'%_]D"!7_;0@3_W<($?^!"1#_BPD0
M_Y4)#_^8"0__F D/_Y@)#_^8"0__F D/_Y@)_TDG O]$,03_2S$$_U T!O]2
M.@C_4D,+_U%.#_]/7!/_36L6_TQY&?]+AQO_29,=_TB='_](IB#_1ZXA_T>U
M(O]&O2/_1L8C_T;0)/]&X"3_1NHE_T;S)?]&^B7_1O\E_T;_)?]&_R7_1O\D
M_4;_(_U&_R/]1O\C_4;_(_U&_R/]1O\C_TDG O]&+P/_32\$_U(R!O]5.0C_
M54(+_U1-#_]261/_4&@7_T]W&O].A!W_3)$?_TN;(?]*I"+_2JPC_TFS)/])
MNR7_2,0F_TC-)O](W2?_2.@G_TCQ*/](^2C_2/\H_TC_*/Y(_RC[2/\G^4C_
M)OE(_R;Y2/\F^4C_)OE(_R;Y2/\F_THG O](+0/_4"T$_U4P!O]8-@C_64 +
M_UA+#_]55A/_5&88_U)T&_]1@1[_3XXA_TZ8(_]-H27_3:DF_TRQ)_]+N"C_
M2\$I_TO**O]*V2K_2N8K_TKP*_]*^"S_2O\L_4K_+/I*_ROW2O\I]4K_*/5*
M_RCU2O\H]4K_*/5*_RCU2O\H_TLF O]+*P/_4BL$_U@N!?];- C_73X+_UU)
M#_]:5!3_66(8_U=Q'?]5?B#_4XHC_U*5)O]1GBC_4*8J_T^N*_].M2S_3KTM
M_TW'+O]-TR__3.,P_TSM,/Q,]C'Z3/XQ]TS_,?5-_R_R3?\M\$W_*_!-_ROP
M3?\K\$W_*_!-_ROP3?\K_TLF O].*0/_5BD$_UPK!?]@,0?_8CL+_V)&#_]@
M413_7E\9_UQM'O]:>B/_6(8F_U:1*?]5FBS_4Z(N_U*J,/]1L3'_4;DS_U##
M-/Y/SC7[3]\V^$[K-_5.]3CR3OTX\$__->Y0_S/K4?\QZ5'_+^E1_R_I4?\O
MZ5'_+^E1_R_I4?\O_TPE O]1)P/_6B8#_V H!?]E+P?_:#D*_VA##_]G3A7_
M95H:_V)H(/]?=B7_78$J_UJ,+OY8EC'\5YXT^U6F-OE4K3CX4[4Z]U*^._51
MR3WS4=H^\%#H/^Q0\T#I4?T^Z%/_.^94_SCC5?\UX57_,^%5_S/A5?\SX57_
M,^%5_S/A5?\S_TTD O]4) /_72,#_V4E!/]J+0;_;38*_VY #O]M2Q3_:U8;
M_VAD(?YE<2C[8GTM^%^',O9<D3;S6IDZ\EBA/?!7J4#N5;%"[%2Y1.M3Q$;I
M4M)(Y5'E2>)2\DC?5/Q$W5;_0-M8_SW66?\ZTEG_.-)9_SC26?\XTEG_.-)9
M_SC26?\X_TXD O]8(0/_82 #_VHC!/]P*P7_<S0)_W0^#O]T2!3_<E(;^V]?
M(_9K;"KR9W<Q[V."-^Q@BSWI791!YEJ<1>18I$GB5JQ,X%2T3MU4OU#;5,U0
MUU/B4=)4\$[05_M*SEK_1<U<_T+)7/\^Q5S_/,5<_SS%7/\\Q5S_/,5<_SS%
M7/\\_T\C O];'P+_91T"_VXA _]U*07_>3$(_WH[#/]Z1!/Z>4X;]'9;(^YQ
M9RSI;'(UY6A\/.%CA4/=8(Y(V5V73-5<GT_26J=1SUFP4\U8NE3+6,95R5?:
M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
MWZH6 -&L)@/'J#<-O*-$&K.>3R>JF5@SHY1@/9R0:$66C&],D(EV4HN&?5>&
MA(5;@H*.7WZ EV-Z?Z%F=WZM:'5^O6ES?M)I=H'N8GB"^EMX@OY6>8'_47F!
M_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX _Y . /6;#@#HI@X V:\/
M ,RO) +"JS4,N*=#&:ZB3B:FG58QGIE>.Y>59D20D6U+BXYT48:,>U:!B8-;
M?(>+7WB&E6)TA)]E<8.K:&Z#NFEM@\YI;X;K8W*'^5QSAOU6<X7_4G.%_U)S
MA?]2<X7_4G.%_U)SA?]2_V@1 ?]X#0#_A@T ]I,, -Z@"0#6J0H TK(- ,>R
M(@*]KS,*LZM!%ZJG3"2AHE4PF9Y=.I*:9$*+EVM)A91R4("2>55[CX%:=HV)
M7G*,DF)NBIUE:XFI9VB)N&AGB<MH:8OI8VR-^5QMC/U7;8K_4FV*_U)MBO]2
M;8K_4FV*_U)MBO]2_VL0 ?]["P#_B@H XI@& -:C" #0K D R[4+ ,&V'P&X
MM#$)KK _%J2L2B*<J%,NE*1;.(R@8D"&GFE(@)MP3GJ9=U-UEGY8<)2'7&R3
MD&!HDIMC9)&G96*0MF9@D<EF8I+G8F64^%QGDOU79Y'_4F>1_U)GD?]29Y'_
M4F>1_U)GD?]2_VX. /]_"0#QC@4 V9L% ,^F!P#)KP< Q+D( +NZ' &RN"\'
MJ+4]$Y^Q2""6KE$KCJI9-8:G8#Z I6=%>J)N2W2@=5%OGGQ5:IR%66:;CEUB
MFIE@7IFF8ER9M&-:F<=C6YKE8%^;]UM@FOY689C_4F&8_U)AF/]289C_4F&8
M_U)AF/]2_W(+ /^#!0#?DP$ T9\$ ,FJ!@#!L@4 N[T$ +2_& "KOBP%HKLZ
M$9FX11V0M4\HA[)7,H"O7CIYK65"<ZML2&ZI<TUIIWI19*:#5E^DC5E<HYA<
M6*.D7E:CLU]5H\9?5:3D75BD]EA:H_]46Z'_4%NA_U!;H?]06Z'_4%NA_U!;
MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
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M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
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M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
M %+_"0!-_Q$ 1_\9 4/_(@$^_RH".O\R S?_.0,S_S\$,/]&!2W_304K_U0&
M*/];!R;_8P<C_VT((?]Y"1__APD>_Y4*'?^C"AS_L0H;_\ +&O_6"QK_WPL:
M_]\+&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4  $;_
M!0! _PX ._\4 #?_&P$S_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#'?].
M QK_5008_UX$%?]H!1/_= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8._[H&
M#O^Z!@[_N@8._[H&CKH  '_%  !PT0  8MX  %3E  !&ZP  /_X  #G_   T
M_PD +_\. "O_%  G_QH!(_\A 1__)0$<_RH!&?\O 1;_- (4_SH"$?]  A#_
M1@(._TX"#/]6 @G_8 ,'_VP#!/]X P/_A@,"_Y$# ?^= P'_H0,!_Z$# ?^A
M P'_H0,!_Z$#_S8M O\Y+@+_/BX#_T R _] . 3_/D$&_SQ,"/\Z6@K_.&@,
M_S9V#O\U@P__-(\0_S.9$?\SH1'_,ZD2_S*P$O\RMQ+_,K\2_S+($_\RTQ/_
M,N,3_S+M$_\R]A+_,_X2_S/_$O\S_Q+_,_\1_S/_$?\S_Q#_,_\0_S/_$/\S
M_Q#_,_\0_S8M O\[+ +_0"P#_T,O _]#-03_0CX&_T!*"/\^5PO_/&4-_SIS
M#_\X@!#_-XP1_S>6$O\VGQ/_-J<3_S:N%/\VM13_-KP4_S7%%?\UT!7_-> 5
M_S;K%?\V]!7_-OT4_S;_%/\V_Q3^-_\3_C;_$_TV_Q+]-O\2_3;_$OTV_Q+]
M-O\2_S<L O\^*@+_0RH"_T8M _]',@3_1CP&_T5("/]#50O_06(-_S]P$/\]
M?1'_/(D3_SN3%/\[G!7_.J06_SJK%O\ZLA?_.KD7_SG"%_\YS!?_.=T8_SGI
M&/\Y\QC_.OL8_#K_%_HZ_Q?Y.O\6^#K_%O@Z_Q7X.O\5^#K_%?@Z_Q7X.O\5
M_SDK O]!)P+_1B<"_THI _]++P3_3#D&_TM%"/](40O_1EX._T1L$?]">1/_
M0845_T"/%_] F!C_/Z 8_S^G&?\^KAK_/K8:_SZ^&_\^R!O_/=8<_CWF'/L^
M\1SX/OH<]3[_'/,^_QKR/_\9\3__&?$__QCQ/_\8\3__&/$__QCQ/_\8_STH
M O]%) +_2B,"_TXE _]1+ 3_4C8&_U%!"/]/30S_3%H/_TIG$O](=!7_1X 7
M_T:+&?]%E!O_1)P<_T.D'?Y#JQ[]0K(?_$*Z(/I"Q"#Y0M A]D'B(?)"[B+O
M0ODB[4+_(.M#_Q_J0_\=Z43_'.A$_QOH1/\;Z$3_&^A$_QOH1/\;_T E O](
M(0+_3R "_U,A O]7*0/_63,%_U@^"/]620S_4E40_U%C%/]/;Q?^37L:^TN&
M'?E*CQ_W29@A]DB?(O1'IB3S1ZXE\4:V)O!&OR?O1<LH[$7>*>A%["GE1O@H
MXD?_)N%(_R3?2?\BWDG_(-U)_Q_=2?\?W4G_']U)_Q_=2?\?_T,B O],'@'_
M4QP"_UD> O]=)@/_7S $_U\Z!_]=10O_6E 0_5A>%?A5:AGU4W8=\E& (>]/
MBB3M39,FZTR:*>E+HBOG2JDLY4FQ+N1(NR_B2,<QX$C9,=Q(ZC'82?8NU$O_
M*]),_RG03?\FST[_)<Y._R/.3O\CSD[_(\Y._R/.3O\C_T<? ?]0&@'_5Q@!
M_UX< ?]C(P+_9BP$_V8V!O]D00KZ8DP/]%]9%>]<91OK67 @YU9[)>14A"GA
M48TMWE"5,-Q/G3+93J4SUDVM-=--MS;13,(WSTS1.,Q,YCC)3?0UQT__,<51
M_R[$4O\KPU/_*<)3_R?"4_\GPE/_)\)3_R?"4_\G_TH< ?]4%P'_7!4!_V,9
M ?]I( +_;"D#_VTR!?EL/0GR:4<.ZV94%>5C8!S@7VLBVUQU*-99?RW25X@P
MSU60,\Q4F#;*4Z XQU*G.L51L#O#4+L\P5#)/;]0WSV\4? [NE/\-[E5_S.X
M5_\OMUC_+;=8_RNW6/\KMUC_*[=8_RNW6/\K_TT: ?]7% '_8!(!_V@7 ?]N
M'0'_<B4"^W,N _)S. ?I<4,-XFY0%-MI7!S3968DSF)P*LE?>B_&7((SPUN*
M-L!9DCF]6)H[NU:B/KA5JS^V5;5!M%3"0K)4U$*P5>I!KE?Y/*Y9_S>M6_\S
MK5S_,*U=_RZM7?\NK5W_+JU=_RZM7?\N_U 7 ?]:$@'_9!  _VT4 /]S&@'_
M=R$!]'DI NIZ,P7B>#\*V71,$\]P6!S):V(DQ&AL*[]E=3"[8GTUN&"%.+5>
MC3RR7)4^KUN=0:U:ID.K6:]$J5F\1:=8S$:D6.5&I%OV0*->_SNC7_\WHV#_
M,Z-A_S&C8?\QHV'_,:-A_S&C8?\Q_U,5 ?]=$ #_: \ _W 2 /]W%@#[?!P!
M[G\D >2 +0/:?SL(SWI)$L=U5!O!<5\DNVUH*[9J<#&R9WDVKV6 .JMCB#VH
M89! IF"80Z->H46@7JM'GEVW2)Q=QDF:7-])FE_R1)IB_SZ:8_\YFV7_-IME
M_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX _W00 /][$@#U@1< Z(0>
M -Z')P'1A#<'R']&$<![41NY=ELCM')E*Z]O;3&J;'4VIVI\.J-HA#Z@9HQ!
MG6241)ICG4>78J=)E6&R2Y-AP4R18=A,D6/O1Y)E_4&29_\\DVG_.)-J_S63
M:O\UDVK_-9-J_S63:O\U_U<1 ?]C#0#_;@P _W<. /]_#P#PA1$ XXD6 -:+
M(P'+B#4&PH1#$+J 3QJS>UDCK7=B*JAT:C&C<7$VGVYY.YQL@3^8:HA"E6F1
M19)GFDB/9J-*C66O3(IEO4V)9=%.B6?L2HII^T.+:_\^C&W_.HQN_S>,;O\W
MC&[_-XQN_S>,;O\W_UD0 /]E"P#_<0L _WH+ /&"# #HB0T W8X. ,^/( '&
MC3(&O8E!#[6$31FN@%8BIWQ?*J)X9S"==6\VF7-V.I5Q?3^2;X5"CFV.1HML
MEDF(:J!+A6JL38-IND^!:<Q/@6KH3(-M^46$;_\_A7#_.X9Q_SB&<?\XAG'_
M.(9Q_SB&<?\X_UL/ /]G" #_<P@ \WT( -Z&!P#9C D U9$+ ,J2'@#!D# %
MN(T_#K"(2ABIA%0AHH!=*9U]93"8>FPUDW=S.H]U>SZ,<X)"B'*+1H5PE$F"
M;YY,?VZI3GQMMT][;<E0>F[F37QQ^$9^<_]!?W3_/8!U_SJ =?\Z@'7_.H!U
M_SJ =?\Z_UT. /]J!@#_=@8 Y( # -F)!@#2CP@ SY0* ,66&P"\E"X$LY$]
M#:N-2!>DB%(@GH5;*)B!8R^3?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\<YM,
M>7*G3G9RM5!T<L90='+C3W9U]D=X=_]">GC_/GMY_SI[>?\Z>WG_.GMY_SI[
M>?\Z_U\, /]L! #U>0( WH," -.+!0#-D@< R9<( ,"9&0"WF"P#KY4[#*>1
M1Q:?C5 ?F8E9)Y.&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17EZCTEV>)E,<W>E
M3G!WLE!N=\10;7?@3W!Y]4AR>_]#='S_/G5]_SMU??\[=7W_.W5]_SMU??\[
M_V$* /]O @#H?   V88! ,^.! #(E08 PYH& +N<%@"SG"H#JIDY"Z*5112;
MD4X=E(Y7)HZ+7RV)B&8SA(9M.("$=#U[@GM!=X"$171_C4AP?9=+;7RC3FI\
ML$]H?,%09WS=4&I^\TEM@/]#;H'_/V^!_SQO@?\\;X'_/&^!_SQO@?\\_V0(
M /]R  #A?P  TXD! ,J2 P##F 0 O9X$ +:@$P"NH"<"I9TV"9V:0Q.6ETT<
MCY-5)(F172N$CF0Q?XQK-WJ*<CMVB'E <H:"1&Z%BT=J@Y5*9X*A362"KD]B
M@K]/88+:3V2$\DEFA?]#:(;_/VJ&_SQJAO\\:H;_/&J&_SQJAO\\_V<$ /9V
M  #<@@  SHT  ,65 @"^G , MZ$" *^D$0"HI"0"H*(T")B?0!&1G$H:BIE3
M(H276RE^E6(P>9)I-760<#IPCW<^;(U_0FB,B49EBI-)88F?2UZ)K$U=B;U.
M7(G635Z*\$A@B_Y#8HO_/V.,_SQCC/\\8XS_/&.,_SQCC/\\_VH  .9Z  #5
MA@  R9$  ,"9 0"XGP$ L*4  *BI#@"BJ2$!FJ@Q!I.E/@^+HT@8A*!1('Z>
M62=XG& M<YIG,F^8;C=JEG4\9I5]/V*4AT-?DI%&6Y*=25F1JTI7D;M+5I'3
M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
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M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
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M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
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M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
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MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
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M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
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M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
M_XH  /^;  #_J   _[$  /^Q  #_L0  _[$ _R4K ?\H*0'_*2D!_R@L ?\C
M,@'_'CL"_QI' O\750/_%6(#_Q-P _\2? /_$H<#_Q*1 _\2F0/_$J #_Q*G
M _\2K0/_$;0#_Q&[ _\1Q /_$<X#_Q'? _\1ZP+_$O8"_Q+^ O\2_P+_$O\"
M_Q+_ O\2_P+_$O\"_Q+_ O\2_P+_$O\"_R@I ?\K)@'_+"8!_RLI ?\H+P'_
M(C@"_R!$ O\=4@/_&U\#_QAL _\7>03_%X0$_Q>.!/\7E@3_%IT$_Q:D!/\6
MJ@3_%K$$_Q:X!/\6P /_%LH#_Q;; _\6Z /_%_0#_Q?] _P7_P+[%_\#^Q?_
M _H7_P/Z%_\#^A?_ _H7_P/Z%_\#_RHF ?\N(P'_+R(!_R\E ?\L*P'_*C4"
M_R=! O\D3@/_(EL#_R!H!/\>= 3_'8 $_QV*!/\=D@7_'9H%_QVA!?\=IP7_
M':T%_QVT!/\=O03_'<<$_QW4!/X=Y@3['?($]Q[[ _4>_P3T'O\$\Q[_!/,>
M_P3R'O\$\A[_!/(>_P3R'O\$_RXB ?\R'P'_-!X!_S,@ ?\R)@'_,C(!_R\^
M O\L2@/_*E<#_R=D!/\F< 7_)7L%_R2%!?\DC@;_))8&_R2=!O\DHP;_)*H&
M_22Q!OPDN0;[),,&^23/!O8DXP;R)/ %[B7Z!>TE_P;K)?\&ZB7_!NDE_P;I
M)?\&Z27_!NDE_P;I)?\&_S(> ?\V&P#_.!D _S@; ?\Z(P'_.2T!_S@Z O\U
M1@/_,E($_S!?!/\N:P7_+78&_2R !_HLB0?Y*Y$']RN9"/4KGPCT*Z8(\RNM
M"/$KM0CP*[\([BO+".LKWPCG+.X(Y"SZ".(L_PG@+/\)WBS_"-XL_PC=+/\(
MW2S_"-TL_PC=+/\(_S4: /\Z%@#_/10 _S\7 /]!'P#_02D!_T T ?\]00+_
M.DT#_#A:!?@V90;T-7$'\31[".\SA GM,XT)ZS*4"NDRFPKH,J(+YC*J"^0R
ML@SC,KL,X3+(#-\RW S:,NP-U3/X#=(S_PW0,_\,SC/_#,TT_PO,-/\+S#3_
M"\PT_PO,-/\+_SD6 /\^$@#_01  _T43 /](&P#_2"0 _T<O ?Y$.P+W0D<#
M\3]4!>P^8 ;H/&L(Y3MV">([?PO@.H@,W3F0#=LYEP[9.)X/UCBF$-0XKA'2
M.+<1T#C#$LXXTQ+*..@2QSGW$L0Y_Q'".O\0P3K_#\ Z_PZ_.O\.OSK_#K\Z
M_PZ_.O\._ST3 /]"#P#_1@T _TL0 /].%@#_3Q\ _4XI ?1,- 'L2$$"YD=.
M!.!%6P;;1&8)UD)P#-)!>0[/0((0S4"*$<H_D1/)/YD4QSZ@%<4^J!;#/K$7
MP3Z\%\ ^RQB]/N(8NC[R%[<__Q:U0/\4M$#_$[-!_Q&S0?\0LT'_$+-!_Q"S
M0?\0_T 0 /]&# #_2PH _U$- /]3$0#_5!@ \U0B .E2+0'A4#L!VD]) ])-
M50?,2V +R$EJ#L5(<Q'"1WL3OT:#%;U%BQ>[19,8N42:&;=#HAJU0ZL;M$.V
M'+)#Q!VP0]D>K4/M':M%_!JI1?\8J$;_%JA&_Q6G1_\3IT?_$Z='_Q.G1_\3
M_T0. /]*" #_4 8 _U4* /]8#0#W61$ ZE@8 -]7) #45S4!S%5$!,944 C!
M4EL,O5!E$+E.;1.V3786M$Q]&+%+A1JO2HT;K4F5':M)G1ZI2*8@ITBP(:5(
MO2*D2,\BH4CH(J!)^!Z?2_\;GDO_&9U,_Q>=3/\6G4S_%IU,_Q:=3/\6_T<+
M /]- @#_5 ( ]UH$ .M=!P#G70L X5P0 --='@#*73 !PUP_!+U:3 BW6%<,
MLU9@$:]4:12L4W$7J5%X&J=0@!RD3X<>HD^/(*!.F"&>3:$CG$VK))I-N"69
M3,@FEDSB)I5.]2*43_\?E%#_')11_QJ44?\8E%'_&)11_QB44?\8_TD( /]0
M  #[6   Y5X  -UB P#68P< U&$* ,IB&0#"8RP!NV([ [1@2 BO75,,JEM<
M$:9:9!6C6&P8H%=T&YU5>QV;5(,@F52+(I93DR244ITEDE&G)Y!1LRB.4<,I
MC5'=*HQ2\B:+5/\BBU7_'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L
M7   WV(  -1F 0#.: 4 RV<( ,)G%@"Z:"@!LV<X ZUE10>H8U ,HV%9$9]?
M816;76@8F%QP&Y5:=QZ367\AD%B'(XY7CR6,5YDGB5:C*8=6KRJ%5;\KA%;5
M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
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M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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M(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@
MC)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4
MFF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5
M_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\
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M#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL   :K4  %ZZ  !2O@
M1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P QRU$!,,M; 2[,90(L
MS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'
M_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@  /<H
M #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@
M'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7
MVO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9
M   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG
M !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\
MEZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8
M[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]
M9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL
M 'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@
M#O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P
M_V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]
M  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\
M  +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX
M /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_
M(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)
ME@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[
M /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20
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M!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4
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M#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33
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MJB&!4;@B?U'+(GY2YR%^4_D=?E3_&GY5_Q=^5?\6?E7_%7Y5_Q5^5?\5_TH
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M)FE>WB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90
MPVL  +EO  "Q<0  JG$  *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^
M:5D/>VA@$G=F9A1U9FX7<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1B
MVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\
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M'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@
MF(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ?E +9WU7#F1\7A%A
M>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]WSB-/=^PA4'?]'E%W
M_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP  DH<
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M%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@  ?YD  '.<  !DGP
M7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M
MGG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9
M_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP  4JH
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MA@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90
M )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0
M'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2
MUX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A
M  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H%
M !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH
M!>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !W
ML0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ
M"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"
M  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@
M7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0
M_ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_
M@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T
M $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P
M /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P
M_X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0
M+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@
M /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_
M#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"
MH@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_
M /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\
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M \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\
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ML1&:/K\1F#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST
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M&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P
MR%P  +]?  "W7P  L5P  *I9# "D6AH GELJ )E;. &46D,#D%E,!8Q850B)
M5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U' &W%1
MVQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P  Q&
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M&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<
MGFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S:%((<&=9"FUF8 UK
M96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IBS!U:8NH<6V/\&%QC
M_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=   FG,
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M$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P(
M;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/
M>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X
M_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<-
M &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/
M1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q!
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MB@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5_PLQE/\+,9/_"S&3_PLQD_\+N'H
M *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H   3J(  $6D"0!"I!,
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M !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@
M?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1
MS!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.
MK  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P
M &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P
M!MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0
MW[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]
M  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-
M  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$
M .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \
MR@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N
M"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC
M  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU
M(MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_
MGP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!!
M /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@
M_P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[
M /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\
M2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J
M /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\
M\P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
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M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
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M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
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M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
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M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
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M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
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M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
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M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
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M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
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M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
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M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
M:% R &50.P!C4$, 85!* 5]040%=4%@"7%!? EI09P-84'$$5U![!550B 93
M4)8'4E"E"%!0MPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L  +]4
M  "R6@  IUX  )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0 8E0O
M &!4. !>5$  7%1( 5I43P%95%8!5U1= E5490-45&X$4E1Y!5!4A@9.5)0'
M352D"$M4M0A+5,P)2E3K"$M4_@=+5/\&2U3_!4M4_P5+5/\%S$X  +M7  "N
M7@  I&(  )ID  "19   AF(  '=;  !M6   9E@, &)8%@!?6"( 75DL %M9
M-@!963X 5UE& %9930%4650!4EE; E%98P-/66P#35EW!$M8A 5)6)('2%BB
M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
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M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
M@R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$FC0!O
M)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X  ,LV
M  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T >2HW
M '<J/P!U*D< <RM. '$K5 !P*UL ;BMB &PK:@!K+'( :2Q] &@LB0!F+98!
M92VD 60NM %C+LH!82_I 6 O_0%@+_\!8"__ 6 O_P%@+O\!VC0  ,4\  "W
M00  K$,  *)#  "90   D#H  (@T  " +@@ >BT2 '<N'@!S+RD <3 S &\P
M.P!M,$, :S%* &DQ40!G,5< 9C%> &0Q9@!C,F\ 83)Y & RA0%?,I(!73.A
M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_^)]$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A
M /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T
M_P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[
M 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H
M[ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P )
M /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8
M[ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4
M /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\
M#0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V
M -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\
MOP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M
M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,,
M=0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X
M *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P
MU@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q
M '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T
M_P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0
M ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\
MH0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ".
M /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0
M$@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O
M )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\
M@ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B
M!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.
M<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_
M '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q
MD! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W
M%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;
M_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6
M ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G
M:QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A
M(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A
M'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U
M &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\
MSS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K
M*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL
M?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8
M +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\
M82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1
M,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"
M  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E
M %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4
M2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F
M2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W
M*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3
M $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@
MF5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y
MH@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0
M (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P
M1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X
M1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9
M  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$
M,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^
M70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*
M-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$['
M "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80
M<%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R
M4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93
MYP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64
M &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8
M*E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?
M6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH
M  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ
M "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D
M&%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,
M;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG
M/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_
M !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=
M.W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .
M<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN
M_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T
M "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T
M WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P
M>/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'
M   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"
M  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\
MD'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2
MDP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "6
M1@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8
M (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP
M!*    "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/
MIDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1
M  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T
M  "O    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\
M +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?
MG0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
M    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#
M  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@
M1*L  #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+
MRP   ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D
M2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4
M "BY   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0
M -\   #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.
M^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\
M%@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P""
M /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\
M\P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_
M !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8
M@P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_
M .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D
M_P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D
M (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L
M_P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @
M .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P
MS "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W
M /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L
M)0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\
M +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\
MI #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#"
M "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *<
M? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_
M )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ",
MKP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6
M 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8
M_P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F
M )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '<
MA@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X
M!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"
M*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\
M '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\
MX1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!
M#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0
M@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0
M ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R<
M<Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A
M&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ
M  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK
M &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X<
M5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K
M.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B
M+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3
M $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P
MG$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5
M*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<L
MH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44
M (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\
M32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@!
M,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)
M  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\
M.C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  "
M3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U
M-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$
M #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4
M<TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_
MY  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(
M &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J
M0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2
M  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4]
M "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/<
M)4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !5
M50  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+
M0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_
M !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P
M1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @
M44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1
M_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\
M #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4
M%EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 1
M6/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E
M   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+
M  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\
MFV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D
M;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K
M4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT
M (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@
M%78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@
M=5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ
M  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((
M  J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4
M (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![
MA   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
M    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=
M  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP
M9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=
MG0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@
M9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698
M $N9   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@
M *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@
ML6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C
M   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@
M  "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(
M ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   D
MKP  %K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
M    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K
M  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0
M#;P   &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<
MWP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X
M=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H
M_0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F
M /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\
M,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"*
M .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\
MS #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V
M #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L
MBP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_
M +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #,
MX0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #"
M (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P
M_P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W
M ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4
MK0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"<
M /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0
M.@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "&
M )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\
M^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A
M #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L
MB@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H
M -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4
MD  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![
M (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7
M  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W
M (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL
M; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V
M(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(
M. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5
M & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P
MI"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G
M$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83
MH@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(
M )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30
M7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,
M&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W
M  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW
M %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X
M1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#
M.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB
M.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?!
M #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P
M=CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#
M)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<L
MX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T
M &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD
M/"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q
M,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5
M  !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^
M #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4
M+37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !8
M0   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U
M1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_
M "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@
M3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J
M.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]
M_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@
M $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@
M(T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >
M0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*
M   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/
M !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\
MHE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O
M3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,
M5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<
M )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@
M(E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .
M4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D
M  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T
M !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX
M!%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$
M;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F
M 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I
M  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0
M>'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &
M<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O
M=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT
M &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04
M 'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P
M>H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%
M  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&
M  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P
M (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%
MCP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7
M!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+
M  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0
M+)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
MI@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "J
MF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,
M !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0
M +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0
MP:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
M    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<
M  #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D
M -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
MOP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
M    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A
M  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$
M_P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W
M )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D
M_P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!&
M /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ),
MY0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y
M /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D
M2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5
M ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\
M_P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/
M $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +<
MF "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P
M /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4
MN !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C
M )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$
M  #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!&
M *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4
MCP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
M    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4
M1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P";
M 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0
MN P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$
M $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '
MI !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14
M *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $
M=0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B
M *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<
M  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)
M &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T
M5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+
M(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+
M0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _"
M $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0
M?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2
M$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5
MWP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L
M &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX
M2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP [
M'/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM
M  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q!
M $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0
M-2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=
M+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA
M10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_
M # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P
M42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R
M)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ
M_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,
M $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@
M+"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F
M+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T
M   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/
M "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\
MID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V
M-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U
M6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<
M )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0
M*CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9
M.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51
M  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T %
M " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&
M$D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")
M6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%
M"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M
M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8
M?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  1
M3 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.
M>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@
M '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D
M"54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P
M58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O
M  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -
M  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<
M %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !=
M=   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J
M#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8
M  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P
M2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0
M=A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !S
MJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,
M #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT
M (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I
M@+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-
M   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,
M  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8
M )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1
MF   "9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B
M"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)
M  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP
M *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
MLP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "Z
MW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$
M  "T    N    +L   "\    O    +X   "_    P    ,(   #$    Q@
M ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q
MU.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
M    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\
M  #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4
M_P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_
M %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /
MIP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P
M /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %,
M\ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #;
M *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\
M  #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5
M -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4
MP "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,(
M50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J
M *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
MY0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L
M %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )<
ML@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP
M ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X
MF0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$
M +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8
M  "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!-
M (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0
M<P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
M    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D
M3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90##
M &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P
MCP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J
M $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@
MW !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\
M 'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8
M70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-
M!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42
M  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9'
M %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\
M0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F
M%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-
M20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_
M #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0
M618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^
M$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06
M_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X
M $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH
M-A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N
M&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?
M  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0
M "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\
MJ38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [
M( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA
M6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH
M )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@,
M,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B
M)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#
M  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@)
M "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V
M&RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+
M2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L
M#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M
M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P
M@%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <
M,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V
M?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8
M '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X
M%3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *
M.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');
M  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0
M  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H
M 4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F
M8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'
M$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;
M  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@
M660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0
M4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/
MK@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD
M $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,
M %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP
M5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N
M   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05
M  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$
M %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K
M=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P
M%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB
M  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P
M%WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0
M?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X
M]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD
M  >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$
M (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P
MB?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
M    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0
M  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D
M<(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
MI0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R
M#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),
M %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M
M +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P
MR0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@
M   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8
M  #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04
M .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H
M8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"]
M .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M_P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F
M &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P
MR0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P
M /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P
MS !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T
M -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8
M  #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!;
M +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L
MGP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'
M  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *(
M6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B
M (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $
MK@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P".
M %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D
M\0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  &
M )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %(
M?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I
M /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T
M"@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2
M &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8
M7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![
M  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &
M4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_
M %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @
M:P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3
M %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8
M_P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800*
M %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\
M1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \
M!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(
M# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3
M #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\
MK2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&
M# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.
M6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP
M )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D
M.Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L
M$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV
M  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10-
M #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V
M)!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-
M/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8
M#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL
M !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00
M@4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E
M'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B
M>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8
M '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1
M'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2
M)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*
M  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2
M !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL
M#2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I
M3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M
M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<
M  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@
M75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -
M,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   V
MKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4
M %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q<
M!CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K
M.\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8
M  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;
M  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,
M $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]
M6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+
M'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD
M  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80
M+%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P
M5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0
M^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@
M !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX
M %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P
M6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O
M   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB
M  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\
M@'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $
M>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X
M)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT
M '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@
M (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('
MB"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&
M  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4
M  "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\
M )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0
MD   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
M    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA
M  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F
M-9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
MLP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%
M)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8
M !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP
M ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&
MXRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\
M"@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I
M /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X
MV0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_
M  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P
M: #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[
M ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P
MZ  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#!
M &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H
M_P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0
M ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$
MJ@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5
M /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +,
M$P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!?
M )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\
M@0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ ">
M !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0
M7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_
M '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !(
MB@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R
M %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$
M_P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4
M '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D
M8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5
M /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P
M%@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!;
M %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\
MN1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!=
M !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D
M7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD
M *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !,
M4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^
M &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D
M  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4
M $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$
M,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0
M+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&
M%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML
M "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@
M@S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q
M#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/
M>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<
M '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!(
M*! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :
M$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[
M  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5
M " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D
M$QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I
M/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7
M%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<
M  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@
M7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4
M'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HB
MK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0
M %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD
M$"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #
M)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$
M  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=
M  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$
M "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'
M1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O
M(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A
M   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30
M.DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(
M-BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U
M]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X
M "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8
M #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0
M._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52
M   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L
M  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\
MB%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   5
M5P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/
M,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64
M 'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08
M"5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0
M63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP
M  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H
M  !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0
M &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N
M>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([
M  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@
M57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M@P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""
M0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<
M #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0
M )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.
ME$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2
M   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H    *
M  "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4
M *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4
MG0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
M    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)
M  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP
M *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
MQ    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?
M4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9
M /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\
MYP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$
M /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /,
M'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N
M ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\
MJ0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7
M ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8
M;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_
M )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X
MN0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"?
M &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8
M_P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A
M *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &<
MBP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U
M /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )
M(P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H
M '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\
MTP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!]
M "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@
M:@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0
M +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X
M:P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8
M &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-
M  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ?
M %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@
M2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9
M%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$
M'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O
M #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0
MB1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!%
M "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0
M>@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0
M 'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L
M.@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J
M (@ * "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
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M______________________________________________\
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M^?K[_/W^_VUF=#$      P$A   !                     0
M          $    ! @,$!08'" @)"@L,#0X/$!$2$Q05%A<8&1H:&QP='A\@
M(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,
M34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY
M>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6F
MIZBIJJNLK:ZPL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1T]35
MUM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\  0$"
M @,#! 0%!@8'!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<
M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M__________^6-        $^G______________________________9I'0
M"0P&"5*Q_____________________________\L[#A,U3%M-3%[#________
M_____________________ZE@-F"&G[:LJ;C9________________________
M_____^"7C;[E_______________________________________M^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]G*O,?__________________________________\^:@6U:1HCJ____
M____________________________Q'P^)A   %2P____________________
M___________@@SP      "Z'[?____________________________^L4Q
M     !=MUO____________________________N ,0        EAS/______
M_____________________]): @        !=S/______________________
M_____Z@U          !<T____________________________WT-
M  !4UO__________________________[GU%          !$U/__________
M_________________*ID+P(   0B-TE8SO__________________________
M_^FD:T$H/V-_E:>ZVO______________________________U;*LLLSD^O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y;N7=V+(____________________
M_____________]N>9S8*  *,________________________________R'\_
M!0    !>S______________________________9@3D        \JO______
M______________________^>3          CD/______________________
M_____]QO&@         0??G__________________________Z](
M    ;^[__________________________X03            9.;_________
M________________[%$             5][_________________________
MN!4             2-;_________________________=!0
M.,_________________________YHEH3            (\7_____________
M____________WYM<+           #;K__________________________^^Q
M?54Y(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^.^G8!\^_________________________________*WA%<P#@ =K/______
M________________________THI,%0      <O/_____________________
M_______6?S8         2\G___________________________J1/@
M    +ZO__________________________\!:            &I7_________
M_________________XTD            "(3_________________________
MYUX              '?_________________________M"4
M &K_________________________?0               %OT____________
M___________]*P               $SK______________________^E
M             #SA______________________\P#                "W9
M_____________________YF*82<              "?7________________
M_______MOHE5)P           "7<__________________________[*G79=
M2CPR+2PP.4?>_______________________________]YMW6TM#3V>3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]2[UO______________________
M___________GN(]J2R\5;_______________________________Y*%G- <
M    /,G____________________________6@CL         $I?_________
M_________________^V%,0           &__________________________
M_Z9"             %#A________________________[&D
M #?)________________________LR\              "*V____________
M____________>0               !"G_______________________R-
M              "9______________________^I                  ",
M______________________]&                  !_________________
M_____]\                   !T_____________________Y<
M          !J_____________________\X                   !C____
M__________________\I(@$               !A____________________
M__^YHX!7-Q<           !H___________________________ZTZZ4AGQU
M<7!R=X&4____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]NZG8)I:=/_________
M_____________________\B393T9    '9[_________________________
M___;CDP3         &[__________________________]M\+
M $77_________________________XLJ             "*T____________
M____________PD0               .7________________________?0$
M              !________________________G-@                !J
M______________________^=                  !8________________
M______]&                  !'^/___________________^D
M           UZ?___________________Y8                    EV___
M_________________[P                    8SO__________________
M_^L                    /PO____________________\
M       *N?____________________\G                   *M?______
M______________]P                   -N?_____________________@
MG(QP54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,
MS];@_/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O3O./________________________________2J85E2"P2
M 87____________________________QJW$\#P       $_@____________
M_____________]5_-0           !^R________________________XW4=
M              ")________________________D",               !G
M_______________________50P                !(]O______________
M______^*                   NW?____________________\X
M           7R/___________________[X                    $MO__
M_________________YP                     I?__________________
M_[H                     D____________________]P
M        @O____________________\                     =/______
M______________\3                    :/____________________]"
M                    8/____________________]Z
M    7?_____________________1                    8?__________
M____________)                   9O______________________R:R9
MB7UV<6QI9V9G:W!ZC/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^+%JI%Y87?_____________________________
MW:9W4"P,     #'$_________________________^"23A,           "/
M________________________TG =              !@________________
M_______N;P\                WXO____________________^6'
M           4P/____________________]                     H___
M_________________ZX                     B?__________________
M_YX                     <O___________________[P
M        7____________________]H                     3?______
M______________H                     ._____________________\.
M                    *OG___________________\S
M    &^G___________________]>                    #]O_________
M__________^/                    !M#____________________0
M                 ,K_____________________*P
M ,C_____________________@                    ,O_____________
M________]Q8!!04# 0       08-&,O_______________________SKX=C/
MS,W/T-+4U]SBZO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________QVL;_
M______________________________'&HX1H33(8 !6K________________
M__________^Y?$88          !Q________________________UWPO
M           [X______________________?9 D                ,M?__
M__________________]T P                  C?__________________
M_\45                    :O___________________YD
M        2____________________[8                     ,/W_____
M_____________]<                     &>?___________________8
M                    !=/___________________\.
M     ,'___________________\O                     *__________
M__________]2                     )[___________________]Y
M                 ([___________________^E
M (#____________________8                     '3_____________
M________-@                   &W_____________________?
M             &G_____________________UPT                  &C_
M_____________________W                   &'_________________
M______]0/$9.5%E=861H;'!V?HG_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^_5NZ.+<UJ5___________________________XOXYD02$%      !2_/__
M____________________]YU6&              7P?__________________
M___E;!8                 C?____________________]C
M        7O___________________YT                     -?S_____
M_____________Z$                     $=G__________________\H
M                     +O__________________^X
M     *'___________________\,                     (K_________
M__________\M                     ';___________________]-
M                 &3___________________]O
M %+___________________^4                     $#_____________
M______^\                     ##____________________J#@
M             "+_____________________1                    !7_
M____________________@0                    OU________________
M____R L                   +L_____________________UX
M          #E_____________________\D<                  #:____
M__________________^= 0             '#A?%____________________
M____U;F\P<?.U=OAYNWT^_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^-_/____________________
M_________^S&I8AM5#LA!P RWO_______________________]>262D
M        H/______________________B38                 9_______
M______________]F                    ,O;__________________Y4
M                     \C__________________Z<
M     *#__________________]<                      'S_________
M__________\                      %[___________________\E
M                 $/___________________](
M "S___________________]J                     !C_____________
M______^+                      7S__________________^O
M              #A___________________5                      #/
M____________________)                     "^________________
M____5                     "N____________________BP
M          "?____________________RPX                   "2____
M_________________U<                   "&____________________
M_ZH*                  !Y______________________]M
M      !F_______________________W50                !%________
M_________________VHC*S4_2E5@:G5^AY&<________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________HS[:=@VE.N?______
M___________________LLH-<.AT"        >_______________________
MQ6TI                0/____________________^#&P
M    !\O__________________Y(                      )C_________
M_________Z0                      &K__________________]T
M                 $'___________________\.
M !W___________________\Y                      #H____________
M______]@                      #.__________________^%
M              "W__________________^H                      "C
M___________________+                      "0________________
M___O%@                    !]____________________/@
M          !L____________________:0                    !:____
M________________F0                    !)____________________
MTA8                    Y_____________________U@
M       I_____________________Z(                    9________
M______________56                   $______________________^[
M+P                  ^/______________________JRD
M    S________________________\E'      <3("X^4FB$[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________35R?____________________________K2L))W74(H
M#   2O_______________________\5]11<             $=C_________
M___________$4                    )___________________Z(,
M                 &C__________________Y0
M #;__________________]H                       ?L____________
M______\5                      #$__________________](
M              "B__________________]U                      "#
M__________________^=                      !I________________
M___#                      !2___________________G#P
M           ^____________________,P                     K____
M________________6                      8____________________
M@0                     %____________________K
M        ____________________WB(                     \O______
M_____________UP                     W____________________Y\
M                    S/___________________^A*
M    M_____________________^@%@                  G/__________
M____________>@(                 =________________________WH+
M               %3/________________________^B5VAT@(V<J[S0Y___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________MX___________________________
MTJ-Z6#HI(QP6#@8  )______________________K%(.
M &G__________________^1#                     #3_____________
M_____WD                       #C_________________\T
M              "R__________________\3                      "%
M__________________]/                      !=________________
M__^#                       Z__________________^R
M           <___________________; P                     "____
M________________*@                      ^___________________
M3P                      Y___________________=
M        U/__________________FP                      P/______
M____________Q <                     K?__________________\#,
M                    FO___________________V<
M    AO___________________Z,                     <O__________
M_________^-$                    7/____________________^1!@
M                0?_____________________K7P
M'?______________________RDL                  /______________
M_________\M7   ,&"0Q/TY@=(NGQ___________________________U^?R
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9
M$0D"          #;_________________W8                       "G
M_________________[H                       !U________________
M__\'                      !&__________________].
M           :__________________^,                        _?__
M_______________!                        V__________________Q
M&0                      OO__________________1
M        I/__________________:P                      C?______
M____________D0                      >?__________________MP
M                    9O__________________WB$
M    4____________________TH                     /___________
M_________W<                     *____________________ZP*
M                %O___________________^=%
M /____________________^*                     /______________
M_______630                   /W_____________________IRX
M             -7______________________Y@J           &&"U%8.#_
M______________________^H8W2!CYRKN\WB^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___B,X!)0T-?4%)/1DE,10 2$O__________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
M  #_[@ .061O8F4 9(      _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#_\
M% @"10;/! $1  (1  ,1  01 /_$ )L  0  !@,! 0             $!08'
M"0H#" L" 1   0,# @,#! L%#PX%$ $5  $" P0%!A$'(1((,1,)\$%187&!
MD:&QP=$B,A0*X15V.'CQ0B.5M=46MC=7E[<86!I28C/3))0V5I87UQDY67*2
MU-:(@J+20U2T)56&QD>'F+C(2;+"4W,T-2:FJ-CR1'5C@[-D=$5E)W?_V@ .
M! $  @ #  0  #\ W^#?X-_@W^                    "W^YFZVW&S>*UF
M;;I9I8,&Q>A5&37?(*^.CBEG>BK%1T,'SJNYW&?1>[IJ:.6>14^:Q2G\ERK'
M,-M4U[RF]6^QVN#1'U=PG;"QSU^C# SC+4U#_P ['&U\CO,BGQ))'$U7R/:Q
MJ>=R^\GG50239/?3:WJ(P2DW)VARJERS$ZNON-K^N14]7;ZVCN-KJ7TU50W6
MSW."DNUGK.5&3LBJH8I)*::*9K5CE8YT%A6<XON'8H<DQ&ZQ7:TS3U-+WS8Y
MJ>:&HI95CE@JZ.ICAJZ.;31[62L8YT3V/1.5S57\BFCG8DD3N9JJJ:\45%3M
M147147V?,"[95IR         L!O7U5]-W3G1R5>^&]FW.VTC:=M5%:<CR:WP
MY-74[D<K9+3B5-+4Y1>>9&*J)24<RKHO MMGN\6UFU\#IMP,^Q?%7-B29E%=
M+M3,NU1&J*J.HK+$^6[UVJ-71(8)%70D]TR&QV1JNNMUH:%4;S)'/.Q)WMX\
M8Z9JNJ)>S\ZU08D-W/M"721B3)J?9_"MS=[*QKG?5;E]0I]M\/K(FJ]G>1W3
M)F566Q.5[?HOL#=$UU5')REG*/J_VMR2U)=\!6Y9A1.GFIVU;:>2R4O>P.Y9
M(Y672)EUIY.*.1LE(U58Y'=BH8 ?$4^T1; ] .YERV2J>GG?;<[=&BM5KO\
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M>US7L:YJHDRCEBE3FBD9(GI8Y':>SHO!2Y)-"\1R
M
M
M
M
M
M
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M\DH84X)/*:X4]2B(CN[>O_:Y-$5?^"OT7?"9)RZ1F0(X
M
M
M
M
M
M
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M ^1FMULT]=11=]&RH=3U#E@;4%/5PU*?H;M')VQNX/3VOSR>M#N@5R9(R)
M
M
M
M
M
M
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MS0]O#R]'EVG$YNG%.SX 4S5TW;P[/9]DE,T6A\ I>L@^EY?#Z"4S1]OK\O?
M*7JX>WAY?$2F9G;Y>PO8 =2-T<.?:+K+>Z5LC[?=JF669557NI;A*JRS,D<[
MF<K*IRND8J]B\S>&B:]7]R<06T7)UWHXW+;KG,]\B)JJ4E=)J^6-RKJJ1U#M
M7L\R+JW@B)KU]S[$TM-:MTHXT2W7"5RO:B?-I*MVKWQZ=B13<7,\R<6\$1-9
M!=YI:-&RHJ]R]>77^H?VHU?4Y$U3VRU:1>?E]U?B52VB1>I$]GC\I;Y(O95/
M4GYI3$EY_K^WU_)V_ ?7=>IOE[1])'[">PGYA]=SZE]U/S2%=>>/T]/;^)!W
M7J;Y>T?O=^OWONG[W7];[_W3C^_/K\O^,.Z]3?+VC\6/7T+[*?FGYW/J7W4^
MZI]MO7I?[Z_'JBGRL?\ 6^Y\B*?*Q>I/:X?(?*Q>RGLI^814=Y_KO7V^6A\+
M&GK3V3X6+U*GOH?"Q>I%]Y280WGS\_OE2V6X2*Z.@FY7HNK:>15TDUT3EIUU
MX2(NFD:?2U^:FOS43M/T\[OOQRL@P?)*I5Q^X3\MFK9WKI9KA._A2O<Y=&6R
MND7TZ0S+S:(U[W)K<>.SX4:]1N(W'J[Z?L8CEW\V_L;7;G8K9Z5&5^\> 6.D
MTCN5'30,1+KN/@UM@TIT5/K=UL\7U)KI9J2W4SOJHGCJE21JHDB)H[^O1.SV
M7)[OF]!4QW[-&PA              #GC9Z?;]7J]DY&-\Z^U\I^HFJZ'TUNJ
M^KS_ "$QBB]7M?%\IS-;KV]B>^<[6^9/+UJ<Q-H(==.'Q$2UNO'S)[_W")8S
MS>9.U?+T@G5/!V</=]PB6-\ZI[!%L;V+[B KC$[]D6'7VU91B5^O6,9+9*N.
MNLV08]<ZVSWJU5L>J1U=NN=OFIZVBJ&(Y41\;VNT54UXDRHIZFBJ(:JCJ)Z2
MK@<DD-332O@GA>G8Z*6)S9&.37M144K+"<RS';G*;%G.WV59'@^:XQ7Q77'<
MNQ&]W+',EL%RA1R15]FOEHJ:2Y6VLC:Y422&5C]%5-=%4YH^9BH]%5KD^BJ*
MJ*WUHJ<44V9N@[QHHKNZR[5]84]/05S_ *K;+'OE14L=-;:J16MAACW,ME*C
M(;9+(]$1;O11I2ZN1:F"!C9:I>U6WN^"3=Q:,T<V.1>2*GO[&(V-Z_11+K"Q
M$;$JJG]F8G+Q^<UJ(KS=9\*;[3%1WZ7&MA?$:JZ*SW27ZC8\5ZI;90Q45DKI
ME8VGIX][['1-CIK%/-(U&NR*VPMH>:1KJVDI8V3UZSNFN.NC*CAV(DJ=G_5I
MYO90V**&NHKG14=RMM92W"W7"EIZZ@KZ&HBJZ*NHJN)E12UE'54[Y(*FEJ8)
M&OCD8YS'L<BHJHIV5CD9*QDL3V21R,;)')&Y'LD8]$<Q['M56N8YJZHJ<%0W
M(K5=;9?;9;KW9+C07BS7B@H[K:+O:JRGN%LNMLN%/'5T%QMU?2234E=05U),
MR6&:)[HY8W(YJJBHI-T77BG%%XHJ><BC[(\
M
M
M
M
M
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M6\JTELO3G4K'Q15MNI&5+0U\=4G)JB2(FNG]4B=JIZT\Y,SLX:UQ,0
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MK**KB@K*.IC?#-''(QS4G;'M>U',5'-7L5/+M*V(XNH?0
M
M
M
M
M
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MVBJ&LGIIV*UR=BK.F/:]J.:NJ+Y:+Z%0N 3 O2?0
M
M
M
M
M
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M-$5%1%1=47BBD\.<K(_0
M
M
M
M
M
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M0.Y/FN7@JZI_6JOF]LV%2_AOGD8
M
M
M
M
M
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M(O:B)[9D!*X-@(^P
M
M
M
M
M
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MHZZG5ROIJR"6)WSF*AS%0',7,
M
M
M
M
M
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MJ!<NW6K5K?F+YM$T7C[/H*JI:/7153WCE!4C;3\WZ+>ST>@F:4?#Z*Z>PG
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M2.7F<U%_3(R5D;3X
M
M
M
M
M
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M015*1SQ<RNBF:YB\6J";'(5L
M
M
M
M
M
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M0C5FD=)4?>W*::[PNY/F4].^E9HW5NH[>E0F=0
M
M
M
M
M
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M^;7W9KY&)3K<*^&._P")R=V_YKJJ7*+#2T<3DTD:VL>B*J.<UPRM%=F[$
M
M
M
M
M
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MNE!*CDT1R24M4Q=?/J"-/HJ$
M
M
M
M
M
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M78<4J\#J62.5TE.S;^^W7#[9"Y>*<OWDLU*]B(JHD;VIP5%1!=PCSO>
M
M
M
M
M
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MIZT3VE\Q R)P7U+\>A 2^?\ X7RDNF\_K1/AT+IV=WT/<]SBGO$%)VN]CXB
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MJONL5<O!K&*G9J[G4'9PG)F<
M
M
M
M
M
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MZ9))&HNO.QKM-&ZCN"3\V!P
M
M
M
M
M
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M1+HY5UXHK4]8.Z14!L>@
M
M
M
M
M
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MBIZF*#N:3\V.
M
M
M
M
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MZ(OZ%2U#W>PYK8OAE0SOF;PTC2^8 !^M3540 $4Q..OH^,$7"WL3VO=XKI[
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M[F5TTF?U=8B\.;O8$@@TT7327CKYAVT)T9^0
M
M
M
M
M
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M1_*%WR_?7SO_ "BN/]N '^NL\6__ 'C76!_#CG'ZZC^4+OE^^OG?^45Q_MP
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M7U<W+W5LJ*S[T7B17KHB16>\LM]SET<J(O+$J(JHB]J:@9'R[(
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MM4_U>*2=SW,A[Z5SN5.&KE4 VO#NR
M
M
M
M                                          :P/C"X@['.J>R93%&J
M4N?;8X[<9IM%1K[M8;C>,<JX>U$58;704+E7_P#:(GF,9/5[:%MVZ-%=&M7N
MK_C-OJ'O[$=5T%166Z9GH564L$"_]4A3MT;R537^9\3=?915:ON(B QDT%5I
MRZ+Z/C]@ZUT\W9Q^4@05E15FFFB^C7T^HGE/.FB<?+T@%5TE=V?.3S<?E0F\
M-0J:<?+S $^AN'!./;Z_@5/D)E'5>OR^+W@"-2X\/I=GK^53G2J33Z2>[]Q0
M#BDN/#Z6NOKU\O=/A]4G'CY?![P!)ZFX:HOSO:U^'T$#+4Z^?W->/EH 4Q65
MVNOSO+T$JGJ/6 4?7UFNNB\./DA)*B?77C[X!1=PJ_I?.]O[JDBJ)NU?:X>\
M?#W>9/;\O6"BJ^IUUX\?9]SM\Z^T2&HEUUXG$"CJZHUUX^G7\PDE1)V^7K\P
M!2-;+Q7CY>782:9_;Y::_(@!3-5)KKY>7W252N[?=]I.SW0"13O[?+U)ZNU2
M72+JNGMJ<3UXZ>CX02N1W:OHX>7MD(JZJJGP"&/P E=;7)'K%"J*_BCWIV,\
MRM;_ %_P>SV2:X7)L?-# ].\XI(]%_L?I:WTO]*^;V>R3U]Q2+6&!R+)Q1[]
M>#/,K6_U_I7S>SV8R.L?K,9B\%SVJV>NJ399+]8M^69C0/5T>*M170U5GL52
MWYLN2.T5LU0Q5;;TU:Q5J=5IY&Z3TN]/9]PIYTFOG5?@*>=+KYU7M[.'NF&B
M*UOD>Z23FDDD>KWO>JO>][U5SG/<Y5<YSG+Q55U5553B<_VD]/EV'"Z3TK[2
M' Z7\Q/C4J"CM/9\WWNWT^;SD.Y_H]TAWO\ 3[2$,^3[B>CV2K*&UZ<OS>Q4
M]Q2'<_APX)YU(9[_ &U]Y"%?)V\?97T>I"M+?;/G)\WT$*]_G\R?"0CWZZ\?
M94@WO^XGRE?6VV_1^:0KW^?SKV)Z"#D?Y_:1/C(*1_;Q]E?B+@6RW?15$]'8
M0CW>;7V5(.1W;Q]:KZ_00,C^WRT0N+:Z'Z/S=%].G @WN[5]I"!D=[J^\A 2
M/^XGH3TER;50Z<OS?1["D&]WF]M2"D?[W!" D?Z/83XU+F6FB^CP^7[J$WQ/
M%KYG63V/$,:HWU]]R*Y4UKME,U'<JSU#]%FG>QC^YI*6)'33RJG+%"QSW?-:
MJDRQG&KUFF1V7%,=HWW"]7ZX4]NM],S71]14/Y>\F>B*D--3Q\TDTCOF11-<
M]RHUJJ6XW/W)P[:' ,OW.W O5-C^%X-8;AD607:I75*>WV^%97LIX6ZRUMPK
M)$;#2TT2.FJJF2.&)KI'M:MT[#;):J>"GA8KY9GM8Q$]*^=5_.M:G%=>"(AL
ML[3[=6G:?;S%< LR,=38]:XJ>HJFL:QUQNDJNJ;M=)4:UOZ+<+C-)*NOT4<C
M>Q$-B7:S;^V;78!C."VI&.@L5MCAJ:IK.1;A=)E=4W:Y/3M1]?<9I)=%UY&N
M1J<&H>>9U1[_ &1]4&_FYF^.3MEIZK.<BGJ[5:I)63)CV+4,<5KQ+&XY(HX8
M94L6.45-3/E:QBU$L;YG)SR.5>RUNHH[=14]'%IRPQHU7(FG.]>,CU_X;U5?
M47$+@%@2-  (AJ=B>[\8.:)NOMK[R C8FZ^VNGM><$WIV=GI\E^'0$SA;V>[
MV>TA$(FB:$_I8^SR^#W03>!GW/:[/;U.1B<54J6CC[/+3Y= 3JG9V>2^6B',
MU-50JRBB[/:\O8] )]3,[/S?+[ASHFJHA6%#%V>_]U//P!/Z9G9P][3R^X<Z
M)KHB%:4$/T>'#A['N]J J.EC[.'EZ/01")V(GL%<V^'Z/#T>M/<[05+21]GE
MYO-Z^'ND2U-51/-\17EN@TY>'NZH"IJ2/L^+R]M")8FJ^QQ^0N!;(/HZIZ/Z
MK[@*IHX^SR\M4(IB=J^T7$MD'T>'M\$^509#=E;;][=N[*KFHV6X25UQD1$T
MU[^KEC@<J_GE=2P1KK[7F*GM[.2EC]+E<]?;543_ *U$-NSPRL+=AW1UMJ^:
M)L-;EU5E&95C4CY%<ETR"NH[7*]_!9G36&V4C^9431%1J:HU%476(T[]
M     \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
M                                &83H8\>#Q.O#_J[-0;0]1^39MMC:
M701.V/WRJ*[=C:J:UP.IE^\]JMF05_[(<$H7MI6IKC5SLTJ(KM'Z/>CK\;;]
M2F\.V$E/'8LLK+C9X%:U<<R-\M[LKH6JS] @AJI?K5MC5&(G]R34[NWCQ74#
M?:\+7[55T4]<URQS:'J.I*?HSZBKS)0VJU4F:9##<MC=P[[5+]7BH\-W2J::
MV,QB\7*I9K%:\C@H&K)-#2TE?<:EVBY,MF>M/;W<>6DL66,9@&5U"QP0,N%4
MV7'+K4O^8V.@O+V0I1SRO3YL-6V--7-8R65Z@&TPQ[)&-DC<U['M:]CV.1S'
ML<B.:YKFJJ.:Y%U14X*AW-145$5%145-45.**B]BHOG10#Z/T
M    TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^U^\@'FB&(@
M ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M
M
M
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M\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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M\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                              =3>N?:Y^\'2=O;
MAM+!]8NK,.J<IL,3(UDJ);Y@]13YA;:.DT17-J+I-9/JB*G:E0J+\U5+4;XX
MN[+]J<ULT4?>526>6Z4#4;S2/KK))'=Z:&+1%5)*I]%W*>J147@JD+6Q][2S
M,3MY.9/98J/1$]:\N@-+FDJM-./W/5[9AFAF]?EY=I2(*EI:OL^=H36*;LX^
M7EYSE:[7@O;\()]!6=G'W_+0F$<_KT\O1VI[1]@FD==Z]?+M(ME0OI^3WOD
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MX:;=?@O=/U6: :09CK
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MV8 W/3("
M
M
M
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M:@ET]=V_.U\O>U^$AI)^WCKY>[[I\J]5]7EZ026HJ^W5R^_Z_,0$L_K\OC^
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M?*KHK<U8HUX+4O1.]=YOT)B\(TT\ZZN]2%O[GESY5=%;D6)BJJ+4R)^B._\
ML;%U2-OK75?4ATGW1ZF[Q7MJ+/MS#)::1>:*3)*R)JW2=-=%6V4<B.BM\;D1
M=))$?,J+P;$Y-5I%9G/<KG2.<]RZN<]5<Y57M57.U55*16=SW*Y[U>YRZN<]
M55SE7SJY>+E*46=SW*][G.<Y=7/5RN<YWG555=55?9.D-QHJNX5-16U\]16U
ME5(Z:IJZN:6IJ:B9ZZNEGJ)G/EED>O:YRJJ^<_4D7U+Y>R?7>>KWSZ27UJGL
MI^:2A]FXK\SWOA3S^T?O.OJ]_P"4=YZO?^X.]_KO>^X<7WF\_(O_ !5^#L'>
M*G;IY>V.\]7O_<'>^OWON'VRS?UGO?$G$^%D_KO<^X?"R^M$]CC\I\++[*^R
MOYI'PV?C]'S^7M_ <:O]">Z<:R>ROK4XEE]?N?*3>GM'9\WWO<]*_<.)TGI7
M7U)Y:'"Z3UZ^I.PX72:>KWU*AI+1V?-][RX\/=.%TGI73U(<#Y/S$^,AWR>O
M3X5*HHK3V?-\Z>[]U"'<_P!/!/1Z?E(=\GYA"OD_,3XRKJ&U?1^;ZT^0AWO]
M/!/,A"O?[:^\A"OD]?'WD*TH+7]%>7T(O JC \ S?=3+K+@>W6+WC,<PR&J;
M1V?'['2/K*ZJE7B]ZM;I'34E/&BOFGE<R"")KGR/:QJN2:XUC&1YO?K?C&)6
M:X9!?KK.E/0VRVP.J*FHD7BY=&Z,B@B8BNDE>K8XV(KGN:U%4DEXO-ML=OJ[
MK=ZZGMUMHHEFJJRJE;%%&Q%1J:N=Q<^1[D:UJ:N>Y4:B*JHA<.R62HK)HJ>E
M@?//*J-9'&WF<J^=?0C43BJKHB)Q4VG^@'PCL/V';;-UNHFGLNX6\+H?K-IQ
M)6Q73!-N7U$/)Q9*U]+EV601O<CJN1JT-)([^Y6221QUKLVG2MT(V/:YUOSS
M=>.@R?<)C6U-LL;>2LQO#Y7L^:_YR+#?;_"UR_H[D6FIWK^@->]C*A<>F^._
MS\\HKOA>.P]QA=RIJFUWB:KA3ZUD]OJ8GT];1302(OU6R5T3W,?"J=[41+RR
M\K'OA.QV*8-3V=L=9<DCJ+@FCHXD^=3TBZ<-/--.W^J7YK5^CV(X[0;V=.53
MCCJO*<!IIZ['D5T]?8F+)45]E;Q62:BYE?/76QGG;\Z:%.*\S$<YO=6]8\M.
MKZF@:Y]/VR0)JY\/;JYFJJZ2)/;<GK3BFKMUB= %PP&2Z;D['V^KN^#:OK;Y
MA$*S5UZQ%B\SIZNT=X^6KO..QKIK'K)5TC5U=WD37R1W#.HY29BP    !$L3
MBB>9/@0$1"WL]WY 1T3>SUKK[2'ZB:JB$WIV=GYOM^Z"9PM[/+M^1#G*@I8^
MSAY>CT_F F\#/+T>2'(Q.U?:3XRIJ./LX>CV_P T$[IV=GE[WN',Q-7>QQ\O
M;*LHHNSVE]GV/6"?4T?9P]Y?+\TYT3540K"@B^CP]'L+\B@J"EC[.'EY?"1"
M)JJ(5K;X?H^GW%^105%2Q]GE\'ND0U-51/=]@KJWP]G#T=J?&@*EI(^SAY=G
MO$2Q-7>QQ\O;*\MT/T?B7Y05/21]G#W?:_,(EB<=?1\9<&V0?1\_9YU^) 53
M1Q]GM>;R["*8G!5+AVR#Z/#T=J?*H.X_3MCW=4EYR69BHZ=[+/0N5-/T&+NZ
MJN<U535S))5A1%3AK&Y.*]D^MD6C7RKY_FI['!SOB]PV(/!NV>2BL>Y>^-QI
M'-GNE33[<8M42,1B_>ZA^J7[*YHN9O/)3U==);8FO;HQ)*21OSE1>4=F":F<
M           'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L
M                                               WCOLF/C25FUV=
MV+PN.I++)I-LMR[U5?R1\IO=8Z2+ ]T+Y6OKJW922IJI4928KN=<9YJFQQM5
M.XR>9U*QDCKLU8,C71#U!26:Y4VS66USG6>[U#_V#5M1(JMMEYJ9%DDQY7O=
MHRBO$KG/ID3Z-8Y6(BK.G*!Z-1E>           -,+[;1^(+TH_E?T_\3&Z)
MC^\0[]S+"?P[;^U^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/
M']S+-OP[=^U^S &YZ9 0
M
M
M
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M\%[I^JS0#2#,=8
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M         :87VVC\07I1_*_I_P")C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M      >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
M
M
M
M
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MMOFD9I37#<"X,6*PTK=>7O?O'1.GN+U8[FAJ(Z7F3EE!W3)\;,H
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MGQ:!7N=DN-MGJZ>D@;Q;+>*!T3:^T(C53G>]KZ9KEY4F<NFH&!XZU
M        &TK]DMZ\JGI6\2FW=/>3WN2AVEZW+''M1<:2HG6.U46\F.MN-_V4
MOLD:R-5]PN-QFN6+TS6M>KYLE8KD1K.9G<WH?W+?A>[D6+5E0L=CW$IDLDK'
M.TACO]*DM5CU2J:\99972T;-$75U6FO!-4 ]6,S5@        &F%]MH_$%Z4
M?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_ !!>J[\K
M^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
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MKUN=;3??.\W3OJY:>&E6?OKU<+C/'^@4[&\K'-9PUTU554#N>7
M
M                                                  *?DRS%8<HI
M,'FR;'XLUK['69/0XA)>;<S**W&K=74=LN&0TF/NJ4NU18Z&Y7"GIYJMD*T\
M4\\<;GHY[46%6NHFUK+<ZLI6W"6FDK(Z!:B)*V2DBDCAEJF4JO[]]-%-*UCG
MHWE:YR(JZJ@!4!%
M
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MX@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MHG];Z #8D.U0
M
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M.95XJB^8 ]:TSA
M
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MOJJEJ**JJ:*KB=!54D\U+4P/T1\-13R.BFB?HJIS1R,5%]: $G.
M   ]+/[$MFM7<.A+JTV\D[Q:/%.K./+Z5SDB6-)L[V?V^L]7%&Y$[_YJ;>QN
M5KEY$5^K417/5<NOAXW!\NVV<6I=>[HLW2O8JZ:<USL5K@>U%^EP^]2+IV<>
M':H!NBF0,
M
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MNM$R[4J5T:N7@ULM&Y[57S(H![D9L;
M
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MM.">VOEYR433=O'R\O=!#/?IZU7WCB)3--V\?+Y?@!P@EKWJ]=5[/,@ /@
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M3E+X@                \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK-
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MM6FGJ^[=%003R1M[BF>O,J(W5--=5 ,57]+ \$K^<;N!_P"SOO?_ ,R"RO\
M+:Z>/\:[I_DKD7ZW #^E@>"5_.-W _\ 9WWO_P"9 _EM=/'^-=T_R5R+];@!
M_2P/!*_G&[@?^SOO?_S('\MKIX_QKNG^2N1?K< /Z6!X)7\XW<#_ -G?>_\
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M5CFOJ]S]PZI[6\C7U.:Y).YK=57E:Z6YN5&ZJJZ=FH!)?]83U]?SX>K_ /\
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M45U-<;374UQH:A$715@JZ.6:GE1%_J7* 5P3$
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M355*3J-W-UZQZ2U>YVX=5(UB,;)49IDD[T8BN<C$?+<G.1B.<JZ=FJJ 2?\
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MJ*US535%14X*BH <A^@
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M>Q3 ;U7RQS=0NYSXGH]J7B@B54[$D@L5IAE9[,<L;FKZT ,)IUY
M  /1U^Q"8B^BZ8>N7/%AF;'DF_.VF(LJ'5%.ZGE?A.WMPO,D,5*U?K4,T#<_
M:Z21Z=W*V1B,XQR:98?#KH5CP[<>Y<KN6KR6T4*.5S%:JV^URU"M1B?/:YJ7
M--57@J*FG8H!O!F1<       TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^
MU^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S
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M99'JKY))'JJN<JJJJNJG6!SG.<KG*KG.57.<Y55SG*NJJJKQ554 XS\
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MV^H7'\PCB[RLQ&[3QI6N1C.:6HLU4B1PWJB9HJJL:-GC:FLD4:*U5 S>G8H
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MB*NNMO7?&9+N]N7>X7]Y35V;9&ZCDU1W/0P72IIJ%^K5<WYU'"Q>"JB>950
MZ EL           #U;OL@VSE7MAX/./YE64LE.[J"ZB-ZMWJ1TS9&R3V^U38
MULA3RM2555*=\NSDKH^5$8J.5Z(JN5SLU_0G8'V?8:EKY&*Q<HRK(;ZQ7(J*
MZ*%U'CK')S?G5=8%5--$XZ^?50-HH[D@      &F%]MH_$%Z4?ROZ?\ B8W1
M,?WB'?N983^';?VOWD \T0Q$           'I=_8E_Q!>J[\K^H_B8VN,N_A
MX_N99M^';OVOV8 W/3("               =;>K#JZZ>.B#9/*>H/J=W,L.U
M^V.*0Z3W2[RNEN=]N\L4TMNQ7#[!2MFO.6Y=>%@>E);J"&>IE1CW\J11R/92
M6;YUBNW6/5N4YC>*:S6>B;\Z:=RNFJ9W-<L5%04K$=45U=4<J\D437/=HJZ:
M(JH!YCGC%?:<NJ;Q#ILLV1Z<Y<BZ6^CNO=46NHQVSW)M'O+O#9W(^GE?NSF=
MDJG_ 'GQV[4ZKWF+V:=MO6*9\%PJKJU(W1X>]^NL+,]TW5V.XFZKPS I%="Z
MEIYN[O\ ?H.+7+>[A3O7N*2=O;1T[DBY7*V5\Z:*@&KX=.
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MEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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MQ]\RI1WAL+%?/78U-.]9*F)&-5\E*]5J:=J.7]$C:LJ@;$!VI
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
M !M>_8V_]KAD?Y(&\O[=MH3NST#?NY5?X"7_ /5&Q 'J=F9\   QG>*=XIW3
MGX4?3G<=[=[;BV^YC?6W&S[*;*6>XTU+FV\6;4M-'*EJM22QU*V7%;*M3#-?
M;[-#)2VFED8B,GK)Z.CJK0[S[SXILGBDN19%*E37U*2T^/8]3RL9<;]<6,1>
MYAU1_P!7HJ?G:ZIJ7-5D#%3@Z1T<;P/(7Z__ !">IGQ*=_[YU"=3>:27^^U/
MUJV85A]L2:AP/:K"WW"IK[=@FW]A=-,VUV.W.J5YYI7S5]?-K45D]14/=(N"
MK<_=++]W,HJ<IS"X+55+^>&WT$/-';;+;UE?+%;;73*YR0TT2OXN572RN^=(
MYSE50#I 6Z                   *BQ++LJP')[!FV#9+?L-S+%+M0W[&,K
MQ>[5]AR/'KW;)V55NN]DO5KGI;C:[E0U,;9(IX9&21O1%:J*1=#75MLK*6XV
MVKJ:"OHIXZFCK:.>6FJZ6HA<CXIZ>HA<R6&:-Z(K7-5%10#T??L__P!ITMG4
MY6X/T5>(;D5KQSJ)KY+=BVSG415,H;+BN^=>]'4]NP_<A(_JEKQ/=RND2*"W
M5D,<5MR2=Z0*VFN2PLN66/I@ZPH<PDMVWNZ=7#297*L5%8,J>D=/19)(NK(J
M"[:<D-%?)%T;%(U&PU;EY=&3<J3 ;K)D*
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M  [A%>       &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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MVS<:D@7ZM,Q&TM#F%-3QZR55%$J]W3WN*-BOJ:5NC7HBRPHC$?'"!M8'=4
M             X:BHIZ.GGJZN>&EI:6&6HJ:FHE9!3T]/ QTLT\\TKFQPPPQ
MM5SG.5&M:BJJZ'R][8VN>]S6,8U7O>]4:UC6HJN<YRJB-:U$U55X(@!YAOVC
M[[0Q?NM?*LOZ(.CC+JBT='&)7AUHW*W%L%54TM?U/Y)9JABU$$=4UM/-!LG8
M;M J4-(U59D%1 VX3N?3_4XHL._5EU35.X=;7[=8%7/@P&AJ%@N]UI7O9+F-
M73O3G:CT1CFX]33M_0F)PJG-25VK>[:T#3_.B(
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MAZNJ,GQ^)8X6UTLCN,UVMKY&Q5*K\Z5CF2_.<LJM VR#NZ
M                               <-13P5<+Z>IACGAD3E?%*U'L<GK1=
M>*+V+VHH)5>[%9LEM=99+_;**\6BX1+#66^X4\=32SQKQ3FCD141['(CF.31
MS'(CFJBHB@M1D&WDK>\JK"[O4XN=03O1)&IY_JT[U1KT3S->J+I^>5>!\N15
M[/<,:N]G0U7T_P!;R#9NH6OI]732X1=:MC*V%NJJYMBN]4]L57&S5.6"K<R1
M&HNDTCE1BBTU3'-32R4\\4D$\;E;+'*QT<C'>AS'HCD4X3&O?;==K#<:NT7R
MVU]GNM#*L%;;;G23T-=2S)Q6.HI:ED<T3]%U1'(FJ+J" <[S)V>=?+S IF:;
MMX^7E[H(9[_<^$XW.UX)[:DIGGTUX^7R@A7O\Z^TAQDGFF[>/EY>X"&>_P Z
M]OF3R\P)5--V\00SWZ>M5]XXW.UX)[:DHGGUUX^7R@AG.\R=OG7R\YQDIFF[
M>/EY>Z"%<[S)V>=?+S E,TW;Q\OE^ $,]^OJ1/?.-SM>">VI*)Y^WCY>7N A
MGO\ .O9YD\O.<9*9INWB"&>_SK[2 E,\_;Q\OC500SW^=>WS)Y>8^'.TX)[:
M^7G)1--V\?+R]T$,]^GK5?>.(E,TW;Q\OE^ '""6O>KUU7L\R  ^       3
M6SV.[9!6,M]FH*BOJGZ?H<#-6QM543O)Y7*V&GA15XO>YK4])]LC?([E8U7+
MZ$^%5[$0N!MMM7N'O!DM-B&VN)7C+[_4JQ5I+53<T-' YZ1_7;K<)G16ZSVY
MCW(CZFJEA@8JHBO35 =G<)V0H+8L-QRM\5TKF\LD=KBU6V4[NU$J7.1KZ^1J
MZ:MT;"BZHJ2)HI-(*!K='3?/=V\GYQ/9_JE]XSM=+7A7XC@S[9FG4'4T&>Y5
M"L%;28%0J^7!K-.FLC&7R::..?+ZR%W)S1*V&W->CV.95L5KP7\8QD;&QQM:
MR-C6L8QC4:QC&HC6M:UJ(UK6M31$3@B$Q,O%-34]'3P4='!#2TE+#%34M+31
M,@IZ:G@8V*"""")K8H888FHUC&HC6M1$1- ?0.8
M   'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]
M+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M        #S9_M?\ XJMLWTWBQ;PW-E<EI[KMSTZ9(N9]1%VM%5%/17[J CH*
M^T6?;_ZW2O>R>GV@L%UJVW*)'JS[_P!SEIIXF5-I:IB3Z[MZH<DOU%M+CU8V
M:TXI5_?#*IX'M='4Y0D4L%/:^=BJCFV*EG>DK==/K,SF.1'P( :3YCS
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MLJR6;NXF\]+8[-"]RT%AM*2.?#0TK51.\E77FGF<B/GDU<NC4:UH&/ M6
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M6+)$RKA;(^EJ.[<YK*NCE5T4S=5Y)6.:O% "^Q4@
M                          !*+M8;5>XNZN-)',J-5&3)^AU,7G_0YV:2
M-37CIJK5\Z*?BHB]I;+<C9W;G=FW_4,YQBANSXXG1T=U8U:.^6Y%U5%H+Q2K
M%70,1Z\RQ*]T#U1.=CDX L]?=K[C3\\UEG;<($U5*6=60UB)Q71KUY:>?33M
MUC7T(IPOC=I\WBGG])C$W=\/C-K&M7==I[Q#F=K:KI(\>O$M-:LH@9\Y>[@J
MW=Q9+NK&MU5RNHGJJHUL3EX@M374E9;YG05]+44D[?\ M-1$^)^FNG,B/:G,
MQ=.#DU1?,0ZHJ+HJ*B^LQVY9C.489=)K+EN/WG&KM#JK[?>[=56VJ5B.5J31
MQU442S4[U;\R5G-&Y.+55.()8]_G7M\R>7F/PHF:;MX@AGOT]:K[QQN=KP3V
MU)1//KKQ\OE!#.=YD[?.OEYSC)3--V\?+R]T$*YWF3L\Z^7F!*9INWCY?+\
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MV(V7#[!3(U4H;/2I$^JE:WD^MW.NE=+<+O7O:FCZBJEFG?\ GGJ":'V5X
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MV[RFH6ZT..V;O.>&RV2&1[J:E;I\Q]5*KEEJ)$3]$F>JIHU&M:!C5+1@
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M>&I*[5$7GK^U4X- W>S(H
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MFFJ:F:6HJ*B62>>>>1\LT\TKUDEFFED5SY997N5SG.55<JZJ 2\X@
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M)69D<U9R,K,BO/=\E1?+Y)$QM76R:_.93,5O=T\6J]U UK55SN9S@,CY=D
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MD3ZB[8D^9WS:6_00+)<K8U[G<K(KK0P++&W@G?P*B:OFX@>CH980
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M)9ZC#J]NNG?-O\7<6R)%7@B_?^.C=Y]>73M75 /80,\(
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MV2/NU>Z16<ELI*5O(KW*[333554$:?15(
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M_;BYO=H'\%I:[*+U/1HBM8QR-HWUJTK.=(TYM&)S*FJZJ =+BWP
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M5SFW]VR._P!JAJ:FGC<KFT5SA5U+=[?JJN<OU"YP2Q(J\7(Q%\X!W'*^
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M;W7"SUS)*[&+^V+NH;Q;$>C')(Q%<V"Y4+W)'4PZKR.5KDUC?&YP&*<LH
M        5KMKGM]VKW&P#<_%IW4N3;<9MBN>XY4LD?"^GON'WV@R&T3MEC_1
M(G17"W1N1S>+535.),;1<ZFRW:V7BB<K*RTW&BN=(]%5JLJ:"IBJH'(Y.+5;
M+$BZIV 'O+X%F=DW'P;"]P\:G^M8YGF)XYF=@J=6K]8LF46>COEJGU8KFKWM
M#71NX*J<399MEPI[M;;?=:-W/27.AI+A2OX?/IZV".I@=PX?.BD10"K".
M
M                                                  /.#^V\_C3]
M#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
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MZ5$ZPV.^SMQ7(T5RI$EKO4T,,=7+IKHRUW)D%4Y417*R%S4^D >R09\@
M  #Q9?'1R2X95XP/B)7.Y.YJBEZH-Q<;C7O)I?\ P?AU='B%I;S5$DLB<MKL
M<*<J*C&:<K$:Q&M37TZD*N6MWWW5FF75[,RNM(G%SOT*@D2A@35RN7A#3MX=
MB=B:)H@!BA+)           'K0?9*]IK=MQX+>S&6T5/2P5F_&[6_N[-[= V
M5L]1<;7N3==DJ:HN'>1L:ZJ=8MG*)K%8KF+3-BXZZHF;[H?L<5IZ?<?KHVL;
M)DM\R>^5"M14<^6&[38ZQTNJ)J]::P1HFFJ<B- -E@[=
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MLK9E=W'+F5@:Y47EBD=2VN_T[5<O,C6RNHY6,;JFKY7:(NJJ!OTF38
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MQ
M                                                      'G!_;>
M?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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MW+W-S/-9'O=!>;U4K:VOUUALE'RT%D@5%TT=%:J6%':(FK]5T34 Z&EM
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MM<UR(YKD5%34U['L=&YS'M<Q['*Q['HK7,<U51S7-5$5KFJFBHO%% .$^0
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MTT51TZ[:/B=SM;07N%5Y7-TEILIOM/,W1R-7YDT3DU[%TU35-% ,YYV/
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MNDUK;FZLL6&I,S7ZO;87]Q>KS!S(J))75<;J.-Z:/;'#,GT9>(&]N9)@
M            #QC_ !].E6CZ/?%KZR=K+%;6VS"<CW&;O5@$%/3MI;9%BN^5
MHM^Z*6JRP-1J16G$K_DU?8XFZ(C5MCFMU:B.7 !U-X5'@>^&?66FA2&W5=V3
M(;6UC49"VBR."*\]Q3M33E@H:FLEID3S=SPX<0##N6&           /7J^RT
MY7/E'@>]'L%4M1)58I<.H'%)*BH>Q_UB"AZC]V+A;$@1B(K*>BM%UIZ5J.X_
MH"KV*AG5Z,JYU;TZ8&U_.KZ*7**%7N5%YFQY9>Y8>73L9'!,QB:_U(!L'':,
M
M                                                     \X/[;S^
M-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
M                    %S]I=[MYM@\KIL[V,W;W,V9S:CT2ER_:K.LHV^R:
M!K4>B,COF)W2TW-L:MD<BM[WE5'*BIHJDYL>19!C-:RY8W?+O8+C'IR5UEN5
M9:ZQNFO!*FBF@F1-%7AKIQ -E3HC^UR^)ETTS6G'>H.7#>M;;2C='#44NYE)
M3X3NY2V^-.$%FW=PRUQ_7*ITBJY]3D=FR.I>B\J2,:C>7MQMWUR[OX@Z"DRE
MU!N%:(U1KF7AC;??&1)^=I[[;X4[QZKQ5]73U;U[-4X: ;L?AS?:/_#:\1"I
MQ_!;=N'4=.6_U[^I44.R>_T]JQ:KOU\J59 MLVZS^*MFP7/9*FN=W=%2,JZ.
M^U;51WWLC55:W(;M1U9;2;J/I;;%=7XGD]1W<;<>R=T%&^IJ7Z-[FTW-LCK;
M<U?)PC8CXZEZ<>Y3L0#/D=F@              #3"^VT?B"]*/Y7]/\ Q,;H
MF/[Q#OW,L)_#MO[7[R >:(8B           #TN_L2_X@O5=^5_4?Q,;7&7?P
M\?W,LV_#MW[7[, ;GID!     ,,WV@CJD7I)\(OK)S^WUKJ/+,YVY?L+@_<R
MMAKG9%OM74VVE366V5_".NQS%<@N5X:Y/GM;;G*SYZ-+ =4.9_L&V,SZZ12+
M'77*TKC-NY51LBU>2R,M#Y(E7LDI**JFG1>U$B73B >- 8!@          "(
MI*2JKZJFH:&FJ*VMK:B&DHZ.DADJ:JKJJF1L-/34U/"U\T]1/,]&,8Q%<YRH
MB(JJ?;&/E>R*)CY))'M9'&QJO>][U1K&,8U%<Y[G+HB)Q50#W!?#)Z2+?T*]
M _2OTKTU'1TEWVJVCQRCSQ]#'#'3W'=3(8I,LW7O$:P*]LD=VW&OMSGC57R.
M2)[45[].9=BS9_!HMMMLL+PMD<;)[+8Z2.YK&C49+>JIJUU[G3EU14GNU3,Y
M.*KRJG%0#O67)                     /&_P#M$W2=#T@^+KU98=9K4VU8
M/NIE5)U%X!%$G=TC[)O=2_LPR&&WT^B,I+;9=R:B^VRGA9I'%%0M:Q$8C43
M?U580W!-\\WH*>%(+=>JUF5VMK4T8M-D3/K]4V)NB(R&GNSZF%K4X-;&B)P
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M/K.)97=Z%8%75S**ZMI[W33HB)HD<U575+4XJO-$[S: &V =V@
M        #Q&?%QWKINHCQ.^N_=ZW5?U^R9-U0;MT.+U_UA*IM=AN(957X3AE
M:R5/F)'5XICE'(UC5<R)KD8USFM1RZ[F^60LRK>'<J^Q/[VFK,QOD=%+S\_>
M4%#6RV^WR(Y.&CZ*DC5$35&HNB*NFH!CM+5           'M1^!UM)4;)>$7
MX?."5<#J6MFZ:L#W KJ62-\4U)7[PP5&[U=2U$4DTSXZJFJ\Y?'*U5321KOF
ML^@W8.Z<[&_'=C-KK;(U62.Q&VW21BHK7,EOS77V1CVJYRH]C[DJ.]:=B=B
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M(UUN]@N]@J)&M7D1;!<(+A3)(Y/FI)(W(I.77151BZ:HW@!HWF.0
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M9L&*6>/N[9CUIH;11(J-1[X:&GC@2:7E1$=45"L621W:Y[E5>*@%Z"H
M            #S2_MLFUL5BZZ.E'>&"F[ANY/2W5815RL8UD59<MJ]T<MNDM
M3(Y&HZ6L;;-SZ2%[E55[F*)O!$XXBO$-LS:;<C";\UG*EVPQ]N>Y$1$DFLMY
MKIE>O#C(D-X8U5_J4:GF -+LQ^           'K ?9$JBHG\&K XIIYIHZ/?
MK?BGI(Y97R,I:=V2456Z"G8]RM@A=554LJM;HU9)'.TU<JKFTZ%WN=L%;4<Y
MSDCR;)6,15548U:N-ZM8BKHUJO>JZ)PU55\X!L\'<0
M
M                                   \X/[;S^-/T/\ Y/\ N%_&+ 8F
M_$3_ ,--NOP7NGZK- -(,QU@
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M<B(EXO\ =,@J6-7YW)C]!%04R/TX]U(_(GJB+P<Z/7M: ><D8H
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M:EM/8MQ:>GLW/*]&0P9)2RR28[,]SET_NIU1/1M1$U=+51JJHC5 /59,U
M              !C*\87KILWAV>'CU&=24]VAMV=4.&UV";)4KI8FU=WWPS^
MDJL?VYAH:>5K_KK;!=)W7NMB:G,EJM54_@C%5+/[\;D4^U6U>5Y:Z=L5RCM\
MEMQUFJ(^?(KHQ]+:6QM5%[SZM,Y:B1/_ *S ]?, >)\][I'.>]SGO>Y7O>]5
M<Y[G*JN<YRJJN<Y5U55XJIKT*JJJJJJJJNJJO%55>U57SJH!\GX
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M;58KID=3&U>#I+[7LMM*LB:Z<\++!+R\$5$E7T@&C28XP          #VA?
M5VJ@V;\'/P\\1IX/J\=WZ=,7W5='R0LYI]]JVZ[WU,^D#G,7ZS4[AODU5>=W
M/J]$>KD38%Z9[*VP;";64+6\J3XI1WI4T:FKLEDGR)[M&JJ?/==57TKKQXZ@
M&7,OF                       :4WVV_$*6MZ*NCO/7TDCZ[&NJ.\XA3UR
M4D;XJ:ES?:?*KS64CZY8734\E;-M] ]L39&-F2G<YS7K$U68]?$0H62;>X%<
MU8JR4F95%"V3D16L9<;)6U$C%DY5<Q9'6MJHU%1'<JJJ+RIH!YL!B1
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MY45VGCYZ7"[#=LB7F:JQNK96PV.@C54X)*R6[NG9KYX-?, >KV9LP
M           #S^?MS-%1QUOAA7)E-"VOJZ7K-HJFL;&U*B>CM\O2K/0TTLNG
M,^&EFN=0Z-J\&NF>J?24Q@>(['&DFSLJ,:DKV;@1OD1$YG1Q.PIT;%7M5K'3
M.5$\RN7T@&@:8Q@          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_ (49
M)_WQ  ;/QW&
M
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M<4         TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
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M9"[1/T.OO%SMU-$_5>/&AIZENFG'F[>&B@>G89A@
M  #5?^V$[20[A>$-59TE+"^KV'ZDMFMQ6UJT_/4T]!D:9/L[5TT=2V2-]/2U
M=7N?2ND:[GBD?#'JSG;&]G2_KQL;;IL4^Y<C5DQK+;!=4DY=7LBJ_KEA>Q'H
MJ*UDC[PQ51=456IPU1%0#RIS"N           9"/"9W6?LEXG70)N6M4VBH;
M!U;;$TM_JG/IXTBQ+)=P[%BN9*DE744E)$YV*7NL:CI98XFJJ*]S6HJI=+9"
M]KCN\.V-WYTCBI<XQME4]5:G+0U=UIJ*OXO?&Q%6BJ).+G(U/.J( >W@;$P
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MGI:>)JTZJD<$$;6M3T( 5-_K]_&2_P!X3U ?IQ8_UA(S^4WOY^^EE']\4_\
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M?F(F3KPY[RO/NICTCUT5N*WFDC\R*U;W0W!_%VFKN:F3@GFXKV 'H!&3X
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M_P!\0 &S\=Q@
M
M    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
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M[JWIS-75%9B=KB>JM^:E'!?JNH8U$=SISK71*NJ:+RIHO: ;ZIDP
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M')B.!K)QLE+4K)<;TUFG))D-PC2-)XN9.=M+$UM.Q53G[YS&R(!KA'4T
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M&-TLEQ;&5='5N6>%R8]9:5%C71(U3E1K6HC4UV]\[FZ\;S;IW!7*]LN?95#
MY>=%6EH[S64=)JCUYFK]5IV</-V:(G  QWEJP
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M:'H(MS:+8RHJD1$==\XO]>Y45RJO=45FM::\R:)HEN[&\//VJH!M;'=<
M               T _MSG_RN_P#IL_\ PCF,/Q'O_0U_ZP__ #& - ,QA@
M        'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O\ PHR3_OB  V?CN,
M
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MFZ^7LDBR/<3,+I32MY9*&6^U\5M>FB(NMLIIH+?JJ)Q7N]5\X!T/+:
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MK^*^=0"RQ3P
M !L[_9$LB99/&6P&VON$U$[+]AM^,=BIHDJ%9=GTV-4>6+;ZA86/C;#''B[J
MI%E5L?>4S41>=6-7N'T+U24^_P!;(5E=']>QK):5&)S:3JRCCK>Z?RHJ<J)1
M\_SM$U8GGT /6!,VH    !YP?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6:
M :09CK           /78^RKV-]I\#KI)KW5+9TR?(NI"^1Q-C5BT;*?J7W:Q
MI:9[E>Y)G.?CSIN9$:B)*C=/FZKG/Z+*98.G/!Y5>COKE7EM2B::=VC<OOE'
MR*NJ\RJM+S:\/I:>8 V(#M2                   : ?VYS_P"5W_TV?_A'
M,8?B/?\ H:_]8?\ YC &@&8PP          #U>OLAO\ L;<+_* WV_5RUF;+
MH5_<#M_X49)_WQ  ;/QW&
M
M              /.#^V\_C3]#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
M         !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M           #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MBH8ZIH9J>:6GJ(I()X)'PSP3,=%-#-$Y6212QO1KXY(WM5'-5$5%310"!.,
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ME371-9&NJ?KM;65G)W?UNJJ*GN^;G[OOY7R\G/RLY^7FTUT37T $@(4
M                                              V/?LH'^VUZ<?P
MZB/XCLX.V71+^,/BG_ZKRK]KMQ /6[,XP    !YP?VWG\:?H?_)_W"_C%@,3
M?B)_X:;=?@O=/U6: :09CK           /7Z^RX_["CH9_Z3/_OA]01G:Z-?
MQ;=N/_+#]OF4 &?X[/                   &@']N<_^5W_ --G_P"$<QA^
M(]_Z&O\ UA_^8P!H!F,,           ]7K[(;_L;<+_* WV_5RUF;+H5_<#M
M_P"%&2?]\0 &S\=Q@
M
M         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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M$0           >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M    >*CXW5OK;9XNWB+TU?3R4L\G5IO!<&1RHB.=17;**NZVZH315_0ZRWUD
M4K/2QZ&O=U$Q21;Z;K-D:K'+G%]E1%[5CFK'S1.]A\4B.3U* 8M2S
M    !Z>/V*:MHY/"_P"H2VLJ875])UZ[CUM31MD:M1!1W#IZZ8X*&IEBUYF0
MU4ULJ&QN7@YT+T3Z*F8CP]I(UV<RF)'M65FYEVD?&BIS-CEQ;#VQO5.U&O="
MY$7SJU?0 ;@YWP                       ,?GBS310>%AXE;YI8X6.Z!.
ML.%'RO;&U9:CIZW#@@B1SU1%DGGD:QC>USW(B:JJ%K][W-;LONZKE1J?YL<\
M;JJHB<SL6NK6IJOG<Y41/2J@'B%&NN             >[)T96>BQ[H^Z4;!;
M6R-M]CZ:]B[/0-FD665M%;-K\6HJ5LLJHBR2)! WF<O:O$V2MOX(Z7 \)IHM
M4BI\1QN"-'+S.[N&S44;-5\Z\K4X@'90JX       H/<[=';?97 LGW2W=SO
M$]L]N,+M<]ZRS.,XOUMQK%\?M=.B=Y672\W:HI:&EC5SD8Q'/YI)'-8Q'/<U
M%EEXO-IQZV5EYOMRH;/:;?"ZHKKC<:F*CHZ6%O;)-43N9&Q-5T35=5541-54
M T6/%(^V.T%KFR3:'PL\/I;W4,;<;14]6&[F-U+;5#*J.IXKOL_M%>XJ:HN#
MHM>^IKCEL$</.WDELDT:H]<;V\O7O%"ZKL6S% RH<B2P/S>^4C^Y:[BUL]AL
M50UCI=/I,EKFHW5-'4[DX@&A[O9O?NWU'[IYEO;OKN!DFZ.Z^X-T^_.89SEE
M<M?>[U7-IX**G[V1&QP4U'04%+%34M-!'%34E+#'##''%&QB8U<BR*^99>J_
M(LDNE7>;W=)N_K[C72=[45$B,;&WF71&LCBB8UC&-1K&,:C6HC41 "UA)0
M                        ",M]ON%WN%#:;30UESNESK*:WVVVV^FFK;A<
M+A6S,IJ.AH:.F9+45=95U$K8XHHVN?(]R-:BJJ(<D44L\L<$$<DTTTC(H88F
M.DEEED<C(XXXV(KWR/>J(B(BJJKH@!M8^%[]D\ZU^L.IQ_<OJ^9>.BKI]J9*
M2O?;,KLS9NHW.;4Y8YGTV-[97%8DVYCK(FO@6X94E-5TCW,GBM%PA71>ZNS?
M1)N'GCZ6[YVE1M[B[U9*L-;3H[*[E NCE926>73[U)(B*WO:WD>Q51S8)6@'
MHT=#7A[=)7AS;14VS72=M/9]O;!+]5J<KR695O.X>X][IHGL_9%N)F]<U]ZR
M:Z*Z:188WO90V]DKH:&GI:=&PMRN[<;6X/M18F6#"+)!:Z9W(^MK'?W1=;M4
M,:J?6[K<9$6HK)M7+RHJI'$BJV-C&:-0#NF7"           / ZW'M]':=P\
M\M=NIXZ2WVW,\HM]!21(J14M'1WRNIZ6GB1554CA@C:UNJKP0UE[O%'!=;G#
M$Q(XH;A6Q1,;]%D<=3(QC$]36HB %&$O           -N[9/['5UQ[Y;,[1[
MUX]U.]*-HL&\&V.!;I6.U7FHW>2\6RS[@8K:<LMMONJ4.VE71)<J*BN[(Y^Y
MEDB[UKN1[FZ*O>G'N@K<;([!8\AI<QPF"FOUGMEYIX*AU][^&"Z44%=#%-W=
MI?'WT<<Z([E<J:HNBJ@!<[^A,=??\Z[H_P#[YWH_T6DX_P!7CN;_ ([8)_QL
M@_68 ?T)CK[_ )UW1_\ WSO1_HM'^KQW-_QVP3_C9!^LP _H3'7W_.NZ/_[Y
MWH_T6C_5X[F_X[8)_P ;(/UF ']"8Z^_YUW1_P#WSO1_HM'^KQW-_P =L$_X
MV0?K, /Z$QU]_P Z[H__ +YWH_T6C_5X[F_X[8)_QL@_68 ?T)CK[_G7='_]
M\[T?Z+1_J\=S?\=L$_XV0?K, /Z$QU]_SKNC_P#OG>C_ $6C_5X[F_X[8)_Q
ML@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';!/\ C9!^LP _H3'7W_.NZ/\
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MFQBZ45MMUXIF4EH==?K;JBY4,M#&]4K+;3PK"QD[E7YZ+KIIKV &ZN9"0
M #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_QV>
M     - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0#,88          !Z
MO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
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MMK-I]L*MC7-95;>854L:_3F:V?&[9*UKM%5.9$=QT734 [M%PP
M                                  #S@_MO/XT_0_\ D_[A?QBP&)OQ
M$_\ #3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=
M&OXMNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8
MP_$>_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O
M[@=O_"C)/^^( #9^.XP
M
M           !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M        #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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M*ZV[XPW'DTCR'#;%<>\1%Y72TE1<K+(Q5TT61D=LC54\S7-](!JE'2@
M      WL/L/6Y4=NWC\0/9^2;67,=L]B=RJ2G=J[ECVURG<3%[A-#K,C8^=V
MZ]*V72-5?RQZN3D1'9)/#HNZ17_="PJ[C7V?&[NQJZKHEHK;K1RN;\[1NJWM
MB+PXZ)QX 'HD&50                       US?M6>Y,> ^"?U)69*KZG7
M;KYIL)MM;9&SN@FED=O+AN>W2E@Y7M67ZYCF!UL4K/G(ZG=)JFFJIU1ZUKNE
MKZ><MI^?NY;W<,9M$*H[E<JK?Z"YS,;HJ<W>4ELD1R>=JJ >1R8-0
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MA+6MGWQW6HU:K$?G.07%C51$Y8[Q7RW>)&HC(T2/NZY.5-.#=.*]J@8P2S@
M         ![6O@FY8[-/"-\.:\/J9*I:/I$V5Q-)9::*E<UN!8=;L%93)%"R
M-CHZ-F.)"R14YYF,21RN<Y7+L*=/%<MPV,VHG5ZO[O!<>H=58UBHELH(K:C-
M&HB*D:4G*B]KD35=54 RAEY
M        #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
M    >OU]EQ_V%'0S_P!)G_WP^H(SM=&OXMNW'_EA^WS* #/\=G@
M         #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\ ,8 T S&&
M   >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #9^.XP
M
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M1R/2.+*K%?\ &WO<J(WF6E9?:9CE5>V:LL4;&^E[D0 ]9TS>@
M           &DM]MMWMCQ[I%Z.>GB"N[FMW4Z@\JW8JZ2&H='-4V?97;ZKQA
M8ZN*-Z++;WW7>RGE1LB*QT],QR?.B16X\?$0R)*7!<"Q5LG+)>LIK;W(QKM'
M/@QZUOH^5[475T2SY"QVB\%<Q%[4 /-P,2H          !G[^S#;*2;T^-+T
ME]_0NK;#M,_<K>O(GM9*Y*"/ ]MLG7%*YZQJU&-CW'NED9JY4;K(B+S*J-=V
M=Z.\>7(>H+!^:-9*:QK=\AJET<O=I;+36?4I%TTT1+M-3IQX<?/V 'K^F=L
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MJ8]4UCJ8*"FAA14[8ZJ1/. >BX96@
M           #R7/M9^T#ML/&?WDR=M)]3HM]]J-B]WZ"-E/%34TK:? Z/:"Y
M5=,V%K&R?7;]M+62SR*G/)5/E<Y5555<('6_8EL_4#?ZQ(^[CR6R8W?8D1K6
M,<C;9'8II&(U$1>\J;'(KE[5>KE4 UJCJ,           >O)]EHW+AW%\$OI
M1HUG;/=-M+MO?MI>E;P2*:T;VY[?K) K=/FNBP_);8B\5YE^=PUT3.GT97=M
MUZ>,)CYD=-:)\BM%1I^==!D5SJ:=NGI2@K(=?3V@&PH=I0
M                              #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\
M#3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=&OXM
MNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8P_$>
M_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O
M_"C)/^^( #9^.XP
M
M       !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M    #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                ..::*GBEGGEC@@@C?---,]L<4,4;5?)++(]6LCCC8U5<
MY51$1-5/QSFM:KG*C6M17.<Y41K6HFJJJKP1$0 \.SQ+NH^EZN_$!ZP^I"UU
M[KGC>Z_4%N3D&#UKT<CY=N*;(JNS;:L=SLB=S4^ VNVQKJUJZL[$[#7.W=RQ
MF=;H9YEL,BS4E[RB[U5ND775;2RJDI[0BZHBZMMD,2=B=@!T>+<@
M  &?;[,!C'[*/'&Z)(Y:6HJ*&QU&_63UTE._N_J?WBZ9=Y:NU54[NWZO^R'Z
MG&Y.//WB-[%54[.='-']=ZC=NT<Q[XZ9^35DBM73N_JV(7]\#W+_ %'UKNT7
MTZZ 'L!&=P     TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M          #TN_L2_P"(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
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MRO35$7@;(5'5TUPI*6OHIF5%'6TT%725#->2>FJ8FS03,U1%Y)8GHY-41=%
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M,L%V?;6V2RR,>Z.>*Z7^>*TP55,]KF*E1;8JI]4WC_VCS]B@>+L:_(
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MJY%;&4:,C:JZ]W'48Z]RZ<$=+Q[0#=I,AP
M                  !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;=?@O=/U6
M: :09CK           /7Z^RX_P"PHZ&?^DS_ .^'U!&=KHU_%MVX_P#+#]OF
M4 &?X[/                   &@']N<_P#E=_\ 39_^$<QA^(]_Z&O_ %A_
M^8P!H!F,,           ]7K[(;_L;<+_ "@-]OU<M9FRZ%?W [?^%&2?]\0
M&S\=Q@
M                                                          #S
M@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K\%[I^JS0#2#,=8          !Z7?
MV)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M        &OG]I4\1N@Z /#;W%LV,WV&@W]ZKJ&_]/^S5#3UOU:]VZWY%:'4N
MZ^Y%"R&6*O@AV_P:YO9!6P__ &G?KK:N9425#J[U<[L1;8;27:GHZEL63YM'
M58O8(VR<E1%%5P<E[NT:-5)&MM=MF5&R-^A4S0Z]H!Y"9@I
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M<T5*_'+W<K+4KIRMDDMU7+3=_'Q5%AJ&QH]BHJHYCD5%5% +'%.
M  'K??9;>N.#K"\*[;'"+]>)+ANKT@UB]..;0U=0^:NFQ3':2*X;-7QC99)9
MOO7-MK5TEHCD<[]$K+'5Z(C6HAG'Z,]QFYYLO9[=4U"RWK!)/V)W%LCU=*ZB
MI6)+8*E$<JN[EUH>R!%5>,E,_P! !L=';$                   H7=#<G#
MMF]M=P=W=Q+Q#CV ;783E.X>;7VH170V;$\,L==D60W.1K?G/;0VFW2R<J?.
M=RZ)Q4EMYN]!8+1=+[=9VTMLLUNK;K<:EW%M/0V^FDJZJ943BO=P1.73M70
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MEO-'4R1(J\7SQ0QIQ<@!Z=AF&
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M #/\=G@                  #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\
M,8 T S&&           >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #
M9^.XP
M                                                         !YP
M?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK           /2[^Q+_
M (@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M    .O?5-U3;%]%^Q>>=1W4=GEKV[VIV[M;KA>[W<'++5U]7*O=6K&\;M46M
M=D669%7*VEMUNI6OJ*NH>UK6Z:JE+9IFF-[?8W<\LRRYPVJR6J%9:BHE7626
M1?FP4E) W]$JZZKDT9%$Q%>]ZZ( >.KXOGB@;F^*[U@93U"9?3W#%]N+)3R8
M1L'M945C:B#;C:VWU]556ZGK6T\CZ"IS3)JFH?<;[61\W?5DJ0QO6DI:6./
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M6FJ;]_,U6.KO;8U_1*'%:*H1[6/5-%C?>KG V-NBKS003M<FCDU \S(Q!
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MBFBD:CXY8I&*YDD<C'(K7(JHJ+JAW_:YKFHYJHYKD1S7-5%:YJIJBHJ<%14
M.0_0                                      "C]P\#QC=/ ,XVQS>V
MQWG#-QL/R; \NM$VG=77&,OLM;C]_MLNK7)W==:KA+$[5%31W80%UMM'>K9<
M;/<8DJ+?=J"LMM= [LFHZZGDI:J)>WA)!*Y/; /#&ZP>F_*^C_JFZ@.E_-6U
M#LAV+W8S3;F>NJ(/JRWVW8]>JJEQ_*:>%%5&V_+<>2EN=*J<'4U7&[SFN%GF
M)5N"9GE&'7!'+58W>[A:72/;R?68J6H>REK&M_\ K5=2\DS/2QZ '7 I,
M      JC",URO;;-,0W%P2_7#%LXP'*+!FN&Y/:9?J]UQS*\6NU)?,=OULG5
MKDAN%HN]!#40OT7EDC1=",MUPK;1<*&ZVVIEHKC;*REN%OK('<L])6T4[*FE
MJ87<>66">-KFKYE0 ]KGPIO$"P;Q,>A_9GJDQ2IM=/E%]L<&,;T8?;IVO=M[
MO9C-)24FX6*34RS355);WW*1MQM"S\LU38KA15+FM[[1-A793="W;O;<X_F=
M$^%E94TS:/(*")R*MKR*C8R.Z43F<SGLB694E@YOG/II8WK]( R+EUP
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M;]7+69LNA7]P.W_A1DG_ 'Q  ;/QW&
M
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M[*PWVGB1\V&Y1:KK4/1G,]MLN,=38JEK=$5R-6MN-*]WF1L>J]G #ROS"^
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M
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M999Y9)YY))III'RS32O=)+++(Y7R222/57OD>]5555555750"#.,
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M6XS;<SQ?(,3N[.>VY%9Z^SUFB(KV0U]-)3K/%KIRU%.YZ21N145KVHJ*BIJ
M>'IU6=->Y71YU'[S],&[UM=;-P]D\^OF#7]$AFAI+HVVU'/9LGLZ5#6RS8[F
M%AGI;K;)E32HM];#*G!Z&NAFN(W? LLR##K[$L-UQVYU-MJOFN:R9(7:T]9!
MS:.=2U],YD\+OST4C5\X!U^*7
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M_84=#/\ TF?_ 'P^H(SM=&OXMNW'_EA^WS* #/\ '9X
M  T _MSG_P KO_IL_P#PCF,/Q'O_ $-?^L/_ ,Q@#0#,88          !ZO7
MV0W_ &-N%_E ;[?JY:S-ET*_N!V_\*,D_P"^( #9^.XP
M
M                                    !YP?VWG\:?H?_)_W"_C%@,3?
MB)_X:;=?@O=/U6: :09CK
M              /IC'2.:QC7/>]R,8QB*YSW.5$:UK415<YRKHB)Q53]1%54
M1$555=$1.*JJ]B(GG50#UNOLSWA3U'AP=#E+G6ZV-.L_51U7ML.Y6[5+<8'Q
M7G ,+IZ.IDVJVAJ8IFQR4%=CEGNU1<[Q Z*.HAOEWJ:29TK*&G<W.-TA[*OV
MFVY9<KW2+!FF;?5KO?&2M5*BV6]D;ULMB>CM%CDI()W33M5$<VIG>QVJ1LT
MV/#MB       :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$,1
M       !Z7?V)?\ $%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
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M"*-B+WM?8.9ROX<TE(YWSOT"-C@/-$,1
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MH_7L=5NCT5>ZD: >F(9>@        #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M6GB3?OGDFUCZVUL9'+4K6[?WQM)! K$D<Z6LLE93K1OY'\5E<J,>FCFZHK5
MS ^&!]K"Z,>MG),:V9ZF,<DZ+]]\BJ*>TV"LRC)Z;)-@\XO<[HZ>DMUHW/FH
M;#5X1?+O/S.AH<AH:6A:YT=-#=:NJDCC???9SK;V_P!PZNDL&7TB[?Y+5.9!
M2R5E8RKQFXU#E1C(H+PZ.F?;JF=VJMCJHV1IP8V=[U1% VMCNN
M
M                             ><']MY_&GZ'_P G_<+^,6 Q-^(G_AIM
MU^"]T_59H!I!F.L
M        W&/LK_@EUO5ENY9O$+ZDL1D_DQ;%Y8VHV4QJ_P!"B6_?C>O&*[GC
MNZ4=4Q4NVV>T=WIFRUDJM^J7/(8HJ!'3QT5VIF=]NB_IXDS>^T^Z>6T*_L.Q
MNNYL>HZJ/]"R7(:.35)^[>GZ/9['.S61=.2:J1(M7)'.Q /3@,P0
M!IA?;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_
M8E_Q!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("           :2GVLCP7
M'[ZX#6^)GTUXDZIWCVGQV&DZHL2L5$LE=N5M%8*2."V;J4M+3:/J\NVEMT'<
MW1>[DEK<8:QZR,2SQQSX\.MSI]7)+9)N_B-"K[_9*5L>94--'K)=[%2L1L-Z
M8QG%]=8XF\LW!724:(NJ=PB. \W(Q+
M         &\)]EL\!BNWARO#/$PZP,+DI]G<,ND-_P"E7:[)J%\;MU<TM-1'
M-;-ZL@MM7$G/MOAUPB[RP0O1/OW=X&U:_P#@^DC;<LB_1GTT27ZMM^[V>6]6
MV&WS-JL*LU9&J+>KA ]'0Y#50O3C::"5NM*U?_MB=J/_ +$Q$E ]'0RP@
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MLE/2[BX]2,=71M5(X\DM<:1PI?Z.)=.2I9*Y&5L+=6LD<V1FC).2,#9@.W@
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M>][U5SGN<JJYSG*JJYSE7557BJDL555555555=55>*JJ]JJOG50#Y/P
M          RT>#KX3N\'BT]4UIVAQ!MRQ;9?"IK1DO4;O)%3L=1;<;?U%7,U
MM!:I:F"HHJW<;-DH*BCQZ@<R5)*ADM5,SZE1U<D=\-A=D;]OAF<%BH$EHL?M
MSH*O++^C$[NTVM[W?H4#GM?')=KCW3XZ6)475Z*]R=W&]4 ]C;8?8S:SIGV<
MVXV"V2Q"VX'M3M1BMMP[",5M37?5[;9[9&J))45$KGU5RNURJGR5=?6U#Y*J
MOKIY:F>22:5[W9[,:QNRXA8+3C&.T$-LLEDHH:"W44*+R0P0IVN<NKYIYGJK
MY9'*KY9'.>Y5<Y54"[1/         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M7WRRI?JIU!8[C;)\6DU5M5)>K)7.8E,B*Z58>9O!($50/09,HH
M
M                          !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;
M=?@O=/U6: :09CK
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M,1           !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M!#2TE+#%34M+31,@IZ:G@8V*&""&)K8X888VHUK6HC6M1$1- ":',
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MZ)(]%>YK$CA:YRI'''&C6- L$4P
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M5YFQ2/1.2EN]+&Y$J*=='-=\YO-&YCW 8FRR(
M           !D:\,OPO^IOQ3^H"V[)]/V.R4M@M=1:Z[=[>.]452[;W9G#JZ
M>=CL@RBMB="E=>*^*BJ&6BRP2)77>IB<R/NX(JFII[L;0;.9AO1E$./8O2JR
MEA?#)?;_ %$;UM>/T$CG(M562)R]Y/*V-R04[5[R=[51-&H][0/7_P##U\/_
M *?_  U>F;"^F3I[L?U:Q6"-;GF.:W.EM[,TW5SRNAA;?MP,[N-!34S;C?+F
MZ%D4+-.YM]!#!1TZ-IZ>-J9V]K=L,8VCP^WX?BU-R4U*G?5]QF9$EPO5SD:U
M*FZ7*6)C$EJ9E:C6I]&*)K8VZ-:B '=\N*           ><']MY_&GZ'_P G
M_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_I,_\
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MUXFPC(HT8SE5'UU!&Z65?S\E2Y55550#T-S*<
M
M              ><']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
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M553'@][Y7OEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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M4.1P0M5M#4IJC6SHB4TZJG*K7JL30-?8ZN@
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M%^9266JC5Z?G71NUTXH@'H0F4<
M
M   \X/[;S^-/T/\ Y/\ N%_&+ 8F_$3_ ,--NOP7NGZK- -(,QU@
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MU;+E5UIV,^IN>UK966&V=Y/3VB-VBIWG-+5*USFK-R+R@&?0[-@
M   'R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-:U$U55X(A^*J(BJJHB(FJJO!
M$1.U57S(@!Y>_P!I9\?&^];6Y.5=$'2=F\U'T9[9WYUHW#R_&:Y[(NIW<'':
M]%JJQ]RIN[6NV9Q"\TO)9J6-[Z.]UM/]]Y'5$7WL2EPX]774U4[AW>MVZPBX
MNCP"T5*P76OHY51,PNE)+\^196:=Y8*"H9I3L15CJ)&]^JN;W/(!J(G18
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M.:JM1'-5%3@4_/3STLBPU,$U/,U$5T4\;XI&HY$<U59(UKD1R+JG#B@!+3A
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M9EN^"9)(V'^Z4MK[A&ZWW-(?T:6SU]7$S1TB*6JWJVQH=WMN,APBJ?%3U5=
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M@FX=WP2NJXFMK9+K/8;I75V9I%(Q(V1OE:L%&G+W<D;Y7(WN^Z5P'HWF5\
M
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M<1Q_&V.9R2R6FUTE+55+45%UK*YD?UVM=P3YTLCW:(B:Z(@!V@*R
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M>U"PDT$U-+)3U$,M//$Y62PS1OBEB>WM9)'(C7L<GG1410"7G$
M 7;V?V!WTZA,DCP_879G=3>G*Y)((VXYM3@&5;@7IKJAZLA66W8K:KK501O<
MB_/>UK$1%55T15)Y8<8R3*:M*#&;!>LAK7*U$I++;*VZ5"*]=&\T5%#,]J*O
MG5$0 V(NC_[)5XK'4?/:+QN_B^!]'FWU=R5,]XWGR:BO>?RVU[%_1;3M3M]4
M9%>Z>Z-G^:M%D-5C<B-:YZNT[M).U."=#^]>6N@J+[16W [7+H]U1D%9'47-
MT*IVP62UOJZEDR.X=W5/I%T15U[-0-P7H)^RA^&?T@5-ES+>2RWCK;W8M4C:
MIMWWSM]OIMHZ.O8J-;+:-A[9-6XO<*-T2<:?)ZO*&)(Y7L5BHSD[X;9]$VT.
M"/I[A?Z>HW$O<*H])\DBB98HY4['08U"Z2CECY?SE9)6)JNJ:<- -F2S6:SX
M[:;;8<?M5ML5BLU#2VRSV6S4-+;+3:K;0PLIZ*WVVW444%'0T-'3QMCBBB8R
M.-C4:U$1$0[>T]/!200TM+!#34U/&R&"GIXV0P00QM1D<4,4;6QQQQM1$:UJ
M(B(G  F1S               &JW]JU\4*Z=$71/0=-FT&3NL?4)UFMOV&I<[
M75.AOV";#6J"&#=+*:&>GD[ZTW;+7W*EQNWS/:USJ>NN-12R,J:%KV=+NM?>
M2;;O;R+$;%6+393N E30=]"]6U-MQF%K6WFMC<QW-!/7+,RDB<J(JMDE<Q4?
M&BH!Y59A8       .2**6>6*""*2:>:1D4,,3'22RRR.1D<44;$5\DDCU1&M
M1%5571#]:USG(UJ*YSE1K6M15<YRKHB(B<555 /9+\!SPOL;\+WH0P+ [I8*
M6EZC-X+;8=TNIW(7Q4TEVEW NEK[^W;=K<(H^]?CNT=LN#K320)(^G6N6OK8
MT:ZOEUSZ=-.SE)LWMK;+9-2L9E=^AIKUF-4J,6=UTFAYHK5WJ)S+26.&58&-
MU5O>=[(FBR. ,U)V#                         +?[B[3;5[P61^-;M;:
M;?[HXY)'40R6#<7#<<S:R/BJVQLJXGVK);;<Z%T=4V%B2-6/1Z-3771"5W6Q
MV6_4ZTE\M%KO-(J.:M+=;?27&G5'HB/18:R*:-4>C4UX<= #!+U?_9?/",ZK
M;;=*FP[#R=+&?UD<SJ'.NF&YIM_0T=2J/DIHZC:RLIKWM#/:VU3D6:.FL=%5
MR0ZQQU4'S7LZV9WT<;&9K#,^EQI<+NDB.6.Y8=-]ZXXWZ*K$=99&5%B="C_I
M(RFC>K>"/;P5 -'KQ3/LP77-X>5HR?>#;1]/U<],F/QUMTNVX&V]CK;=N1M]
M8*1CZF:Z;G[3+4W:XT-GM])&]]3=K+5WFW4T$+YZUU Q6M,=&\_1UN/M9!67
MZT*W.</I4DFGNEIII(KM:Z5B*]TUXLG//+'!%&BJ^>G?/$QK5=(L::( :TQU
M%             /;)\&C=.KWG\*7P^L_N-1)672KZ5-H,;O%=,L;I[A>]O\
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MN:O:A82:":FEDIZB&6GGB<K)89HWQ2Q/;VLDCD1KV.3SHJ(H!+SB
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M?K]MFEIII:;Z[E^07&EYI:2:HIW=]15<<B<KUT1VBZ+JB 9CB_8
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M!]5I?JOU'ZM3_4OJ_P!5^I]S']5^J]WW/U;ZOR]U]7[KYO)IR\O#30 G!S@
M
M
M
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MQU$\3^+)HK?5LN+X'IHNK)TI>14\Z.\P![9!L-
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M"Q6>WVB%6M^BU8[?3T[%:WS)IH@!>(GP
M
M
M
M
M
M        !(\GR"WXEC60Y5=ED2UXS8[MD%R6%84E2WV:@J+E6+$M3-34Z2)3
MTSN7O)(V:_2<U-52&K*J*AI*JMGU[FCIIZJ;EY>;NJ>)TLFG.YC->1B]JHGI
M5 #P3L\S.][C9SF>X62S_6LCSO+,BS._U.KE^L7O*+Q67NZSZO5SE[ZNKI'<
M55>)K/7.X5%VN5PNE6[GJ[E75=PJG\?G5%9/)43.XZK\Z215 *4($
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MZ^XP\%5=4[FJ;HOYY./G ,RY?X
M
M
M
M
M
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M7+Q55U7B 7^*G
M
M
M
M
M
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MA<U5T6-[NU$T4#V)#/.
M
M
M
M
M
M                                  >,S]H Z7*WI+\7+K.P-+?)18QG
MNZ%PW]P.7NTCHJS%-^&MW,6*U-YG.^]^.9+?[E94UTTEM;T35J(JX ^I[#9,
M'WSW MG=+'1W.\RY/;'::1R462HEXY8$U5>ZI*NJEI_^%"OF ,-I8,
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MYIE@R7<-*2Z/BFC:D]OQR!LRV*D5517QR5T50ZKD35.$T;7-1T:@&TT=S@
M
M
M
M
M
M
M            #2$^V8>'=<=T-D=HO$5VYQYUPR+I[;%M!OS+0QQ.KEV8R^_R
M5FW^4U3>[;//;<#W+O=312HQ[WL;E7?*Q(8)I(\=?7[M5+><=L6ZUII5EJ\6
M1+%DRQHBR?L?KJE9+76O3EYG0VR[U#XW:*JHE;S:<K7*@'G!&)L
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M8*A9F\JOYHDAN#^\;R(JZIJFB:@%=?RLNEC^<OT__P ,NW7_ #C)C^S?"_\
M&_%_T_M/_*P!_*RZ6/YR_3__  R[=?\ .,?LWPO_ !OQ?]/[3_RL M_DGB%=
M F&_7_V7]<71_BOWJ[O[Z?LDZE]E['][>^[KNOK_ -],UI?J?>]^SE[SEYN=
MNG:A+*O=+;*@[WZ]N-@E%W&G??6\OQ^F[GFY>7O>^N#.[UYDTUT[4 .K6?\
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M6M:C6HC6M1&M:U$1K6HFB(B)P1$0 Y#]
M
M
M
M
M
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M2O;VIR7*U=XG]SSO:B,;=+8LC8JEFC=7:2-1(Y&:@8C2Q@
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M'20-1."?.EJ*B33GJ*RJE59)I7ZOED<KG*JJH!?(J,
M
M
M
M
M
M
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MR)NLU+(Y7L5%5JR1\LC@,4Y90
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M/4SOU?++(KI99%5[W.<JJH%X"?
M
M
M
M
M
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M[!%3;#[<7RFG^N4U5@^VMQ6M=E-ZM<W*V.\9%)5(LD$=526^VSIPRC[*]%N
M;</I+[F#H<^RV%8YHG5M*C,:M-2QW>,?;K1+WBUM1"[1$GJU?Q:CV10N -J
M[H
M
M
M
M
M
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MWINZ2-_MW;;='<M+E6+;:9,[ 8^S1]PW%N%#0X):85U1$DJ[C"Q55$1=2O\
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MP01LBAABC:C61Q11HUD<;&IHB(B(B $P.4
M
M
M
M
M
M
M             L_OA_F"_8%<OY2?^9__ #7\/OO_ )\/V%_L"[.'WR_9[_\
M>]V?_720Y'^QC[V2_LN^\/WF_P"W_LC^]_WL_P#WOWS_ +E]T U9>L;^AS][
M=_\ /;_(,^^'>?W=_)/_ &<_7_KG,_7N_P"0_P#-^N=_KWWFY_[/YSICGO\
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M+>7E3ETY=$Y>73EY=.&FG#30 Y#]
M
J                                                     /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biosimilars.jpg
<TEXT>
begin 644 biosimilars.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%-=TC5G=E1%!9G=@JJJ@EF
M9B0   222  "3Q0 ZBOG&\_:W_9TL-7?2;GXJ>'U6&Z%E<Z_%!K5UX*LKO=L
M:WO_ (@VNE3^ [&:)]R3)>>)8# Z2+-Y9CD"_0UI=VM_:VU]8W-O>65Y!%=6
MEW:317-K=6T\:RP7%O<0N\,\$T3K)%+$[QR(RNC,I!(!\V_&;]K#X7_ OXR_
MLN_ SQK;^*YO&G[7/COQO\//A7+H>C6VH:';:_X ^'FJ_$S77\6ZC-JEE-HN
MGOX<T>[2PN+2RU66YU$QVSV\$)DNH_ID,"H;LP!&?]K&/YBOQ!_X*3_\I)/^
M"%/_ &=;^U!_ZQS\0:_;I?\ 51_2+^:4 ?+^J_MN?LB:'JFI:+J_[2'P;TW5
MM'U"^TG5=.O?'FAV]YI^IZ9=S6.H6-W!)<AX+JSO+>:VN87 >*>*2-@&4U0_
MX;P_8T_Z.=^"/_APM _^2:_C-^/A/_"]_C?R?^2R_%;N?^B@^(Z\FR?4_F:_
M3Z7 >"J4Z<WC<4G.$)M*-'3FBG;X/-_=YZ?C-;Q,S*G6JTUEV!:IU)P3;Q%V
MHR<4W^]2O9?U?3^XO_AO#]C3_HYWX(_^'"T#_P"2:/\ AO#]C3_HYWX(_P#A
MPM _^2:_ATR?4_F:,GU/YFM/]0<#_P!!V+_\!H__ "'K_3TR_P"(GYG_ -"[
M ??B/_EOK_3T_N+_ .&\/V-/^CG?@C_X<+0/_DFC_AO#]C3_ *.=^"/_ (<+
M0/\ Y)K^'3)]3^9HR?4_F:/]0<#_ -!V+_\  :/_ ,AZ_P!/0_XB?F?_ $+L
M!]^(_P#EOK_3T_N+_P"&\/V-/^CG?@C_ .'"T#_Y)H_X;P_8T_Z.=^"/_APM
M _\ DFOX=,GU/YFC)]3^9H_U!P/_ $'8O_P&C_\ (>O]/0_XB?F?_0NP'WXC
M_P"6^O\ 3T_N+_X;P_8T_P"CG?@C_P"'"T#_ .2:/^&\/V-/^CG?@C_X<+0/
M_DFOX=,GU/YFC)]3^9H_U!P/_0=B_P#P&C_\AZ_T]#_B)^9_]"[ ??B/_EOK
M_3T_N+_X;P_8T_Z.=^"/_APM _\ DFNZ^'?[4?[.OQ:\1KX1^&7QK^&OCOQ.
MUA>:JN@^%?%NE:SJITW3VMUOKX65G-),;:U:[MEGEV[(S/$&/SBOX.LGU/YF
MOU;_ .",Q)_;5L\DG_BT'Q*[_P#3UX0KAS+@O"8+ 8O%PQF)G/#8>I6C"2I<
MLG"/,D[03LWH[-.QZ64>(689CF>!P-3 X.G#%8FC0G.#K\\8U)Q@Y1YJC5U=
MVNK;.SV/ZY****_.C]9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J.:))HI(98XY8Y8WCDBE17BD212CQR(P97C=25=64JRD@@@
MD5)2-C:<G P<GD8&.3D$'\B#[T ?DG\5_'?[86E?'^?P1H'BCP_X(\%:!\3_
M  ??^ -#3Q1^SIHGA[QW\/?$GB+]GGPGIGAB]T;Q)J\_Q2NO"_A;P9:_M/\
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M/_0'UW_P6G_X_1_;I_Z ^N_^"T__ !^M[ ]!^0HP/0?D* ,'^W3_ - ?7?\
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M\EW^-_\ V67XK?\ JP?$=>35_16'_P!WH?\ 7FE_Z1$_D[%?[SB/^O\ 6_\
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MP]&_[X?_ .)HW#T;_OA__B:_@@_X:%_: _Z+O\:__#L_$'_YHZ/^&A?V@/\
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M .)K^"#_ (:%_: _Z+O\:_\ P[/Q!_\ FCH_X:%_: _Z+O\ &O\ \.S\0?\
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ME.<\3AN:-6511FWR1J<D%34ZD*?+.HW&%.K.BJJJP^! 0P#*0RL RLI!5E8
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M0C.W=G&1G&,C.:/];^'_ /H/_P#+7&^7_4-YO[O,/]0^*O\ H6+_ ,+<N_\
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M?>Q)<030-);7,J+-%+$S"2-U7=H **** "BBB@ HHHH **** "BBB@ HHHH
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M)=74TC]Y110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.<Y/KSS]>:"JGJH/?D \GJ?QI:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>collabprofitshare.jpg
<TEXT>
begin 644 collabprofitshare.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KY(_;+_:9N/V6/AEX;\<VNF_#R\N/%/Q7^''PMAU+XM?$M_A%\-/#
M#_$#6)M,_P"$G\:>/H_"OC*31-&TH0'.S0;IKV\N+2R$EMYQF7ZWKQ+XV_!'
M1_C;;_#2UUK5KO3+?X;_ !B^'WQ@MX;:QT^_AUJ^^']Y?7EIH6HQ:C')''IN
MHO>E;JX@7[7!Y4;VY5^0 >-_#[]M;X3ZI+X"\(^/O'7PV'Q(\9R^%K)[OX*:
MQX\^,?P(L]7^)%[J'_"J-!7]H"/X;^&/!%GKWQ*TFUM;GPAH?BEO#.J^(M1O
M+;3O#]GJRZGX=NM<7QE^W5\%]"_9)\?_ +9G@^U^(/Q3^$?@?PQ=^*+1_!7P
MZ\;?VYXUL+:#3I%NO!FDZUX?TV^US0S+J<<-WXLL[:?PMIAL=<DOM6BCT#6&
MLZ_BC]C+3?$/Q5UKQ=:?$_Q;H/PU\;?$OX,_&GXE?!K3M#\)'0O%OQ5^ 2^
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MAPPZ9IJ#PU^UI>?">7QG8Z=JMM%)>P2Z%8_"NVT[0[EUE,B:U>3ZA%-)962
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M]_@C\;_^%J'Q3X1\!Z5\4M:T*Y^%(^'A^(MAJ"?#76M.\>Z?'>^&H(]9\)7
MUO2);VSBF>+Y_3_@EA\)%\/WWA$?$;XE+X9O=7_::O;6S23P^;[PSH_Q^A\)
M6'@_PMX/U&?2[A-%T']G31O ?@W1/@Y8W%EJD%IIGAW3[7Q%!J\#7D=UZWX&
M_8M.B?%K0OCOXV^+_B?Q_P#%>'7_ !?KWBO6Y?"_A?POHWB-=<^%.B_"#P]I
M&G^'M%1X?#FC>$?#ND3:O;1VU]J5[J_BCQ!X@U'4M0%A<:9I.D 'E6O?\%2O
M@_;>/;KPCX7\'>/O$^@V'Q%_9C\'_P#"RE\+^+K?P#XL\/\ [47A*Z\6^"/%
M/PJUFP\*:O\ \+,O)+0Z1::7X3\/QR:UXHN=75]%#P6-U(OT5IW[<7[-FKW'
M@JST?QGX@UF_\<V;ZA:Z=HWPN^*^KZCX4L(?'VL_"F[O?BGI^F^"+J\^#UKI
M_P 3_#OB'X?:E-\48?"2:;XN\/>(M'OS;S>'M;:P\#\%?\$W/#_@/6O@W<Z-
M\7?%<GA[X5Z/^RG]O\/WOACPQ+-XN\8?LE^"KWX<>#/%4VMQ^5>Z'!XD\&7T
MMAXH\.64-WIW]I6]IJ^BSZ9+_:$&HR^-O^"<6B>+XO"UG%\7O$6B6^A?$;XO
M>/VUNP\!?#K_ (63X>N_BW^T'XQ_:$U&Y^$GQ<CTFU^(WPD\166K^+F\)3ZS
MHVOZOH^M>&-&TN74/"2>(!<ZQ. ?7?QA_:-^$?P)?1X/B/X@U6QOM<TSQ'K]
MCI7ASP7XX\?:U%X6\&+IDGC/QIJFB^ ?#GB;5-$\"^#H]:T<^*O&NLVEAX8T
M&35M*M=0U2*\U33[:YXNU_;1_9JO/&NI> X?B5"NJZ-XCUCP?JNLW/AKQC9^
M +#Q7HOPJL_CE=>')_BA=>'XOAO_ &U/\'+Q?B;IFGIXI:XU7P7;7^NZ<MS:
M:?=-'YQ^UM^PA\-?VK_$WP_\=>(I/#UGXN\ ^'/&_@6RO?%_PJ^&_P 9-$?P
M5\1M0\*ZMXDAL?"GQ0T76=%T?QA9:KX,T*^\)^+[:"8Z4W]I6&LZ'XGT?4I-
M,3,U;_@GS\,-<\.:KX+U'Q%KC>"-:^.NN_&'4/#%CINBZ19G1_$'[*FH_LF7
MGPXLO[(M[(:3X?A\$:G+J]A?Z7;V=]INKQVUOI\%KI5O!:Q $GAW_@HI\"M?
M\7>-]+0^+;;PKX>\&? #Q#X0U:3X<_%I?'7Q.\0?'_5OCI!X;\+>!O@Y<_#N
MU^(WB5I/#OP6E\9Z)K'AK1]=LO$/A?5]1UL+IND>%=7U"E^,O_!1'X&?#CX?
MIXN\&7M_\4=9O="\!^)M/\/Z+X>\>VECI^B>/_BO#\(='G^(/BB'P1JFE_";
M4+OQ=:>*M"TO0_B2OAK6=5\3^"_$_AA+&WU+1-7&G^4>-/\ @F+HWQ1M#J7Q
M<^,NJ?%SQUI$?P5C\%:U\1OA-\)_$G@[24^!6G?'WPWX9_X23X7R:-#X5\;C
MQ)X3_:,\?6/C:747TZYN]=FL/$OA*Y\&W&GZ78:=JWO_  31\)VWAH^!_!'Q
M6\1?#SPAXI\&?#?PI\6O#GA#X<?"K0-%\>7/PF^)7B'XK>$-:T72- \+:%H/
MPWFN?$OC#Q/IOBVQ\):4MIXE\,7EA:,VG^([&X\5:D ?ITK;@3C&&=?7[CLN
M?QVY]LXYZTZFJH48']YFY]68L?R)P/:G4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!^)OQ2^*'Q(^"_[8_P =+[P]XN\5
MW&E?M4>*_A[^Q[X!T6]U?Q!XA\-?#3]HZS^!_P */'_PE\9:)H$US?Z7X*TK
M7/ ?CSX_^)/'M[I6GV%CKEY\(?"G]M-/J5U93/\ ,OP4_;H^)GP+^%G[(7PO
M\*>+$^(MCX=TG]G+POXXL?BC>:1JOCWQ9X5^-?[3OB3X(6_BV;XC^//C3:?$
M_P"(FN:/X2M;36&D\ _"[QK'X?\ $>FW9^(_BJ[M[RZT;P__ $@FPLC*9C:6
MIF-REV93;PF0W4=N+2.X,ACWF=+4"W28MYJ0 0JXB 2J \-^'UEM)QH>CB:P
MMKBSLIAI=@);.TN[B"[NK6UD%ONMK>YNK:WN;B"$QQ37$$,\J-+$CJ ?C!I'
M[;?[1,K>#9/'OQ:_9S^$&G>+/#OQZ^)/AWQ'XS^'7B5_#'C)/A#\<Q\'O#/P
M.T.>'XC6NK:EXUUW11#XP\;:EX8LM;\66VI^)/#FD_#[P!KUCIFJS:QZ%^S+
M\;_C?H7Q>\)>"?%'BCPOXM^&7QH_:9_X*9>$=%TB[T[Q#<>._!LGP0_:2^+F
ML>'+Y_'.I>*+ZVU?36TBUO/!X\$P>%--TSPQHEGX6AT+58DT:_LM3_6.70]&
MGCL89M)TV6+2[\:IIL<EA:.FGZFOVC;J%BC0E;.^7[7=8O+817*_:9\2CSI-
MTL>EZ;%)#+'I]C');SWMS;R):6Z/!<:E))+J,\+K$&BFOI)9)+R5"LET\CO<
M-(SL2 ?CM^U]XX\+^'/VC/ /B/P1\59KKX@Z!^T1^SEX6^(/@ZQ_:1^)FD?&
M;PSH&O>-/A19MX%^"O[)45OIGPS^*G@+XG^&?$$\WQ=\2:W=7=U8>%]:\<^*
M= NM=\5_#WP]I/ACO_V:?CM\-/#O[4O[<GA_Q3^UWX?^)-OH%C\*_'<\OC+X
MS?#^[L/!&E:)X'\=WWQ$MO#?A'0]3T_0/AYX(\!6&D6?_"1VNGZ1;O:/I][X
MH\=ZOJOB+4-7UJX_4:;1='N-5M-<GTO3IM:L+>>TL=7EL;634[.TNBIN;6TU
M!XFO+:VN"JF>"":.&8@&5'-<5-\'?A3,NL!OAQX'B?Q!IVN:1K-Q:>%=#L+W
M4=-\2VT]GK]I<ZC86%MJ#1:Q;7-Q#J.+I7NUE?SF<L30!\D?MM?$W]FW0_A[
M\+O$GQE^+WB"U\)^*_$?_%M?AE\._C%IOPR/[2OBG5_"MY>>&_#4/B:V\5>!
MI]6T'2M*GN/'0NYOB+X2^'FAQV5GXX^(.K_\([H-M+#^:GBGQ3KNB?#3Q-8_
M'3]J+Q!<^// '["OA/Q_^R'XQ\"_'[Q#=Z?X[^/U[XE_:&_X2$^ ?$/AS6M&
M@_:H^)7P_P!5T_\ 9]^#TECXLLO&.I^-M/DLM1U?PF)OC1XHLM2_?[6? 7@C
MQ#IEAHNO>#O"VM:/I4<<.F:3JWAW1M3TW3H888K>&*QL;^RN+6SCBMX(8(TM
MXHU2&&*)0$C11;M/"7A>PLM&TVQ\.:%9Z?X<G^U>'[&TT?3;:ST.YV7,?VG1
MK6"UC@TJX\N\NX_.L([>79<W";]LT@8 _)SP]\>+#PE^W%K]E\1/VB)-7\;Z
M[^QF^L:W^S]I'Q,\&ZU'\//B;I'C/1KZZ^'GPH^#ND7%G=:OX^$,VM/#>Z[I
M?B'XA>-VFTW3+S4&\.Z9HFC:?XK_ ,$QOB%X\F^,'@KP[XO\?:%X]E\>_LN:
MOXZU36_AY^T1XW^/]_XN\4:5XP^'<$GCK]K#PCXPUB^T?]FOXXW&@:WI4&A>
M"OA8=4^'VNZUKWQE\,KXFN=+^&G@#3;+]N6^&_P^;7_^$K;P-X./B?[:NI?\
M)$?"^@G7?[12,0I?_P!L'3_[2%ZL0$2W7VK[0L8"+(% %=#I^AZ-I,^I76EZ
M5ING7.LWAU#5[BPL+2SGU2^9%0WNHRVT,4E_=E%5#=7;33E0%\S;Q0!^$?QP
M_P""F?QI\ _$KX[Z3X!NOAOXI\.^&O!'[<%IX4L?$&A>&M!U/P3\0OV4/A+\
M3?'6BW'B7PWI/QI\5?%K4O#^L^)/AQ?Z%J^J^.?AW\*M%\8:'=Z=XL^' 70+
M[0=2\4^Z:]^UY\>?!WQ:OO@)X\^)7P*\&-:_&SPEH6K?M":YX#U'1_!'ASPK
MXL^ &K?&W2/ 5UX6UGXI6NGP^+/$7B/0]1\)^%?%>M>-=.M-2\):;JZ?V%+X
M[CTN;4/UCD\.Z!+<:C=RZ)I$EUJXC&JW$FF6+SZD(K"?2XAJ$SV[2WHCTVZN
M=/C%R\H2QGFLUQ;2R1-+=:)HU\EU'>:3IMVE[+8S7B7-A:7"74VES17&FRW*
MS0NL\FGSP0364DP=[26&*2W,;QHR@'Y6_"WXB_#ZT_X)3?L]_$/]J'X]>*OA
MEX,N?A!\$]8^(WQ'LO'VM^%/%7B^[O;_ $.5/!,'BZ[FN/B%+<_%?6FM/!+:
M7X>U.T^)GB*TUU_#>AZS8Z]J0NT^=? WB#POJ%Q\(=)^,WQQU?PI^QM\0?&O
M[5/B/P]HS?M1WU_9_#'7_#6D_ 1/@1\ ?BQ^TAX)^)=U>6^NP>&'_:#^.&G^
M 9/BOJND^$M=NM$\%Z-K7B*Q^%_A6YD_=75O#7A[7=*?0];T+1M7T60HTFDZ
MII6GZCICM&YDC+Z?>6T]FQ20ET+0$JY+J0QS69IW@#P-I&AS^&=*\&^%=-\.
M75VE_<Z!I_AS1;+1;B^CDM9H[R?2;6QBT^:[CFL;*5+F2V>=)+2V=9 UO"4
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M?]A%;_TY( I#T."1P>0,D<=0.Y'I2T5S@?C7J?CG_A"?^"E_B"YAO/%7QO\
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MI%I#8:7I5G;:?IUC;J4@M+*SA2WMK>%225CAAC2- 23A1DDY) /Q0_X*3_\
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M<0Q3PO\ M6_M/;XIHTEB?;^QW\0&7=&X9&VLJL,@X8 CD U^U$?ASP]Y:?\
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M9GU/QAX<T"X%[:V_PEL)95%GJ]RT(6[AV7"Q.=X78Q_Q"7-O^AIEW_@.*_\
ME7]6]+A^GV]/[R_]]#_&C>G]Y?\ OH?XU\IK_P $0=*8$_\ #U#_ (+,##NO
M_)Z>@GA791U^#.>@[\^I)YIW_#C_ $K_ *2H_P#!9C_Q-/0?_G-4?\0ES;_H
M:9;_ . XK_Y5_5GY7#ZJWI_>7_OH?XT;T_O+_P!]#_&OE7_AQ_I7_25'_@LQ
M_P")IZ#_ /.:H_X<?Z5_TE1_X+,?^)IZ#_\ .:H_XA+FW_0TRW_P'%?_ "K^
MK/RN'U5O3^\O_?0_QKUOX*NG_";)\R_\@C4_XA_?L_>OSZ_X<?Z5_P!)4?\
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M98?Q#_GUB]ZU 0>A!^A!_E7XKK_P1DO%4*O_  5J_P""U 50%4#]MC0,  8
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>costofsales.jpg
<TEXT>
begin 644 costofsales.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%=,T]=7>UEU5;*U74Y+))([.34%@C%])9QS%I4M)+L3/;)(Q=8&C5CD&M"@
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MJ*DW_0#'^V'^S?%&D47C^.**-%CCCC\+^+8T2-%"HB*F@*J*B@*JJ %  4
M4[_AL?\ 9SQC_A873'_,M>+\\>_]A9/3G/7H<@FOY)M+_:3^+-[^R9=?%CP]
MK'PQ\:^.?"QT4^-]5UCPGXZ^&TGABQNT\)7LMMK?PCULRZN_CC5K3Q"$T.&T
M\0:7X&N=&O\ 2O'%MJ%_9)+X>O>J_:3_ &CO&GPD^)/B/PYH+6=MX=\*> ?#
M_C""\3X;^(/B/HNH:YK/C37O#ESHGQK\<Z)KVDV/[-7@:UTJRT;6M-^(GB*Q
MNK35-*E\8>*%N9-.\"WV@:EY3X!X-CAUBI8SB!4_8X:L_P!_EWP8J.(E!*I]
M35&<H+"UE4Y*LH\\52IRJ5FJ9[\?%;Q$EC/J4<NX3=;ZQC,-;ZMG-^?!2P,:
MDG2_M%XB$:KQ^'=%5*,*GLY2KUH4L-%UG_5=_P -B_LY9S_PL+GT_P"$;\8;
M>N<[?["VYSSG&<]Z/^&Q?V<>/^+A=./^1;\8<CT;_B1_/_P+-?RK:1^T=XH/
MQ8\-^&-:U;PUN\5_';Q7\&K[X-VG@W7(O''PX\/6MGX[O/AW\5=9\?-J\FGZ
MYI7CJQ\'Z-KT<A\/6'A+7-!\=Z8G@35+N_\ #FL2WWI7QNU+XMZ;X@^'>G_#
M3XH:%X7U#Q]XGTSP=H_A#6_A'H_C>"YDL+?5?%OCSQCJ7B2[\7:)JFFZ-X9^
M'^CZI>RZ=8Z=*\NL0Z'I\%T)_$&^VZ(>''"E6A6KTL3G]54:T:,Z<,3E?M7.
MHJ3II1GA81YINM3BJ,I1Q"J2]E.C&JG!<E3QCX\H8G#86O@>%*$L5AYXFG5J
M8//705*DZBJRE.GCJDG"FJ%:<L1"%3!RHP=>GB:E!JI+^F'_ (;'_9S_ .BA
M#_PF?%W_ ,H:/^&Q_P!G/_HH0_\ "9\7?_*&OPO9@68IO5"S%%=@SJA)VJ[+
MA6<+@,R@*6!( ! #<GU/YFO0_P"(2\-_]!F=?^%."_\ G<>/_P 1^XQ_Z%O#
M?_A)FGE_U./+_A];_NE_PV/^SG_T4(?^$SXN_P#E#79>!/VB/A!\2]?7PQX*
M\6C6=;:RNM16R_L7Q!8YL[(PK<S?:-1TNTMAY9N(1L,WF/O^1&VMC^?O)]3^
M9KZ__8?GG@^.D4D%I+?2#P7XG7R(IK:%]K3Z+E]]W+#%A> 1OW'((4@''DY[
MX:9#EF39EF&'Q6;2K8/!UL12C5Q&#E2E.E!R2G&.!IR<7;51G%OI),]_A;QJ
MXISOB+)<HQ>!R&GALQS'"X2O/#X7,(UXTZ]6%.4J4JN:5:<9I-N+G3FD]XO6
M_P"V%%8/]JZI_P!"Y??^!^B__+"C^U=4_P"A<OO_  /T7_Y85^&G]0&]17+W
M/B*XL]GVO1I;7S-PC^T:OH$&\IC<$\W5$W;=R[MN<9&<9&:O_"81?\^,?_@^
M\-?_ "WJU3G)7C";3V:BVGK;=+OIZF<JU*+<95(1DMU*44U>S5TWV:?IJ=E2
M,2%8C&0"1G@9QQD]AGK[5QW_  F$7_/C'_X/O#7_ ,MZ/^$OB/6QC_\ !]X:
M_P#EO3]E5_Y]U/\ P"7^7FOO)^L4/^?U+_P./^?G^?9GY:M^T'\=/#/[>?B7
MPM\3/B=K/A#X+Z[&_@_X8?V-X"^'_CS]F^\U*YB^(\'ABT\7^/=*U^Q^*OPZ
M^-*ZSX.UP>);/Q?-IW@K4+CPAJW@[3H;,7F@:^/*/B/^TG^U9\%;WX^?#F7X
MD?$/7?&5G\//@K>?!]OBU\-/@CIGCGXS>.M:_:'TKX6?$;4/V3K3X56&K_#E
MO#_C?P_XE\.>&OA%X:_:%N+C5?!?Q6\6^ =8^)H3X7R^*-7/Z,O^SW^S3+\8
M=;^/D_P)^'=S\6O$?AJX\*:WXPN4\%W%UJ6E7L.J6>IR7=A-J+Z3-K.L:3K.
MH>']:\1R6+>(-8\,S?\ "-:EJ5SH8%A6/X?_ &7?V4O#&A>+O#.C_ #P!#H?
MCC3=&T7Q%8WE[H&K"?0O#6H_VSX4\/Z;<:QX@O[OP[X?\'ZUC6_!NA>&[C2-
M(\(ZVD6L>&[+2]2ABND/95?^?=3_ , E_EYK[P^L4/\ G]2_\#C_ )^?Y]F?
MFAX__P""COBKX4? OX\?#[QQ\6]=^"_Q^A\4?%?PO\-=4_:@T7X0:+\9/@]X
M.\&? SP[X\A\<_$>R\":?#^SS\1/%_B/7]4@/P*TWP++X@T'Q1:^.? UMXQ3
M6=0\$_%G3]*^X_'W[4?BN3]A+X._&OX6Z^OBWQ=\:&_9=\!:7X\\&:'H7CB*
MPU_X]>/?AW\,=<\6Z)HUQ=:3X2U76-'U;Q5JJZ#9:Y<V/@ZW\7_V1%XM^R>%
MH-7$?T)X,^$_P1^'W@'Q/\,?"/POT#2?!7CB'5X?&^E?\)!I-_<^-#KVCQ^'
M=6N/%^N:IXDOO$/B>_O?#\%MH<FHZ[JU_?II%G9:;#<Q6=E:PPP:A\'?@+J_
M]IKJWPB\):K!K'PH\._ [4[+4]3\/:AIUY\*/"6I:GK'AKP7-IEYKL^G'3=%
MU36-0O\ 3YUM5U&WNIDF2]WVUH8#V57_ )]U/_ )?Y>:^\/K%#_G]2_\#C_G
MY_GV9SG['_C[QIXDTOXL>"/B9KWQ)U/XA?"KXDVWAO7-(^+6C_"2W\<>&M.U
M_P"'W@GQMX>LK_Q5\"VM_AA\0=.U+3_$#ZWHWB?1= \)ZM:66H#PIXJT Z_X
M<N];UK[$KP3X6^$/AC\%?#4GA+X7^ ]'\(Z)<ZG=ZWJ,5CK^B7-_K>NW\=O#
M>:]XBUO4]?OM=\2:Y<VME864NLZ]J6I:FVGZ?IVG_:OL6GV<$'I/_"81?\^,
M?_@^\-?_ "WH]E5_Y]U/_ )?Y>:^\/K%#_G]2_\  X_Y^?Y]F=E17&_\)A%_
MSXQ_^#[PU_\ +>C_ (3"(=;&/_P?^&O_ );T>RJ_\^ZG_@$O\O-?>'UBA_S^
MI?\ @<?\_/\ /LSLJ*P%U?4G577P]>LK*&5EU#165E89#*PU$@@@@@@D$<@X
MK0L;NZN?-^TZ;/I^S9L\ZXLI_-W;MVW['<7&W9@9\S9G<-N[#8S-B_1110 4
M444 %%%% !4<T23120RQQRQRQO')%*BO%(DBE'CD1@RO&ZDJZLI5E)!!!(J2
MD;&TY.!@Y/(P,<G((/Y$'WH _)/XK^._VPM*^/\ /X(T#Q1X?\$>"M ^)_@^
M_P# &AIXH_9TT3P]X[^'OB3Q%^SSX3TSPQ>Z-XDU>?XI77A?PMX,M?VG_$OQ
M)@BT?PKXJO/&FL_"S2?A%>^*;#3H],B_62SM+:QM+>RLK:WL[.UA2WM;2UAB
MMK:V@B4)%!#;PJD,,<:!46*)%C0#:BA0!7XW:MJ]AX"_:B^,OB[2=)\.:U\*
M]1_:-^&.E?$KXJ^)_P!E'1_'6G_#;XJZ]H/PV\*+X53XP:I^T[X>^(<]L#-X
M#T\^*?#GP2U_P#\)=>\006=Q<"QT?Q';Z#^S(.1GZ]L8Y/!Y/(Z'WS0!^(/_
M  4G_P"4DG_!"G_LZW]J#_UCGX@U^W:?ZJ/_ '8__9:_$3_@I/\ \I)/^"%/
M_9UO[4'_ *QS\0:_;M/]5'_NQ_\ LM..Z]5^8'\XWQ'_ .2B>/\ _L>?&'_J
M2:G7&5V?Q'_Y*)X__P"QY\8?^I)J=<97]G8+_<\)_P!@U#_TU _S<S+_ )&&
M._["\1_Z=F%8GB3PWH?B_1+_ ,.>)+ :GHNIK;"\M!=ZAI\I>RO;;4K&YM=2
MTF[T_5M,O]/U&RL]0T[4M+O[+4=/O[2VO+*Z@N(8Y%VZ*Z)1C.,H3C&<)Q<9
M0G%2C*,E:491DFI1DFTXM---IJQR0G.G.%2G.5.I3E&<)PDX3A.#4H3A.+4H
MSC)*491:E&23331\RR_LE_"N7X5K\'TU;XKV'A>[:PD\4:EHWQ7\7:7XP\?R
M:7INE:1IJ^//%OVJZUCQ!9Z7I^A:-:Z/I/GVFDZ+#IEG!I-E9V\;PR=1JO[/
M/@#78KN/6]5^*&J/KN@6WA?QW=S_ !8\;6U[\6?#]G%K-K::5\7)]*U+31X]
MAM].\0:OHB7%]%;:A)X=O'\.7-[<:$%TX>Y45QK+L DHK!X;E4(4U%T8-<E-
M24(V::LE4J+S56JG=5:G-Z$LXS64G-YAC.>56I7<U7J*3JU72=2=U)/FE*C0
M>FSH4&K.C2Y/-+/X2>#K+Q9;>,5?Q7>7NF7VJZKX<T'5O''BO5_ O@S6=<TV
MYT;6-:\#^!=1U6X\->%-4O\ 2+[4-+6?2K&*#2=/U/5;/PY;:);ZMJD=[:TC
MX8^%='E^&]TK>(M7U'X4>'O$?AGP?K/B?Q3K?B;7%T_Q9I^C:5X@NO$&L:S=
MW5_XHUS4+#0-.@DU[6YKK5% O"MP#J%WYGH-%;1PV'A=1H48IS51J-."O4C.
ME.,W9:RC.A1E&6\71I-->SA;GEC<9.SGBL1-JFZ*<JU235*5.O2E33<G:$Z>
M)Q$)QVFJ];F3]K/F****W.4*^R/V%/\ DO4/_8D^*?\ T=HM?&]?9'["G_)>
MH?\ L2?%/_H[1:^=XN_Y)G//^Q;B?_3;/L?#[_DM^%O^QWE__J33/VHHHHK^
M23^_S\T/^"C*JUE\(=RJV+SQOC<H;'^B^&>F0<=*_+S8G_/./_OVG_Q-?J)_
MP48_X\OA%_U^>-__ $E\,U^7M?U%X<M_ZFY1J]\PZ_\ 4SQI_#GC&D_$7B"Z
M7PY3T_ZDF7#=B?\ /./_ +]I_P#$TA6, GRX^ 3Q&A/'MMYI]'Z?Y]Z^WN^[
M^]GYC9=E]R/GK0/C[8>)OC7XT^$.C^ ]<O;'P!:7$7BKQS!JOA!X=%U^RFN5
MN[;4_ XUC_A/+7PO)$EG!I/C)=$GMM;U+4+1=.TR70KNR\0W.3_PTWX9C^&/
MQ4^*=[X"\<Z+I/PM^(/_  KZ[T3Q)I^D>&_$.HS7'_"OQI?B?5;;5;Z&T^'O
MA6Z3XBZ1JNMZAX[NM)G\"^&+/5?$/C6TT86-WIMO3U?]G/5==_:'TGXW:IXW
MTJ[M?"MC!/X0L_\ A7VA67CS2M2AG\7A/"-_\2M+N+'4]6^$XM_%3/=^'+C3
MO[=UR"TL?#^LZ[<:;I=G>S<[8_LZ_%;5=&^*^@?$'XH?#/5]+^)WQ+TWXM36
M?A;X2^*],T]O$FG-\/H)_"/C'1_$WQ:\1V7CCX2>(])\ Q:5XN\&3R:1J&NV
M^L7L4VOI9Q)93> JN>J-=*%1S]OF$:$I?4>5TG1;P,VE57LX1K<L(QG*K5J)
MRG7G"+Y(_7*APLYX5NK1C3^JY1+%1B\S<E76)@LTII^P;J5:F%<YSJ4XT*-*
M7+3PM.I-.<M.Z_:LT>T@T:RD\$Z=%XEU?QSXM\!*]]\6?AMI?PBCU3P5X-T?
MQWK=Q:_M!7TD?@#58Y-%UJ.QTO2[*U/B"Z\3:/XNT&\TG33X-\0W]G[+:_$J
M/5_A5H?Q1\-^ _&/B!O$^B^'M5T+P+;:=IMAXON)O$UY96%E9Z@=2O8-$T:R
ML9+W^T-;\2WVI?V!IOAFUNO%"7-YIHM1=_.5O^Q[]EN)-9&J_"#4+N[\0Z[K
M]Y\*]<^!<.J_LN6EQXC\.>$_#>IZCX<^"$GCN--$\82Q>%[G4[KQD/$-S-JU
M_P",/&:7.C6@UR>[7TBS^$'Q=\&_"FW^&'PM^-6C:"VB_#W1O"GA3Q9XO^&L
MWB[6]"\31^,-3U?Q%XG5!XULK:;1O^$/U"W\%_#OP?,MS;_#T:1I.J3ZMXMM
M[%-(<PM3/5.N\73JRI_5ZBHJB\O=55HPI>SDDZM.$IU7[;2IRT(S]FI1IT^9
MN<=1X7E#"+ 5Z$:WUK#O%>WCF\:#H3G6^L1DU3KU(T*,?JR3H*6*E3]M*-6M
M6Y8Q]+^&_P 05\>CQII^H>%KKP?XJ^'7C%O WC/P[=:EI/B.TLM:;PSX:\96
M-QHOB?1DCT[7])U/PUXNT/48)Q::9J=A-<7&EZWHVEW]JT4OI.Q/^><?_?M/
M_B:\H^"_@+Q!\-O!I\+^(;_P3J=S'K.I:I%J'@K0/&&B#4I-7:*]U;6?%EWX
MZ\=?$/Q+XI\;ZYK3W^J>(?%NH^(#<:O)<P)+:QFU5F]9KV,-+$>PI_6&_;.-
MZB;A=-MM1DZ:C3G*,;1E.$*4:DDYQHT5)4H?.XZ.$6+K+!J/U922I-*I:24(
MJ4HJM*=6$9S4I1IU*E:=*+5.5>O*#K5&[$_YYQ_]^T_^)J.9(_)F_=Q_ZF7_
M )9I_P \V_V:FJ.;_4S?]<9?_1;5T1;NM7NNK[G))*ST6SZ+L?TD^!/^1)\'
M_P#8K>'O_3/95U=<IX$_Y$GP?_V*WA[_ -,]E75U_%N+_P!ZQ'_7ZI_Z6S_2
MC _[E@_^P7#_ /IF 4445SG4%%%% !1110 50U26ZATW4)K(@7D5C=R6I:RF
MU)1<QV\KP%M/M[JQGO@)0F;.&\M);H?N([FW>19DOU0U6U:^TS4+)#:*]W8W
MEJC7]D-2L5:XMI85-YIYGM1?6H+@W-F;FW%U!YEN9XO,\Q0#\9;CPKJ'Q!_:
M \-_$K5_A+XUM[C5O'7PL\1>)+/6?V,?VF]$\*ZWXO\ "$7AS2K3Q]XLT>T_
M;4M/@]<^)=%N-*M[_P )^//&7PC\6:W\/].T?PD;FZ\277@C3[^;]J ,#'ID
M?AGCN?S[]>]?B?H_P>\-6_Q];1_AA^SE\$M>T;X4?$OP#X4\6^,O!W_!/#X6
MZ3IGA_QIIFC>!_$OBB71/B)XG_:;\)^(;9M-?6H=<@\1>&? /B>U\(27D6DZ
M;/XOU;PU>?:OVP'TQR?;N>>IZ]??J0.E 'X@_P#!2?\ Y22?\$*?^SK?VH/_
M %CGX@U^W<?,<?\ NI^@!K\/O^"ETDD7_!1[_@A9)% ]S(O[5O[3^V!)(HF?
M/['?Q !P\[QQ#:I+D,Z[@I5<L5!_:5-4U0(G_%.7W"+_ ,Q#13V'<:C@_4<&
MC8#\;O&W[.FM:CXT\8:@GBC184O_ !7XDODB?3]39XTO-;O[I$9E;:S(LH1B
MOREE)'!%<Q_PS/KG_0VZ'_X+=5_^*K[5UTLVN:TS(8V;5]29HRRL8V-[.60L
MA9&*$E2R,R$C*L5()RJ_*JGTCO%C#U*F'I9]@HTJ$Y4:<7D.22:ITI<D$Y2P
M#DVHQM>3;=[MMGY;5\&O#^M5J5JF4XF52K.=2;_M7,U><Y.4FDL4DDVW9))+
M9)(^/_\ AF?7/^AMT/\ \%NJ_P#Q5!_9GUP D^+=" '))T[5  !U));  [D]
M*^P*\6_:*U'5=)^"?Q!OM$^)>C_!W5H].T>*Q^)?B&ZO],T+PI)=^*_#]I-/
MJ^OZ9INL7_A#3]9LY[GPQ/X]MM+OW^'G]NKX[^S2#PYBG1^D?XNUJU*BN(,"
MG5JTZ2D^'\D:3J3C!-QAETIM)MMJ$92=[1C*5DX_X@MX>_\ 0HQ/_AVS3_YK
M/*?^&9==W;/^$KT3?EE*?V;JN\,H)92N[<&4 E@1D $D 4J?LQ^()!NC\4Z,
MZCDLFEZNZ@8SDE20!CG)/3GI7P-^S[\:/A5JG[+'PRM?BS\6/CO9GPIXK3P9
MI/PK\*_M4V_BS6?VBO'VN_";P?XOT#P;\+/V@?#VK^!?B!XB\,^!-.UBX\4>
M(-"\2>.- T[X,^,KW6KCXW:Y!X-\)>&[&'3\?W/CGP#H'ASXA?&CXS?"_P"+
M/BCX(_LI_![Q=XN\&P_M=?&?X>^,O'OB;3?&'Q2U#Q!-\.= ^#>L>$/!'Q4\
M4^/8#X8\#>'/B/XGTCQEI7Q-\=^"8_#<_@KP];^)9[F/VY>.WC#"M.A+B7!J
M<*SHQC_JUD2E6?M%3A*BY86-*:<G#VLO:JC3]O3C"M6G[6-$_P"(+>'O_0HQ
M7?\ Y&V:;=_][/N3_AF?7,9_X2W0\;BN?[-U7&X#<5SNQN"D,1U .<8H_P"&
M9]<PQ_X2W0\* 6/]FZKA03M!;YN 6^4$X!/ YKY:^%?Q3\=7_P"T%H7B;XB:
MSJUMXB\8?M<?M ? FX^'6G_M&:^GC#PCH'AA_BC_ ,('8>)OV4O[(O?AI9?
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M7\QTVZ\7-<XO-(?:+NW\/K%PNH<9,$G7T^M?GK_PIOXF_P#0H:C_ .!&E_\
MRPK]_P"".,.$<JX8RW 9IQ5PUEN.H/&^VP689[E6"Q='VN88FK2]KAL3BZ5:
MG[2E5IU:?/"//3J0J1O"2;_C;Q8X<XBS#C[/,7@,ASK&X6K'*U2Q.$RK'8G#
MU/9Y1E]*?LZU&A.E/DJ1E3GRR?+.,H2M*+2\RHKTW_A3?Q-_Z%#4?_ C2_\
MY84?\*;^)O\ T*&H_P#@1I?_ ,L*^K_XB!P%_P!%QP=_XD^1^7_4=YH_.O\
M5#BW_HEN(_\ PQYGY?\ 4+YH\RHKTW_A3?Q-_P"A0U'_ ,"-+_\ EA1_PIOX
MF_\ 0H:C_P"!&E__ "PH_P"(@<!?]%QP=_XD^1^7_4=YH/\ 5#BW_HEN(_\
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M"\.Z1X=TU?#VC>&?#O@]O B:9X?N=)O]9\+:,]Z+>:_U>_?7M2N9M0N;L?I
M/ZG]37XU6WQK\):W^TSXIGO?BQX/^*OA[Q1\6O!-S\*=9\*?\%)]&\!:=HGA
MNYTGP?HZ^$(?V>_!'C?1M"U^/2_$EAJNI16M[;>)-;^)$NNSV6M1D/:V3_LH
M"",CD9/.<]SW_IVZ=J /Q!_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^
MXO\ Z"*_$/\ X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@#X
M!\0?\A_7?^PSJG_I=<5D5K^(/^0_KO\ V&=4_P#2ZXK(K^-\7_O>*_["*W_I
MR0!2@XST(*LK @,KHZE)(W1@4DCD1FCEC=6CEC9HY%9&92E%<X'FUU\&?@]?
M^&_#G@W4?A)\+-6\(^#K1]/\(^%M;^''@K7O#OA:QE$0FM/#FC:WH>HZ?HD%
MQY$!NDTVWMOM;0PM=&9H8RN_!X$\"VL?A:*V\#>![:+P*''@:*W\&>%X(_ P
MD^^/!*1:0B>#@_5QX9&E!B Q!8 CJJ*T=6K+XJE1ZREK.3]Z=^>6KWGS2YGO
M*[O>['=]W_7_  R^XQT\.^'8]=N/%,?AWP]'XHN],CT6[\41Z#HZ>)[O187$
MD.BW?B1+$:Y=:/#(JO#I,^H2:?$ZHT=LI1"N</ O@8?\(OCP-X(_XH=%C\#Y
M\&^&"?!$:JJI'X*)TDGP>B*JA$\-'2T0*NP#:N.IHJ>>>CYY72Y4^9Z12<4E
MKLHMQMM9M;-B"BBBI *];^"O_([)_P!@C4__ $.SKR2O6_@K_P CLG_8(U/_
M -#LZ^AX3_Y*;(O^QGA/_3L1K:7I^J/KVBBBOZO$?._Q^_U/A7_KMK'_ *+T
MZOF^OI#X_?ZGPK_UVUC_ -%Z=7S?7\R>(;?^N&;:],!_ZK<'_DON *0Y ) R
M0#@9QD]AGMGUI:",@@]#P:^*N^[_ *_X9?<!^?-K^T;\7M/_ &W-8^"GCH^%
M? ?P[OM&:V^%GACQ%\.O'$5W\6D>;Q1-X?\ %W@?X^V&K7WP\'C3Q4^@WEH?
MA5XHT70S8Z;H.O:9IQU'Q9I$VIZI''^TA\>-.^#G[1/BSQ?H?PTT;QS\+/VH
M--^$,USX4TOQI\0/ 7PC^%NM6GP,U'7?B3XN@M6T;Q;\4K;X->'?B;XB\2^-
M-4T>P\%6'B/^POMT>E^%O!UEJ%Y![]_PRK\&Q\9K[XZKI/B-/&=]"+I=.3QQ
MXP_X0;3O&9N_$%S)\4=(\ R:U+X1TSXF,GB;5HX?%%MI"FQN[F?Q#I]G:^*[
MS4->O,GP9^R1\/?!$/Q'AL/B%^TIK"_%75!XC\7S>*?VC_B5J]\?&2-X4\CQ
M_P"'M5L[[1]6\+>/+6#P/X6L;?Q'H=_:O_9>E#2KBUN=/OM2MKSWI8O*6Z+6
M'E^[P^ C5C]7IKGK4*T7BN1JLTHU:*:E.LJM2K4LI-4[H>EM-_\ AONMKMY+
M75GQM9?MQ?$GQ3XWF^ OP_UJR^(7C.Q\9^.1IWQJ^&G[/FN^.D^)OPR\)_"[
MX)>/K#5?AU\&G\?Z)X7O?$D^O?&^Q\,>)/%%Q\2X?A@N@^#=3\2^$?MFI^+_
M  QIEM]KV7[1GA70?V8O#G[1'C;Q!X<UG3KWP?H%[+<^$[36/!^E^,O'>MZE
M#X2TKP5X/T3XE36?B+PWXA\5?$*6'P5I_A7QK,FL^%?$=Q=:5XDN'CT+4M1J
MZW[+WPK&E6-K:W'Q,TWQ-8>*_$/CE?BSI/Q<\?:=\<+[Q;XNT;3/#7BS6M8^
M+<&L?\)5J[^)?#&A>'_#.J:7?S3>'H] \->%=-T?1M)B\*>&6TC?TG]GKX0Z
M-IMGX=M_"$&H>"-/\ >'?AM8?#+Q/>7GC3X56N@>%_$6K^*=,U1/AUXREU[P
MS<>.I]9UN_N-;^(M_9WGC7Q%']EBUO6;TVD,@G%8K**L:"HX:O3]G5IRKVA0
MA/$)2G]8?M*?*J7M8^QE2IPIJC0E&JHTE&4&AV_X.W;IJM+/S=]3@?V0?B_X
MP^,_PM\2Z]\0M9^&^L>-O"WQR^//PSUI_A7<PW/A&TL_AY\3M>\-^&[6SD75
MM8N+PQ:!9V4'_"07=Q;-XO%N?%5MIVFVVJQV%M]35Y=\)_@K\+/@;HWB'P]\
M)O _AWP)HWBGQQXN^(VN:?X=TG3=)MKWQ7XVUBZUS7+PPZ;9644=E'=W<EMH
M>E*AL/#FCI;Z)HL5II=K!:IZC7F8NI1J8FO4PT73H3J2G2@XQAR1D[J/)%RC
M%1>B2;226H/?3^O^#W\PI&^Z_P#N/_Z :6D;[K_[C_\ H!KE;=GJ]G^7_ 7W
M MUZK\S]!M%_Y VD_P#8,L/_ $EBK3K,T7_D#:3_ -@RP_\ 26*M.O[*PO\
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M*<I)V>-35TUHTF'S_/\ R_JWH?H!17Y__P#":?\ !9C_ *1:?LY_^++='_\
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M^++='_\ H9*/^$T_X+,?](M/V<__ !9;H_\ ]#)1_P 0\XP_Z%'_ )D,K_\
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M\,R=LTGX><8--?V1NG_S,,K_ /FT%HT[[-=_+R_JWI?^@;1?^0-I/_8,L/\
MTEBK3K\8K/\ :G_X+/6EI:V@_P""2'[.KBUMH+</_P /1=#7>(8EC#;3^R:Y
M7=MSM+L1G&YL9/VC^R5\6/VTOB<_CL?M=?LB_#G]EI-%7PV? 3> ?VI;']I(
M^-FU ZX/$JZJME\)/A=_PAX\/"ST,V;2'6_[=.LW00:?_9)-[_3%",H4*,)*
MTH4J<9*Z=I1A%-73:=FGJFUV8C[,HHHK4 HHHH **** "BBB@ HHHH ****
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MX888[?3]-B$*2S&&*%;B_OI!+J.J7\B?:-2U2[O-1NWDNKJ:1^\HHH ****
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M7\#^)O#=AJ-]KVB-_P %)_%O[/\ X5TGX+^#/!_B_P"#'Q^\5:[\9H_@W?\
MQ'\?:OJVIS>,? GQ&^&7C'XD'PK)XEL?#'@R7XK7GP;U+QQ;ZY:7>E#2/6M4
M\4_M.^!)?^$C^%NO?M)6_P -O%OQ<^'GP*^$GAO]I;6]1MOBK>ZO^T+\.;KP
M!X[^($_AKXAS0^.]:\'_  *^,J?"CXJV3ZPD^L:9X;TO]I,>!;6;X=W?A9$
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M[02<<C'/145AB<-0QE"KAL52A7P]>#IU:-1<T*D'O&2ZI]4!X_\ \*0\%_\
M/36O_!A%_P#(E=_X9\,Z;X3TTZ5I;7+6IN9[LF[F6>7S9]F\;UCC&P;%VKMR
M.<DYKH:*\W \/9)EE?ZS@,LPF$K\DJ?M:-*,)\DN7FC=='R1;7= %%%%>R ?
MUZTA5202H)'0D#([\>G(!_"EHH 3:O/RKR"#P.0>H/J#WS2;5(P54CTP,?EB
MG44 )@ D@ $]3CDXX&?7 I:** "O#OC%^S[X$^-\V@3^,IO$$3^'(M2BT_\
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DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>financialhighlights.jpg
<TEXT>
begin 644 financialhighlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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MN-%?5+:]T#3M9DTZ>UFTFXFCDL9X'LI70@'$^!?V[/A'XD^*7Q#^%/BIM3\
M:OX4^+-U\,/#NJ^(- \;6GAS79K?]GWX??M#QCQ5XHU7P?I'A;X7^,KOP=XM
M\175K\-O&NN6'BR73/ VL:HMKYAET^T]H^#/[1_PE^/BZF?AKK>LWTNEZ3X<
M\2-:^(_!'CGP%?:EX/\ &0U1O!OCKP_8>//#GAN]\2> O%XT36?^$7\;:%;Z
MAX:UQ]*U&*QU*6:SGC3P.^_86\-^*]'U;3_B+XYU?Q9<^+_V@(?V@_'\MIHE
MCX;L?$^OWG[,]C^S1XI\.VUC8W]W<Z!X>\0>'[>\UZ-K/5;C5M'U&^^R6>H2
MP6D,YUOV/?V(OA]^Q_;>(X_"8\'WM]K6A^#?!L&J^'/@K\(?A-J3^$/ $.JQ
M>'H_$]]\,O"^AWWC;Q3>-K%S>^)/$.N7G]FWNHHEYX?\+>%&NM634P#P:?\
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MMX?T?X=-J.I12:5XVT3P+HVF:+X@T>#2S86V@ZQ!K.K^(@#W+XT?M0R?!O\
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MC^UU^TGXA_9G\'P>.K;P]\)7\)6>FZ_J/B/QA\;/CUHWP)\(VNHZ7#:3^'O
M'A^_N/"?CG6/$?Q'^(.=6B\)Z3'H-CHBG0[X:EKL5]/I>E:CEV7[6VL:A\9O
MV=/A=_PHKXA^&]%^/'PY\0^-[SQIX[N=%\,-X-UW2?A_H?Q MOAP/"D=QJNO
M>(/%=E8:I>6/C>[2/2/#/A'4[.WTRVUKQ'JMW=Z?I'H7QT^"GCCXJ-9GP=\;
M/$'PSM9="UWPKXF\/-X(\ ?$?P?XCT;Q \!N-3D\->.](O+>Q\8Z1;I=V6@Z
MXMS=Z*+'5M1L_$WA+Q5;-9Q67SUJW[$GQ$TSQE^S1J'PK_:.N? OP_\ V5_
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MGBSPYX$U74M&\=ZS>^+O"%Y:_$7X=_ V36K+XC>+M6UGP[\';;6T\9ZO#J3
M'Z*45^0GPN_;2^-'QCUG0?@EX*\3^"+3XB^(/C1\4/ Z?%3Q_P#L_?%#X8:C
MH/@;X2_!_P #_$37]0\7?LI?$+QWX8^)/A/QOK?BKQ[HOA7P?I?BGQAX=B\3
M> DO?C)INAMH!T:PUS/L/VWOVE?B)X-^*6N>!M&^#7A7Q)^RG\&O%7Q$^.&B
M>(M*\7>(M&^*_C[P1\5_VDOA7JW@7X:ZQ'XH\,3?#OP9K1_9<\:>(=+^(.KP
M_$:YTY_&OA+39](U,^%?%"ZT ?L717+>!_%NG>/?!GA/QQI$5Y!I7C'PSH'B
MK3(=1MVM-0AT[Q'I%GK-C%?6KDO;7D=K?1)=0-\T,ZR1GE34?C7Q]X(^&^BG
MQ)\0/%WASP5X?6[M;!M:\4:Q8:'I8OKUF2SM#?:C/;VXN;IT=;>'S/,E96"*
MQ!H _&CQ_P#\K$'[.'_:)O\ :2_]:D^$-?N)7\_E_P#%;X8_$'_@X._9YUGP
M)\0O!?C'2;+_ ()1_M(VE[J/AGQ-H^MV5G=M^U!\)IUM;NXTZ\N(K:Z:""6X
M2WG:.9K=?/5#$RN?WH_X27P]_P!!O2O_  /MO_CE &W16)_PDOA[_H-Z5_X'
MVW_QRC_A)?#W_0;TK_P/MO\ XY0!MT5B?\)+X>_Z#>E?^!]M_P#'*_+/_@K3
M^VQXV_91_9YT'4/@IJ>E6WQ#^)WC=/ VF>*WAT[6AX-TVUT+4O$.MZU8Z9=M
M<6=UK<EM8V^F:2VH65[IUE-J$FH7-M/+:VT$OM\-Y!C^*<]RSA_+%2^O9KB8
MX:A+$3=.A3;C*I4K5IQC.4:5&E"I5J<D*E1P@U3IU)N,)>-Q#GN!X9R7,<^S
M+VOU++,.\17C0IJI7J>]&G3I48.4(RJUJLX4H<\Z=-2FG4J0@I37ZS!E/0@_
M0@_RI:_B3_9%_P""KW[8/P\^.G@-_B)\4_&_QQ^'WB?Q/H/ACQ=X"\5?V1K>
MHWNG:YJ46DQW7@N\D@TFXTGQ797.H17.EQ_VI;Z3J\\::7K,9MIHKJR_JED^
M/7Q^\07$MOX/_9QT7PI;-O2'5/CM\=_ O@^6!E)'FW'AKX56?QJU<;2N#93W
M5A=;B4D,!!8?;\<^$O$7 F/PN#S'&9'B*.,PTL1AL;#-<)@:53V4HPQ%%4\V
MJ8"O.M0E.$I1HTZT73JTG&;FYTX?&<%^*F0<;8'$XO 8/.L/5P>(CA\3A)Y9
MB<;5@ZL>>A5]IE<,=1C2K)3C!UJE*2G2J*45%0G/['I-PY&02.H')_(9/Z5\
M8"P_:H\5Q+_PD'[1/P(^%L/F M9_"WX77_C'6EC(R57Q;\4?'$NCLR'Y%<_#
M50XRY2,D1K*?V=_"VNRM+\3/VE_C_P#$U)XRMYIEW\8Q\,_#MTSC]XCZ#\"=
M.^%5M):,0-MG=RWD(0!7\PEV?XG^S,MHW>*S_!2M=3HY=A<PQN)4DUI'V^&P
M& J*S=I0S%Q;6DF?9?VEF%5)8;(L8N:SA5Q^)P.#P[3ZR5#$8['4[/>,\O4D
MM6EL?3_BSQ[X'\!V/]I^./&/A;P;INUF.H>*_$.C^'+(*GWV-UK-[90A5_B.
M_ [FOGZ7]M;]G>[N)['P5XOUGXN:G#N"6'P1\ ^/_C'YSJ<%!J?P\\-:_H%N
MN0?W]]K%I:C:Q:X4*Q%GPI^S=^R-X+N4U#0OA5\(?[:259_^$DUK1M&\5^+&
MF4DB67Q9XL_MSQ)-)N^;S)=5=RP#%L\U]"QZ_P"&842*+6-(BBC18XXH[VU2
M*.-%"JB1K((T15 "JJA0!@ "CFX;H72I9UF3U<:DJV!R:*:::4\/&CGCJ1>J
MERXND[;<K::.7B&MJZN3Y>M$Z<:.,S:36EW&O*KD\826\5+"U5=ZW2/FH_'_
M .,WB-(I/AU^R-\5+BWE<HFK?%OQ;\-/@]I+9;Y97TT^(_''Q!@@*?,YN/ <
M-RI^06K/D*[[!^VQXIDE2[\0?LW_  =L)DRO]B:#\1?CGK\ 8;A'%J.M:G\%
M= CG081II?#^I6Y?<ZV[J K?2P\2>'1P-;TD#T%];#_VI2_\)+X>_P"@WI7_
M ('VW_QRC^V,/2N\%D>48::TA6JT\7F56UTTZE+,\7B\OG/364<!33OI!:(/
M[(KU;?6\ZS;$1=G.C2J8;+Z5TM53JY=A<+CX1?1/'3DM+RD[W^9A^S9X\\0I
M"WQ*_:M_: \2.&)GTOP-?^"?@IX?:,G<8;<_#7PCIOC:&/.0KS>/;J[5 $^U
M?>+:6G?L7?LQ6E^=6U;X2Z'X^U<\C6/B[J'B'XT:NKX&9(M1^+.L^,[J"3(#
M*UN\.P@; H  ^A_^$E\/?]!O2O\ P/MO_CE'_"2^'O\ H-Z5_P"!]M_\<I2X
MCSNTH4<QKX*G)-2H98J>4X>2>ZEALLAA*$OG3?7NQQX>R:ZE6P%'&U(M.-;,
MG/-,1&VW+B,QGBJ\4NRJ)>5DK2:-H&A^'-.@TCP_H^EZ%I5JNVVTS1M/L]*T
M^W3 &R&RT^&WMHEP -J1*, #%?!_[0?_  2]_8U_:7\?3?$_XC_#6]M_'&H^
M1_PD.N>"_%?B'P5)XK:UCC@@N/$UKH-Y;V.JZBEO%':MK+VT6M36L4%O/J$T
M5M;+#]V?\)+X>_Z#>E?^!]M_\<H_X27P]_T&]*_\#[;_ ..5EE6?YWD6,EF&
M39OF.5XZI"=*IB\!C,1A<14I5'&52G4JT:D)U(3E"$Y0FW%SA";7-&+6F9Y%
MDN=82. S?*LOS+!0G"I#"XW"4,30IU*:<83ITZL)QA.,92@I02DH2E%/EDT^
M6^%/PF^'/P/\!Z!\,OA1X1TCP1X&\,VSVVC^']%A>.VA\Z5[B[N[F>:2:\U'
M4]0NI);S4]6U*YN]3U.]FFO+^[N+F5Y&]$K$_P"$E\/?]!O2O_ ^V_\ CE'_
M  DOA[_H-Z5_X'VW_P <KSJ]>OBJU;$XFM5Q&(Q%2=:OB*]2=:M6K59.=2K6
MJU'*I4J5)MSG4G*4IR;E)MML]"A0HX6C2PV&HTL/AZ%.%&A0H4X4J-&C3BH4
MZ5*E!1A3ITX)1A"$5&,4E%))(VZ*Q/\ A)?#W_0;TK_P/MO_ (Y1_P )+X>_
MZ#>E?^!]M_\ '*R-3;HK$_X27P]_T&]*_P# ^V_^.5=L]3T[4?,^P7UI>>3M
M\W[-<13^7OW;-_ELVW=L;;G&=IQT- %ZBBB@ HHHH **** "BBB@ HHHH ^;
M?VD/V8_"/[3>D>"=&\8>,OBIX4L_ ?C.S\>Z5'\-?'=UX0M]3\0Z7:SPZ+)X
MLTS[!JFB^,-.T&\F77M$T?Q)IFHZ9IGBBRTKQ-:VJ:WHVE7UGRNJ?L?^&/%%
MCX>T+QW\3OC;X]\.>&O L'AFQL_$OQ1\3#5)O%VE_$[P[\5/"OQANM;T*YT*
M6/XM^!=?\*Z/;^"?'6FVNG:SH6E'4=,^T75AJ%Q:M]>44 ?&B_L-?!W^QYQ)
MK7Q8F^(EQXTT_P"(/_"\Y/BGXI/QMM_%>E>$+_X>V%W9>.TG1K+1[?P%JNK^
M$1X.M=*B\$RZ3J^JO/X<EU34;O4I&ZY^P5^SIK&C>&?#EIH?BWPOH&B>!IOA
M;K^E>#_B'XT\.Q?%#X87FLZKXDU3P%\7KJSU@ZE\2M#UKQ+KWB/7]:NO$E]<
M>(M4U+Q;XW-WKTEIX[\9VFO?9M% $4$$-M#%;V\4<%O!&D,$$*+%###$H2.*
M*- J1Q1HJI'&BJB(JHBA0 )",\<_@2/U!!I:* /PZ\?#'_!Q!^SAU_Y1-_M)
M=23_ ,W2_"'U)K]Q:_#OQ_\ \K$'[.'_ &B;_:2_]:D^$-?N)0 4444 %?+?
M[7W[)/PR_;-^#]]\(_B8=3T^!-2M/$7A;Q7H#VT7B'P=XJTZ&YM[+6]*-Y!<
MV5RKVE[>Z;JFEW]O-8ZII=[=6LHAE-O=VWU)17;EV8X[*,=A,SRW%5<%C\#7
MIXG"8JA+EJT:U-\T)Q=FGVE&2E"<7*$XRA*47QYAE^"S7!8K+<QPU+&8'&T9
MX?%8:M'FIUJ-16E"2NFN\91<9PDE.$HSBI+\+/V7/^"&/PF^ GQ@\+_%OQ[\
M7=?^,\O@75;3Q'X0\)S^#--\%^'8/$VF3"XT?6O$0AUWQ)>Z^-&NUAU+3=+B
MGTNP&J6MO<ZBNI01):#]TQQ117L<3\7\2<98REC^)<UK9IBL/06&H2J4L/AZ
M5"BI.;A1PV#HX?#4^:3<JDH48SJ-)U)2<8V\GAOA/A[A'"5<#P[EE++<-7K/
M$5HPJ5Z]2M5Y8P4JN(Q56OB*BC&*C"$ZKA35U3C%-IE%%%?-'T04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%13B1H)EBD$,IB
MD$<IC$HC<HP20Q%E$@1B',990^-I8 Y  \N@."R@YQ@L,Y/08SU-.K\9OB5\
M>_"/A3XP7/@V/QG^UCXF\6^'?BM9^"?'OC?2?C+X?\+Z1X1TPZS^SSX,;Q?I
M?P6MK6;P?KVE3?$3]ICP!X4T#PMJ/PS@OO%L&A>/M;TJ;6;+0M+;Q7^Q6E6]
MY::9I]IJ&H/JU_:V=M;7FJ26UO9R:E=00I%/?R6EHD=I;27<JM/)!:116L3R
M%+>&*$)&H!?HI"0.O?IW)XS@ <DX!.!V!I<C&<C'KV_.@ HI,C /8].#D]^!
MU/'/ Z<TFY1CD<C/KQZG'0>YXH =1110!^'?C_\ Y6(/V</^T3?[27_K4GPA
MK]Q*_#OQ_P#\K$'[.'_:)O\ :2_]:D^$-?N)0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'.#CK@
MX^O:EJK?7*V5E=WC0W5PMK;7%RT%E;R7=Y,L$+RF*TM80TMS<R!"EO!$IDFF
M9(D!=@* /RKUA-9N?VM_B+#XVT7XKZ/>WOQ6^%-]X(N?AO\ LV_ '7?!OCGP
M/X*T;PM<>%-<\3^//&WP^\5?&#6-3\"^*]1\9VVN^+[36M'TOP)8WL!^'LND
M36M]JLWZNCI^?H.,^W;T]J_$'Q[\+)O%?[2.K:Q9_#_Q8NF_$CXY_ ;XRW'Q
M;U[]C#XK:Q\?OAU/X9L/A==6O@7P/\;EO(/"WAOP?!!X=;1+K5M433C\+-'\
M3?$OPSJ7A3Q9-->7LW[? 8&/K_,]/0>@],4 ?$7[</C#X'>#O!_@*[^._P 5
MO&O@_0+[QK/IWA?X4_#[XFI\+/$_[0_CBX\,:TN@_#6RUJP\1^!O$M^FG*;O
MQG-96?C_ ,&>$=-_L&/Q5\3M;MO OAW4Y8>?^"?B\Z7^RK\/_ OQ+_:T\$:9
M\5[WX9W?C&_^(^E?%#X=>/?$6A^ $^($.D/K>F^+?&4>HZ/X_@^'UEKWA[X3
MZC\9?$6@:KIFO^-(+3Q'KMK>:YK2Z?=_:'B[P#X'\?VMM8^.?!WA7QC96<TE
MQ:6GBKPYHOB.UM9Y8_)DFM[?6K&^A@EDB_=/+$B.\?R,Q7BN</P3^$)BBM6^
M&G@5K"#PI=>!H-*;PKH;:);^$+_6[?Q)?^'(-"-B=&AT>^UVSLM6O;"*P2WO
M+^QLKFY266SMVC /QC^#OQB\,_$3]G3_ ()T>&?B#^T%JFJ_ _Q%#\1?#?Q]
M^)<7Q\U?3]<UCXA^&O!6N:C\'/!/Q9^-7ASQII/BO19_%GD>(/%4SWOBK2+W
MQEXH\(^&M&OVO[75FT?4?+T^+6O^(?A?\0]1^-'[0WQ3\)W'PZ_94\9^-OV%
M_&#?$WQ'X&U_XPZOHWQT_:C\*^ _BPEKI>H>'(_C]\3-5^'_ (1_92MH_"/B
MBV\<VGBK3?B+8ZA-H.JM\9=3%]^_FF?";X7Z+HFL>&M(^'/@/2_#OB&>.ZU[
M0=-\'>&K#1=;N84A2*XU?2K32X=/U.:)+>W2.6^MKAT6"$(P$4>WJ+_P[H&J
MRZ1-J>BZ3J,V@7L>IZ%+?Z=97DNC:C%!);1:AI,ES!*^FWT=O-+;QWEB8+E(
M)'B241NRD RO %_XHU3P-X-U+QMIEMHOC+4/"OAV]\6:-9R-+::3XFN]&LKC
MQ!IEM*Q+26^GZQ)>V<+L26BA0GDTWQQXBU[PQH9U3PYX$\0?$74A>6MN/#OA
MK5/!^D:DUO.S+/?B\\<>)/"NABWL@H>>(ZJ+R1746EM<,&5>PHH _GYO?&'B
MGQ)_P<&_L\WNO_"OQAX!O8/^"4?[2,,6D>(]:^'.J7E[&?VH/A-)]LM;GP7X
MW\4::MLK)%;NM[>V5WY\IV6CV\;7)_>K^U-2_P"A;U3_ ,"]"_\ EO7XK^/_
M /E8@_9P_P"T3?[27_K4GPAK]Q* ,/\ M34O^A;U3_P+T+_Y;T?VIJ7_ $+>
MJ?\ @7H7_P MZW** ,/^U-2_Z%O5/_ O0O\ Y;T?VIJ7_0MZI_X%Z%_\MZW*
M* ,/^U-2_P"A;U3_ ,"]"_\ EO1_:FI?]"WJG_@7H7_RWK<HH P_[4U+_H6]
M4_\  O0O_EO1_:FI?]"WJG_@7H7_ ,MZW** ,/\ M34O^A;U3_P+T+_Y;T?V
MIJ7_ $+>J?\ @7H7_P MZW** ,/^U-2_Z%O5/_ O0O\ Y;T?VIJ7_0MZI_X%
MZ%_\MZW** ,/^U-2_P"A;U3_ ,"]"_\ EO1_:FI?]"WJG_@7H7_RWK<HH P_
M[4U+_H6]4_\  O0O_EO1_:FI?]"WJG_@7H7_ ,MZW** ,/\ M34O^A;U3_P+
MT+_Y;T?VIJ7_ $+>J?\ @7H7_P MZW** ,/^U-2_Z%O5/_ O0O\ Y;T?VIJ7
M_0MZI_X%Z%_\MZW** ,/^U-2_P"A;U3_ ,"]"_\ EO5ZRNKFY\S[1IMUI^S9
ML^TS6$OF[MV[9]BO+K;LP-WF;,[QLW8;%ZB@ HHHH **** "BBB@ K)U]2VB
M:PJVS7C'2]1"VJ6C7[W)-E.!;I9+>:>UVTY/E+:K?6;7!<0B[MB_GQZU(W*L
M/8]\=O7M]: /PM\,? W4?"/Q3\ 03_ ;PHBV/B;X<ZH-?TO]C3Q+X?MK-;N;
MP]K+RVNMZO\ \%$-7N-'N_#SW3V&H:E)X/\ $D.AZUI=]Y>C^)8K!;?4/W2'
M]3_,^Y_^OUP.E?CE+HWA"T_:^^,%WXD\+?!+3]>U7X^> M1TJ^^(?[''QM^/
MGC_6H(_!GPTT[3O$'AO]HFVU#0O!?@N"2ZTY],\-^&;*PUK2/@_?:*VL:AJ]
M['K3Z5I7[&C^I[8[G_)/<\T +1110 4444 %%%% 'X=^/_\ E8@_9P_[1-_M
M)?\ K4GPAK]Q*_#OQ_\ \K$'[.'_ &B;_:2_]:D^$-?N)0 4444 %8WB+7],
M\+:!K7B76K@6FD:!I=]K&I7!Q^YL=.MI+JY=5++OD\J)A&@8-)(41?F85LUX
MY\<_A7?_ !F\!W7@*V\87'@VQU2^L9M9O;728]6GU'3K&0W0TDQ37]@D-O<7
ML=I/<R!I&ECM1;;!'-(U 'R-^S-^V/I_BO4O'^F?%76H=%GO?$-YXG\&-=K<
MR0VOA[4&83>%UDMXIMH\-QP6UPDLJCS8+R[E>7;;-C[7T_XO?"O5"J:?\2/
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M= T:PB*B6^U76-5N+33M.LXRRA[F\N8859E4ON90=_(]?;\<XQ^?'UK\[O\
M@J)X5T;QO^R'\2O"EU\&_'WQO\6:WX?\5Z=\+/"W@+X?:[\2;G2_BA?>"/$U
MCX3\4:EH>E+)IVG0://=3_V9XG\01#3_  YKUQIFI6=S8ZS%IMY#TGQ6^+WQ
M2^-7PWO_ (:?LX^$?'/P]^+GQ*^%^H^,/#_B7XT^'O%_P=T?P9X:L/BAX?\
MA]XSTS6=9A\->+_&'@+XN:CX5U/Q#KOPGCO/A[K%D]S9VGBRZCN-,TJXL;@
M^D=2^/\ \"]'\%ZM\2-6^,OPLTSX?:#XHUGP1K?CF_\ B!X4M/".C^,_#NO7
MGA;7O"6I^(Y]6CTBQ\3:+XFT^_\ #VK:#<7::KI^MV5WI=U:17MM- EKQ#\<
M/@SX1'@1O%7Q9^&OAM?BC):0_#5M>\=>%M(3X@RWZ6,EC'X)>_U6W3Q2UZFI
MZ8UH=#:^2Y_M+3A"SM?V8G_&GX _!;]H3X&WW@+XC?$C]G.VTKX>_!7]LO\
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M%>F!MT5B>3XC_P"@EHG_ ()+_P#^:"KMFFI)YG]H7-C<9V^5]CL9[/9C=O\
M,\_4+[S-WR;=OE;<-G?N&T O4444 %%%% !1110 5EZY9#4=&U;3S/J=L+[3
M;^S-SHMTUCK%N+FUFA,^DWR/&]EJ<6_S-/NT=&MKQ89E92@-:E% '\]7A/\
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M_P#6I/A#7[B4 %%%% !117EOQ4\6:QX2TS2KO1GMDFN]1>VG-S;BX4Q+:3S
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MM@'W]13(Y(YD26)UDCD4/'(C!D=& *NC*2K(ZD,C*2K*0RD@@T^@#\._'_\
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ME_S\:U_X46O_ /RSK:HH Q?[!LO^?C6O_"BU_P#^6=']@V7_ #\:U_X46O\
M_P LZVJ* ,7^P;+_ )^-:_\ "BU__P"6=']@V7_/QK7_ (46O_\ RSK:HH Q
M?[!LO^?C6O\ PHM?_P#EG1_8-E_S\:U_X46O_P#RSK:HH Q?[!LO^?C6O_"B
MU_\ ^6=']@V7_/QK7_A1:_\ _+.MJB@#%_L&R_Y^-:_\*+7_ /Y9T?V#9?\
M/QK7_A1:_P#_ "SK:HH Q?[!LO\ GXUK_P *+7__ )9U=L[""Q\SR9+V3S=N
M[[9J.H:AC9NQY?VZYN/*SN.[RMF_"[]VU<7:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _#OQ_\ \K$'[.'_ &B;_:2_]:D^$-?N)7X=^/\
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M_B_\,+^U!_\ .2H_XB'_ /@CU_T=_%_X87]J#_YR5?M1@>_YG_&C ]_S/^-
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N'KQZ]OSZ>W7KQ0
MM%%% !113=Z;MN]=W3;N&[/IC.?TH =111_7I0 4444 %%%% !1110 4444
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MRQ6]M!%$@)VJ"22 ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gainlossonfvcontcons.jpg
<TEXT>
begin 644 gainlossonfvcontcons.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M] 6Q_P#!XW_RGH WJ*P?M?B'_H"V/_@\;_Y3T?:_$/\ T!;'_P 'C?\ RGH
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MO\%_\\]:_P#!?%_\ET?\+O\ !?\ SSUK_P %\7_R77R/17S?_$3^*.^7=/\
MF$GY?]/_ "?WL#ZX_P"%W^"_^>>M?^"^+_Y+H_X7?X+_ .>>M?\ @OB_^2Z^
M1Z*/^(G\4=\NZ?\ ,)/R_P"G_D_O8'UQ_P +O\%_\\]:_P#!?%_\ET?\+O\
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M0 4444 ?B!_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$5^(?\
MP4G_ .4DG_!"G_LZW]J#_P!8Y^(-?MY'_JX_]Q?_ $$4 /HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ^=_C]_J?"O_7;6/\ T7IU?-]?2'Q^_P!3X5_Z
M[:Q_Z+TZOF^OYD\1/^2PS;TP'_JLP8!1117Q0!1110 4444 %%%% !2-]U_]
MQ_\ T TM(WW7_P!Q_P#T TI;/T?Y#CNO5?F?H-HO_(&TG_L&6'_I+%6G69HO
M_(&TG_L&6'_I+%6G7]E87_=L/_UXH_\ IN(@HHHK< HHHH **** "HIYX[:&
M:XF8K%!%)-(P1W*QQ(TCD)&KR.0JD[41G;&%4D@&6D/0\[>#SZ<=>>..M 'S
M?<?M$7B3R7%E\ ?VBM6\*I<B+_A,K+P'H4%G):Y.[4(/!>K>--,^+EU:!09$
M%M\-Y;V9,&WLIVDB5_H+2M3M-9TVPU:P,[66I6=O?6ANK.]TZY-O=1)-%]HL
M-1M[34+*?8Z^;:7MK;W=O)NBN((I4=%_%/XMZ-XT\5?M7^)](B_:+NKV'PG\
M=OA_KW@W3?"S?M,>(G^'OB#Q+JW[-=WKN@>+=.\ ^ M8^#OAS5/ 'PI\ ^-/
M#_A#PCK'B:70O%T7[27BKQE\4+?P>S75SXH_;I00.23R>N?4\9/) Z GJ!GO
M0!^(/_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#017XA_P#!2?\
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M!]=_\%I_^/T?VZ?^@/KO_@M/_P ?K>P/0?D*,#T'Y"OZO$8/]NG_ * ^N_\
M@M/_ ,?H_MT_] ?7?_!:?_C];V!Z#\A1@>@_(4 8/]NG_H#Z[_X+3_\ 'Z/[
M=/\ T!]=_P#!:?\ X_6]@>@_(48'H/R% &#_ &Z?^@/KO_@M/_Q^C^W3_P!
M?7?_  6G_P"/UO8'H/R%&!Z#\A0!@_VZ?^@/KO\ X+3_ /'Z/[=/_0'UW_P6
MG_X_6]@>@_(48'H/R% &#_;I_P"@/KO_ (+3_P#'Z/[=/_0'UW_P6G_X_6]@
M>@_(48'H/R% &#_;I_Z ^N_^"T__ !^C^W3_ - ?7?\ P6G_ ./UO8'H/R%&
M!Z#\A0!@_P!NG_H#Z[_X+3_\?J_8WYO?-S9W]IY6S_C]MOL_F;]W^J_>/OV[
M?GZ;<KUSQ?P/0?D*7 '0 4 %%%% !1110 4444 %%%% !1110!^('_!2?_E)
M)_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#017XA_P#!2?\ Y22?\$*?^SK?
MVH/_ %CGX@U^WD?^KC_W%_\ 010!\ ^(/^0_KO\ V&=4_P#2ZXK(K7\0?\A_
M7?\ L,ZI_P"EUQ617\;XO_>\5_V$5O\ TY( HHH) !). .23T ]37. 45X+;
M?M*_".\^-MS\ ;76=<G\=V5M,+R_B\%^+Y/A_:>(+5Y6OO MW\2DT5O!-IXZ
MTVQB.J:EX>N]9@-C:LME<7::^'T5*<O[3'@:?6_#FA>&/!WQR^(\_B7P?X4\
M?P:C\,/@IXP\;:!HO@SQUK7B+1/!_B'Q;KEDEM9^&+'Q')X3U_5M+_M#]_-X
M:L/^$B>"+3KBW>3I>"Q:M?#5HJ5.%5.5.44Z53F]G4O))<D^62A*]I.+2;L-
M)O;J?0U%>;_$CXJ^%/A</#D&OP^*M<UWQGK%]H/@OP9\//!OB+XB^//&.IZ3
MI5UK^M)X:\(^%;*^U2_L]!T&SN-:U[5YEM-'T;3A;O?ZA#<:AI=K?6/!?Q1\
M$?$'["/"NK7-XVI^"_#WQ#T^#4-%USP]>W/A#Q-?ZOI&GZI_9?B+3M*U:UEM
M-:T+5-"U_2M0L++5_#6MVZZ7KEA8W5S:I-G]7K^R5?V-7V+O:KR2]F[-QTG;
MEMS)QO>S<9):QE8L[7Z?Y6_S7WGH%%%%9""O6_@K_P CLG_8(U/_ -#LZ\DK
MUOX*_P#([)_V"-3_ /0[.OH>$_\ DILB_P"QGA/_ $[$:VEZ?JCZ]HHHK^KQ
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!%?,/QO_9*
M^&GQZ^+_ .S!\;_%^H^+].\<?LD>._&WQ#^%1\/:KIUIHL^O>/\ X>ZK\,]>
MC\6Z7?Z-J9UO3AX;UB\:PM[6ZTJ>UU+RKHW4T2O;2?00TK4P !XCOL  ?\@_
M11T]AIP'Y "@#X@\01R'7]<PC_\ (9U7^%O^?^X]JR/+D_YYO_WRW^%?>O\
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M^S[D8KZ;_LC4?^AAO/\ P7:)_P#*ZE&DZD.GB&]'TT_11_+3J]'*/#!Y7F>
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M:I_T,=]_X :+_P#*^@#>HK!_LK5/^ACOO_ #1?\ Y7T?V5JG_0QWW_@!HO\
M\KZ -ZBL'^RM4_Z&.^_\ -%_^5]']E:I_P!#'??^ &B__*^@#>HK!_LK5/\
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MJ$=JQ\AKF26.3 ![5@#H,=3^).2?Q/)]Z*^+4_;6\,0WW[/6B:S\)_C5X?\
M$7[0?C>Z\%V6EZQX*>RM/AP8Y?B-%I>L_$GQ)=74'AO2H/$\GPVU*/POH&C:
MGKGC/5X]3T[5$\-P^'[;6=:TS.D_;H\$CXZ:O\&H? 7CB>P\/?%SP_\  77/
M'8O/ T$-I\5_%'AC0/%^CZ=:?#FY\61?%O5_!KZ+XDTTW?Q%TWP3/X9M&74=
M7,DO@S1-;\6Z> ?<=%("& 89P0",\'!&>1V-+0 4444 %%%% !1110 4444
M%%?%7QE_;5\-_";Q/\2]%T_X8?$GXFZ'\ _!VB_$']HOQ?X%_P"$,_LSX0^$
MM?T?7_$EC+-I?B3Q7H/B+Q]XCM/"/AS4?'.L^#_A[I7B#Q!IG@W^SK\6UUK'
MB'PQX?UST'PY^U#X'\7?M!R_L^>'= \<WU_%\*;[XK1_$B;PZ^F_"S6;"QUO
MP+I4V@>$/$NISVEUXVU:VM/B)X8UK4M4\*Z9JG@[3K/4[;39O$S^)$U#1--
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MZCH/[7.B^"O 7[1_@^'0=(O?BAH^CZ9X*UOX3ZK\4?@+K?B7XB?#WP.?'?\
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MT&< =AQ3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>incometaxprovision.jpg
<TEXT>
begin 644 incometaxprovision.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3H94Z>'Q>(HP<L-BG)PI5I0CS-8U)R<8>\TDFVVDEH!]D?\ "XO ?_03NO\
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M^P+?_H(:[_X/=4_^2:L#<R/4?F*,CU'YBL/^P+?_ *"&N_\ @]U3_P"2:/[
MM_\ H(:[_P"#W5/_ ))H W,CU'YBC(]1^8K#_L"W_P"@AKO_ (/=4_\ DFC^
MP+?_ *"&N_\ @]U3_P"2: -S(]1^8HR/4?F*P_[ M_\ H(:[_P"#W5/_ ))H
M_L"W_P"@AKO_ (/=4_\ DF@#<R/4?F*,CU'YBL/^P+?_ *"&N_\ @]U3_P"2
M:/[ M_\ H(:[_P"#W5/_ ))H W,CU'YBC(]1^8K#_L"W_P"@AKO_ (/=4_\
MDFC^P+?_ *"&N_\ @]U3_P"2: -S(]1^8HR/4?F*P_[ M_\ H(:[_P"#W5/_
M ))H_L"W_P"@AKO_ (/=4_\ DF@#=HJK9VB641A2:ZG4NS[[RZGO)<MC*B6X
M>20(,?*@;:N20 2<VJ "BBB@ HHHH *0]#SC@\],>_((X^A^E+5#5;I['3-0
MO8TMI)+2QO+I([RXEM+1WM[:694N;J"TOYK:W9D"SW$5C>2PQ%Y8[6Y=5A<
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M]BZV,@'!&GYP1D9Q>$=#ZUZ7?Q>(Q8WI>[T0H+2Y+@:?J()7R7W $ZJ0"1D
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MN5*-Z56E*,Z562BJB<9).E.-1EO6^FEN_P#7Y=;V_>@_'KPX, Z-K0)X /\
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M4]:\.MIUQ;VTEU=:A>6OAF]U/1]"\60ZI87HLO%FFZA;VV/#\7/V,O#7Q?\
M%_C""U\">'_BP\OCKPWXA^,,7PBUC2SXMUWX<:=+??$KP+HOQOC\$PZ!X_\
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M/_#9C?\ Y1Y_GV9_65O3[U_77\^S/U-HK\LO^'UW_!,'_HZ2+_PQ?[3_ /\
M.0H_X?7?\$P?^CI(O_#%_M/_ /SD*/[ S[_H29Q_X;,;_P#*//\ /LPMZ?>O
MZZ_GV9^N_@;_ )'/PO\ ]AS3_P#T>M?=U?S<^%?^"W?_  2XTWQ+H.H7?[4\
M4=K9:I:7-Q)_PHK]I\[(H90[MC_A2'H,#) R1D@9(^KO^(@G_@D5_P!':K_X
M8?\ :=_^<K7[5X78'&X'+LSAC<'BL'.>.C*$,5AZN'E./U:DN:,:T(2E&Z:;
M2:333=Q'[,45\Y?LO?M:?L_?MF_#>X^+G[-OC\?$?X>VGB?5?!MQX@'A;QMX
M0\OQ)HEII=_J>G?V5X^\->%=<;[-:ZUIDOVM-,:PF^T[+>ZEDAN$B^C:_4 "
MBBB@ HHHH **** "BBB@!" <9SQZ,P_/!&?QI-H]6_[[?_XJG44 -VCU;_OM
M_P#XJC:/5O\ OM__ (JG44 -VCU;_OM__BJ-H]6_[[?_ .*IU% #=H]6_P"^
MW_\ BJ8\88 ;02&C.6^8X616/+9/ !P/7I4F1G&1GKC/./7%+_3K0!\Q_L:?
M"OQ3\%/V6_@;\*?'-IIEGXN\!_#_ $?P[K]MH]]'J>FP:E9FX\]+'488+9+J
M "1=DZ0Q!LG""OIK:/5O^^W_ /BJ=D<\CCK[<9Y]..?I2$@8R0,\#)ZGT%%D
MME8+M[NXFT>K?]]O_P#%4;1ZM_WV_P#\53J* &[1ZM_WV_\ \51M'JW_ 'V_
M_P 53J* &[1ZM_WV_P#\51M'JW_?;_\ Q5.HH ;M'JW_ 'V__P 51M'JW_?;
M_P#Q5.HH ;M'JW_?;_\ Q5&T>K?]]O\ _%4ZB@!NT>K?]]O_ /%4;1ZM_P!]
MO_\ %4ZD!!S@@XX.#T/H?2@#YF_;(^%_B_XS?LO_ !M^%O@".SF\8^./ FI:
M!X>AU+53I%A+J-U-:M&EWJ3).MG"T<<H>9HI  =I4AJ^ED3 (8L3N<_?<_*7
M8J/O=E(&.W3M4@(/0Y^E)D>H].O?TH 3:/5O^^W_ /BJ-H]6_P"^W_\ BJ-R
MYV[EW?W<C//3C.:=0 W:/5O^^W_^*HVCU;_OM_\ XJG44 -VCU;_ +[?_P"*
MHVCU;_OM_P#XJG44 (!CIG\23_,FEHHH **** "BBB@ HHHH **** "BBB@
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MW:B,A]M?G!\)?B'^T+I'C3]F+1=,_:!F^-6H_M=?LK?$CXNZE<>/_"WA75/
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M7'BOQ9E_:A^#]Q^R983_ !ZA\1:)K'[46B>%/B9<6_PWTM/%7Q'\._$/Q?\
M$C5=%\*ZCK4TMQI'A/P;X(\(S>&]'D;PWX?C\8^)=6\.:9=7?BK2=(DUG3/$
M'U;\#OV9O@/^S7IVNZ1\"?A?X5^%^E^)KV#4=<T[PG:7%C9:C?V\FH3I>36T
MMU<1+<O<ZMJ=U<30K$]U=W]W=W1FN9Y)3D_&W]DK]G']H[4_#NL?'#X0^#_B
M7J?A*-D\-7GBBTN[N70V:X:Z$^F>3>VR6EY'<.\L%]&@O+=I)/(N(Q(X(!\]
M>-O#_BW6/VXOAKX:\'_'[X\:1#'X9O/CS\5O %OXI\)'X56'@'PY+IOPZ\'^
M ;7PI=_#:]UB&7XJ^/;G4-=O]0/B^.YM=&^'/CJ"SFM;[7M*ETW]#P, #.<
M#)ZGW/UKCM&^'O@GP]K?_"2:+X7T73O$/_"'>&_A^VN6UE&FKR>"O!]YK.H>
M%_#$NHMNNYM&T*_\1:[>:;92RO';76KZC.G[R[F9NRH **** "BBB@ HHHH
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M!9GA*V!S#"T,9@\0HQKX;$TXU:%50G"I!5*<TXR4:E.$TFM)1B^B/C4_L)?
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>interferon.jpg
<TEXT>
begin 644 interferon.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHW_@TL?_ (_1_P )'X>_Z#NC?^#2Q_\ C] &S16-_P )'X>_Z#NC?^#2Q_\
MC]'_  D?A[_H.Z-_X-+'_P"/T ;-%?!'[9W[3?C'X'VWP[E^&EUX0U%_$MSX
MHBUG^U;1]<$*:3;Z+)8F 6&KV'V8N]]=>893*)0J! GEL6^$_P#AXW^T/_S[
M_#C_ ,)34_\ YIZ_1\@\+>)^),JPN<Y=_9WU/&.NJ/M\5.E5_P!GQ-7"U.:"
MH34?WM&HU[SO%*6E[+\_SSQ*X<X?S3$Y1C_K_P!;PGL?:^PPL:E+]_0I8FGR
MS=:#E^ZK0YO=5I7CK:Y^\=!Y!P<''!]/?GCCWK\'/^'C?[0__/O\./\ PE-3
M_P#FGH_X>-_M#_\ /O\ #C_PE-3_ /FGKV?^((\:]\HZ?\QU3R_ZAO-_<SR?
M^(Q\(=LU_P#"*'_S1Z_T]/I?XF?\$[-3^,W[5?B'XR?$;QOX$O?AUK7@75/"
M#R^'/AK'X0_:"O?#WB/P_P#$OP?KGPFUWXJ:#K=IHVM?"=O#_P 0$'_$S\(7
MWB?58]!\-:7J%W'=^'8_%.IY_AC_ ()GK?Z7=:%\2/B)HF@Z?I7PK\!?!GP_
MJ?[-/@5/@AXM\5>'OAU\1/"/Q+T;QA\7]>U35_B#;>.?%%WKG@S3[270)M(/
MA"ST[7OB3;26VJVGQ(U2QTWP8_\ !0C]IA=-366TCP(-(DOWTJ/5#X+UD:>^
MJ1VZ7<FG+>'Q)]G:]2UDCN&MA)YHB</MQ4*_\%$/VD6>TC33/ 3R7ZQ/81IX
M+UII+])I7@A:QC7Q&7O5FGCD@A:U6599XY(8RTB,HA>"G&3NU/)FDW%VQ\W:
M4;<T7;#:..O,GJN5WMTI^,'"2LG#-DVE))X&.L96LU^_U3OH]GI;?3TV#_@E
MMK6F>$D\/ZW\5?#7[3>FQ_&+]I#XFR_#;]M'P GQJ^#FH/\ 'WQM#XAL]?F\
M&Z'?^!H(OB?X!T8Z[IFF^+[^VU_3;R;XA?%"73]"\-GQ787'A_ZK\$_LZ?'W
MX:_!OP_\$/"WQS\$:YX;\(?#7PIH&CZS\1OA1K7CC5=8\56'CK6M7\7Z%XGM
M=8^)D\=W\$M9^'%UI'PK\)^#TU&7XA>"]%T_^T;OXG^+;Z.$-\++^WW^U,^H
MR:,GACPL^LQ1M+-HR?#GQ0VL0Q*BR-+-I2ZX=0BB6-TD:62V6-8W1RP5U)HV
MO_!0[]I.^NHK&QTOP'?7L[F*"RLO!6MW=[/*H8F*&TM_$<MS+* CEHHXFD4(
MY90$;"7@KQBTVJF3-*$:C:S"32A)7C-M8>W*TI-2V:BVGH[/_B+_  FFDZ>;
MIN3@E]05W.+BI02]O=RBY)..Z;BFE<_2;]D?]FZ\_9P\,>/]-N[_ ,#68^(7
MQ!D\?P?#OX/^"KCX;_!#X6"?PCX3\,7GAKX5>!+K6_$$VA:;KFI>&KWQ[XLN
M%O;2'Q!X^\6>)_$$>C:2^HS0R_6E?A7J/_!0?]IO1[C[)J^A^"](NS&DPM-6
M\!^(-,NC#(76.86U_P"(+><Q2&-Q'*(_+<HX5B5;%#_AXW^T/_S[_#C_ ,)3
M4_\ YIZJ/@GQG.,90ED\HR2<91Q\W%IVU36&LUJ]5H["?C#PC%N,HYM&2=G%
MX&*:?5-.NFFM='^NG[QT5^#G_#QO]H?_ )]_AQ_X2FI__-/3)?\ @H[^T0D4
MKK;?#<LD4C*#X4U0@LJ,RY \3@D9 R!UJEX(<:NW_(HUM_S'3ZV_ZAO-_<_E
M/_$8^$%NLU_\(H?_ #1Z_P!/3]YJ*X?PIXTTK5_"_AO5M0UO0X[[4] T;4;Q
M([^TAC2[OM-MKJY6.%[EWB19I7"1L[LB@*S,02>LM-1T_4/,^P7]E>^5M\W[
M)=07/E[]VSS/)D?9NVMMW8W;6QG!K\BJTY4JE2E.W/3G*G*SNN:$G%V?573/
MU.G.-6G"I&_+4A&<;JSY9Q4E=='9ZKN7****@L**** "BBB@ J.:))HI(98X
MY8Y8WCDBE17BD212CQR(P97C=25=64JRD@@@D5)2-C:<G P<GD8&.3D$'\B#
M[T ?DG\5_'?[86E?'^?P1H'BCP_X(\%:!\3_  ??^ -#3Q1^SIHGA[QW\/?$
MGB+]GGPGIGAB]T;Q)J\_Q2NO"_A;P9:_M/\ B7XDP1:/X5\57GC36?A9I/PB
MO?%-AIT>F1?K)9VEM8VEO965M;V=G:PI;VMI:PQ6UM;01*$B@AMX52&&.- J
M+%$BQH!M10H K\;M6U>P\!?M1?&7Q=I.D^'-:^%>H_M&_#'2OB5\5?$_[*.C
M^.M/^&WQ5U[0?AMX47PJGQ@U3]IWP]\0Y[8&;P'IY\4^'/@EK_@'X2Z]X@@L
M[BX%CH_B.WT']F0<C/U[8QR>#R>1T/OF@#\0?^"D_P#RDD_X(4_]G6_M0?\
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M?=G[5_\ #SGX5_\ 1//B/^?A/_YH*/\ AYQ\*S_S3SXCG\?"?_S05^*E=O\
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MJ6UP[8\)^(,X6%V)Q]DYX'3KZ5U1RS,;K_8<9NO^8>MW7]SS7WHYWFF6V?\
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M()/VA?C[((4Q)\<?C X\RW"28?XD>)V'F)+&LB/S\Z2*LBME74,"!XYY,/\
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M#1O_ ).K\%_)A_YXP_\ ?J/_ .)H\F'_ )XP_P#?J/\ ^)K;_5"G_P!!\_\
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M]HW_ ).'^/\ _P!ES^,7_JR?$]>-5_KOE/\ R*LL_P"Q?@O_ %&I'^4V:_\
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M^&K_ /@L_P#](COV=?\ Q:/H7_T)=?P4?W"?&_\ P<7_ /((_9$_[#'QM_\
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M'/W_  6/_P"C3?V>O_$SM#_^=91_PY^_X+'_ /1IO[/7_B9VA_\ SK*_2_\
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MFWF_N9\,45]S_P##G[_@L?\ ]&F_L]?^)G:'_P#.LH_X<_?\%C_^C3?V>O\
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MNM,DUJV\(OKNDIXGN-'B=HY-5@\/->#6)M-C=61[^.R:T1E8-,"#0!T]%%%
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MTZBB@ HHHH **** "BBB@ HHHH _"_\ ;)\)Z?H_Q#_;9M_C+\+-=^)GB/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M .,C:,''3(QV[>E+M7).U<D$$X&2#U!]0<#.?2EHH 0 #H ._  Y]>*6BB@
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>oie.jpg
<TEXT>
begin 644 oie.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\R?&?]K+X6_ G
MXR?LO? [QO!XJ?QE^UQX[\;_  \^%D^BZ1:7V@VVO> /AYJOQ,UQ_%VI7&J6
M,NBZ?)X=T>ZCT^XM;/59;K4C%:O;01,]U'])B[M2 1<08(!'[Z/O]&Q7XB?\
M%+88;C_@H_\ \$*X9XHYHG_:M_:?#Q31I+&V/V._B PW1R*R-A@&&5.& 88(
M!'[4QZ!H9C3.C:3RBY_XEMB!R!V%O@#V'% ' 77QF\'V=U<VDJ:P9;6XGMI"
MEC$T;26\KPNT;_:AOC+(2CX&Y2&P,U!_PN_P7_SSUK_P7Q?_ "77R[KRJFNZ
MVB*J(FKZFB(BA41%O9U5450%554!550 H    Q637\\5_$SB:G7K4XO+^6G6
MJ0C?"2ORPGRJ_P"_WM'7U8'UQ_PN_P %_P#//6O_  7Q?_)='_"[_!?_ #SU
MK_P7Q?\ R77R/16/_$3^*.^7=/\ F$GY?]/_ "?WL#ZX_P"%W^"_^>>M?^"^
M+_Y+H_X7?X+_ .>>M?\ @OB_^2Z^1Z*/^(G\4=\NZ?\ ,)/R_P"G_D_O8'UQ
M_P +O\%_\\]:_P#!?%_\ET?\+O\ !?\ SSUK_P %\7_R77R/11_Q$_BCOEW3
M_F$GY?\ 3_R?WL#ZX_X7?X+_ .>>M?\ @OB_^2Z/^%W^"_\ GGK7_@OB_P#D
MNOD>BC_B)_%'?+NG_,)/R_Z?^3^]@?7'_"[_  7_ ,\]:_\ !?%_\EUN^'?B
M=X9\3:D-+T_^T([@V\USOO+:*W@$<!C#@R_:'^<F5=J[>0&Y&*^*J]4^#MK;
M7GC%(+NW@NH3I6HOY5Q#%/'O5[/:_ERHZ;ER=K8W $@$9->OD/B%Q#F.<Y9@
M<2\"Z&+QE##UN3#2C/DJ3C&7+)UI*,K7L[.S8UU\E^J7ZGU[]JMO^?B#_O\
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M_@K_ ,CLG_8(U/\ ]#LZ\DKUOX*_\CLG_8(U/_T.SKZ'A/\ Y*;(O^QGA/\
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M?ZGPK_UVUC_T7IU?-]?S)XB?\EAFWI@/_59@P"BBBOB@"BBB@ HHHH ****
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M -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\
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M_B#_ )#^N_\ 89U3_P!+KBLBOXWQ?^]XK_L(K?\ IR0!1117. 4444 %%%%
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MV?V._B OR1[ER%SN<Y^5 S<[<']HTUTA%']C:]PB\'3"#P!U'V@X/MG@\9H
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MUT%C?F]\W-G?VGE;/^/VV^S^9OW?ZK]X^_;M^?IMRO7/']E87_=L/_UXH_\
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M>@_(48'H/R%+17]7B/G?X_ "'PK@ ?OM8_\ 1>G5\WU](?'[_4^%?^NVL?\
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M2*5'PLXBI5J55XK)I*G5IU''ZSB_>4)J3C[^65(:VM[].I#7WH3C>+>G]?\
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MUKPC>^%]2\6WTWQ';]2:* $ P /08_SU_4D^I/6EHHH **** "BBB@ HHHH
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H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>otherrevenues.jpg
<TEXT>
begin 644 otherrevenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4=.M%?/7[56L^)- ^ OQ U/PC\2O"OPC\0I:Z'::;X^\::I;>
M'_#NCR:IXJT'2IK:]\3WNC>([/P?/X@M;VX\,Z7XUO?#GB.S\%ZQK6G^*KOP
M]KEOH\FE78!]"9&,Y&.GX],'T.>,>M&1G&1GTSS7\[WA'XY?$G7O^"97BC7/
M"7[0'QL^'7C7X'ZAX('CG5_&?Q ^&GQ=\6:Y/>^&?AIXOTSP?X%_:+TJ%H]3
M\%ZK:>*;/4O%<NNZ=??&?0UU'7_ASJ=_X->VTN_B^J_VSO%VM>$/BAX\^- \
M<6?B'X;? [X$?#[XBZG\+?#?[<OQ3^ 'B^1-*\8_&#5?$UWHWPE^%UN=#^(6
MO_$*TL/"GAWP+=?$[54\+>,=9\,W'PUTZ/3Y;G7-7LP#]=\C.,C.,X[X]<>G
M!I"RC + $],D#/..,^Y ^IK\_P#X>>*O'5I^WW\6?"/BCXT:AXM\*ZU^SE\/
M?&GA+X:R1Z#X=\-?#V:?XM?$W119Z9X=LI;G6=0\67.CZ?;1>,?%/B#5+Z]U
MB:SLK?3]*\+Z5IT&DGS+]KCQ+=^*O$NC0? C]I3QY??';QU\/_#FJ_LW?#;X
M7?$'0-(^%W@SR]?OI=4_:1^-?]G)J&B>./@S=?:=,TW7;;XDRZOX?\2Z9X;;
MP+\%]%G^)OBN>^8 _4ZBFINVC=R><G\3VY(&.@)) X+,1N+J "BBB@ HHHH
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M!#*2""//Z@@@TG_"7^%/^AET'_P;6'_Q^OA_7P!KVN   #6=4     ^W7'
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M/_M_0_\ H,Z5_P"#*R_^/T?V_H?_ $&=*_\ !E9?_'ZT/LMM_P ^\'_?F/\
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MAI*K*,;17NJ-[M-LT_I?\'U_K;[@_P"%C>!?^AGTS_O_ "?_ !-'_"QO O\
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M-^ 5SJ5SIET?&EE\$+*PMI?!VEZ9;]A^TWXK^#'Q<U'3O!S?!OXH^'M:^/\
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MT_38A"DLQABA6XO[Z02ZCJE_(GVC4M4N[S4;MY+JZFD?O*** "BBB@ HHHH
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M7!U:D/9SG0I*$I4[QER2:WCS1C*W= %%%%>L FU<YVC/K@9_/KV'Y4!5 P
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>rd.jpg
<TEXT>
begin 644 rd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +J 3T# 2(  A$! Q$!_\0
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MYXF@*%$TSQ'I+?V1K>D-97)BUC2/$?AC4X-4L-0LEM+FTU/2[^[MX_&_%O\
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MKFQTB*]OETK36LM/:_OY+9[VX /VP_X2"\_Z DG_ (.-"_\ EA1_PD%Y_P!
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MX_\ <7_T$4 ?!&O_ /(>UW_L-:M_Z<+BLFM;7_\ D/:[_P!AK5O_ $X7%9-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^('_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"KC_W%_P#017XA_P#!
M2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 010!\$:__P A[7?^PUJW
M_IPN*R:UM?\ ^0]KO_8:U;_TX7%9- !1110 4444 %%%% !1110 5ZO\&?\
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M6[FWO[GQS8&/QW-=QR>(6MHOT<H **** "BBB@ HHHH **** "BBB@ HHHH
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MN:\7IK_ZN3_KG)_Z U 'Z#:?>QZC866H0QSQ17UI;7D<5S$T%S''=01SHEQ
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M% 'P1K__ "'M=_[#6K?^G"XK)K6U_P#Y#VN_]AK5O_3A<5DT %%%% !1110
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M_DON#Z_CO^@W&?\ A37_ /D_+\^[/4?^%U_%;_H>=;_\D/\ Y!H_X77\5O\
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M>ST445\><H5]K_L!_P#)P,/_ &(GB_\ ]':#7Q17VO\ L!_\G P_]B)XO_\
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M/BM_XKSB[_YT&/\ K%P__P!#S)__  Y8/_Y=Y_GV93HJY]@N_P#GE_Y$B_\
MBZ/L%W_SR_\ (D7_ ,71_P 0%\<O^C,^*W_BO.+O_G0'^L7#_P#T/,G_ /#E
M@_\ Y=Y_GV93HJY]@N_^>7_D2+_XNC[!=_\ /+_R)%_\71_Q 7QR_P"C,^*W
M_BO.+O\ YT!_K%P__P!#S)__  Y8/_Y=Y_GV93HJY]@N_P#GE_Y$B_\ BZ/L
M%W_SR_\ (D7_ ,71_P 0%\<O^C,^*W_BO.+O_G0'^L7#_P#T/,G_ /#E@_\
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M\+?]=M7_ /1>G5\YU]&?'O\ U/A;_KMJ_P#Z+TZOG.@ HHHH **** "BBB@
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M*Z3B"BC_ /5^/7'Y<TF0<X(..O(X^M "T49!Z'-("#T(/T.?\]#^5 "T444
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MW_8[R_\ ]2:9^U5%0_:+?_GO#_W]3_XJC[1;_P#/>'_OZG_Q5?R2?W^?E_\
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MH _$#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H(K\0_P#@I/\
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M !#3@+_HELK_ /!=7R_Z>^7]65OG_P#X9O\  W_03\4?^!NF_P#RKH_X9O\
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M..&4AAP:;1TZ45Y1(5ZW\%?^1V3_ +!&I_\ H=G7DE>M_!7_ )'9/^P1J?\
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MG_I=<5D5K^(/^0_KO_89U3_TNN*R*_C?%_[WBO\ L(K?^G) %%%%<X!1110
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M5Y_GV9]-T5\R?\-I_LA_]'+?!K_PLK/_ .(H_P"&T_V0_P#HY;X-?^%E9_\
MQ%'_ !#OQ!_Z(/C7_P 13/O_ )W^:^\/]:.&?^BDX?\ _#UEO_S5Y_GV9]-T
M5\R?\-I_LA_]'+?!K_PLK/\ ^(H_X;3_ &0_^CEO@U_X65G_ /$4?\0[\0?^
MB#XU_P#$4S[_ .=_FOO#_6CAG_HI.'__  ]9;_\ -7G^?9GTW17S)_PVG^R'
M_P!'+?!K_P +*S_^(H_X;3_9#_Z.6^#7_A96?_Q%'_$._$'_ *(/C7_Q%,^_
M^=_FOO#_ %HX9_Z*3A__ ,/66_\ S5Y_GV9]-TC?=?\ W'_] -?,O_#:?[(?
M_1RWP:_\+*S_ /B*9)^VK^R$D<KM^TO\&0J12NQ/C.S 55C9F8G9P% ))[ $
MT/P[\0;/_C ^-=G_ ,TIGW_SO\U]Z&N*.&+K_C).']U_S.LM\O\ J)_K7LS]
MH]%_Y VD_P#8,L/_ $EBK3K"\+7UEJGAGP[J6FW4%]I^H:%I%[8WMLXDMKRS
MN]/MKBUNK>0<207$$D<T3CAXW5AUK=K^F\/&4*%&$XRA.%*G&<))QE&4814H
MRBTG&46FFFDTTTU<]M-22E%J49).,DTTTU=--:--:IK1H****U&%%%% !111
M0 4444 %%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MW&<1QY_NH/S  _4
MU^(G_!2?_E))_P $*?\ LZW]J#_UCGX@U^W2_P"JC^D7\TIK5I=V@/P'\?\
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M22?\$*?^SK?VH/\ UCGX@U^W2_ZJ/Z1?S2G'=>J_,#_.1_:-_P"3A_C_ /\
M9<_C%_ZLGQ/7C5>R_M&_\G#_ !__ .RY_&+_ -63XGKQJO\ 7?*?^15EG_8O
MP7_J-2/\ILU_Y&>8?]AN*_\ 3TPHHI1C(SG&1G'7'M[^E>@< E!!'4$?6OT>
MT?X._"?Q'^R!H6N^&? UAJ/Q+TW6=-\1_$C5=>UKQYX6^*VDZ2EMHUWXB\0>
M"/#UUI,_@GXG?"B#POJ^EZAIFA^&Y%UFXM=1N?$D-_+XGTRZL)KVH_#G]G7Q
M7XWD\3^&?^%+'X,>$_BG\2OAS>0Z9I/QM^$,,WCR3X?^/_%_P-\)_$OQ?\0_
M&?B*[/PY\2WO@^+2_%_CK1K3P#K/ANXM-5D\2V'A;1]4L-;MOD'QE@E/%1>7
MYLHX2OF.'K3^JTY1Y\!&FZ=Y0KSC1_M.554\J6+>&>-G\'+&4'/ZS_5#&..&
M:Q^5MXNAE^(I1^L5(RY,=*<:GNSH1E566Q@ZF:2PT<0L'!^_>49QA^:=%?7O
MQM^&?P\\,ZE^S)KMZ/"O@ZP^+WAV34_BMH7PA\37/Q"\+>%(_#_QAUGP%K>L
M^ -4GUOQD-3EU+PEIKZH^C:5XF\8:):^,=+UG3-#U:]@273;+KOVA/A3\.-,
M^$VM_$3PEI7PC\-7/A[]HF7X6^%K;X0?%+5?BAIWC/X7ZMX.\4>)M \0^,KO
M4_$GB==*\=Z=_P (S837<9E\*Z_>V/B.Y/B?P!X<-IHC7/93XFP5266I4,6E
MF5?$8:G4Y:#I4J^%QD\!4A.4<1)UD\53E&%3!QQ--4^7$5)T\/.%5\=3AS&4
MXY@W6PKEEU'#XBK3YJRJ5*&)PE/'0J0C*@E2<<-4C*=/%O#5/:*6'A&>(A*D
MOA2BBBOHSY\*_8O_ ((6_P#)^EC_ -D4^*G_ *5^#*_'2OV+_P""%O\ R?I8
M_P#9%/BI_P"E?@RO@?%/_DW/&O\ V3N9?^H\C[KPR_Y.#P?_ -E!EG_J53/[
M3:***_RU/]+C^:/_ (.+_P#D$?LB?]ACXV_^FSX:5_,'7]/G_!Q?_P @C]D3
M_L,?&W_TV?#2OY@Z_P!(_H__ /)IN%_\>>_^M%FQ_GIXZ_\ )T>)?3)O_6>R
MD****_93\B/1/A=\)OB)\:?%MKX'^&'A74?%OB6ZM[B\-E8^3#;V-A:J#/J.
MKZG=R0:=H^G1R/#;"^U*YMK>2]NK.QB=[N[MXI.@T#]GCXZ>*#XF30OA/XVO
M+GP=J]WX=\2:?+I::;JVG^)K#3)=:O\ PK#HVKW.GZMK7BNQT:"75[OPOX>L
MM8\00:4JZE)IHLI[>>;V3]B'XA>%OA_\7FE\9^.O#O@OPWK^GVFGZI!X[\"R
M^-_ASXGATZ^?68-,\7OI]PFO^$+C3;^ULM:\*>+M MKFZM=9M9-)N9M/M]8%
MV/>](^./[+MU;^#-!M(/!NA_#;X9_%7XC^(]9T/XD?#;Q[XY\=>//AUX[T;P
M!=367P0\022:_KGPS\41Z]X7U[1/#EWXB\7>%?'?AG0U^&5YJ_Q#U6T\*ZMH
MZ?#YOGW$&#S3&X/!95/%86EA<)7HXJGE>8XN$7.GC9XB-2=*MAXXFO5JT*&$
MPN%P<9QHRK/%8S&0A3J8>'V>4Y)D6,RW!XO&YG##8FKBL51K8>>98##3G&%3
M!PH.G"I1Q$L-1I4J]?%8G$XMPE5C1^K83"5)3IUY_!DWP5^+%MX"@^*$_@+7
M8O 5SI5KK\/B)SINUO#E]J*Z18^*&T8:B?$L7A.]U1X].L_%D^B1>&KJ\EAA
M@U61IH?,9X9^#?Q)\8>%[CQKX?\ #D%SX6MM0U72FUF_\4^"?#L,^I:'I^GZ
MKK%CI]MXH\3:)J.KW.FZ?JVEW-W'I%E?&(:A9Q<W$Z0G[9U?XX_!?4?@?J'A
M1-9\$*UQ^S!X1^#FA7LG@;QO_P -7VGB_1=0T35V\*^,_BE%HT?P[UK]G[3_
M !%!J*OHEEJ,L]U\--*\*^'-,L8_$.GFW7D/A1XX^$OA#2])\$^-OB=\'O&W
MPJ\!_%7XD:EXL\,Z[^SKKOB+Q9\6? GB"S\-6;2?";QIKGAN^U?P^_C6#PW;
M#3;36;_X-^(/ASKT&F^)[_5]=MHUM+!1X@S]X/%U993.GB:.8UH4*4LIS>HJ
MV6TL.JB<(4>?VF-E6<,-"I*MA\)5J2E*/)"G.2;R+(EB\+2CFL*N'K9?1G7J
MQS3*:?L<QJ5U2ESSJ\OL\'&DIXB<(TL1BZ5.*4E*<X1?P."&56'(90RG!&0P
M!!P0",@C@@$=" >*6CCLKJ.2J22":1%)RJ23!4$TB+A'F"()G5I B!MH*^Y/
MB_Z[?@]5\PJM>_\ 'E??]>5Y_P"DTM6:K7O_ !Y7W_7E>?\ I-+3CNO5?F*6
MS]'^1_I&? K_ )(I\(/^R7?#W_U#]&KU6O*O@5_R13X0?]DN^'O_ *A^C5ZK
M7^0F9_\ (RQ__89B?_3TS_5W+O\ D7X'_L#PO_IB 4445PG8%%%% !1110 4
M444 %%%% 'X@?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7[=+_JH_I%_-*_$7_@I
M/_RDD_X(4_\ 9UO[4'_K'/Q!K]NE_P!5'](OYI3CNO5?F!_G(_M&_P#)P_Q_
M_P"RY_&+_P!63XGKQJO9?VC?^3A_C_\ ]ES^,7_JR?$]>-5_KOE/_(JRS_L7
MX+_U&I'^4V:_\C/,/^PW%?\ IZ84445Z!P'K2_'?XQI\+[?X+I\2?%\?PQM-
M;BUZU\)1ZW?QV-M=VYBEMK.WECG6Z@T*TU""+7+/P[%,FBVGB)!K]O91ZJ!<
MB_JW[1WQ[UW6O#7B/5_B[XYOM>\'ZE?ZUX;U5]5C@N]-UO5K,:=K&NN;.UMH
MM5U[6]-SIFO:YKD6J:MKVF-)INLWM_8336\GBU%>?_9.5<TI_P!F9>YSJ8FK
M.3P6&<I5<9!4\94E)TFW/%TTJ>)DW>O!*%5SBK'?_:F9\L8_VCC^6%/#TH16
M+Q"C&EA)^TPE-)5+*&%J7GAH6Y:$VY4E&3;/2]:^,OQ6\177B2]UOQ_XCU&Z
M\7Z'X;\,^(I)9[6%;[PYX.UBQ\0>$]!MK>SL[:UT/1_#>N:98:KHFG>'(-'M
M=/O;998(E\R<2Q?$#XO?%'XJG33\2/'GB+QG_8\FHW&FKK5S;M%;7NL-;MK.
MJ&"RM;."ZUS6FL[0ZUXAOHKK7M9-I:_VIJ=W]GAV><T5I#+LOI3HU*6 P5.I
MA^;ZO4IX6A"=#FHT\-+V,HTU*ES8>E2H2Y'&]&E3I/\ =TX16<\?CZL*M.IC
ML94IU[>WA4Q5><*_+5G7C[:,JCC5Y:]6K77.I6K5*E5>_.4F4445V'(%?L7_
M ,$+?^3]+'_LBGQ4_P#2OP97XZ5^Q?\ P0M_Y/TL?^R*?%3_ -*_!E? ^*?_
M ";GC7_LG<R_]1Y'W7AE_P G!X/_ .R@RS_U*IG]IM%%%?Y:G^EQ_-'_ ,'%
M_P#R"/V1/^PQ\;?_ $V?#2OY@Z_I\_X.+_\ D$?LB?\ 88^-O_IL^&E?S!U_
MI']'_P#Y--PO_CSW_P!:+-C_ #T\=?\ DZ/$OIDW_K/92%%%%?LI^1!1110
M4444 %%%% !5:]_X\K[_ *\KS_TFEJS5:]_X\K[_ *\KS_TFEIQW7JOS%+9^
MC_(_TC/@5_R13X0?]DN^'O\ ZA^C5ZK7E7P*_P"2*?"#_LEWP]_]0_1J]5K_
M "$S/_D98_\ [#,3_P"GIG^KN7?\B_ _]@>%_P#3$ HHHKA.P**** "BBB@
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MNJPK\\JT?\32\>?]"3A'_P (\Y_^?GK_ $M3_B6C@?\ Z''%?_A9E'_SD/\
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MZN'J*I"-:-+**-25-RBN90JTY-:*<7J?BQ_Q$._\$?\ _H[.^_\ $<?VL/\
MYQ5'_$0[_P $?_\ H[.^_P#$<?VL/_G%5^T^![_F?\:,#W_,_P"-?@)^YG\1
MG_!:K_@K+^P-^U5IO[.$'P"^->N_$.7P/J?Q3G\5)8_ ?]H[2CI$/B&P\#0Z
M/)*?$/PBTA9Q>RZ1J"(+1IVC-LQF6-6C+_@U_P -1_!3_H/^+?\ PS_QH_\
MG>5_JL8'O^9_QHP/?\S_ (U^X<'>/?%G!/#N7\,Y9E?#N)P.7/%NC6Q^&S.I
MBYO&8W$8ZK[6>'S7#47RU<3.%/DH0M3C!2YI*4I?C/%O@?PKQCG^.XBS+,N(
M,/C<P6%5:C@<3EU/"P^J8/#X&G[*&(RO$U5S4L-3E/GK3O4<W'EBU&/^5/\
M\-1_!3_H/^+?_#/_ !H_^=Y1_P -1_!3_H/^+?\ PS_QH_\ G>5_JL8'O^9_
MQHP/?\S_ (U]/_Q-+QY_T).$?_"/.?\ Y^>O]+7YS_B6C@?_ *''%?\ X691
M_P#.0_RI_P#AJ/X*?]!_Q;_X9_XT?_.\H_X:C^"G_0?\6_\ AG_C1_\ .\K_
M %6,#W_,_P"-(RY! )S@X^8]<<=Z/^)I>//^A)PC_P"$><__ #\]?Z6I_P 2
MT<#_ /0XXK_\+,H_^<A_E11?M5? R<S+!XF\33M;3M;7"P_";XQS-;W*)'(]
MO<"+X?N8+A(YHI'@F"3+'+$[($D1FF_X:C^"G_0?\6_^&?\ C1_\[RO]+G]G
M+X9>,OAWXD_:BU'Q9:6]I9_$[]IKQ/\ $KP<]MJD.H->^#]2^&/PB\,V-Y=Q
MP,6TVZ;5_">NV[:=<XN(H;>&X;]U=19^G\#W_,_XTO\ B:7CS_H2<(_^$><_
M_/SU_K<_XEHX'_Z''%?_ (691_\ .0_RI_\ AJ/X*?\ 0?\ %O\ X9_XT?\
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M%Q:W6L>*/$9WW.M:C)+::9H\7V$:C<7%IHT;V$=S!HEMIL%[+=7T=S>7'J]
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MH9K>WF(_9]P&F@BE8#_A9/BTX!D1B!GG .,\XS7X$W5E9?9+O_0K+_CTNO\
METMO^?>3_IE7]@O_  55_P"":/[0/[:OQL^'7Q#^$FM_"_3-"\*?"S_A"]2A
M\<^(_$&C:E)JW_"7Z[KOF6EOI'A'Q!!+8_8M2MT\Z6Z@E^T+*GV?8JR/^7T_
M_! G]M>2">-?%O[/.Z6":-<^.O&H&Z2)T7)_X5F<#+#)P<#/!Z5_H'X4^)?
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M?[-&@>$$\ Z#\!/A#H?@V+Q=I/CZ+PWH_P /_#.EZ5#XWT">.?0?%L-M8Z=
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MP[HGA7PQI>@:BT0O=%LO#NAP:9/:II5B(/D#XI?\$T?@3\2_B)IOCRWOM8\
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ME(*D@@T^NI--)IIII--.Z:>J::T::V90444U71L[65L==K X^N#Q3 =1110
M444$@=2!R!SZGH/J>U !1110 44$@=2!DX&>Y]/K02 ,D@#U/ H **,@]#GJ
M/Q!P1^!X/O10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!^-'_!2&.-_BWX%+Q1.1\., O&CD#_A)]7. 74D#/.!7
MYW30P>3-_H]O_J9?^7>'_GFW^Q7[4?M;?LM?$/XZ^.?#7B7PAJ?A.RL-'\)?
MV%=1Z_J&IVET]Y_;-_J&^%+'1M2B:W\BYC7>\J2>8&7R]H#-\IR?\$ZOC>T<
MB#7_ (;9>.1!G6_$.,LC*"<>%LX!.3U^AZ5_EGXW>#?B;Q#XJ<;9SDO!&=9E
ME>8YI"M@L=AL/3G0Q-)8#!TG.G)U$W'VE.46VEK%GYUF^59A7S'%U:6#JU*<
MZB<9QBG&2Y(*ZUVNK?(_7'X6@#X9_#P   >!?"(     \/:=@ #@ =@.!7=U
MS/@O1[KP]X/\*:!?/!)>Z)X;T+2+N2V9WMWNM,TJTLKA[=Y(XI'A::!VB9XH
MW:,J6C1B5'35_IUDU&IA\GRJA6@Z=6CEN!HU:<E:5.I3PM*$X271QE%Q:[H_
M0:*<:5*+5FJ<$T]TU%)I^C&N2$8@X(4D$] 0#R>O\J_F<_9__;3^/_P:^&WP
M]^*OBJS_ &FO'$^L?L;?"_XM>,/!G[0'C_X=_$"#X\?$?X[_ !1^#'P?^&?C
MS]GFW^%LGC+Q7X/\#^$/&GBSQ)JGQAT2\LM#UGPQX+\<?#JRB^&&L^(M;T>Z
MT;^F4@$$$9!X(/0CT->77'P0^#5YH>@>&+SX4_#J\\->%O NL?##PYX>O/!G
MAZZT/1?AMXBM=#L=?^'^FZ3<:?+86G@K7+/PQX<M=7\+Q6ZZ+J,&@:+'=V4J
MZ79"'TC0_-+6/^"@/[0>D?#6T\57_P"SPGARY\,>)?BM:_$?Q'XR\/\ QFTO
M2H/"?PQ\)_#CQAIWBZV^$>A>"/$_[1/A/P=XRMOB#=Z)K7CS7/AWXAT'X3:W
MX+O6\26?B'2_&G@*]UN:Q_X*<ZQJ/Q1^(8M?@_>)^SYX#U_XI^$;[XQZK:>/
M]*\&:7%\*O@]K7Q;U#XN^(?BDG@W4?APOPOUL:%/HFG:%X:D\1_$F'PSJ6A_
M$^+0M4TJ]O?#.E_>-W^R-^RS?^$_#?@.^_9R^!]YX+\':G>:UX6\*W?PL\%7
M.@:#K&I-;-JNJ:7IDVBO:VM_K)M+?^V[J./SM;6)$U9KU%"CI[C]GSX$77CC
M4?B9=?!KX6W/Q#U?0W\,ZKXVN/ /A:?Q3J7A^711X;ET:^UN72GO[K3IO#BI
MX>GM9YGCGT"*'1)@^E0Q6: 'YK>!?^"A/Q^\9>,H?@LOP/\ "VD?%V[^,7PH
M\$)=^,IOB#\.O"UGX(^,/P5_:(^+FE^*IO#'B?1'^)#:AX9_X9_U72Y-+U+2
M?#\WB^'5["Y@L_"$WVN#3Z/B7]LK]H3XC?"CX8?$?P=IOPO\%:?\6/CE^R[>
M?"K1-&^*-S<_$)_A_P"+OVK?!OPD\3^%/C7H5_X2N%T2SUC0=2D/BS5_!4.K
M0Z#J\NO_  NB$WB;3M)\2:U^E_@C]G'X ?#0Z:?AY\%/A5X';1M1L=7TI_"?
M@+PSX?DT_5-+TOQ9HFF:E:2:7IMM)#?:=HOCOQIH]C=JWVBTTKQ5X@TZWDCL
MM5NX)9]._9Z^ ^CZKXAUW2?@Q\+=+UOQ;XNT+Q]XHU?3O 7A>QU+Q%XV\+ZX
M/$_ASQ9K5]:Z9%<ZEX@T+Q.9/$NDZK=R2WEAXCN+K7K>6/5KNZO)@#YQT/\
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M>N=0UZZ@EL;6Q]?H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXB7,E[X]UFW&H:5<>5J/C2^D-_XINTQ+KVH)#?ZFUS>003Q 'E_[0'QU\=>
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M\$%L ?F_X>_X*I?$+QSK'B+7_"/[-OBVW^%VD:)K%D=4\2:!XTLIM'\2:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>rdpiechart2017.jpg
<TEXT>
begin 644 rdpiechart2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MX;U_9L^Q:=)_PD'CT:YJ_C*7P!I?P_?X)?&J/XKW_BL_#37?C%IFEVWPGE\
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M9*5 ,DGE111[W+-Y<:)G:B@ '\_GP?O=-_9FTS78?A]XJ\/_  /MOBK^W/\
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M4=&TK4)I;1+"66]TZSNY9;&.[CODLY)+B&5Y+1+V**\6V=FA6[CCN503HL@
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MP.-/T/\ <PZ;IYC\DV-H8?L;:=Y1MH#'_9[ *UCL,>W[&RJJM:8^SE5"F,J
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M!?ASXG>"O'-M\2X/A?HYDM+7PY]^T@4#&,\ CEF/4YYR3D^YR??FEH ****
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MQE_P4+16_8R^/9958IX2MW0D E7&MZ6H93V8!F (YPS#H37V;7QI_P %"O\
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M_; F\ ?%O7?C%\)OV!=/\!^&_@S#K?B_X:?#'5OVC/$7[8?C+4O$6J^$]?\
MB=X5F\8>(T\+?#CP]X.TFYM?B)\.6^,-Z_@2X@M_ T<]OH) /O']GO\ 8=MO
M@IXW\%?$2]\4>&=5\2:"GQWO/$<?A_PGXRL[/Q!K_P :;/X :*NM1:S\2OBO
M\7/'BW?AWPW\!=)T.XN=?\9>(KS7+?4HX89M"TO1K+26G^//["^A_'5OVA)=
M6\9G3+CXV-^S#J>DLFB:EL\+^(OV6O&=[\0/!LFLW&A^+?#&N^)_#FL>)9K<
MZMHNE:_X-U6STYM3&@^)=*UJ]M=;T_YS\)_\%&/BN\.FZ3XZ^$FAZ3XX\3>$
M4^)7@CPGH]W_ &OK'B[X>?"74/C'8?M+:CIUGX?\5^+M._MS1T^#^C7/A71(
M/$E_-X6U?]H#X1^#?&3ZMK-EK-SJ?#> OVW?V@_B]X?^&>M^,?!.I_#Z"\^(
MG[(7Q"LI/!D6E:-=>+?!OQIT_P")VM:O\(X- M/C!\2]9\:06]IX/TV+0_B)
M<IX&\.?%<ZOY%CX*\*ZAH-]82 'J^K_\$U-=;X<^&_#7@WXL>#_A]X[@UCXM
MZWXC^)WACP)\7[3QAI^L?%J+P79WWB3X:^.(?VFK?XNZ'XBTG3O GAV"]M/B
M)\4/BEX#\?WFC:#?^.O ^H#PYH-I836__!,.#2?B-\4_&?AGXQWWAX^-M3^/
M7CGP;XKMM%\;7'Q<^&WQ:_:#\*^*?#_BOQ[H>O2_%^/X1VUUI5]XT\3ZGHMS
MX9^!WA#Q7]@U2+P[/XMCM+ WU_P?AC_@H=\8]0\-^#+_ %.+]G>YNOB[X$_9
M ^*7A'7-%U7Q9)X.^%NA?M4_&_3_ (/)X"^*6H7'B&:;7?%OA[^UHM6\)>)]
M*?P18_$G4_#_ (T\/-X-\%KX?35[WF]2_P""CO[16GZ5\1]1M?!_P/UR/X!^
M&?$^M_$"\LQXYM-(^+-SX%_:[\<_LUZJ?A?J*^)-37P5HOBC1O"A\266IZ\G
MQ&/@OQCINO>!;NW\;6<8\46 !]%? K_@G>/A+\4M/^+.I^/_  MJ.L_\+8\'
M_%K6- \)_#[Q+H7AV;6_"?[,_P 8OV;PFE7?CCXK_%'QE%>ZKI_Q5C\4ZAX@
M\0>+/$6KRWNCWNF[Q;ZR+C3]3P'^PGXQ\,:;\ ?"'B'XW:+XG^'O[+WCOX7Z
MS\'] @^#VF:)K@\&?"OP[\4/#NB:7XZ\5CQ=JEWXF\;7&G^/M%M9_%.F6?AG
MPM!_PAW]JVOP^B\0^);_ %6Q^<OB7_P4-_:4\">*-<^#NF_"[P7XR^)G@OQM
M^TA9^(/&OA?P[J=QX$UCPM\"O 7[//Q%TJSC\)^*?C+X'U#P7J_B?2?VC-(L
M?$?B.Z^)'C/3_ FF^ _$GCH^%/$>E:I#HNA=^?VS?VE?$VOZI#I/A7X5>"/#
MNN?':S_9D\*:9JUEXA\7^/?#?CSQO^Q%X;_:8\-^,/$5]H/C*T\&>(-.\"^/
MM9NO NN>%?#JM'\0-$6#Q#X?\:^&'M(;37@#] _V?/@__P **^&L?P]'B#_A
M)]GCOXP>-1JW]F?V1D?%;XP^/?BN-.^Q?;]2_P"0&/&_]AF\^U'^TO[-_M+[
M/9?:_L5O[97RM^PYXU^(WQ)_8[_9E^(7Q<\7>'?'?Q*\<? [X9^+_&7BSPMX
M?;POI&L:WXE\(:1K=S,-#.N>(8[+4HOMRVVNM;:A'87>N0ZC>Z=I'AZPN+;0
M--^J: / ?CIK+16FC:%$V!=S3:E=@'#&.SQ#:H>.4:>:63T+VZGL#7S;7I_Q
M?OVO/&][#O#QZ=9V%C'@YV'R/MDJGH WFW;!L>@YR"!YA0 4444 %%%% !7Q
M]^W_ /\ )F/[1/M\/Y",\X(US1<$>XSP>H[5]@U\?_M_ G]C']HK )Q\/9B<
M G &N:*23CH .23P!DG KZ+A#_DK>%?^RDR+_P!6F$/ XK_Y);B;_LGL[_\
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M;?Z;#XN7PEH?B?U;]E?_ (*+_LZ?M?\ C+6?!7PCUJ6]U*T\'2_$CP[*^O\
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MT?PUX[\'_$CQ?\6_@#X/\%1W\GPKL@W]B:?HH!^@OB[]GS]GF7PGK,.J^!/
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M^EQ'VYIG[#7PJTR_B\2CQ?\ &'4/B'_PM+X?_&*Z^)NK_$F^U3QMJ'CKX=^
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MYNB_;XM+SX[_ ! ^&WBOPU%>^"/"'AGX;?M.?#.Q\??%[]C3XM?M3>"/$'Q
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M (#(RL 0& (# '( !+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M08?@KXBOT\1>(-7N;O4H_%\%K;Z=HEA8OI-=11],>,/VW/V3H=/\%WD_Q/\
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M%O"6H^(]7\+^'-4UQ(!J5]H?AS5/%_BG4-#TJYN)++2KSQ%K=S9PPRZG>/*
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>rdpiechart2018.jpg
<TEXT>
begin 644 rdpiechart2018.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MX;U_9L^Q:=)_PD'CT:YJ_C*7P!I?P_?X)?&J/XKW_BL_#37?C%IFEVWPGE\
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MAW-Y<B[FS.D,4;2M'%'&T\GFS,B*IFE\N.+S)2H!DD\J**/>Y9O+C1,[44
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MZ[_&=UXL_9TAO](G^+5CX]O_ (B_#[PII.E_M->+OA1;>)/#S>&?#TOPJ?\
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M-O 9+2!H[>0PQ%XV\M-H!_/IXJ_:K_:^\3_!/X0ZIXF_:#^'7PCU+QU\+_\
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MTG\$/@QXM^*7BVV\/65I)=_$GX0S_&/6O"=CX+NM=@\<Z/J>B^'=>\#:??\
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M/F&4XAW<(8W#5*,*T8NSJ8:LU['%4KZ>UP]2K3;T4V?K>2\19%Q'AEC,BS;
MYIA].>6#Q%.K*C)JZIXBDG[7#U;:^RKPIU$M>6QXI\<_A!\$OBGX9U^Q^.&E
MZ5?^%/$OPY\?? W7EUWQ!>>'])OO _QVN?">@>*O"\]U!J>EPPWGBO4- \*:
M?I%]%/#KMGJT=E%X<O+74KP>=XAXE_9L_8XL/B'X6T*^OK'P%\6=:U3PQXH\
M#:=X:^-OBKX:_$C4$^'OPYM/A';6W@ZU\.>.- \5W'A9OAOHUKX5\6:%H22Z
M!KUEIUO=^(+6ZU;3;34+3S?_ (*<:+X6UGX1^!GU'X9_%GXG^-M!^+?PC\7_
M  [TOX:_"7XS?&&VT*_\'?&SX2^)_%7BK5O#_P ,O#7BGP]I&LZ#X*TG7+WP
MKXC\9V-MJ-DT>MV?@._CUO4+RUO/%/CQKOPT^,/QITSP'HW[/'QW\'Z;\0/%
M_P"S%\8OBK^TM>_L>_M+WOB+Q'<> /$7ASQ5\)_AO\/-8M/A3=W7P]\1:#)H
M5A:_$SQGX[O_  %I/P1T+5_$MK8:/J'Q%\1Z_JW@_P 0]D^SKC]GS]D'X!_#
M^ST76[7PI\-?AVU]^SQH&GGQC\1+W0]#.H_L\ZGHNH_ 31+35/%7B2&&2^\.
MZCX8TAM/TY+Q[SQ(VGB/58]6!G#9NJ?LS_LE6WB;6]3_ +3G\'ZWX4EUGQKX
MXT[PO\=?'7@"W'AWQKXVU[XHW%E\2]#\,>/-!MM1^&MQ\0-<\7>,]"\-^,;2
M7PAI.I>)/&HT&UL]*\4>*-/U/R#XS:O!X@^/GP^^,7C3X#?%_P")/P3\"^!_
MVK_@!JWA*7X#:]XVUBR^*&K>+?AA;Z;XRTSX:R:;J6K^)_AS\6_ _@SQYX \
M-_%2RTBZ\)0:/KD(U;5]'\%^.M7U6+Y(\-?LK_&?X?\ @7]GG2]:T'QCJVI_
M#_X;?"/Q)^T!!KGA^Z^)/A.WU?5]5^&6@Z?X#TG0?!0L/&?QKC^'-O\ !3X?
M^*?B=X<TKQ=J.FM;?"SPCI^@1QZ3\1_$-JX!^G&M_L1_ 36]8U_7A9?$7P_J
MWB'QGXH\=SW_ ()^-/Q>\!W>DZWX_CLE^)MKX8O/!WC71+OPKX:^*-YINGZ[
M\1O!^@3V'A?Q;XNT_3_&NI:2WB^PLM<M]B?]CKX!7'Q#TGXFOX6UQ?$>B^*O
M!_CZPLHOB!\08O" ^(7@3PE%\/\ PU\0[KP(OB<^#M0\>6?@.WM/!MQXOO\
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MV^L>*?#UG/K&C>&M3T?1-=U?3KOWFB@ HHHH **** .*U;XD_#S0/%WA_P
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MXKLO!#&_:I^/?@W_ (:VUFU_:(^&_B![[]KOX1:=\.?"/Q#T3P1\/_%WPN^
M7Q2_9E^'OQ,T'_A#- ^+7Q7^%_AK4]9\5:UJCZ;X8T7XO>,_AAIDUYX:^*5W
M;W^K?$!HO!*_MH_A/PO)I>GZ')X=T)]&TJ:TN=+TE](TY],TVXL)/-L9]/T]
MK8V=E-92_O+26VABDM9"7@:-R33M1\+>&M7;47U7P_HFIMK&GVVE:LVH:3I]
MZVIZ99S3W-IIVHM=6TIOK"UN;FXN+>SNS-;07$\TT422RR.P!\J_LO\ QYE^
M.MIX-\4M\7?A[K0\3_L\?#7QQ>_";3_ TW@KXBZ3KFJ^+OB%X>USXKW5E?\
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MPCK.OZ?!J$-K<6ES+8S7FG0QW<=O=6T[V[2I#<0R%94^>?B+^V9X<^"7[/\
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M7-U#HGAK2[72K#[9>R^??7\T5K&ANM1OI_W]]J-VT]]>S_O;JXFD^:@#\./
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M]3_&S0GO] M-9@1FET2Y/G[5S_H%]LBF=L<A8)X[:1CT6,RL>E?+% !1110
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M< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0-/'B>\M]#MK[4[?1H+K6_MT\6E0:EJ$.G)(+.*^NXX%N) #N**** "BBB@
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M^'.K>';^]T[QYJ5KX;BN[#PSHWKG_!2[X]?M)_"V\M;#]G=?B38^*]&^#?Q
M^)/A2'2_#UWJW@3XD>._#%X;C2OAXMGX=_9[^-NO^,_%::5I=Y=:CX(U+Q7\
M$O#[^&];@UA/%NIW45UJ'@GZ4T7]N3PSK_P;O?BC8_"WXEV/B"^^/NN?LV>
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M&6>YF5NZXXK[2HKZG%<=\6XN+A4SK$TXM6_V6&'P4K?]?,)1H5/7WS' ^%G
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M'PDL_A]JWC/QOX0UOX81W?CRU\4:/X4UKP)K_@".Y\3V6MWV@I+=#Y_\'?\
M!,/P+X-\+?%#PSIGCHZ9;?%3X=?M?^!=3LO"?PX\&^!_"_AZ?]L/2/@#I_B[
M4/"/@_PT;/1M&T[PG=? BTO?#FA 3O>_\)+J'_"0:UJ>I6K:QJ7:_$C]@;2_
M&\GCN\M?&^A/<>-O$WPA\23Z3\0?@_X-^*/A*";X3?"6_P#A+IR_V1K-_I6M
MV&HR66H2>)=*\3>#?%?@KQ/H.NQ1VHU;5?#=SJVA:F ?1?P2/[._AA[SX;_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>reserves.jpg
<TEXT>
begin 644 reserves.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %U 3T# 2(  A$! Q$!_\0
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M^-1\8:/XS^/>LN_PT^)/A?Q%XD\=>&O#7P^TKX9ZIKGB;6_">E>![3Q=X3\
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M'_[+7XB?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MVG^JC_W8_\ V6@#^:'XE_\
M)2?B)_V/WC7_ -2?5:XFNV^)?_)2?B)_V/WC7_U)]5KB: "BBB@#AOB)\-/
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M3XDAQ\1OB$)&5W'CSQF'=4,:LX\3:IN94+R%%9LE4,DA4$*7<C<>+H ****
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M6@6?CK0-:TWX%V^C6WA[Q=966@:-:ZW/?RZK!I^H.-/\*^$=6NOMNB@#YB^
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M^#/%PU/]EOXH_%'^Q?$/COXD^%/B[XFL]8T[X'?!+0;?Q=I_A;47\ >&=/\
M%_A[X6OX@EU"P?P_^SJC QSU.<]R223U. >H&>!@4 ?B#_P4G_Y22?\ !"G_
M +.M_:@_]8Y^(-?MVG^JC_W8_P#V6OQ$_P""D_\ RDD_X(4_]G6_M0?^L<_$
M&OV[3_51_P"['_[+0!_-#\2_^2D_$3_L?O&O_J3ZK7$UVWQ+_P"2D_$3_L?O
M&O\ ZD^JUQ- !117%_$7QQI_PV\$>)/'>J6-]J6G^&K*WO;JSTY[:&XE2YU.
MPTI'DO+UXK#2].M9]1BO-;UO49$TWP_H=MJ6O:BPL=-N 0#M**^.K+]K 2?#
M7X9^+]5\+>"M!\0_$NVUO4=.BU7XU^$U^%MIX>\,:9HM]KWBZ;XJ:3I6O2/H
M\>H^(M$\)Z?HB>#7\8WGBW4#I\FBP:597>NCMO&?[1%KX1\,?"C65\'W&KZY
M\3M7^&T5QX:T[Q7X<U.'PCX4\=^.O"/P_O?&]]XM\/OK?AO7M#TK7?&NA6GA
MZ;0;B6W\>W=]##I%Y8PP:O<Z2 ?1]%>"/\:=1L_C'HOPIU;P;IMH/$VI>)]/
MT2:Q^)'AK7?'EOIOAG0=5U]/B!XK^%NEV4FI^%?A=XC329=)T'Q7=>(;R\AU
MK4O#=CKVAZ3<>(K>"TG^+GQ<\2?"RR\1^)U^&5[X@^'_ ($\-6/BSQMXLD\7
M:3X>G-A>:E/87&C_  _T"YTW4Y_&WBK1X(8;_4-*U'4/!MC>3:KH/AO0-6UC
MQ+K"6-J >Z44YU*.Z'.8W>,Y5D.48J<HX61#D<I(JR(<JZJP(#: "OM3]@7_
M ).#@_[$7Q;_ .C]#KXKK[4_8%_Y.#@_[$7Q;_Z/T.@#]Q**** /R[_X*5_\
M>GP;_P"OSQW_ .DGABORKK]5/^"E?_'I\&_^OSQW_P"DGABORKH **** "BB
MB@ HHHH **** "HI_P#43_\ 7";_ -%/4M13_P"HG_ZX3?\ HIZ /Z</ /\
MR(W@W_L5/#G_ *9K*NMKDO /_(C>#?\ L5/#G_IFLJZV@ HHHH **** "BBB
M@ I&Z'C)P>.F>.F>V:6LG7H!<Z'K%LT)N%N-*U&!H%MYKMIA+93QF$6MM>:?
M<7!D#;!!!?V4TQ;RHKNVD=9XP#\6OBGX=U5?VO/&/C"+X+Z7<?$I?CW\$M'\
M(^"K7]EKXI>(4^,?PN"?#NWU?XR>(/VJ]*N8O!?A?4O!%KK/BV_L%O=3TKP_
M\/(_AW!X5\3>$_$FI>([>?6?VZ7IR,=?YGG!Y&>N#R,X/2OPZ\)^"/&NJ_$[
MP+K6O?!?6TF@\3_#Z.?5)OV)OCGX9BM+/PW-H.DZ7<S:O/\ \%"_$.CZ/_9&
MDZ591#7=2\*>)([!+,:EJFD:\\5U;7O[BC^I_F?<_P#U^N!TH _$'_@I/_RD
MD_X(4_\ 9UO[4'_K'/Q!K]NT_P!5'_NQ_P#LM?B)_P %)_\ E))_P0I_[.M_
M:@_]8Y^(-?MVG^JC_P!V/_V6@#^:'XE_\E)^(G_8_>-?_4GU6N)KMOB7_P E
M)^(G_8_>-?\ U)]5KB: "L?7M-OM7TF[T_3?$6L^$M0G^S/9^(_#ZZ9)JVE7
M%K>6]Y'/;V^M6&IZ1?0RFW^R:CINIV%S8ZII=S>Z=<+&EUY\.Q10!\<?#?\
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M=0\-Q;7,+P7$$RGAHIH9'CD4\%&8'K5J@]#GIWH _%B/P5\.M=_:I\;6=O\
M#WX86R?"GXO_  V\%^'+SX;_ +#GCWXV+8Z=X?\ !OPXOM(LO&_[0EB\OAOP
M9\0M#2>&VU'3X+6PL_A=X9B\(7.HB]F^T:G>?M,/ZGMCN?\ .>_7O7P+XBOO
MV4=.^/\ KUN?BI\7[/XK7WCCPD_BSPMX ^*G[2;^"+;QK+IWAY="TOQ5X4^'
M^J7'PLT6^OM$?P[-K6CZW:6!U#0KS3KSQ1;RZ9=V\S??8]O4_P ^>OO_ /6X
MH _$#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]NT_P!5'_NQ_P#LM?B)_P %)_\
ME)'_ ,$*?^SK?VH/_6.?B#7[=(1Y4?(^['W'^S0!_-%\2_\ DI/Q$_['[QK_
M .I/JM<37;?$O_DI/Q$_['[QK_ZD^JUQ- !1110 4444 %%%% !1110 5]J?
ML"_\G!P?]B+XM_\ 1^AU\5U]J?L"_P#)P4'_ &(OBW_T?H= '[B44F1ZC\Q1
MD>H_,4 ?EY_P4K_X]/@W_P!?GCO_ -)/#%?E77ZJ?\%*B#:?!O!!_P!,\=]/
M^O3PQ7Y5T %%%% "8&2<#)01DX&XQK(\JQEL9,:RR22K&3L66220*'=V:9IY
MW9'>>>1XSF-WFE=XR""#&S.6C(*J04((*@]0#45% $PN;E7:47-R)6 5I1<3
M"5E7&U6D#[V5=JX4L0-HP.!B,/(H4+)(H5_-0*[J$EX_>H 0%E^5?WBX?Y5^
M;@8;10 YW>1B\CO(YQEY':1S@ #+N68X  &2<  #@ 4VBB@ J*?_ %$__7";
M_P!%/4M13_ZB?_KA-_Z*>@#^G#P#_P B-X-_[%3PY_Z9K*NMKD? )'_"#>#>
M1_R*GASN/^@-95UV0>A!H **** "BBB@ HHHH *J:A<_8[&\N]BR_9K6YN/+
M>:&V23R87E"-<7!6"!7*;6FF(BB!,DA"*QJW10!^0_A*[^+C?$#7/C5X=\/_
M !I^'7PQ^(GCWPYXV\>IX:_:3_8AU3X)6LUE;Z)H?B#Q%,'\%Z[XA:UU+1-%
MMI/%K:5XR36M96SDEM+ZUU22.=?UJTS4].UK3K'5](OK34]+U.U@O].U&PN(
MKNRO[&[C6>UN[2Z@9X;BVN('26">)WCEB='1V5@Q\HO_ -G7X ZKXF?QKJ?P
M1^$FH^,)+DWLGBB^^''@Z[U^2^,J3B^DU6?1I+R2^66-76^DE>\5AE9UYS[+
MTZ4 ?AW_ ,%+H1/_ ,%'O^"%D1DGA#_M6?M/CS+>5H)EQ^QW\0&^25/F4-C:
MX'WD+(>&-?M&F@Q[$;^UO$'(0\ZQ<D\XZGC/OP,^U?C#_P %)_\ E))_P0I_
M[.M_:@_]8Y^(-?MVG^JC_P!V/_V6@#^9_P")*[/B-\0D#.P3QYXS3=(Q>1MO
MB;5%W2.>7=L9=SRS$L>M<77;?$O_ )*3\1/^Q^\:_P#J3ZK7$T %%%% !111
M0 4444 %%%% !7V7^P?;"[^/L,)GNK<'P/XK;S+.X>VF^6?0_E\Q/FV'.2O0
MD*3]W%?&E?:G[ O_ "<'!_V(OBW_ -'Z'0!^TO\ PC\?_06U_P#\&]S_ (T?
M\(_'_P!!;7__  ;W/^-;]% 'Y5_\%'=/6QM/@_MN]0NO-O/'.1?7DEV$VVOA
MGF(2?ZLMGYR/O *#TK\NZ_53_@I7_P >GP;_ .OSQW_Z2>&*_*N@ HHHH **
M** "BBB@ HHHH *BG_U$_P#UPF_]%O4M13_ZB?\ ZX3?^BGH _I4\"Z$DG@G
MP>YU775+^%O#S%5U:Y51NT>R.%4'"J,\ <#M7=6.GK8^;MN]0NO-V9^W7DMU
MLV;O]5YGW-V[Y\?>PN?NBL'P#_R(W@W_ +%3PY_Z9K*NMH **** "BBB@ HH
MHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]NT_U4?^['_P"R
MU^(G_!2?_E))_P $*?\ LZW]J#_UCGX@U^WD?,<?^XGZ &@#^:#XE_\ )2?B
M)_V/WC7_ -2?5:XFOT$\9?LR^&-3\8>+=2E\3^(XY=1\4^(M0DBBM=(,<4E]
MK-]=O'&7A+E(VF*(7)8J 6);-<W_ ,,L>%/^AJ\3?^ FB_\ QFOA:GB/PK3G
M.G+&8A2A*4)6P.+=G%V>JHM.SO\ =Y@?#]%?<'_#+'A3_H:O$W_@)HO_ ,9I
MR?LJ^%Y'2./Q/XIDDD8)'''8Z/))(['"HB) SN['A54%B> ":C_B)7"?_0;B
M/_"'&>7_ $YZ:_=Y@?#M%?:]K^S+X(O;&VU2R\;:Y>:9>V:ZA9ZG:+X?N=-O
M-/=2R7]K?PJ]G<V#J"4O89GM6 )$I )$S_LN>#XWMXY?%_B&*2\N/L=G'-#H
M,,EY>&-IA96<<L:/=WIA1YA:6RRW/E(\OE>6C,'_ ,1)X43L\9B4T[-/ 8RZ
M:M=->QW6M_3S ^(J*^W!^R[X.::2W7QAX@:YB@ANI;98M!:ZBM+F1X;:[EM@
MAGBM+F:*2*VNI(UM[B6.2*&1WC=55_V7?!\;VT<GC#Q!%)>7'V.RCEAT&*2]
MO#&TPL[*.2-7O+PPH\WV2V66X\E'F\KRT9@O^(E<)_\ 09B/_"#&>7_3GS?W
M>86?8^(J*^X/^&6/"G_0U^)O_ 31?_C-'_#+'A3_ *&KQ-_X":+_ /&:/^(E
M<)_]!F(_\(<9Y?\ 3GS?W>8'P_7VI^P+_P G!P?]B+XM_P#1^AU<_P"&6/"G
M_0U>)O\ P$T7_P",U]&_LL_ S0O 'Q7B\0Z?KNLZA.OAG7K#[-?6^G1P%+R7
M3&>3=:QK+O3R%"#.T[FW X%=6"X^X:S#%X?!8;%5YXC%584*,98/%04JE1J,
M4YSI1C%-NUY-)6\P_0_2NBBBOLP/R[_X*5_\>GP;_P"OSQW_ .DGABORKK]4
M_P#@I8RK:?!K<RKF\\=XW,JY_P!$\,=,D9QWQTK\JMZ?\](_^_B?_%46?;^O
MZ: =13=Z?\](_P#OXG_Q5&]/^>D?_?Q/_BJ=GV?]?\.OO =13=Z?\](_^_B?
M_%4;T_YZ1_\ ?Q/_ (JBS[/^O^'7W@.HIN]/^>D?_?Q/_BJ-Z?\ /2/_ +^)
M_P#%46?9_P!?\.OO =13=Z?\](_^_B?_ !5&]/\ GI'_ -_$_P#BJ+/L_P"O
M^'7W@.J*?_43_P#7";_T4]/WI_STC_[^)_\ %5%.\?D3_O(_]1-_RT3_ )Y/
M_M46?9_U_P .OO _IR\ _P#(C>#?^Q4\.?\ IFLJZVN2\ \^!O!F/^A4\.?^
MF:RKK:0!1110 4444 %%%% !1110 4444 ?B!_P4G_Y22?\ !"G_ +.M_:@_
M]8Y^(-?MY'_JX_\ <7_T$5^(?_!2?_E))_P0I_[.M_:@_P#6.?B#7[>1_P"K
MC_W%_P#010!\ ^(/^0_KO_89U3_TNN*R*U_$'_(?UW_L,ZI_Z77%9%?QOB_]
M[Q7_ &$5O_3D@"O$_P!H[P_!XK^"'Q$\-W5QX^M+36M)TRSO;OX8^%I_'/C.
MVLE\3Z!=WDUEX'L[NQU#QMH@MK65/'/@W2[E=7\5_#Y_%>@:0D^I:A:P2>V4
M>GJ""#T((.00>H((!!'((!'-9T:CHUJ59;TJM.K';>G-36ZDMTMXR7>+6C#^
M=RTG\%1?\$M=4T7QMX2F\ :=#?\ A._^"EM\+/"7[0'@'P/\?_%$.A_"WQ)/
MXD_X4A+9:UKUM'X'U--8LI]*N8XOA#XJ\<>$)OB3X;L]5O#*T'TC^U3=6_Q-
M^+?Q(^*T%AX9^*'@KQ-\%OAM>?L>Z+KG[/?Q0^+2?%SQ9I'BSXGWWQ(^$_@S
M6]+'AO5OV??&?B;QI!X)OK_XCZ7/X3^(\6E7'@GQA9:_!X*^&6KVUY^S$%Q<
M6I)M+BXM"RJC&TFEM2R)]U#Y#1Y1<#:GW%P-H&!0US=,TS-=7+-<@+<LUQ,S
M7*CHMRQ<F=0. LQ< =!7O2S]NO*O'#5(REB,765\4I\D<7+"3J1I\^&E[.<G
M@X*I4CI*%6O"C3PZE2=!W[*VVJWT_P ^OR^?Y(^ _#%W'\8/AE'+X)UC3OVN
M=%_;6^-?C[X]^/7\&^(3/J/[+OB"X^-$B2:M\65T.U\,^+_A)XF^&.I_ WP/
M\*?"=GXCU*ULO'/AW1;;1/"^DZSX(\02Z?P?[2<\GQ*\?^*_BU_86E>.O"_C
M#]G;X*ZU^QQX8\<?LT_%KX@ZE\4O%$.H?$#7/'?PF\/S11>%?$W[,_CSQ+XO
M/@/5-9\:QKX*^*NFZ9>>"?%,FJ6'A+X7ZWIUS^T_FRF-83+*84<R)"9',*2,
M,-(L1;RUD8'#.JAR."2*=Y]QF8_:+C-R"+D^?+FY!))%P=^9P222)MX))/4F
ML89W*&)CB?8-SC2]E_'3Y(RQ'UF<*+G0FZ5+F4:5*FKNCAG6I1FZE55Z0W]_
M>[OV_P [_HM"$/+(!)-'Y4\@$D\/GQW/DSR /-#]JA58;KR96>+[7"JPW6S[
M1$JQR*H6BBO#_K^MQ!7K?P5_Y'9/^P1J?_H=G7DE>M_!7_D=D_[!&I_^AV=?
M0\)_\E-D7_8SPG_IV(UM+T_5'U[1117]7B/FK]HK3=-U"'PC_:&G:?J'DS:V
M8?M]C:7ODEXM-#F+[5#+Y9<*N\IMW[5#9"BOF+_A&_#G_0N^'_\ P1:3_P#(
M=?57Q^_U/A7_ *[:Q_Z+TZOF^OYI\0<17AQ=FL(5JL(I8"T8U)QBKY;@V[)2
M25WJ[+5Z@8O_  C?AS_H7?#_ /X(M)_^0Z0^'/#8!)\/>'P "2?["TG@#DG_
M (\ZVZ#R#]/K^G>OC/K6)_Z"*_\ X.J?_) ?*NB_'GX4^(?C?XK^"6C?#'Q;
MJ#>"+>_MO%/Q2M/AEIES\)="\7:-=:E!KO@K6?$L#2:CH]]HR::\=UXEU31+
M3P3+K<J>%[?Q#)K)@BNG>"OCY\'OB1X!^(GQ%\ _#CQOXMT?X>_$.[^&8T?2
M?@S+'XS\<>((['P/J.F7W@3PAJ]KI6KWGA?Q%9_$+P[?Z'XE\3Q^$]-.@O>>
M+=9?1?"EJ=9?RC4/V4/B'>_MHQ?M)6^O?"O0=$TS1K*2'7O"'ACQ3X,^+GCB
MWLKGQM#!\'/BO-H?B0^!O'7@<V6O>'X]4^(GB'PYK/BVZT#PMX:TG1-#T'Q-
MHH\52;?PY^&'[6FAI^T2_B:;]EJQO/C/\5-0^+NGC3-2^,_C_29+C6_#?PN\
M#^)_AKXQL-?\(^ +U?#/B3P?X#UJ ^/- U.Z\2:'J_B&TNH?".L6FF3VU_[E
M26#Y:;I8ZJW]6P,Y\^,K1C&O*HHXNFTX<\_W;<^>'*J7*X^R<I1L[+3;5_<M
M.S];Z_<=/8_M!>"=7%UHNA_LZ?%[7?B?I/C_ ,5_#7Q-\'-*^&?PZE\:>$O$
MG@KPOX.\:Z])XA\27/C6U^$5MHLOA?XA^!=0\,:G:_$R[D\:7WBO2_#WAJQO
MO$%OKFG:+V$GQE^![? WPY^T+IND+KG@#QIIO@V[\%VFD> K23QIXLU?XA:_
MIOA'P7X*T?PE>V]A>?\ "<Z]XRU:R\(IH&H7%@FG:[]K35M0L=-TZ_U*W^6[
M+]E[]I_X??#S6_A[\$O$GP!^'7@[XE?%;7O'/C[X9^%_$OQH\$>'OAYX)U#P
M7X6T"X^''[/_ ,0K'P;XN\6>&+KXB^*]+\2>._BMX_F\)^'=<LKWQ1J=C\)K
M+P3J=_<>+K;W7Q3\$/B/XK^&W@OX<Z7!\$/A5I7PNTKX!^./A7IO@JT\>Z[H
M/@WXW? GXBVWBC1_#DEGJ%OX8_M;]G^;PEH6A>$H4M[31_B0LFJ^)M1F426F
MB&55IX13H>SQU7V4L33]K-8NLYQH7M7C.D^:5-J37L52>(4*<*LWB,4ZE%1;
M275/[^WIWW_3IZG\+_&/@3XHVOBN.U\ W'@[Q1\/_%DO@?X@^ O&WA?PE9^*
M_!OB9=#T3Q396NH-X>O_ !-X:U;2]>\*^)?#_BCPQXD\,^(M;T#Q!H>K6]S9
M7_VF'4+*R]/_ .$;\.?]"[X?_P#!%I/_ ,AUY'\&/ACXE\&ZQ\7OB#X^OO"U
MU\1/C=XU\.>*?$MAX%&NOX+\+Z/X%^'WAWX9^!?"7A^_\3067B#7CIF@>'YM
M4USQ-J^EZ+<:UX@U_41:Z)I>DV&F6]>[5Y>)Q%2-:2H8FNZ?+3>E>K**J.E!
MUH0E)J4J<*SJ0I2=W*G&,G*3;DY,7_A&_#G_ $+OA_\ \$6D_P#R'37\->&R
MC@^'?#Y!1\C^PM)Y^4_].=;E(WW7_P!Q_P#T USO%8E)_P"T5]G_ ,O:G_R0
MX[KU7YGZ":$B1Z)HZ1HL:)I6GJB(JHB*MI"JJB* JJJ@*JJ %     %:M9FB
M_P#(&TG_ +!EA_Z2Q5IU_8>&UPV';W]A2_\ 3<1!1116X!1110 4444 %%%%
M !1110!_/]_P5\^+7PN^!G[<O_!$WXJ_&?XB>"_A3\-/!_[4?[2][XI\>_$+
MQ)I?A/PCX>M;W]DSQGHUE/K&O:S<6NG:?%>:QJFFZ5;27,\<<NH:A9VP827$
M8/VNG_!8_P#X)0!$!_X*0?L2Y"J/^3E/A5V '?Q*#^8!]J^]_&?PY\ ?$:SM
M-/\ B!X(\(>.+"PN&N[&R\8>&-"\46EG=/'Y+W-K;:[I^H06UP\7[MIH(XY6
MC^0N5XKSK_AEO]FK_HWSX'_^&C^'?_S-4 ?C]K?_  55_P""9$^M:Q-#_P %
M"/V-I(IM6U*6*1/V@OA\R21R7L[1R(PU<AD="K(P.&4@C@YK+_X>H?\ !,S_
M *2"_L<?^) ?#_\ ^6U?LK_PRW^S5_T;Y\#_ /PT?P[_ /F:H_X9;_9J_P"C
M?/@?_P"&C^'?_P S5?E-7PHRRK5J57FN/3J5)U&E2P]DYR<FE>-[*[6NOX6#
M\:O^'J'_  3,_P"D@O[''_B0'P__ /EM1_P]0_X)F?\ 207]CC_Q(#X?_P#R
MVK]E?^&6_P!FK_HWSX'_ /AH_AW_ /,U1_PRW^S5_P!&^? __P -'\.__F:K
M/_B$F6?]#;,/_!6&_P#D/ZN_*P?C5_P]0_X)F?\ 207]CC_Q(#X?_P#RVH/_
M  51_P""9@&?^'@O[''X?M ?#\G\AJQ-?LK_ ,,M_LU?]&^? _\ \-'\._\
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MJ5.@Z<?88>CAURN<7)\T:*D[O>32T2L'XU?\/4/^"9G_ $D%_8X_\2 ^'_\
M\MJ/^'J'_!,S_I(+^QQ_XD!\/_\ Y;5^RO\ PRW^S5_T;Y\#_P#PT?P[_P#F
M:H_X9;_9J_Z-\^!__AH_AW_\S5>1_P 0DRS_ *&V8?\ @K#?_(?U=^5@_&K_
M (>H?\$S/^D@O[''_B0'P_\ _EM1_P /4/\ @F9_TD%_8X_\2 ^'_P#\MJ_9
M7_AEO]FK_HWSX'_^&C^'?_S-4C?LM_LU;6Q^SY\#\X./^+1?#OKCC_F6J/\
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MBB@ HHHH **** "BBB@ HHHH ****+KO_7]-?> 4444 %%%% !1110 4444
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MWQ8\"^$_B9IDWPZ7PK-H'C_18/%^@/IFO375]/W_ ,.OV8/@7\*-;B\2^!/
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MXHU;5?BW<WO[2,FJPZS%\2/"V@>"O$D&C^%/ "6.LZ[XSUWP=)XVU3P[X/\
M VK>(=&\->.)?$=GI>B?H'^SU\9K#X]?"S1?B-90^'K22^U#Q'HVI6/A;QMI
M/Q!T6RU?POXAU+P]J$%IXDTJUTR296FTX7)T_7=!\+^+-'%PNE^+/"OAO7[6
M_P!(M>%3]BK]FF#3[+2K'X</I.GZ;\,O!GPAL;70_&OQ$T)+?P/\-_$:^+?A
MS;*=&\76+MXB^'GB+S=3\ ^/'9O'W@J:\U./PUXGTRVU74H+KV3X8_"KP%\'
M?#)\)?#S0O[$TB;6-;\1ZC)<ZIK7B'7->\2>)-1FU7Q!XF\4>*?$^I:UXH\5
M^)M<U"9[K5_$7B76=5UG49=AN[Z58HEC /0Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BC./_U$_P J3(]_R/\ A0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?$/B"/P+X!T[4;VXO['P)X+30/"-I>NMU!HJ310M$ >\4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>restructuring.jpg
<TEXT>
begin 644 restructuring.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KY(_;+_:9N/V6/AEX;\<VNF_#R\N/%/Q7^''PMAU+XM?$M_A%\-/#
M#_$#6)M,_P"$G\:>/H_"OC*31-&TH0'.S0;IKV\N+2R$EMYQF7ZWKQ+XV_!'
M1_C;;_#2UUK5KO3+?X;_ !B^'WQ@MX;:QT^_AUJ^^']Y?7EIH6HQ:C')''IN
MHO>E;JX@7[7!Y4;VY5^0 >-_#[]M;X3ZI+X"\(^/O'7PV'Q(\9R^%K)[OX*:
MQX\^,?P(L]7^)%[J'_"J-!7]H"/X;^&/!%GKWQ*TFUM;GPAH?BEO#.J^(M1O
M+;3O#]GJRZGX=NM<7QE^W5\%]"_9)\?_ +9G@^U^(/Q3^$?@?PQ=^*+1_!7P
MZ\;?VYXUL+:#3I%NO!FDZUX?TV^US0S+J<<-WXLL[:?PMIAL=<DOM6BCT#6&
MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
M5^&^O67BB?2F\4>%-%W?"CX73>+/"^BR_8O$4G@+2!:7>A6NJ^+;?Q)V<G[*
MWA:]_8[C_8YU3Q+X@N_"0^!%M\"IO%\$.EV?B9],M/",7A2'Q)%;"VGT2+6(
MA!#JB6CV4^DFZC%O+:S63/"P!Q/@G]N[X0^(_BQXV^$OB9==\ :WHGQ*\&?#
MKPG-XG\*^/=/M]<O_''[/'PV_:!T.S\:7NH^#=.T/X1>,M2TSQKX@T/2?AYX
M^UK3?%&J3^!]4F@M5OKF/2(?9?@[^TI\'OCS-?6_PS\2:CJLUGH/A[Q?;1ZU
MX.\;>"F\0>!_%LFI0^%?B#X.7QMX<\/'QK\//$TFD:G'X>\>>%!J_A367LY/
ML6JR*\#2^#W7[$5EXFL=;/Q"^)FL^*=:\9?'_P"%G[0?CN^L?#&C^&M-\0^(
M/AW\#O ?P.U3P_::-9WEZVB>'_&.C^!TUB\-MJ=SJNCZAJUQ!I=_Y%I9.C_V
M-_V#OAO^QP-9'@UO"E])<^%O"W@#1]1T?X-?"7X:^(!X+\&M=-H__"9^)/ /
MAK2]=^('B^_,]O)XC\1:S?VFDZC=:;::AIOA'0M2N-8O-5 /&]4_;N^-_P /
MO%'QV'Q=^"OP7T'X=? /XQ?L[?"+Q1XI\'_'7XA>*?$%_<?M'^*/@UIOAGQ'
MI_A;4?V>/#<#6/AWP_\ %^WU'6]+37;C6+_7-$D\/:!:ZB-4M-17Z9M/VYOV
M8[IO#L3?$&^T^\\16_Q3O!INM> ?B-H6J>&;/X':SHNA?&6^^(VG:SX3L+SX
M7:?\+K_Q%H+>-M1^(L/AC3]$L-:TC59[IM,U33[NZJ>)_P!D/P]XGUOXRZU+
MXU\06DOQC^.?[+OQRU"&#3M*>/1-4_9@U/X/:IH>A:;)*F^YTWQ5)\'].CUF
M[NBU]8+K5^VF,C6]GCDKC]@GX<ZWJOQGF\5^*/$OB'P[\=/"W[5W@KQEX=,.
MF::@\-?M9WGPGE\9V6G:K;127L$NAV/PKMM/T*Y=)?-36KNXOXIGLK%0 =S9
M_MP_LXW_ (>;7[;Q1XP,\FN^'O#FF>#)O@[\9;7XJ>(]4\8:#KOBKPA_PB7P
MAN_ %O\ $[Q9IOBGPMX7\3^)]$USP]X3U#0[KP]X7\5:P^HPV7A;Q%+I:?'3
M]J6+P-^REKO[3GP.\)6O[0832_"6H^!/!6G>)9O!<OCZX\5>-?#W@^WT*UU>
M^\/:S>:'X@6YUJ>U32-4\.C4(O$5B?#6K6VE7K74EC\@M_P2+^"\W@:TT34)
M_AK>>,/#_P 0/#GC[PUKD?[+G[/FE>");CPMX'\=_#FQM/B#\+-$\*:=H7Q(
M;4O#'Q,\:W6JZGKNKVEU8>*]0M]?\#+X(AM[C2+_ .X]!_9K\*>%_@5X ^ _
MAV_30]"\ :_\,/$MAJ&@^$_!7A:*YU7X;_%;PW\76DC\*>#M!\.>"M&A\1^)
M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT+E]_P"!^B__ "PK>HH P?[5U3_H7+[_ ,#]%_\ EA1_:NJ?]"Y??^!^B_\
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M>;[.K9_8[^( ;,OE3;-JDM_JFW$!!MW;A^TJ7?B'8F-%L<;5_P"8X3V'<:.
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MT ;U%8/VOQ#_ - 6Q_\ !XW_ ,IZ/M?B'_H"V/\ X/&_^4] &]16#]K\0_\
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M6>A8VKTU#4L=!TSI.<>F>?6OQ@_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\
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M.E:;!:6MM':6X!]:45@^5XE_Y_-#_P#!?J/_ ,MJ/*\2_P#/YH?_ (+]1_\
MEM0!O45@^5XE_P"?S0__  7ZC_\ +:CRO$O_ #^:'_X+]1_^6U &]16#Y7B7
M_G\T/_P7ZC_\MJ/*\2_\_FA_^"_4?_EM0!O45@^5XE_Y_-#_ /!?J/\ \MJ/
M*\2_\_FA_P#@OU'_ .6U &]16#Y7B7_G\T/_ ,%^H_\ RVH\KQ+_ ,_FA_\
M@OU'_P"6U &]16#Y7B7_ )_-#_\ !?J/_P MJ/*\2_\ /YH?_@OU'_Y;4 ;U
M%8/E>)?^?S0__!?J/_RVH\KQ+_S^:'_X+]1_^6U &]16#Y7B7_G\T/\ \%^H
M_P#RVH\KQ+_S^:'_ ."_4?\ Y;4 ;U%8/E>)?^?S0_\ P7ZC_P#+:CRO$O\
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M?ASPEH\6G^'M%U34 E_JXU'59H(M,T+3=4OY_)B /HG[)XA_Z#5C_P""-O\
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MS+>_]):_^"U'_B;&@?\ SEZ /J7Q Z?V_KOS+_R&=4_B'_/]<>]9&]/[R_\
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MS/J?C#PYH%P+VUM_A+82RJ+/5[EH0MW#LN%B<[PNQC_B$N;?]#3+O_ <5_\
M*OZMZ7#]/MZ?WE_[Z'^-&]/[R_\ ?0_QKY37_@B#I3 G_AZA_P %F!AW7_D]
M/03PKLHZ_!G/0=^?4D\T[_AQ_I7_ $E1_P""S'_B:>@__.:H_P"(2YM_T-,M
M_P# <5_\J_JS\KA]5;T_O+_WT/\ &C>G]Y?^^A_C7RK_ ,./]*_Z2H_\%F/_
M !-/0?\ YS5'_#C_ $K_ *2H_P#!9C_Q-/0?_G-4?\0ES;_H:9;_ . XK_Y5
M_5GY7#ZJWI_>7_OH?XUZW\%73_A-D^9?^01J?\0_OV?O7Y]?\./]*_Z2H_\
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M;1EU'5S)+X,T36_%NG@'W'12 A@&&<$ C/!P1GD=C2T %%%% !1110 4444
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M_ASX9T.3Q+;Z_K7CG7/%7BN3P58GP_<^')8=;L]-\1:D+%9I+G[7+9V%W<*
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MT&< =AQ3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>sga.jpg
<TEXT>
begin 644 sga.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
M]FGQI^TMXK^/NH>)#I>A_#_PWI/AG0O'G@G3+KPX-$O;G5)/%G@*Y\1>+-5N
MVU739O#%CIOAZ&/3=<F\6VPL?2;C]O/]FBT%A;77BCQQ!XCU/Q)XG\'6GP_?
MX(_&_P#X6H?%/A'P'I7Q2UK0KGX4CX>'XBV&H)\-=:T[Q[I\=[X:@CUGPE<#
M6](EO;.*9XOG]/\ @EA\)%\/W_A$?$;XE)X9O-8_::O+:T27P^;[PSI'Q^A\
M):?X/\+>#]1GTNX31=!_9TT;P'X-T/X.6-Q9:I!::=X<T^T\0P:O$;R*Z];\
M#?L6'1/BSH7QX\;?%_Q/X_\ BO#K_B_7?%>MS>%_"_A?1_$0UWX4Z-\'_#NC
MV'AW1D>+PUHWA'P[H\VKVT5O>ZE?:QXHU_Q!J.HWXL)],TG2 #RK7O\ @J5\
M'[;Q[=>$?"_@[Q]XGT&P^(O[,?@__A92^%_%UOX!\6>'_P!J+PE=>+?!'BGX
M5:S8>%-7_P"%F7DEH=(M-+\)^'XY-:\47.KJ^BAX+&ZD7Z*T[]N+]FS5[CP5
M9Z/XS\0:S?\ CFS?4+73M&^%WQ7U?4?"EA#X^UGX4W=[\4]/TWP1=7GP>M=/
M^)_AWQ#\/M2F^*,/A)--\7>'O$6CWYMYO#VMM8>!^"O^";GA_P !ZU\&[G1O
MB[XKD\/?"O1_V4_M_A^]\,>&)9O%WC#]DOP5>_#CP9XJFUN/RKW0X/$G@R^E
ML/%'ARRAN]._M*WM-7T6?3)?[0@U&3QO_P $XM$\70^%K.+XO>(M$M]"^(WQ
M>^(#:WI_@'X=?\+)\/7?Q;_:$\8_M":C<_"/XMQZ1;?$?X2>(K+5_%S>$I]9
MT;7]7TC6O#&C:7+J'A)/$ N=8G /KSXP_M&_"/X$OH\'Q'\0:K8WVN:9XCU^
MQTKPYX+\<>/M:B\+>#%TR3QGXTU31? /ASQ-JFB>!?!T>M:.?%7C76;2P\,:
M#)JVE6NH:I%>:II]M<\7:_MH_LU7GC74O </Q*A75=&\1ZQX/U76;GPUXQL_
M %AXKT7X56?QRNO#D_Q0NO#\7PW_ +:G^#EXOQ-TS3T\4M<:KX+MK_7=.6YM
M-/NFC\X_:W_80^&O[5WB?X?^.?$4GAZS\7^ ?#GC?P-97GB[X5?#?XS:(_@G
MXBZAX5U;Q+%8^%/B?HNM:+H_B^QU3P;H5]X4\86L$W]DM_:5AK6B>)]'U*33
M$S-6_P""?/PPUSP[JG@K4?$6N-X(UKXZ:[\8M0\,V&FZ+I%D=&\0_LJ:E^R9
M>?#FR;2+>R72?#T7@C4IM7T_4-+@L[W3M7BM[;3X+72K>"UB )/#O_!13X%:
M_P"+O&^EH?%MMX5\/>#/@!XA\(:M)\.?BTOCKXG>(/C_ *M\=(/#?A;P-\'+
MGX=VOQ&\2M)X=^"TOC/1-8\-:/KMEXA\+ZOJ.MA=-TCPKJ^H4OQE_P""B/P,
M^''P_3Q=X,O;_P"*.LWNA> _$VG^']%\/>/;2QT_1/'_ ,5X?A#H\_Q!\40^
M"-4TOX3:A=^+K3Q5H6EZ'\25\-:SJOB?P7XG\,)8V^I:)JXT_P H\:?\$Q=&
M^*-JVI?%SXRZI\7/'6C1_!6+P9K/Q'^$OPG\2>#M(7X%:=\??#?AD>)?AA)H
ML/A7QN?$GA/]HOQ]8^-I-1?3[J[UR6P\3>$KCP;/IVEV&G:MY_P31\)V_AAO
M!/@?XK>(OAYX/\4>#/AMX5^+7ASPC\./A3X?T;QY<_";XE>(?BMX0UK1='T'
MPMH6A_#>:Y\2^,/$^F^+K'PEI*VOB7PQ>6%JS:?XCL;CQ5J0!^G2MN!.,89U
M]?N.RY_';GVSCGK3J:JA1@?WF;GU9BQ_(G ]J=0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %,?[H_WX_;_ ):+_/H?4<4^B@#^
M6;QS\5_BEI7[)/QA_9D3XJ?$V+7)_#>L_MZ^'?B,/'7C&'Q39? BZ\<:CK.N
M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK:JB*JZQJ@555550+ZXP%50  !P   !@#@5DX'H/R%;'B#_D/Z[_ -AG5/\
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M8\7--J5WJWAKPWX]\.IK.I^(M8L=!G\.VVIV\5E^\XZ?B1V[$C''IT]1WYH
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MBBB@ I&^Z_\ N/\ ^@&EI#]UN,_(_'K\IXI2V?H_R''=>J_,_0;1?^0-I/\
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MUO[4'_K'/Q!K]O(_]7'_ +B_^@B@#X U]577=;555576-3554!555OIPJJH
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M\_5](?'[_4^%?^NVL?\ HO3J^;Z_F3Q$_P"2PS;TP'_JLP8!1117Q0!1110
M4444 %%%% !2'[K<X^1^?3Y3S2TC?=?_ ''_ /0#2EL_1_D..Z]5^9]U:1J>
MI+I.EJOAZ]=5TZR57%]HX#J+:(!@&OPP# ;@& 8 X8 Y Z"QN[JY\W[3IL^G
M[-FSSKBRG\W=NW;?L=Q<;=F!GS-F=PV[L-B/1?\ D#:3_P!@RP_])8JTZ_LK
M"_[MA_\ KQ1_]-Q$%%%%;@%%%% !1110 4444 %%%% 'X@?\%*"!_P %(_\
M@A220!_PU;^U!R>!_P F<_$&OVZC=/+C^9?N+_$/[H]Z^"OVX?\ @GG\-?VZ
MKOX':[XN^+_[1WP,\<?LZ^,/%/CCX5_$G]F7XDZ7\,/'^@:YXS\)2^!_$#)K
M^I>$?%NVWO?#5S>:8RVEM9S_ &>^O86N'@NI86^4?^',M[_TEK_X+4?^)L:!
M_P#.7H ^I?$#I_;^N_,O_(9U3^(?\_UQ[UD;T_O+_P!]#_&OEB3_ ((AZ;-)
M)-+_ ,%4_P#@LU)++(\LLC_MJ:"7DDD8O(['_A37+.[%F/<DFF?\./\ 2O\
MI*C_ ,%F/_$T]!_^<U7X77\*,UJUJU59IER52K4FDXXJZ4YN23M2:ND];7V=
MKZ7#ZJWI_>7_ +Z'^-&]/[R_]]#_ !KY5_X<?Z5_TE1_X+,?^)IZ#_\ .:H_
MX<?Z5_TE1_X+,?\ B:>@_P#SFJR_XA+FW_0TRW_P'%?_ "K^K/RN'U5O3^\O
M_?0_QHWI_>7_ +Z'^-?*O_#C_2O^DJ/_  68_P#$T]!_^<U7S7^U[_P2>O\
MX#?L[_$CXK>$/^"I?_!7ZX\1^$K+0;C3(O$7[9.CWNC,^I^,/#F@7 O;6W^$
MMA+*HL]7N6A"W<.RX6)SO"[&/^(2YM_T-,N_\!Q7_P J_JWI</T^WI_>7_OH
M?XT;T_O+_P!]#_&OE-?^"(.E,"?^'J'_  68&'=?^3T]!/"NRCK\&<]!WY]2
M3S3O^''^E?\ 25'_ (+,?^)IZ#_\YJC_ (A+FW_0TRW_ ,!Q7_RK^K/RN'U5
MO3^\O_?0_P :-Z?WE_[Z'^-?*O\ PX_TK_I*C_P68_\ $T]!_P#G-4?\./\
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M[_TEK_X+4?\ B;&@?_.7K]E$?H]\?G3R?"OS+_KM8_B'_//3O>OF_>G]Y?\
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M !1110 4444 %%%% !1110 4444 %<#\5OAMX9^,OPO^(_PA\:174_@[XJ>
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..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>spinraza.jpg
<TEXT>
begin 644 spinraza.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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M"VBL_#FD>%/#.BOJ-K%:S7U]JWB/7O$&HZE?M97&F:9I(!Y3KW_!47X26OQ
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M88(;=#';PQ01F2:8I#&D2&6XE>>>0JBJIDFGDDFE<C=)+(\CEG9F(!+1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!./_K
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M$^MZ#I'Q2U#4O&]G#;>$-& /WTHJO:+<):VZ7<B2W2PQ+<2H@C26=4432H@
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M_P#T%-;_ /":U7_XU7Y<44?\1_XY_P"@;A[I_P P&-\O^IGY/[V'_$2>(?\
MGUEG_A-7\O\ J+\G]_D?J/\ \-6?!_\ Z"FM_P#A-:K_ /&JZ_P1\=?A[\0=
M<'AWPW?:E/J;65U?B.ZT:_L8OL]H85F;S[B-8]P,\>U,[GR=N=IK\B:^E_V3
M?^2N1?\ 8K>(/_1FEU]%PEXU\89YQ-D>48RADD<+F.983"8B5#!8N%94J]6%
M.;I3GF%2,9V;<7*$TF]8M73]/)>/<\S#-LOP->GEZHXK%4:%5T\/6C44)R2D
MX2>)DE*U[-QDDWL['Z@T445_5Y^RA1110 4444 %%%% !1110 4444 %%%%
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M:1_SVN?_  6:K_\ (-;]% &!_P )-I'_ #VN?_!9JO\ \@T?\)-I'_/:Y_\
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M_P""D_\ RDD_X(4_]G6_M0?^L<_$&OVZ0CRX^1]V/N/]F@#\4_&W_(Z>,/\
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M>,M'NV3PW#<1M=:5XEU2PN&CN'UI6GC::W<I,RJTRD2,JLQ XO\ X;F^!_\
MSR\>?^$K;_\ R\K\U/CS_P ES^-?_98?BG_ZGWB&O**_AK'<)Y3/&XN<EBKR
MQ5>3_?K=U9-_\N_7[_(_GRODF"E7K2?MKNK4;_>+=S;_ )3]@O\ AN;X'_\
M/+QY_P"$K;__ "\H_P"&YO@?_P \O'G_ (2MO_\ +ROQ]HKE_P!4<H[8K_P>
MO+_IWY/[_(R_L/!?]/O_  8O_D#]@O\ AN;X'_\ /+QY_P"$K;__ "\H_P"&
MYO@?_P \O'G_ (2MO_\ +ROQ]HH_U1RCMBO_  >O+_IWY/[_ "#^P\%_T^_\
M&+_Y _8+_AN;X'_\\O'G_A*V_P#\O*/^&YO@?_SR\>?^$K;_ /R\K\?:*/\
M5'*.V*_\'KR_Z=^3^_R#^P\%_P!/O_!B_P#D#]@O^&YO@?\ \\O'G_A*V_\
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MDDMDI26TFF@             P  .  . !P!P*6BBL" K]4O^"./_ ">=:_\
M9(_B/_Z5>$J_*VOU2_X(X_\ )YUK_P!DC^(__I5X2KZ'A/\ Y*3)?^QCA?\
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M(NXG:JKA0^OYB/\ A^#^T+_T23X-?]__ !S_ /+JC_A^#^T+_P!$D^#7_?\
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M66GVP"Q6L"1*I(!]?Y'!R,'@'(Y/H/6C(SC(SC.,\X]<=<5^;OQ,7]I/X/\
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M]<=\>M-+H &+*%)P"6 !// ).,\'\C7BWCGP=\6M0\7R^)_ 7Q3T_P ,:?\
M\*VUKPA8^$O$?@]_%7A:#QQK'BWPQJ.F?$G4+.PU[PQJVJW/AOP]IVNZ):^'
M(M?TFRU)M:66\OH4@)/YY:?\0/%VN_\ !,KP;\8?BC\8OC9=^//!NBZUK%UX
MH^'/BG1/ACX\^,'CBT\;>*OAQX(\):UJ&A>$9M"T^W\?^*+WPUI,MGHGA[3-
M/L-0O+&[L[>.WLH[9P#]=P0P!4@@]"""#]".*6O)_@7X'\6?#;X0_#[P-X[^
M(/B+XJ>-?#?AJPL/%GQ!\4W=O?:SXI\1D/<:UJ,US;:7HZ/9#49[BUT=)+"*
MZBT6VTZ&]DN;U+BZG]8H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *",\?Y_S[T44 ?(GAG]A_\ 9Y\(>(?C-?\ A_P/HFF^#?CYH&D:
M)\3/A)9^%O EE\.-9GTB(6RZO!;:?X1L_%FFR7UH&CO_  W9^+H_ 4FH7.J>
M)[?PC:^+]>U_7]4]/^"O[.'P(_9QTO6=$^!'PG\#?";1_$%]!J6LZ5X$T&T\
M/:=J%_;1SQPW=Q9V2I;F=5N;EBZQH7DN)Y9-TLTCM[910!\[?&;]DG]FC]HC
M6=#\0_''X(?#CXJ:WX9LWL/#VJ>-O#=GKE[HEJ\]Q<E-*GN@6L)!->7;I<6W
MEW$?VJY6.54GE5]Y?V;O@"OQ#T[XM?\ "F?AD?B=I,=@FF^/7\%Z!)XLLWTO
M2X-"TR[@UR2Q:_74M/T*WAT.QU8S'5+31HTTJWO8]/'V>O:Z* #ITHHHH **
M** "BBB@ HHHH **** /FOX^_LI?"']HFX\(:YXRT.TT_P ??#[Q#H/B3P+\
M3=)\/>!]2\;^%[OP_J4FJ0:?:7'CCPEXRT+5/#MY<S3RWOAKQ%H.LZ&=0:T\
M0V5C8^*M'T+7M+=J/['O[+^K?&&#]H'4_@5\-;[XV6NJV.MVWQ2N?#-G)XV@
MU/34L([&ZAUX_P"F1FW72M,98D<0-+I]G-)$\UM$Z_25% '*>./ _A'XD^$]
M=\"^//#^F>*O"'B>PDTO7_#VLVXNM+U;3Y7CDDM+RW)42PL\4;E=P^9%(((K
MR/X=?LE?LS_"3PCJ_@'X:_ OX8^"O!&N^(?#GBS5_"7A_P ):78^'+[Q+X1U
M?3]?\,:Y-HZ1-8C4] UW2M-UK2KN.%);+5K&VU&$K>1+,/H>B@ _S^?6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHI"0 22  "22<  <DDG@ #J: %
MHKAO^%G?#C_H?O!7'!_XJSP_U'4?\A+M6EI7C;P=KMV-/T7Q7X:U>^:.29;/
M2]>TG4+MH8=OFRBVL[R><QQ;U\QQ&43<NXC(SDJ]&348U:;D]$E.+;>FB5[W
MU6A"J0;LIP;>B2DKM]MSIZ***U+"BC(& 2,GH/7OQZ\<T9!Z'/4?B#@C\#P?
M>@ HH!!Z$'DCCU'4?4=Z* "BDR,9R,=<YXQZYH!! (((/0@Y!^A% "T444 %
M%%% !115*\U+3M/,8OK^RLC*&,0N[JWMC($V[R@GDCWA=R[MN=NY<XR,S.<*
M<7.I.,(*R<IR48J[25VVDKMI+7=BE*,4Y2DHQ6[DTDKNRNW9*[T]2[16+_PD
M?A__ *#FC_\ @TL/_DBM:&:&XBCGMY8YX94#Q30R)+%(C#*O'(A9'4CD,K%2
M.A-13KT*K:I5J51I7:A.,VEIJU%NRU6_<F-2G-M0G";6K491DTN[LV24445J
M6%%-#HQ(5E)'4!@2.W(!R.?6G4 %%%% !12 @@$$$'H0<@_0BEH **,@=3CM
M^/I1D9QGGKCOCUH **** "BBB@ HHHH **** "BBB@ JEJ7_ !X7O_7I=?\
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MQ+K%G#<V2Z39[)+_ *_]D[]I'XV?&[]H7P_=>/G\'Z!X'^(W[#?PJ_:+\&>
MO WBJ^\5Z?I%I\4OBCXK;0KGQ'>ZIX>T.XF\5VGA"WTO1-3U?2\^'-:O+34?
M[(L;&'3@]W^B<GPW^'TTUS<2^"?"DL][XNT3Q_>2R:!IC277CCPUI6C:'X>\
M7SN;;,OB70]&\.Z!I6DZT^=0T_3M%TJRM9XK>PM8XL#P#\#/@Q\*]2U?6/AG
M\*/AS\/]5\0/=OKFI>#/!GA[PS?:NU]J4FL78U&ZT;3[.:[2?59IM2DBF9XO
MMTTMTJ+-+(S 'JE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "B@G )].> 2?R')^@YI,].O/L?3//''XXYXZT ?G!K'[>5MH?[2OQM^$'B'
M6OV5O ?@7X :QI\/C>]^(O[2U[X=^.^J>$D^ ?@?X\^)OB!X2^!=M\+-335?
M"^@:3XSFTL7<OCJW2\_X17Q'J+R6@M5LS[?I_P"VY^SIJ-WH&CQ^*?%EMXI\
M3?$";X6Z1X#U/X1_%_2/B._CR'P79?$A= U'X=:KX%L_&NAM<?#J_@\?VFI:
MWH6GZ-<>"TO/$J:C_96G:C<VD?B[]CWX>>/-%_:OT#Q5J6L7-G^U=XBL?$6O
M7^G6^CZ=XA\"7>F?!GX6_"'3)/!NM/87K_:M+/PKTCQGIL^LV^H6\7B"[N;>
MYL+S2$%G-RO@+]C9_#_Q4T'XY^.OBWXC^(OQ8M_%NJ^*/$^OW'A;PQX8TGQ!
M$_PDN?@YX8\/V/AW0XWM_#>C>&-"O]6U[-M>:AJ.L>*O$&NWE]?1Z3-I>BZ.
M <E^TG_P4*\&?L[^,?C%X O?ASX_US7O@]\ _"O[06K>(;S0M>\/_"N[\+^)
M/B%?^!)M,?XF'P_JFA6&L:4FF7FLO#)YPU$0S:-IJSZO8ZG;V7K-]^V]^SGI
M^GRW=QXI\6MJ=OXT\3> KSP3:?"#XQ:A\4=/U_P;X=T+QEXJ?4OA/I_@*Z^)
M.G:%H7@KQ5X4\::AXHO?"\'AR/PIXL\)ZVFJ26GBC0#J/)_M'?L6Z;\?_%OB
M#Q,/B1KW@F#QS\(=/^#OC_2M/\/Z!K<6MZ!X6\?S?$SP+J6E7^J>5>>'-6\/
M>*-2UT:@8#?6'B/2=4CLKVSMKC2[#4(_,OCM_P $U?AK\<?'WB;XI:OKVF3^
M--;^)/B#QQIP\=_"CX<?%SPGH6D^,O@U\ _@[XK\-VW@OX@:9?Z1<74T'[._
M@CQAX<\6,8-;\/>)#?V;C6/"M[?^'[\ ]L_:J_:.\7_!W]F'Q#^TQ\$/"OPW
M^,^@^%O!DWQ0O+3Q'\3-<\":1XB^'$7AJX\0P:KX,\2^&/AS\38]6U35DDTD
MZ/;WNFZ;HUUI]]-?R:Y";>&VN^(\%_MN6.F_%WQ;\!?V@_#VA?#?XD>$]6^!
M?AJ34/ &I?$/XH_#>]\2?M -KEMX!T[4/&\WPJ\'VG@B'7]=TZP\&^%KWQ];
M^&X_%_C743X<T))[R.V%[[3\2?V;/"GCW]EKQ'^RG8:E=>$/!>M?!X?!G3M3
MT'1?#=G=>'_#D/ARW\,V,^EZ!IFEZ/X3LY+&PM83;:5INBZ7H-KM%M8:98V$
M<%I%R?BW]DK0/%GC?XH^-9_&>OV5S\4/B?\ LB?$Z^L+:PTI[72KW]DCXA^%
MOB#H&DV<LJ&6XLO&=WX7M]-U^6Z)NK"TNYIM)*7$<1 !DV__  4#_96O?#&E
M>,M.\>^(-5\-:S:>+]8L=4TCX4?%W54_X1/X>2:1;?$'XAWEOIO@6ZO--^%G
M@74M<T_1/%WQ3U"WMOA]H/B%KGP]>^(UUG3]0LK7U#2?VH?@CKGQ/D^$6D^,
M)[_Q<NN77A2&ZM_"WC!_ U_XTT_PI_PG.I^ M*^)_P#8 ^&NK?$#2_!N[Q/J
M/@;3?%EUXIL]$M[Z_FTM8],U,67QAX\_X)6?![QUX9^!VD:AK&DZMK7P:^%V
MN_!5?$'Q ^$'PJ^+-OK?P]\2ZY8>(]0N+#PO\1-"UKPUX5\<Z7JNGI-X<\7:
M997ME:P:CJUCXA\->*;&XL[;3_0/AS_P3E^#'PN_:.O/C]X8L?",+2>,O$GQ
M*TS2;GX-_">\\9Z-XY\7>&KGPOKG]E_&2Y\-3?$2P\%"WU#5-5TCPCI5UIEQ
MHVIZI>:9:>(SX#^S^"K< [G7OVS-$\%_M0>/_@)X\\+1^%_!?A+X!I\:='^+
M\_B-;FRU_4_#O]KZQ\4/ 5QX7&CPRZ5J/@[P'_PC7CG2=0BUK4V\4Z7=^*XU
MTW25\'37.I^<_!K_ (*1?"KQ5\'_  !X_P#CIID_P'\;>+;CXD2^)OAU"GB_
MXI0?"GP_X!^./C+X')XK^*7C;PIX%@T7X>^%=0\1^%1:7?BKQY;^%?"^FZZ^
MMZ-'K-_;>%]8UB'O_CE^P]X(^//BX>+?$GC/QAH\J_$KX(_$%K'P]_95M!=Z
M?\)]/\9>&/%'P_U.:XM;B>_\$?&?P!X]\5?#[XDZ8WE3W?AG5IX=.GM;M8+B
M'S/5?^"<^E75IXWTG2/CA\0?#V@?&G3?BQX,_:#TJQ\/^"KH_%'X8_%'X^?'
M'X]OX0LKW4-*N;KP'J6@7W[0WQ1\"6?B[PXTVHWW@SQ-=?:;*/Q18Z!XAT(
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M\0>)/B9\*/$G@3XL^*?C9^S%\/-;_8<UB]\5_%CPK\2_A-\2)+WQX?#'B_\
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MIQ5*.+E6G*LX-TZ4:;K0C*E*O3HQKT74_93_ (;1_9?SG_A;NA_3^S_$V/\
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M4=?SH3Q2V\\UO*0);>::WF".7036\KPRA'XW()(VV-@;EP<#-19/J?S->VO
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MMU:W5O+#-!-(A4,5=?PH_P"%K_%'_HH_CG_PJ=:_^3*/^%K_ !1_Z*/XY_\
M"IUK_P"3*[)\'UJD)4ZF)PTX3BX3A.E*4)PDN6491E=2C)-IQ:::T:LW;DAQ
MA1A*,X8;$0G"49PG"K",H3BU*,HR5G&49*\9)III--/;^C6[^/\ XRNM=U_7
M&T3P3_Q/=-N]%CTUO#7EV6@Z-J6I76K:SI_AV;3;W2]2TT^(;^\GF\37Z7K:
MEXA1A:ZG=366ZU?E-(^)VMZ WF:/H'@:RFM=4N=:\/W \'V-Q=>#]2NH+:"6
MX\*7=W-<7-DJ&TMKJSMM3EUFTTW484U+38+2]+S-_/K_ ,+7^*/_ $4?QS_X
M5.M?_)E'_"U_BC_T4?QS_P"%3K7_ ,F5YT/#G"4X2IPC@8TYQIPG35"?).-.
M"IQ4HMVDW!SA.4DY5(3J1J.2JS3[I^(6)J3C4F\;*I&4YQFZT.>,IR4Y.,K<
MT4IJ,X13482A3E!1=.#A_09=_%7Q5>Z??6MQ;>'6U/5O#UIX2UKQ:OAZU'C/
M6_#%E%IUM#H>K>(#(7NK22RTC2].O;A;2'4]1TZPM[._U"YA#AY]/^+GBO29
M+F33;#PG9D:_JGBC0%B\*V'E^!-=UFUAL]1U#P!&Q9/#336]K9>7;JM[:6US
M86&HVUO#J=G!>K_/9_PM?XH_]%'\<_\ A4ZU_P#)E'_"U_BC_P!%'\<_^%3K
M7_R96C\/L.X.FU@.1MMP^KMQLXPIN*C:RA[."I<B7*J-Z*2IRE A<?5E)37U
MY35K36(CS74G-2YMW+VDI5>=OF=6U5OVB4H_N$%(&,-QZ[F/U+-EF)[LQ+$Y
M))))HP?0_D:_#W_A:_Q1_P"BC^.?_"IUK_Y,H_X6O\4?^BC^.?\ PJ=:_P#D
MRN__ %2Q/_070_\  *G]=_Z>G%_K;AO^@.M_X'3\O^#^'?3]PL'T/Y&ONG_@
MG:"/VCH,@C_B@/&'4?\ 3?0:_E4_X6O\4?\ HH_CG_PJ=:_^3*_7?_@B)X\\
M;^(?VY[+3M>\8>)];T\_!GXGSFQU77-2U"T,\-UX.\F8V]U<2Q&6+>_ER;=R
M;VVD;CGXKQ&X9KX7@/BS$2Q-&<:.19A4<5":;4:$FTF]+^I]CX?<34,5QOPM
MAXX6K"5;.\OIJ3G!J+G7A%-I:M)O[EYZ?V14445_G,?WZ?D?_P %5-3TS3;'
MX''4=2TW3A-?_$(0G4-0L[ 3&.S\)F01&[GA$I0.A<1[B@9=V-RY_'O_ (2?
MPQ_T,WAO_P *#1O_ ).KZ6_X.,$1](_9$WHCXUCXVXWHKXSIGPTSC<#C/?'6
MOY@?)A_YXP_]^H__ (FO[_\  _AR&/\ #'AS%O%RI>UEG/[M4%/E]GGV9T_B
M=6-[J%_A5F[:I7?\+^,O$4\!XC\086.%A55-91[[JN+ESY'EE1^ZJ;2MS\N[
MO:^FQ^]'_"3^&/\ H9O#?_A0:-_\G4?\)1X9'_,S>&__  H-&_\ DZOP7\F'
M_GC#_P!^H_\ XFCR8?\ GC#_ -^H_P#XFOUC_5"G_P!!\_\ PFCY?]/_ %_#
MS/R__6ZK_P! -/\ \'R_^5>O]+7^D&U_:(M[7P5!X)2\^%S6ZR_9[[62WAV+
M7-8\-FWTJWE\*ZK>V>H6KW.G7L6CV=GJ>H(8M=U'2(H](GU,6\2R&QK/[2%K
MJWB33_%D3?"G2-9L()]-/]F:@SZ3=>&[K2[O1;GP;-X?U7QAJFB6W@^72KZZ
MLO["TBQTN"*.9W@DBG9IC_-MY,/_ #QA_P"_4?\ \31Y,/\ SQA_[]1__$UY
MJ\.,H4Y5%.*E4^L>TMAFHU%BU".)C4@L3R3A5C"*E3G%PM""45RJWH?\1#S5
MPA!TVXTUAU3O7O*F\(W+#RIR=%RA.DY3<9QDIWE*\G>5_P"BZ7X[6YOX[NSU
MCX?:5:V?@CQ!\/M&T;3-1T^'2- \.^)K74K;6!I,5QKUW?\ ]JWCZQJM[/J^
MHZCJ%[/?7\TUR\T:PPQ\UIWQ$\'65M96ETGPTUB*TU*_U":34]6B%UJ<5]IT
M.GKI&I7FE^)M,N9-&L7A.I:?:VLEG/!J<UQ/+=W$$OV5?Y]O)A_YXP_]^H__
M (FCR8?^>,/_ 'ZC_P#B:Z(<!X&G%QIXJ5.\5&4J=!PG)+VFKJ1Q*J2ES5Z\
M^=R<W4J2JN3J2<C"7'.-G)2J8:%2TN9*=;G@F_9*RIRHN"CRT*4%!1Y%3IPI
MJ/LX\K_H:\=_%O0?'_B*\\3W]W\/-&U/4I)+C4_^$>UF*VMM0O9"NZ]G@U/Q
M-K!CN/+2.$+9R6MJ(XU/V;S"\C<;_P )/X8_Z&;PW_X4&C?_ "=7X+^3#_SQ
MA_[]1_\ Q-'DP_\ /&'_ +]1_P#Q-:T."L/AJ-+#T<;.%&C"-.G#V',H4X)1
MC!.6(;Y8Q7+%7M&*C%62LLZW&F)Q%6I7K8.G.K5FZE2?MN5SG)WE)J-%1YI.
M\I.UW)N3N[M_O1_PD_AC_H9O#?\ X4&C?_)U17'BCPP+>X/_  DWAO MYR?^
M*AT7H(G)_P"7['3UK\'/)A_YXP_]^H__ (FJU[##]BOOW,/_ !Y7G_+*/_GV
ME_V:VCPA3NO]OGNO^8:/=?\ 3_U_#S,7Q=5L_P#8:>S_ .7\NW_7KU_I:_Z6
M/PX=)/A[X$>-E='\&^%W1T971T;0K JR.A975@059258$$$@@UVE>5? KCX)
M_"    ?"[X>X & /^*/T;@ < >U>JU_EIF*Y<PQL;WY<7B%?:]JLE<_TNP#Y
ML#@Y;<V$P[MZT8,****XCK"BBB@ HHHH *H:I+=0Z;J$UD0+R*QNY+4M93:D
MHN8[>5X"VGV]U8SWP$H3-G#>6DMT/W$=S;O(LR7ZH:K:M?:9J%DAM%>[L;RU
M1K^R&I6*M<6TL*F\T\SVHOK4%P;FS-S;BZ@\RW,\7F>8H!^,MQX5U#X@_M >
M&_B5J_PE\:V]QJWCKX6>(O$EGK/[&/[3>B>%=;\7^$(O#FE6GC[Q9H]I^VI:
M?!ZY\2Z+<:5;W_A/QYXR^$?BS6_A_IVC^$C<W7B2Z\$:??S?M0!@8],C\,\=
MS^??KWK\3]'^#WAJW^/K:/\ ##]G+X):]HWPH^)?@'PIXM\9>#O^">'PMTG3
M/#_C33-&\#^)?%$NB?$3Q/\ M-^$_$-LVFOK4.N0>(O#/@'Q/:^$)+R+2=-G
M\7ZMX:O/M7[8#Z8Y/MW//4]>OOU('2@#\._^"ET33?\ !1[_ ((61+--;LW[
M5O[3^)K=HUF3'['?Q ;Y#+%-'\P&UMT;91F VDAA^TBZ/<[(S_;^N](^LVF$
MG)7@G^R1G_:X&1GIFOQA_P""D_\ RDD_X(4_]G6_M0?^L<_$&OVZ7_51_2+^
M:4UJUZH#_./_ &BE*?M"?'Q"[R%/CC\8%,DA4R2%?B/XG!>0JJ*7?&YRJ(I8
MG:JC 'CE>R_M&_\ )P_Q_P#^RY_&+_U9/B>O&J_UWRG_ )%66?\ 8OP7_J-2
M/\ILU_Y&>8?]AN*_]/3"BBM31-#UKQ+K&F^'O#FD:GK^OZS>0Z=H^B:-8W&I
M:MJM_<';!9:?86D<MS=7,Q!V111L<!G;;&CNO=*481E.<HPA"+E.<FHQC&*;
ME*4FTHQBDVVVDDFV['#&,IRC"$93G*2C&,4Y2E*3M&,8J[<FVDDDVV[+4RZ*
M]WU?]F3X[:!XZU[X;:W\/+[1_&?ARVMK_4M*UK7/"7AZ&73;VYN+*RU71=6\
M2>(-&T?Q+I5Y=VEW;6]_X>OM3A:XM;F%S'+!(BP6_P"S3\?KRZ\8V5G\)/&-
MW=^ -<U?PQXMMK6VT^>?3/$WA_3CJ^O^&[2*+46D\2>(-"TD?VIK6B^$EU_4
M]*T\B[O[6WA9';SEG63.*FLWRMPE2IUXR_M#"6="MR>QK)^VUI5?:4_95/@J
M>TI\C?/&_H/)\W4G!Y5F7/&K4H./U'%75:CS^UHM>R_BTO9U/:4_BA[.?,ER
M2MX?17IU[\%OBQIW@2U^)U]X \0VO@&]T[3M9MO$LL5E]G;0]8O1IVC^(9=.
M2];7K3PUJ^H-'9:3XGO-(M_#VIW4L$%CJ=P]S;B5/"'P8^+'C_P_JOBOP5\/
MO$OB;P]HL]]:W^J:5:V\D37FEZ7_ &YJMAI=M/=6]_XCU+2=$*ZQJ^F>&;/6
M=1TK2GBU#4+6VM9HI7V>99<J52L\PP*HTJ[PU6L\7AU2I8E-)X>I4=3DA73E
M%.C)JHI22Y;M(R67Y@ZM.BL#C76JT5B*5+ZK7]K4P[3:KTZ?L^>=!I-JK%.F
MTFU*R9YE12 A@&4AE8!E92"K*P!5E(R"K @@@D$$$$@TM=IQA7[!_P#!#:![
MC]NZRB2YN;1C\%OBDPFM&A28;;OP;E0T\%Q'M.<G]V3N52" "#^/E?L7_P $
M+?\ D_2Q_P"R*?%3_P!*_!E? ^*>OAQQK_V3N9_^H\C[KPR_Y.#P?_V4&6?^
MI5,_LO\ [&N?^A@US_O[IG_RIH_L:Y_Z&#7/^_NF?_*FMZBO\M3_ $N/YE/^
M#B&REM-(_9)\S4+^^WZQ\:\"]>U81;=,^&V3']FM+7!?(W[R^=J[0N#N_F2K
M^GS_ (.+_P#D$?LB?]ACXV_^FSX:5_,'7^D?T?\ _DTW"_\ CSW_ -:+-C_/
M3QU_Y.CQ+Z9-_P"L]E(444 9.!U/ K]E/R(**]UD_9Q^*4'PCT[XUW-AX?L_
M!FJ7]K#!!>^+_#-IXHAT&_&G+8>.KSPG-J8\06_@:]N=3MH(=<^P.X@(UJ2R
M3PY-:ZQ/??\ 9H\>L/!TVG>)O@YKVG^.M5\::3H>L^'_ (N^%]4T2*7X=>%I
M/&7C>^UK4AY$>CZ)X9T!%N-5UNX1].@NY[;2_.;4IA:CR_[;RCWG_:6":A5Q
M-"I)8BFXTZ^"I2KXNC-J34*N'HQG5JTY-2A2A*<DHQ;7I+)LUO%?V=C$YTL-
M7@I8>HG.CC*L:.%K0BXWE2KUIQI4JD4X3J24$^=I/Y[HKV_PG^SW\2/B'XSF
M\#?#1?"/Q.U*S\/W'BC5-:^'OC71/$G@G0]&M;>^N)I=>\:J]IH6D79%@]M;
M:;>3IJ&HZC=:;I6F6][J.H6]LWE'A?P]K_C;6='\.>$-%U3Q+X@\0316VB:)
MHUG+>ZIJ4\T+7"Q6UK$"W[NW26YN9I#';65I#<7M[/;V=M<7$733S# U'64,
M7AW+#4*6)Q,?:P4L-AZRJRHUL1%M2H4ZL:%:5.=51C.-*I*+:A)KGG@<93]B
MYX7$)8BM4P^'E[*;CB*]%TXU:-"2BXUJE.5:C&<*;E*,JM--)SBGCT5U_C_P
M+XE^&/C?Q5\._&5G;:?XL\%ZW=^'O$5E9ZC8ZQ:6NJV/E_:8;;5=,FN=-U*!
M?-0QWMA<3VEPIWV\TL95VY"MZ-6EB*5*O0J0JT:].%:C5IRC.G5I58J=.I3G
M%N,X3A*,H3BW&46FFTTS"K2J4*M2C6ISI5J-2=*K2J1<*E*K3DX5*=2$DI0G
M"<7&<9)2C)--)IA5:]_X\KW_ *\KO_TGEJS5:]_X\K[_ *\KS_TFEK6.Z]5^
M9G+9^C_(_P!''X':1</\%_A$XUW6HPWPO^'Q")+INQ<^$=&.U0VELP4 X 9F
M/<DYKV&QLI;3S?,U"^OO,V;?MKVK>5MW9\O[-:6N-^X;]^_[J[=O.?.?@5_R
M13X0?]DN^'O_ *A^C5ZK7^0F9JV8X_\ [#,3_P"GIG^KN7?\B_ _]@>%_P#3
M$ HHHKA.P**** "BBB@ H/(/T_SZ_P J*AN)X;6":YN)HK>"WBEFFGGD2&&&
M&)&DEFEEE*QQQQ1JTDDDC*B(K,Y"@D 'YRZE^RCX[F_:1\:_%B\\$_"#X@Z3
MXG^(W@SQ7I'BOQO\5_C+8?$'PAH7AW2/#NFKX>T;PSX=\'MX$33/#]SI-_K/
MA;1GO1;S7^KW[Z]J5S-J%S=C](!_4_J:_&JV^-?A+6_VF?%,][\6/!_Q5\/>
M*/BUX)N?A3K/A3_@I/HW@+3M$\-W.D^#]'7PA#^SWX(\;Z-H6OQZ7XDL-5U*
M*UO;;Q)K?Q(EUV>RUJ,A[6R?]E 01D<C)YSGN>_].W3M0!^'O_!2V:&W_P""
MC_\ P0KFGECAB3]JW]I\O+-(D4:Y_8[^("C=)(RHN6(49898A1DD _M0NO:'
MY<8_MC2B<1#C4K$YP5Z$7&#[8SGMG(K\6O\ @I2JO_P4B_X(5*RJRG]JW]J#
M*L P./V.OB"1D$$'!P1Z$ CFOVU6VMO+C/V>#.(O^6,?<KT&W ]L=.V*:W5N
MZ _SE?VBV5_VA?CZZ,KH_P <?C"Z.C!T=&^)'B=E='4E65E(964E6!!!(.:\
M<KV3]HP ?M#_ !^   'QS^,0     ^)/B?  '  [ <"O&Z_UWRG_ )%66?\
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MK;;;>[U?](*_87_@AI<V]K^W?8S74\%M$/@K\4E,MQ-%!'N:[\&87S)71-Q
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M<2>7_4G\_P /6Q_Q KQ2_P"B9CT_YG?#WE_U-O-_<SX8HK[G_P"'/W_!8_\
MZ--_9Z_\3.T/_P"=91_PY^_X+'_]&F_L]?\ B9VA_P#SK*/^)@/";_HJ9?\
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MS_\ TB._9U_\6CZ%_P#0ET?\-7_\%G_^D1W[.O\ XM'T+_Z$NOX*/[A/C?\
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MM5U?1-&\7V^F6U[J>A?8?[5M4TO7](\01-:?VE:WMENDN='A@E\^UE'D2R[
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(W*L,D94\
MK]X<=1[^GO0!7%[:-=O8+<P&]B@BNI+031FYCMII)H8;E[<-YRV\LUO/#'.R
M"*26&:)',D3JL-GJNF:@\R6&HV-Z]O@7"6EY;7+P%BP43+!+(8LE' WA<E6
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MY^@5 !1110 4444 %%%% !1110 4444 %%%-=TC5G=E1%!9G=@JJJ@EF9B0
M  222  "3Q0 ZBOG&\_:W_9TL-7?2;GXJ>'U6&Z%E<Z_%!K5UX*LKO=L:WO_
M (@VNE3^ [&:)]R3)>>)8# Z2+-Y9CD"_0UI=VM_:VU]8W-O>65Y!%=6EW:3
M17-K=6T\:RP7%O<0N\,\$T3K)%+$[QR(RNC,I!(!\V_&;]K#X7_ OXR_LN_
MSQK;^*YO&G[7/COQO\//A7+H>C6VH:';:_X ^'FJ_$S77\6ZC-JEE-HNGOX<
MT>[2PN+2RU66YU$QVSV\$)DNH_ID$, PZ$ CZ$9K\0?^"D__ "DD_P""%/\
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MJ2S.->CBI\^$QJRJIRY.G0JTZ5-9;4K4XSBL1B\7>I4QJG.C@\-BJ3HT\/\
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M_,W97'^KV[3][=QYS\"O^2*?"#_LEWP]_P#4/T:O5:_R$S/3,<?_ -AF)_\
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MOZJ[ZV7_ ! KQ3T_XQE=%_R.^'M%:*M_R-NB=O2-O3X8HK[G_P"'/W_!8_\
MZ--_9Z_\3.T/_P"=91_PY^_X+'_]&F_L]?\ B9VA_P#SK*/^)@/";_HJ9?\
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MQO\ \'%__((_9$_[#'QM_P#39\-*_F#K^AW_ (*(_!W_ (++_M^6GPCM)_\
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M$D_!O4?V>O&5T=6\":5H7@SP"?VAM/\ VYI=&@LO 'AZP\&V%I\4=1_9ZO\
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M=)NOL5Q/]GU/0M4#:;K-A-LNM+OU-G?107 \NMG>F,[UQD#.X8R<8&<XR<C
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MXC:/<^';CPOK_P #=;>?2@#]ZTGADDEA2:)Y8?+\Z))$:2+S5WQ^8BL7C\Q
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M^&'P<_9Z\87,/AB5]1L?AC\;+WP'\>_CW;R!4\#R^(/B=\*HOB_Y/A&VFM(
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M0#C(VC!QTR,=NWI2[5R3M7)!!.!D@]0?4' SGTI:* $  Z #OP .?7BEHHH
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M%5/!4$<G! /)ZGGUR<_6EHH ,#T'7/X^OUI JCHH'T '\J6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>zinbryta.jpg
<TEXT>
begin 644 zinbryta.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KY(_;+_:9N/V6/AEX;\<VNF_#R\N/%/Q7^''PMAU+XM?$M_A%\-/#
M#_$#6)M,_P"$G\:>/H_"OC*31-&TH0'.S0;IKV\N+2R$EMYQF7ZWKQ+XV_!'
M1_C;;_#2UUK5KO3+?X;_ !B^'WQ@MX;:QT^_AUJ^^']Y?7EIH6HQ:C')''IN
MHO>E;JX@7[7!Y4;VY5^0 >-_#[]M;X3ZI+X"\(^/O'7PV'Q(\9R^%K)[OX*:
MQX\^,?P(L]7^)%[J'_"J-!7]H"/X;^&/!%GKWQ*TFUM;GPAH?BEO#.J^(M1O
M+;3O#]GJRZGX=NM<7QE^W5\%]"_9)\?_ +9G@^U^(/Q3^$?@?PQ=^*+1_!7P
MZ\;?VYXUL+:#3I%NO!FDZUX?TV^US0S+J<<-WXLL[:?PMIAL=<DOM6BCT#6&
MLZWBC]C/3?$/Q3UKQ?:?$_Q;H/PT\;?$OX-?&GXE?!K3=#\)-HGBWXJ_ $>
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M/#\PU*ST'0M/MK6'5+R>UA-V//D / _$'_!1'X::1\8/A+X4M++3[GX*^/\
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M?#>T^)?]K1Z]9'3/VOM.A\%P>'U\0IY'P-\46OAF"VA\(V1LD^K?B3_P4O\
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MIY9)I&:1W8@$]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M Z"BN?\ ^*F_Z@?_ )4Z/^*F_P"H'_Y4Z .@HKG_ /BIO^H'_P"5.C_BIO\
MJ!_^5.@#H**Y_P#XJ;_J!_\ E3H_XJ;_ *@?_E3H Z"BN?\ ^*F_Z@?_ )4Z
M/^*F_P"H'_Y4Z .@HKG_ /BIO^H'_P"5.C_BIO\ J!_^5.@#H**Y_P#XJ;_J
M!_\ E3H_XJ;_ *@?_E3H 37_ !=X4\*BU;Q/XF\/^'!?&9;(Z]K6F:.+QK<1
MFX6U.HW5L+@P":(S"'>8A)&7VAUSSG_"WOA1_P!%-^'O_A:^&?\ Y:5^9_\
MP4Z746LO@M_:B:<V+[Q[Y'V1;AB";3POYGF?:@0 1MV^7R3NW\;:_)CRXO\
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M?^%U?_YG/ZE_^%O?"C_HIOP]_P#"U\,__+2D/Q?^$X!)^)WP\  ))/C;PR
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M ^FZ*** "BBB@ HHHH _)W_@J/\ \>/P2_Z_O'__ *1^%:_(FOUV_P""H_\
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M?PG_ /)_U9^5_P!G?^'HFA_]$:US_P +/2O_ )1T?\/1-#_Z(UKG_A9Z5_\
M*.OQB_X9G_X+*?\ 2/S]G;_Q8#HO_P X6C_AF?\ X+*?](_/V=O_ !8#HO\
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MY^SM_P"+ =%_^<+1_P 1=\//^B@?_AISSR_ZEOG^#[!_Q"WCO_H1K_PYY/\
M_/#^K/RONT5A?\,S_P#!93_I'Y^SM_XL!T7_ .<+1_PS/_P64_Z1^?L[?^+
M=%_^<+1_Q%WP\_Z*!_\ AISSR_ZEOG^#[!_Q"WCO_H1K_P .>3__ #P_JS\K
M[M13_P"HG_ZX3?\ HIZQ_P#AF?\ X+*?](_/V=O_ !8#HO\ \X6F2?LR?\%E
M)(Y(_P#AW[^SLOF1NF[_ (> :*=N]2N<?\*&&<9SC(SC&137B]X>)I_ZP/=?
M\RG//+_J6^?X/L#\+..VG_PAK5?]#/)__GA_5GY7_K&^'7_)/_ __8G^&/\
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ME)@>@[]O7K^??UI:* $"J.B@?0 =L=O;CZ4%5)R5!(Z$@$CO_/FEHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839518128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Apr. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,007,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840022976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">443.2<span></span>
</td>
<td class="nump">340.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3,131.1<span></span>
</td>
<td class="nump">2,810.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">446.0<span></span>
</td>
<td class="nump">384.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">496.7<span></span>
</td>
<td class="nump">423.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">501.3<span></span>
</td>
<td class="nump">498.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">448.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">42.5<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(5.6)<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,596.4<span></span>
</td>
<td class="nump">1,786.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,534.7<span></span>
</td>
<td class="nump">1,024.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">(38.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,493.7<span></span>
</td>
<td class="nump">986.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">322.5<span></span>
</td>
<td class="nump">239.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,171.2<span></span>
</td>
<td class="nump">747.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 5.54<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840085472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(29.0)<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">1,185.9<span></span>
</td>
<td class="nump">742.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 1,184.2<span></span>
</td>
<td class="nump">$ 742.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840773168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,108.0<span></span>
</td>
<td class="nump">$ 1,573.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,808.0<span></span>
</td>
<td class="nump">2,115.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,939.2<span></span>
</td>
<td class="nump">1,787.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">553.5<span></span>
</td>
<td class="nump">532.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">890.8<span></span>
</td>
<td class="nump">902.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">895.9<span></span>
</td>
<td class="nump">962.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,195.4<span></span>
</td>
<td class="nump">7,873.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,200.2<span></span>
</td>
<td class="nump">3,057.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,334.7<span></span>
</td>
<td class="nump">3,182.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,794.5<span></span>
</td>
<td class="nump">3,879.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,907.8<span></span>
</td>
<td class="nump">4,632.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax assets</a></td>
<td class="nump">2,277.4<span></span>
</td>
<td class="nump">595.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">380.1<span></span>
</td>
<td class="nump">431.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,090.1<span></span>
</td>
<td class="nump">23,652.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">231.9<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">345.8<span></span>
</td>
<td class="nump">395.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,571.1<span></span>
</td>
<td class="nump">2,901.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,152.1<span></span>
</td>
<td class="nump">3,368.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">5,929.4<span></span>
</td>
<td class="nump">5,935.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liabilities</a></td>
<td class="nump">1,331.1<span></span>
</td>
<td class="nump">122.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,640.0<span></span>
</td>
<td class="nump">1,628.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,052.6<span></span>
</td>
<td class="nump">11,054.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(303.9)<span></span>
</td>
<td class="num">(318.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">17,334.6<span></span>
</td>
<td class="nump">15,810.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">14,053.7<span></span>
</td>
<td class="nump">12,612.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(16.2)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">14,037.5<span></span>
</td>
<td class="nump">12,598.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 26,090.1<span></span>
</td>
<td class="nump">$ 23,652.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818639760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839828128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,171.2<span></span>
</td>
<td class="nump">$ 747.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">168.9<span></span>
</td>
<td class="nump">512.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">43.4<span></span>
</td>
<td class="nump">37.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">76.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">26.1<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(134.0)<span></span>
</td>
<td class="num">(195.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(46.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(121.8)<span></span>
</td>
<td class="num">(684.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">257.6<span></span>
</td>
<td class="num">(195.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="num">(34.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">1,457.1<span></span>
</td>
<td class="nump">235.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">4,068.9<span></span>
</td>
<td class="nump">1,884.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,919.2)<span></span>
</td>
<td class="num">(1,256.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration paid related to Fumapharm AG acquisition</a></td>
<td class="nump">600.0<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(194.7)<span></span>
</td>
<td class="num">(210.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(855.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
<td class="nump">1,346.6<span></span>
</td>
<td class="num">(744.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(250.0)<span></span>
</td>
<td class="num">(583.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net cash contribution to Bioverativ Inc.</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(268.6)<span></span>
</td>
<td class="num">(901.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="nump">2,535.1<span></span>
</td>
<td class="num">(1,410.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">1,573.8<span></span>
</td>
<td class="nump">2,326.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 4,108.0<span></span>
</td>
<td class="nump">$ 924.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830755600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS. For additional information on our voluntary withdrawal of ZINBRYTA, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy, a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our accompanying unaudited condensed consolidated financial statements (condensed consolidated financial statements) include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU No. 2014-09 that have the same effective date and transition date: ASU No.&#160;2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenues, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which provides guidance on the presentation and disclosure of collaborative arrangements. Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have any future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with AbbVie and Samsung Bioepis also represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues are recognized as the underlying sales occur. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our condensed consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborations with AbbVie and Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of our product, which may occur at a point in time or over time depending on the terms and conditions of the agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, as of that date, and recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net adjustment to retained earnings reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of the new standard resulted in the reclassification of where we recognize changes in fair value related to certain equity security investments. Prior to adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leasing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard establishes a right-of-use (ROU) model that requires all lessees to recognize ROU assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required to leases existing as of, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our condensed consolidated balance sheet with no material impact to our condensed consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> offset by a corresponding net increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read Note 15,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Net Periodic Pension Cost</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our condensed consolidated statements of income. We adopted this new standard on January 1, 2018, using the retrospective method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of this new standard, the other components of the net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our condensed consolidated income statements. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reclassified from operating income to other income (expense), net in our condensed consolidated income statement to conform to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This new standard provides guidance to better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this new standard resulted in additional disclosures. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon the adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our condensed consolidated balance sheets. Changes in the fair value of derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an on-going basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instrument used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in the same line item as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822444048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Karyopharm Therapeutics Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired the exclusive worldwide rights to develop and commercialize Karyopharm Therapeutics Inc.'s (Karyopharm) Phase 1 ready investigational oral compound BIIB100 (formerly known as KPT-350) for the treatment of certain neurological and neurodegenerative conditions, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB100 has not yet reached technological feasibility. We have also agreed to pay Karyopharm up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$207.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, as well as potential royalties.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830719008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Restructuring</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We recognized restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated statements of income during the fourth quarter of 2017. These restructuring charges were substantially incurred and paid in 2017 and were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized restructuring charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our condensed consolidated statements of income. These restructuring charges, which will be substantially incurred and paid by mid-2018, are primarily related to severance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822535200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">728.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">258.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">986.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">751.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">958.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">371.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">178.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">550.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">464.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">212.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">545.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">188.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">363.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,538.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,631.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">749.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the three months ended March 31, 2018, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues for the three months ended March 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">606.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">761.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">641.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">806.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(227.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(299.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(77.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(326.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(412.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">121.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">695.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">859.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">201.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">657.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">859.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">349.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">93.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">443.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Bioepis and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">140.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaborations with AbbVie and Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822396032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">594.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">148.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">906.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">890.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">906.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830719008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(537.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(535.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,700.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">304.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,689.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">696.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">696.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,974.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,250.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,723.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,971.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,160.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,811.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,283.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,489.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,794.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$103.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$448.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, in the prior year comparative period. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization of acquired intangible assets was primarily due to the prior year impairment charge related to our U.S. and rest of world licenses to Forward Pharma A/S's (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$298.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc and our U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. The net book values of the TYSABRI and TECFIDERA assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,178.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$322.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. In March 2018 the European Patent Office (EPO) issued its decision revoking Forward Pharma's European Patent No. 2 801 355. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. Based upon our assessment of these rulings, we continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of 2017. Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">330.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">402.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">379.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">255.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">242.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">270.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,907.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes in foreign currency exchange rate fluctuations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822470064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,143.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,143.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,836.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,813.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third-party pricing services. For a description of our validation procedures related to prices provided by third-party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,490.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,517.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,482.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">994.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">994.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,788.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,736.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,851.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,736.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,898.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,188.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,932.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,938.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals, Stromedix Inc. and Biogen International Neuroscience GmbH in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$273.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. Changes in the fair value of our contingent consideration obligations were primarily due to an increase in the probability of achieving certain developmental milestones in the prior year period and an increase in the interest rate used to revalue our contingent consideration liabilities for the current year.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830719552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,561.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">948.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. Upon adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">912.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">913.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">248.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">248.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,008.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,011.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,570.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,569.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,808.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,809.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,116.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,123.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,124.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">77.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">77.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,008.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,011.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,068.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,884.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 assets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822658912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018. Among other provisions, the new standard required modifications to existing presentation and disclosure requirements on a prospective basis. As such, certain disclosures for the three months ended March 31, 2017, were modified to conform to the new disclosure requirements. For additional information on this new standard, please read Note 1, S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ummary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as cash flow hedges and any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,734.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,875.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">110.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,971.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect the net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$127.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is expected to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2018</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2017</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recognized as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$572.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$564.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">114.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830876672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,631.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,559.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715734272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, increased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by net income attributable to Biogen Inc. of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and a net cumulative-effect adjustment of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> recognized to retained earnings upon the adoptions of ASUs 2016-16 and 2016-01, partially offset by share repurchases totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the adoption of ASUs 2016-16 and 2016-01, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program). Our 2016 Share Repurchase Program does not have an expiration date. All share repurchases under our 2016 Share Repurchase Program will be retired. Under our 2016 Share Repurchase Program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$218.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains available for share repurchase under our 2016 Share Repurchase Program.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock (2011 Share Repurchase Program). Shares repurchased under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under our 2011 Share Repurchase Program, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822543024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amount reclassified, net of tax, upon adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(316.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(29.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(133.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(130.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(314.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(325.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715735072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818847728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units, cash settled performance units and performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance Stock Units (PSUs)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018, we began granting awards for performance-vested restricted stock units that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of the actual performance metric achievement. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> PSUs that will settle in stock were granted at a weighted average grant date fair value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$317.58</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Cash</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018, we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of the actual performance metric achievement. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through the vesting date, once the actual vested and earned number of units is determined. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> PSUs that will settle in cash were granted.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840792592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act), which was signed into law in December 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low- taxed income (GILTI). These changes became effective beginning in 2018. We do not recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and instead account for any taxes assessed as period costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017, we recognized within our provision for income taxes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> provisional estimate under the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. During the first quarter of 2018 we recognized no significant adjustments to these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Transition Toll Tax</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on undistributed foreign earnings. The Transition Toll Tax was assessed on our share of our foreign corporation's accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and all other earnings were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. As a result, our estimate of the total withholding taxes may change as the amounts are finalized. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Status of our Assessment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and remeasurement of our deferred assets and liabilities will be completed as additional information becomes available, but no later than one year from the enactment of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our preliminary estimate of the Transition Toll Tax and the remeasurement of our deferred tax assets and liabilities is subject to the finalization of management&#8217;s analysis related to certain matters, such as developing interpretations of the provisions of the 2017 Tax Act, changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries and the filing of our tax returns. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the new GILTI tax on international earnings, limits on the deductibility of certain benefits and executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act. The effective tax rate for 2017 also reflected the impact of a favorable settlement related to a state tax matter in 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intercompany transactions. In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> offset by a corresponding increase to deferred tax liabilities of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2018 on similar matters.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to our revenues from anti-CD20 therapeutic programs and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830793136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(50.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(63.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$895.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$962.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and include prepaid taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$587.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$657.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">657.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">524.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">194.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">206.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">186.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">297.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">178.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">159.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">176.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,571.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822658912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2007 we entered into a collaboration and license agreement with Neurimmune Subone AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. Our anti-amyloid beta antibody, aducanumab, for the treatment of AD resulted from this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on sales of any resulting commercial products and make payments upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune. Under the amended agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab.&#160;Our royalty rates payable on products developed under the amended agreement, including on potential commercial sales of aducanumab, will now range from the high single digits to low teens.&#160;As we consolidate the results of Neurimmune, we recognized this payment as a charge to noncontrolling interest in the fourth quarter of 2017 and treated it as a distribution. Under the amended agreement, we also have an option that will expire on April 30, 2018 to further reduce our royalty rates payable on products developed under the agreement, including on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our condensed consolidated statements of income. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration agreement with Eisai Co. Ltd. (Eisai) for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement), Eisai may elect to share in the benefit and cost associated with the royalty reductions discussed above. Eisai has elected to not share in the benefit and cost of the October 2017 royalty reduction. For additional information on our collaboration arrangement with Eisai, please read Note 18,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our investments in Neurimmune and other variable interest entities, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6696773584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Inc. (AbbVie) for the development and commercialization of ZINBRYTA, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary withdrawal of ZINBRYTA for relapsing MS, as discussed below.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory) where development and commercialization costs and profits were shared equally. Outside of the Collaboration Territory, we were solely responsible for development and commercialization of ZINBRYTA and paid a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Article 20 Procedure and Voluntary Withdrawal of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the European Medicines Agency (EMA) announced a review (referred to as an Article 20 Procedure) of the use of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury, and recommended restrictions on its use. In January 2018 the European Commission (EC) adopted a final and legally-binding decision restricting ZINBRYTA's use to adult patients with relapsing forms of MS who have had an inadequate response to at least two DMTs and for whom treatment with any other DMT is contraindicated or otherwise unsuitable. For additional information on the Article 20 Procedure of ZINBRYTA please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The EMA subsequently started a second review following cases of serious inflammatory brain disorders including encephalitis and meningoencephalitis.&#160;In parallel, we and AbbVie began discussions with the EMA, and in March 2018 announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS as we and AbbVie believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated. Subsequent to the voluntary worldwide withdrawal of ZINBRYTA, the EMA recommended the immediate suspension of ZINBRYTA's marketing authorization and a recall of ZINBRYTA from pharmacies and hospitals in the E.U. As a result of our voluntary withdrawal of ZINBRYTA, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in inventory charges and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in losses related to the termination of research and development contracts and clinical trials related to our voluntary worldwide withdrawal of ZINBRYTA in our condensed consolidated statements of income, net of an expected AbbVie reimbursement, in the first quarter of 2018.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenues of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect our share of an overall net loss within the collaboration, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. These results include the collaboration's estimate of future returns of product in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada. These results include the collaboration's estimate of future returns of product in the E.U. and Canada. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our recognition of income to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada was not significant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with AbbVie, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai to jointly develop and commercialize E2609, a BACE inhibitor, and BAN2401, a monoclonal antibody that targets amyloid beta aggregates, two Eisai product candidates for the treatment of AD.&#160;Eisai serves as the global operational and regulatory lead for both compounds with all costs, including research, development and sales and marketing expenses shared equally by us and Eisai; and, if applicable, following marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai will co-promote BAN2401 and E2609 and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;was reflected in research and development expense in our condensed consolidated statements of income related to the advancement of our E2609 and BAN2401 programs, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have the Aducanumab Collaboration Agreement with Eisai for the joint development and commercialization of aducanumab. Under the Aducanumab Collaboration Agreement, we will continue to lead the on-going Phase 3 development of aducanumab and will remain responsible for 100% of development costs for aducanumab incurred in support of this agreement until April 2018. Eisai will then reimburse us for&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;of aducanumab development expenses for the period April 2018 through December 2018, and&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;thereafter. Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$63.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;was reflected in research and development expense in our condensed consolidated statements of income related to the advancement of our aducanumab program, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai also co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Eisai, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control and is based on paying for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total investment made by Samsung Biologics into Samsung Bioepis in excess of what we have already contributed under the joint venture agreement plus a rate that will represent their return on capital. If we do not exercise this option by mid-2018, this option will expire and Samsung Biologics will have the right to purchase all of Samsung Bioepis' shares then held by us. Should we exercise this option, our ownership percentage would increase to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of BENEPALI and FLIXABI in the E.U. in the first and third quarters of 2016, respectively. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. In August 2017 the EC granted a marketing authorization in the E.U. for IMRALDI, an adalimumab biosimilar referencing HUMIRA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we and Samsung Bioepis will make royalty payments to AbbVie. We expect to launch IMRALDI in Europe in October 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect Samsung Bioepis's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in revenues in relation to these services, which is reflected as a component of other revenues in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on to these and our other significant collaboration arrangements, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655102656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Abbreviated New Drug Application (ANDA) Litigation relating to TECFIDERA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June, July and September 2017, January, March and April 2018, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Caribe Holdings (Cayman) Co. Ltd.&#160;DBA Puracap&#160;Caribe, Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceutical Inc., Slayback Pharma LLC,&#160;Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shilpa Medicare Limited, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd., Accord Healthcare Inc., Par Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Zydus Pharmaceuticals (USA) Inc. and Banner Life Sciences LLC. In addition, we initiated patent infringement proceedings pursuant to the Hatch-Waxman act against Stason Pharmaceuticals, Inc. in the U.S. District Court for the Central District of California, Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of New Jersey, Accord Healthcare Inc. in the U.S. District Court for the Middle District of North Carolina, Par Pharmaceutical Inc. in the U.S. District Court for the Southern District of New York, Sandoz Inc. in the U.S. District Court for the District of Colorado and Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cases against Accord Healthcare Inc., Zydus Pharmaceuticals (USA) Inc. and Sandoz Inc. have been dismissed in the North Carolina, New Jersey and Colorado courts but will continue against those parties in Delaware. The cases against Par Pharmaceutical Inc. in both New York and Delaware have been dismissed because Par Pharmaceutical Inc.&#8217;s ANDA application has been withdrawn. The case against Stason Pharmaceuticals, Inc. in California has been dismissed, but the case against its partner Sawai USA, Inc. will proceed in Delaware. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial has been set in the Delaware actions in December 2019 against all parties other than Banner Life Sciences LLC, and a trial has been set in the West Virginia action in February 2020. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and oral argument has been set for June 2018. For additional information on this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO decided to revoke our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO issued its decision revoking Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has stated that it expects to file an appeal to the Technical Board of Appeal of the EPO. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information on this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action in the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish &#8216;263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU &#8216;127 Patent) (&#8220;Administration of agents to treat inflammation&#8221;).  The Polish &#8216;263 Patent concerns administration of natalizumab (TYSABRI) to threat MS. The Polish &#8216;263 Patent was issued in 2013 and expires in February 2023. Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (on January 11, 2016), the German Patents Court (on March 3, 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which was issued in 2011 and also concerns administration of natalizumab (TYSABRI) to treat MS. The EU '127 Patent expires in February 2023. The Dutch counterpart was ruled invalid and we have appealed. In January 2018 the German court announced that the German counterpart was invalid. No date for a hearing on the merits has been set in the Italian action.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018 a jury found that EMD Serono and Pfizer infringed the '755 patent but that the &#8216;755 Patent was invalid under the law of anticipation. Biogen, EMD Serono and Pfizer have filed motions for judgment as a matter of law and these motions are pending. A trial date against Bayer and Novartis has not yet been set.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 the tax authority of the State of Goias, Brazil issued assessments for the period January 2016 through February 2018 relating to tax on the circulation of goods and totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties.&#160;We dispute the assessments.&#160;We are unable to provide an estimate of the potential loss or range of loss at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830220944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pfizer Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we completed an agreement to acquire from Pfizer BIIB104 (formerly known as PF-04958242), a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia (CIAS). AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the closing of this transaction in the second quarter of 2018, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We may also pay Pfizer up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$515.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the dosing of the first patient in Phase 2b, as well as tiered royalties in the low to mid-teen percentages.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we entered into a new </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ten</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases. Under this agreement, we will make an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and purchase </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of Ionis&#8217; common stock, at a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> premium based on the closing price of Ionis&#8217;s common stock for the 10 days prior to the date of this agreement, for a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The premium paid on the equity will be recorded as research and development expense in our condensed consolidated statements of income.&#160;We have the option to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, depending on the indication, and royalties on net sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The transaction is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and is expected to close in the second quarter of 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649490624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We also plan to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in the previously mentioned areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS and relapsing MS and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing MS. For additional information on our voluntary withdrawal of ZINBRYTA, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within our core and emerging growth areas. For nearly two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy, a rare condition that affects movement, speech, vision and cognitive function, Parkinson's disease and ALS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.).</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, our accompanying unaudited condensed consolidated financial statements (condensed consolidated financial statements) include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an on-going basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our condensed consolidated financial statements and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This new standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU No. 2014-09 that have the same effective date and transition date: ASU No.&#160;2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards may result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five step model prescribed under ASU No. 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S. we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration typically utilize the most likely method and reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenues, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which provides guidance on the presentation and disclosure of collaborative arrangements. Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have any future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i) </font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reimbursement of our selling and development expenses in the U.S. for RITUXAN; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(iii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration with Genentech, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in our 2017 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with AbbVie and Samsung Bioepis also represent collaborative arrangements as each party is an active participant and exposed to significant risks and rewards of the arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues are recognized as the underlying sales occur. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our condensed consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborations with AbbVie and Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of our product, which may occur at a point in time or over time depending on the terms and conditions of the agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This new standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, as of that date, and recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net adjustment to retained earnings reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of the new standard resulted in the reclassification of where we recognize changes in fair value related to certain equity security investments. Prior to adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Leasing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard establishes a right-of-use (ROU) model that requires all lessees to recognize ROU assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This new standard will become effective for us on January 1, 2019. A modified retrospective transition approach is required to leases existing as of, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. While we are currently evaluating the impact that this new standard may have on our consolidated results of operations, financial position and disclosures, we expect that the adoption of this new standard may materially affect the reported amount of total assets and total liabilities within our condensed consolidated balance sheet with no material impact to our condensed consolidated statement of income. We are unable to quantify the impact at this time as the ultimate impact of adopting this new standard will depend on the total amount of our lease commitments as of the adoption date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> offset by a corresponding net increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We will recognize incremental deferred income tax expense thereafter as these net deferred tax assets are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information, please read Note 15,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Net Periodic Pension Cost</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our condensed consolidated statements of income. We adopted this new standard on January 1, 2018, using the retrospective method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of this new standard, the other components of the net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our condensed consolidated income statements. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">March&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was reclassified from operating income to other income (expense), net in our condensed consolidated income statement to conform to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. This new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this new standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#528134;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This new standard provides guidance to better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this new standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this new standard resulted in additional disclosures. Prior to the adoption of ASU 2017-12, to the extent ineffective, hedge transaction gains and losses were reported in other income (expense), net. Upon the adoption of ASU 2017-12, we recognize all fair value changes of derivatives in earnings in the same line item in our condensed consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our condensed consolidated balance sheets. Changes in the fair value of derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an on-going basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instrument used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in the same line item as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649490624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">728.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">258.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">986.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">751.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">207.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">958.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">371.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">178.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">550.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">464.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">249.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">212.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">462.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">305.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">239.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">545.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">188.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">363.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,538.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">985.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,523.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,631.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">749.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">606.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">46.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">761.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">159.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">641.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">806.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(227.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(299.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(77.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(326.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(412.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">121.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">695.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">859.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">201.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">657.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">859.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">349.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">93.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">443.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Samsung Bioepis and other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">140.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633412288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">164.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">594.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">148.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">906.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">890.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">906.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839716944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(537.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(535.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,700.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">304.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,689.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">696.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">696.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,974.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,250.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,723.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,971.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,160.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,811.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,283.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,489.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,794.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018 (remaining nine months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">330.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">402.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">379.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">255.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">242.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">270.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,907.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840425936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,557.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,143.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,143.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,836.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">22.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,813.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">147.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,490.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,517.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,482.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">994.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">994.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,788.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,736.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,851.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,736.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,898.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,722.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,188.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,932.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,938.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">470.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830694480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,561.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">948.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">161.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,773.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of March 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">912.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">913.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">645.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">895.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">248.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">248.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">307.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,008.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,011.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,570.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,569.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,808.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,809.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,116.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,123.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,124.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">77.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">77.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,008.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,011.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,068.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,884.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656139936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,734.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,875.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">110.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">65.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">60.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,971.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2018</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended March 31, 2017</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of March 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">114.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">32.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822519456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock', window );">Reconciliation of equity attributable to noncontrolling interests</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(16.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653372544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amount reclassified, net of tax, upon adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(316.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(60.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">31.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">37.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(29.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">44.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(133.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(130.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(303.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(314.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(325.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(37.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830821072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,172.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819818768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">28.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">36.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830807872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820227008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(50.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(63.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(14.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(41.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">657.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">524.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">194.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">206.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">186.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">297.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;font-weight:bold;">178.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">159.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">176.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">653.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,571.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840365968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Net deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=biib_AccountingStandardsUpdated201707Member', window );">Accounting Standards Updated 2017-07 | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior period reclassification adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=biib_AccountingStandardsUpdated201707Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=biib_AccountingStandardsUpdated201707Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827699824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember', window );">Karyopharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of milestones</a></td>
<td class="nump">$ 207.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827637104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2017CorporateStrategyMember', window );">2017 Corporate Strategy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2017CorporateStrategyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2017CorporateStrategyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843007232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">1,538.0<span></span>
</td>
<td class="nump">1,631.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=biib_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">985.5<span></span>
</td>
<td class="nump">749.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">986.9<span></span>
</td>
<td class="nump">958.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">728.9<span></span>
</td>
<td class="nump">751.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">258.0<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">550.3<span></span>
</td>
<td class="nump">648.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">371.4<span></span>
</td>
<td class="nump">464.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">178.9<span></span>
</td>
<td class="nump">183.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">462.1<span></span>
</td>
<td class="nump">545.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">249.7<span></span>
</td>
<td class="nump">305.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">212.4<span></span>
</td>
<td class="nump">239.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">363.9<span></span>
</td>
<td class="nump">47.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">188.0<span></span>
</td>
<td class="nump">46.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">175.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">120.9<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">120.9<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=biib_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=biib_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827800480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 761.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">806.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(299.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(412.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">859.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">109.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">159.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(71.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(77.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">121.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">606.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">641.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(227.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(326.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">695.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">46.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 43.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828009520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 859.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">201.8<span></span>
</td>
<td class="nump">189.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 657.5<span></span>
</td>
<td class="nump">$ 572.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840598960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Other revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">443.2<span></span>
</td>
<td class="nump">340.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="nump">349.6<span></span>
</td>
<td class="nump">323.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Other revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">93.6<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 340.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827876592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty Revenue</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(5.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">17.9<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">$ 140.6<span></span>
</td>
<td class="nump">$ 58.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822512928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">36.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="nump">19.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6839963440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 164.3<span></span>
</td>
<td class="nump">$ 162.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">594.3<span></span>
</td>
<td class="nump">605.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">148.0<span></span>
</td>
<td class="nump">157.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">906.6<span></span>
</td>
<td class="nump">925.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">890.8<span></span>
</td>
<td class="nump">902.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="nump">$ 22.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842383632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 8,283.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,264.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">$ 448.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,489.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,385.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,794.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,879.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment made to Forward Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2018 (remaining nine months)</a></td>
<td class="nump">330.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">402.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">379.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">255.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">242.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">211.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(537.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(535.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,700.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,689.0)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 304.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 298.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,974.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,971.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,250.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,160.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,723.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,811.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 322.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 696.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,178.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842409680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase in goodwill</a></td>
<td class="nump">$ 270.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">322.5<span></span>
</td>
<td class="nump">$ 239.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">4,632.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">4,907.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase in goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843442128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,008.2<span></span>
</td>
<td class="nump">$ 5,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,773.7<span></span>
</td>
<td class="nump">1,229.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,836.2<span></span>
</td>
<td class="nump">6,444.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">147.7<span></span>
</td>
<td class="nump">111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">498.0<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">$ 470.9<span></span>
</td>
<td class="nump">$ 467.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">645.7<span></span>
</td>
<td class="nump">634.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,557.9<span></span>
</td>
<td class="nump">2,609.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,143.2<span></span>
</td>
<td class="nump">1,919.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">307.1<span></span>
</td>
<td class="nump">643.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,773.7<span></span>
</td>
<td class="nump">1,229.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">28.3<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,813.4<span></span>
</td>
<td class="nump">6,433.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">147.7<span></span>
</td>
<td class="nump">111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">147.7<span></span>
</td>
<td class="nump">111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,557.9<span></span>
</td>
<td class="nump">2,609.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,143.2<span></span>
</td>
<td class="nump">1,919.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">307.1<span></span>
</td>
<td class="nump">643.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">498.0<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">498.0<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840306464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 5,932.7<span></span>
</td>
<td class="nump">$ 5,938.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">6,188.3<span></span>
</td>
<td class="nump">6,483.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,490.7<span></span>
</td>
<td class="nump">1,517.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,476.0<span></span>
</td>
<td class="nump">1,482.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,007.3<span></span>
</td>
<td class="nump">1,032.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">994.6<span></span>
</td>
<td class="nump">994.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,788.8<span></span>
</td>
<td class="nump">1,851.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,736.7<span></span>
</td>
<td class="nump">1,736.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,898.2<span></span>
</td>
<td class="nump">2,077.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,722.1<span></span>
</td>
<td class="nump">$ 1,722.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827271056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="num">$ (5.6)<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 498.0<span></span>
</td>
<td class="nump">$ 470.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840675568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Changes in valuation techniques</a></td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 273.7<span></span>
</td>
<td class="nump">$ 279.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6840681776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 3,773.7<span></span>
</td>
<td class="nump">$ 1,229.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">51.5<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,561.2<span></span>
</td>
<td class="nump">948.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 161.0<span></span>
</td>
<td class="nump">$ 247.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6837888832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 3,008.2<span></span>
</td>
<td class="nump">$ 5,172.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.3)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">3,011.0<span></span>
</td>
<td class="nump">5,173.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">912.9<span></span>
</td>
<td class="nump">1,039.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">913.7<span></span>
</td>
<td class="nump">1,039.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">645.0<span></span>
</td>
<td class="nump">1,570.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">645.4<span></span>
</td>
<td class="nump">1,569.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">895.0<span></span>
</td>
<td class="nump">1,075.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">895.5<span></span>
</td>
<td class="nump">1,075.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">248.2<span></span>
</td>
<td class="nump">844.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">248.4<span></span>
</td>
<td class="nump">845.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">307.0<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 307.9<span></span>
</td>
<td class="nump">642.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822619440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">$ 1,808.0<span></span>
</td>
<td class="nump">$ 2,115.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">1,809.3<span></span>
</td>
<td class="nump">2,116.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">1,123.0<span></span>
</td>
<td class="nump">2,730.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">1,124.2<span></span>
</td>
<td class="nump">2,730.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">77.2<span></span>
</td>
<td class="nump">327.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">77.5<span></span>
</td>
<td class="nump">327.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">3,008.2<span></span>
</td>
<td class="nump">5,172.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 3,011.0<span></span>
</td>
<td class="nump">$ 5,173.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842460512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 4,068.9<span></span>
</td>
<td class="nump">$ 1,884.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (9.4)<span></span>
</td>
<td class="num">$ (1.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830681072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">17 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822809808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 81.6<span></span>
</td>
<td class="nump">$ 85.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6842363952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 142.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (113.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="num">$ (5.6)<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 572.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember', window );">Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">114.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,971.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,198.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="num">(32.9)<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,734.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">110.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">65.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 60.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on foreign currency derivatives, net, before tax</a></td>
<td class="nump">$ 127.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655821968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,631.5<span></span>
</td>
<td class="nump">$ 1,559.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,300.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="nump">$ 260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822500256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract', window );"><strong>Reconciliation of equity attributable to non-controlling interests</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, beginning of period</a></td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Translation adjustment and other</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, end of period</a></td>
<td class="num">$ (16.2)<span></span>
</td>
<td class="num">$ (11.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828414624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="nump">$ 583.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Equity increase during the period</a></td>
<td class="nump">1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,172.9<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases under the 2016 Share Repurchase Program</a></td>
<td class="nump">$ 2,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retire of common stock, shares</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="nump">$ 218.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember', window );">2011 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6841295776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">$ (318.4)<span></span>
</td>
<td class="num">$ (319.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of January 1, 2018</a></td>
<td class="num">(318.4)<span></span>
</td>
<td class="num">(319.9)<span></span>
</td>
<td class="num">$ (316.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(24.4)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">37.4<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">13.0<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(303.9)<span></span>
</td>
<td class="num">(325.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of January 1, 2018</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(2.3)<span></span>
</td>
<td class="num">(12.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(104.5)<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of January 1, 2018</a></td>
<td class="num">(104.5)<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="num">(104.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(60.4)<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">31.4<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(29.0)<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(133.5)<span></span>
</td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(36.8)<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of January 1, 2018</a></td>
<td class="num">(36.8)<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(36.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(37.3)<span></span>
</td>
<td class="num">(32.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="num">(175.5)<span></span>
</td>
<td class="num">(334.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of January 1, 2018</a></td>
<td class="num">(175.5)<span></span>
</td>
<td class="num">(334.2)<span></span>
</td>
<td class="num">(175.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">44.7<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">$ (130.8)<span></span>
</td>
<td class="num">$ (314.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Accumulated Net Unrealized Investment Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827312000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">$ (41.0)<span></span>
</td>
<td class="num">$ (38.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">322.5<span></span>
</td>
<td class="nump">239.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,523.5<span></span>
</td>
<td class="nump">2,380.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,172.9<span></span>
</td>
<td class="nump">747.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(37.4)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">32.9<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843524112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc</a></td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822831536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 50.4<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">45.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(12.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(21.9)<span></span>
</td>
<td class="num">(18.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(28.5)<span></span>
</td>
<td class="num">(29.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (39.4)<span></span>
</td>
<td class="num">$ (33.0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828964848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 50.4<span></span>
</td>
<td class="nump">$ 48.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">45.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">36.1<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6716119840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments Share-based Payments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="nump">66,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 317.58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822630384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(11.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">21.60%<span></span>
</td>
<td class="nump">24.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828725888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 322.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Remeasurement of our deferred tax balances in our provisional estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent', window );">Current deferred tax liabilities</a></td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax payment, including penalties and interest</a></td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember', window );">Foreign earnings in the form of cash and cash equivalents | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember', window );">Other foreign earnings | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TransitionTollTaxRepatriationTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Toll Tax Repatriation Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TransitionTollTaxRepatriationTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGrossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of noncurrent deferred tax liabilities, which result from applying the applicable tax rate to taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGrossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6837838400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 859.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations and milestones</a></td>
<td class="nump">524.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">194.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">186.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction Payable</a></td>
<td class="nump">178.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses accrual</a></td>
<td class="nump">176.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">653.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,571.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,901.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">$ 16.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(50.5)<span></span>
</td>
<td class="num">(63.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on sales of investments, net</a></td>
<td class="num">(14.4)<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">$ (38.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 657.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6626606384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 895.9<span></span>
</td>
<td class="nump">$ 962.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 587.5<span></span>
</td>
<td class="nump">$ 657.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829725136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.5<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Neurimmune</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalPotentialPaymentstoNoncontrollingInterest', window );">Additional Potential Payments to Noncontrolling Interest</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalPotentialPaymentstoNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Potential Payments to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalPotentialPaymentstoNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828910880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Inventory charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446.0<span></span>
</td>
<td class="nump">$ 384.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496.7<span></span>
</td>
<td class="nump">423.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Inventory charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | E2609 and BAN2401</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.1<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Aducanumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">U.S. | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember', window );">E.U. and Canada | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6822510144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2012</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.8<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.9<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6830220944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSought', window );">Brazil tax assessment, including interest and penalties</a></td>
<td class="text">30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSought">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSought</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6843056144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 496.7<span></span>
</td>
<td class="nump">$ 423.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember', window );">Pfizer | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totalpaymenttoentercollaborationagreement', window );">Total payment to enter collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Ionis Pharmaceuticals | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Ionis Pharmaceuticals | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones [Member] | Pfizer | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonpurchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonpurchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totalpaymenttoentercollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total payment to enter collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totalpaymenttoentercollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>119
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    " #&AIA,2E]JT>\    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+/3L,P#(=?!>7>NFG'A**N%Q GD)"8!.(6)=X6K?FCQ*C=VY.6
MK1."!^ 8^Y?/GR6W*@CE([Y$'S"2P70SVMXEH<*&'8B" $CJ@%:F,B=<;NY\
MM)+R,^XA2'64>X2ZJM9@D:26)&$"%F$ALJ[52JB(DGP\X[5:\.$S]C-,*\ >
M+3I*P$L.K)LFAM/8MW %3##":--W ?5"G*M_8N<.L'-R3&9)#<-0#LV<RSMP
M>']^>IW7+8Q+))W"_"L90:> &W:9_-;</VP?65=7_*ZH5D6]VO*UN&T$;SXF
MUQ]^5V'KM=F9?VQ\$>Q:^'47W1=02P,$%     @ QH:83)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M(N>L]_CPMSJL+P7<ANHP2VTT9V?V5+9"61\%R(.'=C,B#@,"S1!P0@3*]R2
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M+TXH8AX#)K_"Y+>(]E_$?;% L#6PN,@W7>2>7]RXR+<%BDV!P@N4-P+%*D;
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MXC[T497=J19QX'GRA!%%H@PE[AP<-7<C'"2N'2V:14G@696$>4<:>$3BVHE
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MWV&NYYJ2N?@?< &)X4$)YBB-='$EY>"\43,+2E'B==H['?=QNDF3&;8-X#.
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M^@\V&Q)J%XXW_FS&,1L-A]WT@]C\C8N_4$L#!!0    ( ,:&F$P=LBFJM0$
M -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL=5-A;]P@#/TKB!]0
M<ERZG4Y)I%ZG:I,VZ=1IVV<N<1)4"!F02_?O9TB:IEWV!;#Q>WXV)AN-?7(M
M@"?/6G4NIZWW_9$Q5[:@A;LQ/71X4QNKA4?3-LSU%D0505HQGB0?F!:RHT46
M?6=;9&;P2G9PML0-6@O[YP3*C#G=T1?'HVQ:'QRLR'K1P'?P/_JS18LM+)74
MT#EI.F*ASNG=[GA*0WP,^"EA=*LS"95<C'D*QI<JITD0! I*'Q@$;E>X!Z4"
M$<KX/7/2)64 KL\O[ ^Q=JSE(AS<&_5+5K[-Z8&2"FHQ*/]HQL\PUW-+R5S\
M5[B"PO"@!'.41KFXDG)PWNB9!:5H\3SMLHO[.-VDAQFV#> S@"^ 0\S#ID11
M^2?A19%9,Q([];X7X8EW1XZ]*8,SMB+>H7B'WFNQ2Y.,70/1''.:8O@Z9HE@
MR+ZDX%LI3OP?.-^&[S<5[B-\_T;A?_*GFP1I)$C?$/!W)6[%[-\E8:N>:K!-
MG"9'2C-T<9)7WF5@[WA\D]?P:=J_"=O(SI&+\?BRL?^U,1Y02G*#(]3B!UL,
M!;4/QX]XMM.8388W_?R#V/*-B[]02P,$%     @ QH:83&\NJ?.V 0  T@,
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MP9_--&23X;"?_P];/G'Y%U!+ P04    " #&AIA,)69;_+0!  #2 P  &0
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M*CDCO@3CL<SH)@@"!84+#,)O%W@ I0*1E_$Z<=(Y90 NSU?V;[%V7\M96'A
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MMC? ZPA2DF5)<L\4%YJ6>8R=3)GCX*30<#+$#DIQ\_L($L>"IO0:>!9MYT*
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M^F<S?H*YGEM*YN*_P 4DA@<EF*,RTL655(/S1LTL*$7QMVD7.N[C=)->8=N
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M;#$D-"X<;_W93&,V&0[[^0>QY1N7OP%02P,$%     @ QH:83$8VC!:P 0
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MMIO6;'*"[><7Q)9G7/X&4$L#!!0    ( ,:&F$R$H\*QM $  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;'U386_;(!#]*X@?4!*2M%%D6VHZ
M39NT25&G;9^)?;91@?, Q]V_'V#7\S9K7X [[KU[=QS9@/;%M0">O&IE7$Y;
M[[L38ZYL00MWAQV8<%.CU<('TS;,=19$E4!:,;[9W#,MI*%%EGP76V38>R4-
M7"QQO=;"_CR#PB&G6_KF>)9-ZZ.#%5DG&O@"_FMWL<%B,TLE-1@GT1 +=4X?
MMZ?S/L:G@&\2!K<XDUC)%?$E&A^KG&ZB(%!0^L@@PG:#)U J$@49/R9..J>,
MP.7YC?U]JCW4<A4.GE!]EY5O<WJDI():],H_X_ !IGH.E$S%?X(;J! >E80<
M)2J75E+VSJ.>6((4+5['79JT#^/-83?!U@%\ O 9<$QYV)@H*7\GO"@RBP.Q
M8^\[$9]X>^*A-V5TIE:DNR#>!>^MV!X/&;M%HBGF/,;P9<P<P0+[G(*OI3CS
M?^!\';Y;5;A+\-T?"N_7"?:K!/M$L/]OB6LQ#W\E88N>:K!-FB9'2NQ-FN2%
M=Q[81Y[>Y'?X..V?A6VD<>2*/KQLZG^-Z"%(V=R%$6K#!YL-!;6/QX=PMN.8
MC8;';OI!;/[&Q2]02P,$%     @ QH:83 8\UCFP 0  T@,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL?5-AC],P#/TK47[ 9<L&C*FM=#N$0 )I
M.L3Q.6O=-KHD+DFZ'O^>).U*.2J^-+;K]_SL.-F ]MFU )Z\:&5<3EOONR-C
MKFQ!"W>''9CPIT:KA0^N;9CK+(@J@;1B?+-YR[20AA99BIUMD6'OE31PML3U
M6@O[ZP0*AYQNZ2WP*)O6QP KLDXT\ W\]^YL@\=FEDIJ,$ZB(1;JG-YOCZ=]
MS$\)3Q(&M[!)[.2"^!R=SU5.-U$0*"A]9!#AN,(#*!6)@HR?$R>=2T;@TKZQ
M?TR]AUXNPL$#JA^R\FU.#Y144(M>^4<</L'4SQM*IN:_P!542(]*0HT2E4M?
M4O;.HYY8@A0M7L93FG0.$_\-M@[@$X"_ K"Q4%+^07A19!8'8L?9=R)>\?;(
MPVS*&$RC2/^">!>BUV)[.&3L&HFFG-.8PY<Y<P8+[',)OE;BQ/^!\W7X;E7A
M+L%W?RG<K1/L5PGVB6#_WQ;7<MZ_*L(6,]5@F[1-CI38F[3)B^B\L/<\W<F?
M]'';OPK;2./(!7VXV33_&M%#D+*Y"RO4A@<V.PIJ'\UWP;;CFHV.QVYZ06Q^
MQL5O4$L#!!0    ( ,:&F$S!X.S_M $  -(#   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;'U3VV[;, S]%4$?4#E.EG:!;:#I,&Q "P0=MCTK-FT+
MU<63Y+C]^U&RZWFMMQ=)I'@.#RDJ&XQ]<BV )\]*:I?3UOONP)@K6U#<79D.
M--[4QBKNT;0-<YT%7D60DBQ-DCU37&A:9-%WLD5F>B^%AI,EKE>*VY<C2#/D
M=$-?'8^B:7UPL"+K> /?P'_O3A8M-K-40H%VPFABH<[I[>9PW(7X&/!#P. 6
M9Q(J.1OS%(RO54Z3( @DE#XP<-PN< =2!B*4\6OBI'/* %R>7]D_Q]JQEC-W
M<&?D3U'Y-J<WE%10\U[Z1S-\@:F>#Y1,Q=_#!22&!R68HS32Q964O?-&32PH
M1?'G<1<Z[L-XL]]/L'5 .@'2&7 3\[ Q453^B7M>9-8,Q(Z][WAXXLTAQ=Z4
MP1E;$>]0O$/OI=A\3#)V"413S'&,29<Q<P1#]CE%NI;BF+Z#I^OP[:K";81O
M_U+XC_R[58)=)-C]M\2UF+<JV:*G"FP3I\F1TO0Z3O+".P_L;1K?Y$_X..T/
MW#9".W(V'E\V]K\VQ@-*2:YPA%K\8+,AH?;A>(UG.X[9:'C333^(S=^X^ U0
M2P,$%     @ QH:83"X.VF>W 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL;5/;;IPP$/T5RQ\0[P+9IBM RJ:J6JF55JF:/GMA "N^4-LL
MZ=]W; @E*2^V9SSGS)GQ.!^-?78=@"<O2FI7T,[[_LB8JSI0W-V8'C3>-,8J
M[M&T+7.]!5Y'D)(LV>T.3'&A:9E'W]F6N1F\%!K.EKA!*6[_G$":L:![^NIX
M%&WG@X.5><];^ '^9W^V:+&%I18*M!-&$PM-0>_WQU,6XF/ DX#1K<XD5'(Q
MYCD87^N"[H(@D%#YP,!QN\(#2!F(4,;OF9,N*0-P?7YE_QQKQUHNW,&#D;]$
M[;N"WE%20\,'Z1_-^ 7F>FXIF8O_!E>0&!Z48([*2!=74@W.&S6SH!3%7Z9=
MZ+B/TTUZF&';@&0&) O@+N9A4Z*H_!/WO,RM&8F=>M_S\,3[8X*]J8(SMB+>
MH7B'WFNY_YCF[!J(YIC3%).L8Y8(ANQ+BF0KQ2GY#YYLP]--A6F$IV\49ML$
MV29!%@FR-P2W[TK<BCF\2\)6/55@VSA-CE1FT'&25]YE8.^3^";_PJ=I_\YM
M*[0C%^/Q96/_&V,\H)3=#8Y0AQ]L,20T/AP_X-E.8S89WO3S#V++-R[_ E!+
M P04    " #&AIA,@#EI$^H!  !F!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6QU5-N.FS 0_17$!ZP3((&- &FS5=5*K11MU?;9@>&BM3&U3=C^
M?6U#*&6G+]@S/G/.C,U,.@KYJAH [;UQUJG,;[3N3X2HH@%.U8/HH3,GE9"<
M:F/*FJA> BU=$&<DV.V.A-.V\_/4^2XR3\6@6=O!17IJX)S*WV=@8LS\O7]W
MO+1UHZV#Y&E/:_@&^GM_D<8B"TO9<NA4*SI/0I7Y3_O3.;%X!_C1PJA6>\]6
M<A7BU1J?R\S?V82 0:$M S7+#9Z!,4MDTO@U<_J+I U<[^_L'UWMII8K5? L
MV,^VU$WF)[Y70D4'IE_$^ GF>@Z^-Q?_!6[ #-QF8C0*P93[>L6@M. SBTF%
MT[=I;3NWCC/_/0P/".: 8!- )B&7^0>J:9Y*,7IRNON>VB?>GP)S-X5UNJMP
M9R9Y9;RW?/\8I^1FB6;,><($:\R"((9]D0@PB7/P+CS PT,TP]"%AVOU,,()
M(I0@<@31/R4FFQ(QS",N<D!%#N\(3&-L1##,?V[RB(H<$8)@(X)A0EPD1D5B
MA"#:B&"8 RZ2H"()0G#<B&"8>"-"5O\Y!UF[#E=>(8;.39>5=QDB3X'KD[_P
M:0)]I;)N.^5=A3;=YGJB$D*#267W8)ZN,4-O,1A4VFYCLY=3ZT^&%OT\U<@R
M6O,_4$L#!!0    ( ,:&F$QFO*Q*[P$  &4%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;'54VVZ<,!#]%<L?$ ,+NW0%2-E$42NUTBI5VV<O#!?%
MQM3V+NG?US:$4N*\8,_XS#DS-C/9*.2+:@$T>N6L5SENM1Z.A*BR!4[5G1B@
M-R>UD)QJ8\J&J$$"K5P09R0*@CWAM.MQD3G?61:9N&K6]7"62%TYI_+/"9@8
M<QSB-\=SU[3:.DB1#;2![Z!_#&=I++*P5!V'7G6B1Q+J'-^'QU-J\0[PLX-1
MK?;(5G(1XL4:7ZH<!S8A8%!JRT#-<H,'8,P2F31^SYQXD;2!Z_T;^Y.KW=1R
MH0H>!/O55;K-<8I1!36],OTLQL\PUY-@-!?_%6[ #-QF8C1*P93[HO*JM. S
MBTF%T]=I[7JWCM-)DLQA_H!H#HB6@-3ID$G(9?Y(-2TR*48DI[L?J'WB\!B9
MNRFMTUV%.S/)*^.]%5&09N1FB6;,:<)$*TRX((AA7R0BG\0I>A<>^<-WW@QW
M+GRW5H\3/T'L)8@=0?Q?B9\V)7HP8> 72;PBB8<@W(CX,!]<Q=XKLO<0[#8B
M/DSL%SEX10[O"?8;#0\D_.!)4J]&ZB'8BO@PAXT(6?WF'&3C&ERA4EQ[-UQ6
MWF6&W$>N3?[!IP'TC<JFZQ6Z"&V:S;5$+80&DTIP9UZN-3-O,1C4VFX/9B^G
MSI\,+89YJ)%ELA9_ 5!+ P04    " #&AIA,- .F$[<!  #2 P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R.2YX;6QM4^V.E# 4?96F#["%#NHX 9*=-483
M329KU-\=N$"S+<6V#.O;>UM8Q)4_;>_M.>=^]#:?C'UR'8 GSUKUKJ"=]\.)
M,5=UH(6[,P/T>-,8JX5'T[;,#19$'4E:,9XD;YD6LJ=E'GT76^9F]$KV<+'$
MC5H+^_L,RDP%3>F+XU&VG0\.5N:#:.$;^._#Q:+%5I5::NB=-#VQT!3T/CV=
MLX"/@!\2)K<YDU#)U9BG8'RN"YJ$A$!!Y8."P.T&#Z!4$,(T?BV:= T9B-OS
MB_K'6#O6<A4.'HSZ*6O?%?1(20V-&)5_--,G6.IY0\E2_!>X@4)XR 1C5$:Y
MN))J=-[H1053T>)YWF4?]VF^.?"%MD_@"X&OA&.,P^9 ,?,/PHLRMV8B=N[]
M(,(3IR>.O:F",[8BWF'R#KVWDJ?'G-V"T((YSQB^P:0K@J'Z&H+OA3CS_^A\
MGW[8S? 0Z8=M].RX+Y#M"F11(/NGQ/>O2MS!\.15$+;IJ0;;QFERI#)C'R=Y
MXUT']CX^(OL+GZ?]J["M[!VY&H\O&_O?&.,!4TGN<(0Z_&"KH:#QX?@.SW8>
ML]GP9EA^$%N_<?D'4$L#!!0    ( ,:&F$RE!C4]T@$  )P$   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;'54VV[<(!#]%<0'A#6[=J*5;2F;JFJE
M5EJE:OO,VN.+PL4%O$[_OH =Q]W2%\,,9\Z9P3/DD](OI@.PZ%5P:0K<63L<
M"3%5!X*9.S6 =">-TH)99^J6F$$#JT.0X(3N=AD1K)>XS(/OK,M<C9;W$LX:
MF5$(IG^?@*NIP E^<SSW;6>]@Y3YP%KX!O;[<-;.(BM+W0N0IE<2:6@*_)@<
M3YG'!\"/'B:SV2-?R46I%V]\K@N\\PD!A\IZ!N:6*SP!YY[(I?%KX<2KI _<
M[M_8/X;:72T79N!)\9]];;L"/V!40\-&;I_5] F6>E*,EN*_P!6X@_M,G$:E
MN E?5(W&*K&PN%0$>YW77H9UFD^R9 F+!] E@*X!#T&'S$(A\P_,LC+7:D)Z
MOON!^5^<'*F[F\H[PU6$,Y>\<=YK26F2DZLG6C"G&4,WF'<$<>RK!(U)G.@_
MX30>OH]FN _A^ZUZ^A_]0Y3@$ @.?Y5(;TJ,8?9QD30JDD8(#C<B,4P:%\FB
M(EF$(+L1B6'N;T3(ICL$Z#;,A4&5&F68R8UW';U'&KKK'3[/[5>FVUX:=%'6
M]6CHI$8I"RZ5W9TKN'-/Q6IP:*S?WKN]G@=F-JP:EK> K ]2^0=02P,$%
M  @ QH:83&,H-W'4 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL=51MCYP@$/XKA!]P**Y[VXV:W%[3M$F;;*YI^YG5\24'8@'7Z[\OH&?M
M'O=%F.&9YYD9&;))JF?= ACT(GBO<]P:,QP)T64+@ND[.4!O3VJI!#/65 W1
M@P)6^2#!"8VB/1&LZW&1>=]9%9D<#>]Z."ND1R&8^G,"+J<<Q_C5\=0UK7$.
M4F0#:^ [F!_#65F+K"Q5)Z#7G>R1@CK'#_'QM'=X#_C9P:0W>^0JN4CY[(PO
M58XCEQ!P*(UC8':YPB-P[HAL&K\73KQ*NL#M_I7]DZ_=UG)A&AXE_]55ILWQ
M :,*:C9R\R2GS[#4DV*T%/\5KL MW&5B-4K)M?^B<M1&BH7%IB+8R[QVO5^G
M^22]7\+" 70)H&O P>N06<AG_I$95F1*3DC-O1^8^\7QD=K>E,[I6^'/;/+:
M>J\%I8>,7!W1@CG-&+K!Q"N"6/95@H8D3O1-. V')\$,$Q^>;-7379A@%R38
M>8+=?R5^N"DQ@$FBL$@:%$D#!/&-2 CS3BOV09%]@""Y$0EA;MM%-K=#@&K\
M7&A4RK'W,[GQKJ/W0/WM^@>?Y_8;4TW7:W21QMY1?Y-J*0W85*([6W!KGXK5
MX% ;M[VW>S4/S&P8.2QO 5D?I.(O4$L#!!0    ( ,:&F$POFC7RW@$   $%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;'54VVZ<,!#]%>0/B%FS
M+.D*D+*)HE9JI56JML]>&"Z*C:EMEO3O:QN64N*\8,_XS#DSQC/I*.2K:@!T
M\,99IS+4:-T?,59% YRJ.]%#9TXJ(3G5QI0U5KT$6KH@SC )PP/FM.U0GCK?
M6>:I&#1K.SC+0 V<4_GG!$R,&=JAF^.EK1MM'3A/>UK#=] _^K,T%EY8RI9#
MIUK1!1*J##WLCJ?$XAW@9PNC6NT#6\E%B%=K?"DS%-J$@$&A+0,URQ4>@3%+
M9-+X/7.B1=(&KO<W]F=7NZGE0A4\"O:K+763H7L4E%#1@>D7,7Z&N9X8!7/Q
M7^$*S,!M)D:C$$RY;U ,2@L^LYA4.'V;UK9SZSCSW\+\ 60.()L / FYS)^H
MIGDJQ1C(Z>Y[:G_Q[DC,W136Z:["G9GDE?%><Q+%*;Y:HAESFC!DA=DM"&S8
M%PGBDSB1=^'$'QYY,XQ<>+16CQ,_P=Y+L'<$^_]*/&Q*]&$^$(F](K&'X'XC
MXL-\\HL<O"*']P3[<"/BPWSPNQ*O2.(A(!L1'R;:B.#5$^0@:]=\*BC$T+G&
M7WF7_GX@[@G_@T_#X1N5==NIX"*T:03W7"LA-)A4PCMSJXV91XO!H-)VFYB]
MG+IR,K3HYX&#EZF7_P502P,$%     @ QH:83&AF/+[/ 0  G 0  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL;51M;]L@$/XKB!]0'&*[761;:EI5
MF[1)4:=UGXE]?E'!>$#B[M\/L.-Y'E\"=WY>[@A'-DKUKEL @SX$[W6.6V.&
M R&Z;$$P?2<'Z.V76BK!C U50_2@@%6>)#BA4902P;H>%YG/G521R8OA70\G
MA?1%"*9^'X'+,<<[?$N\=DUK7((4V< :^ [FQW!2-B*+2M4)Z'4G>Z2@SO'C
M[G!,'=X#WCH8]6J/7"=G*=]=\*7*<>0* @ZE<0K,+E=X LZ=D"WCUZR)%TM'
M7.]OZB^^=]O+F6EXDOQG5YDVQP\855"S"S>O<OP,<S\)1G/S7^$*W,)=)=:C
ME%S[7U1>M)%B5K&E"/8QK5WOUW'6O]'"!#H3Z(9 )B-?^3,SK,B4')&:SGY@
M[B_>':@]F](E_5'X;[9X;;/7@L9Q1JY.:,8<)PQ=878+@ECUQ8*&+([T/SH-
MT_?!"O>>OE^[IU%8( X*Q%X@_J?%9--B").&39*@21(0N-^8A# /89,T:)(&
M!#YM3 *89'M<9'4[!*C&SX5&I;ST?B97V67T'JF_77_AT]Q^8ZKI>HW.TM@[
MZF]2+:4!6TIT9QMN[5.Q!!QJX[;W=J^F@9D"(X?Y+2#+@U3\ 5!+ P04
M" #&AIA,:)GTV+<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6QM4]MNW" 0_17$!X1==K.)5K:E;*JJE5IIE:K-,VN/;10N+N!U^O<=L..X
MJ5^ &<XY<V'(!NM>? L0R*M6QN>T#:$[,N;+%K3P-[8#@S>U=5H$-%W#?.=
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M([7UDN$X2+V+(>HQZPZ#1Q@T(#S-/DA@2&*-[]QQ'-Y*;"!,=(O90I@Y'$@
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MC=F7<.!<@2XQFFBS*SU,AP.%@S+;5.^%&RGNH'C;3TLTC.SB+U!+ P04
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M%9PY+A-<D< 54_BY*T"F72&(\> (<Y!A[XD2.'=<9[B"D\=-@BLF7@3"Q:X
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MQO9KO!#\J%O+\-K?KOX!4$L#!!0    ( ,:&F$Q*%)T"ZP$  "X%   9
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MB C2)E752JT4;=7MLT,F :W!U';"]N]K&\(2\+;)0["',V?.C(=QUE'VRDL
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M4$^J$Z4"I$K/D=U=RLMKW! X";6,Y9KU$[S?"-H.MY,[7I'Y7U!+ P04
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M[WU].Y\H%42*]!S9UZ4<V..F)B>AEHE<,S.US$;0;IC([OBW(/\#4$L#!!0
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M<R]S:&5E=#4P+GAM;)59VVZK1A3]%8OW \P5B!Q+2:RJE5HI.E7;9V)/8NN
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M=NQ.M<OUW/W8KT[_OS:?=?OK^T:R=!V_=X$&S,,%PT<8;B.V+D(+&_(%!)E
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MEV#FLXE!@OCQE[H$"99 P?V[:D"8 !;1Q8 :R 6,XAF*F1Y$CUM%8(]M$'[
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M&   &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6R5F5UOHT84AO\*XC[
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M>Q?K\=".B57]=!_)_%.H_@)02P,$%     @ QH:83""]T.[T!   MQL  !D
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M[66[?(7!SF;;\TMN7YON,6F?J^$J:7AIRN-X31:=[^I6_P-02P,$%     @
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M.ZDIJ/I<V):5I692.OY:4K_WJ0V'ZV?V+R9X%<P#;=F6EW^*O3RM_-SW]NQ
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M"CA!#":(38+X*L&$Y+K'9 ;3&$P2!?&D$A<4Y\&,6@E()0&HD F5'I./5OE
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M0\3@.&,='T_&F< )")B Z 1DDH!:$]5KF-;46I,F66 /Q54QB@(*PR0@3 +
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ME)G.]%QT';5;*-[TMP49KJSL/U!+ P04    " #&AIA,\U(X05 #  !Q#@
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MK616@LP2B^FUV# /5"ZLARPL!,GD(=DPJ?T0$-B?:S"G"*8/Q0IZ$#'PH"R
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M"#RU4X=LHJN?U1&4@VL]LZ9$^^8U$D]EI,3 O90_<J"11)!1Z["'=@MY)$2
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MPL"K$D^L6#1J I(2OOB1R[:%DKFKX*@&M-M6QM8AI0"=)>O)KR+#8I,P@E0
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MCC5JA",LZPE^+=C%I00_A&D=,JXHF:QLUG BK\4DS8P=D9>GH>T*BK9Z.IJ
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M6&CN16_M:O)+JJ.HF]VH&U$R6/6NWA*DC5^*P^6F0:-WTD^_LABX:N;28!D
MYE>J33+P*U5'6G'0XY\Z56_(=O.D(<[HDMYF&OE'ZC9\Y:G;3Z,SP@0S#8>/
MDH,WG+V?4$9K"[^O"YW>X&N$_" _C;/+5IL3$RD?R3#$!K9?>55'R, &#G&A
M30.TIM01SM+RE"WULX;KMXXF,-@B:S666E<IY9;S9@H?2>MQ,)1JQ0EQ+TD
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M@WIR%-<";"T* K!),A$);6>+5#78^T>73Z&/^SD8.:+RS_9IJTDN9)*II**
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MT6X/</W[2!!'^-:+=KMNY<3/0KI%KWJ?AW1*=#MP['GK;H\Z_9,!AV]S^,)
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M'U&;S53)O&D@T3]8X556]UB7U*_N8$2_[G"-Q']PI:JWAMQCUZJ"&L.Y]-2
M"=GM;FR4G;RT]#:,*$>QL2'@C34+M,:UXS9.=$DYN%6Z-^E_S>-]JA(\;.B]
M!H5V@!-%Z!#LI(XLZ7/P]19L24^B;[>.S,9(:U7+RAD*9 'F;TQ=0-LU*Y8:
M9S#_ HGUK4]<Z1/;C&*UYC#-=SJ5\)+Y>F4-0DM-:TP&XVD\GVHIMI>&ZGU8
M+W#A\^)'*SEOLXLAT!3#+ZE ^!'2R.L$<]9GW,J7!%,T)+-##<?,UL0;C18C
M:HWQ$&)^[R/XB9[F"X>,H^F3G=8DL;PF'4C-863-!TTLW\!463UR*A;:^VOL
MZB9=)(?H7TJXND&13AGF@*^N,P06]B1<FZ,R*U\QP5UQ7GOV>YKO%=F9JJY6
M2TJI4UKF""5/Q4+K5P7/$/XO2C+IMY1;A+>:W*GM5('K>$+K>.;X#"7SGBF/
M(9%9&V,AS-A#L25MGEN<)-,8@T$X!P8;.,753^5@W1[11W#VO?VN9C>^-LJW
M)D*JQ:'YJ"5.>.)5]$]B;L1H9TR,U=#:EH/6^+C],.CK0L Q3]P<K>8$#Z[9
MJ>#R,P":[25D6PH [F%]>0*G(R3\.B&-O!/!>::B,URC,7"+4&93RMURO9XP
M5GN$$L#1*9#^N7%>M$X?K1/(WUE69L'G^CEKQ;V2D8..N-X)1Q@X3IDX#,\7
ML[O<5RH;/*N_'7T"(&]PNMVA!IW_$>*HQD@%N?6>,E0]DSP:F!E>;YB8%C-=
M[, 6A_CTX)AB&.!&5U:W-*R0'SS2HNNU;R0EQ5'ERZT<M&>S]#[]$DD;]LJ_
MV'8[H,:"3O]_.CK?8TK?8UK_XA->M*#2;0JR*EGA][5=ZO!*M>\BH8!V7.]X
M99W'1,8<>4!!LZP-:"X)%POAJ[IUHW/G0[/U8KVK)YA>B#*CWK14"MFL*9RD
MBNZ4W<?\M;S2+J,&R"%T[@7T:>9\J XNY-J* [0TR++(9Z;MJ^O/<.+P)S!9
MMS[\R&MOEFVJI'5*9N!)<@<D"8>;75XQ B Y*MB.:?LAY?@<=.3P\KISU.61
M4:-L,E>Q28(88S88'VI".3=)DUSN@<I!V1HU6,L&<W&)]XY";G$"XI"BL->$
M@Z<=RE$F1B%9#C&WHEQ^+EY:!R?Q)&6DM:Q4W&.ZH= R)U_2#*E[6B#!L)42
MUH@QY^9ALUY(40D06"H<?Y*0;$78-E.;"2X&4&ZJ.2_M4DG@+J5HA=N 2VG+
MX0CLUQ5"DS5VV&[,C "=&KN"OL2KSOE=VIJ!K48_,+I(&$:\B3#SASB<<&8N
MXW7O.W'.PB_:0_-"Z;(&*S)+,.N:OBF(@W!!D$AMNE "Z^0%2OT(A3">9=H]
M'.PDT?0"N<-8H4O;Z OVV2GV-,?C1N9%=/_.7?K9V",:DMJ<>).[H>0G+#A$
M)U;B=6Z3%./)N6BXX44NH"M>+N<@ Y- P+FPW=Z\?IY'\_B8<"PTX=;#S<*W
M;A'YAQY%#7-9<?RQK%P?>\/^27>$*<NKO(ON^?]2UL5U))_@7+R,]7-0_C?/
M>BG/<@'5]LF<)LZI/2A\Y!;1*JX.JJ 'FM@=W='$M,A!CT^2K%!C<1103HE%
M_YN'/8^'46NZ!U7Y+)CPL(<&@ 1S>V!V4\<@4.VFY/U&4O+U!/R9P%."M5DE
MCD=63,XVB59,A]61IJ5)"JZ10%FNA@]*]$-+U@G/G$#CV2PAGN=_;IY]=+2=
M9].>6)9=LY2(<GL3?TT:LN?J=[ME]K%MT5N?$DH5@WP(_SQ?B[3_;_D$@<HK
MX>PGA.0XH6?@TP-;\!BM/(E$MLWC1YR4.\F<H>:>,D%CRC%1Y@RN2T5S6QQW
MZG([IEZQ+S>E9A HK:>7,:=Q="N%<]%\LE[EP,^IA2*9"9213%[#T7><QN,[
MJ54/?-,?J\(\;ECD#,8 ]#X%FI5O>9$X7E@#,A;I2L.0E)O0TSY^N19NQ6H>
MAC%ST1=/QGPUV#7G:"D*)9)L\6&J%%BCV,\SYC*MCRFL#:\<0V]]GJ"D*%*$
M5N.2\0.<4T,R?R&;B)(B+]G.0#G<\5=W1>09I7FD#5/KHY+%O<1N^T,G-Z7-
M:>U,EI5@:GBT3&=I3/4$8-#4@YL=M"QY?$SERGG^>(B/$'FQ7^#MY;N;RX,J
MN: %<Y&8*$!_-7&&_%/"20N;\<DU7 F@%9T<%&8HBQ-P(F@*8[*2,+)?LQ+#
M<&DD$8-1UX4O4@]KCMAAQC52DQCDSQUP-5^VY8O.1>:%@/W<8@WI^VIIT# M
MR$S+TI'BKRFOJ#=_MK##$-'JGD1TKEH;&#GE3NEUF%/P0G/^4''$DKJY7L6W
MMQ:Z^6H]1_QX1HG"^KC:'^VX;&_.,H)!L3X"]NSTS*;3JV46RK/DD"JS+C!C
M%?&!&2:#)H$JAMM;*@+!H<I#E$@3_7U/I)_FZQ+Q91F3F#[H"'B?+&_N9$8W
M6,D CNT!HVB!,:]I,PE%VQ%,^.F1@<]5T+,^NP*ZI?' :8E=2X@:;55:4\=*
M,GZUL$,/73*,5T\8LN_NDT)^A;[PUC;\O-%DHYN*X6?U9:JS.F7*R4P8*4Z:
MZU]+979W+0BO-7$BF%5)=MHZ1B8;7%86:UKVRY6-*)]-2' VT&:.MN(&"F%N
MWC1U2AJJASW/O+FWEF)"[D1X^_NRD6[=3'VJ'&1BAH")?+O1124!$$D >-VU
MYJRGQICX2:$L)/5]?]0=?>=BJ)FNW##:7CKM@G .8O.J+:1"$XT0<65N)?S\
M2,,!M@@[PZ(T+$ F0B=*U7CI.3:%HUNY1&DNMHC(W41\U3A)YEF1:A)DG\5O
ML5HLF_F_6KY/0:XLZ.B@ UHA[4<I8NP?YFRCNW:':H*PVCC$*U!T"ZH+>#!?
M$LKRD)A4^^Z(V66JLV!_*S30-_#WVW"(TGQ+K$<%#WUJLQW4<^<LX]3?;Y*G
M>,M1$X6(WJ*@>^"-\[EXVE#RQSU'2\FA*:2A/ &>U8Q=;.EPVBL>,IZ6$_"Z
M!F"$6SNF$TZ:-_F)VE6ZIH$S:MU6H7/QQW(9M 0&ZXP#?')+_ 9(1BCE>E!(
M)P)>AMP=N8RD,G3)H)W[.,G@HM(QK2I\7&]W8>? 0:LTWC9=MJ9LFS(29EL\
M=,TP(X?"K31G_L!VG7W&59!OR , (X8E .F63!(4&$,N58=F7F*XCHO)(5N)
MRR[:M# =>_LZ>5@O2<U=+ABD0#)P3) #LW.LNVU5E4!XUI6\3>=B?,$EQ)6#
M\:X+]& 0B[PI:*$WDL]68# 51W!MHA2[7F L[%1FZA[1.S:XU)%O2?+1Z!8E
M5SQQ1EJ@FR>LS&[DAMU#C\*%KH<8G70BJP9_PSI@I% C=8\=/C[5T\7V*7<K
MU<4SVA8GHJT+HZ2XK]HSUSV! [L.I< !X@&_ V68_B%<FEPN&**#'E.V$.19
M@[#+ #"$LR.<[MSHP 2<<M@MA'U)D4U>!/'X2@-7+LS!*')RHGM4MN ([@<;
M$NJT;X\W'!A$F!,(*-5@23C%GHOS1A /SOJBOJH#Q*M]%U$*^^]LZ2>WGV^>
MD8_"QB62LS%>.+]9FNEURV*MK\W4LN&5L$6?R_8)OGOCE&_B#LBZT;(WGQL#
MATI_S8I":HB5(VT:X@EK!A0>RZ)YVSJJVT@B%6?&!'6%E601ID/#AC<ND(VE
MW;SBTK8P[*_<8EZ1D,W:8EC48%4BQ.\_%DN\!U\7ZSNA_$[$JZH)]=W-V+8A
MP?ZB'DX/DG''9S\,E< XNHT?0/AG<Z1ZRL.8ZE(/L=Q62FM8U%2N3!J,OS)-
M[6%;4)?KSS]YRWJ)T8G42Q1V4WF)@$=:-_D>;?#!749;S,G4-Y7\.#"6C]-5
M+N;#8UJ+ECSC&%$:<G--+GYRU#OX$6.8BOCP(EM1K+'4^*58 YX3LX8;W%),
M-)$1^4OH<) /W"FD94TA5;(QQRVE;A/NE@NY^ +#)C-TJGU6M ':?2]_X\4$
M]R8;F1Q]!9VLS-RT>'5C3TSXGK*-'%*Q<?D(4&]*4D^0[P[TT.+YF=@[4JV4
MF(5:)$%N,$G2%\GJ/B?S/WL=XNVQU8TAT[$(7[&Z\X)TNE5#F9$NFNB_'KT]
M",)\E2=B.%Z!GL"<73LN!+UZKBIJ52V^?!3&EV=!2_7);H\NIRVB+?5&36I/
M2@JZD1FZ4RLU:<]<QX45SI*SI#9R";@IM+!VMYK#_W,F+)H3503G]HL7?$(9
M%I5V4.IALNCL^QIS'5E8Z =X( <="WHG/S/'K;K* +?I/#A%(O)BQ_HF76[$
M.+5*12B<>6.92D&_PI56SE)E55_P7K@%6D^^3I.EEAYE0#9J3CF<K<(J(T'S
MO,:QNSUO)2]5J?$=<%2&*&?3$#N871U93N'M[L%FN8;*QI8D$Z 4BITK\CZZ
M%O^6GZQU*=AEK>\#;5>=E=]2>04N_TU7ISC&E?'/\98CUZKD8_$W@TW12%M"
MR?Q 8BC9N7W/+N4-:1.SM*12?P)MRRA#W@+GZW*UN5MJ%?^69+71D$+GZL33
MY6-%#T>P='=>N48U_QMEY7,Y^EPNA<HY//;99$1Z>QUGF!&:+F19WTVT?_WO
MXYL#=@0X>T'I,_[A%[<I9DU!__99AX.))9_"$'6WF-S0#28C5017<(Y750!
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M<,B38Z#N_NG0V;>.1W@ZCH?'KIQK>WUSJ@HQ.NE3Q,>@<];KUT,;+\.2:;_
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MU+6*NAJ[/<<*:'IGL2N:'*BBW-^Y-U$],,6L!)&"KKH[9@D$SV_TCBN.I_0
M"E>620&RY7JRS),L+ET6^VGNBZ$Z\<J/IVNR7$I;K@T3A(;I\!**QG1YXVM3
MXQ1:^73-E,XY:BH%<HT ;1-2\LCP"#C@K\\=*V 54:\Q#6J*5?VF"2<=ESPP
MJYA/7;&^*S&_%_FBY58F[P;]^GU)H7[QQC:C\;^[KYF!7!R;4D$S 1*8'45(
M5@+WX.Q;+EUC!:U22ZA5\D0^WN= 34!1&JT"E^1T+0URG( BM<:8, 38\'M[
MX5\51',$FLXRQL[X56%'&9QT\@%_2B9(^E>\H"]:3\K;'APGT@>*O*02JM"W
M:'UHF$G1\\ 70N4(T56LZD*0+_/>2TI"4I2[B:3!S>Y#QD)7S 4J00-D/C(U
MZQQ@BTMEP1]O\S2&"^A5$?^.Q,(B?;4>&=UX'&-L!.9CA]$+F;JE$*E?2]9U
M-"IZ$,U=KD7-VJK$#6T.;B]"!%@%!Y.AQ6JIJ>86<IU1NDH7VY,T@RDUEW@S
M-B$$(UQ)E(S6CMT8H/ [ @!>&1?D%U.NP )K-=9F[EHQ.$+F>G4T(; 0RJF#
M&%TT6!)#EU.9X7F=>^R:S:7ZY3Z=\QHIFBZ_W8*F<U",&$N;\MXLL=+OE'S1
M/M+/Y^:"E9[+HI+9:^U,"K:7Y"LP/<Y6P1<81]15T7@*_=-0TCHJS]N$G.Q:
M0U.;7%P75*,AJGWR]"OM".HG&[,:12VPA[.6K:I!/!B&,)7R\,BOI8U7EY>O
M^KTCH_#]EN6/A/>Y>G/8.SH;G0Z.!@<=,N$5Y0I$N4." 74D-\)@$G$\Z/C]
M%>472Y8KA(,*X>/OMP1VI%0\#UQX.2U$S@D3?Y?3^_3W?'E?)/^GO6_];2-)
M\OQ7ZH,'0RTH#8MO>H %U+*Z6[=^:"1[>F<']X$B2S*G)5++(NWFH/_XRWAE
M1E9F%HNTO#<''- M2V15/B,CX_D+\"RU+J[.;T_._(:-1L" 9?=3K&(V6VQ(
M%"UWR^DS5,3#XG>">"BH4.Q%-T3^!8+.RUVY*2#G7N)61?69@H8#9W^]?6:$
M@*E"9UL6VS4EC[(Y]+G<F4%/0;$5W<;34;PIX6[%+IN9808VRP78@:L3:?42
M@O*K '>I\AS+;/ML=A8SJ6S@YJO10/$]3GW>$<\ 88&I8/M,B /YP..2?M'>
M?7 <KG")Y%#IA7B5:PYLBZ#,U<0E/Y%%'QB T)@'G>F!DBKD5L8;A61@@!M5
M^;6@+JR6H4K=3IRA2O8.U%LVY)R=8D()(A245/.\!M:HKL,6?GFB$NT-TS/_
MHA914JK4X^)AM=Q"!- &+A>0_ZI81%.P)QL5U]XI'GD*.=8 Y;KTMP3Y]#SZ
M08*7W.A7@X[>4<C,@TE)-"G0!Z2*0OH\!)N:P78'?P!F_[38/KD$=DW^4*VR
MJ+94>DU9$2+O&&5G5W*F#[MGYO;J]:=*BT4Y\7IZN:HQ3?8'&1_BW_+P.(=9
ME^S&BNP()?(=BFS\HDHS.7 "\2!ML/@GZ5@+.CQ;AQ03UO]QPZZM^I4XU!#\
M#=!.ME?+0X!]Z/?M\4<K/U&_>9M92][5A&2Z?]4=:?(!1"MQ8?&R,XPK&H\\
MZPX\8,&&:=L\AEGJFM"SK1D49N (E=E[/4@O0MNP,V;Y:) H!UK?5O9UNJ"D
M(A)EG3W@9\.@3V]GJ\WF]&9EFEYEYY ROX;,WZLG!..F'3\G4V@^&7G1PVW!
M>+!XCIBEM"J+^JL@(J4TS3PZ($DI:\EO)T'5U"^@J!5?JY^SKHHU51@4[6ZQ
M\E%#,JF0?&]T1>8,DJR#*4-,::+:S0M$2D8EQJ)J+HQP^8544W=(@-2?B]4S
MA <OOEBM1X!O@PL=/Y@7) ]O./,HN-;ML3;BU,-Z]14PBP"Z 580DD87T%]I
MF+=1[\S$6^]N3USK9#F%8@\01OK/SX41_M=_+*6CK'7^YH1G^81"5#M[8JI1
MJ+RVN:=M";K0VGWG"2#/Z'FU#QE1Q:P]U,,FD&PH!+!;X8=&A %C"T:<NZ&?
MOP4A3*"]GA\)D( 44U@',ZXUVN^]=1 \.,-' ??B^;/1>!^?>-(X;"LYD98S
MG8&R)=NQ"V,S0=<IL 8H;8#;:ZF=034S+-THY<O:%8@>UE-&!(%=WI#D%JX<
MW/I?X8J!PR^&;2$&JZY"$TQN.Y=]:DW.3Y3[ +<%K(M;R"JNC@]TZ++YN>@4
M(DC-X7."+I$J'VC_MY40'?RFC<]H6X@FP6+R$:!^-.+UWV[.X]B&@+Q_>WWU
M_N;\OQ)/&"JB9CZ].S?=O8L_59K3"V:)QZE1:XS,O#+*6+E0JX'WG2W28A5-
M+_T)X5DLR+C-;;RY^OCI/\_?QSL&R]O/J_G#KPNPD#WNGIX_F\N@G<W,[BV!
MWO&3V0Z(X+'8_FHN?U \WKX]4=JROC!^.O^OO_TUL1;F-<XN,7<:G3;7XX>+
MF\N_?KJ-OREE&Z5(+9 U(%8OYQ4(:SLF1]O5LN!P"N@VVH.[^5,!.=D%N&])
M*+4?H+H'YK7'W2G U0#.MVA ,/:;U0R\E^# KB_[X->R>#$H[R:@8/N!I%^L
M,%/ST!) A!!H/S-&E.EM3FHH0]Z;66T<J]E\%D296%X>&$>,;.[SP%T[+:)Z
ME>/MF?.0#G&HVZ64<4$0+:#KQYV/3<4\+'H5T&8M"WP+X%7GQ6P*X6E?K8O!
M1B:G2Z[=DQ)F*5RY^=N9*\')(P(@1\KX7F_,:5RL.-K-W0/@7/_*YGKN<U%J
MZ4-3EY;:>*0!F]0 J,'(?]MD(E"0<*N$$WB900\?5F1T W0$3%!=2VX3^,?
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MMO Z*4*9@F5#Q_,J[F?5L:IN8!]'HJJZ:#'HQ?G?[.6LJB.LE(F6&!ZKL9!
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M#2SQ#.EH*'L>O(:J=:5\)ETI,>48O'($F//BD1TDQTY!2GHB(@:[G>D&'%%
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M@%>Z2IWD@R@V8JD]QJ)Z+&..)VVJBRHJ3[636U^[KJK*M (Q=HL<L3U7ED=
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MP$SD\"$H>>3L_1EDM%3Z?2AT.H.OKK:D\6FN=8F;B(F4CJ2?8F.V7WA5F\E
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MQLBT_"=NTE?9).]6Q(%6APV/DQR6^KU"\!EB. +X)UL=//3P03\A+4H?X\E
M"?4MLD'"AP.O[6X?+@%P@K,#M(MQ @?(E-)A1^EBSE^?>[V!QM:AWG*R?79
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MO7SRS939I3W%[)$3-$^C_Q(M]B]$DD#T[ VM$F5KB+1P'%D2BVEA3+(:>FN
M;<:IDGA3ETU0O3X: 6%UA[*D;G6[@YA:<Q.@+F^#8/WTX(^XHZ;?N W5*XEO
MX5L+0>4$XR=;3::JS#:[V:.RDI..^/ ]NL,7LYY3K0VPWJ85SI'L%[E2KARD
MH@"6N<=SS$GM17JWB !DCM/YW6Q:0'TY5(ES<O75*,4=]O74CDQ[Y"1SJW)
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M@R.QD$[R<6"9LD:^([L ,@^[J?&S[A%N;VTWV [BM/PAZPWP'Q2V&;0=7%1
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MEGXXQALG 86O6 S7Q\67J(-N6Q;WVT<D[9JW$S"SL?,G17"#N\-'FL4_L_<
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M5X%//+37N!=O']9@G0I6N[L'W$55',;L .C#^<(L!HE.DOV;=MPD\0?CYSS
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ QH:83)E<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #&AIA,7Y<0]50"  "O!P  &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ QH:83#2C2X$1!
M=Q(  !@              ( !@@L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( ,:&F$SO<-[+H (   8)   8              "  <D/
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #&AIA,44.R
M::@$  #A%@  &               @ &?$@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ QH:83#1;^-+' 0  9P0  !@
M ( !?1<  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,:&
MF$SQ+D+<?P0  "<5   8              "  7H9  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " #&AIA,ZDS[![8!  #2 P  &
M        @ $O'@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ QH:83 H1J$2T 0  T@,  !@              ( !&R   'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,:&F$P=LBFJM0$  -(#   8
M              "  04B  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " #&AIA,;RZI\[8!  #2 P  &0              @ 'P(P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,:&F$QM7#[$M@$
M - #   9              "  =TE  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ QH:83"5F6_RT 0  T@,  !D              ( !
MRB<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #&AIA,
MX /].[0!  #2 P  &0              @ &U*0  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,:&F$PIMW=>M0$  -(#   9
M      "  : K  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ QH:83#06="&U 0  T@,  !D              ( !C"T  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #&AIA,+]ZU&+4!  #2 P
M&0              @ %X+P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ,:&F$S&&*.RM $  -(#   9              "  60Q  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ QH:83)-=\[RR
M 0  T@,  !D              ( !3S,  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " #&AIA,>@7"_+,!  #2 P  &0
M@ $X-0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,:&
MF$Q)RY9ZM0$  -(#   9              "  2(W  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ QH:83(A"GE^U 0  T@,  !D
M         ( !#CD  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " #&AIA,1C:,%K !  #2 P  &0              @ 'Z.@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,:&F$R$H\*QM $  -(#
M   9              "  >$\  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ QH:83 8\UCFP 0  T@,  !D              ( !S#X
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #&AIA,P>#L
M_[0!  #2 P  &0              @ &S0   >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ,:&F$PN#MIGMP$  -(#   9
M  "  9Y"  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MQH:83( Y:1/J 0  9@4  !D              ( !C$0  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " #&AIA,9KRL2N\!  !E!0  &0
M            @ &M1@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ,:&F$PT Z83MP$  -(#   9              "  =-(  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ QH:83*4&-3W2 0
MG 0  !D              ( !P4H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " #&AIA,8R@W<=0!  "<!   &0              @ '*
M3   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,:&F$PO
MFC7RW@$   $%   9              "  =5.  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ QH:83&AF/+[/ 0  G 0  !D
M     ( !ZE   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,:&F$R;.F\<M $  -(#   9              "
M ;U:  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ QH:8
M3$(+52[% 0  -00  !D              ( !J%P  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " #&AIA,;:!-EEL"   #"   &0
M        @ &D7@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( ,:&F$Q?YBA3#0(  *L%   9              "  39A  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ QH:83!S:%ZH. @  O@4
M !D              ( !>F,  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " #&AIA,E;T6D7L&   ;*@  &0              @ &_90
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ,:&F$SS_"ML
M8 ,  .L.   9              "  7%L  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ QH:83$H4G0+K 0  +@4  !D
M ( !"'   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #&
MAIA,$X<!^T\"   N!P  &0              @ $J<@  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,:&F$S5A"N_;@(  "((   9
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M970U,2YX;6Q02P$"% ,4    " #&AIA,[VNNXL@%  !L)@  &0
M    @ $BA   >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M ,:&F$S6!NX!^@(  *,,   9              "  2&*  !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ QH:83%=]T(T^ @  B 8  !D
M             ( !4HT  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " #&AIA,>;\:3VL"  #&"   &0              @ ''CP  >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,:&F$S^3-:"60(
M !D(   9              "  6F2  !X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ QH:83  -YO5O!   $A@  !D              ( !
M^90  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #&AIA,
M"C+V]UX"  "Q!P  &0              @ &?F0  >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,:&F$PGF6#8$@(  'P%   9
M      "  32<  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ QH:83+)GM!W3 0  ;@0  !D              ( !?9X  'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #&AIA,GX47Y;\!   @!
M&0              @ &'H   >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( ,:&F$P@O=#N] 0  +<;   9              "  7VB  !X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ QH:83&K))3WP
M 0  2@4  !D              ( !J*<  'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    " #&AIA,BJ?#!AX"   %!@  &0
M@ '/J0  >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ,:&
MF$Q:O#-<P@(  .X)   9              "  22L  !X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ QH:83&&'@KGK!   W!H  !D
M         ( !':\  'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4
M    " #&AIA,Y:9IK.\"  !T"P  &0              @ $_M   >&PO=V]R
M:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ,:&F$P&7@6:O@(  - *
M   9              "  66W  !X;"]W;W)K<VAE971S+W-H965T-C@N>&UL
M4$L! A0#%     @ QH:83'*SFKJ? @  0PD  !D              ( !6KH
M 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #&AIA,5O!,
M^Q4#  #U#   &0              @ $PO0  >&PO=V]R:W-H965T<R]S:&5E
M=#<P+GAM;%!+ 0(4 Q0    ( ,:&F$P^9S1>1 (  ' '   9
M  "  7S   !X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
MQH:83,DD]-IG @  M@@  !D              ( !]\(  'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    " #&AIA,T34_25$#  ">#@  &0
M            @ &5Q0  >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    ( ,:&F$P_.G%+4 ,  $P-   9              "  1W)  !X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ QH:83.,6I$/1 0
M7P0  !D              ( !I,P  'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q02P$"% ,4    " #&AIA,22H$&C$"  "^!@  &0              @ &L
MS@  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( ,:&F$SS
M4CA!4 ,  '$.   9              "  131  !X;"]W;W)K<VAE971S+W-H
M965T-S<N>&UL4$L! A0#%     @ QH:83!68U#AU @  -P@  !D
M     ( !F]0  'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
M" #&AIA,[DO%1L@!   2!   &0              @ %'UP  >&PO=V]R:W-H
M965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( ,:&F$QB*WX$]@(   T,   9
M              "  4;9  !X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L!
M A0#%     @ QH:83*GW>$0%LP  Y,L" !0              ( !<]P  'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ QH:83-!H86Q@ @  7PT
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;72YX;6Q02P4&     %D 60!A&   SYP!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>336</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>124</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Restructuring Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuring</Role>
      <ShortName>Restructuring Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Revenues Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenues</Role>
      <ShortName>Revenues Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2132100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2133100 - Disclosure - Subsequent Events Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</Role>
      <ShortName>Subsequent Events Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Revenues Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesTables</Role>
      <ShortName>Revenues Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenues</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2326301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2327301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Restructuring Restructuring (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual</Role>
      <ShortName>Restructuring Restructuring (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuring</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Revenues Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesByProductDetails</Role>
      <ShortName>Revenues Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Revenues Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Revenues Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesDetailsTextual</Role>
      <ShortName>Revenues Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesRevenuesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2420404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2420405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2421406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2421407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2423401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2424403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2426402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2427403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2427404 - Disclosure - Share-based Payments Share-based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-based Payments Share-based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2430401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2431401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2431402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2432401 - Disclosure - Litigation Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationLitigationDetails</Role>
      <ShortName>Litigation Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2433401 - Disclosure - Subsequent Events Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20180331.xml</File>
    <File>biib-20180331.xsd</File>
    <File>biib-20180331_cal.xml</File>
    <File>biib-20180331_def.xml</File>
    <File>biib-20180331_lab.xml</File>
    <File>biib-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>125
<FILENAME>0000875045-18-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-18-000010-xbrl.zip
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M+*89>CQJJB777@!_ X5?H1B<C^8%=<8#L3E=$+AER8T@I8B/U*7Y2T8K*VS
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MH?)QZB,0WF!"J+1:$SZ>5P*N17)"0>$,-<L.UM421CL,;[1F7)&@B'6!>R;
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MDN7MD*YGQ*6<U=1X+P4("]*)=$8(*05!6F 0HI?$I=?/P;>F"Y*[]E9I$H;
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M HY74,TUQ#&@*T::0%$IA<!T)]1^;-TE2$S[R2"PW;8GC*;#2-$F9??<0*P
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M5? DIKJX\S#KX?O!L1,](I<=[X=0BH':%*7J%<1H,&9?=?>PW]F>\'!W&9]
MPX/GJ(?Q7%55%6K&:L6!1&9)NT99!TC&8>M/$;57JP<AK]QD#X7EA\]+$DGV
M]J;X/)"!F\"%!,92)6WE?F2%[0NO5VNR+://PZ26,GM2#@),KFPU%70,V:"\
ML\HRE;(K(&ZH"%^L]7XX/Y49'3M;<)A?>C*5)Q@7T\GB1)I:KZVZ!<D&!BR\
M7U-16MC*6B)@3PP-#!>O(6T:P_9]F._#8G(Z_3Q9_+?,2!S^0T[N1A_3%*Y,
M@L*DK73@F\0!T$6.@16T"QM'HAS?;!O)CETHCBO46*U0R[?D):++4'(?L=B.
M=XFM0*O/8%^$AL^7^RHUAZ:HZ)0&1F4AYNBSXBJ#?]-<3T1@A.GSNS+9SKG/
MN>:2O*ZV#+%<1JH0D\L<<)K!H#NJ2;"XRH[X>DWVV-P7<C,A>Z.RSA"%(*D1
MY9RC:4WH4M9=7:[.8'Q9UCM.[LO90C#91VVY"O8F!$YYK@6G98HU=3C_NS/?
M?KDOM9 Q:Y\8X$,(GF.9SI9:=H5]4G5D&\]BMCO?<GT/^#.;Z\,?T[/?IS^Q
M[3ZMGT__< VH."1!-BT%!;RK4FS:VZ:30^6][BXSG>I(TQ\G[OZ*+Q].GDX7
M;S^VV<7)Y.P_>6OL./ )A6V1-<<6N9QK"2U6KN&31.K2SU22^5J/TGZMS/N;
M0+Y;1L;LIG7S@2LLJU)2<O/5$F/B**>IF4PQ:^8\:KT+]'E8S$<J.K_:<7FI
MJN1]25I+ M$A%ID:SA&/X0MIV[VH,ZZCUMM/S,<I.@P%VDU33Z0-KR?C5R<G
MP)0$?.64$Y;&6[;3%'8ZR=D@YR-5_6.^XX[56)QBG;0J4%IB515 25R,@*^Z
MPP06:1=(\*"46ZHY#+LX\AD5-@OR/,\"(Z9(;*,*0LP"Q4%VL0OIEK"C[!Q3
M\8CFV!F#FTQ<M[B0BN5PQYFN!:^<#XPBG2VU"W?@NKEY+],<C\77(/PJR4-
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MRFC>K@%<OT^79>.C#/3#YR\3^;H[S[B6?[2<6?A F^H]#?Q=0%E\@69T#=B
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MTJ2O:PLLK0,G8Y0C&"Y"H@K>U]X;]'6W_@%4>(B1^.'8IS@3.2J)[0PZ&+)
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MJ?;VD1)TU@9YUY !GS/9!,7D6 B<7)GVZ*F[Z=E"K$.I<1R$Z8+<*J%.7+&
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MR8M\JQ>9R/F;<Q\GONWYRF?<)@N+I'65TTCV*JE+4I?[$\ Z;121 )( [D\
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MS[?]_UMQ!<B ?LRW3WUXW:?E5TG 'E@E8/U_A? _8!6;@VC,UG+$'[&7M1\
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M'H$*^ 0E8HGK/BIKG%UX5?8QL,!<2/RF+75PGKXI@T9C7$SSF3VCO)MH5#A
M*1R'G5]]OOK:_W@#3 \N5L!!ZDTQ20X;*#H$LQ1T&[SM"LR"JX\5;<Q^O/E'
M_US?"::%8_\ \VRPZL[;JT\W%V#\5F)(ND+?3,"]WUSDB9.KZK?J^XSDP6AG
M+P^SD%UCP)=8,NJ;A::UKX>KYD-.:P)%TX#2#5AT (8#1_2E%(&\^A&!WP?/
M PO2<>8#41L$F.KUKG%E-,_;_?Y%JW9>[U^U^Y>M6OVR>5%K=EJ=XP@PS>@*
MFA,)BQ$&I3(!C,)QZ"A#D(]!BT=(5T%E#'I082%H*?\A0A ^J^-:40 DPS&(
M)KS/0JV,OI'W),]VEH8-:#RW/U%[05/\G'RHBXZ#,R]D>,WTP2J$"KZIXT37
M_/:N]DY]EA-NQI^WYPYP>((1_ ESBF+6REN;2'$6__'+RS#S;%#)_-)9#G5[
M:>+RYBFJ>DQUXZ?UP?"E(?EH3ITWWK_7VP]Z\&^\O7O(@Z=UI[D3SQ=XW;<[
M'Q'MYQ;IB$0W7?NKFUT.!U'M,*A6N,R@V7"- SV09V*TQ<^6_^:36);[O_T,
M#SL1HZ;(J"7@Q]<X\%*8>O,N8L*-SX[OI*ZS(/8!*:;E"W%RXS)XF(,;>NF=
M*B\RI??']%<RL,<8KMHTPE2(47^TAX*40_K*H;$'W;"&ED5EP0M/!L2"Q(+[
M-%AFFPT'A=[]Q,8(B1")T!Y9\;,@$"<.)#N"6/"(69#L"!(A$J&\[ @J>[8J
M@S0X=6Q39]1/.)[7V*9<>L&D.N]SPNIY1N.TWMBZT'S!*%<X/$R=/BNW^B)
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M<-R-MT 6-,X)V,^1G2.WR3#:N 7#.JIC'Z,''SW*TTA#6NJ?+);C]24P<;_
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M:(L_@Q'BF8ZG]XP#>^!9SWI[(\"0,L;?QL^.9V->4,!A/#"@!T 665&[N7I
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M:5%) $H7+",T'R@CYHRY98;6*&TSHZZOQ]IT:Z,"X,O^_O7G4)X^<#XYFRM
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MX.30^>LMEQ)!HWD:7KI;)7\HN%D$P7<%JJ?]3KVS>ZJ7AH?+XS"^AFD9D,L
MR(RY!V^KMFJ=5KL,P'HHV,D(N ,$+#'0;1G:]AS!C'_=;><X1>=9FC$T,305
M9YR5Q:'8>]S:6V^7[M<[.:TWMV>&E87K2NW&,B"RK59NS"L]K+5J[7YCB\!6
M%>S*G!7_&$I8X<K?9_[.K NV2!U/% %0L]7XX:?U"^WGN^_)[?Z_:S<$)%.^
MYPK;M9QHI (Q^.>7SY?_$M(=B:\?+W_^=GWQ[Z?)8?[^RX]1<'PGY>S#A1W(
MNSM?W<G0]MPO8S/!ZA8)= N+/',\Z[>__?=__25S@>5X0>2K+^-S;SI3;D"7
M?E..#-7HW O"X&8B?74F S7Z*A^GR@V#Y%; 0"X2[YL:__7=U46KT>S_H_GO
MVXMWPA[!!](*CZ^ZG<95HW75OVCT.J=7G=-^\_+BLC>X;)]TSOKMYKN_+>Q.
MEK*W]A3H\ED]B&_>5*Z'^Z<V-XL2S3Y@0N8FK9S%NI4&D3J]?O.TJ[]\T*\S
M])R1?AR1]'B(-!4Q49_<ZHT7B*!'[&R[H!_A%]WY%1<;-FL/I?D2;_K!#D&H
MK UHD&4]<?D=_U:YT*.[0(YVJWARZ)2-B1)CSP%3!5Y%$$*)()I.I0^_"T20
M6;R57;S2BX]!801_""_R4=!&^ 7^W"5S%.43WA;^0^PCO#%>Y$W5T^/JGJ+<
M!N(U9[$T%JB+_\[>U/7\J73F&11_D]Q8T\52CF-^\]=WC7?T;U!+5OSOEP/#
M@ST*)_ GK,EH1.!11\X"]2'^8PGTTY?*YAXE&K*_,LML\^PE_4J]]@_/J^"5
M^MXLZ8V7O_7ZO;Y\NX]_638;AYB6)*Y7[E122Z$)5ZRMN%IS7GF^"$&_W$Y\
MI<0G^,TD$.L,ZDL7M<@GZ5L3T6[67F%?;\Z]Y4N4WJIEOWJWCJY= 3=S0+L'
M[U\C!\].62Q17>7N16;^#'?UEJ"?PH<"^2/V6SFUD@RYE@4W;OW,T[I7^UC?
M5*!(KV'$9*3NE>/-T!<2NY3M\F?&E2G3B),W-1HTM]""LS0,R&?XY3VRXB/Z
MMU*NBI"ETXKZ^4VK* W+E+F>L:IVVXT";]B]JXD[Y2I?.F2_R='4=NT@]&5H
MWS\=_.?&WIL9%?T<\Y8Y+?G@[8;#:[_:.JV?Y,5 51$4;K^Z3JM%PQ#K]$NO
MNC:WO4H@AROT6J>1GU2RL\Q*;W=*;Z\DD>YWTL\]5[':(L8^X&I&.I<SR@[[
M Y.8UB5#69A^^))H/K=)?:5./6KGJ%/?2MN4B_<['7X%G5^2 ,"J>4O"7@69
MUE+<RCU"^RS1JB*L+Q-/]H+7><$O26PF?YFT/(6 S4]>TMB.@[]K%,U)+\<"
M< [^LK(]N.#O28>#O^S-;L8KUU1X(T+Y7:CQ6%DA^ZQ;\%E[)9CM434SF'W6
M<JC1P_%9FZWMA9ZJ)JWLM&[?:755: IMA0Q#WQY&NHHU],29[=TI5X U4"^&
MH[GA)3>\+)BH[1QS7KC;)9M$)82_$J/<EG%MS^%+ U:;6UT6TSYI:R_V\NXV
M&;+N97L7&02>95,+EP<[G @EK0EV<,%6+VLOGOG>G2^G 3=XX08OZR[?[PXM
M>[5X;O#"#5[>HDVXP4NAX2)N\%+$=NQ>9+C!R^X0FQN\<(.7+09"0*G]IO!N
MV&HV<NUGFJ3NJK-+B<E8UN8M98XJK:!9-\>JES)P$8>\RQORYHCV!L394VBA
M^YWFE[94%<Q@ VA-F-F>JN-[%6"<V(?_^+:ENWZ_QB#B7/EU1]ZLWEF]<Z[\
M6QJE=//K7U@506&=MJ[R.YB(0(6A YIL!J*+9XBNI5B?Y5;[56^S.F-UQNKL
MU2E%^37.JXJ<L#9;S2I?68'EK\".&O7<CN^X<HNU(&O!5Q5 LQ9D+?AR+9@)
M3B9N'MR-/F;E^'90;^38XX>].]9K!Z?7-)GZK68K-SZJBKRP?GNU?K-D,&'U
MEH=ZX[,X5F^LWEB]L7K;EGJ[G,X<[U'%NFT6^=9$!DK,'.D6HM.XD]5\ DJ.
MT_]>2]JJR#CKQ.W):17$T0C@UCK)547.N)G4OL\!*ILDKE",6QGU4Q6)9,W'
MWN#R(5Z. WNJ(BCL!KYU)@\[A<7K/A[)PTDRE=6O!^-9\DB>-Q*0NQN_V2'=
M[DB>%[ PMS/F=L8%$S77.4C<SIA-H/+!7XE1;LNXMN?PI0$KQ[%3W,YX3]H9
M;[M]\:]*J""TIS)4U&AR+&U?W$LG4G$38F\(.TUF8K#4K!B_7RK<K5$&W/K"
M7C(G9YOET0D9TFLIN 3>AYHC^VKF 8^[=W@3VQO!#T#3WDW(1-5=,>@F4R!D
M/47N\V@:.;".>R7DZ#]1$.+W 0[K@ > [3NW3E_!8RSOSJ40&#WV]TCZH?+Q
M E^-'7B2L";2O5,!6<N3)&?"MV%-9#(;PL*K1R&-"8$EX \SBS_VE4,_L3QW
M9-/3GYX8\G*6RDAJEL6:_>)9+#7#VD-IOL2;?J#HHJ4_66J8E\VQO"&:_D*\
M<?3UYI=G^FKN(W4:C7ZK/5Q!'4T,6+.X2:7BYMGJB4UIT'V&!%O#H(O(1VDF
M^+%]\#=C40-QP?Z=-?&@Q%#=25?<P>U)].6#]$>! #Z9DZ8G.^3 $P!.'FS'
M,0B15*/4!9&9;@K7@(@KDP@5B(E$Q$"04>KX$=!_#KL,!*&XX[.%IZ$ UN[C
MIR[ C1](_S$6?5J &('(UP6VCL>+<#WZ:^P'KQ=F Q1&P_\@RFB$PC4AO"%^
MQ2^7)/CU?@H00.!.$<(5?4WP1\]PH^E04Y-62:] 1)K!/34(XBM+_TZ%F1]G
M:(9XJ(!+;#/>: C_E+X+-]'!!+-J&8;2=O'!>+T%E@C\<XY<4R6#")Z*V C:
MV0XF<+7!>-AA&PB6$&,%G8$3@*DFJ X"?.B%LA2];KL97Z0I3_NT]C9UL1T0
MV9H$?95H]-E@LL&.3>6CB!RM>IQ'VBB@;?B@E+N\[CS?HO%#H;<G(2OT":U&
MT4N(F72UK,62.2=4(W6'O;_-E=(*(^DLR!1B'7PSL=6]MGK$P++ X@=&=1YK
M ED6+0NXC@  &00DV X"1 M 4"OR?;@,F 4,%1!,%Z^<^ZV%3W)0!44S>*^Q
MC3<;*0#I*?Q),43S@HMKTCA1%^<KXHTU$W",T5]/3,5K87%C98<(%37$PHPQ
MAGZ^)L5L!EI2#]Q0_KV=BO>KI;L4PIR[IU&*5664?*$B1GJZ6"&>>M2&7U&[
M_4(?1;W\4Q>FW:R)E0W-\WQFK=@E=;NU1F,Y$)OK!A%RK37VP)KT58*U:-T(
M[8+@OP!<Y%W63%OPB M]\3^UF[UZI]CMK9YW^3+_Z?RYZCQVGU[B/F&0YEGO
MB3!YA1T>L-_T%K_I8:+<)0_'H\7#:G44:Z3 5E.)XT2[-U0K72Z*<I'CA+M"
MOZ2PVY*;%43FA^Q'L1_%?M1V_2BZ6RS&B]'RN047N@/M@DTX2SH /H!%(R!<
M;)59CA<@1;.!]CCX'V:4 JJ)&I#!4MF]-LJ-(O,:A!=I#,HCW@LD]8V-=W ]
MG0*K\51O=FU>Z8P\^!5H)]N)P&!4OT=V^,@>+WN\[/&RQQO^='*R0X^7U$+6
MX7T:*N*___)C%!S?23G[<&$'"+N 2U_&643[IL\MS[$(@/(*SU#W?)5D/P>W
M('!G#J#TW_[[O_X2W^H24!<D(OBJ?+HB^1'9X/"/;VK\UW=7%[CA_VC^^_;B
MG;!'\ '@]W'GO-\8G+;;%U<G5YVKWN#TK'MYUCQK-RZZY^WSL\&[ORU@0I:D
MSXR0797C\+3!NN#<MG*&D%;JW'9Z_>9I=\U!:4S05%Y '0BB;;XN[K:A$W@)
M+3'0U%JG:HV-2T6%I_4QJ6,P$ZQ('Z#+P,QAYJG(/!5Y[>7[/=9XKQ;/4Y%Y
M*O);U %/12ZTS(2G(A>Q';L7&9Z*O#O$YJG(/!5Y._44:TX[/T=3Y<L0 * 0
M]MTMD)9.[AD7<V*L0^0?!K75L9_/*L1#$BR7D&'HV\-(!TE"3YS9WIURQ;5K
M/1/%Y#)D+D,N0QW?"J(V:\U>JZ@NGUR)S'JX% A88J#C2N074ZMWTBNJ+>IA
ME"*S@?>DUWJA7(_RG]AOW;T^8'W)?FN!L%;=[EJ_FB*2XSA=,4TO!&]VZKEQ
M'F$F.?0U3,FMH><]JE:SR;VA&?X+@/^#Z0W=:G;R,_"K(BELOZ^9$93DK%-R
M'A96!<J*8!ML]4SN'=OO;+^S_<[V>REQ3;>:\F:F!9@[2NI%Q;:FH1V8Y5[
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MTANJZ_35V('[J9&06-EC>=,98(ZN#X+W4KYP/$0/Y4^%8\NA[=BAK8\RS7,
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MM) .U&'MSMJ=LX'>T"V_E9\$5450.!F(DX'*MP.<#%0"@X.3@=A>*9&]PLE
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M7HV;-Q]-FXQR,]%B3H?>RJ<58,>G&'"N16AQK4!WU[FU3+"[>B-VWAEZ.WG
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MBJP0U8(]4TA.O(<97*/E9)3'<R?*&>$ $AIU QL,% E4NC!-&_@>2.J/8NZ
M?\D020+,ZJ/LXBUM/[YI70R =T? U:CUHM!"60=*@@B9Q\/G62J#=H&W '2(
MG#!NS 5O/O7\! /TY!,D$"Y\(D'F)"ITV%J<2#F=@>#!=42[810 O314S&D0
M_01J40UD\DG(],ZGNB5F]@\$ QIQQF9E^-(A !A\G4AX3%<T!@C)(H5_PZZ
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ME^=7UQ>7WP;50DRRCUQP]\A*0I&]4;-03][!4!5\(=U(XE14+;?XD\',!XL
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MO?WRWD0QU"B)&\;T&ZKP ;EL@6Y9;#(AR;F'97W$S^ +-)L_=GK=6K_7I/?
MTZ+LS_$G_5K[]+36:9Z((WSU/^-?VAI[KZ$M\TE\4):<Q])9;IQO$OI*AO'I
MSJ<;O?$G_8:8WE'4Q9ZJ</+HB'$TQ<B-PD@-H!:>X5+,*\YI2-Q7X<BA<N8#
M,3U-8"2?\".,?<5B/4^J^L*_27 !R74<W%B11 MM1L +#NC;(+$HKDQ\Z]SV
MK<C6.^GA!]*_BY*C]@0,\#+T3\G9U$DVL;&+1W:9<VZ,+F-<1R?HK,B$Z6X]
M$P:$5[IW&)H"I0=J*-1A\9\];X3:I?CT%WU*"C;"",_X1L^GPE0]!'X9^1[P
MHQO+JD&.+[,D/:%R*$J1:I2\RZ]?Z.1DI$755_?>;XJP(:&* 20WTOI=--L]
MT8'_-R &?QD0JZ49#?H8W6! #&[)+W<$;A4ST9:#YKB98-E&:)N&07(BIG<5
MR?N$CEL4 E18+=%O-$6[TTEV5@;) _#I\0DJX)?Z/K-][5RDQR&MSDKE0- R
MTKD>@/9PJ;)"2C3 ,Q8Z0"#6B97'K;(F+KD-9YXY6- :) [VP\(UDV5RBRCM
MQN0QR#M?Z4_C_!*:L@?OL,)DPB68\*96@R-[1,>.L#Q,T:$G$A52R\ V>B8-
MI-#S'_3)T]+]@<(D;C/E3^WPF372Z2LNT@4#Y@[>>>$'-:'U+9HC0\PR@QM/
MY6^8QH)H[@ ?A/@<EU0BJ\M]4Y>[/S]Z6GT:P/@&(&/LX3R/CLJD-3^#FDK.
M0,29[:G?Q<^?SOX.$@@F@Z/CJX0H**]?/6=FHL^^%\UJ8DB)F6'F2-EXM9CZ
M'$P6S(_X #;5RO,_^VST<;/3ZK:U,C8_2'"]^Q-^]376SIF?&#UL82@\F'D:
MQ$R"X)(FT ]J@@[NB&;+*/[+7[+/P8_-<\11_'FK\=-@!+B#4<+D^%C>478@
M"A;J>80?1TXU_B07-G\"CX@ _:DEH2A:RL=$NZ7' -@!P_P!)L)0'-W^^V9P
M]NWZO19G>NRGF_KS]Y]7=[#I[455EXT[M.OBY@&36 S,DY>N01?P8?!S3:=V
M;L0J.M<@$U^9"^<F?M0MQ>?O(G!SO51I-9LU,O#,EO\,X)_L9F N/O)BZZ%M
M?ISHF7-O.E4^@5KRH&^8:'DTQ__OLQQJNY08BM88O6D46I-:_&2\\35N!_R=
MS31*M/<OXL\I ZVV->")VK$F&KYJX^?V??Z93VSI;;R<[*O3RVF?V*P\5O<+
MAN_UG"G1S^Z'SG# -(0(%F.LH?GOYQYG'E0'%!)$:#1UP9Y2DBQG3_/(%*O
M@I6QLW@+-%=5W:G[<Z_3B7>WJHE-Y $\IB>[P&(-5$L L>+30$>LCW2*D_,8
M?W$-;D'\[?L8:#*Y-9D#H,S9]DN.U](LIKE#QB&\@GP$],B>GZXZ@CJBGX$B
M 3&(QE@>Z*,QBE$]M&1->A(\ Q.WQ-GE[>#F\MN7S_1Y]A+\]O)?MX-_7@\
M"B\_78@;Y7NN9V+Y1^DGFS[KV^79]17<Z^L8-L(WM]'_@%M8WG%R7?)CN@,
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M*(E%3P2-)S-F<IKB9:YP&*E94O85YE-3DEQ-^ QSA*B9$65 9?.UYQ/_?H]
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MKFH/VXU6J\5"[%8+7\*ZLF)SA9U6!.(V;+VZ'9:APR\S'XSPADRNSN+W8;Q
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M5#8@H+"!;@T&-&/H?5CXBMM\/@:C:P,7E]2& ,A]\/ID#8,_B4]RGKJ1 ?A
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MT50;!J2(L;X1X[T@3Q?&TGU0064A2]ROW5((4KJPC,:YF;5-S?P**_?P;5G
MX<>0P[]9H--Z"#@7\>U]'!OJ'+%L6$@%,3 -4YF&H'P8,B%.KR*^K:X,J"YR
M0NIM-:M\!DH^L[D5_,8C-@6<)$VF8L)GH]LS%.8ID!8C+79R6FS8&:@KL:N+
MI) >6\TL=S,_B,XC'LS9A(_AMMQ.LEA*T6?4 &*Y 01HNX-5PY(V)&U()>FO
MVC]T5 XBH8+TK;3IH*[JE K2*W<Z3567!?>[WV]3U259)+H<5%-ITT&H5U$$
MDRY4PS2'ZN8\4FG3?J5-FRN0UM0N^?,%]T(K<GSOT@^C&S^XFUD!O[!"/OEF
M/>,A\2@ OGB0Y\4C%^XEOOUUFG_QY5W"B^=OKN7M7 )U;72OS99YT[NZ;'>-
M0>>BW^I=WUS>=+J]B[YY<W'0$BC1MNDE"^E8$Q7B/IR/+5F+E.\$X[_CSQS+
MI'S;$>5)HE2*6_8,$VZQC&GMQ8O ?PBL.94P40G3VLNK78-4J<7O5<)$]FW^
MNGV](V['*[X E2_*8>]G >?L,WQG%JXML[CVL#XV*RHJ)V!%!7A4@*>)R&Q3
M@$<%=%1 =V0,KT+UF^YQG\\RF2R,T%>-/6>GY&CU]1XZQ&9U.B<XG6. GL*1
M%#IP$47X]8WP4P!_"^)4%%ID-B+EU),!M&68V9GS\T<>8IPX@'\"Q\8?]S.(
M*,=^W2$_J7=2[Y1@_YZ4P1Y-&":=MF77&NS>&/(H<D&3+4!T\0P1^S.2/E.D
MSSH*TW=)G9$Z.SEUUE;7\:,N<D+:;#6K?",%IEZ!G;6:RH[O-M(NY[5J!]I6
MT'&7TVC2@J0%E^_7(2U(6G!W+5@(3F9N'MQ-?$S*\?V@WE)8CD3>'>FUD]-K
M)32'JXN\D'[;6[_A4!I2;RK4&YW%D7HC]4;JC=3;H=3;]7SA^L\\U6U94^*%
M:WFEZ#1J>K6<@*+N])Q:7I%./)B<UD$<$P%4EI))#:^VTJ5&;97I73R.=NQY
M1<[@&L78;2GL8T*:CS3?R7F#G8&Z>$I=!(7<P'69F0L'%!=\.%G?A,;&9D+D
M%):O^\[:9?7PVH.VE"1#^I4\RSTP]<PLJWOH>J+515AW$T]R2-<.--C0C,[Q
M;#>>R&-,X;H*)<\L;Y)^15G?!6K@?(C&#-3 .:^%Z9<U3H*Z-Y,)I 7\:8QR
M!\:UBL.7!*PNM6X^<NOFPS5@7MT!^@KH] @7/O);+XR"6#SE)\OQ/OEA>.O=
M158DGOQU>N-XEF<[EEM(4-NEN_/EI=%O7[2'-\-AKWLYZ%R,!L-AN]N]NK@V
M^Y>F0=V=T^[.8=[>6;3FY-,IMR-LV0QTAP5YS(Z#@'OV,W[P9 430?X J!RR
M"0_A&Z+;LQ4RV.8'O*^3;RY:WMCZ&2Z9H+TM+A;.G27[?20['N(#P5SWYWS_
M)M %$O\K#B-G^KS-UBUI)LW[0@^'S4&KV^H-3+,'2QYTU76)-@PE;:+;W4HW
M6C:K_/;M3I7?_L"T7\?-2P)Q\%#?!I_A;>M%L[[.+_HWLUUZUV[<G1YMSK:;
M\X5'#(VL\ ]G:&?Q#;V<=7O][]QVK3!TI@YPTS3PYVST]?(6C(7(9U\7/ ![
M$FR.6V$[L#/GG2VKN\17I\-7_H,GSH3A1FHXB7K/J]J=3XGG20$\]6>8U):?
MVO)KS:D$EP271V="@DLMX+(BPZB.<?[TG3]R+U:7PT!"KYX^:X4_00T103YJ
M+8U.^1WO2-\H@Y['RY U%19.*DV!K1';4GZLQKA)VIBXBK0Q:6,=M'&+E+$^
MRIC\P;4:*#_#4)W=3KKH@+I(8S;35=U43*,8-,>BPLY%_:&)5!_Q%ZD^4GWE
M.%/EZ[Z]G*EJ\=X^_M+Z"I*#*79%Z?NZO>^K@]6*5QO,K>#!\>1+6G'DIQ](
M@1*?4$%"#9/BJ2"!"A(JEF^R.L-DVX*$K5N84$$")8Y300+Q5;E\E18D7#D!
MMR/W63(5KHNJ$BC-MI;!)65IMFIHN?V1JJXPLHM5<QC^5'9,K1WS:L"PA*"$
MH(2@1T-02D>AA$A-],U>)W$5S2!3>_Y6YX1&<;^>\EZ]Q^<82CJI%Q153\%]
MC8"F2=<R=I8DGE!5B<8\I@UXD;HKM=6H\M;(Q^<8?>;&G!;&4V)AA?!==VXZ
M)(1KC])G"B>BURWC;[<</X*:JM&'W!7BL>H#%*FS975FDCI3//!JNZ$';V5I
M+R5/FR\2KHW>HO3&^WGR?GML)7_$FWX4(RGM-6=0;]-JLG[(@Z(9"SL,<%AS
M4S]T\*#WQG*"OUMNO-/XAHL;<] 9F'W#&%YT1_"_G?Z%.>H-#>/:-*]' QK?
MD(YOR*<WA"+A=0KD9H](;S'F;!'P$%Y1CD5[>Q;#V'*1 U@XXUS.8\ O^W$4
M1G G?. DV_WBB(=&,F9-O-+,#_GFJ1#[CWC88B^K46&1I(BW6NH*)KI*ZB4Z
MK?=EO;_W^O<F[0^T2-HG4YE<B</D]%!ST9>E'Z@!A<51:OB;LOM6T/[L=K]J
M!Z+TKI2^2*RU.[36V!Y9E=3>N#0$&@GK6>W@F]5;]&K8<QV#EZ]=9O&$OR9^
MQ>VV?@59('6T0/0B',UJ7Q.Z&(4AZ*D\@E#A8_3CG=W(29P1LY"81Z4@=? Y
MV0X^1E/9J!LMN$B?Q*H34@>?'&OLN$[T3"IA;XUJVT',)UE>FHCW^Z@G2#&0
M8CB&8C ZZA*ZM. C?50#^:6:TN=XSH#KX[IX,&=NHDR=XZI0+426H/\8-&N;
MZG*?M& C?9#_E$.\$NCRI",*\%* EP*\VDDO!7@IP*L#(<F84Q3@[9 M1^J
M KS'UJ@4X"7%0(JA\HI!\[$;1Z?:6R]',S;$C(V.T35;G5Y_T.Z!0%+)")6,
MG%Z\BNBC*)Y7R[QL\1O5@FA4H4"U(*=7"W)"T"*+/*ZXS>=C'BB;)U3V(: V
M_>RH"(1L"CH*K&?@DHX"ZW04J#N]J M5X7XM=9W>:QB*I8 +0?$NTG3K@?:*
MA%F9G[X1)!,D[P;)RG)C3Q.23\ATIK2)FJ9-Z$XU0NS"_08=LJ+)BB8K6FE
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MY:W;$N#JD8U=&RKUUI^MX#>^H;^$;N]\]HD_<I<9NR@& BT"+=5\> >/=Z9
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MSIPM,"(T$9H9Z1!,T.-.5&H>DP1?!^X"L!@FJAB\#(%YBRBW/W[V!-WN\$%
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M*YX\Y(%$$(IXOI",*206N5,>U"7:!4.'F!4U1\F424XB+;<!YG)VJM- +2<
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MBC^BGD]R**RT6%_D_.6K+ARSK[AJZ:EYSF;V5FDKV:0ULCC?$4U/<OJ*<W-
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M<"0+9CY9^B8%;S;)$H2%\<2YHU*$2O#'6<G8"E52)"Y44V'!U;9FC#/ 7&%
MAY?);R^;!HIB(V\D#Z.AP56',R!V1MS,?=@AC*;@>#:.AL>=EH3)T!R'!/F
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MD*5+<#FZW(JB!ED]*RU<7>0%\5$C"Q+.K>N[W-JEFGAS'?J\))W5IYS-VI:
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MM^C'W-FV@?V1./J&RI)(MN7* ]OD(;]X-%Z%_ZRREW>PLV'+9K.7IYSL0'>
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MC_"+!_+[R6(.WX<[4X[W &]]M'3OW_[RRQ'>QW^/__WM_P%02P,$%     @
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M56TI(Y;%U)A>GUK!&?'Y*(M0SL8&CG$4N>YAQ%:P1&N#MM&"EK;%'(\4+:9
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M4_W)88HQ]BXPX^/M"9X3NI)<&5A'1T5CGF':]:2'.G*/8FH@(N?DZ/7(.!>
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MMX\J[M#;E##U44H]8(E)]+0;B:4W#SY%1'VH46?$J>+[&57B.S<F^#= D=
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M-BD>,";D>.8IXWH<F'E&0:T4OWQHVJ2K7SMI)(\+5QQ+I;/N[CDER":ID*.
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MPG0XQ11S9\]29\L+#ZVW0? OQ5OOXJ<X7>Z,N[@I4K'\Y+:3 MKP";F(.0R
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MK0%(6!5<3$BXJ!;I/;&X_5+B8+-D-/;%@S46_9[+N\GWKX?3K(NR:._V'6O
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M1#M!)1*,"B8DMY664$$Z'K^A/X/E43&+=KYX71398G(LV#_T6(*##H(*#K0
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M8+\<HZ0>X?G0X<S=DE=M@(R66?=R$:[!N>*CC1*GC%7$&*8(]$["H/4>2QQ
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M+^2BU<9I&T ;5('MU&\B"0;*<T2HU(XJ:H  ^_0VUJ&H8JP)\I6D]W5!/>I
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M+%@JW18EV"EW@EXM>DLHPIY)0:3'Q"C+ -CG+3)*U B'L8'9-3R(XY@)6\^
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M+3^D]]L;9'V08CJ;I*?+>I]JDR@ !!'2$2_+\QU".4(KN6F 8GRA?W<3Y,.
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MI\W8EGG.@B/&PK2HN)/8(4I\\!IWTH$0]HQOF[T'I$_E.9\'2*S7M;^RN"H
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M[+$M<?>AR+_.2G]K^3G?I6?LULXJN3;GI (BG_,-[]\L=BW_.TN/3S-]=)Y
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MQM5"VH'T?1)BE&L.(^%!3_N.G[/)5?#=BO1T7N>SQQ(3HF%9WDH))2$4,T]
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MW)\9)%8TIL-;)[H#IA.'L\LRW3P\&Q;ZVU]6T(-@+])MEE]7Z2:>0:B_\'&
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M8+1?N]T6-R]_8KW=/OI"PQ!I& IQP] _O?+AW8_[XM_^4)=W]VM%S\\#\%L
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MGX9U.]EWQ[[>I*#-S;EYPCVY,Y@Z/#A5>>V0H]8+O2LWQ=M=<5<O:))!DC!
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M.366F;0_>G[$1.8/CXP$C1-!Z\5T[XW8<'Y!ZL=JS7E(_FC>GG]"9 26=:>
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MX]Y#)7I]+3Y?6QRZ-2!(3Y<\,F.F0'L@DPG-8QXN2(HE8?,0#UOP+YVBM>7
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MNU@\.B=@'68,IU5WKV9$/DTW<$Z.!CR*1^9R/N!%QB[N^#@B>QX2Y<Z=\X<
M7/!DFX@Y,8@SR1!4'T=)B!!*!!6\+Q^DB [+Q1@8\BY?^ZS"NI_;K15L")MV
M*1E/- [.RDQZ)L!4HQR0.@]U<N'(*QD::VXLDC0+3D!"LQB0,,/-58,4QWT:
M"'" ++,SKWYWE+2,BW3,ZPP9YV&<DF.=@)DL[Z*7<-$F:1ZZ8(7\?(K%T'OM
MAQ*KN[MR?QBO>;2LVNS*S==BLVPLLDP $N$T1@(GF"$LD]YBRB/#%=402_YK
MW8[@]F\CGL(S?!AQ"*-ZRC$6E69*\I1#KL6AGU</SQ-T06M<T#H/[7'BR=-W
M#9VQHZM-ST\9O-T<+I_YN*])I;O=MOSRT%['^;EJPB0%2Q&E/OKU[4:M*XKZ
M6 Q,,R(!Q! C%'.F@J4TR_J\E# ]7#TR..\*N/?!\#S!V"VD)X\S;AHS13UU
MY'\<#E]=!;TSP<&;X-2=8%<%CQT*.H\F._+@MD$N*/A$+3\/T9_*^6H6HV_H
MU-(;)(#34,73:9QDC)(X@\WC/'N#$3 ]T3' D'?)9V6E)O#@[:I8-J+RT_XQ
MJUYOBA;NT E!GU=;<?="Z'"A?J;*'_-)SYU9'9=UP/9<Q='<D5>%SI(;_;NJ
M#_L5K>7].^*0IG$L$(<LDQ!3@!#M*BY2#(0PO:+:W()WF>I!!76#ZBJXS[?!
MMP9;\+^#GP (@_OB\!"?Z175%GSJJ91O(LWDZ<C@]9[!%I"*).OZH5B-?1GU
M,V8NZ,\0'N<A/(,\>';C]% V3-*"U>;$#&4L3%.62IYAF,)PO\C?FU$B9UAV
M9?SY41* :B7ULL( 9"LQYCSJ9P"]$6B>]E/,3:\L3SEY)=-G1=\\-,4>_@LY
MO0$\:!]N6ZW*9N&7KS_FY>KMAN?WY2Y?+T J,\! E";*(I4T8A)UUB+,#3-R
MME:\:\L1F!*6<O6FW 3+/3;#@VZV-.IIRAC\F4G+"7$-I$ 1QU\ASL]9MY>9
MN2 P0[F<A\X,]N+I<3<GK!@<J7VX>U@W3VZW!15*[.ZWQ6VQJ<MOQ=O-LKHK
MWE5U<]OKAYO/^?<%Y"G-HE@*% /%5IRPN-<^E++$^*RM4^O^5>H(^' EZ_(4
M<K!6:(T/YKIM $T=FY!Y0WT[H7Q?S_4(:[ '&_RQ@?O/^R<XJINF3'7TH[XF
MA%Z214]-,Q.Y].7=\U/#'EG4E==/Q2XO-\5*Y-M-N?E:GZ#*BIMR6>X6F#*(
M0A!&**48-V]3PNXRS!3@V#"5[L"@=Q'M, ;% :298KK@5$\D1R;33!=[%CMT
MP1]/I?( <.2GAUYG[(+P.:1['EKGTJ'*6]<TO,AI6^3UP_;'R7I8+8:5;A()
M2%-UBV*DXM+.4$@BMM@47QM@>@IF84!KD)'](#O%HE\7>\#4I;[RG8K[:L.G
MTVR8T],I7Y397>?4<76:[!KY-J=G?%Q0G0'DS4-EACCP]"JGH5S8EQ8L& X3
MCE*08!5W90BCA'=WXJ;-VY F)?46GS<9$-:5]5TQP=,Z@O_^3VD4)O^GHVJ"
MUZFTK2)PRJ*WZH&I2P:,2@6T*9V'V QQX-72 $,N=,7FEW)3;=L2JWW9U )D
M(0NC9EU'4AY*@A(A.C,9Y(9++N//>U]@/2EM+ _ #-=9YK3IR8I7OCR(RIE"
MT7%5YBEI%S3&FM]Y*(P]_,I1/YNB '_!H(JN! Z1"K5H2F* <)]_HC%/AX4_
M7B"-$C*Y"8G\-(EM&#5Y:PQ7R0$5]E.'9S;L&X5T7IMW'B(]MM->RN<-.7?U
M#M6"@R@$4@6X ,$8,H%CUL]#C #;J_WLC(TBXB<GRMM3CS:B/IQ6/;D>E5$S
M(7[YI:EY/2]U02F=,3L/#73GCN$S4H8\Z>]5?BLV#X54CC8'5YL:_;^4NUO^
M4.^JNV)[K-NG49@QAILWK""5B<AHG DD84@EBV2FO;GFQIS/';868= T?=!A
M#'Y3((,.Y60'5339N[C;YI;_>0Q*YUX]VW?SP9JC(?JY^+YCBHV_+4 "$@H@
MH# C(68$T9AUYE$H5(BAU$2[I,"14:-0H\=G.ER-JPE<4>I$]ORPZ4'W&J!!
MBW1>RM<3:"]]YFWPN] ^"[?,Q,^6-_W;3;?EMWS7UF\IF7WHKMGXOXK55[6L
MHTOU1VW4E)7U<EW5#]OB>$(:)V$:QFJ!AS*8I)'@@""69E%(*1&9;MGD$ AA
MG&28)"#E3**4<I9!SI@@*<F2+),>2\2/J(,3V.T2X@ \."(/CM GBVX&T'QA
MV(_1>/-0@E$\?79/Z%CL:F?FE[?%ZF%=?+AY7^TKZNE=^Y+,AYL/#[MZI_J_
M G;$_;&JV\K[^G.;->K5+&6 8:2T0\8H0EP"G$6]=H#$\(HO5Z@ !@GGB/,X
M%(@CP 24(4A"@G&4,.;_.7%9;8ORZ^;PBL/R1W!3;7_+M_M[P9IFK8/=;:X"
MAT(I2='FW)K3*;NJR0TK#KX6S=\HEGG=U"MN]W.+8:)_K!;6S/3/L&D-4_T'
M#YH2^LZ'X.!$\WLG;@0GLTKOB(H+V^S_9-&AHR:XE.\?N9'G,:.,[O73C/\D
MK)O/-"_.@G_*RTUSV.#MYGJ7[XKF]S[<R'*3;Y9EOOY8;)4.WJG_.,&99%&$
M0$1A%,<ADXGDL(]7P]#TCFOW^) @"2<JCH8\1"PBE&024HDA(2@)L?^36-</
M=W?Y]D<C2KM;-;_<W!3+]N3/JO>P5K^NU0S5UL/G=3OG[.MACC%PM6G_NAH%
MJ^;!LW;RJJMUN6K_4MW1T8I?V9X:L9VA1NL9IG/5'+N$B_7-5= X<3@8-J.)
MR1'?6E/4V&T[M\EJ=/_/3EO3M(2C">P,OL,<*_-RVQ:+'U'&) ()@;*I'8\P
MH&J&E9U(00ICI].7,;I,B2>%@" $)(K#-!6*NV;%F<594V\ZYN1UH^ =KE%I
M\C'WZF\I/_*VH.;Q;.9TXG'?HDZFG4F;TGZI=";!5C8WOAS<:7ZL=ZA?,%T%
MC4_[,S)SGZ),V\9^@O+6"WX7TY,_[\TF)\^MH/T0T/9KOBG_T2HB[X/SIL1K
ML_IXHI8G&'O<=9]A1#S%$<JP(#B&) U9'(:9$C 2Q@+ 2/OAX5' ^!.M4_Q7
MP2,/VNGGXY/IYZA81S<FVQ5P0OX%51JW<>>A12/[_/0-GPD8-P^)>;56?U!M
M6X&DVZT:4$6WN]%6EK[\QY_5KVJ%K\]"+9*XB9R0H)SQ&- H2I.X QJ&(C&I
MRI@ GN?ZC=. ZI%/P:E3K4PIM]XLS_U(<.K9(:@ZKU2S:7O3^'F6S6X?0H_7
MXIYC9U?MHA4^C]X)YC%K34G V2!ZHK;0/Z=VF#C_5%1?M_G];;G,U_1[62\D
M2,,$Q3@3),9QK*RG.)-)0L,$ @;-IB5K*YYGEU,\*H)5B$SG!'O^-*5]%.K,
M%-J$-4_'M\Z0<O%$UE B9Z)RP_UX=F[*#3/:FE-\?6HMJ^[R<K- F00P)$@J
M:R E<1J#\& O4?]%C#3'VLJHFK/'9*HZ]@QJJLXHY U1G==X\Z,[YVBYI#N#
MJ9R)[@SWXZGN.&+F-=U9-B4AVQ^+7Z\7D8J9<)H1DN(((,QQ%,']AWG&1*@5
MU!A\SK.2_/K3]4]ZPF%"P66%\.2]F13\^O[M9Y$%UY_I9W%M(P%UL?SI:_7M
MYX,W>P4X_,?3P7_T^(51;D''M,/9!G!EW?1F@<%1";*RWI_4;O84]A6EOQ1W
M7XKM J<<0,F:Q4^8$1$AT#S?D:21PL(DPR8A@@M[GH>X^.G7G_9/PN:;?)6;
MA0E.^-0+&,:FTC9T"$[A705=M?)?]Q!'#B<T2+L06+BD?!XAAE./*G\=U#+%
M<KTL-OFVK-JE%1(\SD248 Q33#(8"<:Z=$X4XM0JO6)DP7OB?H]E6%K%C#/#
ME(HWNDP3WGI,^4VEG)*ADT:Q(F\>.C/0AW/IDP&,Z&\_[DW\NJGOBV5Y4Q:K
MPY()HX3%(8D0DAC2&""NXK.#/0&$6>K$VLI(FG(5G$"SS:'84ZF[*3<&BW92
M8TB@I\VQ,_Q<W.,:RNE,%&BX'\]VG-PP8ZI$\G!8[Q!"28";)] H33"%@F4X
M!*3?I>(1MY$A0Q.C:5"'RTYW3(DS$QV/G-DJ3@=IHL76R\QH:(TEE?,2&ELG
MSJC,($ZT'Y50/_WAYF13O VL.$$B9$ 2 =(,A!&.2%_7%66IT24V=A8\"TP#
MJJE].2UEZ8I=\K/E+1:++$M^]83(/[5F.N2#53_/5+Q$W 69&D;T/%1JH ]/
MWZMPP(CV2XG/*GKREXMX#DJ940EXDL4$8DD0$0F"73 F42AC$_5R;=NSKKU8
MO7=^Z%DMZIPWAY[83=D29C+HN!'\/)IHQN8%;?35+O-036_>/7TTT2N+KRGM
ME[+\LJ!?OORY+ [?1QD,(8!)0C)$D$RQB'CW?0"15@1H_E7?ZMABT5,["THN
MZYA?-@P5JH7Q^B)Q*".K:MF>:&N/DDS$S",,KKK*$TUN/&B4-@7PH+//?'I!
M0>W]GE8;!^"NAK:X@9Z)LL[+P^?#!%$@A5++5+41C4&"LN[S!(>1MIR9?-1W
MV4(#Q6#H&O&AH66^J#"3LA:%C9(9T6$@9+YHL=,Q37KT].S$M7-R9N/]#-3,
M"G8UL-7-5L$?M]7J8;G[L+TNMM_*9=$NN$/,1083&G-&.<YB%(7=#JA,&3/:
MD;0RX%GC#ICVRZ@#+KM$G!U]>DM3[\R92:(5:5Y6F2\1<V$I.8C'>:P7A[E0
M.>Q75NK2/GMQZ#&'K<T89Q%EC$$HA4@197'6G8F3242,BJCLK4RC,U;YL0%4
M&LF-9Q:=:,XDN:VS_+PN/0,XG97^#/'C91$:S(S6FNT_W[YGG_[C,SU$4@"F
MG,<I9CC->!PF$1#=GJ=D"&EIC\UW/:M-A\9@M6)*C,;ZS2,G9MK1 ;%9Q9GR
M8K"0\\B/W5I.GR>]Y=QC!\^MZ"QIF,&BSA9Y-;P3F*2I(@R(FC49?1_%(#P8
M8A(RDH6(PS !$I,$,]@9HC'55SZ[S_M.736@VE#A ,LD;V/'ETY"RSM5AJFM
MIRQ9I;GLZ#))>'FGS3+U94Z?9AKL)8?/)L0&L3,#%1WH0.6LIYAL9:J(-=\\
MW.5?#C:2$"HC$$8RX3&.*8>R#U4Y@@;;F:9?]KVEV>,QV<0SID=G:],G,X;;
MFST4JRU.8W9,MCE]LF2YU6G EN:^YQ,GS^Y]VI(Q UFTQUZYZ YFV3T'%V2]
M*S?%VUUQ5R]DA'$"($@PX(AD0L8<=! ESHSV'$8%YEF*'=ZCU_@4M$X9YA['
M;6B]=.5LV]AL4AFY>;UD1ETVQ85DZB0M/H_\ZS2N5S,8<:8S4KW[</.GJEK5
MU]5ZM8A%S&.! 4LR04+$8,H.\QZ*&8Z-:K9-O^UY7GB[^:;(K;8_@N5MOOUJ
M^IR$,5.ZJNR/)%-AK=LW&EHL00-F;%%\Q,1%7;/C;"[29(G^F;H,84'_P?6Z
M4#][JR0K*[X5Z^J^D2CQ_;YY+$Q\7ZX?5NW;IG]_*+?%ZNWFX[9:%G7=@%O
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MFD%_-O7Z/J&+YKBP1)FDU>>Q@IG&]3./$$[ O_F+N_V4=]QP9X!1)A(:Q8F
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M Q@#"3!D14,F_1%BIH\''#:Z:$B*@2#Z(\=.";5)TE/ 1^Z=DSX[#F:@>9;
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M?4.=J)SV+H.H3U;;HORZ*0Z&=MU5[)!P@B /"041CM.P?33S8 HRJ+75.<B
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MV6+$"B90=B6J)8:$<8-P-[NLC J_O=WS-I"QF@RD$K*P>1V # 'G$;2K(5W
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MHWN1R9^&_L5VZF2A>D3.8NGAZ]^MJM]G#VWI:ZZ(D2(7"M$"N)46!GH'24-
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MHC3GA F,<VP5@$,&"E::G)#"L)PGU[8.6W;GP/64MB&4!DK;2%SVEK8]GPW
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MDB4 4('T;_P>T&='\,/$)NU@^(G39$8A3,S>IK\Y-]\ASP[0LP/V[!\.?=;
M'WG5,(3I,Z(YR@!.0V3'<;6^P 0)$_$O-_?5_'%9?;R5L\V]Q>+^RU4A_Y@M
M';JO397/'D2I(&6",KNJ*A 6G#'&6Z6P0J$,#I/M0..:"@Q80:DI%>:&4DAD
MP0M M,1"PZ!'B7H)]9?'AX?9^LF=C-XN5K/5S6*VW"V.LC\6VWO77^]QW>J$
M_3/+:K/)MO>S5<9 -I\];5R5PO)Q7LV;/[W8/>#NA*;Y177P/$S\8P^BG]Q?
M</3"!+X#ZL9$=HPWOSA":]6\O7YS*4T/H_.,BB<:EVGH=BKGZE&^[3!MYC]F
MBZ4S9.KU%VOW2W6S4Y>#98657<QC"!'7AA0& :.ZN<P #NR8[&,1 H%R@9'$
M"F-,J)"%8C931%+9E85(WT#YM]GZGU5;M3ROOK4%CKNK5YL]WC !C<*TGVJ.
M37&85.[1_7);KW_96'S9 >#%)=*#NS.Z&)/Y:8AA5(_J=-]I>,N)MG9Y(W>/
MTE=S\=3<@9O=;!]GR]_:-.M)S;;5"R7&4A4*R0)BK8DPT)0Y[&9IH2@,;Q78
M&PH'=B6-0"&9T=AHQD@)H>*H+)&VZ7OZ:S='Z>K- ?%1DOJ?V>SU?.^KH6F'
MS4]<)S->8:I[!#L[X,Z^/65'R+,.>N:P7UR+AU!]1J1'&<%IJ/<XKK[1\6,D
M?GWU_G,U6R[^7<W_-ENLW/VBCZLCD"\02"FA7;1";72N<XJ49+33"607M&'R
M'F(9*5P:;:!VKRX;DG.5BQ)RR0M8*J6#.G+U+#"M;ZIJOLG<EV1%_'D2W%>U
MHY+O)]*78CU,DSN4F8/979FLW5NW!ZV^M 8','E&<E.,QS04-HEG=?JON6>+
MMC>/=B#/!9(,YZ3DC%,"-%*%Q%A(J]Y ]FR=W<=4<H7<H^O9K*T7?_Z)Z2C$
MA2>>#:QI'&N=8^F=G'$PN=-0K#BNG.KR-IP?7TTRL\6Z*5;=E>>MYK\N9M\6
MRR9#^:V:.0SSCZO/+FM9NZ.OU?SW>K7N_E',-HM6/*]5+HE4 )><0%44)2HQ
M+4E)C$TXM 0JI+!H/%2)JY*<(VTM^%57P.IV08^\R3IW7,ZR=ZCY4\<N98U/
MNT3&LZ?8!<;83V2G.;QABGP8V6X$FT3BZMP8OC=Z2;0Z&MEGA'W\ 9U&%+B
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M"9_6]4U5S3?&CHDK)^2K^6^S[>/:KN$_WO(?L\72H7!^V7_YQ;W_U&RJ75/
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MR+%35E->@JS?'G-P9L75B:IIK)&Z0:\\=!4S#;AN/WI&5JNVF66Y;?,_4*2
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M>LJBE.?PG$Z;3*H>4&>/VW*W6Y7UA065[5Z7FYT6JCY??)E=#C^_.':GL%W
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MP4Q>+^0".V5U.*XXU3.*7LXF&KMB&EH:PC#GLXB6W U44+E<S]?7)UXDP;3
M!&&BVH6$,(FR_D42) 'Q<@!\"(#1#X#?=&"]'P ?Y(=!2CJ6 [PJ:@]ZP@?
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M[;5IJ'!P*ZMQQX*E4N_4K$MOK>H8L7O4!^BJ=1TH?BRW,Y"+'(." ERD("T
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M5@J]"N4:?K1YCM]N_A344693J:GXR&Y6]>9,ZJKST OT5_5NKQ)N9<&X8CV
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M1:7&@\IUFD>@+DO9$RQ.U%7K\O0;2L_T7=ND51O'H-7LDU:^HLK#&;FL[GK
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MVXQDIYJY[>M6\U7T;JU\5$N!PWM)WIDWV\^^-.5VP4PCO7KEZ21=#O> .3J
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M.\3JBU?)ZZ 8# =C[J8U!LQAG^CXEG;;]O;ZN%"7^O*R^7.6"9!@KH]?I5A
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MJ5A'9FZ4G<(?A:WFCU^V3B!]G%JV6L _Y S#H#3 :$2)9L(QSQR"UE&/ 16
M"7J^&6:S0;CT^/>(_O3!0 D'BA.$HBP"<&0QDI5$!$/[[]GC*+V7+8+],%=T
M_'E=_>=BG2;CR^F[XH]'OMZTG,0_#E>'&]2WT6S?1W5,/P$9@!FR!'N (<!<
M$L376%C%-+XLXIU*A#(?Q+GH]CF^[?VUNBKOD]I^+>Z^%-,]K-KV>."2*4LU
M-MJ;* O!V/E*,D!DK7GX]9"G(ZV7K0.=;<;:R!^_J\G58'HU^^T^)<S$YQF
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M*(0$)Q6R$+JL$V#W%E=F-NX,NI])?=F+]?RU*&^F@_O;T7 PKENHYWF;X(&
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MGQ[:/@W4D8UJZR'^-IG=%\/1]:BX.FSW[&H3&.71H9&(4L^P(H":.'&O973
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MB 2<1PN+\XV!!1AK<AMF+_V:YHK=PI33 <VWNFRKY[<&P7U;AUO6!=BN-F4
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MX^+]]=-Y=?;^^OUB/IL/)E?+3(U*]@_E;+2L?+;4<?I4=!S8[WMP:^D- 3#
MC:'&$.AHI+YVV$/ H60,<:VS;C7GW;[ID&_/JXR?15>Y%N4'Z?;Z5&\FF\K)
M[Z_]:#*8#$>#<315K\OI7<IR.H[U+;TK4">YD0(Y;"#52"IIXUK@&9:2<LB:
MI//T?/OR'/P_C]9Z\B7LD&_]L6\VDUOX#HY]4[ *(X6!I!1X2J 0+N*8E!L=
M1^EYDV3]7EV.U>.OH&.=Y3)<R^'JSN3)E9O,1_/O;R;+KS?U=8+ENBNI9<];
M#B:UU&@;D.:>6^\@(((J+!1 A /GK9<N@EZKXDF=T,E5,4K3"TE_2'*21[-*
M_%%8C?!C<3-* UM=*;Q%L%V/1CD0T$I* Y"F-KHXT<>"E%E@D)7<-DREZ,)U
M;%4[9:OPG!8=JZ=B4Z1,[O&;^$5\^U_%MIR^G<\&)I $V#D1?59J(98:6(VP
MQXY99%S#^RQ?GY*;X=.-EM=%HWQ<3@;C_UL,IFYR9>-TOT/1NQX/"!E/B$(>
M*D'C$B2IQ51Z$3GL 08-;UQY3;IN":(N/VH_&A=3$\=T4T[W?])/G@S"FVC3
M:J<4%30NZAISI2R1P .-G6\R:Y/7I>3FZ'2CWTK@=/!FAV(?/Q*T]EP)FVX%
MLA01(*5%@ ++C6**\"8Y9_1U:;0!+-VJ,OJ9H_)J_[2\]=G 4C*;5EZGN+'!
M-CH#1D-KH?%**]5$N>QU*K<)/MUJ^6&Y\/$GVW: ]CP=(C&Q@YQ+Y2&-?I>$
M"EFFHQ>(I42T2:X[?YV:;H90#EVON%A?VX^>#T(Z9P$2WGM+572KERE0S)'H
M)C 'F@3'Q6O6]^D8=:-Q%8=VM1S>>'"S0\M/G@E$N+C&.!&M"$=5G(B<8$)S
MJZ.I2)UMDG4H7Y=FF^#2J4=<WMV5DT_S<OC[I]N(S^S15LE^]WA/PR"T80AP
M@0%'E)@X,Z6K@(2-<G,A;!/_Z>%PS^M0?.MH90HQNL$T'629Q4EH.>*S;8@_
M'TB-W>Y=30*'4F&BM2(D+IN022 XL8PZIX4 LM9*DT?*.ML3.]L$;>("X4$4
MUB7G7"OG""-*>P.9Y>3BBM<U5WC9#;1G^EAM,1^,QN=+8FGSFY7."P-1NA G
M;<I[3B"PP@M$D,2<--XD:&,C4L5)_FHT7J3-ID_%,!W]&Q6SQRG+<0&X7ZR4
M^_[Z!;M2 D*M?<@V7A2((01%]Y"X5-P8&P EJA E6C1:G?N3U=D>L7;N,)Y!
M&[DVV1N*IK]O[^! J<0.WQID]):IL#:":RDFC#'%*IR=)Q?&^G.1]'EA_=XH
M]+P?3MH'/5C9^E#3P+TFFA+$L 9I?XUB[RJ))6X4 NTAA7O!G5I\/EE%)Q_W
M7WJ2[^^7Z8O)9;V['Y??BV+YXP^+Z?!V,"L^C >3_?<C']=+$.G6I^CF.J4(
MM@92@W$E&P>-2OOWTJMH3]EE+M!/)M3GT5WQ]V(V+ZX^QE^GHV'\TW)(OTU&
M>ZXTJMTV()O*\! 8I9#I)C%B'*SD@ 8UN:.FEQF@W9"G ZA/ILRO@^GOQ;PN
M2;8_'1@#'GO*.&(( :,$$QL4B&UTT6,O4R*[H44KX)Y,A$>YPP]#^%3,Y^/B
M:K0*>N[G1NT.@A%&0D$L0(923S3&B%<260>:S"(]*F/0+5FZ0ON5N*9O:]3,
M;>L507&+)== <F6\!MQ"3S=3,6J4\=W#BG^7X72>JKV3YT\]F(V&T12T:<S%
MU1'!TV.:!ZF(D@8ZPXG7C!*L'-E(HU&3S=A79+YW28.R<ZWDFF/?%?-518YT
M8JA&]'[K\X%9J"V"%#DIM> 2.*8VZP?#%W/JL1N%/[\4IP6(ST*?NK0)7F/!
MH84RN2M 84#))B /O;"70I>6-+J/'T=BF8L7_RA&-[>I1$"$=W!3O%LD,_/]
M]8N4B!HSSK%=!: QE_%KHPXJ@RAW.%6-72&"L&IX?J,_[,HR&76,?M_XN(2S
M!3(N^PG0>P\-AH!X"82+_P6;X+.2.NO=!MT[!=U1Y41.GJ*$;+7"7FY7U"CN
ML;-1<,I818QABD#O)(Q2;[#$LE$B4*\FO>QD:PWS7,R*ML%T>>QY,%XG(RXQ
M4?/Y=/0E.D&I!$:YVC@;S(JK#X/ORW3(Z31=KW2HCE/SS@.V3A!I* "46:\X
MU=)4J!E/+LX[;8- Y9FU<-9E>FW:O/RTK_YS,9LG<8Y=L _W&!@&GB$)@$!
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M60GT+&>6P&LF66>0G\?'>UOC0-&.%L$XYX0@2&HGI(ZX,KOY?"2#%Y:BV5U
MX%1$<S'FL0=RW"["@99!:4PUD<HB+)$F AB],30-QQ=7'::QWI]?#=0JON?@
M4TWR!,2@LMQ$DU ["JU V.N-;0C@Q=5_[)(I1X)YGH5I0^?:"].F1;! ,R,8
ML\)@A*QWV)F'R%NC,K2]/)S=-EG:P;4'.Y'/+/A7OA.I.'>(<ZBU3<4X+2,&
M6^F=P,9P VHE8G8C[:?A;7&U&!?OKZO4B>6MJ[-14NA,?W_TMQV)%(=V+UMZ
M0U!8>X<$A4P!3FE*#3<5AD3)K ?6SKSC69M.SV^N/(LJSE"IKJ,RL))I$4TR
MCXP$.GH.2#!0R2U-O9O=7@\%L[/EA"*PQVDD.Q,[*P(KN'):>04)@]II2I35
ME=Q.NDM-_VB#"2<4@3T.[7.RK.TBL)"E#Y=$ZU%PX)5@'FY6&DSTQ25.M\J&
M4XK '@=X[BSIPU-^G:CD";T%#0C3&%&!@7?64.RC2[3&):XI38II]C!B>>ZE
MMWL-_3CY_0I+Y[A5! )+N>40$5'A(J3/6O3E?GG[\Z?Y8#KOE+^=\J>%E/_C
M='+.!?T?H_GMB])\LZ>U^3X^*^RTEO*O<;%*%\^_F0S'BZOBZLW$#::3^%@M
M-ZCK,01KO>$D_L<;J04@2#RL=(AG2@V2J^]B4MP,YL75Y\XG]IP?1E]5^4H_
MIT_%?#Y^>D=U]]_/HY<&:+!"4!M@'-8::<0EW$1]F&ZRY58_-O[T@_GWM]*V
MVGX<N\@)@*$SB$HAN:, 2KZQ32$P32SZHW.G5G:1FUP.H;O72 \VB=*MZ(O!
M^.FX7OE6D7'"6J&M==(0317P5L;7&R_BDLI1K;,Z/_I6$41:$($@Q]9CJ8 V
M*54L84@@\>Q2HZ.-Z-315M%QJG@M!^H$8]QI1!AS!-DX-VM&UU(A GS6@L.O
M)QI5FPN'#^$=IX#7> C/*PM8*GF/K6*2V+CV@TI"R!M=;MI#BC51<=U#>,<A
M^EI/7#ELC7<X67(6*9VN:&"5E%+BBS[K>XJRFYZX.@[ORSIQ!2U7T4% 2DFA
M(.#"\,TGBKAN4K^PAYLRW7&M<^@OY\05PAX[1A5#4AN /6.5/1M7!8R;1(U?
MTR&_II3K&OC7?>+**!?'I07'4 D8?2?HU[)2Y"%L,J^]IF-]C4G6&>0_3MY#
M.L*-#6 :6I?NQG(";W#A7#9<8B_37^P>YUS\6U89?7-W/QA-T[=I;@?3F_W7
M,FQM$"R%3!IJJ$1<0:<X8;"2+KI8%Y8[W:G^MQ4&;@KX63,&XY C,+,WD_0O
MJZ^O&-Y.1O]<[&7:T7T%3".R3AH$/,)XF6>A-E,\)4W.]O306\A)PJYU<9[X
MV9M)U%(QFW\<S(M/\[3=O#8B!C?UCY;MZR1 XA1"BCG#/>5&8Z%$A0(!JDE]
M]!XZ$SD9V9D2>KP__JZ<#)<5D??M_37J-R#M&" R.OZ8:F IB'!56$%@F]Q=
MV\LK27)2-J=FSKEWOK2M9T_'\\KWS+T#&-ET@YJ'E&JF.1%2>&80MHCK7NR9
MGW1SP%)7*<M!Q^']7FOGO(7WI').D&$N$97+XPU*&BLBQ%3!2&8C+_;41R-R
M[=Q!SZ^27*OD@XQF,)U^CV-?RIE$=+/YZ"XM]1OI9^^OGYH%I]"[A?<$!)4'
MT!E*":+:>FF<@I13'R=QX$03;[B7%2DZIG=^E63WEVM\KR\R19\FBM9A>1>O
M"YHP*JD"7#H531$A(%>4"@\)PI[3)J6>>EE1HQ.R]T SN4S&:/K&P0[&C[[5
ML]F*CRZL3--'FEJB'Y#2JZN;4&M8CO4["3@J0W'HL#"8*FV$MHQQ*@RS2M!Z
M[E4W2*3+A9]=,!P%^74P_;V8)Z(]"%-GHCFAM^ @226+=3(]:.*I)AH1@9EC
M#C/>9".BES9A%[39<G%TMVHXXZ2Q3M'^8>8."GB<O@DR4!(J<-HV!198SP76
M%JI:B0G=&^G;;BJOGY6]IWW@D*6%E3HE0%S4A.8LDE12 *W4CE_8I0%=$&./
M@=T6[+D,YP=X/L?W'LBO?OEP8- #%SU>1QFF%GGEM([SFXL_\%A<VH4E+6MZ
MYZW?)\)['M*8Z$#>E-/1OY8*/%C-Y'#CX#1E4D%DN#&4 *DUE9Y$"#7ED*,F
M^X\])%43M>]E4 O8YF*4*>_NBFDR3#X,[HOI01)M?3X@'Y$"QFI#XM<&H$0@
M20<I<([ RRMUVZ:ZGUN\+0"<BSP?B_O%='@[F!7J9EJL]DX.,FAWH\ QAHAP
M*IWQ5&,O'#+ 6P$TBS.Z;%+&O8?I#QV2J#6,<S'IUW)2?%^Y=7XQN3K,HNT-
M0A2$$F@DLH10[[%62%DB5'0"$3>NR>YO#],5.F10*_CF3(IY<"L.<F?;XT%A
M+(541AO#*4-,>ZU%Q,U'0Q)HVV3NZ67>0(?<:0'?;.;/5F_B;8U,Y0,M@XY.
M"/?$"H<E99XKP5"<7R&B2DK2J!1)#]>R;OVS=K'.R:W'<<OYDUW &J&U>AT$
MB+F+YB%*:SH%&"EC%()(6V4LT8UN#^BE\=T:&[:PK'6X^T&VDTD6C)0 Q05>
MI40*(+UTSDKL/)>>"VDO;D^C;1(<Q;$CT3[_UL7Y+D//O7=A%8K3" 9$80,9
M@A1%IXD82K5PSM=S3;O>NU!?HTZ6M^64TT^#)YMCM?<O#O01)(780<_^?WM?
MUN3&C:S[?G_,.=B7EQN!U:$(6=*5Y)DSYP5!LZN[.<-F]7"1W?/K+T"RV"M9
MQ=I87;(]8TMR 0U\^2&12"0R&>>2(D*C@L4%#@JYT7H(VR/(T3N,=J'O[>0^
M^6>^3$>(?0#36QB=OMRHV$,02&*FXY2UPP 00]*#R_W\ 6(CNS[K@!<OC_B=
MX#X@WI5FEJG<1Y# 8\#C[NQ]7-? 1;-2%!C :%N.BWNM,^-\YM7"O?:3>I,O
M[_/E9)T]=UV8W<N%TP_HJ[0-"EDDH/&,&,X=QRE/83$/C='HS.@.))QWBWG;
MW/F4+YK0YV7S@&4\$E '6#Q@2$AI*N91S,8[.[J([,LPJ"'LM4GT2QXQ721#
M\TSM4]HP*..5XE R3I2T@LJ4.V(_@WC2;/)299#1S1T3IVW 6Z5,5:53I6UP
M7#&)H&)$&"&-@PJQ_3R\@K0)<09Y(W(!XC3$O#9W?LV7ZYO)31:G^'E]FRVW
MKZ[T9/JO[.I,_7-^3T%8;P&1R"#+F-4B;L6NF*,CC0J8GEVL?02\ZEP"W;*L
MJLJJU5EP6$DJ'#96.B4T8][J8J;I*KL!U]A?7.M$"'TY$%[B4AHV\':#H*$$
MF&",B(LSXQ9J8"V%0*2K@68W)/Q=N@9J$JQ5F/M_W7O<2_>Q0C3!6?T$0953
M$0&KK-#.4 'XP4I(?XTUMJ K3VB7Z/>6!^WHR"M<A)4W#EIH+;GF6'..XYH#
M3AR4N/1F=!ZLCCCQ,C=:V\!?GFZU:!8 U=@1BXCU1%L/$/7B8"-(-CIZM2GX
MRIPZ$^7+<TE-IYN[S3PE2OAEF:]6ORV6V60^^T_\;30Q=':=+[/ODS_K:;9J
M?0>;ZLM*Z"!4DJ 4Q>@/AR5CU,C*JEZ$E]V(8LCT354"NZ+OL[X#Y-@#AJGS
MW$$"M7NR,RGEF]!WD"7Q!D;@)L(8 ('OXH$_3</DJYKVX],>0CRQ$8,D<8H:
M*"WR4JF#XPG()@>7\[.&Y^O)?(14; #XY0,*7]RGC3B@$$*M 4TE CRB2L7_
M2>85L*EX /"T4@&VOM5!FM.ODW4;Y\JWNPI(2:F %P!82"W36D%OM/0.,9N.
M\F,[!G1!F,JJHA497'Z3>CZ-5))VMOB\R/Z139:'I%0M</3MC@.CT"B,'/54
M4(V$-M9P+P@@@DM(1I<(LCLZU>1M*W(9-(N;6V%5.P_<,,,=H81H&O_BDH!X
MM/(\6JPHW=V,+<IHV&QN(INA,5I=K[-EG-?WVV6^N;E-=6W2%%=MJNC2GQ&@
M8XQRY(%PC#)B==0/CG"4\FAR@GM]'_Y3\KMM$;T7FK>MPRO]G."@U)YQIXR-
M.L,*)0W3!##FI072]GK>_HON+8FI=CS.68.NI*#;Z#9(1^-"MT I+BC@6D"@
M4AHX"H@2#C3)O##(>+#.27H!J?3,R3)MVE;7P5#H#((F92FE '&-H@RP9%P"
MB"!OXH\89/S8D+G91#*7-Q/J78LS)[RVDGC!# 44*""P%?$@8)W3#C7AW_G!
M91=TF/>V?9^)^*5X]?S5RK.5L<VP?@;;RKH*/(*,5$3#NHB(1II*R(7"ADK-
M"&D2FB'^XF!7<KC\7<Z+*XP1W^4XX+3D7DD<[2/&B?3"2NHB%:A&B%5ZF]<-
M$E^6^33+KE8^\CR1;)L\?4OAAU.!;2=@J=EC8-IC;+5BC A*.%:*6@2M!D!A
M)AMEYAO@"^HNR)-?0A"7-YRV 15?G\0#U3.E7G<3(@824$ZE59A&$0@,M>>"
M,PUTW/6;U+8<I+.[!U)VB/_ F)@">VI:]6_T$U+M;@VUD<:#>+)! ED&L$>.
M^(BWKA0.\)["M(;#Q5H"N+QUE>J=;";SG\;&,BD;J3;&PJ@L(.#:,8@D!\D[
MQ3BL5*2KLD\J6TYNLL?=]*UZ,\>]3A4:!RE]W'LE0512JN*O.#86*P0I)?$4
MT>2>=9!1 UT(.N\8]0NN\?)U/XA .36?;Y^!/OVCLQ;]B0X"<AX2AIBC@%.O
M4@E/M ]=1$K!2FZ'KA_]O5%\>:4?GORN>N*]:ET%2:"%@G&FHJ%$&=-<%6GF
M$)%<C?88U0I5CK[[ZP3] :5":RD%'Z4.&:.=33?QSHMHP!</,)#0L$D2H@&R
MKSMZU,S$=Q[\ Z)?BYGX!"<IH[-E" DEE;6$'C!6!(PL"V3KS*B=B>\\W&O?
M!W];IZ1<-[/I$SU_.C'(\1;!:Q;-.ZJE0-A[8!P]9(!#AOHF#I[WR95S99EW
M@7-?>ND-I?VQ0BJ&4\V"5 )&W*S4G#-MO>$"[&>*@:U6_O;]/ ;M;0-L$?,V
M-<^7?+F^SN>S_ S=<VB3JEH*CH$TABLFI >ISL5^W(B!T;T,:$>()2JG+KP7
M/,QOE\;/4^67<&X(YAX:H2FF7A-C**+:6N2CR :1*?]$D9HJQ<'/ZRBX" 20
M1 C/+%4^5;$W).ZSW!FJ':Q4]_@]*8(NR%*G\F]="5S^IJD*"2NT#A!HA#6-
M1IA-+T:$-L2F])+(6.&0[M5<&0GSVH>]+[H] <?,)ZO5['J67>D'DR^VB&PF
M\\)];N.N6UD9-NDV** =0X 8Z=,S#RDY@] JQ!ART4)K$ELVR/<X/1"T1WGT
MQ=RG80/INO;SXLDD*Q/UC%X"LI1YYZ%3)D+/L;)8,ZB,(M&*M:[)=?P@'\[T
MP,ONX._)MO^PB+],:5PN:LSOQV!GJ^D\7VV650H)GF@54(J\L<1[+"$50$DA
ML (("&P0D[22<=K;7*OM1\>;!9?2H A)&16&2H"4C8=/R+#AD<UD?.7L6I'\
MJPVF-8#[7[G[6_01+6 ME>!Q=P;(8XJD%I)X$$7++3#<<G>Y!>RNK[/I>O8C
M.PS_:[0XDB$R6VQFBYO/]]ER*\_5_C]]S:;Y8CJ;SW9KJQR7EGY",(!Y#Z&"
M!F!*TV8#%)74(QU/CJ)12OIWIQ8J\^EEWN:+R**W;.%OSN[%%-8^BS*?S+]%
M%FPB0QZ>?7PVC\_J/40;B6*14@1119FA&AA*@>>>>@6YZO6RJP\.]\ZW2GSO
M4F9#XGJ:4'IR\#'R:/Z&95R3Y,>Z#1JG-_$<XFC_4Z:(!%$=1?2BGN(0J":&
MVR ]6>^!W2T):TBT]ODRF]TLGGUA9[%ADMGL,=RZ)KW+N@\<. TY,QQ8134D
M$L5#-22,2H:,]I6BG-^3/^P]T+QEH0V)[O$/3:3#;-U4;S]V%)P 'L;Y.V$8
MQ9(+$G<R"[B3DD*/FL0(5G>=]?B2Y3U0N+9XAD363WDZHV_B9[_/,_?G?;98
M93:+A)CND5Q<[5]-;W_;D-%G_K1 D3!6&.*(C;ABICT4S&@,E"+4RB97;8/,
M8O,>:-^M#&M'&E49^J^3Q>8Z7=<L(Y9V-XDW.=VPQ^"XE5 ;@8P!%%FD$#?4
M"FB@%HR@)OGAS\YPTWU$VZ58VZ^4AJZUMP\Y.M#/VWZ#8D1J084BZ8&[)Q(R
M0#&C(AID',HFX39GY\SY2Q.W*ZTA,7M7 ?'JGYO]'69#0K_L+G#KM=%(8$DD
MI<0)ZK 6(*6]$I*J)B\=SLZ[\Q>/6Q'29>G[%I2M7*X$CH E0D&8'N#%[4AA
M;8#77#!OJ'--[D_D\%)$#9.H+0CF8M>QET]FT/:M+)#41>PUY3Q::,Y"8E/1
M'RD=!D*R2F9UQW/=$29*9_I0]DSY:)N "62.4&&!XA8@#"$BQ3R)AB-[CM>*
MQ(^%4S3$MK>HY<?=S^?+3]D?:CK--]NA?UGFB_C+:;9[GGWZS?%9_01DN$JU
MBQ F0$I#C4-HCP6D2/;ZF*9'GM7GQ,NPY0[1[HMYZ6WCYVMUE=]O3\IE];K?
M^CS$S95R*9EE$CMMO(5&%C,32([L!7M'4L];![HWY768_[?U9'$U65ZM?KN_
MBM93_)Y!5LJI2NT#0$X#9)V$E ()2 3 'N9N<:_A1-V3K)GX7^JI#@#N[<'Q
M9#Z)"^K;;9:MTYWX5G2G-\%C30*@C -G!$&,&,<80)05,X14-DG\/,"'QNWO
M=RT!>TGJE";-.-XH>(<MQ$A9;;6VC!.*>3%+YVFO^<6ZIT]S85=@3RUD^^*/
MW0LD+B&U6F7K4NZ\W2!8A)3B4@-)E '44^E,,3M"Y<AVKC;$G'> :^V;Q>*G
MKR?QX\GOL_EL_7 Z>\KQ%H%Z(Y!@0F,?%2V&R#]NX?&_-;E'&> 6U"(7V@6V
MOT=VZSC9[,I-EHNX!1_/NG.Z05"& B>I2CEFN!;",DV+V7$%^BDX_AYITRJN
MM57(/MHMV__PU-L1&_;4YP%+(RDV4"H0]UX!-?>X&"W6N(F_9H L:,]^;1'4
M-BEPU)XXW2 HQ2ABJ:0YQNE=F:>N<(I"B=A(W,/M"*V$ ;40;8L#L\7Z-KO.
MEW?Y]72RNHTG\_2O[#'AQFDKHUYO*:^8U\)#J(6DP%,J[<%JHI2,G#WG"OP$
M?[H!O#:YMK?H^R&6FALE+4)<4TI8:1ABA@%L#0'JX LBN(F],2 SM0N2M 9J
M?QE,]MNLVJQO\Y3"HL2]]G:#@*E"DFND'2=6$**!!?O9(8T:1=:<G=WA/1DG
MK<)Z.=*4.D>.-0D4*.6,5%Y3@SDQ3@)1S%!"TZ14Z8 VI+;$7,J:6JC6WG5^
M^Z]O_Y4XDD8P79_>;][Z-@"KO07Q_]PB&2<*D=/%. T:V[5.<W'E[0+:E\+8
M[X@FW4,MC[O/3GT>-#,ZS@- KYQ&Q,1MM-"L"$LPUNN;IE1I$=/>MY<GN^O'
M"FF&3[8+UCFK''%2B&B&&P@%<@?@-&Q2YN'LUT3OVD)I =TAQ9Q?-L6$C)#'
M-4<8X(IXA@2#Q75:<G..+)]Z2QSJ(&W$>7+H71/NWW?H;)%=SRH%T#YO$:"#
M2D"(I8Q&)M; 8%.XNI'CIDGVO2'OGJWRK!UL+W!__7%_6U;4Z?L4%\9FF8"L
M=IU]O'TP7E!JI: 1. BU8<:KP[J)^\KX+R6:\ZH+I"^LH=YZ.?$8.9F*:3R_
MTR_F_7"^:JO]HX+ 6CNB?(K)I(AY@T%QFX@H9TW>E[\3GU5G.K$OH=3V7'Q?
M3A;[,AOY?)ZL@.Q^LEX><CL<,?TJMPTB/;]43L!XD"+6*.-YX?=/D5,_P7&C
M/KFZ0GD 6Z]ILN_N&P=IJ::,48<@Y<(C3OCAV*X@:[+I#C#!0.^;;CV8^R*7
MV=QMYI-TW-F=>SY?OWB$,(NGGOMY/ Q]R9:S_.HQCOP$Z>IW&D]. @(DK!>>
M<"V94PX??-<0-KDL/#LWP'LE8V_P7\ LG-S-%EO!?LD6D_DV[_GBZL,BBBI;
MK>,<EYOLJIK55Z6G8$W*&&81$]1:#!@GX' 8X[I1?8ZSG_B_5SIVBWG_3Z(O
M7BZJ]0SS/!60T(Q8*JD15F)I$-%6:B:,U;4JM[==$*I:$K6SRT.=WVW 5GE*
MF?)*"6H T8YK8CR!Z2$#D$TR0 XRC6\KS#E:':IS ?2F']:3Q4U*GK,]@2:]
M]DN>7_TQFU\N:4(Q@)V.?3:\LW3'6?T$1U,MI7C@YL90(HETC(I49$FX2(YJ
M@<47Q*.*_CBOH^ M Q !#PR3%",BC?6.(6DC2)C )M[R06J,COB2]RB$RVN-
M2]?!N(SRX%8"RZ),O.' ( &D0+N:H5I#22H]B^S:%/&SQ6R=?8Q[UJL9E:5I
MJ=Y)P"HN!(N\(L9Q%TD+*"Z0\  W"5 9X%5N1RPY:G:T#']OKY!?5_ M>[_^
M=HO@/9<"2^6H0 0("9W@Q?R4XDW\+(/<D[H0?7F-[!I07Y)*Z9?+[/A;HLIM
M [-046\-%X1K0!CD'#_.F?1:4;>'-X9-)5^!24WPK7^O];":_+Z<?5GF*37H
MZ8C<M[X-CFD ?3R=.0RTHLQ:=$" ,=6KZ7L9'M246]XNLOUY:J^RZ^,*5C_\
M.OEGOMR6/2U]&7)63R%:]M)2!9E'\2\EG!:FP$,8.+* WAZVLVX%,!!"/L[A
MT^2N?..KT5N@FB#+I&'*:2BL@ (?C%7BP.B>I'3$FO/8V8(D^F-H5.S3N&M\
MC3*./_0VGH%L]B.;Y_<INJ7T>4.E]L$YH2%T$#'L$!":4JR*N3M+1O<TID-V
MO&)B^_CWQ;WOR\E5=C=9_BMYGK:_28"49Q8YV2X(IQPS$K X-9CL'8[9XXYC
MFW!M@%MQGUQK$_?>7FNU8@Z>T4L0B!HOB8[F-?!4&V6 /^PIGC<)EAM@%'$/
MIF!WX ^ A&>:@&?V%*1!6G" N>8(*\JY(Z# @U(RLKS(G3"E.AM;D$#]G!F;
M]<?9-$4M7WV9K,M3KAS[/FCJX\"D- 0#S! 4W,G]> US>&0'ALZDF;>/=7\1
MOUOS,;OZGDUO%_D\OWGX.KNY/<&HBBV#IR2%4"&H+32.((/98;Y&HUZK]+Y_
M;G6#>FT-]&%QE@(Z\GG@0$#&HQF*A..(VA1<4XP61M-A7.93+_JG':C[4C][
M1_/GY;=L^2..N\0T?^OS8+@R-!YL(_&II5AP"&PQ,XSQR#+X]&"#MX!RS_Q)
M9]3]8%>E9O71-@$SR@"1'G*',7.:0E  9KA%(_-<-1/SVYQI#&KM'4G][?,G
M]S^GMZ&GWP0?#7\A8%2IADM!/(6T<&$8!<:6P:<%^>3M(%G_ACB;7L]2*H22
MR^'GGP7JE(,*&0BD$@1CA90K1F>!&-EM7<MR;@9F7[O U[CYE9D.AV^B6>6]
ME-$:0D(0*VPTL0YT%9PW"108X /7'NR%NM#V2H_R%.:/7P6BO85<,\NYM!Y1
M)B4]G**@Z35DK7N*U)#?6PRHA5U?'/@UDO]N<U?*@F??!:*P,]@@1:G!--79
M?M29WO?K'^LC=+&6'//V$.R-#9,_J['AZ7>!(LV=-=$>1LF!E]*9%%=I)B7C
M[].2>#=L:(#@ &YL/E;(WE>E>;""(&0X@( 9 I$3%NB#^X6")K4&!YCYX+(7
MA751[R\,Y_EX/V5K]^=TOKF:+6X.KQ.JO+.MWDV07%CM.:-4&<,@)8""PQE-
M]OO&HP_=U2X]7L7A=(;\Y77>;ZOL>C/_.+L^];JH2O.T]T=@%0**LQ1Z0CPH
M I$L,')TUE,WM*BL]VHCW^ 6Z&0\TDDFG==!P PS@Q B2CD)O(A&2.&7M)R9
M)D4,!^C%Z91)G2)_>?VU2X54SU[;-@V.4F^D$YX1**'&\<AB#C.._^OS5O(G
MT%NU4!](4/\KG.I']+_J*C"@O&11YQ*%HI$B&47%E:VE@#4)+CS[8G,T/.Q8
M"I<Z0VS7T'ELK-)!4!0"X9@VA'JG)?94B6+V4H$F*6@&Z"SOB8$=(-\7[]1=
MOES/_K.5Y>?KEU,YP;?3#0-V1 (#A!?(0VU RO]5S)8XVB2(XVS_R&AT7:N8
M#\"R4]/I+M]@=O5T:O5LO2.=!8@LL)Q2EQ89MX :# M4C 9-HJBKIX64.R8N
MLILTOO?/Q,[E, !V1N#J,3$V#,@[*CQ'T=!%CA. H#V<V GE3:)ES\_^F*\G
M\U%S[GS$A^0;;N@3#EY9I@"VUG $+$KVQ6%E60N:G&_E3\JU#G#OBW$?9^O9
MS5:.W[+U>IZEEZ11$6_B/_^81*E>?<^WQ4&_3)8GJQR<U4\02I&HVHU2B ")
M.(.6'DY5S>XC!NC/Z_0VHDO@+ZCV/BQ:N1([VDU<CD8+0X%T !#)H760' P,
MT2AAS""O\_M)?-:A"/HB8S',#W?WDUF4X!,+=?=':85]/.UDKMQ'0-P(X&#<
M'$3*?.Z)9\6RM]BJ)GF_W\LM60L$.9*QLVWX!W#,>'I(VM>N^9JE"-\H\A1O
ML9I.YO_()B?+E#;O/;B(?P0+0.9)1,XH# _N>@EYDV/R )]N]:,[^Y?+,/G\
M*?MS_?V/;/XC^S5?K&]K7N95Z#AX2+UBPAA!L6,:4X4?#X%:-3%#!_AV;(@L
M;BB281(XK<3O?^2M\7;?7^#44**I1<)RA"B6&!U.D,RB)E$09]_&C,=D[4,6
M ^9I_/'U0KU.]A@,EY9@C#RV0AH&M09%UDBGI&GBT1Q@Q.M@F5I#%L/EJL\W
M[=FU18=QQY$86$BBV#4'FC&ABQM^1X1O<O=X=B&PGUFKUA#&@*D:OVV7JO';
M0!PR;AN+ A"C7B/%"V$X1UR3D-H!%@D;+%'/%\4C42]<Y>/%:^S1E_E 1'IB
M%.)2840X(H9HZZC'J883K5;EL1L\'A_)%#.J7M/C68L0?P#50'N-<=S,!>5"
MRF*.'BG1IPMQ:%JALOR/%O!H@O5[RJ,359CUVD>M">*QQ@M(*2UF9J0>60+]
MQO*MDC3G/$C?9](<*2GG@#I)D?)$6$@?%QB-TQX7;9J)N7+2G/- [3NEBN"(
M,<BAXDYBARCQ#!:C Y*/;+]I04JG4JJ<!V9?.J*]\D\J @1(M,UYW(2]0@01
M7\Q/$M[D?G.0U^QM;RSMX'I)WK17ZPEQYCS46@&A-46..G>8,Z*XUX*XEZOU
M5%GR9]=Z.@_?VMN.W]Q-[F\GRSMU<WKC>?5A\-8Z"93P#DC@(&,LGKIW(X22
M^Y$9J2U*+&\1UKX#<3Y6R,+QZMO@)#%,"*.(B/S3$'''BCEI8T:;F[^=;:<I
MGGUS9+\NKNQF.5O<?,F6L_RJ EW>:A8@P81H*!CT3 +I/#:'U1#GVN2:=8!*
MIH&DC]5);@YJ?X&G^UKP>_>NSA;9]>QTC.F;+0)2&ABK"<7(,:J,E%@<0$.H
MR3EX@!'-[9&F'3S[5C=?\_G<Y\L48%U!RSSY.B"LXD8K/5/(<!:5,82%LR#^
MRKNQG8?Z<=<V1[IO!E6@36"1_1X)(I&4U!#AE2^L.TBI:G(S??9&=+]5X]_6
MD^6Z%[[4DN015IP)9-]4V#[/B'IPF4U6F<UV_Z[ CS?;!>8P%-9PHI%P).E@
M?)@KB6?'<6Y$;=*E#5R'J$ZLDMI#J8E/?VO%,3ILJ:"9.CG[1+13)V[1[>/F
M3I3)>3!>_N9_>Q!</1_5Z._],8 J&A$"&T\ILUP(S+'@TC(H'6.5$FY6=&>5
MYI#9"N![A%S''O]US-EU9C>!*B<DM18;JBC&5-)4X$P+B(&AW/9:[FUXAF1E
M^>>]B:"O+:%P!>6GLJ_ZS3K!]3K J92L7?R8P+6T7/*H1@FA0BIEJ0?>Q3]S
M#CC8Q%DW8*.E&RH/0$!]4_V)U_,,YK[1*FA+K$$6>"SC$B92\KBBL0&:>4R(
M:W+!,,CD?_U2L3GBO9E3/V+3?/EP,;/I,(*SC*03K0(Q&'NH!18 6@J@9F1?
M&]!(1&BEX.'>YEIE'9]J%@146",C*>9,1<IRX% Q6\[ Z#)>MR+Y5[[9U@#N
M>]WNPYU'M'P!,=IAZ$3*D4\X$ @)*2!"W#"G0*5;J8[G^BE;GS/))Y\'[ 3@
M2BMMK*0T_D,2! 25W@!KB!MA&H06)'ULN=8'MK][M_U0OT[^^'42+>[99)Y2
M07R^_AIEN/R1G;KK+V\<+.#1FF#$42NH@DXRBHV"2'-FB,2]7N'V2J=:HC_&
MH[;P[9U5?\^7__JP^++,I]GJ?%H=;QV\%RYN=BS=9%,ID$)<I#R%P)GD%VH2
M^CK(V[MN>-4:P+T3*YVD5_$LDXXQYQ/K>.L@4#Q+Q;.5IA13:.*:DH#(> 3B
MG'B)>XU6>K_$:@W@VK&-AZ$LLO5TLTQ03!97BWRQ_\UQ[^_I=H%IY27A#*?(
M<D?3F1O%91*M X)P/(@W(,CYJ4IZR-K8 CVZ +9WC7,ZK>S3SZ+="#S&#%D,
M $60:\"0\Q[)E,^9-WK!-4 G:M<6])EP]D^,4SKEQ->!&N6)]8 Q1JG34!/I
M-.<((67C?)MDYAA@8&RW-*F+:M_ND O? ;?O#9'"6JL-LE!:ZC5)SZBP1E&(
M"OJ(^N6\(8^^[L/XS8XC9U^ME7414L0_(Q!0P"$U@DLA"6.8J^3IX_:G<G)6
M9L31NXE6P>YQA:_6*9WEZL/B;Y-X5(]C_K"(>C7^L5NL9^M9K75_PKPM_7$G
MEO;YG02+&3082DR9BB9:M/HX5HHJA9326%5Z]-7-2G]SZ&?>853N(W#AF?,:
M:RX8A1 H0KBWGD7Z.6O9:,HI=DF1O!_PA[3VZU^$#$<%*,,]ETQ3SJRG40$C
MP>+)SQI$T[/[2MM<UYO]L4E43^IRLH< +44I!$,KNS4SI84'# 0'L,_EWYW5
MWB4YCN[[;0+?US'PV)CU@YE/5JO9]6RZK_NT4VHEK_?K=!>8=E(0S352#%.!
M0?Q7@0RW_1:5[O.%94M\J;(9M2N"OLCY<L!']MFRA #G=!,,P  Q3B/"QE-%
MC8F_WR%A(*(C>QG>+5GRWN10V\_^*=LL9W=WFT5V.H7 R^^"X50  R7!F&E@
MXD$.DV)\U#=Z?S<H,[I;X>7M07S1'?/A8X7< B4M Q86$(0@,A(8#Z&1QAY0
ML[R2+^K]^-TOL@_61KNWI&J3AZW!^CW_=;;(EW'$WVXCG+?Y/,KQ9"Z^DPU#
MP@\C2Q)V44EKR>+,@=684T5PM?R5[WQ;JR/[EYG6V@2Y]I[U-4N)Q*(09HME
M_C"9KQ^6DW5V/WE(4\[3._B[;#E-P3:3^9L!!35Z"5P(I0GABFLN('-2493F
M1B6UU+F155IKFT#=(UZ;3>KJ:IL1:#)?ML*KNOT%116&<78X:GKMJ<62RC1?
MKK$U\=?CND_LA&$]8=\"U[[DZPA2_/F%2EWGZ1(T7ZPCAK&CFP*7<II5[BK.
M,JXFS(E11E&KO#%HNZ(4IJF89I.SW0#+]'3,L*Y@;Q0RM7/W'??V)4_\9G*J
M!F3=KH+R2ADNL*$BGGA@U-4NF@$.Q;,Q\A W>15_=E&==TJN[F%OA5QZ%JD_
MO5WD\_SFP>1W]Y-%&MCM9*V6F<WB>.\B#E??<YW]EA;$*I_/KE+-P+)[U5,T
M;/V'!H\<TH)2[KBPG!**XDEK+R)MR6@>?G=/K6,<OK3,>KH_?*P<?+' H%2#
MT\2M)VX[V6+Z\&%QG2_O=JS\/=^L'T?XZV2=E&.%J*&Z70:NO)9( I+R@"AL
MM,>(4TLXC1:\D94V@HY0RFXF\V*XBZO'V>W)7Q9D4*E]T-)!Q*""V,1SBF!"
MP?@_B[U$%%LX&KW2'U%>5NKN0 R]JXK'7[4>6?!]\N?T41YEMM[;7P=.!%;:
M4,((]_%O#1"RGAJC"$""5'I(V%40Y#[3X1/2E44''&T3,-!& T&A AQZAATW
MKIBGIJ1)%.^ '(.M2/I8QLF&F/:>HU1MUK=;YV7)9?[;#:)I[Q"62CMG?"HU
MX('6Q>R@14V>& V(,2U*^1AOFL!Z.=*47K<?:Q*P)-Y$.Y5%=+2T\8"H#PN-
M0CVR>A]-Q5S*FEJHGL>;5=R[;_(?_SW--XOU\F%'F_UO7C)F_\=!?WV#&X__
M,2X;+Z*F1<!28%W"@5$;EP]16DA*FMQRO@L6G"NVO"&"O6N*)XKR8X5;\9/M
M D<$(<8)MYA+ R) 3A4P8<9Z+?ORKC>;%M#MBTDO#E1V<C>YR5;?\LW-[1D'
M]F?-@@)2Q>,0 ]Q!B!W1 H.X9HB73C&-1Q+VVK+47YX[VP.XI^/F-@.O>>)8
M\[/%9)&NO;[%#K/DI=N=/B_FN/J\O)DL]AGS'@>:"+:X^O)DYI^O7P^]BA>K
ME?Z#5XQ"QC%BSE+/N+*1)T@@1#BFC%TP</[Q/NHP_B<.F//>T)S=5_ I#Y9@
MP@'MX[^UI-H H8QC#B)@>HVJZ</5U3.;\G[E,S2E=.G<8^]#-\F4/ C%?4;I
ME-!!*8&V>;B1UTAX>,D7O,5@2]_N//LP'@V08X9 (@SD<>_T\0^*&1'J1W9.
M[ID%+U_O-(&^+X-83^9QXMFWVRQ;?\QW$=AE932/- D1'T$@)@! "#C!W A=
MS-!B,;+C=UWQOBQYV Z:E^1+>=G,HXT"5QHI0S0T1$C@#"7 'V#3>F0>W^;"
MKL">6LCVQ9^=A;)+7O!Q-OE]-M]&'QQ](5.I74@)V221/DZ4 N<09P@4<\68
MC2P$O0VAY]W!VQ>5#@JXBBOP]<=QS4$!H1 6(>FU,UQY7,PJGAV:9"L8H/^O
MI>VJ,8Y]L4--I\M-1/^1S'MZ5S@]E+8-0"/DO2<114[C-&7\=3%G0^GHDFQ>
MUI)N6Q[]O>>;;W8HS>?Y'TEGIZ":(M_C7HV?X&&E]H$*X85-[V29((!HSA@_
MV Z.]UJ"KP\NMLB&5^_ZVL>[-\-\7XC;Y'>_QR6X7Z@[A_HZ+=E9E.C>J;0#
MKL@A=<IPK]UI .GN***17AEIC*3VDA4H<>%&5T2T.U;V)H2>M^:OV\=#CT"5
M;\@O6P1L;$JH!"%U&"&6;K</5HRGKLDV/,B4Q-V1K!V$^V*0N[N?YP]9]C6;
M)R_W:SQ.<*FT;= >&\* EL1ZA5*^'GHP:"TR30(#!OB6JSM.M8UT;[EAHDY=
M+W=O'+_LGC46D"RN*N6TK=A#P!H8SP%CFD(E*8)4%08Q=JI1QJP!/NSJCFG=
MX%W[19?)YY$4^6Y3SG;%ZE:3-/O)6U5P2]L$#(P3.KE>D/+0,&9UX1[$'-@F
MKTO9S\"3MA'NU5MZ%(XR=^G1AL$+)>/I!4++K4E!HEH4#CT,1:-T,/SGLIM:
M!;I76IW/IS?FA[W64'D#J"4 NE16MMC <=S4FQ0Q$C^#8FH7W_[B<7=O1W>Q
M@/MJK%4KJYUN&B)P0&I&L/.,"(V$8JZ8L<"-&#7((]UE/:LMBZ,_ CZ^A$X#
M/Y'1HZQ)H!BRE&_0:\F@%18C"@\S9(*/S7W:GLC?*#G1 L)]*[$] A5TUO[+
M0+PBEDM&E44..6F5HX^VHFRBHJJ[-N6.,8OL9GNV?J>,:0)L7T3Y93);I/CT
MSXMODZ(&PS[W\PG2G&@5..6&0X\EY91BISV'YG%75[VFHWK7*J<]D/LBD\^7
MV>QFL;/OI@_?EY-%/(,F(19ST=EU_.;[Y,\3Y#JCE\! 7$F<&N<-CJ8 LP+P
M [;2-8FP.MN;^:[)UAWHO9[[/N6+_'Y[893R:#W!J.SX=[1A "@EXU7.2.8%
MM5PP6%P28,18$WTV0#=F9P1K%>6^.%6'3L?G2(% QDF-'6+2&2\@L,4<M8!-
M8K+.=W3V4$*R(R:U!?#0GJU4_K!(N/5\.GT^<-GZ!5>KK-ISE==?!^^8,1[
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M(G@_1^SLV.+VFPCY96J<EB"M[QS]_?>_S;(29^B3;P(23F((=#PQ,XX(T?%
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M8VT$MQXC6\S2"-WD-#= SC07=@7VU$*V+_X4]M;7;)K-?J254WJY>:Q)D%Q
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MRZN3 8BNKSN[>'B--N9C7:MJU7-/M I01SLU'FL-$7(;>TN-+N:IO&N2Z'F
M%+TP5_*NY')A_I5&MYUL%YCU+KU+B-:#54!#@>EAKE2,K79-*U*OQJ1:^/;%
MI>20BS_K5BVN;#SPSO/[-'3W9UI]Y15Z*[0.SD*FG4O3%Q82SVTZ>N_F+2CL
M-6BNCT-$2RQX5?BL;:3[RZ\VCWW>I*"_Y60>QZ^N[F:+].0DXO(CVT^AO)CO
M6?T$+"1$0G(I*(,4>NF@*+  7C?)JS/(F)AN6-<EYGWQ[\L6OU)Z/?TL,,*
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M-K+7,Y<E1;T(D/,D] XB0)2#TEJ-*%:8>!9M'[B?C^*(-O&F#_'B\ITPKK:
M!K./'\.QRN5\\\Y#7%!4<FP8!AP:RYERA0VE &1-]N@ATOKBMF?O(JO_BF:V
MF-UM[KY/EC?9^M,FK;%49/[YVXQ?XKBW]<#B:#_O]/^3!?MA$7\SS=[TJ;?^
M,P)EFBH220&AAX++:'4=%  VKDEHR7NT"5HD4CX,D35X$/9G]U1N\6<$C)1
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M3PUTAX5B&WGF!WA_V I9NH.W+SWT81%/W=G!</RXSQM88H2?:!4,)X!QAXT
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M !$              ( !     &)I:6(M,C Q.# S,S$N>&UL4$L! A0#%
M  @ QH:83"[C7"T %@  Z D! !$              ( !$0$" &)I:6(M,C Q
M.# S,S$N>'-D4$L! A0#%     @ QH:83(\(JXU3)   99$! !4
M     ( !0!<" &)I:6(M,C Q.# S,S%?8V%L+GAM;%!+ 0(4 Q0    ( ,:&
MF$PF$">-@&8  %3Z!  5              "  <8[ @!B:6EB+3(P,3@P,S,Q
M7V1E9BYX;6Q02P$"% ,4    " #&AIA,FD2!6ZT$ 0".Y@P %0
M    @ %YH@( 8FEI8BTR,#$X,#,S,5]L86(N>&UL4$L! A0#%     @ QH:8
M3) I%C#BG0  Y<(' !4              ( !6:<# &)I:6(M,C Q.# S,S%?
=<')E+GAM;%!+!08     !@ & (H!  !N100    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
